

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 6 Mar 2020 03:49:45 +0000
To: Haskins, Melinda (NIH/NIAID) [E]
Cc: Selgrade, Sara (NIH/NIAID) [E]; Crawford, Chase (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Please review: House Oversight Letter on Coronavirus Diagnostics

I do not understand why you are asking me to "review" this. Is this an FYI??

From: Haskins, Melinda (NIH/NIAID) [E] (b) (6)>
Sent: Thursday, March 5, 2020 9:53 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Selgrade, Sara (NIH/NIAID) [E] (b) (6); Crawford, Chase (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: Please review: House Oversight Letter on Coronavirus Diagnostics

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 6 Mar 2020 03:00:23 +0000
To: Muniz, Maria de Los Angeles
Cc: 'Birx, Deborah L'
Subject: RE: National Blood Supply

Maria:
Thanks for the note. I will bring this up in our discussions
Best regards,
Tony

From: Muniz, Maria de Los Angeles <MMuniz@vitalant.org>
Sent: Thursday, March 5, 2020 9:53 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: National Blood Supply

Dear Dr. Fauci: I am an ex-alumni from the Department of Transfusion Medicine at the NIH. I am sorry to bother but I wanted to notify the Coronavirus Task force about potential blood shortages if blood centers get blood drive cancellations due to the fear in the public.

We are starting to see this locally and my concern is that other blood centers in the country are facing the same issue.

I tried to contact the office of the vice president, and all I could do was to send an email, which might get lost among thousands.

I am hoping you see this and perhaps bring this to the table. Blood centers use updated federal information when educating donors, staff and hospitals but the current fear is triggering blood drive cancellations. This might be experienced nationally and will impact the national blood inventory.

Thank you

Maria De Los Angeles Muñiz (Angie), MD

Medical Director

o 201.389.0439 | c (b) (6) (please call cell phone first)

mmuniz@vitalant.org

Vitalant Montvale

Vitalant Cleveland

Vitalant Cord Blood

Bank

102 Chestnut Ridge Road
Montvale, NJ 07645

333 East Bridge Street
Elyria, OH 44035

1 Pearl Court
Allendale, NJ 07401

Community Blood Services, Lifeshare & Blood Systems are now Vitalant.

From: Conrad, Patricia (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 5 Mar 2020 21:27:53 +0000
To: NIAID OD AM
Subject: FW: 03 04 2020 Dr. Anthony Fauci RE Invite to join my head table at Global's AcceptAbility Gala on Wed 5/20
Attachments: 2020 03 GLOBAL AcceptAbility Gala Save the Date.pdf
Importance: High

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Michelle Whitten - Global <mwhitten@globaldownsyndrome.org>
Sent: Wednesday, March 4, 2020 10:35 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Ashley Sparhawk <asparhawk@globaldownsyndrome.org>; Marisa Cucuzzella <mcucuzzella@ajsfoundation.com>; Rotrosen, Daniel (NIH/NIAID) [E] (b) (6); Deckhut, Alison (NIH/NIAID) [E] (b) (6); Rothermel, Annette (NIH/NIAID) [E] (b) (6); (b) (6)>
Subject: 03 04 2020 Dr. Anthony Fauci RE Invite to join my head table at Global's AcceptAbility Gala on Wed 5/20
Importance: High

Dear Dr. Fauci,

First let me say we are very grateful to everyone at NIH for working to contain the coronavirus, especially your team at the NIAID. Your interviews are articulate and informative - they give Americans some comfort and some concrete ways to think about protecting themselves and what to expect. It must be a stressful time and we want you to know that we have confidence in our NIH and CDC to contain it and to help stave it off globally as well.

On a happier note, I wanted to reach out and THANK YOU for all you do for our Down Syndrome research through the transformative trans-NIH INCLUDE program. It is making a HUGE difference!!

To this end, I am writing today in hopes you will be able to join us on Wednesday, May 20th for our AcceptAbility Gala at my head table. Attached is our save the date for the event. We are excited to have Caroline Cardenas as our 2020 Ambassador, Rep Pete Stauber as our keynote ((b) (6)), and Reps Lucille Roybal-Allard and Jaime Herrera Beutler are Global's *Quincy Jones Exceptional Advocacy Awardees*. We believe the gala will be quite lovely and meaningful to so many.

We do understand that attendance cannot be considered if the coronavirus situation worsens. However, if things are looking much better (touch wood) we would be deeply honored if you and our friends from NIAID could attend. Looking forward to hearing from you soon.

All the Best, Michelle and family

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 5 Mar 2020 11:00:39 +0000
To: (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E]; Greg Folkers
(b) (6); Marston, Hilary (NIH/NIAID) [E]
Subject: FW: New concerns for our randomized trial

What do you think? I see the FDA Commissioner every day in person.

From: Kalil, Andre C <(b) (6)>
Sent: Wednesday, March 4, 2020 11:27 PM
To: Beigel, John (NIH) [E] (b) (6)>; Davey, Richard (NIH/NIAID) [E]
<(b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID)
[E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: New concerns for our randomized trial

I want to share with you my concerns before the situation gets worse.

I have received many calls from physicians from all over the country about how to get
"compassionate use" remdesivir. (b) (4), (b) (5)

(b) (4), (b) (5)

I would appreciate hearing your thoughts on this critical issue.

Best,

Andre

Andre Kalil, MD, MPH, FACP, FIDSA, FCCM

Professor

Department of Internal Medicine

Division of Infectious Diseases

Director, Transplant ID Program

Associate Editor, CMI, Official Journal of ESCMID

Editorial Board, CCM, Official Journal of SCCM



University of Nebraska Medical Center

985400 Nebraska Medical Center, Omaha, NE 68198-5400

(b) (6) | fax 402.559-5581

(b) (6)

[UNMC](#) | [Facebook](#) | [Twitter](#) | [YouTube](#) | [Flickr](#)

"Lucky? Obviously you haven't heard anything I've said. It was a matter of applying Bayes' Theorem to estimate the conditional probabilities. Giving due weight to the prior probabilities..."

Robert Ludlum - The Ambler Warning

The information in this e-mail may be privileged and confidential, intended only for the use of the addressee(s) above. Any unauthorized use or disclosure of this information is prohibited. If you have received this e-mail by mistake, please delete it and immediately contact the sender.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 5 Mar 2020 03:29:00 +0000
To: Dave Doern
Subject: RE: Go Tony

Dave:

Many thanks for your kind note. I hope that all is well with you.
Best regards,
Tony

-----Original Message-----

From: Dave Doern (b) (6)
Sent: Wednesday, March 4, 2020 12:19 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E]
<(b) (6)>
Subject: Go Tony

Tony,

You always do the right thing.....comforting for all your (b) (6) friends to see you up front in this serious coronavirus attack....

We'll do the praying and you go Keep doing the hard work.....

Thanks,

Dave

David Doern

Sent from my iPhone

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 5 Mar 2020 03:19:47 +0000
To: (b) (6)
Cc: Greg Folkers (b) (6)
Subject: RE: Conference Planning with respect to coronavirus.

There is no way of knowing for sure. I would wait until May and see what the dynamics of the outbreak are globally and make your decision then whether or not to cancel.

From: (b) (6)
Sent: Wednesday, March 4, 2020 5:46 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Conference Planning with respect to coronavirus.

Dear Dr. Fauci

Dr. Miriam Kelty formerly of NIH referred me to you. I am on the board of directors and planning committee of the Applied Superconductivity Conference that is planned to be held in Tampa, Florida the last week of July. Over 50% of our expected 1500 attendees are from outside the continental US. Our planning committee appears to have three options:

1. Hold the conference on the original dates
2. Postpone the conference a few months
3. Cancel the conference

It would be most helpful to decision process if you can give us a prediction (anonymously of course) of how the effects of the virus will pan out.

I look forward to your reply.

Bruce Strauss
ScD, MBA, PE, F-IEEE

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 5 Mar 2020 02:59:22 +0000
To: Aliantha Angel
Subject: RE: A humble request for your wisdom

(b) (6)

From: Aliantha Angel (b) (6)
Sent: Wednesday, March 4, 2020 9:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Re: A humble request for your wisdom

Oh my God...

I honestly never expected you to reply and I thank you from the bottom of my heart for being so generous!

(b) (6)

Is there anything I can do for you besides being grateful?

You and yours are in my prayers!

much love,
Aliantha

On Wed, Mar 4, 2020 at 9:45 PM Fauci, Anthony (NIH/NIAID) [E] (b) (6) > wrote:

Dear Ms. Angel:

The severe complication of coronavirus are heavily skewed towards the elderly and those with underlying conditions (Heart disease, Chronic lung disease, kidney disease, diabetes, etc.) Most of the pneumonias are pure viral pneumonia and so this vaccination will not help that. However, on the chance that you have a pure viral pneumonia that gets secondarily complicated by a bacterial pneumonia (pneumococcal) the vaccine would be beneficial. If you are 65 years of age or older, you should get the pneumonvax23 vaccine anyway regardless of the risk of coronavirus infection.

Thanks,
Tony

From: Aliantha Angel (b) (6)
Sent: Wednesday, March 4, 2020 8:44 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>

Subject: A humble request for your wisdom

Good evening!

I know you must be completely busy and inundated with people wanting your time. I apologize that I have nothing to offer in return and completely understand if you don't have time to answer. I called the CDC but they were totally unhelpful. I have a question that makes sense to me and I was hoping you could answer and the answer might help a lot of people.

I understand that over time I, and everyone else, will very likely get COVID-19 and that most people won't even realize it because it will be minor. I get that, so this is not a panicked question.

I also understand that while most cases will not be severe, the bad cases are complicated by pneumonia.

So my question is: If someone has been vaccinated against pneumonia, will that offer any protection in the event that they do contract COVID-19 and perhaps provide some barrier against the worst effects?

Thank you for your time if you have read this and I apologize if this is just another in a long line of ignorant questions, but it made sense in my brain so I thought I would at least ask.

Be well, be happy, and may life be kind and generous to you, those you love, and those who love you!

sincerely,

Aliantha Angel

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 5 Mar 2020 02:50:29 +0000
To: Gordon, Joshua (NIH/NIMH) [E]
Subject: RE: Question re: (b) (6) coronavirus case

Josh:

You should counsel the rabbi to cancel the services this (b) (6). Are the local/city/state health departments (b) (6) doing any contact tracing?

Tony

From: Gordon, Joshua (NIH/NIMH) [E] (b) (6)>
Sent: Wednesday, March 4, 2020 9:44 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Tabak, Lawrence (NIH/OD) [E] (b) (6)>; Collins, Francis (NIH/OD) [E]
(b) (6)
Subject: Question re: (b) (6) coronavirus case

Dear Tony,

I know you are swamped but (b) (6)

(b) (6)

Is my reasoning sound? Should I counsel them to cancel services this Friday/Saturday? I'm hoping you can spare a bit of time for this advice, (b) (6)

Best,

Josh

PS (b) (6)

PPS great job today in the hearing

Joshua A Gordon, MD, PhD
Director
National Institute of Mental Health

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 5 Mar 2020 02:47:27 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Dr. Fauci for ABC News 20/20, Friday 9pm Ashton / Muir

Do you think that we can do this? I like Jennifer Ashton.

From: Strauss, Eric M. <Eric.M.Strauss@abc.com>
Sent: Wednesday, March 4, 2020 9:45 PM
To: Oplinger, Anne (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E]
(b) (6); Fauci, Anthony (NIH/NIAID) [E]
(b) (6)
Subject: Dr. Fauci for ABC News 20/20, Friday 9pm Ashton / Muir

Hello:

I wanted to make sure you are still considering our request for Dr. Ashton and David Muir to interview Dr. Fauci for our 2 hour program ABC News 20/20 **Friday from 9pm to 11pm.**

If a remote interview from a studio-on-the go mobile unit is preferable we can certainly arrange that.

Thank you for your consideration.

Keep up with our latest on the developing novel coronavirus outbreak:
<https://abcnews.go.com/Health/coronavirus>

Eric M. Strauss, ABC News
Managing Editor, Medical Unit
www.ericmstrauss.com
Phone: (b) (6)
Connect on Social: T/I/F = @ericMstrauss

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 5 Mar 2020 02:36:30 +0000
To: Rich Silverman
Subject: RE: Coronavirus Question

Richard:

Right!! Even if there was no coronavirus threat, (b) (6)

Best regards,
Tony

From: Rich Silverman (b) (6)
Sent: Wednesday, March 4, 2020 8:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Coronavirus Question

Dear Dr. Fauci,

I apologize in advance for this email. I am *sure* you are too busy these days to answer coronavirus questions from the general public. However, you are the only individual I know of who can be trusted to speak intelligently about the pandemic.

I know there is no preventive vaccine or cure, and there probably won't be for quite some time—despite what our ersatz President says. But there is something I don't understand. Since the coronavirus causes pneumonia, wouldn't it be a good idea to vaccinate more of the general population with Pneumovax 23 or Prevnar 13? That certainly wouldn't prevent people from catching coronavirus, but perhaps the resulting pneumonia onsets might be a little weaker/short-lived? (b) (6)

I figured it couldn't hurt, right?

Bravo for your efforts to keep our population intelligently informed on this situation.

Sincerely
Richard E. Silverman

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 5 Mar 2020 00:10:39 +0000
To: Bassar, Peter (NIH/NICHD) [E]
Subject: RE: genetic screening

Peter:

Thanks for the note. This would not be feasible in an outbreak setting if you are talking about GWAS or any kind of sequencing. Things would be moving too quickly.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Bassar, Peter (NIH/NICHD) [E] (b) (6)
Sent: Wednesday, March 4, 2020 6:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: genetic screening

Dear Dr. Fauci,

I watched you and Dr. Collins (via videocast) with admiration and pride yesterday during President Trump's visit to the NIH.

This morning, (b) (6) and I were discussing the spread of COVID-19. We were opining about why some people only have mild symptoms while others go on to develop ARDS. While we understand that age is a factor, we wondered (b) (5)

(b) (5)

Regards,

Peter J. Basser, Ph.D.
Senior Investigator, Intramural Research Program (IRP), NIH
Head, Section on Quantitative Imaging and Tissue Sciences (SQITS)
Associate Scientific Director (ASD), Division of Imaging, Behavior and Genomic Integrity (DIBGI)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Institutes of Health (NIH)
13 South Drive, MSC 5772
Bldg. 13, Rm. 3W16
Bethesda, MD 20892-5772 USA

(b) (6) (O)

(301) 480-0163 (office FAX)

(b) (6)

<https://science.nichd.nih.gov/confluence/display/sqits/Home>

This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you have received this email in error please notify me and the system manager immediately.

From: (b) (6)
Sent: Wed, 4 Mar 2020 18:25:52 -0500
To: Marc Reinoso
Subject: Re: Coronavirus Covid 19 and smoking

Smoking is terrible under any circumstance

> On Mar 4, 2020, at 6:04 PM, Marc Reinoso (b) (6) > wrote:
>
> Hello Dr. Fauci,
> In my review of data it appears there is a negative association with smoking . Should smoking cessation be mentioned during public announcements to help discourage smoking?
>
> Thank you,
>
> Marc Reinoso MD

From: Conrad, Patricia (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 4 Mar 2020 21:27:42 +0000
To: NIAID OD AM
Subject: FW: Meeting to Assess Evaluation of COVID-19 vaccine candidates for risk of enhanced disease
Attachments: March 12th-Tentative list of questions to be discussed_JPC mg-sb[16212]-version4March-1239-CLEAN.docx, Draft agenda.Acc Assess ED.4Mar202011_with annexes.pdf

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Steve Black (b) (6)
Sent: Wednesday, March 4, 2020 4:26 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Robert Chen <robert.chen@cepi.net>
Subject: Meeting to Assess Evaluation of COVID-19 vaccine candidates for risk of enhanced disease

Dear Doctor Fauci,

I am writing to you as a member of the SPEAC project which CEPI has funded to assist with the evaluation of the safety of vaccines in their portfolio. As part of this effort, we are assisting with developing preclinical and clinical testing criteria to evaluate the risk of enhanced disease following vaccination with COVID-19 vaccine candidates. As you know, this had been an issue with some prior SARS vaccine candidates.

We are convening a two day virtual meeting of experts via video conference next week on March 12 and 13 between 8 am and 1 pm Eastern time each day. Participants in the meeting are shown in the attached agenda but include Paul Henri Lambert from Geneva and Barney Graham from NIH. The meeting will actively involve the participants on the agenda the first day

and on the second day the meeting will be open for several peer reviewers including Stanley Plotkin and Andy Pollard to review and comment on possible small and NHP animal models as well as appropriate immunologic testing to be done in early phase one trials.

I am wanted to make you aware of the meeting so that you could attend all or part as an observer if you wish but also to invite you to consider joining on day two as one of our formal peer reviewers. The goal of the meeting would be to share recommendations with CEPI COVID-19 developers as well as other interested parties.

Any comments you have on the agenda or draft questions for consideration would be greatly appreciated.

I look forward to hearing back from you.

ATTACHMENTS: DRAFT AGENDA; DRAFT QUESTIONS FOR CONSIDERATION

Steve

Steven Black MD

SPEAC Project work package lead for CEPI

From: Conrad, Patricia (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 4 Mar 2020 21:16:44 +0000
To: NIAID OD AM
Subject: FW: TIME 100 Summit

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892

(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Alice Park <alice.park@time.com>
Sent: Monday, March 2, 2020 6:19 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: TIME 100 Summit

Hi Dr. Fauci -- as we discussed, sending along an invitation for you to participate in our TIME 100 Summit, which will be held in New York on April 21-22. We would welcome your insights on a panel addressing COVID-19, likely moderated by me.

I certainly hope you will be able to join us; please let me know either way. Looking forward to hearing from you. Best, Alice

PLEASE NOTE NEW PHONE NUMBER

Alice Park

TIME

(b) (6)
alice.park@time.com
@aliceparkny

From: (b) (6)
Sent: Wed, 4 Mar 2020 09:46:55 -0500
To: Michael Gerson
Subject: Re: Coronavirus Live Updates: Fatality Rate of Covid-19 Is Higher Than the Flu -
The New York Times

Talk later. Am in Hearing

> On Mar 4, 2020, at 8:10 AM, Michael Gerson (b) (6) > wrote:
>
> Can this be true?
> <https://www.nytimes.com/2020/03/04/world/coronavirus-news.html>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 4 Mar 2020 11:21:47 +0000
To: Emanuel, Ezekiel J
Subject: RE: RE:

No evidence in this regard, but you would assume that there would be substantial immunity post infection. It is an RNA virus and so you can expect mutations, but not sure how much is going on. Will have to check.

From: Emanuel, Ezekiel J (b) (6)
Sent: Wednesday, March 4, 2020 5:58 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: RE:

Sorry the phone. Is a person likely to be immune once they caught the coronavirus once? Do we know anything about likely drift?

Ezekiel J. Emanuel, M.D., Ph.D.

Vice Provost of Global Initiatives

Chair, Department of Medical Ethics and Health Policy (on Leave 2019-2020)

Levy University Professor

Co-Director, Healthcare Transformation Institute

Perelman School of Medicine and The Wharton School

University of Pennsylvania

Phone: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, March 3, 2020 10:57 PM

To: Emanuel, Ezekiel J [REDACTED] (b) (6)

Subject: RE:

Thanks for the note. I do not understand your question, See spelling below

-----Original Message-----

From: Emanuel, Ezekiel J [REDACTED] (b) (6)

Sent: Tuesday, March 3, 2020 9:59 AM

To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>

Subject:

Tony

Hope they are greatng you better about media appearances after my call with trump.

You were great at then press conference yesterday

Question:. Lilelynimmunitynince a person has the Coronavirus infection?.

Ari is pestering me

Ezekiel J. Emanuel, M.D. Ph.D.

[REDACTED] (b) (6)

From: (b) (6)
Sent: Wed, 4 Mar 2020 06:19:58 -0500
To: NIAID Public Inquiries
Subject: Fwd: (b) (6)

Sent from my iPhone

Begin forwarded message:

From: Patti Taylor (b) (6) >
Date: March 4, 2020 at 12:30:52 AM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Subject: (b) (6)

Dr Fauci

My name is Patti Taylor and I'm a nurse. Been one for 30 years. (b) (6)
(b) (6). Sounds too simple. Anyway I was
thinking of the Coronavirus and maybe it has something like an autoimmune part to
it that makes a person unable to fight back....
Just a thought. I think a lot.
Sent from my iPhone

From: (b) (6)
Sent: Wed, 4 Mar 2020 06:19:08 -0500
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: (b) (4)
(b) (6)
Attachments: PastedGraphic-1.tiff, ATT00001.htm, (b) (4)Executive Summary.pdf, ATT00002.htm

Pls respond

Sent from my iPhone

Begin forwarded message:

From: "Gupta, Sanchay" (b) (6) >
Date: March 4, 2020 at 1:40:30 AM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) >
Cc: Shaheer Piracha (b) (6)
Subject: Meeting Request - (b) (4)
(b) (4)

Hi Dr. Fauci,

(b) (4)

Thank you in advance for your time.

Very Best,
Sanchay Gupta

(b) (4)

Cell (b) (6)

From: (b) (6)
Sent: Wed, 4 Mar 2020 06:17:35 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Press inquiry_Russia

Sent from my iPhone

Begin forwarded message:

From: Валерия Попова (b) (6)
Date: March 4, 2020 at 5:13:38 AM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) >
Subject: Press inquiry_Russia

Dear Dr Anthony S Fauci,

My name is Valeria Popova, I am the senior editor of Channel One (Russia). We would like to invite you to take part in the popular international Russian-American project on Channel One. The big game is a television program, within the framework of which two points of view on international events are presented: American and Russian.

One of the presenters of the program is Dmitry Simes, chairman of the Nixon Center, a US citizen. He was foreign policy adviser to former US President Richard Nixon.

Only high-ranking officials participate in this discussion: presidents, diplomats, heads of ministries.

This is an honest and reasonable discussion. It would be a great honor for us if you joined her and discuss with our experts about situation with coronavirus. We work live and can use teleconference or skype for communication.

Hope to cooperate!

Channel One is the broadcasting leader in the Russian Federation. 250 million viewers in Russia and abroad. Today, Channel One programs have the opportunity to watch 98.8% of Russians and more than 250 million people in the world.

Channel One is the recognized leader of the Russian television, the most popular and favorite Russian-language channel in the world. It started broadcasting in April 1995

and became the successor to the state television and radio company Ostankino, which was the main broadcaster in the USSR and covered 99.8% of the population of Russia. Channel One's daily programs: the best entertainment shows, unique documentaries, latest news and analytics, the most headline movies and TV premieres, exclusive sports broadcasts and popular Russian music. Channel One combines innovative television broadcasting concepts, the vastest national traditions and cutting-edge global trends in a unique format.

Hope to cooperate!

Sincerely,
Valeria Popova
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 4 Mar 2020 03:09:35 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Routh, Jennifer (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]
Subject: RE: CNN Global Coronavirus Town Hall / Thursday / Dr. Fauci

Let us discuss the feasibility, desirability and potential for clearance or not.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Tuesday, March 3, 2020 8:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Routh, Jennifer (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6)>
Subject: FW: CNN Global Coronavirus Town Hall / Thursday / Dr. Fauci

Is this what you are talking about? Seriously recommend from wdc but again – this is really late – 10 pm to midnight.

From: Johnson, Christie <Christie.Johnson@turner.com>
Sent: Tuesday, March 3, 2020 6:45 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: Re: CNN Global Coronavirus Town Hall / Thursday / Dr. Fauci

Just making sure you received

Christie Johnson
CNN Worldwide
Senior Editorial Producer
C: (b) (6)
Christie.Johnson@turner.com
www.cnn.com

From: Johnson, Christie
Sent: Tuesday, March 3, 2020 11:16:51 AM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: CNN Global Coronavirus Town Hall / Thursday / Dr. Fauci

As promised, here is the big ticket item I wanted to flag for you. I was waiting to get through yesterday's hits to loop you in as to not overwhelm you. I have been speaking with the WH and VP's office to see if Dr. Fauci is available to join CNN this Thursday for our global town hall but wanted to make sure you have the info. Would you mind checking to see if he's avail?

Info:

We are reaching out to invite Dr. Fauci to join Anderson Cooper and Dr. Sanjay Gupta as our featured guest on the upcoming CNN special town hall - *Coronavirus: Facts and Fears*.

THE LATEST:

This Global Town Hall program will broadcast in front of a live audience [from 10pm-Midnight EST on Thursday March 5](#) from the CNN studios in New York City. We would cover all expenses for someone from the task force to join us live in NY. If Dr. Fauci is unable to come to NY, we will take him remotely from DC.

Coronavirus: Facts and Fears will feature interviews with a wide range of front-line experts fighting to contain coronavirus, along with patients and others who have been directly impacted by it's spread. We're really hoping to include a voice from the administration in order to comfort and inform our worldwide audience.

Thoughts?

Thank you!

Christie Johnson
CNN Worldwide
Senior Editorial Producer
C: [REDACTED] (b) (6)
Christie.Johnson@turner.com
www.cnn.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 4 Mar 2020 03:08:49 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: CNN Global Coronavirus Town Hall / Thursday / Dr. Fauci

No. This is not what I was talking about. I received a text from Governor Cuomo of NY State and he wants me to come up to NYC for a Press Conference with his Health Commissioner, Howard Zuycker.

From: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Sent: Tuesday, March 3, 2020 8:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Routh, Jennifer (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6)>
Subject: FW: CNN Global Coronavirus Town Hall / Thursday / Dr. Fauci

Is this what you are talking about? Seriously recommend from wdc but again – this is really late – 10 pm to midnight.

From: Johnson, Christie <Christie.Johnson@turner.com>
Sent: Tuesday, March 3, 2020 6:45 PM
To: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Subject: Re: CNN Global Coronavirus Town Hall / Thursday / Dr. Fauci

Just making sure you received

Christie Johnson
CNN Worldwide
Senior Editorial Producer
C: (b) (6)
Christie.Johnson@turner.com
www.cnn.com

From: Johnson, Christie
Sent: Tuesday, March 3, 2020 11:16:51 AM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: CNN Global Coronavirus Town Hall / Thursday / Dr. Fauci

As promised, here is the big ticket item I wanted to flag for you. I was waiting to get through yesterday's hits to loop you in as to not overwhelm you. I have been speaking with the WH and VP's office to see if Dr. Fauci is available to join CNN this Thursday for our global town hall but wanted to make sure you have the info. Would you mind checking to see if he's avail?

Info:

We are reaching out to invite Dr. Fauci to join Anderson Cooper and Dr. Sanjay Gupta as our featured guest on the upcoming CNN special town hall - *Coronavirus: Facts and Fears*.

THE LATEST:

This Global Town Hall program will broadcast in front of a live audience from 10pm-Midnight EST on Thursday March 5 from the CNN studios in New York City. We would cover all expenses for someone from the task force to join us live in NY. If Dr. Fauci is unable to come to NY, we will take him remotely from DC.

Coronavirus: Facts and Fears will feature interviews with a wide range of front-line experts fighting to contain coronavirus, along with patients and others who have been directly impacted by it's spread. We're really hoping to include a voice from the administration in order to comfort and inform our worldwide audience.

Thoughts?

Thank you!

Christie Johnson
CNN Worldwide
Senior Editorial Producer
C: [REDACTED] (b) (6)
Christie.Johnson@turner.com
www.cnn.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 4 Mar 2020 02:55:36 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Covid-19 Vaccine
Attachments: Press Release Preview - EIN Presswire - Press Release Distribution Service.pdf

Please take a look at this and act accordingly

From: KUMAR SHAH, MD (b) (6) >
Sent: Tuesday, March 3, 2020 9:48 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: Covid-19 Vaccine

To
Dr Anthony Fauci,
Director
NIAID/NIH
(b) (6)

Dear Sir,
Humbly, Endocrine Technology, LLC is pleased to forward the enclosed press release for your comments and advice.

--

Best,

Kumar Shah, M.D.
Diplomate American Board of Internal Medicine
Endocrinology, Diabetes & Metabolism
326 Livingston St, Suite A
Brooklyn, N.Y 11217
Office: 718-222-1065; c: (b) (6)
Fx: 718-222-1350
www.etdiabetes.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 4 Mar 2020 02:27:43 +0000
To: Siegel, Marc
Subject: RE: Dr. Marc Siegel: Coronavirus public health response has been handled well; we have right leaders at helm | Fox News

Thanks, Marc

-----Original Message-----

From: Siegel, Marc <Marc.Siegel@nyulangone.org>
Sent: Tuesday, March 3, 2020 9:23 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Dr. Marc Siegel: Coronavirus public health response has been handled well; we have right leaders at helm | Fox News

<https://www.foxnews.com/opinion/dr-marc-siegel-coronavirus-public-health-response-has-been-handled-well-we-have-right-leaders-at-helm>

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 22:52:20 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: COVID-19 Webinar

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Donna Prosser <donna.prosser@patientsafetymovement.org>
Sent: Tuesday, March 3, 2020 5:37 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Mike Ramsay
<michael.ramsay@bswhealth.org>; David B. Mayer <david.mayer@patientsafetymovement.org>
Subject: COVID-19 Webinar

Hello, Dr. Fauci,

My name is Donna Prosser, and I am the Chief Clinical Officer at the Patient Safety Movement Foundation. We are planning to host a webinar on Friday, March 6 at 8:00am PST to update our network on the coronavirus outbreak. Our network consists of 4,710 healthcare organizations across 46 countries, as well as patients, families, individual clinicians, and technology companies across the globe, who partner with us to achieve our goal of eliminating deaths from medical error.

During Friday's webinar, we plan to focus on how to keep patients safe from harm during this outbreak, and would love to have someone with your expertise join the call for a brief comment. Would you by any chance be available and willing to speak with our network sometime between 8-9am PST? We would be grateful for any amount of time that you could spare during that hour.

Thank you for your consideration!

Donna

Donna M. Prosser, DNP, RN, NE-BC, FACHE, BCPA

Chief Clinical Officer

Patient Safety Movement Foundation

p: 949.297.7066 **m:** (b) (6)

a: 15776 Laguna Canyon Road, Irvine, CA 92618

w: patientsafetymovement.org **e:** donna.prosser@patientsafetymovement.org



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 22:51:35 +0000
To: Bob Isman
Subject: RE: How to put COVID-19 statistics in perspective

Thank you for your note.
AS Fauci

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Bob Isman (b) (6) >
Sent: Tuesday, March 3, 2020 5:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) Redfield, Robert R. (CDC/OD)
(b) (6); briefing@nytimes.com
Subject: How to put COVID-19 statistics in perspective

Today (March 3), CNN featured a discussion with NY Gov. Cuomo regarding a new COVID-19 case in NY City. He happened to note that there are currently about 15,000 patients in NY hospitals with the flu. Although multiple government agencies, scientists and health experts keep reminding us that there are far more cases, hospitalizations and deaths each year from influenza than this coronavirus, it strikes me that a more effective, more visual and less fear-producing way of presenting this information would be to present the current number of cases, hospitalizations and deaths from EACH of these diseases side by side. If the number of flu cases, hospitalizations and/or deaths isn't available on a daily basis, we could use extrapolations based on known rates. I think this would certainly go a long way to putting the relative risks of these diseases in clearer focus.

Bob Isman, DDS, MPH

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 22:50:50 +0000
To: Jlevyusa
Subject: RE: Idea to help with Coronavirus infection

Thank you for your note.
AS Fauci

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jlevyusa (b) (6) >
Sent: Tuesday, March 3, 2020 4:17 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Idea to help with Coronavirus infection

Dr. Fauci,
I first want to thank you for your service and efforts in combating this international health problem.

I'm neither a physician or a scientist so please accept my apology if my idea is simplistic or isn't feasible. But I was thinking about some of the information presented on why it seems to be less prevalent in children. One theory is that they are exposed to so many other coronavirus's that they experience cross-protection. So I was wondering if anyone had investigated the idea to flood adults with other, less lethal, coronavirus's as a way to develop some level of immunity? Ideally coronavirus's that are a match to what children would be exposed to is what I'm suggesting here. I wouldn't expect that this will totally protect an adult but it might reduce the severity of the illness if an adult becomes ill and help while a vaccine and treatments are launched.

Thank you for considering this idea.

Best,
Jeff

Jeffrey Levy

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 22:50:07 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: my feeble attempt
Attachments: COVID-19.docx

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Tai Te Wu (b) (6)
Sent: Tuesday, March 3, 2020 2:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: my feeble attempt

Dear Dr. Fauci,

I have seen you on the television commenting about COVID-19.

Therefore, I have decided to squeeze some information out of their nucleotide and amino acid sequences as enclosed. Hope that you may soon find a cure with all the available data on this virus.

Best regards.

Tai Te Wu

From: (b) (6)
Sent: Tue, 3 Mar 2020 13:36:59 -0500
To: Barasch, Kimberly (NIH/NIAID) [C]
Subject: Fwd: Informal coronavirus teleconference: agenda + background documents
Attachments: image001.png, ATT00001.htm, 01 March_Chapeau_Critical preparedness readiness and response actions for COVID 19_DRAFT.pdf, ATT00002.htm, 01 March_COVID 2019 response scenarios_DRAFT.pdf, ATT00003.htm, 01 March_Preparing for Widespread Community Transmission_DRAFT.pdf, ATT00004.htm, 18624 Swisscom Call code.docx, ATT00005.htm

For the 7 am folder pls

Sent from my iPhone

Begin forwarded message:

From: "KABIR, Sophia" (b) (6)
Date: March 3, 2020 at 1:35:53 PM EST
To: SHOC <shoc@who.int>, Office of the Director-General <DGOOffice@who.int>, "Redfield, Robert R. (CDC/OD)" (b) (6)
(b) (6)
(b) (6)
(b) (6) David
Heymann (b) (6) "Felicity Harvey
(b) (6) "Chris.Elias"
(b) (6)
, Jeremy Farrar (b) (6)>
(b) (6)
(b) (6) "Fauci, Anthony
(NIH/NIAID) [E]" <(b) (6)>
(b) (6)
(b) (6)
(b) (6)>, "COX, Paul Michael" (b) (6),
"SCHWARTLANDER, Bernhard F." (b) (6)>, "MINHAS,
Raman" (b) (6)
"Conrad, Patricia (NIH/NIAID) [E]" (b) (6)>, "MAHJOUR,
Jaouad" (b) (6)>, "FALL, Ibrahima Socé" (b) (6), "Thomas
R. Frieden" (b) (6)
Lynn Banks (b) (6), President | Resolve to Save Lives
<president@resolvetosavelives.org>, (b) (6)
(b) (6)
"AL-SHORBAJI, Farah" (b) (6)
(b) (6), Robynn Leidig (b) (6)
"DRURY, Patrick Anthony" (b) (6), "Dr VAN KERKHOVE, Maria"

(b) (6)

(b) (6), "POOLE, Marcia" "GRAAFF, Peter Jan"

(b) (6), Tarik Mohammed (b) (6)

"(SPmig) Carlos Navarro Colorado" < (b) (6)

Ryan Morhard

(b) (6), "BRIAND, Sylvie" (b) (6)

"MORGAN, Oliver" (b) (6) "Harries, Jenny"

(b) (6) "Awwad, David (NIH/NIAID) [C]"

(b) (6) >, "SIMONSON, Stewart" (b) (6),

"SINGER, Peter Alexander" (b) (6) >, "(SPmig) Carlos Navarro Colorado" (b) (6) >

Cc: "RYAN, Michael J." (b) (6) >, "FARES, Christine Youssef"

(b) (6), "BOKO, Ivana" (b) (6) >

Subject: Informal coronavirus teleconference: agenda + background documents

Dear colleagues,

On behalf of Mike Ryan, allow me to share with you the following background documents ahead of the informal coronavirus teleconference tomorrow at 13.00 CET:

(b) (4)

Please find below, the key questions for your consideration and input tomorrow. We do not expect you all to address/speak on all the questions but just as a guide to your thinking and the ones you have views/advice/ideas.

(b) (4)

(b) (4)

The dial-in number and passcode are attached.

If you experience any technical difficulties joining this conference call, please contact the WHO HQ EOC operator at: **+41 227 912 490**

Best,

Sophia

-----Original Appointment-----

From: RYAN, Michael J.

Sent: Tuesday, February 25, 2020 10:07 AM

To: RYAN, Michael J.; SHOC; Office of the Director-General; (b) (6)

(b) (6); Felicity Harvey
(b) (6); Chris Elias; (b) (6) Jeremy Farrar;
(b) (6)
GREIN,
Thomas; COX, Paul Michael; SCHWARTLANDER, Bernhard F.; MINHAS, Raman;
(b) (6) MAHJOUR, Jaouad; FALL, Ibrahima Soce;
Thomas R. Frieden; Elhadj SY; Lynn Banks; President | Resolve to Save Lives;
(b) (6) AL-SHORBAJI, Farah;
(b) (6); Robynn Leidig; DRURY, Patrick Anthony; Dr VAN KERKHOVE,
Maria; (b) (6)
Cheryl Cohen; GRAAFF, Peter Jan; POOLE, Marcia; Tarik Mohammed;
(b) (6) Ryan
Morhard; BRIAND, Sylvie; MORGAN, Oliver; Harries, Jenny; Awwad, David (NIH/NIAID) [C];
SIMONSON, Stewart

Cc: SINGER, Peter Alexander

Subject: Informal coronavirus teleconference

When: Wednesday, February 26, 2020 1:00 PM-2:00 PM (UTC+01:00) Amsterdam, Berlin, Bern, Rome, Stockholm, Vienna.

Where: Upper SHOC (For Call in: please see dial in details attached)

Dear colleagues,

Dr Tedros would like to invite you to the next informal discussion about the ongoing 2019 novel coronavirus.

The teleconference will be hosted tomorrow Wednesday, 26 February at 13:00 CET and the dial-in number with a passcode is attached.

If you experience any technical difficulties joining this conference call, please contact the WHO HQ EOC operator at: +41227912490

It would be appreciated if you could kindly confirm your participation to Ms Sophia Kabir, email: (b) (6) mobile no. (b) (6)

Best,

Mike

Sophia Kabir

Executive Officer

Office of the Executive Director

WHO Health Emergencies Programme (WHE)

Tel. (b) (6)

Mobile (b) (6)

Website: [WHO in emergencies](#) | [WHO Facebook](#) | [WHO Twitter](#)



HEALTH
EMERGENCIES
programme

From: (b) (6)
Sent: Tue, 3 Mar 2020 12:42:58 -0500
To: Oplinger, Anne (NIH/NIAID) [E]
Subject: Fwd: Interview request from the Jesuits

From Patty on Fauci email. Not for several weeks

Sent from my iPhone

Begin forwarded message:

From: Mike Jordan Laskey <JCUcommunications@jesuits.org>
Date: March 3, 2020 at 12:32:38 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Subject: Interview request from the Jesuits

Dear Dr. Fauci,

I host the [AMDG Jesuit Podcast](#), which reaches a faith-based audience connected to Jesuit institutions around the country. I would love to welcome you onto the show to discuss the coronavirus and how your Jesuit education has shaped your career. It would be great to have 15-20 minutes of your time. Thanks very much for your consideration.

Best,
Mike

--
Mike Jordan Laskey
Senior Communications Manager
Jesuit Conference of Canada and the United States
1016 16th Street NW 3rd Floor
Washington, DC 20036
202.629.5933
jcucommunications@jesuits.org

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 13:57:03 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Corona Virus and a possible path to a vaccine?
Attachments: Origin of Co-Vid 19 and possible path to vaccination.pdf, PastedGraphic-10.tiff

Pls respond

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: expand@omcasa.com <expand@omcasa.com>
Sent: Tuesday, March 3, 2020 5:00 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Corona Virus and a possible path to a vaccine?
Importance: High

Dear Dr. Fauci -

Thank you for helping millions of people with your research over the years.

The following information was culled from <http://poleshift.ning.com>.

Perhaps this article may help you and your colleagues develop a vaccine that may combat the Corona Virus. You were the first one I thought of who may be able to deem its worth and explore its research for practical purposes.

Some of the links have included nih.gov so maybe your colleagues have already read this.

With my limited medical knowledge, I have taken the liberty to highlight key points that seem important.

Wishing you and yours all the best for remaining healthy in Mind, Body & Spirit.

Warm Regards & Appreciation,

Liz Jan

LIZ JAN BAmst, CAPS

Vaastu Homes instill Harmony, Tranquility, Abundance & Love; featuring
Universal Design & Aging in Place for safety, comfort & accessibility.

Design & Consultations
540.300.0638

expand@OmCasa.com

www.OmCasa.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 13:55:34 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Covid-19 — Navigating the Uncharted

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: El Bcheraoui, Charbel (b) (6)>
Sent: Tuesday, March 3, 2020 3:26 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: Covid-19 — Navigating the Uncharted

Dear Dr. Fauci,

Thank you for your useful [editorial](#) published in NEJM last week, it helps confirming that the situation does not need to be as grim as the panic that most people are experiencing.

I am writing an editorial and hoping to submit it to The Lancet soon. Differently from NIH/US Government institutes, I have more room for reflection in my viewpoint.

For that reason, I was wondering if I can have a call with you to get your opinion/advice on the direction of my editorial. I know how busy you are and I can understand if you do not have the time, but if by chance you are willing to have this call, I'll be happy to share my editorial's draft first. As a background, I am an EIS graduate (class of 2009), and trained by Robert T. Chen.

Thanks,
Charbel El Bcheraoui, PhD, MSc
Head of Evidence-Based Public Health,
Center for International Health Protection,
Robert Koch Institute,
Nordufer 20, 13353 Berlin,
Telephone: (b) (6),
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 13:54:16 +0000
To: NIAID Public Inquiries
Subject: FW: Zinc gluconate by inhalation for early coronavirus in elderly?

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Arthur (b) (6)
Sent: Tuesday, March 3, 2020 1:48 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Zinc gluconate by inhalation for early coronavirus in elderly?

Dr Fauci,

Since the elderly's response to pulmonary coronavirus infection may be impaired, especially in those with a chronic disorder, is there any information re: delivering by inhalation, low concentrations of a Zinc salt. Is there a potential rationale in early coronavirus infection to try to minimize serious pneumonia, were such inhalation shown to be reasonably safe?

Thank you,

Arthur Bobrovc, MD
Stanford and Palo Alto VA

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 13:53:42 +0000
To: NIAID Public Inquiries
Subject: FW: Coronavirus: Six Eyed Sand Spider, Habanero, water, Qi

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Lily Carnie (b) (6)
Sent: Tuesday, March 3, 2020 12:07 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Coronavirus: Six Eyed Sand Spider, Habanero, water, Qi

Dr. Fauci,

(b) (6)
(b) (6). I am an author on a Chinese form of healing called Qigong (a field I have studied for over 30 years), and am exploring Coronavirus from the perspective of a combination of the venom of the Vietnamese Six Eyed Sand Spider (entering the cells externally), Habanero capsaicin entering cells internally, the elevated water levels of infants and children and their higher levels of Qi in relation to them not getting the disease, and Qi from Traditional Chinese Medicine, Acupuncture, and Qigong.

I believe that the above combination can be beneficial in the study of Coronavirus. I am sure you are extremely busy and I am but a simple author but I just wanted to try to touch bases in case the above might help.

I live in (b) (6).

I would be truly honored to hear from you.

Lily of the Valley Carnie

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 13:52:17 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Possible treatment of COVID-19 pneumonia

Pls respond

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Paul Tone, MD (b) (6) >
Sent: Monday, March 2, 2020 11:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Possible treatment of COVID-19 pneumonia

Dear Dr. Fauci,

Nitric Oxide (NO) has been shown to contribute to the pathogenesis of influenza virus-induced pneumonia in mouse model (Zablockiene et al., 2012).

Zablockiene B, Ambrozaitis A, Kacergius T, Gravenstein S. Implication of nitric oxide in the pathogenesis of influenza virus infection. *Biologija* 2012; 58(1): 15-25.

NO overproduction in influenza virus pneumonia results from a sustained stimulation of inducible Nitric Oxide Synthase (iNOS) (Akaike et al., 1996).

Akaike T, Noguchi Y, Ijiri S, Setoguchi K, Suga M, Zheng YM, Dietzschold B, Maeda H. Pathogenesis of influenza virus-induced pneumonia: involvement of both nitric oxide and oxygen radicals. *Proc Natl Acad Sci U S A*. 1996 Mar 19; 93(6):2448-53.

NO overproduction in influenza virus-induced pneumonia can generate highly reactive oxygen species, peroxynitrite, via radical coupling reaction of NO with superoxide

[resulting from influenza virus-induced increased levels of xanthine oxidase (XO) (Maeda and Akaike, 1998).

Maeda H, Akaike T. Nitric oxide and oxygen radicals in infection, inflammation, and cancer. *Biochemistry (Mosc)*. 1998 Jul; 63(7):854-65

Peroxynitrite causes oxidative tissue injury through potent oxidation and nitration reactions of various biomolecules (Akaike and Maeda, 2000).

Akaike T, Maeda H. Nitric oxide and virus infection. *Immunology*. 2000 Nov; 101(3):300-8.

The crucial role of NO in influenza virus-induced pneumonia was demonstrated on iNOS gene knockout mice: at inocula sufficient to cause consolidating pneumonia and death in the wild-type control mice, iNOS gene deficient mice survived with little histopathologic evidence of pneumonia (Karupiah et al., 1998).

Karupiah G, Chen JH, Mahalingam S, Nathan CF, MacMicking JD. Rapid interferon gamma-dependent clearance of influenza A virus and protection from consolidating pneumonitis in nitric oxide synthase 2-deficient mice. *J Exp Med*. 1998 Oct 19; 188(8):1541-6.

Both influenza and coronaviruses could have the same pathogenetic mechanism of inducing pneumonia, namely harmful overproduction NO.

I would like to present you my innovative idea: Suppressing NO overproduction in COVID-19 complicated to pneumonia with Methylene Blue (MB)

Arguments pro:

MB is known as a guanylate/guanylyl cyclase inhibitor but it is mainly a NOS inhibitor (nNOS and iNOS).

MB is an inhibitor of superoxide generation by xanthine oxidase and NADH/NADPH oxidases.

MB is a small molecule capable to penetrate in tissues and cells

MB was administered intravenously in patients with refractory septic shock and Hepatopulmonary Syndrome of advanced liver cirrhosis.

MB administered intravenously will definitively reach the cells where NOS is induced by COVID-19 complicated by pneumonia both in animals and humans:

- Airway epithelium (including alveolar epithelial cells);
- Alveolar macrophages;
- Capillary/vascular endothelium (endothelial cells).

MB is an inexpensive medication.

MB is non-toxic molecule in humans

There are only a few cases of MB toxicity published in the literature. These cases occurred in very peculiar situations:

Hemolytic anemia in patients with G6-PD deficiency

Severe neuropathology after intrathecal administration of MB

Eye injury after topical use of MB

Tissue necrosis due to the extravasation of injected MB

Jejunal atresia following intra-amniotic MB

Serotonin reuptake inhibitors (SRI's) interact with MB, causing a serious adverse reaction consistent with serotonin syndrome.

Very truly yours,

Paul Tone, MD, PhD

Internal Medicine and Gastroenterology

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 13:51:29 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Dr. Fauci. I have a possible reason children are immune to the coronavirus.
Please read

Pls respond

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Rob Klein (b) (6) >
Sent: Monday, March 2, 2020 10:25 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Dr. Fauci. I have a possible reason children are immune to the coronavirus. Please read

Hello Dr. Fauci. I am a (b) (6) pharmacist from Ontario, Canada. I was just reading an article that stated covid-19 cases in children under nine y.o. are almost non-existent. I wondered why, and then an answer dawned on me. They have an immunity because one of the childhood vaccines all children get is giving them cross immunity to coronavirus as well. A study should be done immediately to see which one gives cross immunity, if indeed that is the reason for their seeming immunity to this virus. The immunity must wear off over time which is why adults and seniors seem to lack prior immunity and get sick. This hypothesis is certainly worth investigating. If this is what is happening, maybe millions of lives could be saved by a simple booster of an existing vaccine. Please let me know your thoughts on this matter. Thanks for your time. Rob

Sent from [Mail](#) for Windows 10

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 13:21:11 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Sky News

We should discuss

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Szweda, Jakub (Interviews producer) <jakub.szweda2@sky.uk>
Sent: Tuesday, March 3, 2020 6:16 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Sky News
Importance: High

Hello Dr Fauci,

Hope you're well. I'm a producer for Sky News, looking after our flagship evening programme Sky News Tonight 7-10pm UK time (2-5pm ET).

I was wondering if you might be available for an interview on the coronavirus outbreak? Either today or another day this week.

Happy to explain in more detail.

Any questions, please let me know.

Best,
Jakub

Jakub Szweda

Interviews Producer | Sky News

Phone: +44 (0)2070320436 | Mobile: (b) (6)

Address: 2nd Floor, 4 Millbank, Westminster, SW1P 3JA



Watched by 169m people in 138 countries

Information in this email including any attachments may be privileged, confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received it in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. SKY and the SKY marks are trademarks of Sky Limited and Sky International AG and are used under licence.

Sky UK Limited (Registration No. 2906991), Sky-In-Home Service Limited (Registration No. 2067075), Sky Subscribers Services Limited (Registration No. 2340150) and Sky CP Limited (Registration No. 9513259) are direct or indirect subsidiaries of Sky Limited (Registration No. 2247735). All of the companies mentioned in this paragraph are incorporated in England and Wales and share the same registered office at Grant Way, Isleworth, Middlesex TW7 5QD

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 13:10:22 +0000
To: George GAO
Cc: Mascola, John (NIH/VRC) [E]; Conrad, Patricia (NIH/NIAID) [E]; Graham, Barney (NIH/VRC) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Vaccine—confidential PPT
Attachments: 20200303 For Gao laoshi.pptx

George:

Thanks for the note. I will send this to Dr. John Mascola Director of the NIAID Vaccine Research Center and Dr. Barney Graham to follow-up with you.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: George GAO (b) (6)
Sent: Tuesday, March 3, 2020 7:12 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Vaccine—confidential PPT

Dear Tony

Hope this email finds you well and the US will soon get the COVID-19 down.

(b) (4)

All the best
George

发自我的iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 10:57:14 +0000
To: Mascola, John (NIH/VRC) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Graham, Barney (NIH/VRC) [E]
Subject: Important - POYUS and VP visit slides
Attachments: VIP visit to VRC Coronavirus Short version - for 3-3-2020.pptx

John:

Yesterday when I spoke to your IT/audio visual guy I told him to pull out the single slide with the comparative time lines for various vaccines over the years and show it on the screen. I then asked him to have the full set of slides ready for me to show. I have now abridged that "full" set so that I can whip through them if it looks like the discuss slows down. I am attaching this abridged version here. Please ask him to substitute this shorter version for the full set from yesterday. Call me if you have any questions.

Thanks,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 03:40:19 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: RE: Can we get comment please?

I am not going to comment. (b) (5).

From: Billet, Courtney (NIH/NIAID) [E] (b) (6) >
Sent: Monday, March 2, 2020 3:16 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6) >
Cc: Routh, Jennifer (NIH/NIAID) [E] (b) (6) >; Folkers, Greg (NIH/NIAID) [E] (b) (6) >; Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Subject: Re: Can we get comment please?

(b) (5)

From: "Burton, Tom" <tom.burton@wsj.com>
Date: Monday, March 2, 2020 at 3:09:17 PM
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6), "Lane, Cliff (NIH/NIAID) [E]" (b) (6), "Billet, Courtney (NIH/NIAID) [E]" (b) (6)
Subject: Can we get comment please?

Folks, we're doing a story that focuses in part on the administration's conference call from last Thursday noon about a decision to send out more CDC coronavirus assays despite the fact that they had become contaminated and compromised. We understand that Dr. Fauci was one of four federal doctors (the others being Drs. Hahn, Shuren and Shah) who strongly recommended the assays not be sent out. I want to give Dr. Fauci a chance, on or off the record, to comment on the story please.

Thank you,
Tom Burton

--

Thomas M. Burton, Staff Reporter
The Wall Street Journal
1025 Connecticut Ave. N.W., #800
Washington, D.C. 20036
W: 202 862-6611
Follow me @TomBurtonWSJ

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 03:11:52 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: Alert: Questions from Sen. Alexander for tomorrow's hearing

Bob:

Please do me a favor and provide answers to the questions below from Sen. Alexander
Thanks,
Tony

From: Haskins, Melinda (NIH/NIAID) [E] (b) (6) >
Sent: Monday, March 2, 2020 8:30 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Crawford, Chase (NIH/NIAID) [E] < (b) (6) >; Selgrade, Sara (NIH/NIAID) [E] (b) (6) >; Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Marston, Hilary (NIH/NIAID) [E] (b) (6) >; Folkers, Greg (NIH/NIAID) [E] < (b) (6) >
Subject: Alert: Questions from Sen. Alexander for tomorrow's hearing

Dr. Fauci,

We just received a number of questions from Senate HELP that Sen. Alexander plans to ask you at the hearing. Chase will pull together the epi info. Let us know if you want to discuss these.

Melinda

Sent from my iPhone

Begin forwarded message:

From: "Hallett, Adrienne (NIH/OD) [E]" < (b) (6) >
Date: March 2, 2020 at 8:15:00 PM EST
To: "Haskins, Melinda (NIH/NIAID) [E]" < (b) (6) >, "Selgrade, Sara (NIH/NIAID) [E]" (b) (6) >, "LaMontagne, Karen (NIH/OD) [E]" (b) (6) >, "Berkson, Laura (NIH/OD) [E]" (b) (6) >
Subject: Fwd: Questions from Sen. Alexander

See anticipated questions below.

Begin forwarded message:

From: "Coulter, Margaret (HELP Committee)" (b) (6)
Date: March 2, 2020 at 7:29:15 PM EST
To: "Pence, Laura (HHS/ASL)" (b) (6), "Bradsher, Kris

(HHS/ASL)" (b) (6)>, "Berkson, Laura (NIH/OD) [E]"

(b) (6)>, "Hallett, Adrienne (NIH/OD) [E]"

(b) (6)>

Cc: "Bell, Kathryn (HELP Committee)" (b) (6)

"Pfaff, Melissa (HELP Committee)" (b) (6)>, "Vogt,

Andrew (HELP Committee)" (b) (6)>, "Graham,

Grace (HELP Committee)" (b) (6)>

Subject: Questions from Sen. Alexander

Hi Laura and team,

Thanks for all your work in advance of tomorrow's HELP hearing. Below are specific questions that Sen. Alexander plans to ask Dr. Fauci and would greatly appreciate concise answers to – he is happy to allow Dr. Fauci to elaborate if there is additional time. Additionally, he plans to ask Dr. Schuchat a few questions about CDC covering patient costs from quarantine.

Thank you very much and look forward to seeing you all or your colleagues tomorrow.

Best,
HELP team

Questions for Dr. Fauci:

1. How many cases are there in the world? In the U.S.?
2. How many deaths so far in the world? In the U.S.?
3. How many countries have cases of the coronavirus?
4. How do you know if you have the coronavirus?
5. What are the symptoms?
6. How do you protect yourself?
7. Should we all be wearing masks?
8. If not, why should health care workers have to wear masks?
9. What are the most effective ways to protect your families?
10. If someone has coronavirus symptoms, what should they do?

11. If a doctor has a patient with these symptoms, what should they do?
12. Who is most at risk?
13. What is the mortality rate?
14. Can you explain why there have been relatively few reports of cases in children?
15. This is the peak of the flu season –
 - a. How many flu cases have we had this year so far?
 - b. How many deaths have we had this year from the flu?
 - c. How is the coronavirus different from the seasonal flu?
 - d. Is it possible that we could reduce the infections or deaths from the seasonal flu because you need to do the same things to protect yourself for both types of viruses?
16. Can a person transmit the virus even if they are not showing symptoms?
17. Are your agencies doing any research to determine when exactly an individual may transmit the virus to others?

QUESTION FOR DR. SCHUCHAT:

- If a patient is under a federal government-required quarantine, who pays the bills?
- Does their insurance pay first, and then does the CDC cover the remaining bills as the payer of last resort?
- If CDC is the payer of last resort, does the agency pay the doctor or the hospital directly – or is the patient obligated to send their bills to the CDC?
- How and when is this information made available to the patients under a federal government-required quarantine?

From: (b) (6)
Sent: Mon, 2 Mar 2020 19:06:49 -0500
To: Johnson, Richard Allen,M.D.
Subject: Re: Telecast today

Thanks, Dick.

On Mar 2, 2020, at 6:57 PM, Johnson, Richard Allen,M.D.
(b) (6) wrote:

Tony,
You were the star of the broadcast today! Your intelligence, confidence, warmth, and humor are what we all need with COVID-19. Please keep these coming. You appear to have a great working relationship with Dr. Burks.
Very best,
Dick

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 2 Mar 2020 17:56:05 +0000
To: Michael Gerson
Subject: RE: Q

See my edits in red for accuracy

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Michael Gerson (b) (6) >
Sent: Monday, March 2, 2020 11:41 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Re: Q

This is the descriptive portion of my column. I don't want to over or under-state:

America is entering a disturbing new stage in the coronavirus outbreak. There has been community spread in at least one and likely two locations in Washington State. And it appears the virus was being transmitted for at least a few weeks before current cases were recognized. So we can expect dozens or hundreds of cases in those locations unless contact tracing is especially efficient.

That means the disease is loose and easily transmitted.

The crucial issue now is the real mortality rate, which remains uncertain. The stated mortality is 2 percent. American experts are hoping the rate turns out to be considerably lower. But the math remains troubling in any case. If only 5 percent of the population eventually gets infected (which is on the low side of some estimates) and the mortality rate is 1 percent, there still would be a few hundred thousand deaths.

At this stage, the main tool that public health experts have is social distancing – the attempt to keep as many people as possible in affected areas out of sneezing distance from one another. This means measures such as closing schools, cancelling events in theaters and stadiums and encouraging employees to telework. States and localities ultimately make such decisions rather than the federal government. But according to some health experts I consulted, Washington State should be taking such measures right now. The effectiveness of social distancing is limited when action comes too late or ends too early.

The goal of such policies is to keep the R_0 (reproduction ratio) as low as possible. When people are in close proximity, a single infected person can spread the disease to several others, boosting the R_0 of the disease as high as 2 to 3 and causing an exponential increase in cases. If the R_0 is less than one, the epidemic will gradually decline and stop on its own, with or without a vaccine.

A vaccine, however, would be tremendously helpful. There are at least ten vaccine development projects underway. But the one furthest along at the National Institutes of Health (NIH) is still about six weeks away from starting the process of **a phase 1 trial in human volunteers that will take 3 to 4 months to complete and to show that the vaccine safe and produces specific antibodies. A phase 2 trial will follow and will take at least 6 to 8 months to determine if the vaccine is efficacious in people at risk for infection.** Then production would need to be scaled up by a willing pharmaceutical company to deal with a global crisis. All this **in total will** take at least a year – assuming there are no unpredicted scientific obstacles in the way.

On Mar 2, 2020, at 7:54 AM, Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]> (b) (6)> wrote:

Mike:

Social distancing is not really geared to wait for a vaccine. The major point is to prevent easy spread of infections in schools (closing them), crowded events such as theaters, stadiums (cancel events), work places (do teleworking where possible). States and localities make these decisions, not the Federal government. The goal of social distancing is to prevent a single person who is infected to readily spread to several others, which is facilitated by close contact in crowds. Close proximity of people will keep the R_0 higher than 1 and even as high as 2 to 3. If we can get the R_0 to less than 1, the epidemic will gradually decline and stop on its own without a vaccine.

[REDACTED] (b) (6)
[REDACTED]

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Michael Gerson (b) (6) >
Sent: Monday, March 2, 2020 7:22 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: Q

Is the overall strategy for social distancing just to keep the percentage of Americans who get the disease low until a vaccine is available? This seems much harder to do in a free society. Does this mean closing schools? Public transport? Do states and localities make such decisions?

(b) (6)

On Mar 2, 2020, at 6:11 AM, Fauci, Anthony (NIH/NIAID) [E]
(b) (6) wrote:

Mike:

Thanks for the note. We are clearly getting "community spread" in at least one and likely two non-contiguous locations. It was likely spreading in Washington State for at least a few weeks before the current cases were recognized, which means we can expect dozens and dozens of cases (or more) in that location unless we are very lucky and/or the contact tracing is highly efficient. The precise mortality rate is still uncertain. The stated

mortality is 2%; however, even if it is half that (1%) and only 5% of the population get infected, you are correct in that we can have a few hundred thousand deaths. The really critical issue is what the mortality rate actually turns out to be. I am hoping for a considerably lower mortality rate, but that might be wishful thinking. Whatever it turns out to be, the major tools that we have are public health measures, particularly social distancing, which we have to start doing right now in Washington State and thinking about in other locations. That is really the major weapon that we have. Even though we go into phase 1 with one candidate vaccine in about 6 weeks, vaccine is out of the question for at least a year or more if you want to make sure that you have an effective vaccine, i.e. some efficacy data before massive deployment.

We are meeting with pharmaceutical executive today and I will bring up the issue of what the fastest possible timeline would be to have a deployable vaccine.

[REDACTED] (b) (6)

[REDACTED]. I hope that you are well.

Best regards,
Tony

-----Original Message-----

From: Michael Gerson [REDACTED] (b) (6)

Sent: Monday, March 2, 2020 5:04 AM

To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>

Subject: Q

Tony,

I was with Francis yesterday, and the news seemed pretty sobering. It seems like the virus is out in the general population in the Pacific Northwest and Silicon Valley. A pandemic now appears likely. Francis gave me a guesstimate that 5 to 20 percent of the US population may end up infected. Depending on the mortality rate, this could result in hundreds of thousands of deaths.

Not for attribution in any way, is this a fair summary? How and when will we know if the disease is on this track? Do we have any better info on mortality yet?

And is there any news on the vaccine front? As I understand it, we are not even to Phase 1 trials on anything. If a vaccine is promising, are we talking about late Fall as the earliest possibility? And are there any substantive measures that could be taken to make sure pharma steps up to produce a vaccine on a massive scale once we have it?

I'm not sure Americans have been adequately prepared for this possibility. That is partly a political problem (in my view). But what needs to happen soon to get people prepared?

Hope you are holding up well under all of this and taking care of yourself.

Mike

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 2 Mar 2020 17:26:54 +0000
To: Reddy, Sumathi
Subject: RE: ?

For COVID-19 the mortality rate is approximately 2%. For seasonal influenza it is approximately 0.1%

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Reddy, Sumathi <sumathi.reddy@wsj.com>
Sent: Monday, March 2, 2020 10:49 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: ?

Hi there
Wanted to see what's the most up-to-date info you have on mortality rate for covid-19 versus influenza?

--

Sumathi Reddy
The Wall Street Journal
"Your Health" columnist

M: (b) (6) Q: +1 212 416 2945
E: sumathi.reddy@wsj.com
T: @rddysum
A: 1211 Avenue of the Americas, New York, NY 10036

From: (b) (6)
Sent: Mon, 2 Mar 2020 09:24:45 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: 60 Minutes / COVID -19

Let us discuss

Begin forwarded message:

From: Denise Cetta (b) (6) >
Date: March 2, 2020 at 9:20:42 AM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) >
Cc: Jon LaPook (b) (6), "Stover, Kathy (NIH/NIAID) [E]" (b) (6) >, "Routh, Jennifer (NIH/NIAID) [E]" (b) (6), Katie Brennan <BrennanK@cbsnews.com>
Subject: 60 Minutes / COVID -19

Dr. Fauci:
Good morning.
I know you are busy, so forgive me for reaching out directly, but time is of the essence.
I know you spoke with Jon about doing a 60 Minutes story on COVID-19.
We are interested in potentially crashing a story for this weekend.
Is it possible for us to have a quick brainstorming phone call on what such a story might include if based at NIH with you?
Some ideas...

Following you closely as you engage in meetings, getting up to date info, giving your opinion, going to task force meeting at WH or elsewhere.
Are you using the same "DNA platform" you showed us in the Zika story to build a potential vaccine for COVID-19? Or is it another approach?
Will you be meeting with any patients who are currently infected? Bringing any patients to the NIH for care/evaluation?

Let us know when you can talk.
Denise



Denise Schrier Cetta
Producer, CBS News, 60 Minutes
Cell: (b) (6)

From: (b) (6)
Sent: Mon, 2 Mar 2020 09:20:56 -0500
To: Shlomchik, Mark Jay
Subject: Re: Is this true?

I have been very explicit in stating publicly that I am not being muzzled or censored. I say exactly what I want to say based on scientific evidence, I have stated this on multiple TV programs over the past few days including at a major press conference with many, many reporters present including several TV cameras. I could not possibly be more public about this. No censor. No muzzle. Free to speak out.

On Mar 2, 2020, at 9:11 AM, Shlomchik, Mark Jay
<MSHLOMCH@pitt.edu>wrote:

OK, well that is good to know. It has been reported by many outlets including the NYT. So if not true I think it is critically important for you to say so publicly and show that it is not the case. It is critical, critical that we all have faith in the science and medical leadership. Your personal integrity is at stake here in the community and the world, and is a proxy for the integrity of science and medicine.

According to one house member, the following:

Garamendi told MSNBC's Hallie Jackson that Anthony Fauci was scheduled to do all five major Sunday talk shows, but says Fauci canceled the appearances after Vice President Pence took over the administration's response to the disease.

Trump on Wednesday named Pence as the official overseeing the government's response.

"I can repeat what he said, he said, 'I was not muzzled. However, I was to go on the Sunday talk shows five of them. The vice president's office then took over the control of this situation, and told me to stand down, not to do those shows,'" Garamendi said, quoting Fauci.

We cannot mince words about this or have nuances. If you were told not to appear on Sunday talk shows, then a reasonable person would have to assume your speech indeed is being controlled. Whether you call it "muzzled" or censored is a matter of semantics. Is it factual that you were told/asked not to appear on these shows as had been scheduled?

I hope you understand my reason for and level of concern. I am certain it is shared by many of your colleagues and citizens.

Best,
Mark

Mark Shlomchik, MD, PhD
UPMC Endowed and Distinguished Professor of Immunology
Chair, Department of Immunology
University of Pittsburgh School of Medicine

W1052 Biomedical Science Tower
200 Lothrop St
Pittsburgh, PA 15261
Phone: (b) (6)
Fax: 412-383-8098

(b) (6)
<https://www.immunology.pitt.edu>
<http://immunology.pitt.edu/person/mark-jay-shlomchik-md-phd>

Check out our gene targeting and flow cores: <http://immunology.pitt.edu/departments-resources>

On Mar 2, 2020, at 9:03 AM, Fauci, Anthony (NIH/NIAID) [E]
(b) (6)>wrote:

The story is not true. I am not being muzzled or censored.

On Mar 2, 2020, at 8:51 AM, Shlomchik, Mark Jay
<MSHLOMCH@pitt.edu>wrote:

Dear Tony,
Is the information in this article true?
<https://www.businessinsider.com/who-is-anthony-fauci-speech-controlled-by-trump-coronavirus-2020-2>
If it is, I think that—in the interests of public health and the integrity of science in the US—you must not acquiesce but instead resign and speak out.
If it is not true, then please refute it and set the record straight.
Sincerely,

Mark Shlomchik, MD, PhD
UPMC Endowed and Distinguished Professor of Immunology
Chair, Department of Immunology
University of Pittsburgh School of Medicine

W1052 Biomedical Science Tower
200 Lothrop St
Pittsburgh, PA 15261
Phone: 412-648-8771
Fax: 412-383-8098

mshlomch@pitt.edu
<https://www.immunology.pitt.edu>
<http://immunology.pitt.edu/person/mark-jay-shlomchik-md-phd>

Check out our gene targeting and flow
cores: <http://immunology.pitt.edu/departments-resources>

From: (b) (6)
Sent: Mon, 2 Mar 2020 09:10:54 -0500
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: lay info for people who are at risk for COVID-19
Attachments: Wuhan Coronavirus for Mama.20020301.pdf, ATT00001.htm

Please take a look at this and respond.

Begin forwarded message:

From: Cynthia Bristow <(b) (6)>
Date: March 1, 2020 at 10:12:22 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Subject: lay info for people who are at risk for COVID-19

Dear Tony,

I would like to respectfully ask if someone in your Institute could kindly review the attached précis regarding the current COVID-19 situation and recommend any revisions prior to my disseminating this to my at risk family members including (b) (6) and others in retirement communities who are concerned.

I appreciate that this would not be an official endorsement by you. I am only asking if there is anything that you or others think I could add or subtract from this précis to give solace to those who are in need of knowledge and comfort.

Thank you kindly for your attention to this matter.

Best wishes,

Cynthia L. Bristow, PhD
Chief Executive Officer
Alpha-1 Biologics
25 Health Sciences Drive, Suite 110
Stony Brook, NY 11790-3383
Office (b) (6)
Cell phone: (b) (6)
(b) (6)
www.alpha1biologics.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 2 Mar 2020 10:43:27 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Subject: FW: GPMB: MESSAGE ON BEHALF OF THE CO-CHAIRS: UPDATE: CONFIRMING 4 MARCH TELECONFERENCE
Attachments: Agenda Board telcon 4 Mar Fnl.pdf, Local_Access_en.pdf

FYI

From: Amelie RIOUX (b) (6)>
Sent: Monday, March 2, 2020 5:29 AM
To: Dzau, Victor J. <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Fore Henrietta (b) (6); Gao Fu (b) (6); Gashumba Diane <(b) (6)>; Ilona Kickbusch (b) (6)>; Suzuki Yasuhiro (b) (6); Vega Morales Jeanette (b) (6); VijayRaghavan Krishnaswamy (b) (6); Skvortsova Veronika (b) (6)
Cc: Gro Brundtland (b) (6)>; As Sy <(b) (6)>; Elhadj SY (b) (6); Tore Godal (b) (6)>; Godal, Tore <(b) (6)>; SCHWARTLANDER, Bernhard F. (b) (6); RYAN, Michael J. <(b) (6)>; Pate Muhamed (b) (6); Kanarek, Morgan (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); 'Sheila Austria' (b) (6); Teresa Miller de Vega (b) (6)>; Marston, Hilary (NIH/NIAID) [E] (b) (6); Steven T. Smith (b) (6); Zacharie Gahungu (b) (6); Toomas Palu (b) (6)
Subject: RE: GPMB: MESSAGE ON BEHALF OF THE CO-CHAIRS: UPDATE: CONFIRMING 4 MARCH TELECONFERENCE

Dear Board members,

We are confirming the Board teleconference on **Wednesday, 4 March at 14:00 Geneva time.**

Please find attached the agenda (also copied below) and the call-in numbers. The Access code is (b) (4)

Please let us know if you have any questions.

Thank you very much,

Amélie Rioux
On behalf of the Co-Chairs

Participant access



Access via [Web](#)



Optional dial-in numbers
international

+41 58 262 07 22 (English) +41 58
262 07 44 (Italiano) +41 58 262
07 11 (Deutsch) +41 58 262 07 33
(Français)

[Local Access](#)

Global Preparedness Monitoring Board Teleconference

4 March 2020, 14:00-15:00 CET

Agenda

1. Welcome and Roll call
2. Updates and stock taking on the COVID-19 outbreak
 - Update from George Fu Gao (TBC)
 - Update and Proposal from Jeremy Farrar
3. Discussion: Actions from the Board on the COVID-19 outbreak (30 minutes)
4. Adjourn

From: Amelie RIOUX

Sent: Tuesday, 25 February 2020 10:18

To: Dzau, Victor J. (b) (6);

Anthony Fauci (b) (6); Fore Henrietta <(b) (6)>; Gao Fu

(b) (6); Gashumba Diane (b) (6); Ilona Kickbusch

(b) (6); Suzuki Yasuhiro (b) (6);

(b) (6); Vega Morales Jeanette (b) (6); VijayRaghavan

Krishnaswamy (b) (6); Skvortsova Veronika (b) (6)

Cc: Gro Brundtland (b) (6); As Sy <(b) (6)>; Elhadj SY

(b) (6); Tore Godal <(b) (6)>; Godal, Tore <(b) (6)>;

(b) (6); SCHWARTLANDER, Bernhard F. <(b) (6)>; RYAN,

Michael J. (b) (6); Pate Muhamed <(b) (6)>; Kanarek, Morgan

[REDACTED] (b) (6)
[REDACTED] 'Sheila
Austria' < [REDACTED] (b) (6);
Teresa Miller de Vega < [REDACTED] (b) (6); 'Marston Hilary' [REDACTED] (b) (6)
[REDACTED]
[REDACTED] Zacharie Gahungu
[REDACTED] (b) (6)
[REDACTED]
[REDACTED]; Toomas Palu
< [REDACTED] (b) (6)

Subject: GPMB: MESSAGE ON BEHALF OF THE CO-CHAIRS: UPDATE

MESSAGE ON BEHALF OF THE GPMB CO-CHAIRS DR BRUNDTLAND AND MR SY

Dear Board members,

Thank you to those of you who joined the call on Thursday on short notice.

In light of our discussion, we would like to update you on a few matters:

[REDACTED] (b) (4)

- **Coronavirus outbreak.** We have asked Jeremy Farrar to act as the Board's focal point on the COVID-19 outbreak, to represent and advise the Board on the science of the outbreak and the financing of the response. We thank Jeremy for agreeing to take on this role.
- **Follow-up Board teleconference call.** Since many of you were unable to attend Thursday's call, we wish to propose to hold a follow-up Board teleconference call on **4 March at 14:00 Geneva time**. The purpose of the call will be to discuss the coronavirus outbreak, including Jeremy's proposal for Board action on financing. We would appreciate if you could confirm your participation to Amélie Rioux [REDACTED] (b) (6)). A more detailed agenda and call-in details will be shared shortly.
- **In-person Board meeting.** We wish to confirm that the next in-person Board meeting will take place **Tuesday-Wednesday, 5-6 May 2020, in Geneva**. The meeting will be an important opportunity to further discuss strategic issues as well as a draft of the annual report. We will communicate further on logistical details.

As always, thank you for your support and continued engagement.

With kind regards,

Gro and As

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 23:25:39 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Cc: Marston, Hilary (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: event rundown for 3/2 webcast event

There is no attachment with this e-mail

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lerner, Andrea (NIH/NIAID) [E] (b) (6)>
Sent: Sunday, March 1, 2020 6:01 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Marston, Hilary (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: Re: event rundown for 3/2 webcast event

Sending this again as it is for tomorrow.

Sent from my iPhone

On Feb 28, 2020, at 9:10 PM, Lerner, Andrea (NIH/NIAID) [E] (b) (6) wrote:

Dear Dr. Fauci (and Hilary, if you end up doing this event as ASF's back-up),

I've attached an "event rundown" for the Harvard Forum Webcast, which is scheduled from 11:40-1pm on Monday 3/2—a moderated panel discussion. This is a document prepared by the event organizers outlining the run of show, noting what questions the moderator will pose, and some suggested points the organizers thought you might touch on in your answers.

Although the organizers prepared this document following a planning call, they have made it clear that the "talking points" in this document are of course not a script. I have taken their document and highlighted where you appear. I have also added some comments. Let me know what you think. There are no slides for this event.

Let me know if you would like to discuss further over the weekend or if you'd like anything for preparation.

Sincerely,

Andrea

Andrea Lerner, MD
Medical Officer
Office of the Director
NIAID/NIH
31 Center Drive, Room 7A10A
Bethesda, MD 20892
(b) (6) cell

<2020.3.2-Coronavirus-rundown_tony_AL highlights.docx>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 22:53:00 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Proposal to Mitigate Spread of COVID-19
Attachments: Urgent Proposal to Mitigate Spread Fauci.pdf, HCQ, A Modest Proposal for Mitigating COVID-19 2.0.pdf

Please take a look and do what you feel is appropriate.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Alexander Morden MD (b) (6) >
Sent: Sunday, March 1, 2020 2:36 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Proposal to Mitigate Spread of COVID-19

Enclosed is an article I have submitted which may offer an immediate strategy to help infection control in the general public (and possibly in Oregon & California).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 22:52:21 +0000
To: Tsang, John (NIH/NIAID) [E]
Cc: (b) (6); Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: personal Immune baseline and its impact on infection and vaccine responses

John:

Thanks for your note. I am copying Cliff Lane here since he and his team is involved in a clinical protocol with COVID-19 patients. He may be able to point you in the right direction.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Tsang, John (NIH/NIAID) [E] (b) (6) >
Sent: Sunday, March 1, 2020 2:46 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: personal Immune baseline and its impact on infection and vaccine responses

Dear Dr. Fauci,

Hope you are doing well despite the rapidly evolving situation with COVID-19.

I wanted to send you a paper we just published last week that you might find relevant – please find attached and a NIAID piece below.

<https://www.niaid.nih.gov/news-events/immune-system-status-predicts-future-responses>

This paper asks the question of why do individuals mount variable immune responses to vaccines, infections, and diseases. This extends from our earlier work on baseline predictors of influenza vaccination responses that you highlighted as a NIAID Advance in 2014. A key message is that genetics is often unlikely the answer, but the status of the immune system before the perturbation may offer clues – here we identified such an immune cell circuit involving pDCs-Type I IFNs prior to perturbation in humans and found that its status can predict vaccination and lupus disease activities and is temporally stable within individuals for months.

(b) (5)

Many thanks!

Best wishes,
John.

John Tsang, PhD, Senior Investigator | Chief, Multiscale Systems Biology Section, Laboratory of Immune System Biology | Co-Director, Center for Human Immunology (CHI) | National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) | email: (b) (6) | office: (b) (6) | cell: (b) (6) | web: [tsang lab](#) | address: (b) (6) 4 Memorial Drive, Bethesda, MD, 20892 USA

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Date: Wednesday, December 19, 2018 at 9:43 PM
To: "Tsang, John (NIH/NIAID) [E]" (b) (6)
Subject: Congratulations

John:

Congratulations on being granted tenure by the NIH Central Tenure Committee. Well-deserved! Keep up your terrific work.

Best regards,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 22:50:11 +0000
To: NIAID OD AM
Subject: FW: Outreach from STAT

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Berke, Rick <Rick.Berke@statnews.com>
Sent: Sunday, March 1, 2020 10:10 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Outreach from STAT

Tony,

I know you're swamped but I'm wondering if we could arrange for you this week to take questions from our readers about coronavirus. All of our coronavirus coverage is in front of STAT's paywall and we'd see your contribution as an enormous public service.

We would solicit questions for a "live chat" from readers -- and you could pick and choose which ones you want to answer -- and write most of them in advance.

Among other leading figures, we've done this format twice with Nobel winners and it's quite popular. <https://www.statnews.com/events/stat-live-chat-chat-with-a-2019-nobel-winning-scientist/>

With Helen Branswell, Sharon Begley, Matt Herper, and our whole team, we pride ourselves on covering the coronavirus in the most authoritative and fair-minded way. We've developed a tremendous audience for this coverage. <https://www.statnews.com/tag/coronavirus/>

Our readers are fairly sophisticated on health and medicine, and we're looking to focus on the health aspects, not the White House politics.

In addition, I'd be grateful if you'd consider writing another First Opinion for us, maybe on lessons you've learned regarding other outbreaks and how that might be relevant with coronavirus -- or whatever you'd like.

Your voice of course is very important and authoritative and we'd be grateful to have it again in STAT.

All best,

Rick

--

Rick Berke Co-founder & Executive Editor O: (617) 929-7056 M: (b) (6) @rickberke

STAT Reporting from the frontiers of health and
medicine @statnews statnews.com facebook.com/statnews

[SUBSCRIBE TO STAT PLUS](#) for an all-access pass to exclusive stories. [SIGN UP HERE](#) for free newsletters with the latest in health, biopharma, and science coverage.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 22:47:57 +0000
To: Jeffrey Sachs
Cc: Conrad, Patricia (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]
Subject: RE: Might we speak briefly about the coronavirus vaccine development?

Jeff:

Thanks for the note. Happy to chat. Please give my office a call tomorrow AM

(b) (6) to set up a time when we can chat by phone.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeffrey Sachs (b) (6)
Sent: Sunday, March 1, 2020 2:19 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Might we speak briefly about the coronavirus vaccine development?

Dear Tony,

Thanks as always for your leadership.

Déjà vu of our highly productive discussions 20 years ago!

Jeff

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 22:46:11 +0000
To: pascal goldschmidt
Cc: Sara Sigel; NIAID OD AM
Subject: RE: [REDACTED] (b) (6)

Thanks, Pascal. [REDACTED] (b) (6)

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: pascal goldschmidt [REDACTED] (b) (6) >
Sent: Friday, February 28, 2020 9:00 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Cc: Sara Sigel [REDACTED] (b) (6) >
Subject: [REDACTED] (b) (6)

Greetings Tony,
I know how incredibly busy you are with the coronavirus challenge.
I admire so much your cool and effectiveness in the middle of a public health hurricane.

[REDACTED] (b) (6)

With warmest regards,
Pascal

Pascal J. Goldschmidt, M.D., Fellow A.C.C., Fellow A.H.A.
President and CEO, Alzady International, LLC.
President and CEO, American Healthcare System Ltd.
Dean Emeritus, Professor of Medicine Emeritus
University of Miami Miller School of Medicine USA



AMERICAN HEALTHCARE SYSTEM
European Care Global & Alzady International

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 22:44:16 +0000
To: Silverberg, Kristen
Subject: RE: question from BRT

Kristen:

Thanks for the note. Would your companies be able to effectively advocate for improved health care systems in low and middle income countries?

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Silverberg, Kristen <KSilverberg@brt.org>
Sent: Thursday, February 27, 2020 11:40 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: question from BRT

Dr. Fauci,

I hope you are well.

Last February, I moved to Business Roundtable, which represents CEOs of large U.S. companies. Josh is the BRT CEO, and it's been great to work with him again.

We wanted to check with you on something quickly. Traditionally, BRT has not weighed in on global health security policy, but COVID-19 has served as a reminder that global companies need to be strong advocates for global public health and security. If you had your choice, what would you want to see our companies advocating for, specifically?

No worries at all if you don't have time to respond. We fully appreciate how important your time is.

Best,

Kristen

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 22:32:44 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: ARB therapy in Covid-19 infection

Please respond.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Tom Leopold (b) (6) >
Sent: Sunday, March 1, 2020 8:48 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: ARB therapy in Covid-19 infection

Thank you for responding to my email yesterday about the possibility of ARB therapy in treatment of coronavirus infection. I realize that your research is ongoing. Would you anticipate, however, that the ARB with the most potential role in preventing virus attachment would be the one that has the greatest affinity for the AT2 receptor? Am I correct that losartan is the ARB with the lower receptor (AT1 vs AT2) selectivity and might logically be the most promising ARB to investigate? Thanks. Dr Thomas Leopold

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 22:31:42 +0000
To: JP Hanke
Subject: RE: Coronavirus

Thanks for the note. CDC is already preparing similar public service announcements, which I am sure will find its way to YouTube

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: JP Hanke (b) (6)>
Sent: Sunday, March 1, 2020 5:30 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Coronavirus

Dear Dr Fauci,

I heard this idea on a radio interview with Laurie Garrett this morning – how about getting your committee (or one of the government health agencies) to produce a series of short YouTube videos on how to combat the coronavirus: such things as proper handwashing technique, when to wear a mask, how to ride the subway safely, etc, etc. I think this would be an excellent way to reach the public in the digital age (provided that Mike Pence doesn't try to turn them into campaign ads for Donald Trump), and I strongly urge you to give the strategy serious consideration. I know I would watch them and I'm sure millions of other people would too.

Sincerely,

Paul Hanke
(b) (6) VT

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 22:29:32 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: RE: Report from 'HHS COVID-19 Situation Update' call today

Thanks. Very helpful.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lerner, Andrea (NIH/NIAID) [E] (b) (6)
Sent: Sunday, March 1, 2020 4:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Marston, Hilary (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Doepel, Laurie (NIH/NIAID) [E] (b) (6); Eisinger, Robert (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: Report from 'HHS COVID-19 Situation Update' call today

Passing on some main points from of an "HHS COVID-19 Situation Update" call that took place at 3pm today, FYI.

- The meat of the call was a situation update by Nancy Messonnier (with epi numbers below).
- She noted that the national strategy is still containment.
- However, since there are some US locales with evidence of community spread, there is consideration if some "community level action" may be appropriate, with a move towards a blend of mitigation/containment in certain areas.

Global epi update:

China lab/clinically confirmed cases: 79,824 (+573 in last 24h)
China deaths: 2,870

61 international locations with 7,102 cases so far (Armenia, Ecuador, Ireland, Luxembourg new in last 24h)

107 international deaths

Widespread community transmission occurring in:
China, Iran, Italy, Japan, S. Korea

US epi update:

63 confirmed US cases (16 diagnosed here, 3 in Hubei repatriates, 44 in Diamond princess repatriates)
11 presumptive cases (meaning they tested + at state public health labs, but confirmatory test at CDC is pending)

663 Persons Under Investigation

Andrea Lerner, MD
Medical Officer
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health
31 Center Drive, Room 7A10A
Bethesda, MD 20892

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 22:22:15 +0000
To: Francis V. Chisari
Subject: RE: [REDACTED] (b) (6)

Given what is going on with coronavirus, I cannot guarantee that I will be able to attend the Section meeting. I will try my best.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Francis V. Chisari <fchisari@scripps.edu>
Sent: Sunday, March 1, 2020 5:19 PM
To: PAUL G AHLQUIST <ahlquist@wisc.edu>; Zhijian (James) Chen <zhijian.chen@utsouthwestern.edu>; Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6); Michael Oldstone <mbo@scripps.edu>; Eckard Wimmer <eckard.wimmer@stonybrook.edu>
Cc: Charles Rice <ricec@mail.rockefeller.edu>; Chisari, Francis <fchisari@scripps.edu>
Subject: [REDACTED] (b) (6)

Dear colleagues,

[REDACTED] (b) (6)
[REDACTED] Please let me know if you will attend the Section meeting this year and if you're willing to say a few words of support.

Best regards,

Frank

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 20:32:36 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: SARS-CoV-19

Please respond

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Peter Panus (b) (6) >
Sent: Sunday, March 1, 2020 10:15 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: SARS-CoV-19

Although outside my main area of expertise I have been keeping up with CoVid-19 discussion. One item I have noted is that the disease appears to have a lower incidence in children. The other is that the virus appears to at least in part attach through cell membrane angiotensin II type 1 receptors. Is the lower incidence of the disease in children possibly due to this cohort having a higher proportion of angiotensin II type 2 receptors compared to the adult cohort?

Sincerely,
Peter C. Panus PhD, PT
Professor Emeritus
Pharmaceutical Sciences Dept.
Gatton on College of Pharmacy

Sent from [Mail](#) for Windows 10

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 20:23:14 +0000
To: NIAID OD AM
Subject: FW: Invitation to speak to the National Economists Club

Let us discuss. Unlikely I will have time depending on how things evolve.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Sanchez, Emily <Emily_Sanchez@americanchemistry.com>
Sent: Sunday, March 1, 2020 10:35 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Doepel, Laurie (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E]
(b) (6)
Subject: Invitation to speak to the National Economists Club

Dear Dr. Fauci,

My name is Emily Sanchez and I am an economist at the American Chemistry Council. I am reaching out to you in my capacity as President of the National Economists Club (NEC), which is an organization of over 1000 government and private sector economists based in DC. The NEC holds weekly luncheon events which feature notable experts and economists in Washington.

Increasingly, economists are being asked to assess the economic impacts around the incidence and spread of the corona virus as well as the impact of reduced economic activity due to behavioral changes (e.g. people not leaving their homes to work or shop, supply chain disruptions, etc.). As economists are tasked in assessments, scenario planning and communicating their estimates, accuracy around their assumptions and understanding of the corona virus and Covid-19 is imperative. We are incredibly appreciate of the important work and research that the National Institute of Allergy and Infectious Diseases provides and we are wondering if you would be willing to speak at one of our luncheons about Covid-19 and the latest developments.

Do you think you might have time in your schedule to speak to the National Economist Club this month? We would love to have you speak during the week of March 16-20.

Our luncheons typically take place at the Chinatown Garden Restaurant, 618 H St. NW, with lunch at noon and your presentation from 12:30 p.m. til 1:30 p.m. Talks are normally on the record and open to the press, unless you request otherwise.

Thank you for your consideration.

Best regards,

Emily

Emily Sanchez | American Chemistry Council
Director, Economics & Data Analytics
Economics & Statistics Department
emily_sanchez@americanchemistry.com
700 2nd Street, NE | Washington, DC | 20002
O: (202) 249-6183
www.americanchemistry.com

+++++ This message may contain confidential information and is intended only for the individual named. If you are not the named addressee do not disseminate, distribute or copy this email. Please notify the sender immediately by email if you have received this email by mistake and delete this email from your system. E-mail transmission cannot be guaranteed to be secure or error-free as information could be intercepted, corrupted, lost, destroyed, arrive late or incomplete, or contain viruses. The sender therefore does not accept liability for any errors or omissions in the contents of this message which arise as a result of email transmission. American Chemistry Council, 700 – 2nd Street NE, Washington, DC 20002, www.americanchemistry.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 20:17:45 +0000
To: Thomas Murray
Subject: RE: Have you been muzzled?

Mr. Murray:

Thanks for the note. Please stay silent since I have not been muzzled. I will be on multiple TV shows tomorrow and was on FOX this AM. No one is censoring me.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Thomas Murray (b) (6)
Sent: Sunday, March 1, 2020 11:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Have you been muzzled?

Reference: I'm the nuclear/aerospace engineer who subsequently obtained an MPH at the University of Washington since I was working disease transmission within commercial airlines when I was a Boeing employee. And, my undergraduate degree is in chemistry with a minor in microbiology. I've engaged you previously.

Hi Dr. Fauci,

You've kindly allowed me to engage you, and I'll take advantage of that kindness.

The news media is reporting that the White House has muzzled you. Is that true? Before entering the science/engineering world, I was a newspaper city editor in Southern CA (in the 1970s). Therefore, I get and understand the idea of coordinated messaging. (Plus, due to my media background, Boeing used me to help executives prepare for media engagements on challenging topics.) However, if it's true that you are muzzled, then I will initiate a "campaign" with my congressional representatives and the media to

stop that action. (

(b) (6)

However, ***before I initiate such a campaign, will my actions possibly cause you harm?*** I recognize that you may have backchannels that I may disrupt by engaging.

As I related previously, I trust you since you focus on facts and data, you provide context for the information that you share, and you avoid emotion in your engagements. I think that residents of the US (and, frankly the world) need your insights regarding COVID-19. Plus, you're one of the world leaders with regard to infectious diseases. And, if you don't know, you know whom to ask.

Please let me know if I should stay silent or become noisy.

Thank you. And, thanks for your service to the US and the world during this very interesting time.

Thomas Murray

Sent from my iPad

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 20:13:01 +0000
To: D.A. Sonneborn
Subject: RE: News about SARS-CoV-2 ad Covid-19

You can trust CDC.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: D.A. Sonneborn (b) (6) >
Sent: Sunday, March 1, 2020 3:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: News about SARS-CoV-2 ad Covid-19

Dear Dr. Fauci,

It would be good to know if you still believe Americans can trust CDC's public-facing authority or whether we'd best look to WHO for reliable information about the virus, the disease and any new mutations which might arise. Mike Pence does not have appropriate credentials.

Sincerely,

D.A. Sonneborn, Ph.D.
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 20:09:38 +0000
To: Corey MD, Larry
Subject: RE: Mike Pence ?

I am not going to CROI. I am sending in a taped short discussion of NIH research response to COVID-19

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Corey MD, Larry (b) (6) >
Sent: Sunday, March 1, 2020 3:00 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Mike Pence ?

Ah the great communicator of infectious disease epidemiology and pathogenesis.
On way back from (b) (6). News travels fast among the aficionados.

We need a POW wow with John and Carl on the path to (b) (4) I will
schedule. You coming to CROI ? If not I could pop down to you.
Excuse the I phone typing. On the runway leaving (b) (6)

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 19:49:51 +0000
To: Jon LaPook
Subject: RE: My "CBS Sunday Morning" 5-minutes shpiel on coronavirus and COVID-19

Outstanding!!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Jon LaPook (b) (6)
Sent: Sunday, March 1, 2020 11:27 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: My "CBS Sunday Morning" 5-minutes shpiel on coronavirus and COVID-19

Tony,
Here you go. You can enjoy it in al your spare time. Hope you managed to clear your desk last night.

<https://vimeo.com/user10844306/review/394766243/cba5143d0d>

Best,
Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 19:31:54 +0000
To: Jeffrey V. Ravetch
Cc: Stelios Bournazos
Subject: RE: Fc modifications for protective anti-COVID-19 antibodies

Jeff:

Thanks for the note and the slide. Very interesting. Please send me the preprint when it becomes available.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeffrey V. Ravetch (b) (6)
Sent: Sunday, March 1, 2020 12:43 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Stelios Bournazos (b) (6)
Subject: Fc modifications for protective anti-COVID-19 antibodies

Dear Tony,

I wanted to share a very recent and surprising result we've obtained on the mechanism of antibody protection for anti-viral antibodies. We've previously shown that bNAbs to flu and HIV require FcR engagement for their in vivo potency.

Enhancing activating FcR engagement increases the potency of these antibodies by an order of magnitude, on average, and thus are significant contributors to anti-viral protection.

We'll be writing up this story shortly and would be happy to share a pre-print with you.

Sincerely,

Jeff

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 19:30:12 +0000
To: Grandi, Paola
Subject: RE: [REDACTED] (b) (6)

Dr. Grandi:

[REDACTED] (b) (6)

Best regards,
A.S. Fauci

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Grandi, Paola [REDACTED] (b) (6)
Sent: Sunday, March 1, 2020 12:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: [REDACTED] (b) (6)

Dear Dr. Fauci,

[REDACTED] (b) (6)

(b) (6)

Please let me know if you would like to discuss this further. I was a former professor at the University of Pittsburgh and now (b) (6)

(b) (6) would also be available to discuss. My cell phone is (b) (6).

Best Wishes,
Paola Grandi, PhD, M BA

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 19:22:37 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Novel Treatment for Reducing Symptoms Associated with Coronavirus (COVID-19) - "Non-Confidential"
Attachments: (0) The Science of Exulta for the Common Cold.pdf, 1) METHODS AND COMPOSITIONS TO INHIBIT SYMPTOMS ASSOCIATED WITH VIRAL UPPER RESPIRATORY TRACT INFECTIONS.pdf

Please handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jim Iversen (b) (6)
Sent: Sunday, March 1, 2020 1:53 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Jacqueline Iversen (b) (6) >
Subject: Novel Treatment for Reducing Symptoms Associated with Coronavirus (COVID-19) - "Non-Confidential"

Dear Dr. Fauci,

Sen-Jam Pharmaceutical has a product under development to reduce the symptoms associated with Upper Respiratory Infection (URI). We believe it could provide relief to a large number of people during the COVID-19 pandemic. Our product SJP-002 is a combination of an NSAID and a non-sedating antihistamine and does not include a decongestant. Removing the decongestant makes our product ideal for treating the symptoms associated with COVID-19 in patients with cardiac conditions who cannot tolerate taking a decongestant.

What makes our product novel is that it can be administered early in the treatment phase, thereby reducing the excessive accumulation of inflammation, which typically results in head congestion, pulmonary congestion, coughing, & sneezing. Our experience has shown that at the 1st signs of experiencing symptoms of URI an individual's symptoms can be drastically reduced after taking our

product twice a day for 3 days. The dramatic reduction in inflammation has the potential to reduce the spreading of the virus by means of cough, sneezing, and spreading of germs through contact. Currently, when individuals experience the start of a URI, there is little effective intervention available to change the course of the infection. Individuals delay administering pharmaceutical agents, until their congestion becomes intolerable and excessive.

Attached is a copy of our early research and a copy of our non-provisional patent. I share this information with the hope of providing some background for an immediately accessible, safe treatment, alternative to slow the pace and impact of the pandemic.

Let me know if we can be of any additional help?

Thanks and all the best,

Jim



Jim Iversen
CEO
Sen-Jam Pharmaceutical
223 Wall St., #130
Huntington, NY 11743
(b) (6)
(b) (6)

sen-jam.com

Linkedin: [linkedin.com/in/jimiversen](https://www.linkedin.com/in/jimiversen)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 19:21:51 +0000
To: Lawrence O. Brown, Ph.D.
Subject: RE: Info re Covid-19

I can assure you that I am not being censored.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lawrence O. Brown, Ph.D. (b) (6)
Sent: Sunday, March 1, 2020 1:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Info re Covid-19

Dear Dr. Fauci,

Those of us who seek factual, scientifically-based information to the highest degree that it is possible to obtain it will remain hungry and on the alert for whatever complete, up-to-the-moment information that you may have as humanity proceeds deeper into the Covid-19 potential pandemic. We have trusted you through several previous epidemics to provide such information. Therefore, I know I'm not alone in being appalled and frightened by President Trump wanting you to issue information about the current crises only after it has been cleared by his administration. In his office as President, Donald Trump may be *de facto*, Commander-in Chief. There is nothing about his office that confers Expert-in-Chief on him, and what he chooses to say or not say about Covid-19 and its spread should not be treated by the media or anyone as information that is trustworthy for being factual and scientifically-based information to the highest degree that it is possible to obtain.

I hope that you will find it in yourself and in the mission of your office to publicly assure the American public in no uncertain terms that you will not be censored, and that you will honor the public's trust to continue to provide real, research-based information about the frightening health nightmare that all humans are facing in a way that distinguishes us from China's government in its disgraceful and destructive efforts to muzzle those experts who might be able to save lives by merely speaking truth to a population whose health depends on having fact-based, totally un-massaged knowledge as soon as it is available.

It is with our lives, the lives of our families, and the lives that make up our nation that we are counting on you.

Sincerely yours,
Lawrence O. Brown, Ph.D.
Clinical Psychologist/Psychoanalyst

(b) (6)

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 16:25:41 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Mascola, John (NIH/VRC) [E]; Lerner, Andrea (NIH/NIAID) [E]
Subject: RE: Background briefer
Attachments: 20200229_VRCModerna mRNA candidate briefer - with Fauci edits.docx

Here it is.

From: Marston, Hilary (NIH/NIAID) [E] (b) (6) >
Sent: Sunday, March 1, 2020 10:09 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Mascola, John (NIH/VRC) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] (b) (6)
Subject: Background briefer

ASF:

Attached please find a proposed background briefer for the visit to the VRC (big thanks to John, Barney, Kizzmekia, the rest of their team and Andrea and Greg). We focused on the VRC itself and the mRNA candidate, figuring that the VPOTUS office would have a tick tock etc. VRC also prepared talking points for the round table should those be requested (I have those if you'd like to see them now, but so far the White House has not asked for this).

Available by cell. (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 15:48:15 +0000
To: Sharon Eblen
Subject: RE: Thank You

Sharon:

Many thanks for your kind words.

Best regards,

Tony

From: Sharon Eblen (b) (6) >
Sent: Sunday, March 1, 2020 10:45 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Thank You

Good Morning Dr. Fauci,

I just wanted to say a quick thank you for your recent words to the public. I am a high school physics teacher, and I recognize the importance and the challenges of conveying scientifically accurate information to the public. I watched you speak in the two recent press conferences held by the President, and I appreciated the way in which you communicated difficult information regarding the novel coronavirus. Please keep up the good work during what I'm sure is a very stressful time for you and everyone at the NIH.

Sincerely,

Sharon M. Eblen

From: (b) (6)
Sent: Sun, 1 Mar 2020 10:34:15 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: NPR interview request: Dr. Fauci

Sent from my iPhone

Begin forwarded message:

From: HJ Mai <HMai@npr.org>
Date: March 1, 2020 at 10:29:41 AM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Cc: "Billet, Courtney (NIH/NIAID) [E]" (b) (6)>
Subject: NPR interview request: Dr. Fauci

Dear Dr. Fauci,

I'm sorry to bother you on a Sunday, but with the first coronavirus death of a U.S. patient in Washington state, we are wondering if you would be available for a live interview tomorrow morning our show.

We would like to talk to you about the significance of the death in Washington and what states can/must do to prevent a widespread outbreak.

Kind regards,
HJ

From: HJ Mai <HMai@npr.org>
Sent: Friday, February 28, 2020 6:54 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6)>
Subject: Re: Confirmation of report

Thank you for your reply Dr. Fauci.

Sent from my iPhone

On Feb 27, 2020, at 10:57 PM, Fauci, Anthony (NIH/NIAID) [E]
(b) (6)>wrote:

This is really not true. It was taken vey much out of context.

From: HJ Mai <HMai@npr.org>

Sent: Thursday, February 27, 2020 2:09 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >

Subject: Confirmation of report

Dear Dr. Fauci,

This is HJ from NPR again. I was wondering if you could confirm a NYT report that says the White House has instructed you not to say anything about the coronavirus outbreak without prior approval.

Kind regards,
HJ

<image001.jpg>

| HJ Mai | Editor, Morning Edition | hmai@npr.org | (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 12:39:59 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: VIP visit

I hope that someone in Building 1 is letting the Secretary's office know that the VP and POTUS are coming to NIH.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Sent: Sunday, March 1, 2020 6:58 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6)
Subject: Fwd: VIP visit

See below. This is just a rough draft (b) (6)

(b) (6)

(b) (6)

Sent from my iPhone

Begin forwarded message:

From: "Blackburn, Amy (NIH/OD) [E]" (b) (6) >
Date: February 29, 2020 at 8:16:21 PM EST
To: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6) >, "Burklow, John (NIH/OD) [E]" (b) (6) >, "Folkers, Greg (NIH/NIAID) [E]" (b) (6)
Cc: "Daucher, Marybeth (NIH/NIAID) [E]" (b) (6) >
Subject: RE: VIP visit

Hi Patty,

This is just my really rough draft of an agenda. (b) (6)

(b) (6)

Just let me know the timing of things.

-----Original Message-----

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Sent: Saturday, February 29, 2020 7:53 PM
To: Burklow, John (NIH/OD) [E] (b) (6); Blackburn, Amy (NIH/OD) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6)
Cc: Daucher, Marybeth (NIH/NIAID) [E] (b) (6)
Subject: VIP visit

Per Dr Fauci- for the round table - he is thinking that [REDACTED] (b) (5)

[REDACTED]
[REDACTED]. This will get more fleshed out tomorrow.

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 12:12:35 +0000
To: Bob Franken
Subject: RE: I'd like to talk

Bob:

Thanks for the note. I look forward to seeing you again soon.
Best regards,
Tony

-----Original Message-----

From: Bob Franken <(b) (6)>
Sent: Sunday, March 1, 2020 7:11 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Re: I'd like to talk

Tony,

First of all, thank you for getting back to me, in spite of the fact that you are so busy.
Secondly, it's nice to know they're not muzzled, since you are so incredibly good at making science speak so easy to understand for dummies like me.

Once the dust settles, I'd live to see you, to pay attention to our long friendship. Meanwhile, best of luck.

Bob

Bob Franken
www.bobfranken.tv

> On Mar 1, 2020, at 6:53 AM, Fauci, Anthony (NIH/NIAID) [E] <(b) (6)> wrote:

>

> Bob:

> Thanks for the note. I hope that all is well with you. I have never been given orders to get approval from the VP's people to speak publicly about coronavirus. Ever since I have been doing this since the Reagan administration, whenever a member of the Executive Branch such as me gets invited and goes on National TV such as the Sunday Talk shows, there is always a routine process of clearing it with your department (in this case HHS) who then clears it with the White House. This is routine and has been true for the Reagan, Bush '41, Clinton, Bush'43, Obama, and now the Trump administration. It is merely a formality so that they know what is coming out from the executive branch. I have always gotten clearance with very few exceptions over the past 35 years (usually because they do not want you on TV at the same time that the President is making an important announcement). I have never been muzzled or told that I could not speak out publicly about anything during this administration.

> I hope that this is helpful.

> Best regards,

> Tony

>

> -----Original Message-----

> From: Bob Franken <(b) (6)>

> Sent: Saturday, February 29, 2020 6:12 AM

> To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>

> Subject: I'd like to talk

>

> Tony,

>

> I know you're busy, but I'd like to have a brief conversation with you.

> I'm now a syndicated political columnist, writing for King Features. You don't be surprised to hear that my column is described as "an extended middle finger pointed in all directions".

>

> Notwithstanding that, what I'd like to discuss with you is any orders you've received to get approval from the Vice President's people to speak publicly about the coronavirus.

>

> It can be on any basis you choose, on the record, or off. On background (knowledgeable sources), deep background (sources), whatever.

>

> May I call you?

>

> Best,

>

> Bob

>

> Bob Franken

> www.bobfranken.tv

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 12:03:24 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Connecting you two

Let us discuss.

From: Collins, Francis (NIH/OD) [E] (b) (6) >
Sent: Wednesday, February 26, 2020 7:59 AM
To: Michael Milken (mmilken@knowledgeu.com) <mmilken@knowledgeu.com>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Connecting you two

Hi Mike,

Thanks for your call on Monday evening. I've reached out to Tony Fauci and he is interested in speaking with you about how your connections with philanthropy and industry might help as we face a major challenge from coronavirus. I'm ccing Tony on this e-mail and his cell phone is (b) (6). I've also given him your coordinates.

Best, Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 12:02:07 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: VIP visit

We can discuss.

From: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Sent: Sunday, March 1, 2020 6:58 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] <(b) (6)>
Subject: Fwd: VIP visit

See below. This is just a rough draft. (b) (5)

Sent from my iPhone

Begin forwarded message:

From: "Blackburn, Amy (NIH/OD) [E]" <(b) (6)>
Date: February 29, 2020 at 8:16:21 PM EST
To: "Conrad, Patricia (NIH/NIAID) [E]" <(b) (6)>, "Burklow, John (NIH/OD) [E]" <(b) (6)>, "Folkers, Greg (NIH/NIAID) [E]" <(b) (6)>
Cc: "Daucher, Marybeth (NIH/NIAID) [E]" <(b) (6)>
Subject: RE: VIP visit

Hi Patty,

This is just my really rough draft of an agenda. (b) (5)

Just let me know the timing of things.

-----Original Message-----

From: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Sent: Saturday, February 29, 2020 7:53 PM
To: Burklow, John (NIH/OD) [E] <(b) (6)>; Blackburn, Amy (NIH/OD) [E] <(b) (6)>; Folkers, Greg (NIH/NIAID) [E] <(b) (6)>
Cc: Daucher, Marybeth (NIH/NIAID) [E] <(b) (6)>
Subject: VIP visit

Per Dr Fauci- for the round table - (b) (5),

(b) (5)

. This will get more fleshed out tomorrow.

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 12:01:19 +0000
To: Geller, Robert D.
Subject: RE: COVID-19 Questions

Bob:

Thanks for the note. I hope that all is well with you. Use an N95 if you have them available. Transmission is similar to influenza: respiratory droplets and likely a bit more as aerosol than with influenza. People can transmit even when they are asymptomatic. No approved therapies; however, we are doing clinical trials on 're-purposed' drugs such as remdesivir (Gilead), Vaccine going into phase 1 trial in about 6 weeks, but will not be ready for at least 1.5 years.

Hope that this is helpful.

Best regards,
tony

From: Geller, Robert D. <RGeller@fhn.org>
Sent: Wednesday, February 26, 2020 1:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: COVID-19 Questions

Tony

Thanks for everything you are saying and doing. I'm writing to ask for the latest. Thanks Bob.

What about general care of a patient suspected or confirmed COVID-19. N95 or surgical mask? Any news on how this disease is being transmitted? Anything new on vaccine or treatment?

This e-mail message and any attached file(s) is intended for the use of the individual or entity to which it is addressed and may contain information that is privileged and confidential. If the reader of this message is not the intended recipient or an agent or employee of the intended entity, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received the message in error, please notify the sender immediately for instructions. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 11:55:59 +0000
To: Anderson, Jennifer (NIH/NIAID) [E]
Subject: FW: Opportunity for a Research Position
Attachments: [REDACTED] (b) (6)

Please take a look and handle.

From: M. Burhan Majeed Rana <[REDACTED]> (b) (6)
Sent: Thursday, February 27, 2020 9:07 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: [REDACTED] (b) (6)

Dear Dr. Fauci,

[REDACTED] (b) (6)

Kindest regards,
Rana, Muhammad Burhan Majeed

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 04:14:20 +0000
To: Winnie Stachelberg
Subject: RE: POSTED: Thinking CAP: Dr. Anthony Fauci: The Global Fight Against HIV/AIDS

Winnie:

Thanks for your note.

Best regards,

Tony

From: Winnie Stachelberg <wstachelberg@americanprogress.org>
Sent: Thursday, February 27, 2020 8:02 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: RE: POSTED: Thinking CAP: Dr. Anthony Fauci: The Global Fight Against HIV/AIDS

Tony – sending you an email to say thanks for your steady hand at the helm in this current challenge with Coronavirus. You are such an essential part of our government’s response to this public health challenge.

Please let us know if there’s anything we can do at CAP to assist. We plan on hosting an event next week and I’ll send you details as they come together.

Again, thank you.

Winnie

From: Winnie Stachelberg
Sent: Monday, August 19, 2019 10:42 AM
To: (b) (6)
Subject: FW: POSTED: Thinking CAP: Dr. Anthony Fauci: The Global Fight Against HIV/AIDS

Tony –

Thank you so much for participating in CAP’s podcast, Thinking CAP earlier this month. We think the interview turned out very well and hope you think so, too.

Have a good rest of the month and Labor Day and I hope our paths cross again soon – either in the neighborhood or at work.

Winnie

From: Steve Bonitatibus <sbonitatibus@americanprogress.org>
Sent: Thursday, August 15, 2019 11:21 AM
To: Posted Products <postedproducts@americanprogress.org>
Cc: Kyle Epstein <kepstein@americanprogress.org>; Chris Ford <cford@americanprogress.org>; Daniella

Leger <dleger@americanprogress.org>

Subject: POSTED: Thinking CAP: Dr. Anthony Fauci: The Global Fight Against HIV/AIDS

Daniella sits down with renowned immunologist Dr. Anthony Fauci to discuss how the United States has and can continue to combat the HIV/AIDS epidemic, both domestically and abroad.

<https://www.americanprogress.org/issues/healthcare/news/2019/08/15/473666/dr-anthony-fauci-global-fight-hiv-aids/>

For decades, the HIV/AIDS epidemic has been among the most challenging global health issues to contain. Enter Dr. Anthony Fauci, immunologist and director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health. As one of the foremost experts and advocates against the HIV/AIDS epidemic, Dr. Fauci exuded optimism when talking about the progress being made in both global and domestic containment of the disease. He sat down with Daniella for an interview to discuss his work fighting HIV/AIDS and to share his thoughts on the growing, dangerous anti-vaccination movement.

Learn more about the podcast [here](#).

Daniella Gibbs Léger is the executive vice president for Communications and Strategy at the Center for American Progress. Ed Chung is the vice president for Criminal Justice Reform at the Center. Kyle Epstein is the media relations manager at the Center. Chris Ford is the broadcast coordinator at the Center.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 04:13:25 +0000
To: Howard Schatz
Subject: RE: Commiserating

Howard:

Many thanks for your note. Much appreciated.
Best regards,
Tony

From: Howard Schatz [REDACTED] (b) (6) >
Sent: Thursday, February 27, 2020 8:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: Commiserating

Tony,

Watching the spread of the Coronavirus worldwide(?), I can't help but feel for you, as well as the world's population.

It must be both challenging as well frustrating to be unable to control every important "leak" and then watching the consequences.

I would think it's also sort of exciting, while also being horrible, given this is what you've trained for most of your professional life.

And, I would think that most of your other important works need to be put on hold?

Wishing you (and all of us) the best of luck,

Howard

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 04:02:52 +0000
To: David Folkenflik
Subject: RE: Following up

I have never been inhibited from interacting with the press.

-----Original Message-----

From: David Folkenflik <DFolkenflik@npr.org>
Sent: Friday, February 28, 2020 7:36 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Following up

Dr Fauci - I cover media and flow of information to public for NPR and am also a host. (You and I once spoke years ago when I covered Johns Hopkins over a science research issue.)

You told a colleague the report you couldn't comment on Coronavirus was taken out of context. In what way?

Thank you -
D

David Folkenflik
Host and Editor, NPR's On Point
Media Correspondent, NPR News
11 W 42nd St
19th Floor
New York NY 10036
o) 212.880.3438
m) (b) (6)
e) dfolkenflik@npr.org

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 04:01:29 +0000
To: Andrew C von Eschenbach
Subject: RE: Question

Andy:

Thanks for the note. I am sure that the Chinese are looking at this, but I have not seen any data in this regard. I will try to find out if anyone is looking at this in the USA patients.

Best regards,

Tony

-----Original Message-----

From: Andrew C von Eschenbach (b) (6)
Sent: Friday, February 28, 2020 9:52 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Question

Tony

Does anyone know what the NK cell profile was like in patients who succumbed to Coronavirus? Is there a difference in immune profile between mild and severe cases?

Anyone looking at that?

Miss being there at your side in this battle Andy PS Thank you and your team for guiding the Celularity team to get it right. Also you have as always, my utmost respect for being the "good and faithful servant"

Andrew C. von Eschenbach MD
Samaritan Health Initiatives

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 03:57:44 +0000
To: Strauss, Eric M.
Subject: RE: 500k dead? (Background)

That number seems exceptionally high.

From: Strauss, Eric M. <Eric.M.Strauss@abc.com>
Sent: Friday, February 28, 2020 10:34 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: 500k dead? (Background)

Hello Dr Fauci: Hope you're holding up well. Remember to rest and hydrate!

We had a DHS person tell us epidemiology models for US show worst case scenario 98m get COVID-19 and 500k dead.

I've seen models all over the board. And Dr Jen and I are keeping our coverage on point on what we know and what we don't know.

If that a possible number for our planning? Or is that outlandish?

Thx.
- EMS

Eric M. Strauss, ABC News
Managing Editor, Medical Unit
(b) (6)
@ericMstrauss

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 03:49:57 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: coronavirus

Please take a look and handle. Thanks.

From: William H. Sherman, MD (b) (6)
Sent: Friday, February 28, 2020 11:11 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: coronavirus

William H. Sherman, M.D.
(b) (6)

Anthony Fauci, M.D.
(b) (6)

Dear Dr. Fauci:

I reviewed the publications about the last 2 coronavirus infections. Both MERS and SARS were severe, short lived problems that have not recurred. One would expect Covir-19 to follow a similar path: infect a wide group of susceptible people and then disappear, If that is so, anything that is more than six months away may not be of value—remdisivir or a vaccine. Even if remdisivir works, it will take months to produce sufficient amounts to treat this illness.

Has ribavirin been assessed for an ability to slow down the replication of this virus? We do not need to eradicate the virus. Just slowing down the rate of symptoms progression would allow time for the immune system to mount a curative response.

Ribivirin is the only approved anti-viral that may have shown some clinical benefit against similar coronavirus infections, but the reports are anecdotal and the benefit short term. It was only administered to a few patients who were already on respirator support, and most still died. If their lungs were already destroyed, eliminating the virus would not change the outcome. There were no studies of treating mild illnesses before they progressed to needing respirator support. If the 50 year old coronavirus patient described in the Lancet had been treated in first week of symptoms, before needing respiratory support, he may have survived. On autopsy, most of his lung had been destroyed.

If ribavirin has even marginal benefit, decreasing hospitalization by 10% yields an enormous savings. I do not have access to the data on this virus and the possible effects of the antivirals that have been evaluated. However, ribavirin has any effect on viral proliferation, we can write and a randomized trial of ribavirin, (b) (4)

(b) (4)

I look forward to hearing from you about the data on ribavirin against this virus and your thought on this clinical study.

Sincerely,

William H. Sherman, M.D.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 03:49:28 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: The Aspen Institute event today

Let us discuss.

From: Sabrina Malhi <smalhi@thehill.com>
Sent: Friday, February 28, 2020 11:14 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Re: The Aspen Institute event today

Hi Dr. Fauci,

The whole country is in a panic, could you write on behalf of the NIH regarding the coronavirus, please?
Your voice is very important on this topic.

Thanks,
Sabrina

On Tue, Feb 11, 2020 at 7:12 PM Fauci, Anthony (NIH/NIAID) [E] (b) (6) > wrote:

Sabrina:

Many thanks. It was nice to meet you today. I certainly will keep your offer in mind.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Sabrina Malhi <smalhi@thehill.com>
Sent: Tuesday, February 11, 2020 2:58 PM

To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>

Subject: RE: The Aspen Institute event today

Hi Dr. Fauci,

It was nice meeting you at the event regarding the coronavirus today at The Aspen Institute. Your expert voice on the virus would be great to have in our publication.

As I mentioned, I am an opinion editor at The Hill and one of the areas that I focus on is health care. Please let me know if you'd like to discuss some ideas. I look forward to hearing from you!

Best,
Sabrina

--

Best,

Sabrina Malhi | Associate Editor | [The Hill](#)

**Please note that my email address is now smalhi@thehill.com.*

--

Best,

Sabrina Malhi | Associate Editor | [The Hill](#)

**Please note that my email address is now smalhi@thehill.com.*

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 03:24:03 +0000
To: Gallin, John (OD) [E]
Cc: (b) (6)
Subject: RE: Coronavirus vaccine center

(b) (5)

From: Gallin, John (OD) [E] (b) (6) >
Sent: Friday, February 28, 2020 1:52 PM
To: Lane, Cliff (NIH/NIAID) [E] (b) (6) >; Davey, Richard (NIH/NIAID) [E] (b) (6) >
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Fwd: Coronavirus vaccine center

Cliff and Rick (and Tony if you have time)

My friend Barry Coller is (b) (4) (see below). Do you know if there is any need for this?

Thanks.

John

Sent from my iPhone

Begin forwarded message:

From: Barry Coller (b) (6) >
Date: February 27, 2020 at 10:34:24 PM EST
To: "Gallin, John (OD) [E]" (b) (6)
Cc: Barry Coller (b) (6)
Subject: Coronavirus vaccine center

John,
I suspect that this is an incredibly busy time for you and the Clinical Center.
Tony was fantastic last night. Please let him know that he is my hero!

(b) (4)

(b) (4)

If you know of any organizations or companies that are looking for sites to conduct vaccine studies, or if you would like us to collaborate with you to get studies completed more rapidly, please keep us in mind.

I am going crazy writing our (b) (4) And it just gets harder.

Best regards to (b) (6)

Barry

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 03:17:42 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Brookings Invitation

Let us discuss.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Sent: Friday, February 28, 2020 2:26 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: FW: Brookings Invitation

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: John Allen <JAllen@brookings.edu>
Sent: Friday, February 28, 2020 2:23 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Cc: Lucy Kim <LKim@brookings.edu>
Subject: Brookings Invitation

Dr. Fauci,

Greetings from the Brookings Institution. I'm writing to share the attached invitation for you to speak to our Board of Trustees at their annual dinner on Thursday, March 5 here in Washington, DC. The Brookings Board is a distinguished group of business and community leaders ... I know they would be very eager to hear your thoughts, especially on the coronavirus crisis given its spread into the U.S. If this date does not work with

your schedule, we'd be glad to welcome you to Brookings at a more convenient time.

I very much appreciate you considering our request, Dr. Fauci!

My very best,

John R. Allen
President
The Brookings Institution

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 02:58:01 +0000
To: Hodes, Richard (NIH/NIA) [E]
Cc: Casetti, Cristina (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: SASP and Coronavirus 19

Richard:

Let me refer the e-mail to Cristina Casetti who is in charge of the COVID-19 issues in our program. By this e-mail I will ask her to look into this and get back to Jim Kirkland.

Best regards,
Tony

Cristina:

See my note above to Dr. Hodes.
Thanks,
Tony

-----Original Message-----

From: Hodes, Richard (NIH/NIA) [E] (b) (6)>
Sent: Saturday, February 29, 2020 9:32 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: SASP and Coronavirus 19

Hi Tony,

Please forgive me for intruding on your overwhelming priorities. If you have a moment to read the email below,

(b) (4)

(b) (4) Thanks for any suggestions.

Best
Richard

-----Original Message-----

From: Kirkland, James L., M.D., Ph.D. (b) (6)
Sent: Saturday, February 29, 2020 8:58 PM
To: Hodes, Richard (NIH/NIA) [E] (b) (6)
Cc: Sierra, Felipe (NIH/NIA) [E] (b) (6)>
Subject: SASP and Coronavirus 19

Dear Richard,

I am sorry to bother you late on a Saturday, but I wanted to let you know that we are finding in as yet unpublished

(b) (4)

(b) (4)

Jim

Sent from my iPad

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 01:27:44 +0000
To: Barton Haynes, M.D.
Subject: RE:

Thanks, Bart.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Barton Haynes, M.D. <(b) (6)>
Sent: Saturday, February 29, 2020 8:25 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: RE:

Great job in the press conference today.

Tough and high pressure situations it seems.

Thanks for being there and representing truth and science... best b

-----Original Message-----

From: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Sent: Saturday, February 29, 2020 7:14 PM
To: Barton Haynes, M.D. (b) (6); Marovich, Mary (NIH/NIAID) [E]
(b) (6); Dieffenbach, Carl (NIH/NIAID) [E] <(b) (6)>
Subject: RE:

Impressive!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It

should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Barton Haynes, M.D. <(b) (6)>

Sent: Saturday, February 29, 2020 2:29 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Marovich, Mary (NIH/NIAID) [E] (b) (6); Dieffenbach, Carl (NIH/NIAID) [E] (b) (6)

Subject: FW:

Hi Tony, Mary and Carl:

Every Saturday am, the DHVI team meets in my office to work on moving the HIV vaccine work forward, and now a new contingent is also working on coronavirus vaccine and new therapeutics.

This picture was from 9 am this Saturday morning. Great and dedicated crew listening to the presentation of data!

Best bart

-----Original Message-----

From: Barton Haynes, M.D.

Sent: Saturday, February 29, 2020 2:25 PM

To: (b) (6)

Subject:

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 01:09:29 +0000
To: Routh, Jennifer (NIH/NIAID) [E]
Subject: RE: Clips

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Routh, Jennifer (NIH/NIAID) [E] <(b) (6)>
Sent: Saturday, February 29, 2020 10:32 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Subject: RE: Clips

Dr. Fauci - the clips I've been able to pull so far are listed below:

Hardball (MSNBC last night): https://www.msnbc.com/hardball/watch/dr-anthony-fauci-i-m-not-being-muzzled-79650373756?cid=sm_npd_ms_tw_hb

Lou Dobbs (Fox Business last night): <https://twitter.com/LouDobbs/status/1233555383190507520>

Today (NBC this morning): <https://www.today.com/video/dr-fauci-on-coronavirus-fears-no-need-to-change-lifestyle-yet-79684677616>

Thanks,
Jen

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: (b) (6)
(b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive

information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >

Sent: Saturday, February 29, 2020 8:42 AM

To: Routh, Jennifer (NIH/NIAID) [E] [REDACTED] (b) (6) >

Subject: Clips

Jen:

This AM I did NBC Today and MSNBC. Please make sure that I get the clips.

Thanks

Tony

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 01:05:03 +0000
To: Holland, Steven (NIH/NIAID) [E]
Subject: RE: Human lung mice

Lease the decision up to HHS.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Holland, Steven (NIH/NIAID) [E] (b) (6)
Sent: Saturday, February 29, 2020 11:03 AM
To: (b) (6) Fauci, Anthony (NIH/NIAID) [E]
(b) (6)
Subject: Re: Human lung mice

Thanks for the note, (b) (5)

Steve

--

Director, Division of Intramural Research
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Bldg. 10/11N248 MSC 1960
Bethesda, MD 20892-1960
(b) (6) voice
301-480-4507 fax
(b) (6) email

Assistant lab: (b) (6)
(b) (6)

Assistant to SD: (b) (6)
(b) (6)

From: (b) (6)
Date: Saturday, February 29, 2020 at 10:55 AM
To: Anthony Fauci (b) (6), Steven Holland (b) (6)
Subject: Human lung mice

Hi Tony and Steve, I thought I'd better fill you in on some recent communications. Dr.

(b) (5)

[Redacted content]

(b)
(6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 00:55:28 +0000
To: (b) (6)
Subject: RE: in case you need to hear it

Michael:

Thanks for the note. I hope that all is well with you.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Michael Specter (b) (6)
Sent: Saturday, February 29, 2020 12:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: in case you need to hear it

You are one of my very few heroes.

And in case you have not seen it, here is my personal love letter to the president (in which you feature semi prominently)

<https://www.newyorker.com/news/daily-comment/donald-trumps-anti-globalist-response-to-a-global-coronavirus>

Michael Specter
Staff Writer
The New Yorker
Adjunct Professor of Bioengineering
Stanford University

(b) (6)
Phone: (Work, Cell, SMS) (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 00:53:55 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: COVID-19

Please take a look and respond. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Fred Schaich <fred.schaich@ifaratv.org>
Sent: Saturday, February 29, 2020 12:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: COVID-19

Dear Dr. Fauci,

I'll not be at the CROI this year (b) (6)
So I hope I may be able to ask
you a few questions as a concerned citizen.

Will we learn:

Why there are new cases in the US of unknown origin?

Could this virus infect carriers who do not present with symptoms or present in various levels of very mild infection and never get identified as infected?

Could individuals host the virus differently due to genetics or ethnicity?

Is this virus consistently similar after multiple generation or is it capable of mutating?

Is there an ability to develop an antibody immunity through infection? Can one be reinfected?

Could the level of infection be determined by the amount of inoculant?

Could we learn the level of infect ability of this virus by testing everyone in a given geographic area where there is a deep outbreak? We might also learn about the pathogenesis in a way that we cannot learn otherwise.

If this virus is so transmissible could we end up with almost everyone eventually being infected and present with various levels of serious acute infection and death to indistinguishable cases or just carriers?

With the clamp/filter on information from this administration, please tell us where we may find regular reports at various levels of current science on what we learn about this virus and vaccine progress, and where we may ask questions? I hope there is place for formal and informal community input into treatment, care and vaccine development.

Thank you for all your help over the years with your wise perspective through our interviews and leadership at the

NIH in such a reasonable and responsible way

Warm regards,

Fred

Fred Schaich

(b) (6) OR

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 00:27:04 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Coronavirus - New Idea for treatment & clinical study
Attachments: The Nine Lives of Hydroxychloroquine.docx, Chloroquine & COVID-19 pneumonia.pdf, Remdesivir & Chloroquine Effective InVitro Against COVID-19.pdf, 6-27-19 (5).jpg

Please take a look and respond to them. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6) >
Sent: Saturday, February 29, 2020 7:23 PM
To: vice.president@whitehouse.gov
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Redfield, Robert R. (CDC/OD)
(b) (6) Secretary@HHS.gov
Subject: Coronavirus - New Idea for treatment & clinical study
Importance: High

Dear Vice President Pence,

We are thankful for your leadership of the White House Coronavirus Task Force in gathering the latest information about the outbreak, working with doctors and scientists to find solutions, and communicating with the general public regarding the situation. We were blessed to meet with you back in August, 2019, when (b) (6) had expressed a desire to meet you. I have attached a picture from our meeting to help you remember. We pray for you often.

Since we are both physicians, we have been following the details of the COVID-19 outbreak closely. My husband was researching the anti-viral drug remdesivir this morning, and he came across some articles from Chinese studies that indicated a very well-known drug called hydroxychloroquine (already widely used for 70 years to treat malaria and rheumatological diseases) had very potent activity against COVID-19 infection and pneumonia. This was rather surprising to us, but as we read about the study and the characteristics of hydroxychloroquine, we realized that this could be a very good drug to use for the treatment of high-risk patients infected with COVID-19, who might deteriorate rapidly and progress to hospitalization and need for ICU care. Remdesivir also seems like an excellent anti-viral drug, but it is given intravenously, and is probably reserved for COVID-19 patients who are already entering into severe respiratory distress in the hospital.

Hydroxychloroquine, on the other hand, is given orally, and is cheap and readily available.

Low doses (6.5 mg / kg) have been effective in the management of Systemic Lupus Erythematosus and Rheumatoid Arthritis. 200 mg tablets are usually prescribed twice a day with meals; dosage can be increased up to the recommended 6.5 mg/kg if the patient tolerates the lower dose. **We wondered if the low dose hydroxychloroquine would be able to be studied quickly in various COVID-19 patients, especially those who are older and / or with medical conditions that put them at higher risk for pneumonia and complications (cardiovascular disease, chronic pulmonary disease, hypertension, diabetes, etc.). In addition, hydroxychloroquine may even be a useful drug to prevent the development of pneumonia in patients diagnosed with COVID-19.**

Because hydroxychloroquine is an older drug that is generic, current pharmaceutical companies have no incentive to do studies or research on its effectiveness for any new medical conditions. Therefore, the federal government would most likely have to construct and fund the studies. Perhaps Dr. Fauci has already considered this kind of study with hydroxychloroquine.

We understand that vaccines are already being studied, and Israel is working on an oral (pill) vaccine. Vaccines take time to go through testing and trials, which is why we are suggesting to you that studies be done on hydroxychloroquine, a readily-available oral drug that could “bridge the gap” to provide some potential

treatment and mitigation of the COVID-19 infections while vaccines are being developed and mass produced.

We have attached several articles, which are electronic publications made available in advance (Feb. 4th & Feb 19th, 2020) of the printed journal publications. We will send a copy of this email to Dr. Fauci, Dr. Redfield, and Dr. Azar.

Sincerely yours,
Drs. Paul & Karyl Stanton

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 00:14:14 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: One solution in the armoury to protect Health Care Sector Workers against Covid-19

Please handle. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6)
Sent: Saturday, February 29, 2020 2:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: One solution in the armoury to protect Health Care Sector Workers against Covid-19

Dear Dr Fauci

A PPE device, tested and proven at **Public Health England Porton Down** (PHE), based on innovative technology could be ready to go into production within 20 weeks. It sterilises all airborne pathogens as air is inhaled by the wearer. See www.medi-immune.com and in particular the published report on the tests, by clicking on the report under "The Science" The device is due to undergo further tests, at PHE within the next week, specifically against Covid-19. For verification please contact Professor Nigel Silman at PHE Porton Down.

Health Services around the world are doing what they can to prepare for a significant increase in infections from this highly transmissible virus and if those people in the Health Care Sectors are infected the situation could become untenable.

The production of vaccines is under way but no one expects them to be available within the next 12 to 18 months. The Medi-Immune "ProtectivAir®", which has been under development for some years and could be available within a few months, will give a far greater level of protection than the current masks and respirators and more importantly can remain in use in the future for other emerging airborne pathogens – known, unknown or mutating.

Please take a little time to investigate this option, via the website, or pass it on to those who you believe need to be made aware of it. I will be happy to answer any questions, technical or otherwise, at my email address below or on my mobile number, also below.

Kind regards

James Love

James Love
Director

m: [REDACTED] (b) (6)

t: [REDACTED]

www.medi-immune.com

www.revaxbiotech.com

MEDI-IMMUNE

Groundbreaking Protection & Immunity

Medi-Immune Limited, registered in England and Wales | Company registration No: 04554706 | Registered Office: 4 Lady Bank | Tamworth Staffordshire | B79 7NB | UK

DISCLAIMER: Privileged/Confidential information and/or Copyright Material may be contained in this email. The information and material is intended for the use of the addressee(s) only. If you are not the addressee or the person responsible for delivering it to the intended addressee(s), you may not copy or deliver it to anyone else or use it in any unauthorised manner. To do so is prohibited and may be unlawful. If you receive this email by mistake, advise the sender immediately by using the reply facility in your email software. Any views or opinions presented are solely those of the author and do not necessarily represent those of Medi-Immune Ltd. Although this email and attachments are believed to be free of any virus or other defects which might affect any computer or IT systems into which they are received, no responsibility is accepted by Medi-Immune Ltd for any loss of damage arising in any way from the receipt or use thereof.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 00:12:45 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: A sharing on COVID ARDS research
Attachments: Dexa_ARDS_COVID-19 for Dr. Tugwell.doc, Tsai 2020_Ann of Intensive Care_ARDS_corticosteroid.pdf

Please take a look at this and handle. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Paul Elias Alexander (b) (6) >
Sent: Saturday, February 29, 2020 2:34 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: A sharing on COVID ARDS research

Hi Dr. Fauci, I am a trained epidemiologist and expert in evidence based medicine. Particularly in developing clinical practice guidelines and I teach EBM and GRADE methods.

You have no idea how much I have admired you across the years, your intelligence and poise.

May I ask how I may help you in this matter, this response, I am not talking about money, I wish to help, volunteer.

I draw your attention to 2 attachments...

1) one is a one page I wrote to summarize a meta analysis my team just completed and seeking to publish. It pertains to corticosteroids and ARDS. We are raising that this suggests indirect evidence that we may be able to extrapolate to the COVID patient with severe illness. This within the life threatening issue and emergency and no effective treatment. I share if this can

help you as I know you are leading this and listened to you today with the president. I support this president fully.

2) I share a paper published today, it on the other hand raises serious questions on the use of corticosteroids in influenza associated ARDS, and one may argue this patient set, is the closest to the COVID 19 patient.

My sense is that the accumulated evidence thus far is weak and argues against corticosteroids. For example, this recently published multicenter retrospective cohort study in medical center ICUs across Taiwan sought to assess the effectiveness of corticosteroids in patients presenting with influenza-associated ARDS (virology-proven ARDS and are on mechanical ventilation). Researchers examined the impact of early corticosteroid treatment (≥ 200 mg hydrocortisone equivalent dose within 3 days after ICU admission, determined by a sensitivity analysis) on subsequent hospital mortality. The study revealed that of the 241 patients with influenza-associated ARDS, those receiving early corticosteroid had a significantly higher hospital mortality rate than those who did not get early corticosteroid [43.5% (37/85) vs. 19.2% (30/156), $p < 0.001$]. Early corticosteroid treatment was independently associated with increased hospital mortality in overall patients [an adjusted OR of 5.02 (95% CI 2.39-10.54), $p < 0.001$] and in all examined subgroups. Researchers found that a higher dose and earlier treatment was linked to higher hospital mortality. Moreover, they found that earlier treatment was related to a significantly increased odds of subsequent bacteremia [an adjusted OR of 2.37 (95% CI 1.01-5.56)]. These results underscore the urgency for robust comparative randomized research given this study is based on weaker observational evidence that is confounded by selection bias and confounded. However this was a stronger study that used statistical adjustment and propensity score matching. Thus this study suggests caution with corticosteroid and thus the importance for caution by clinicians as to the potential harms of corticosteroids in this population. These results, while based on weaker methodology, have revealed large estimates of effect, is the strongest evidence to date on treatment for ARDS, and brings us closest to the COVID-19 ARDS patient.

Best,

Paul E. Alexander, MSc, MHSc, PhD
Assistant Professor
<http://hei.mcmaster.ca/>
McMaster University, 1280 Main Street W,
Hamilton, ON L8S 4K1
GUIDE Research Methods Group
<http://guidecanada.org/>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 29 Feb 2020 23:56:39 +0000
To: Les Gardonyi
Subject: RE: Suggestion

Leslie:

Thank you for your note. We are actually looking into the effect of ACE inhibitors on the coronavirus.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Les Gardonyi (b) (6) >
Sent: Saturday, February 29, 2020 3:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Suggestion

Dear Mr. Fauci,

This may be way too presumptive of a note...

As an engineer I've always liked to understand the mechanics of how things work so I looked into educating myself about the coronavirus and it's mechanics. (b) (6)

(b) (6) I've correlated a possible research route for your organization regarding the prevention aspect.

A quick overlook on this strategy is the following:

Coronaviruses are RNA viruses that typically enter human cells when their glycoproteins bind proteins on the cell surface. In the case of the virus that causes SARS, that human protein is **angiotensin-converting enzyme 2 (ACE2)**. At this time, scientists think the novel coronavirus is similar enough to SARS that its entry point is likely ACE2 as well.

source: <https://cen.acs.org/biological-chemistry/infectious-disease/novel-coronavirus-hits-China/98/web/2020/01>

Irbesartan is used to treat high blood pressure (hypertension) and to help protect the kidneys from damage due to diabetes. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Irbesartan belongs to a class of drugs called **angiotensin receptor blockers** (ARBs). It works by relaxing blood vessels so that blood can flow more easily.

source: <https://www.webmd.com/drugs/2/drug-4720/irbesartan-oral/details>

Idea:

Can Irbesartan, being an angiotensin receptor blocker, possibly help prevent Coronavirus infections... since the Coronavirus entry to humans is via ACE-2?

I share this suggestion with you in the hopes that it may help your department in the research to prevent the spread of the coronavirus... or to a presumptuous email slated for deletion.

Sincerely,

-Leslie Gardonyi

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 29 Feb 2020 23:54:27 +0000
To: Ellen Butler
Subject: RE: [REDACTED] (b) (6)

Ellen:

Thank you for your kind note. Very nice family pictures! [REDACTED] (b) (6)

[REDACTED], but in any event, thanks for the note.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Ellen Butler [REDACTED] (b) (6)
Sent: Saturday, February 29, 2020 3:13 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: [REDACTED] (b) (6)

I just watched you this afternoon at the press conference. Over the years I have seen you and wondered along with family members if [REDACTED] (b) (6)

Also I just wanted to say how professional you are and that I don't believe what #45 or his administration have to say regarding the coronavirus but have 100% confidence in what you say and do. Thank you for being the adult in the room.

[REDACTED] (b) (6) I am very proud of you.

Sincerely,

Ellen Butler

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 29 Feb 2020 23:44:17 +0000
To: Margaret Liu
Subject: RE: kudos and comment about JAMA Coronavirus article

Margaret:

Thanks for the note. You make a valid point and I appreciate what you are saying. . On that issue, I have been vocal about making sure that we do not stigmatize Chinese people here in the USA or anywhere in relationship to the COVID-19 outbreak.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Margaret Liu <liu@protherimmune.com>
Sent: Saturday, February 29, 2020 3:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] (b) (6)>
Cc: Alice Huang <stephen.lin@80-20ef.org>; president@80-20.us
Subject: kudos and comment about JAMA Coronavirus article

Dear Tony,

Wonderful articles in JAMA and NEJM. So glad you are still heading NIAID- it is comforting that there are experts of your caliber still in the room. And thrilled that the NIAID has done so much to develop rapid timelines for DNA vaccines and that you highlighted that progress in the article, since people call me the "Mother of DNA vaccines,".

As a former NIAID Council member, I felt I should write to raise an issue that I am sensitized to as a scientist who is ethnically Chinese while American:

Why in the JAMA article was it necessary to state that the first travel-related case to the US was a *Chinese* man (italics mine) who had visited Wuhan. Did his being Chinese either ethnically or by citizenship affect anything biologically?

I ask because not only have many Asian people now encountered increased racism in public places (due to fear that any Asian person is a source of COVID-19), but now that the President is turning this epidemic into additional fear-mongering about "borders" it seems all the more important that scientists do not inadvertently add to "xenophobia" (even though non-white skin does not mean a person is foreign) and do not seem to advance any political perspective.

Sincerely and with best personal regards,
Margaret

Margaret A. Liu, MD, DSc^{hc}, MD^{hc}, FISV
ProTherImmune &
Foreign Adjunct Professor, Karolinska Institute
Stockholm, Sweden
Adjunct Full Professor, UCSF
San Francisco, CA USA
President Emeritus, International Society for Vaccines
Liu@ProTherImmune.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 29 Feb 2020 23:40:04 +0000
To: Tom Leopold
Cc: Cassetti, Cristina (NIH/NIAID) [E]
Subject: RE: ? ALTERNATIVE/SUPPLEMENTAL rx for COVID-19: Angiotensin Receptor Blockers

I have received this message and we are in fact looking into this.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Tom Leopold (b) (6)>
Sent: Saturday, February 29, 2020 4:24 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: ? ALTERNATIVE/SUPPLEMENTAL rx for COVID-19: Angiotensin Receptor Blockers

Much appreciation for all of your work past and present. I am a cardiologist in New Jersey and when I read that the virus attaches to the AT2 receptors in the lungs I couldn't help but think that maybe the class of ARB's that we use so frequently for HTN and heart failure management could possibly block entry of virus into cells and prevent or mitigate the severity of infection. Has this approach ever been studied and is it worth looking into? Imagine if ARBs could lessen the severity of infection how readily available and relatively inexpensive this class of medication is! Would appreciate if someone could get back to inform me whether you received this message. Thanks. Dr Thomas Leopold Email: (b) (6)

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 29 Feb 2020 23:34:59 +0000
To: Tom Leopold
Subject: RE: Angiotensin Receptor Blockers: a possible therapy for Covid-19

Thanks for the note. We are looking into this possibility.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Tom Leopold (b) (6)>
Sent: Saturday, February 29, 2020 5:01 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Angiotensin Receptor Blockers: a possible therapy for Covid-19

Much appreciation for all of your work past and present. I am a cardiologist in New Jersey and when I read that the virus attaches to the AT2 receptors in the lungs I couldn't help but think that maybe the class of ARB's that we use so frequently for HTN and heart failure management could possibly block entry of virus into cells and prevent or mitigate the severity of infection. Has this approach ever been studied and is it worth looking into? Imagine if ARBs could lessen the severity of infection how readily available and relatively inexpensive this class of medication is! Would appreciate if someone could get back to inform me whether you received this message. Thanks. Dr Thomas Leopold Email: (b) (6)

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 29 Feb 2020 23:29:47 +0000
To: Richard Goodman
Subject: RE: Coronavirus question

Richard:

There are no CDC-issued travel restrictions within the USA. The CDC made this clear at the White House press conference this afternoon.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Richard Goodman <goodmanr@ohsu.edu>
Sent: Saturday, February 29, 2020 5:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Coronavirus question

We met many years ago, Tony,

...at an event marking Shelly Wolff's 10 year anniversary at New England Medical Center. (I had the distinction of being the first medical intern in that program who he reamed out.)

My question relates to travel restrictions. The current restrictions appear to be quite limited, but several organizations, including Google, Amazon, and the HHMI have restricted, or cancelled, even domestic meetings. As a result of the HHMI cancelation, my own program director indicated his intention to cancel our upcoming Scientific Advisory meeting and, in the non-academic world, (b) (6)

(b) (6) (which is ironic since there are more coronavirus infections in my town of (b) (6) Oregon than there are in all of New York).

In addition to announcing the new travel restrictions, could you also say something publicly about what doesn't need to be restricted? In particular, is domestic travel OK, or not? Does the HHMI know something the rest of us don't?

Sincerely,

Richard Goodman MD PhD

Vollum Institute
Oregon Health & Science University

Sent from my iPad

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 29 Feb 2020 23:06:38 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Rapid Collaboration for Hand & Nasal Decontamination Formulation
Attachments: NORS-viral review_V3.pdf, 1998 Reiss NO plays a role in viral infections.pdf, 2005 Akerstrom NO inhibits Corona Viral replication.pdf, 2010 Jung Nitric & SARS corona virus.pdf, 2013 Regev Nitric reduces viral infectivity.pdf, 2015Regev Nitric cattle vs antibiotics BRD.pdf

Please handle. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Gilly Regev (b) (6)
Sent: Saturday, February 29, 2020 5:50 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Chris Miller (b) (6)
Subject: Fwd: Rapid Collaboration for Hand & Nasal Decontamination Formulation

Dear Dr Fauci,

Dr Murad sits on our BOD and has suggested that we contact you to help expedite a rapid testing of our product on the COVID-19 virus. I know you are probably overwhelmed but hope you might pass this along or suggest a strategy that would be a win-win for us all.

We have developed a non-alcohol based formulation that utilizes the nanomolecule nitric oxide (NO). as you know, NO is produced in our body and is our first line of defense against microbes. We have harnessed this in a patented formulation called nitric oxide releasing solution/gel (NORGS). We are focused on the development of products for chronic sinusitis, diabetic foot wounds, warts and toenail fungus.

However, internally & personally, we have been using NORGS as an extremely effective natural hand sanitizer and nasal spray to protect ourselves from the common cold and flu for years.

There are strong independent published research that NO is antiviral against Corona viral species. We have data showing definite virucidal characteristics and moderate antiviral effects in host cells.

With the recent concern with COVID-19, we felt we should try to rapidly test the hand rub and nasal spray against the COVID-19 but need to collaborate with a laboratory that could test this for us. Funding collaborators are welcome too, as this was not in our budget but we feel a social responsibility to move this forward.

I have included a short white paper of our data and a few articles to support our claims.

Feel free to contact me any time (b) (6) or have one of your senior staff contact me.

Sincerely,

Chris Miller and Gilly Regev

—
Gilly Regev, Ph.D.

CEO / Co-founder

SaNOtize Research and Development Corp.

Phone: (b) (6)

email: (b) (6)

<https://www.linkedin.com/in/gilly-regev-694b4a16/>

<https://www.sanotize.com>

From: (b) (6)
Sent: Sat, 29 Feb 2020 06:58:29 -0500
To: Heather DaVia
Subject: Re: Thank You

Joseph and Heather:

Many thanks for your kind words. Much appreciated.
Best regards,
Tony

> On Feb 28, 2020, at 8:45 PM, Heather DaVia (b) (6) > wrote:

>

> Dear Dr. Fauci:

>

> Please accept my personal and heartfelt thanks for your continued efforts to keep the American public informed concerning the coronavirus. While listening to you on the radio or at press conferences, your calm, thoughtful, and measured words are very comforting and reassuring. Both your caring response and scientific/medical expertise are an example of the very best in the Federal Government.

>

> Again, thank you for your public service and your efforts to keep us as safe as possible.

>

> Sincerely,

>

> Joseph P. DaVia

> (b) (6)

>

> P.S. (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 29 Feb 2020 03:15:14 +0000
To: Tabak, Lawrence (NIH/OD) [E]
Cc: Collins, Francis (NIH/OD) [E]; Schwetz, Tara (NIH/OD) [E]
Subject: RE: OSTP call

Larry:


Thanks you very much.

Tony

From: Tabak, Lawrence (NIH/OD) [E] (b) (6)
Sent: Friday, February 28, 2020 8:22 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Collins, Francis (NIH/OD) [E] (b) (6); Schwetz, Tara (NIH/OD) [E]
(b) (6) >
Subject: OSTP call

Tony,

Tara and I took the call with Kelvin Droegemeier, France Cordova (NSF), and Paul Dabbar (DOE).



Please let me know if you need anything else. (Tara -if I left anything out please add).

Larry

Sent from my iPhone

From: (b) (6)
Sent: Fri, 28 Feb 2020 19:48:05 -0500
To: Harris, Kara (NIH/NIAID) [E]; Haskins, Melinda (NIH/NIAID) [E]
Subject: Fwd: Coronavirus on surfaces

Public inq pls

Sent from my iPhone

Begin forwarded message:

From: Deborah Greene (b) (6)
Date: February 28, 2020 at 7:38:44 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Subject: Coronavirus on surfaces

Hello Dr Fauci,

I am trying to find out how long the coronavirus can remain infectious on the surface of an object handled by someone with the virus.

My concern is with purchasing items for my jewelry shop that come from China , South Korea, and Turkey.

I have not been able to find anything that addresses this question and hope you can clarify this for me. Thank you.

Sincerely yours,
Deborah Greene

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 23:18:10 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Corona Virus
Attachments: US Biotest Letter re COVID-19 Fauci, A.pdf, Coronavirus- (b) (4)
Rationale.pptx, US Biotest Regulatory History of (b) (4).pdf, US Biotest COVID-19
(b) (4) References.pdf

Please handle. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Samantha Mauro (b) (6) >
Sent: Friday, February 28, 2020 6:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Gere diZerega (b) (6) >
Subject: Corona Virus

Dear Dr. Fauci:

(b) (4)

Please contact us if we can be of any help in moving this potential life-support initiative forward.

Sincerely,

Gere diZerega MD
Professor
Keck School of Medicine
University of Southern California
And
President and CEO
US Biotest, LLC
San Luis Obispo, CA
(b) (6)

Kathleen Rodgers PhD
Professor, Department of Pharmacology
College of Medicine
Center for Innovation in Brain Sciences
Associate Director of Translational Neurosciences
University of Arizona
Tucson, AZ
(b) (6)

From: (b) (6)
Sent: Fri, 28 Feb 2020 16:54:13 -0500
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: Urgent Email/Strategy to attack 2019-nCoV coronavirus
Attachments: Nucleotide_Analogues_as_Inhibitors of SARS-CoV Polymerase_2_28_2020.pdf, ATT00001.htm, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.pdf, ATT00002.htm

Pls handle

Sent from my iPhone

Begin forwarded message:

From: Jingyue Ju (b) (6)>
Date: February 28, 2020 at 4:46:04 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Cc: "Barasch, Kimberly (NIH/NIAID) [C]" (b) (6),
"directorsincoming@cdc.gov" <directorsincoming@cdc.gov>, "Redfield, Robert R. (CDC/OD)" (b) (6), "Davis, Mindy (NIH/NIAID) [E]" (b) (6),
"Eakin, Ann (NIH/NIAID) [E]" <(b) (6)>, "Stemmy, Erik (NIH/NIAID) [E]" (b) (6), "Sciotti, Rick (NIH/NIAID) [E]" (b) (6), "Schiltz, Helen (NIH/NIAID) [E]" (b) (6),
"Krafft, Amy (NIH/NIAID) [E]" (b) (6)>
Subject: Re: Urgent Email/Strategy to attack 2019-nCoV coronavirus

Dear Dr. Fauci,

Following my previous email regarding our work on developing strategies to attack the 2019-nCoV coronavirus, I am attaching in this email our experimental results demonstrating that 2 nucleotide analogues are inhibitors of the SARS-CoV polymerase. Since the SARS-CoV polymerase has over 96% similarity to the polymerase from SARS-CoV-2, we expect that the nucleotide analogues, 2'-F,Me-UTP and 3'-F-dTTP, will also inhibit the SARS-CoV-2 polymerase.

At this point, it is imperative that the prodrug forms (one is Sofosbuvir that is FDA approved for HepC) of these molecules begin immediate in vitro testing with infected cells (similar to the studies carried out for Remdesivir and chloroquine in the Cell Research article at the link, <https://www.nature.com/articles/s41422-020-0282-0>; PDF file of the article also attached) followed by animal testing trials ASAP. Since we do not have access to the SARS-CoV-2 viral strains, we need your assistance to identify resources at the NIH laboratories to embark on this next step

investigation ASAP. We can provide the prodrugs to the labs at NIH that you identify for carrying out these studies. In view of the worldwide SARS-CoV-2 emergency, we'd like your assistance in getting this off the ground ASAP.

I can be reached any time at (b) (6)

All the best,

Jingyue Ju, Ph.D.

Samuel Ruben-Peter G. Viele Professor of Engineering
Professor of Chemical Engineering and Pharmacology
Director, Center for Genome Technology & Biomolecular Engineering
Columbia University
Northwest Corner Building, Room 1000M1
550 West 120th Street
New York, NY 10027
Phone:

(b) (6) wrote:

Dear Drs. Fauci and Redfield,

Scientists in my laboratory at Columbia University are actively engaged in design strategies to cope with the new strain of coronavirus, 2019-nCoV, which has caused a global public health emergency. We have embarked on a project entitled "Nucleotide Analogues as Inhibitors of Viral Polymerases". We provide a summary of this work below.

Coronaviruses such as the newly discovered virus from Wuhan, China, 2019-nCoV, and the viruses that cause SARS and MERS, have resulted in regional and global public health emergencies. Based on our molecular insight that the hepatitis C virus and the coronavirus use a similar viral genome replication mechanism, we reasoned that the FDA-approved drug EPCLUSA (Sofosbuvir/Velpatasvir) for the treatment of hepatitis C will also inhibit the above coronaviruses, including 2019-nCoV. To develop broad spectrum anti-viral agents, we further describe a novel strategy to design and synthesize viral polymerase inhibitors, by combining the ProTide Prodrug approach used in the development of Sofosbuvir with the use of 3'-blocking groups that we have previously built into nucleotide analogues that function as polymerase terminators.

Please let me know if you would like to receive the full manuscript.

Thank you very much for your consideration.

Sincerely,

Jingyue

Jingyue Ju, Ph.D.

Samuel Ruben-Peter G. Viele Professor of Engineering

Professor of Chemical Engineering and Pharmacology

Director, Center for Genome Technology & Biomolecular Engineering

Columbia University

Northwest Corner Building, Room 1000M1

Phone:

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 21:27:35 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Corona Virus
Attachments: US Biotest Regulatory History of (b) (4).pdf, US Biotest COVID-19 (b) (4) References.pdf, US Biotest Letter re COVID-19 Fauci, A.pdf

Please take a look and handle if necessary.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Gere diZerega <(b) (6)>
Sent: Friday, February 28, 2020 3:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Gere diZerega <(b) (6)>
Subject: Corona Virus

Dear Dr. Fauci:

(b) (4)

Please contact us if we can be of any help in moving this potential life-support initiative forward.

Sincerely,
Gere

GERE DIZEREGA
PRESIDENT AND CEO
US BIOTEST, INC.

231 BONETTI DRIVE, SUITE 240
SAN LUIS OBISPO, CA 93401-7310

TEL: (b) (6) ✦ FAX: 805.595.1350

The information transmitted is intended only for the person or entity to which it is addressed and may contain confidential and/or privileged material. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is prohibited. If you received this in error, please contact the sender and delete the material from any computer.

From: (b) (6)
Sent: Fri, 28 Feb 2020 13:41:02 -0500
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: As bad as measles?

Please handle

Begin forwarded message:

From: Ed Charlton <(b) (6)>
Date: February 28, 2020 at 1:07:32 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Subject: As bad as measles?

Dr Fauci, you are the pre-eminent infectious disease physician in the world. I'm concerned the public has lost perspective on COVID-19. At this point, it would seem the r_0 and CFR are more similar to rubeola than they are to Ebola. Can we remind the public of that? Communicating that influenza will kill more Americans than SARS-2 hasn't gained traction. Might someone like yourself or Dr Carson communicate more strongly to the public the risks compared to other viruses they are familiar with, like rubeola, rubella, varicella, etc?

From: (b) (6)
Sent: Fri, 28 Feb 2020 13:39:34 -0500
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: Experimental vaccine for Covid-19

Please respond. Mention risk of enhancement

Begin forwarded message:

From: "William J. Buikema" (b) (6) >
Date: February 28, 2020 at 1:08:50 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) >
Subject: Experimental vaccine for Covid-19

Dear Dr. Fauci,

I understand the need for the various stages of testing a new experimental vaccine, but in listening to you give a timeline for any new vaccine for the corona virus, it struck me that perhaps a modified approach might be considered. Why not allow early use of a vaccine that has passed a phase 1 safety testing, similar to what was done for the Ebola vaccines. If a vaccine is shown to be reasonably safe, why not allow its use in more at-risk people (elderly, smokers) before phase 2 trials are finished. It could also be helpful as with the Ebola vaccines to prevent transmission in hot spots of community acquired infections. There doesn't seem to be much downside compared to the potential for preventing many more deaths than was seen in the Ebola situation.

Sincerely yours,

Bill Buikema

William J. Buikema, PhD, Research Associate
Technical Director, DNA Sequencing & Genotyping Core
University of Chicago, KCB D 1230H&I
900 E 57th Street, Chicago, IL 60637
773-702-1088, cancer-seqbase.uchicago.edu

From: (b) (6)
Sent: Fri, 28 Feb 2020 11:21:22 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: coronavirus vaccine story?

Sent from my iPhone

Begin forwarded message:

From: Olga Khazan <olga@theatlantic.com>
Date: February 28, 2020 at 11:09:49 AM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Subject: coronavirus vaccine story?

Hi Tony -- It's Olga at the Atlantic ... I'm hearing that there's a coronavirus vaccine trial in the works at the VTEU sites. We'd love to tell the story, but everyone is directing me to you and NIAID. Would you be able to talk with me about this today for a story? My cell is (b) (6), and my desk is 202-266-7387.

Thanks,
Olga

--
Olga Khazan
Staff Writer
The Atlantic
olga@theatlantic.com
cell: (b) (6)

From: (b) (6)
Sent: Fri, 28 Feb 2020 08:59:04 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: MEDIA INQUIRY

Sent from my iPhone

Begin forwarded message:

From: Lemonov Alexander <anlemonov@rttv.ru>
Date: February 28, 2020 at 8:13:34 AM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Subject: MEDIA INQUIRY

Dear Dr. Fauci,

My name is Alexander Lemonov, I am a producer for RT International TV channel.

I would like to invite you to appear on "Worlds Apart", RT's 26-minute uncensored one-on-one interview show.

We would like to talk about the spread of the COVID-19 coronavirus, the response measures countries should take, the world's general preparedness for pandemics, COVID-19's possible consequences for other areas: healthcare, economy, security, etc.

Would you be available?

FYI: "Worlds Apart" is an uncensored interview show that is aired on RT International, RT America, RT UK, and RT Russia (in Russian).

All episodes get featured on RT social media accounts, watched by their multimillion international crowd.

Our guests endorse widely different views, and we are happy to broadcast different opinions. Here's the link to our show: <https://www.rt.com/shows/worlds-apart-oksana-boyko/>

"Worlds Apart" has featured:

businessman Richard Branson, lawyer Alan Dershowitz, former Israeli FM Tzipi Livni, UN Secretary General Antonio Guterres, UN Women Executive Director Phumzile Mlambo-Ngcuka, former Prime Minister of Italy Giuliano Amato, former U.S. State Department coordinator for JCPOA Jarrett Blanc, foreign minister of Iran Javad Zarif, adviser on international affairs to Supreme Leader of Iran Ali Akbar Velayati, former chief economist of the World Bank Anne Krueger, Secretary General of OSCE Thomas Greminger, special adviser to PM of Japan Tomohiko Taniguchi, senior fellow at the Brookings Institution Mike O'Hanlon, etc.

I would appreciate a reply.

Kind regards,
Alexander Lemonov
Producer
"Worlds Apart", RT
Mobile: (b) (6)
Office: +7 (499) 75-000-75, ext. 2492

Александр Лемонов
Продюсер
"Worlds Apart", RT
Моб.: (b) (6)
Раб.: +7 (499) 75-000-75, доб. 2492



rt.com



twitter.com/rt.com

facebook.com/RTnews

youtube.com/user/RussiaToday/

plus.google.com/102728491539958529040/posts

CONFIDENTIALITY:

The information contained in this transmission is intended exclusively for the proper use by the intended addressees and may contain confidential and/or privileged material. Any views expressed in this transmission are those of the individual sender, except where the transmission states otherwise and the sender being authorised appropriately. Any review, dissemination and other use of this information, as well as any action in reliance upon this information by persons and/or entities other than the intended addressees is prohibited. If you received this information in error, please note that no confidentiality or privilege is waived or lost by any mis-transmission. Note that we monitor e-mails sent or received. Further communication will signify your consent to the above.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 11:50:04 +0000
To: Kaplan, Edward H
Subject: RE: Coronavirus

Ed:

Thanks for the note. Great to hear from you. I hope that all is well.
Best regards,
Tony

-----Original Message-----

From: Kaplan, Edward H <(b) (6)>
Sent: Thursday, February 27, 2020 10:42 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: RE: Coronavirus

Hi again Tony. Here's a link to a non-technical explanation of the paper I shared with you earlier:

<https://insights.som.yale.edu/insights/new-outbreaks-of-coronavirus-can-be-halted-with-isolation-measures-according-to-study>

I have seen predictions stating that upwards of 30% of the world's population will be infected, but I don't see this happening. What I do see are lots of local outbreaks from imported cases, some larger than others, but all heading towards containment. I find Israel to be an interesting test case. A group of infected Korean tourists who visited the country only tested positive for coronavirus after their return to Korea, joining the large outbreak that has been reported there. The itinerary of their travel group has been made public so that retrospectively, Israeli public health officials could ascertain who was exposed where and when (see https://www.health.gov.il/English/News_and_Events/Spokespersons_Messages/Pages/23022020_1.aspx). Already 1,600 Israelis have been quarantined on account of possible exposure. It has been twelve days since this group of tourists returned to Korea, and no new infections have been reported in Israel associated with this group (there are two Israelis who were infected on the Diamond Princess cruise ship, and one infected while in Italy). See <https://www.ynetnews.com/article/H1nXPa7E8>. It will be interesting (and important) to see how many new infections are detected in the days ahead, and if such new infections are found among those already under preventive watch.

Nonetheless I totally concur with preparing as if major transmission will occur. Much better to err by over- rather than under- preparing (a familiar perspective from those bygone smallpox debates).

Finally, a reporter asked me yesterday afternoon what I wanted the President to say last night. Here was my response:

In a sober way summarize the facts of the outbreak, state that the US has an excellent preparedness team between CDC and NIH, that at the advice of this team travel restrictions and quarantine measures have already been enacted, but as of now the public is at very low risk of infection. Still, citizens should go to [cdc.gov](https://www.cdc.gov) now to learn from our experts how to prepare in the event that more extreme measures are needed, stay abreast of the situation here and abroad and follow the advice of our experts, get a flu shot (!), and know that the US has a very strong public health system that can withstand this challenge.

Anyway, just wanted to share all this with you. Keep up the good work and good luck with the vaccine research, Ed

-----Original Message-----

From: Kaplan, Edward H
Sent: Saturday, February 8, 2020 10:13 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>

Subject: Coronavirus containment modeling

Dear Dr. Fauci,

It has been many years since we corresponded regarding smallpox bioterrorism and vaccination control.

The attached paper on containing a community coronavirus outbreak from a few initial cases via isolation and quarantine might interest you. The news is mostly good - isolation and quarantine can get the transmission rate below epidemic threshold - but the key is rapid detection of infected persons. Also discussed are some ideas for alleviating congestion in the hospital. I hope that you find it helpful.

Best, Ed Kaplan

Edward H. Kaplan, Ph.D.

William N. and Marie A. Beach Professor of Operations Research Professor of Public Health Professor of Engineering Yale School of Management Box 208200 New Haven, Connecticut 06520-8200

Phone: (b) (6)

e-mail: (b) (6)

<https://nam05.safelinks.protection.outlook.com/?url=http%3A%2F%2Ffaculty.som.yale.edu%2FEdKaplan%2F&p;data=02%7C01%7Cedward.kaplan%40yale.edu%7Cb00119dedbe24bc635d208d7bb9b24c7%7Cdd8cbebb21394df8b4114e3e87abeb5c%7C0%7C0%7C637184147315834392&sdata=11LC4xAuAc%2BjdNuG%2BA2oGxcS9LS95PoQRi7yO0dLRd0%3D&reserved=0>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 11:25:43 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Coronavirus update for your upcoming Keystone Symposia meeting

FYI

From: Allison Ogdon <AllisonO@keystonesymposia.org>
Sent: Friday, February 28, 2020 12:10 AM
To: Allison Ogdon <AllisonO@keystonesymposia.org>
Cc: Heidi Daetwyler <HeidiD@keystonesymposia.org>
Subject: Coronavirus update for your upcoming Keystone Symposia meeting
Importance: High



Greetings,

In light of the current coronavirus situation, we would like to provide an update on your upcoming Keystone Symposia conference.

The health and safety of our meeting attendees and speakers is our top priority, and we are carefully monitoring the coronavirus situation around the world to ensure we take the necessary precautions as recommended by healthcare providers and public health organizations.

Currently, ***your meeting will proceed as scheduled***, and we will contact you immediately if anything changes. Decisions will be made on a moment to moment basis, as new information becomes available. We assure you that the leadership team at Keystone Symposia is closely monitoring global developments and will take swift action to ensure the health and safety of all meeting participants.

As a speaker, you hold a very special role at the meeting as a field leader. We very much appreciate your contribution to both the scientific program, and the community of luminary scientists who will convene to direct the future of the field. Your presentation will be a highlight for many attendees, and your insights will inspire others to take on new and innovative directions in their own work. This is the essence of Keystone Symposia -- convening communities of leading scientists to inspire each other to advance biomedicine, and this would not be possible without your engagement.

We realize the current situation may add some inconveniences to travel at this time, but we also remind you that each and every one of our speakers is hand-selected by a committee of the world's leading experts to represent their field at the meeting. You are among a very select few to receive this honor.

The meeting organizers, and our team at Keystone Symposia, have put a great deal of time and effort over the last two years into designing the program, and your presentation is a key part of that. We hope you will take these thoughts into consideration as the meeting approaches.

While this is a time we must all be vigilant about public health measures, we are reminding conference attendees that this is also a time to remain calm, rational and scientific in addressing the situation. We encourage you to engage with your fellow colleagues at the meeting as you normally would, to forge new collaborations and novel ideas that will drive your research and the field in innovative and fruitful directions. At the meeting, we are providing the following suggestions based on recommendations from the National Foundation of Infectious Disease:

- ***The best way to protect yourself against COVID-19 is similar to how you would take precautions against the cold or flu.*** Wash your hands often using soap and water for at least 20 seconds. Cover your cough or sneeze with a tissue or the crook of your elbow rather than your hands.
- ***There is no need to wear a face mask if you are well and do not have symptoms***—masks protect the sick from spreading germs but will not prevent you from getting sick.
- ***Do not assume that anyone of Asian descent is more likely to have coronavirus***—do not forget about the importance of inclusivity and evidence-based information.

Again, we thank you for your contributions and commitment to Keystone Symposia and wish for a very successful and inspiring meeting.

Sincerely,



Deborah L. Johnson, Ph.D.
President and Chief Executive Officer
Keystone Symposia on Molecular and Cellular Biology

KEYSTONE  SYMPOSIA™
on Molecular and Cellular Biology
Accelerating Life Science Discovery



PO Box 1630 | Silverthorne | CO 80498 | USA (regular mail only)
160 US Highway 6, Ste. 200 | Silverthorne | CO 80498 | USA (courier only)
970.262.1230 | 800.253.0685 | www.keystonesymposia.org
Visit virtual.keystonesymposia.org to view our digital content.



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 04:25:27 +0000
To: Kline, Lydia (NIH/OD) [E]
Subject: RE: thank you

Lydia:

Thanks for your kind note.

Best regards,

Tony

From: Kline, Lydia (NIH/OD) [E] (b) (6) >
Sent: Thursday, February 27, 2020 9:45 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: thank you

Tony,

I'm sure many people are telling you this, but I wanted to add my thanks to you for everything you do to keep the world safer and healthier! You are doing an incredible job (as always) out there with coronavirus.

Best,
Lydia

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 04:23:12 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: invitation to speak on COVID 19 at the International ATS Conference in May
Attachments: image001.png, image003.png

Sorry no

From: Fennelly, Kevin (NIH/NHLBI) [E] (b) (6) >
Sent: Thursday, February 27, 2020 9:02 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: invitation to speak on COVID 19 at the International ATS Conference in May

Dear Dr. Fauci,

I don't believe that we've formally met, but I have seen you frequently on 5SE as I admit patients there and often participate in the ward rounds. I am an AI on several of Steve Hollands protocols, and I often help with the drug-resistant TB cases. I have been at the NIH now for over 4 years, although I still feel like the new guy on the block! Most of my career has been focused on quantifying the infectious aerosols generated by TB patients. I am very involved in the leadership of the American Thoracic Society (ATS) as the Past Chair of the Assembly on Pulmonary Infections and TB. I am writing to invite you to be a keynote speaker at a special Scientific Session being added to our International Conference May 16-20 due to the emerging pandemic of COVID-19. The exact time and data are not yet known, but the conference is relatively close in Philadelphia. This would be an opportunity to address and educate global academic leaders in pulmonary and critical medicine, infectious diseases, and public health. We usually have over 15,000 attendees at the ATS meeting. I am attaching the email string below to give you an idea of other speakers being considered.

I can only imagine how busy you must be now, so I apologize if this invitation is a distraction or a nuisance. And I would certainly understand if you are unable to join us given the demands on your time, but we would be absolutely delighted if you could speak.

Please feel to call or contact me at any time with questions or comments.

Sincerely,
Kevin Fennelly
Mobile (b) (6)

Kevin P Fennelly, MD, MPH, ATSF
Senior Research Clinician
Laboratory of Chronic Airway Infection
Pulmonary Branch
Division of Intramural Research
National Heart, Lung, and Blood Institute (NHLBI)
National Institutes of Health (NIH)

Building 10, Room 5-1421
10 Center Drive
Bethesda, MD 20892

From: Saukkonen, Jussi J (b) (6) >
Sent: Wednesday, February 26, 2020 7:15 PM
To: Dela Cruz, Charles (b) (6) >
Cc: Kristina Crothers (b) (6) >; Nahid, Payam (b) (6);
Saukkonen, Jussi <(b) (6)>; Maria Novozhilova (b) (6); Miriam
Rodriguez (b) (6); Fennelly, Kevin (NIH/NHLBI) [E]
(b) (6)
Hicks, Lauri (CDC/DDID/NCEZID/DHQP)
(b) (6) Evans, Scott (b) (6) >; Yeligar,
Samantha (b) (6) McGinniss, John E
(b) (6) >
Subject: Re: PI-TB Executive Committee Call

This looks like a great program. Hope you can get these speakers who will be in demand.

On Feb 26, 2020, at 2:44 PM, Dela Cruz, Charles (b) (6) wrote:

Thank you all for your great suggestions...

Here is a possible Agenda for the Special Session on Coronavirus.

Ideally, we should have some ATS attendees to be speakers. If anyone knows possible candidate, please let us know. I also know that ATS would like to encourage some high profile speakers if possible. Someone from CDC, NIAID, etc.

Please let us know additional suggestions.

I highlighted bold are possible speakers.

We will need to wait until the ATS BOD this week to get the go ahead to invite the speakers.

(b) (4)

Charles S. Dela Cruz, MD, PhD
Associate Professor
Section of Pulmonary, Critical Care and Sleep Medicine
Department of Internal Medicine
Department of Microbial Pathogenesis
Director, Center of Pulmonary Infection Research and Treatment (CPIRT)
Yale University
300 Cedar Street TAC S441-D
New Haven, CT 06513
Phone: (b) (6)
FAX: 203 785-5952

Email: (b) (6)

Faculty

profile: http://medicine.yale.edu/intmed/pulmonary/people/charles_delacruz.profile

Lab website: <http://medicine.yale.edu/lab/delacruz/index.aspx>

CPIRT website: cpirt.yale.edu

<image001.png>

<image003.png>

From: "Crothers, Kristina" <(b) (6)>

Date: Tuesday, February 25, 2020 at 8:52 PM

To: "Saukkonen, Jussi J" (b) (6)>, "Nahid, Payam" (b) (6)

Cc: "Dela Cruz, Charles" (b) (6) "Saukkonen, Jussi"

(b) (6)>, Maria Novozhilova <(b) (6)> ,

"(b) (6)" (b) (6)

>, "Kevin P. Fennelly, MD" (b) (6)> ,

(b) (6)

(b) (6)

(b) (6)>, adam

meyer <(b) (6)>

(b) (6)>, Scott Evans

(b) (6)>, "Yeligar, Samantha M." <(b) (6)>

(b) (6)

(b) (6), "McGinniss, John E"

(b) (6) >

Subject: Re: PI-TB Executive Committee Call

Hi - these are great suggestions.

(b) (4)

(b) (4)

Kristina

From: Saukkonen, Jussi J (b) (6)

Sent: Tuesday, February 25, 2020 9:02:43 AM

To: Nahid, Payam

Cc: Dela Cruz, Charles; Saukkonen, Jussi; Crothers, Kristina; Maria Novozhilova; Miriam Rodriguez; (b) (6); Kevin P. Fennelly, MD; (b) (6)

(b) (6); Evans, Scott; Yeligar, Samantha M.;

(b) (6); McGinniss, John E

Subject: Re: PI-TB Executive Committee Call

These would be excellent speakers to also try to get!

> On Feb 25, 2020, at 11:50 AM, Nahid, Payam (b) (6) wrote:

>

> Agree, these are excellent suggestions. An FYI below on what CROI has assembled for ad hoc session on COVID-19:

(b) (4)

>

> -----

> Payam Nahid, MD, MPH

> Professor of Medicine

> University of California, San Francisco

> Associate Director, Clinical Trials Operations, UCSF Office of Research

> Medical Director, UCSF CTSI Trials Innovation Network (TIN)

> Director, UCSF Center for Tuberculosis (<http://tb.ucsf.edu>)

[UCSF Center for Tuberculosis | UCSF Center for TB](#)

tb.ucsf.edu

>

> Zuckerberg San Francisco General Hospital

> Division of Pulmonary & Critical Care Medicine

> 1001 Potrero Avenue, Room 5K1

> San Francisco, CA 94110

> Email: (b) (6)

> UCSF Profile: <http://profiles.ucsf.edu/payam.nahid>

[Payam Nahid | UCSF Profiles](#)


profiles.ucsf.edu

Payam Nahid's profile, publications, research topics, and co-authors

> Tel: (b) (6)

> Pronouns: he, him, his

>
>
>
> On 2/25/20, 6:47 AM, "Dela Cruz, Charles" (b) (6) wrote:
>
> Thanks Jussi for your great suggestions. We will try to incorporate these into the final session.
> Much appreciated
> Charles
>
>
>
> -----
> Charles S. Dela Cruz, MD, PhD
> Associate Professor
> Section of Pulmonary, Critical Care and Sleep Medicine
> Department of Internal Medicine
> Department of Microbial Pathogenesis
> Director, Center of Pulmonary Infection Research and Treatment (CPIRT)
> Yale University
> 300 Cedar Street TAC S441-D
> New Haven, CT 06513
> Phone: (b) (6)
> FAX: 203 785-5952
>
> Email: (b) (6)
> Faculty profile: https://urldefense.proofpoint.com/v2/url?u=http-3A_medicine.yale.edu_intmed_pulmonary_people_charles-5Fdelacruz.profile&d=DwIGaQ&c=iORugZls2LIYyCAZRB3XLg&r=XoHvlyApUj67iV1KyA1zSg&m=OCAEXv-43B0vEiVlnTNd-DXvFYATijFpvUftbDe3o4&s=XbJr53zMi1g0yYn-iXh9t9_vBPfjcNC8h-iRJ2lihVk&e=



[Charles Dela Cruz, MD, PhD < Pulmonary, Critical Care and Sleep Medicine](#)

urldefense.proofpoint.com

Dr. Dela Cruz completed his research training through an MD/PhD program in the area of immunology and virology from University of Toronto and Yale. Clinically, he is trained in internal medicine, and specializes in pulmonary and critical care medicine

and is currently an Associate
Professor at Yale University in the

> Lab website: https://urldefense.proofpoint.com/v2/url?u=http-3A_medicine.yale.edu_lab_delaacruz_index.aspx&d=DwIGaQ&c=iORugZIs2LIYyCAZRB3XLg&r=XoHvIYApUj67iV1KyA1zSg&m=OCAEXv-43B0vEiVInTNd--DXvFYATljFpvUftbDe3o4&s=F7cVzfOPw5tmgLz95Y984or0dPHCoEYBNsv_iP7GA2g&e=

Dela Cruz Lab

urldefense.proofpoint.com

Dr. Dela Cruz completed his research training through an MD/PhD program in the area of immunology and virology from University of Toronto and Yale. Clinically, he is trained in internal medicine, and specializes in pulmonary and critical care medicine and is currently an Assistant Professor at Yale University in the

> CPIRT website: cpirt.yale.edu

>

>

>

>


>

> On 2/25/20, 9:34 AM, "Saukkonen, Jussi" (b) (6) wrote:

>

> Great!


(b) (4)



[First US MERS-CoV Cases Underscore Need for Preparedness | Global Health | JAMA | JAMA Network](#)

urldefense.proofpoint.com

Confirmation of the first 3 US cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection highlighted the importance of preparedness plans and infection control policies for hospitals and other facilities in dealing with a potentially dangerous infectious disease.



[2019 Novel
Coronavirus—Important
Information for
Clinicians | Global
Health | JAMA | JAMA
Network](#)

urldefense.proofpoint.com

This Viewpoint summarizes the epidemiology and clinical features of 2019-nCoV infection and reviews CDC criteria to guide evaluation and management of patients with possible infection.

(b) (4)

(b) (4)

> -----Original Message-----

> From: Dela Cruz, Charles (b) (6)

> Sent: Monday, February 24, 2020 9:49 PM

> To: Crothers, Kristina (b) (6); Maria Novozhilova

(b) (6);

> Cc: Miriam Rodriguez (b) (6); Kevin P. Fennelly,

MD (b) (6); Nahid, Payam (b) (6)

(b) (6);

(b) (6); Evans, Scott

(b) (6); Yeligar, Samantha M. (b) (6)

(b) (6); Saukkonen, Jussi (b) (6)

McGinniss, John E (b) (6)

> Subject: [EXTERNAL] Re: PI-TB Executive Committee Call

>

> Dear colleagues

>

> Hope all is well.

>

> As part of ATS 2020 in May, PITB Programming has been requesting to see if there would be a venue for a coronavirus session.

>

> The ICC chair and ATS was able to seek out a possible forum for a Special Session on Coronavirus on the Monday Afternoon during ATS.

>

> Payam and I have been discussing a possible session title, content and speakers.

>

> The session title could be --


>

(b) (4)

>
> Many thanks
> Charles

>
>
> -----
> Charles S. Dela Cruz, MD, PhD
> Associate Professor
> Section of Pulmonary, Critical Care and Sleep Medicine Department of Internal Medicine
> Department of Microbial Pathogenesis Director, Center of Pulmonary Infection Research and
> Treatment (CPIRT) Yale University
> 300 Cedar Street TAC S441-D
> New Haven, CT 06513
> Phone: (b) (6)
> FAX: 203 785-5952

>
> Email: (b) (6)
> Faculty profile: <https://urldefense.proofpoint.com/v2/url?u=https-3A-nam05.safelinks.protection.outlook.com-3Furl-3Dhttp-253A-252F-252Fmedicine.yale.edu-252Fintmed-252Fpulmonary-252Fpeople-252Fcharles-5Fdelacruz.profile-26amp-3Bdata-3D02-257C01-257Ccharles.delacruz-2540yale.edu-257C07f45f4dbd774f4a3dcc08d7b9ffc1d2-257Cdd8cbebb21394df8b4114e3e87abeb5c-257C0-257C0-257C637182380425442155-26amp-3Bdata-3DQWWL8cD0cYtHaxgilDZfU7dywmTyCbpP54bLOO2RpHs-253D-26amp-3Breserved-3D0&d=DwlGaQ&c=iORugZls2LIYyCAZR83XLg&r=XoHvIYApUj67iV1KyA1zSg&m=OCAEXv-43B0vEiVInTNd--DXvFYATlJFpvUftbDe3o4&s=TVWeA9SztUxTEK8J5yHFcOkt3CyArZWDsYQDZPgeuEQ&e=>



Charles Dela Cruz, MD, PhD < Pulmonary, Critical Care and Sleep Medicine

urldefense.proofpoint.com

Dr. Dela Cruz completed his research training through an MD/PhD program in the area of immunology and virology from University of Toronto and Yale. Clinically, he is trained in internal medicine, and specializes in pulmonary and critical care medicine and is currently an Associate Professor at Yale University in the

> Lab website: https://urldefense.proofpoint.com/v2/url?u=https-3A-nam05.safelinks.protection.outlook.com-3Furl-3Dhttp-253A-252F-252Fmedicine.yale.edu-252Ftab-252Fdelacruz-252Findex.aspx-26amp-3Bdata-3D02-257C01-257Ccharles.delacruz-2540yale.edu-257C07f45f4dbd774f4a3dcc08d7b9ffc1d2-257Cdd8cbebb21394df8b4114e3e87abeb5c-257C0-257C0-257C637182380425442155-26amp-3Bdata-3DaUEJSTgiaCXmTQiuAB0K0YrMiqFxdd2HiPhGuq8Psig-253D-26amp-3Breserved-3D0&d=DwlGaQ&c=iORugZls2LIYyCAZRB3XLg&r=XoHvIYApUj67iV1KyA1zSg&m=OCAEXv-43B0vEiVInTNd--DXvFYATlJFpvUftbDe3o4&s=s6rnKnYlqiuUr8OIi_HRKyYFhvJwdc4_t9rmpZzqixY&e=

Dela Cruz Lab

urldefense.proofpoint.com

Dr. Dela Cruz completed his research training through an MD/PhD program in the area of immunology and virology from University of Toronto and Yale. Clinically, he is trained in internal medicine, and specializes in pulmonary and critical care medicine and is currently an Assistant Professor at Yale University in the

> CPIRT website: cpirt.yale.edu

>

>

>

>
> On 2/22/20, 7:47 PM, "Crothers, Kristina" <[REDACTED]> (b) (6) wrote:
>
> Hi all - we need to reschedule the call as both Rachel and I will be traveling to the ATS board
meeting next Wednesday. Please let me and Maria know if you could join a call Wednesday March 4
at 4pm eastern instead.
> Kristina
>
> Sent from my iPhone
>
>> On Feb 21, 2020, at 12:20 PM, Maria Novozhilova <[REDACTED]> (b) (6) > wrote:
>>
>>
>> <PI-TB Executive Committee Call>
>
> _____
>
> Privileged, confidential or patient identifiable information may be contained in this
message. This information is meant only for the use of the intended recipients. If you are not the
intended recipient, or if the message has been addressed to you in error, do not read, disclose,
reproduce, distribute, disseminate or otherwise use this transmission. Instead, please notify the
sender by reply e-mail, and then destroy all copies of the message and any attachments.
>
>
>
>
>
>



NIH-001207

CPRRT



the 1990s, the number of people in the UK who are aged 65 and over has increased from 10.5 million to 12.5 million, and the number of people aged 75 and over from 4.5 million to 6.5 million (Office of National Statistics 2000).

There is a growing awareness of the need to address the needs of older people in the community, and the importance of the role of the general practitioner (GP) in this. The Department of Health (1999) has identified the need to improve the health of older people, and the importance of the role of the GP in this. The Department of Health (1999) has also identified the need to improve the health of older people, and the importance of the role of the GP in this.

The Department of Health (1999) has identified the need to improve the health of older people, and the importance of the role of the GP in this. The Department of Health (1999) has also identified the need to improve the health of older people, and the importance of the role of the GP in this.

The Department of Health (1999) has identified the need to improve the health of older people, and the importance of the role of the GP in this. The Department of Health (1999) has also identified the need to improve the health of older people, and the importance of the role of the GP in this.

The Department of Health (1999) has identified the need to improve the health of older people, and the importance of the role of the GP in this. The Department of Health (1999) has also identified the need to improve the health of older people, and the importance of the role of the GP in this.

The Department of Health (1999) has identified the need to improve the health of older people, and the importance of the role of the GP in this. The Department of Health (1999) has also identified the need to improve the health of older people, and the importance of the role of the GP in this.

The Department of Health (1999) has identified the need to improve the health of older people, and the importance of the role of the GP in this. The Department of Health (1999) has also identified the need to improve the health of older people, and the importance of the role of the GP in this.

The Department of Health (1999) has identified the need to improve the health of older people, and the importance of the role of the GP in this. The Department of Health (1999) has also identified the need to improve the health of older people, and the importance of the role of the GP in this.

The Department of Health (1999) has identified the need to improve the health of older people, and the importance of the role of the GP in this. The Department of Health (1999) has also identified the need to improve the health of older people, and the importance of the role of the GP in this.

The Department of Health (1999) has identified the need to improve the health of older people, and the importance of the role of the GP in this. The Department of Health (1999) has also identified the need to improve the health of older people, and the importance of the role of the GP in this.

The Department of Health (1999) has identified the need to improve the health of older people, and the importance of the role of the GP in this. The Department of Health (1999) has also identified the need to improve the health of older people, and the importance of the role of the GP in this.

The Department of Health (1999) has identified the need to improve the health of older people, and the importance of the role of the GP in this. The Department of Health (1999) has also identified the need to improve the health of older people, and the importance of the role of the GP in this.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 04:21:24 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Invitation to Spanih meeting

RSVP sorry no.

From: Jose Alcamí Pertejo <ppalcamí@isciii.es>
Sent: Thursday, February 27, 2020 10:16 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Jose Alcamí Pertejo <ppalcamí@isciii.es>
Subject: Invitation to Spanih meeting

Dear Dr Fauci,

Hope this mail finds you well. We had the opportunity to meet in Madrid during the R4P meeting. I was the local chair of the Conference and had the privilege of introducing your talk to the plenary.

I would like to invite you as plenary speaker to the meeting of the Spanish AIDS Society (GESIDA) that will take place in Málaga, Spain next 30th November 2020. GESIDA Congress is the most important HIV national meetings in Spain that brings together the full "HIV Community" including clinicians, basic researchers, experts in epidemiology and public health and member from NGOs and patients' associations. Overall 700 attendees are expected to come to the meeting.

We would love to have you as a speaker in the Opening Plenary Session in evening the 30th November. Your challenging articles regarding the strategies to end the HIV epidemic in the United States, will be a great topic to be addressed in such session and an inspiration to Spanish researchers. If you prefer to talk about a different topic as the co-morbidities scenario in HIV infection it will be welcome too.

We would be more than happy if you could participate in this meeting.

If know your agenda is always full, even more these days with the current Coronavirus outbreak,

but if you could accept this invitation I think this can represent a real boost in the fight against HIV epidemics in Spain, a field in which the Spanish AIDS Society is strongly committed.

It would be wonderful if we can have you as a speaker.

Best wishes

Jose Alcamí

***** AVISO LEGAL ***** Este mensaje electrónico está dirigido exclusivamente a sus destinatarios, pudiendo contener documentos anexos de carácter privado y confidencial. Si por error ha recibido este mensaje y no se encuentra entre los destinatarios, por favor no use, informe, distribuya, imprima o copie su contenido por ningún medio. Le rogamos lo comunique al remitente y borre completamente el mensaje y sus anexos. El Instituto de Salud Carlos III no asume ningún tipo de responsabilidad legal por el contenido de este mensaje cuando no responda a las funciones atribuidas al remitente del mismo por la normativa vigente.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 04:13:52 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: David Rubenstein's invitation to Dr. Fauci

I always like to do things with David Rubenstein

From: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Sent: Thursday, February 27, 2020 12:19 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: FW: David Rubenstein's invitation to Dr. Fauci

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mary Brady <MBrady@economicclub.org>
Sent: Wednesday, February 26, 2020 6:07 PM
To: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Cc: (b) (6); Judi Irastorza <Judi.Irastorza@economicclub.org>
Subject: David Rubenstein's invitation to Dr. Fauci

Patricia,

David Rubenstein asked that we reach out to you in an effort to schedule an Economic Club of Washington event that would feature Dr. Fauci in a conversation with David on COVID-19. It is my understanding that David had a similar interview with Dr. Fauci in the last week or so.

Below are several dates from David's calendar for your consideration.

Wednesday, April 22 – Breakfast

Tuesday, April 28 – Breakfast or lunch
Tuesday, May 5 – Breakfast or Lunch
Friday, May 15 – Lunch

Additionally, I have attached an invitation letter from Mr. Rubenstein to Dr. Fauci for your convenience. The Economic Club has the ability to turn around an event in a relatively short period of time. As you may recall, our events typically take place at breakfast, lunch or dinner, at downtown Washington, D.C. hotels. Events that feature a prominent world leader, such as Dr. Fauci, generally attract a select audience of over 500 members and guests from among Washington's business and government leaders, as well as the diplomatic corps.

We understand the complexities and constraints of Dr. Fauci's schedule and can be responsive to his needs. If none of the dates above work with Dr. Fauci's schedule, please suggest some that will and we will work with David to confirm a date and begin the process. I have copied Judi Irastorza, who I believe you have worked with in the past, and she will coordinate anything you need.

Sincerely,
Mary

Mary C. Brady

Executive Director

The Economic Club of Washington, D.C.

1601 K Street NW, Suite 210, Washington, DC 20006

Office: (202) 481-3260 | Mobile: (b) (6)

mbrady@economicclub.org

[Our Sponsors](#) | www.EconomicClub.org

[@TheEconomicClub](#) | [LinkedIn](#) | [YouTube](#)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 04:10:35 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Invitation to join Scientific Advisory Board

Please handle.

From: Ajay Gupta <(b) (6)>
Sent: Thursday, February 27, 2020 1:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Re: Invitation to join Scientific Advisory Board

Hi Dr. Fauci,

just a quick question. (b) (4)

(b) (4)

thanks,

Ajay

From: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Date: Monday, February 17, 2020 at 3:59 AM
To: Ajay Gupta <(b) (6)>
Subject: RE: Invitation to join Scientific Advisory Board

Thanks for the note. My position in the US Government does not allow me to join such Boards.

From: Ajay Gupta <(b) (6)>
Sent: Sunday, February 16, 2020 10:21 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Invitation to join Scientific Advisory Board

Dear Dr. Fauci,

By way of this email, I would like to introduce our new biotech company based in California, Celestial Therapeutics Inc.

(b) (4)

We would like to extend an invitation to you to join our company's Scientific Advisory Board.

Please see attached herewith the executive summary and a slide deck of our company.

Thanks and looking forward to hearing from you shortly.

Best regards,

Ajay Gupta, Ph.D.
President, Chairman & CEO
Celestial Therapeutics Inc.

Tel: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 04:07:36 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: FW: Lack of preparedness for the coronavirus pandemic

FYI. Does this deserve a response.

From: Nejat Duzgunes (b) (6)
Sent: Thursday, February 27, 2020 1:55 PM
To: Collins, Francis (NIH/OD) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E]
(b) (6)>
Cc: Nejat Duzgunes (b) (6)
Subject: Lack of preparedness for the coronavirus pandemic
Importance: High

Dear Dr. Collins and Dr. Fauci,

I am sorry to say that our lack of preparedness for the coronavirus pandemic has its roots in the way biomedical research is funded in the United States, as well as in the lack of leadership and vision on the part of NIH and its institutes since the SARS coronavirus outbreak in 2003. I try to expand on these problems in the article below. I would welcome your response to my thesis.

Sincerely,

Nejat Düzgüneş, Ph.D.
Professor of Microbiology
Department of Biomedical Sciences
Arthur A. Dugoni School of Dentistry
University of the Pacific
155 Fifth Street, Room 412
San Francisco, CA 94103

(b) (6)



The Wuhan Coronavirus (COVID-19): Why there is no cure or vaccine

In their *Medical Virology* text published in 1994, D.O. White and F.J. Fenner stated “No convincing evidence has yet been obtained to link human coronaviruses with serious disease ..., but they are an important cause of that trivial but annoying disease, the common cold.” This generalization changed drastically with the emergence of the severe acute respiratory syndrome coronavirus in 2002-2003 (SARS-CoV), and the National Institutes of Health (NIH) immediately sought the expertise of these two scientists at the time. *Now, 17 years later, we still do not have an antiviral medicine or a vaccine against the novel coronavirus* that originated in China, now designated as COVID-19 by the World Health Organization (WHO). On February 21, there were 75,567 cases and 2,239 deaths in China; and 1,152 cases outside China, with 8 deaths, according to the Director-General of the WHO. The two viruses appear to use the same gate (or “receptor”) on host cells to infect them. Despite such expected similarities between new and old strains of the virus, research on coronaviruses has not been a priority for the National Institute of Allergy and Infectious Diseases (NIAID). In the end, all that the Director of NIAID was able offer is “good healthcare” as a remedy for COVID-19 infections.

The major reason we do not have a cure for coronaviruses is that there has been no coordinated effort by the NIAID to establish long-term research programs focused on coronaviruses. Realizing the insufficient progress in this area, the NIAID announced on February 6 a “Notice of Special Interest to highlight the urgent need for research on the 2019 novel Coronavirus.” Grants have indeed been awarded to some scientists since 2003, but such grants are highly competitive, with success rates of applications to NIAID between 14 and 18%, indicating that 82-86% of applicants are unable to obtain funding to carry out research. The *time* and *effort* spent on preparing grant applications to NIH are enormous, diverting these precious resources from actual research to what some scientists call “grantsmanship” (essentially, the ability to sell your idea to a review committee!). These “games scientist play” to procure funding are a hindrance to the progress of science. *The fact that we do not have a cure or a vaccine against coronaviruses over the past 17 years since the SARS epidemic, attests to this detrimental effect.*

Development of a vaccine against COVID-19t is also not straightforward. SARS was probably not considered by NIH to be an important pathogen on which to

spend resources. Even if the biomedical research community had developed a vaccine against coronaviruses, pharmaceutical companies would probably not have considered it a profitable endeavor. *Therefore, it is essential for public funds to be used by NIH and the CDC to both discover an effective vaccine and to manufacture it.*

We need to ensure that long-term projects to develop antivirals and vaccines against coronaviruses and other infectious agents, including tuberculosis and influenza virus, are implemented and fully funded. *We need to have a funding system that does not depend on the often unfounded criticism or whims of grant reviewers.* Although the current peer review system is touted generally as the best way to allocate funding, *it has never been tested scientifically* against an alternative. While half of the NIH budget (currently \$39 billion) may still be allocated for high-cost projects, including clinical trials, the other half should be awarded for periods of 10 years or longer to established scientists who have a track-record of scientific work, as well as to young scientists who are starting their first independent position. The budgets of these grants would be somewhat limited, but would provide uninterrupted funding and alleviate the stress of competing for renewals every 3–5 years. Scientists opting for these grants will not have to submit extensive grant applications. *More importantly, this system will more than double the number of independent investigators.* After a 10-12 year period, the scientific productivity (*per grant dollar*) of scientists on the classical grant system would be compared with that of scientists on long-term funding. *After all, the way we choose the mode of science funding should conform to the way science progresses, by experimentation and analysis.*

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 04:05:11 +0000
To: Robert Durr
Subject: RE: Covid-19

We will be looking at this.

From: Robert Durr [REDACTED] (b) (6)
Sent: Thursday, February 27, 2020 2:03 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: Covid-19

Dr. Fauci,
This may be terribly simplistic, but if Covid-19 binds to ACE2 receptors in host cells, has anyone looked at ACE2 receptor blockers as potentially ameliorating disease severity or infectivity?
Sincerely,
Robert Alan Durr, M.D.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 04:04:26 +0000
To: HMS-Faculty Affairs Senior Appointments
Subject: RE: Confidential Evaluation Request on behalf of Harvard Medical School Dean George Q. Daley, MD, PhD (b) (6)

Dear Dr. Cotti:

I am very sorry, but I just do not have time to do this right now. I am inundated 24/7 with coronavirus issues. I hope that you understand.

Best regards,

Tony

From: HMS-Faculty Affairs Senior Appointments
<FacultyAffairs_SeniorAppointments@hms.harvard.edu>
Sent: Thursday, February 27, 2020 1:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Cotti, Dagmara <Dagmara_Cotti@hms.harvard.edu>; Tekleab, Sarah <Sarah_Tekleab@hms.harvard.edu>
Subject: Confidential Evaluation Request on behalf of Harvard Medical School Dean George Q. Daley, MD, PhD – (b) (6)

Dear Dr. Fauci,

Harvard Medical School is currently considering (b) (6)

Attached is a letter from George Q. Daley, MD, PhD, Dean of the Faculty of Medicine at Harvard University and Caroline Shields Walker Professor of Medicine, requesting your evaluation of (b) (6) academic accomplishments. The following materials are also attached: (b) (6) curriculum vitae, an annotated bibliography of (b) (6) self-selected 10 most significant scholarly works, and the criteria by which (b) (6) qualifications are to be evaluated.

Please confirm receipt of this communication and let me know if you will be able to complete an evaluation. When composing your evaluation, please address the questions in Dean Daley's letter. We would greatly appreciate receiving letters of evaluation by **Thursday, March 26, 2020**. We are grateful for your time and expertise and we appreciate your consideration of this request.

Warm regards,
Dagmara

DAGMARA COTTI, PhD

Program Director for Academic Affairs

Harvard Medical School | Office for Faculty Affairs

Gordon Hall, 25 Shattuck Street, Suite 206 | Boston, MA 02115

office: 617.432.6889 | **fax:** 617.734.4382 | Hours: M-F 8:30am-4:00pm

fa.hms.harvard.edu

Executive Assistant: Sarah Tekleab

Sarah_Tekleab@hms.harvard.edu | **office:** 617.432.7438

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 03:57:45 +0000
To: HJ Mai
Cc: Billet, Courtney (NIH/NIAID) [E]
Subject: RE: Confirmation of report

This is really not true. It was taken vey much out of context.

From: HJ Mai <HMai@npr.org>
Sent: Thursday, February 27, 2020 2:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Confirmation of report

Dear Dr. Fauci,

This is HJ from NPR again. I was wondering if you could confirm a NYT report that says the White House has instructed you not to say anything about the coronavirus outbreak without prior approval.

Kind regards,
HJ

 | HJ Mai | Editor, Morning Edition | hmai@npr.org | (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 03:54:23 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: FW: Idea for coronavirus contention

NIAID inquiries, Please

From: Blanco, Luz (NIH/NIAMS) [E] (b) (6) >
Sent: Thursday, February 27, 2020 2:51 PM
To: Collins, Francis (NIH/OD) [E] (b) (6) >
Cc: Gottesman, Michael (NIH/OD) [E] (b) (6) >; Fauci, Anthony (NIH/NIAID) [E]
(b) (6) >
Subject: Idea for coronavirus contention
Importance: High

Dears Dr Collins, Dr Gottesman, and Dr. Fauci:

I am reaching to you with this idea that might sound weird but I think it might be helpful. I have this idea to reduce the coronavirus infection and spreading. It is very simple but can get more complex as well.

(b) (5)

(b) (5). I do not have the capacity to work or promote these ideas but hopefully you have the power for doing so. Thanks, regards

Luz P. Blanco PhD.
Staff Scientist
SAB, NIAMS, NIH

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 03:54:22 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Coronavirus : CONFIDENTIAL: (b) (4) info
Attachments: image001.png, 2018_Book_UnderstandingTheHostImmuneResp.pdf, Advances in Clinical Chemistry 2018.pdf, BBASR-2016.pdf, Ch-22-francisandtaylor-2017.pdf, chapter-2012.pdf, GSH2005.pdf, HIVclinical trial2015.pdf, HIVclinical trial2017.pdf, macrophages2012.pdf, macrophages2013.pdf, NKCELLS2008.pdf, NKCELLS2012.pdf, RBC-HIV paper_2014.pdf

Please take a look at this.

-----Original Message-----

From: Parikh, Purvi (b) (6)>
Sent: Thursday, February 27, 2020 10:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Coronavirus : CONFIDENTIAL: (b) (4) info

Hi Dr Fauci

You must be swamped with coronavirus related correspondence but wanted to pass on some research that may prove helpful with coronavirus.

This pharmacist also plans to meet with Trump administration in upcoming weeks .

It may prove useful. I havent had a chance to dive deeply into the science of it so dont know efficacy but they are preparing a proof concept.

Main researcher is Nayan Patel and his email is (b) (6)

Sincererely,

Purvi Parikh, M.D., FACP
Allergy/Immunology Attending Physician
Clinical Assistant Professor, Department of Medicine and Department of Pediatrics Division of Infectious Diseases and Immunology Division of Rheumatology Allergy and Asthma Associates of Murray Hill
212-685-4225 (office number)
212-696-5682 (fax)

From: Purvi Parikh (b) (6)>
Sent: Thursday, February 27, 2020 9:43:18 PM
To: Parikh, Purvi
Subject: Fwd: CONFIDENTIAL: (b) (4) info

[EXTERNAL]

Sent from my iPhone

Begin forwarded message:

From: Heather Pixton (b) (6) >
Date: February 3, 2020 at 12:43:59 PM EST
To: (b) (6)
Subject: FW: Fwd: CONFIDENTIAL: (b) (4) info

Hi Purvi,

Here is the email from Dr Patel with his research and other relevant PubMed links. The body of the email provides an idea of what he has been working on and how he hopes to contribute to the current outbreak.

I would be happy to connect Dr Patel with you (or someone you suggest) should you find the information provided warrants further inquiry.

Warm Regards,
Heather

Heather Pixton
CSO Pharmacology & Compliance I CABODI

[<https://res.cloudinary.com/drasifo1s/image/upload/v1544910436/1130-cedrec/cell.jpg>] <tel:+(b) (6) (b) (6) I [<https://res.cloudinary.com/drasifo1s/image/upload/v1544910437/1130-cedrec/mail.jpg>] <mailto:Cedrec@SpectrumHP.com> Heather@CabodiCo.com<mailto:Heather@CabodiCo.com> I [<https://res.cloudinary.com/drasifo1s/image/upload/v1544910436/1130-cedrec/web.jpg>] <http://www.bestefekt.com><https://urldefense.proofpoint.com/v2/url?u=http-3A__www.bestefekt.com__&d=DwMFaQ&c=j5oPpO0eBH1iio48DtsedeElZfc04rx3ExJHeIIzuCs&r=TxeKofMBvUAkTP9Z8swJDduMT3NwOKJuoZJ8jdtz5TG0&m=yoSwihtDq3ar56w9cqDSwhynOIH-OCP4NL4AZXwE63E&s=eCWhMiiUaJaCzK1mNZQpB21poltX9tSrIR2KsTm_Rol&e=>>

(b) (6)

From: Heather (b) (6) >
Sent: Monday, February 03, 2020 12:21 PM
To: Heather Pixton (b) (6)
Subject: FW: Fwd: CONFIDENTIAL: (b) (4) info

Sent from Mail<<https://go.microsoft.com/fwlink/?LinkId=550986>> for Windows 10

From: Cedrec Sumimoto<mailto:(b) (6)>
Sent: Saturday, February 1, 2020 12:30 PM
To: Heather Pixton<mailto:(b) (6)>
Subject: Fwd: CONFIDENTIAL: (b) (4) info

(b) (6)

----- Forwarded Message -----
Subject:

CONFIDENTIAL: (b) (4) info

Date:

Fri, 31 Jan 2020 15:25:40 -0800

From:

Nayan Patel <[REDACTED]> (b) (6)

To:

Cedrec Sumimoto <[REDACTED]> (b) (6)

Hello Cedric,

[REDACTED] (b) (4)

(b) (4)



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 03:53:06 +0000
To: Leonard Schleifer
Cc: Erbeling, Emily (NIH/NIAID) [E]; Mascola, John (NIH/VRC) [E]; Cassetti, Cristina (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Regeneron COVID-19 update

Len:

Thanks for the note. Of course, we would be interested in working with you as you develop these antibodies.

Best regards,
Tony

From: Leonard Schleifer [REDACTED] (b) (6)
Sent: Thursday, February 27, 2020 3:25 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: Regeneron COVID-19 update

Tony,

Obviously you are swamped and the country is likely safer for it! I wanted to be sure you were up to date on our efforts re COVID-19. [REDACTED] (b) (4)

[REDACTED] (b) (4)

We have had discussions with our partners at BARDA and have had contact with the White House.

[REDACTED] (b) (4)

In the near future we will have a cocktail of antibodies ready for testing and we would be delighted to work with you and the NIH if that makes sense.

If you would like to discuss further, please call my cell [REDACTED] (b) (6) at anytime.

Len

***** This e-mail and any attachment hereto, is intended only for use by the addressee(s) named above and may contain legally privileged and/or confidential information. If you are not the intended recipient of this e-mail, any dissemination, distribution or copying of this email, or any attachment hereto, is strictly prohibited. If you receive this email in error please immediately notify me by return electronic mail and permanently delete this email and any attachment hereto, any copy of this e-mail and of any such attachment, and any printout thereof. Finally, please note that only authorized representatives of Regeneron

Pharmaceuticals, Inc. have the power and authority to enter into business dealings with any third party.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 03:42:11 +0000
To: Phillips, Kyra
Subject: RE: Confidential

Thanks, Kyra.

-----Original Message-----

From: Phillips, Kyra <Kyra.Phillips@abc.com>
Sent: Thursday, February 27, 2020 4:33 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Confidential

Dear Tony,

This note is between long time colleagues.

This entire Coronavirus story, and the handling of it, has really escalated into an unexpected journey. I want you to know how much I have respected you professionally and medically for nearly 20 years. I also want you to know that I have appreciated how we have communicated through the years about threats to our world's health and how honest and transparent you have always been. I know you are in a unique situation and I want you to know that I respect that and would never put you in a situation with my correspondence that would jeopardize you in anyway. With that said, I hope you can keep me informed, off the record if need be, so I can continue to cover this story honestly and fairly.

With utmost respect,

Kyra

@KyraPhillips
ABC News
Investigative Correspondent
KyraPhillips.Com
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 03:16:38 +0000
To: Alice Park
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Time follow up

Alice:

I am so sorry that I have not gotten back to you. I have been inundated 18 to 19 hours per day. By the time I get to e-mail it is late at night. I will try to connect with you tomorrow.

Best,

Tony

From: Alice Park <alice.park@time.com>
Sent: Thursday, February 27, 2020 5:17 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: Time follow up

Hi -- do you have a few minutes to talk about the following? Happy to chat whenever you're free. Best, Alice

On Wed, Feb 26, 2020 at 11:50 AM Alice Park <alice.park@time.com> wrote:

Hi Dr. Fauci -- have a couple of requests for you, one of which is to speak at our upcoming Time 100 Summit in April -- about COVID-19. I'll be sending a formal invite but wanted to explore your interest and availability.

Also wanted to speak to you about a story I'm working on concerning the risk of community spread of COVID-19 in the US. Wanted to get your perspective on the CDC warning and where those cases might come from. Happy to chat whenever you're free; I'm relatively free today and this evening. Best, Alice

PLEASE NOTE NEW PHONE NUMBER

Alice Park

TIME

212 522 9830

alice.park@time.com

@aliceparkny

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 02:49:34 +0000
To: Suzanne Bradley
Subject: RE: URGENT

There is much misinformation. I actually have not been muzzled at all by the Vice President. And BTW, it is safe to fly domestically (b) (6).

-----Original Message-----

From: Suzanne Bradley (b) (6)>
Sent: Thursday, February 27, 2020 5:32 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: URGENT

Dear Dr. Fauci,

I understand Vice President Pence has ordered you to not inform the public about Coronavirus without approval. This is quite terrifying, especially since Trump has already shown his desire to spread false or incomplete information about this public health crisis.

I'm planning to fly domestically TOMORROW (b) (6). Is it safe??

Thank you,

Suzanne Bradley

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 02:46:07 +0000
To: NIAID OD AM
Subject: FW: question

Let us discuss, but almost certainly no.

From: Fleisher, Thomas (NIH/CC/DLM) [V] (b) (6) >
Sent: Thursday, February 27, 2020 5:36 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Lang, David <LANGD@ccf.org>; Kay Whalen <KWhalen@aaaai.org>; Rebecca Brandt (AAAAI) <rbrandt@aaaai.org>
Subject: question

Tony,

As you are acutely aware, the COVID-19 situation is on everyone's mind and accordingly there have been questions raised by members of the AAAAI about what the organization can do to provide more guidance in this evolving situation. In light of this linked to the fact that our annual meeting begins March 13 in Philadelphia, we have made the decision to have a 45-60 minute session in the main hall on Saturday (March 14) morning from 7:00-8:00 prior to the scheduled plenary session slated to start at 8:15. My question is whether you would consider taking the Acela up Friday evening returning Saturday morning to host this session with a presentation followed by a Q&A session. If that is not possible, would you be willing to provide a 10-15 minute (shorter if you deem that appropriate) video generated as close to the 14th as possible that we would have projected in the main hall as noted above. If the latter, would you have a suggestion of an ID person in Philadelphia who would be knowledgeable and could field questions following your video. I recognize that even if you are willing to come to Philadelphia, that circumstances could arise that would preclude your traveling in which case we would ask for a video if at all possible. Finally, if neither option is possible, is there somebody in DC (including NIH), Baltimore or Philadelphia who could provide the short review and then sit for 30-45 minutes of Q&A. I am well aware that this is last minute and you have been incredibly busy with issues related to the pandemic, any help you could provide would be much appreciated by my colleagues and me.

Regards,

Tom

Thomas A. Fleisher, M.D.
Scientist Emeritus
Department of Laboratory Medicine
NIH Clinical Center
Bethesda, MD 20892
(b) (6) (tel)
301-402-1612 (fax)

The contents of this message, together with any attachments, are intended only for the use of the person(s) to which they are addressed and may contain confidential and/or privileged information. Further, any medical information herein is confidential and protected by law. It is unlawful for unauthorized persons to

use, review, copy, disclose, or disseminate confidential medical information. If you are not the intended recipient, immediately advise the sender and delete this message and any attachments. Any distribution, or copying of this message, or any attachment, is prohibited.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 02:43:32 +0000
To: NIAID OD AM
Subject: FW: Invitation to speak at National Academies workshop
Attachments: FMT Vaccines SOT 12.20.pdf

Let us discuss.

From: Pavlin, Julie <JPavlin@nas.edu>
Sent: Thursday, February 27, 2020 6:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Subject: Invitation to speak at National Academies workshop

Dear Dr. Fauci,

It is my pleasure to invite you to present at the National Academies of Sciences, Engineering, and Medicine workshop on "The Critical Public Health Value of Vaccines – Tackling Issues of Access and Hesitancy." This workshop will be held on May 28-29, 2020 at the Pan American Health Organization (PAHO) headquarters in Washington, DC. The statement of task for the workshop is attached.

The 1.5-day workshop will provide a venue to examine the current state of vaccine preventable diseases and the impact of vaccine access and hesitancy on vaccine preventable diseases globally, as well as the multidimensional drivers and impacts of declining vaccine confidence. This workshop will explore health systems, research opportunities, communication strategies, and policies that could be considered to address access, perceptions, attitudes, and behaviors toward vaccination. The workshop will be broadcast live over the web to an international audience, and is being hosted by the National Academies' Forum on Microbial Threats.

Due to your in-depth expertise in this field, we would like to invite you to give a plenary presentation on **the development of new vaccines in the midst of an outbreak, specifically on the prospects of a coronavirus vaccine**. The primary audience for the event will be researchers, health practitioners, industry leaders, and policy makers in infectious diseases and global health, so we are looking to initiate this workshop with relevant discussions of barriers to accessing vaccines. Your responsibilities would be to prepare and deliver a 15-minute presentation. We would cover your travel expenses in accordance with U.S. federal government rules. We would be thankful to have your involvement in this workshop. Please let me know if you might be interested. I would be happy to answer any questions you may have.

Thank you in advance for your time and consideration. We understand that this is a very busy time and your calendar may be in flux.

Best wishes,

Julie

Julie A. Pavlin, MD, PhD, MPH

Director, Board on Global Health

Health and Medicine Division – Find us at nationalacademies.org/HMD

The National Academies of Sciences, Engineering, and Medicine

500 Fifth Street, NW
Washington, DC 20001
Phone: 202-334-2171

Follow Us   

The National Academies of
SCIENCES • ENGINEERING • MEDICINE

=====

ORGANIZING COMMITTEE – THE CRITICAL PUBLIC HEALTH VALUE OF VACCINES – TACKLING ISSUES OF ACCESS AND HESITANCY

HEIDI LARSON (Co-Chair), Professor of Anthropology, Risk and Decision Science, London School of Hygiene & Tropical Medicine

MATTHEW ZAHN (Co-Chair), Medical Director, Division of Epidemiology and Assessment, Orange County Health Care Agency

KEVIN ANDERSON, Senior Program Manager, Chemical & Biological Defense Division, Science & Technology Directorate, Department of Homeland Security

ALISON BUTTENHEIM, Associate Professor, Family and Community Health, School of Nursing, University of Pennsylvania

ANDREW CLEMENTS, Deputy Director, Pandemic Influenza and Other Emerging Threats Unit, USAID

AMANDA COHN, Executive Secretariat, Advisory Committee on Immunization Practices, US Centers for Disease Control and Prevention

PETER DASZAK, President, EcoHealth Alliance

EVA HARRIS, Professor and Director, Division of Infectious Diseases and Vaccinology, Center for Global Public Health, University of California, Berkeley

ELIZABETH D. HERMSEN, Head, Global Antimicrobial Stewardship, Merck & Co., Inc.

NONI MACDONALD, Professor, Department of Pediatrics, Dalhousie University, Nova Scotia, Canada

WALT ORENSTEIN, Professor and Associate Director, Emory Vaccine Center

=====

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 02:42:42 +0000
To: Jon Cohen
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Interview request--typo fixed

Jon:

I am drowning right now. However, I am always happy to speak with you. Cannot do it until I dig out from under. Hopefully, soon.

Best,
Tony

-----Original Message-----

From: Jon Cohen <jcohen@aaas.org>
Sent: Thursday, February 27, 2020 5:48 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Interview request--typo fixed

Dr. Fauci,

I was most pleased to hear Sec. Azar's commitment to "radical transparency." In that vein, I would like to interview you about COVID-19 for a Science magazine article I am preparing.

Thanks in advance,

Jon Cohen
Science

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 02:32:50 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Question on report Dr. Fauci told he cannot speak with media unless cleared by White House

That is not what I said. I said for SARS the virus went from bat to civet cat to human; for MERS it went from bat to camel to human. I said we did not know what the animal reservoir was for the jump from animal to human with the novel coronavirus. Please tell her that. Thanks.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)
Sent: Thursday, February 27, 2020 7:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6) Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Subject: Fwd: Question on report Dr. Fauci told he cannot speak with media unless cleared by White House

Q from Donna Young re comments in VP pool report:

Do they now know the novel coronavirus jumped from a bat to a civet cat [skunk] served at feasts in China and then jumped to humans?
Is that the source for certain? Or was he just giving an example? Is there something you can provide to show that information?

From: "Young, Donna" <Donna.Young@spglobal.com>
Date: Thursday, February 27, 2020 at 7:01:00 PM
To: "Billet, Courtney (NIH/NIAID) [E]" <(b) (6)>
Cc: "Stover, Kathy (NIH/NIAID) [E]" (b) (6) >, "NIAID NEWS (NIH/NIAID)" <NIAIDNEWS@niaid.nih.gov>, "Myles, Renate (NIH/OD) [E]" (b) (6)
Subject: Re: Question on report Dr. Fauci told he cannot speak with media unless cleared by White House

Thank you. Also, can you please clarify what was in the VP pool report today.

Do they now know the novel coronavirus jumped from a bat to a civet cat [skunk] served at feasts in China and then jumped to humans?
Is that the source for certain? Or was he just giving an example? Is there something you can provide to show that information?

Thank you again.

Donna Young
Senior Reporter, Healthcare (Washington, DC)
S&P Global News
donna.young@spglobal.com

301.216.2433 desk

(b) (6) cell

@DonnaYoungDC - 'the pharma diviner'

<http://marketintelligence.spglobal.com/our-thinking/news.html>

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)>
Sent: Thursday, February 27, 2020 6:55 PM
To: Young, Donna <Donna.Young@spglobal.com>
Cc: Stover, Kathy (NIH/NIAID) [E] (b) (6)>; NIAID NEWS (NIH/NIAID) <NIAIDNEWS@niaid.nih.gov>; Myles, Renate (NIH/OD) [E] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] (b) (6)>
Subject: Re: Question on report Dr. Fauci told he cannot speak with media unless cleared by White House

Can you just attribute to NIAID spox? I ask because he's on meetings and calls...

From: "Young, Donna" <Donna.Young@spglobal.com>
Date: Thursday, February 27, 2020 at 6:52:48 PM
To: "Billet, Courtney (NIH/NIAID) [E]" (b) (6)>
Cc: "Stover, Kathy (NIH/NIAID) [E]" (b) (6)>, "NIAID NEWS (NIH/NIAID)" <NIAIDNEWS@niaid.nih.gov>, "Myles, Renate (NIH/OD) [E]" (b) (6)>
Subject: Re: Question on report Dr. Fauci told he cannot speak with media unless cleared by White House

Thank you. Is Dr. Fauci stating it is not true? Do I attribute to him or you stating the New York Times report is not true?

Thank you for your help.

Donna Young
Senior Reporter, Healthcare (Washington, DC)
S&P Global News
donna.young@spglobal.com

301.216.2433 desk

(b) (6) cell

@DonnaYoungDC - 'the pharma diviner'

<http://marketintelligence.spglobal.com/our-thinking/news.html>

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)
Sent: Thursday, February 27, 2020 6:39 PM
To: Young, Donna <Donna.Young@spglobal.com>
Cc: Stover, Kathy (NIH/NIAID) [E] (b) (6); NIAID NEWS (NIH/NIAID) <NIAIDNEWS@niaid.nih.gov>; Myles, Renate (NIH/OD) [E] (b) (6)
Subject: Re: Question on report Dr. Fauci told he cannot speak with media unless cleared by White House

Donna, so sorry, it's been a crazy day. We are not sure exactly where this came from. It's not true.

From: "Young, Donna" <Donna.Young@spglobal.com>
Date: Thursday, February 27, 2020 at 5:32:22 PM
To: "NIAID NEWS (NIH/NIAID)" (b) (6), "Stover, Kathy (NIH/NIAID) [E]" (b) (6), "Myles, Renate (NIH/OD) [E]" (b) (6), "Billet, Courtney (NIH/NIAID) [E]" (b) (6)
Subject: Re: Question on report Dr. Fauci told he cannot speak with media unless cleared by White House

Hi. I'm still waiting for a response on this. Could you at least tell me me you are going to respond?

Thank you.

Donna Young
Senior Reporter, Healthcare (Washington, DC)
S&P Global News
donna.young@spglobal.com

301.216.2433 desk

(b) (6) cell

@DonnaYoungDC - 'the pharma diviner'

<http://marketintelligence.spglobal.com/our-thinking/news.html>

From: Young, Donna

Sent: Thursday, February 27, 2020 1:35 PM

To: NIAID NEWS (NIH/NIAID) <NIAIDNEWS@niaid.nih.gov>; Stover, Kathy (NIH/NIAID) [E]

(b) (6); Myles, Renate (NIH/OD) [E] (b) (6); Billet, Courtney (NIH/NIAID) [E] (b) (6)>

Subject: Question on report Dr. Fauci told he cannot speak with media unless cleared by White House

Good Day: Could you please comment on this report from the New York Times that Dr. Fauci has been told that he must clear anything he plans to say about the coronavirus outbreak with the White House before he speaks to any media?

<https://www.nytimes.com/2020/02/27/us/politics/us-coronavirus-pence.html>

"Dr. Anthony S. Fauci, one of the country's leading experts on viruses and the director of the National Institute of Allergy and Infectious Diseases, told associates that the White House had instructed him not to say anything else without clearance."

Has Dr. Fauci or any other NIH official been told by the White House they cannot speak to the media unless cleared by the White House?

Please do let me know.

Thank you for your help.

Donna Young
Senior Reporter, Healthcare (Washington, DC)
S&P Global News
donna.young@spglobal.com

301.216.2433 desk

(b) (6) cell

@DonnaYoungDC - 'the pharma diviner'

<http://marketintelligence.spglobal.com/our-thinking/news.html>

The information contained in this message is intended only for the recipient, and may be a confidential attorney-client communication or may otherwise be privileged and confidential and protected from disclosure. If the reader of this message is not the intended recipient, or an employee or agent responsible for delivering this message to the intended recipient, please be aware that any dissemination or copying of this communication is strictly prohibited. If you have received this communication in error, please immediately notify us by replying to the message and deleting it from your computer. S&P Global Inc. reserves the right, subject to applicable local law, to monitor, review and process the content of any electronic message or information sent to or from S&P Global Inc. e-mail addresses without informing the sender or recipient of the message. By sending electronic message or information to S&P Global Inc. e-mail addresses you, as the sender, are consenting to S&P Global Inc. processing any of your personal data therein.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 00:47:19 +0000
To: Mark Zuckerberg
Subject: RE:

Mark:

Thanks for the note. If we start in April (~6-7 weeks from now) with a phase 1 trial of 45 subjects, it will take another 3-4 months to determine safety and some immunogenicity. The next step is phase 2 for efficacy. We may need help with resources for the phase 2 trial if we do not get our requested budget supplement. I believe that we will be OK. If this goes off track, I will contact you. Many thanks for the offer. Much appreciated.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mark Zuckerberg (b) (6)
Sent: Thursday, February 27, 2020 7:16 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject:

Tony:

I was glad to hear your statement that the covid-19 vaccine will be ready for human trials in six weeks. Are there any resources our foundation can help provide to potentially accelerate this or at least make sure it stays on track?

Mark

From: (b) (6)
Sent: Thu, 27 Feb 2020 17:43:18 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Dr. Fauci--Coronavirus comment 3/2 Healthline MEDIA

Sent from my iPhone

Begin forwarded message:

From: Kristen Fischer <(b) (6)>
Date: February 27, 2020 at 5:20:21 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Subject: Dr. Fauci--Coronavirus comment 3/2 Healthline MEDIA

Hi there,

I'm writing for Healthline about coronavirus and how the virus spread may be different in the Southern Hemisphere (they mention that in the story below). Care to weigh in?

I'd love to know:

1. Will coronavirus be any less severe in the Southern Hemisphere due to the summer weather there at the moment?
2. Will the virus spread in North America slow down due to geography or warmer weather at all? What can we expect in 3 months--and in one year as far as coronavirus in the U.S.?
3. Will it differ in how it spreads/tapers off in Asia, due to proximity of the outbreak?
4. Will this eventually be gone or will it be something that is a new health threat that could return in a year or so?
5. Any insight into the outlook of coronavirus, how it will spread or how long it will be active?

Looking for a brief email response by Monday morning at 10 a.m. Let me know if you can assist!

Warmly,
Kristen Fischer

--
Kristen Fischer
www.kristenfischer.com
(b) (6)

Find your family fun at the Jersey Shore--get your [free weekly e-newsletter](#) today!
See your product or service [Re-viewed by Kristen Fischer](#)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 16:29:44 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Covid-19--Conference Call Invitation

Let us discuss. Likely do not have time for this.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Buono, Lucia <LBUONO@imf.org> **On Behalf Of** Gopinath, Gita
Sent: Wednesday, February 26, 2020 2:22 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Gopinath, Gita <GGopinath@imf.org>; Milesi-Ferretti, Gian Maria <GMILESIFERRETTI@imf.org>; Celasun, Oya <OCelasun@imf.org>; Nabar, Malhar Shyam <MNabar@imf.org>; Christiansen, Lone Engbo <LChristiansen@imf.org>; Buono, Lucia <LBUONO@imf.org>
Subject: Covid-19--Conference Call Invitation

On behalf of Ms. Gopinath:

Dear Professor Fauci:

We are contacting you in the context of the evolving spread of Covid-19, which is already impacting livelihoods and economic activity in several countries. As you may know, the IMF publishes forecasts of economic growth for member countries four times a year, as well as macroeconomic policy recommendations. In that context, it would be invaluable for us to hear public health experts' views on the likely trajectory of the virus—the number of people that are likely to get infected in different countries and the likely time path. We would also benefit from hearing experts' views on the optimal public health policy response in different types of countries (countries with stronger or weaker health systems, different development levels, etc.), and the implied resource needs.

We are planning to set up a conference call with several experts to discuss these issues and were wondering if you would be available to join us. If you would be interested in joining, would you be able

to let my assistant Lucia Buono (lbuomo@imf.org) know of some dates and times that would work for you this week or early next week?

We would be extremely grateful for any guidance you might be able to offer as we strive to do our part in helping member countries respond to the epidemic.

Best regards,

Gita Gopinath
Economic Counsellor and Director
Research Department
International Monetary Fund

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 13:31:19 +0000
To: Conrad, Patricia (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: The global health leaders call, Wednesday 4 March at 13:00 CET
Attachments: (b) (4) Swisscom Call code.pdf

FYI

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: RYAN, Michael J. (b) (6) >
Sent: Thursday, February 27, 2020 7:55 AM
To: Redfield, Robert R. (CDC/OD) (b) (6)
(b) (6)
(b) (6) Felicity Harvey
(b) (6) Chris.Elias
(b) (6); Jeremy Farrar
(b) (6); Fauci, Anthony
(NIH/NIAID) [E] (b) (6)
(b) (6) Conrad, Patricia (NIH/NIAID) [E]
(b) (6); Thomas R. Frieden (b) (6)
(b) (6) Lynn Banks (b) (6); President | Resolve to Save Lives
<president@resolvetosavelives.org>; (b) (6)
(b) (6)
(b) (6)
Tarik Mohammed (b) (6) >
Cc: SHOC <shoc@who.int>; Office of the Director-General <DGOOffice@who.int>; SCHWARTLANDER, Bernhard F. (b) (6) >; MAHJOUR, Jaouad (b) (6) >; FALL, Ibrahima Soce (b) (6) >; GREIN, Thomas (b) (6) >; MINHAS, Raman (b) (6) >; COX, Paul Michael (b) (6) >; AL-SHORBAJI, Farah (b) (6) >; POOLE, Marcia (b) (6) >; DRURY, Patrick Anthony (b) (6) >; GRAAFF, Peter Jan (b) (6) >; Dr VAN KERKHOVE, Maria (b) (6) >; KABIR, Sophia (b) (6) >

(b) (6); FARES, Christine Youssef (b) (6)

Subject: The global health leaders call, Wednesday 4 March at 13:00 CET

Dear colleagues,

Dr Tedros would like to invite you to the next informal discussion about the ongoing 2019 novel coronavirus.

The teleconference will be hosted on Wednesday, 4 March at 13:00 CET and the dial-in number with a passcode is attached.

If you experience any technical difficulties joining this conference call, please contact the WHO HQ EOC operator at: +41227912490

It would be appreciated if you could kindly confirm your participation to Ms Sophia Kabir, email:

(b) (6); mobile no. (b) (6)

The agenda and background documents will be shared ahead of the call.

Best,

Mike

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 04:44:07 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: [EXTERNAL] RE: Hardball Tonight

FYI. (b) (6).

-----Original Message-----

From: Matthews, Chris (NBCUniversal, MSNBC) <kennedynixon@msnbc.com>
Sent: Wednesday, February 26, 2020 2:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Re: [EXTERNAL] RE: Hardball Tonight

When you can and are ready, I would love to have you on Hardball anytime in the 7pm hour tonight, tomorrow or Friday.

Sent from my iPhone

> On Feb 26, 2020, at 11:34 AM, Fauci, Anthony (NIH/NIAID) [E] (b) (6)> wrote:

>

> Chris:

> I am always happy to be on your show. I am hearing that they want us to hold on doing any interviews for the time being since the POTUS might do a press conference tonight. And so the decision is still in flux.

> Tony

>

> Anthony S. Fauci, MD

> Director

> National Institute of Allergy and Infectious Diseases Building 31,

> Room 7A-03

> 31 Center Drive, MSC 2520

> National Institutes of Health

> Bethesda, MD 20892-2520

> Phone (b) (6)

> FAX: (301) 496-4409

> E-mail: (b) (6)

> The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

>

> -----Original Message-----

> From: Matthews, Chris (NBCUniversal, MSNBC) <kennedynixon@msnbc.com>

> Sent: Wednesday, February 26, 2020 9:04 AM

> To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>

> Subject: Hardball Tonight

>

> Dear Tony -

>

> Could you come on tonight to address the coronavirus? We'd like to

> have you on anytime in the 7 hour. (b) (6)

>

> Best, Chris

>
> Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 04:35:33 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Can you chat?

Please set this up. Thanks.

From: Fox, Lauren <Lauren.Fox@turner.com>
Sent: Wednesday, February 26, 2020 5:41 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Can you chat?

Hey Dr. Fauci,

I wanted to reach out because I am working on a big piece about the effort behind the scenes to contain the coronavirus and I was hoping you could talk on background about that,

Best,

Lauren Fox

Lauren Fox
Congressional Reporter
CNN Politics
Lauren.Fox@turner.com
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 04:34:46 +0000
To: Arturo Casadevall
Subject: RE: My OpEd on the WSJ coming out Friday on convalescent serum for Coronavirus

Arturo:

Thank you for your note and for sending the OpEd. Nice Job! I hope that all is well with you.

Best,

Tony

From: Arturo Casadevall (b) (6) >
Sent: Wednesday, February 26, 2020 5:45 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: My OpEd on the WSJ coming out Friday on convalescent serum for Coronavirus

Dear Tony,

I just had an OpEd accepted in the WSJ proposing the use of convalescent sera to stem the coronavirus epidemic. The text of the OpEd is below in blue font (scroll down). I am sure the WSJ will shorten it and edit it but at least you have an advance copy of it. I just wanted you to have it since the WSJ is read widely in DC and I don't want anyone blindsiding you with questions about it.

As you know I have been long proponent of passive antibody therapies in infectious diseases and there is a huge body of historical data supporting this approach. Certainly, with modern blood banking techniques this option can be made quite safe and administration of a few cc's of serum could confer immediate immunity to those who will be exposed – like ER staff. I hope you agree with the message and like it.

Thank you for all you are doing for the country and humanity. If you need me for anything in this crisis rest assured that I am here.

Warm regards,
Arturo

From: Taranto, James <james.taranto@wsj.com>
Sent: Wednesday, February 26, 2020 4:27 PM
To: Arturo Casadevall (b) (6) >
Subject: Re: Asking for a quick decision on the submitted OpEd on stemming coronavirus epidemic

OK, we'll take this and aim to get it out in Friday's paper, though it will likely need some trimming for space.

Dear Mr. Varadarajan,

I wonder if the WSJ is interested in my OpEd. I am trying to get a message out that convalescent serum (e.g. serum from people who recover) can be used to stem the coronavirus epidemic if administered to exposed people. This has been known for over a century, and is well accepted, but not widely known, even among experts today. There was one report that China was beginning to stockpile serum but there has been almost no discussion of this option among world public health authorities. Although I can get this published in a medical journal my hope is to publish it instead in a venue of high readership since this is something that can be done today to stem the epidemic. I am hoping that given the economic consequences of the outbreak that the WSJ is interested. I included a brief bio below. Thanks for looking at this.
Arturo

Proposed op-ed.

To Stem the Coronavirus Epidemic use Survivors Blood.

(b) (4)

Arturo Casadevall MD, PhD

Author's brief bio

Arturo Casadevall, M.D., Ph.D., is a Bloomberg Distinguished Professor and Chair of the Molecular Microbiology and Immunology at Johns Hopkins School of Public Health. He received his M.D. and Ph.D. degrees from New York University. He completed his internship/residency in internal medicine at Bellevue Hospital and specialized in Infectious Diseases at the Albert Einstein College of Medicine. The author of over 800 papers, books and chapters, his major research interests are in fungal pathogenesis and the mechanisms of antibody action. He is also interested in the problems with scientific enterprise and with collaborators showed that misconduct accounts for the majority of retracted publications. He is editor-in-chief of mBio, Deputy Editor of the Journal of Clinical Investigation and serves on several editorial boards. He has served on several NIH committees including the NIAID Strategic Plan, the Blue Ribbon Panel on Biodefense Research, the NAS panel that reviewed the FBI investigation on anthrax attacks, the NAS Federal Regulations and Reporting committee and the National Science Advisory Board for Biosecurity. He was a Commissioner

in the National Commission on Forensic Science and previously served as President of the Medical Mycology Society of the Americas. He is currently the Chair the Board of Governors of the American Academy of Microbiology. He has received numerous honors including election to the American Society for Clinical Investigation, American Academy of Physicians, American Academy of Microbiology, Fellow of the American Academy for the Advancement of Science, American Academy of Arts and Sciences and the National Academy of Medicine.

Arturo Casadevall MD, PhD
Chair, Molecular Microbiology & Immunology
Alfred & Jill Sommer Professor and Chair
Bloomberg Distinguished Professor
Johns Hopkins School of Public Health
615 N. Wolfe Street
Room E5132
Baltimore, Maryland 21205

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 6 Mar 2020 03:48:12 +0000
To: Marston, Hilary (NIH/NIAID) [E]; Lerner, Andrea (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]
Subject: RE: For Review: (b) (5)

Thanks.

From: Marston, Hilary (NIH/NIAID) [E] (b) (6)>
Sent: Thursday, March 5, 2020 10:15 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6)
Subject: FW: For Review: (b) (5)
Importance: High

From: "DLGDESK (HHS/ASPR/OPP)" <DLGDESK@hhs.gov>
Date: Thursday, March 5, 2020 at 6:19 PM
To: "Stannard, Paula (HHS/IOS)" (b) (6) "Agnew, Ann (HHS/IOS)" (b) (6), "Trueman, Laura (HHS/IEA)" (b) (6) "Kadlec, Robert (OS/ASPR/IO)" (b) (6), "Bird, Catherine (OS/OGC)" (b) (6), "Hittle, Taylor (HHS/ASFR)" (b) (6), "Arbes, Sarah (HHS/ASL)" (b) (6), "Murphy, Ryan (OS/ASPA)" (b) (6), "Destro, Brenda (HHS/ASPE)" (b) (6), "Nevel, Amy (HHS/ASPE)" (b) (6), "Tobias, Constance (HHS/DAB)" (b) (6), "Giroir, Brett (HHS/OASH)" (b) (6), "Schwartz, Erica (HHS/OASH)" (b) (6), "Severino, Roger (HHS/OCR)" (b) (6), "Grigsby, Garrett (HHS/OS/OGA)" (b) (6), "Kerr, Lawrence (HHS/OS/OGA)" (b) (6), "Chang, William (HHS/OGC)" (b) (6), "Taitzman, Julie K (OIG/IO)" (b) (6), "Griswold, Nancy (HHS/OMHA HQ)" (b) (6), "Rucker, Donald (OS/ONC)" (b) (6), "Johnson, Lynn (ACF)" (b) (6), "Meyers, David (AHRQ/IOD)" (b) (6), "McNellis, Robert (AHRQ/CEPI)" (b) (6), "Patel, Anita (CDC/DDID/NCIRD/OD)" (b) (6), "Ethier, Kathleen (CDC/DDID/NCHHSTP/DASH)" (b) (6), "Brookes, Brady (CMS/OA)" (b) (6), "Hinton, Denise (FDA/OC)" (b) (6), "Cheever, Laura (HRSA)" (b) (6),

"Espinosa, Diana (HRSA)" (b) (6) >, "Macrae, Jim (HRSA)" (b) (6) >,
"Weahkee, Michael (IHS/HQ)" < (b) (6) >, "McCollum, Jeffrey T (IHS/HQ)"
(b) (6) >, "Frazier, Francis (IHS/HQ)" < (b) (6) >, "Collins,
Francis (NIH/OD) [E]" (b) (6) >, Anthony Fauci < (b) (6) >, Hilary
Marston (b) (6) >, "McCance-Katz, Elinore (SAMHSA/OAS)"
(b) (6) >, "Shuy, Bryan (OS/ASPR/IO)" < (b) (6) >,
"Yeskey, Kevin (OS/ASPR/IO)" (b) (6) >, Rick Bright (b) (6) >,
"Disbrow, Gary (OS/ASPR/BARDA)" (b) (6) >, "Phillips, Sally (OS/ASPR/SPPR)"
< (b) (6) >, "Greene, Jonathan (OS/ASPR/EMMO)" (b) (6) >,
"DeBord, Kristin (OS/ASPR/SPPR)" (b) (6) >, "Vineyard, Michael
(OS/ASPR/IO)" (b) (6) >, "Dodgen, Daniel (OS/ASPR/SPPR)"
(b) (6) >, "Imbriale, Samuel (OS/ASPR/SIIM)" < (b) (6) >,
"Donnelly, Kelsey (OS/ASPR/SPPR) (CTR)" (b) (6) >, "Haris, Mariam
(OS/ASPR/SPPR) (CTR)" (b) (6) >, "Fucci, Michael (OS/ASPR/SPPR) (CTR)"
(b) (6) >, "Roman-Stolte, Claudia (OS/ASPR/SPPR) (CTR)" (b) (6) >,
(b) (6) >, "Austin, Meredith (uscg.mil)" (b) (6) >, "Perdue,
Christopher (OS/ASPR/SPPR)" (b) (6) >, "Herrmann, Jack
(OS/ASPR/OEA)" (b) (6) >, Robert Johnson (b) (6) >,
"Wong, Diana (OS/ASPR/SIIM)" (b) (6) >, "Robertson, Lance (ACL)"
(b) (6) >, "Nicholls, Richard (ACL)" < (b) (6) >,
"Phillips, Christine (ACL)" (b) (6) >, "Blatner, Gretta (OS/ASPR/BARDA)"
(b) (6) >, "Feeney, Kathryn (OS/ASPR/IO) (CTR)" < (b) (6) >,
"Shirley, Mayo (FDA/OC)" (b) (6) >, "Sheehy, Janice (FDA/ORA)"
(b) (6) >, "McDaniel, Eileen (HHS/OMHA)" < (b) (6) >,
Linda Lambert (b) (6) >, "Gin, Julia (OS/ASPR/SPPR)" (b) (6) >,
"Adams, Steven A. (CDC/SNS/DSNS)" (b) (6) >, "Wolf, Laura (OS/ASPR/SIIM)"
(b) (6) >, "Lee, Scott (OS/ASPR/EMMO)" (b) (6) >, "Cooper, Kevin
(OS/ASPR/ORM)" (b) (6) >, "Moudy, Robin (OS/ASPR/SPPR)"
(b) (6) >, "Lawrence, Theresa (OS/ASPR/SPPR)"
< (b) (6) >, "Baker, Michael (OS/IEA)" < (b) (6) >
Cc: "Holland, Tara (OS/ASPR/EMMO)" (b) (6) >, "Delvecchio, Paolo
(SAMHSA/OMTO)" (b) (6) >, "Lobos, Elisa (SAMHSA/OFR/OD)"
(b) (6) >, "Bell, March (HHS/OCR)" (b) (6) >, "Frohboese,
Robinsue (HHS/OCR)" < (b) (6) >, "Knutson, Donna
(CDC/DDNID/NCEH/OD)" (b) (6) >, "Mackay, Thomas (OS/ASPR/EEAA)"
(b) (6) >, "Mango, Paul (HHS/IOS)" (b) (6) >, "Blackford,
Carol W. (CMS/CM)" (b) (6) >, "Bradsher, Kris (HHS/ASL)"
(b) (6) >, "Payne, Skip (CMS/OA)" (b) (6) >, "Gettinger,
Andrew (OS/ONC)" (b) (6) >, "Abbey, Rachel (OS/OSCP)"
(b) (6) >, "Cosgrove, Sandra (OS/ASPR/EEAA)" < (b) (6) >,
"Chaput, Daniel (OS/ONC)" (b) (6) >

Subject: For Review: (b) (5)

Dear Disaster Leadership Group (DLG) Members,

Attached for review is a draft paper (b) (5)
(b) (5) We are asking that you review this draft and provide feedback to us by **8:00am on Friday, March 6**. Please note that we are looking for **substantive feedback only**.

If you have any questions or concerns, please reach out to me at (b) (6) and kindly copy the DLGDESK@hhs.gov.

Thank you,

Daniel Dodgen, Ph.D.

Senior Advisor

Office of the Assistant Secretary for Preparedness and Response (ASPR)

Office of Strategy, Policy, Planning and Requirements (SPPR)

HEALTH AND HUMAN SERVICES (DHHS) | O'Neill House Office Building | 200 C Street SW | Washington, DC 20515

o. (b) (6)

(b) (6) | www.phe.gov

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 11:12:55 +0000
To: (b) (6) (OS/IOS)
Subject: RE: Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov | bioRxiv

Oh, I see what they are getting at. They examined at the single cell level the expression of RNA for ACH2, which is the receptor for the Coronavirus in the lung, and found that when they looked at various demographic groups there was greater expression of this receptor in Asian males. They are thus hinting that this is the reason why there was such an explosion of infections in China. This is possible, but the lowest level was in Northern Italians and take a look at what is happening in Northern Italy. I do not mean to put the paper down since there may be some truth in it. However, this journal (bioRxiv) is not peer reviewed and the data are skimpy. Someone should do a more scholarly study.

-----Original Message-----

From: (b) (6) (OS/IOS) <(b) (6)>
Sent: Tuesday, March 3, 2020 5:54 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Re: Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov | bioRxiv

They asked if this proved certain ethnic groups more likely to get the disease and I said I had never anything like that suggested to me by our leading scientists.

> On Mar 2, 2020, at 10:44 PM, Fauci, Anthony (NIH/NIAID) [E] <(b) (6)> wrote:
>

I do not know what question they asked you about this paper, but any question about this gene expression paper to a non-scientist would be unfair and inappropriate.

-----Original Message-----

From: (b) (6) (OS/IOS) <(b) (6)>
Sent: Monday, March 2, 2020 9:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Redfield, Robert R. (CDC/OD) <(b) (6)>
Cc: Harrison, Brian (HHS/IOS) <(b) (6)>
Subject: Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov | bioRxiv

Was asked about this on tv tonight.

<https://www.biorxiv.org/content/10.1101/2020.01.26.919985v1>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 03:26:29 +0000
To: Collins, Francis (NIH/OD) [E]; Giroir, Brett (HHS/OASH)
Cc: Steele, Danielle (HHS/IOS); Tabak, Lawrence (NIH/OD) [E]
Subject: RE: SARS CoV-2 in humanized mice

Ditto.

From: Collins, Francis (NIH/OD) [E] (b) (6)
Sent: Monday, March 2, 2020 9:32 PM
To: Giroir, Brett (HHS/OASH) (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Steele, Danielle (HHS/IOS) (b) (6); Tabak, Lawrence (NIH/OD) [E] <(b) (6)>
Subject: RE: SARS CoV-2 in humanized mice

Larry has it right. Tony may want to add.

Francis

From: Tabak, Lawrence (NIH/OD) [E] (b) (6)
Sent: Monday, March 2, 2020 8:14 PM
To: Giroir, Brett (HHS/OASH) (b) (6)>
Cc: Collins, Francis (NIH/OD) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Steele, Danielle (HHS/IOS) (b) (6)
Subject: Re: SARS CoV-2 in humanized mice

Brett,

Tony or Francis may offer additional insight, but the (b) (5)

(b) (5)

I hope this helps.

Larry

From: "Giroir, Brett (HHS/OASH)" <(b) (6)>
Date: Monday, March 2, 2020 at 7:25 PM
To: "Tabak, Lawrence (NIH/OD) [E]" (b) (6)>
Cc: Francis Collins (b) (6)>, Anthony Fauci (b) (6)>, "Steele, Danielle (HHS/IOS)" (b) (6)>, "Giroir, Brett (HHS/OASH)" (b) (6)
Subject: RE: SARS CoV-2 in humanized mice

Dear Larry,

Thank you for your patience. The question has been raised, (b) (5)

I appreciate your willingness to continue to work on this and respond to the questions that I am receiving.

V/r
Brett

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: (b) (6)

From: Tabak, Lawrence (NIH/OD) [E] (b) (6)
Sent: Thursday, February 20, 2020 5:29 PM
To: Giroir, Brett (HHS/OASH) (b) (6)>
Cc: Collins, Francis (NIH/OD) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6); Steele, Danielle (HHS/IOS) (b) (6)>
Subject: Re: SARS CoV-2 in humanized mice

Brett,
I have discussed with both Francis and Tony (b) (5)

With regard to your questions:

(b) (5)

(b) (5)

Hope this is helpful. Please let me know if you require additional information.
Best wishes,
Larry

From: "Giroir, Brett (HHS/OASH)" (b) (6) >
Date: Thursday, February 20, 2020 at 12:32 PM
To: "Tabak, Lawrence (NIH/OD) [E]" <(b) (6)>
Cc: "Steele, Danielle (HHS/IOS)" (b) (6)
Subject: RE: SARS CoV-2 in humanized mice

Can you give me a quick call?

(b) (5)

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: (b) (6)

From: Tabak, Lawrence (NIH/OD) [E] (b) (6)
Sent: Thursday, February 20, 2020 12:19 PM
To: Giroir, Brett (HHS/OASH) (b) (6) >
Cc: Steele, Danielle (HHS/IOS) (b) (6) >
Subject: Re: SARS CoV-2 in humanized mice

(b) (5)

Thanks

Larry

From: "Giroir, Brett (HHS/OASH)" (b) (6) >

Date: Thursday, February 20, 2020 at 12:17 PM

To: "Tabak, Lawrence (NIH/OD) [E]" (b) (6)

Cc: "Steele, Danielle (HHS/IOS)" (b) (6)

Subject: RE: SARS CoV-2 in humanized mice

Larry

(b) (5)

Brett P. Giroir, MD

ADM, US Public Health Service

Assistant Secretary for Health (ASH)

200 Independence Avenue, SW

Washington, DC 20201

Office Phone: (b) (6)

From: Tabak, Lawrence (NIH/OD) [E] (b) (6)

Sent: Wednesday, February 19, 2020 11:04 PM

To: Giroir, Brett (HHS/OASH) (b) (6)

Cc: Steele, Danielle (HHS/IOS) (b) (6)

Subject: FW: SARS CoV-2 in humanized mice

Brett,

(b) (5)

Thanks for your consideration,

Larry

From: "Hasenkrug, Kim (NIH/NIAID) [E]" (b) (6)

Date: Wednesday, February 19, 2020 at 5:50 PM

To: "Tabak, Lawrence (NIH/OD) [E]" (b) (6)

Subject: SARS CoV-2 in humanized mice

Hi Dr. Tabak,

(b) (5)

(b) (5)

Best regards,

Kim

Kim J Hasenkrug, Ph.D.
Senior Investigator
Chief, Retroviral Immunology Section
Laboratory of Persistent Viral Diseases
Rocky Mountain Laboratories
National Institute of Allergy and Infectious Diseases
National Institutes of Health
903 S. 4th Street
Hamilton, MT 59840

(b) (6)

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 2 Mar 2020 00:48:25 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]; Giroir, Brett (HHS/OASH)
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: COVID and Chloroquine

Thanks, Cristina

From: Cassetti, Cristina (NIH/NIAID) [E] (b) (6) >
Sent: Sunday, March 1, 2020 7:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) Giroir, Brett (HHS/OASH)
(b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Subject: RE: COVID and Chloroquine

Hi,

Sorry for the late response, I just flew back from (b) (6).

NIAD doesn't have ongoing trials with chloroquine and I heard that such trials are being conducted in China.

We are planning to evaluate chloroquine in animal models ASAP. If any therapeutic with a good clinical safety profile (like chloroquine) appears to be effective in vivo against COVID-19, we are planning to quickly add to them to the Remdesivir therapeutic trial as another arm.

Let me know if you have other questions.

Kind regards,

Cristina

Cristina Cassetti, Ph.D.
Deputy Director
Division of Microbiology and Infectious Diseases
National Institute of Allergy and Infectious Diseases, NIH
[5601 Fishers Lane](#), Room 7G51
[Rockville, MD 20852](#)

Tel: (b) (6)
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Sent: Saturday, February 29, 2020 8:20 PM

To: Giroir, Brett (HHS/OASH) (b) (6)>
Cc: Cassetti, Cristina (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: RE: COVID and Chloroquine
Importance: High

Brett:

Thanks for the note. I will run this by the people in our Program and get back to you.

Best,

Tony

Cristina:

Are we or anyone else doing anything with clinical trials and chloroquine for COVID-19? Please respond directly to ADM Giroir.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Giroir, Brett (HHS/OASH) (b) (6)>
Sent: Saturday, February 29, 2020 9:31 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: COVID and Chloroquine

You know the old data and the new data. New in vitro look promising.
Do you have good visibility on the trials being conducted? Or is NIH running any of these?

Your time is precious, so 10 word response sufficient.

Brett P. Giroir, MD

ADM, US Public Health Service

Assistant Secretary for Health (ASH)

200 Independence Avenue, SW

Washington, DC 20201

Office Phone: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 22:35:38 +0000
To: Kadlec, Robert (OS/ASPR/IO)
Subject: RE: Your thoughts

My thoughts – (b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Kadlec, Robert (OS/ASPR/IO) (b) (6) >
Sent: Saturday, February 29, 2020 10:03 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Your thoughts
Importance: High

Tony I don't know if you saw this but wanted to ask your thought. (b) (5)
(b) (6) Your thoughts always appreciated
bob

<< File: CCDC Epi Report.pptx >> << File:
The+Epidemiological+Characteristics+of+an+Outbreak+of+2019+Novel+Coronavirus+Diseases+(
COVID-19)+—+China,+2020.pdf >>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 03:55:20 +0000
To: Collins, Francis (NIH/OD) [E]
Cc: Tabak, Lawrence (NIH/OD) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: HHS COVID-19 Response - alignment of OPDIV/STAFDIV Efforts

I would recommend Dr. Hilary Marston from my immediate office. Larry should go to the hearing with us

From: Collins, Francis (NIH/OD) [E] (b) (6)
Sent: Saturday, February 29, 2020 10:48 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Tabak, Lawrence (NIH/OD) [E] (b) (6) >
Subject: FW: HHS COVID-19 Response - alignment of OPDIV/STAFDIV Efforts

Hi Tony,

Quick question – who would you suggest is the appropriate NIH representative for this ASPR-led trans-HHS effort to coordinate COVID-19 response? You and I will be testifying in front of the House Approps Subcommittee on Wednesday morning. Would it be best for Larry to represent NIH for the ASPR gathering (though he would normally attend the House hearing), or is there someone from NIAID that would be most appropriate?

Thanks, Francis

From: Kadlec, Robert (OS/ASPR/IO) (b) (6)
Sent: Friday, February 28, 2020 10:23 AM
To: Trueman, Laura (HHS/IEA) (b) (6) >; Rowell, Scott (OS/ASA) (b) (6) >; Bird, Catherine (OS/OGC) (b) (6) >; Moughalian, Jen (HHS/ASFR) (b) (6) >; Arbes, Sarah (HHS/ASL) < (b) (6) >; Murphy, Ryan (OS/ASPA) (b) (6) >; Destro, Brenda (HHS/ASPE) (b) (6) >; Giroir, Brett (HHS/OASH) (b) (6) >; Severino, Roger (HHS/OCR) (b) (6) >; Grigsby, Garrett (HHS/OS/OGA) (b) (6) >; Kerr, Lawrence (HHS/OS/OGA) (b) (6); Charrow, Robert (HHS/OGC) < (b) (6); Grimm, Christi A (OIG/IO) (b) (6) >; Griswold, Nancy (HHS/OMHA HQ) (b) (6) >; Op Divs (b) (6) >; Johnson, Lynn (ACF) (b) (6) >; Robertson, Lance (ACL) (b) (6) >; Khanna, Gopal (AHRQ/IOD) (b) (6) >; Redfield, Robert R. (CDC/OD) (b) (6) >; Verma, Seema (CMS/OA) (b) (6) >; Saxon, Bobby (CMS/CCIIO) (b) (6) >; Hinton, Denise (FDA/OC) (b) (6)

(b) (6); Engels, Thomas (HRSA) (b) (6); Weahkee, Michael (IHS/HQ) < (b) (6); McCollum, Jeffrey T (IHS/HQ) (b) (6); Frazier, Francis (IHS/HQ) < (b) (6); Collins, Francis (NIH/OD) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6); McCance-Katz, Elinore (SAMHSA/OAS) < (b) (6); Krohmer, Jon (dot.gov) (b) (6)
Cc: Ford-Barnes, Arwenchia (OS/ASPR/IO) (b) (6); Waters, Cicely (OS/ASPR/OEA) < (b) (6); Shuy, Bryan (OS/ASPR/IO) (b) (6)
Subject: HHS COVID-19 Response - alignment of OPDIV/STAFDIV Efforts

Dear ASPR Colleagues,

We are at a critical juncture in our nation's response to COVID-19. As we pivot from containment of the virus to mitigation of its impacts, it is imperative that HHS moves swiftly, transparently, and in a unified manner to protect lives and save Americans. The Secretary has charged my office to lead efforts across the Department to prepare and defend our health care system during the novel coronavirus outbreak through the Health Care System Resilience Task Force.

To date, this task force has engaged with public and private sector stakeholders to broadly identify efforts that can be taken to help ensure preparedness in response to a domestic COVID-19 outbreak, and more importantly their gaps, challenges, and potential areas of need from the federal government. Now, we must build on that knowledge to expedite and execute a whole of HHS response to support protection of the health care system that spans public health, health care, and human services.

Please join Dr. Kevin Yeskey, ASPR's Principal Deputy Assistant Secretary for Preparedness and Response, and Dr. Nancy Messonnier, CDC's Director of the National Center for Immunization and Respiratory Diseases, on **Wednesday, March 4 from 9:00 AM - 10:15 AM**, at the O'Neill House Office Building for a working session to align current activities and next steps to be executed as part of a coordinated HHS response to COVID-19.

Please provide the following information to ASPR.HCSRTF@hhs.gov no later than Monday, March 2 at 12:00 PM, and be prepared to share and discuss at Wednesday's session.

- Your Designee(s) name, title, and contact information
- OPDIV/STAFFDIV name
- OPDIV/STAFFDIV current and future top five priorities related to COVID-19 (priority leads, descriptions, timelines)

- OPDIV/STAFFDIV key activities and workgroups (current and under consideration) related to COVID-19 response (include activity/workgroup leads, key purpose, timelines)
- OPDIV/STAFFDIV key areas of concern or challenges identified to date
- OPDIV/STAFFDIV core competencies or other assets it can bring to COVID-19 response efforts

We look forward to working with you on this critical effort to defend the nation's health care system. Thank you in advance for your support and participation.

Respectfully,

Bob Kadlec
ASPR

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 03:26:56 +0000
To: Collins, Francis (NIH/OD) [E]
Subject: RE: HHS COVID-19 Response - alignment of OPDIV/STAFDIV Efforts

Francis:

You are correct about the Israeli vaccine. I cannot imagine that they would have a safe and effective vaccine deployable in 90 days.

Tony

From: Collins, Francis (NIH/OD) [E] (b) (6) >
Sent: Friday, February 28, 2020 12:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Tabak, Lawrence (NIH/OD) [E]
(b) (6)
Subject: FW: HHS COVID-19 Response - alignment of OPDIV/STAFDIV Efforts

Hi Tony and Larry,

See below for a new Health Care Resilience Task Force being convened by ASPR.

The initial meeting overlaps with our House approps hearing.

Tony, who shall we send to this one?

FC

P.S. to Tony – I'm getting a lot of buzz about the Israeli claim to have fast track vaccine:
<https://israelb.org/2020/02/israel-to-have-coronavirus-vaccine-within-3-weeks/> It looks to me that they are conflating having something ready to put into volunteers for a phase 1 trial, and having full scale production ready to go for the global needs. That still seems like it's a year away. Am I right?

From: Kadlec, Robert (OS/ASPR/IO) (b) (6)
Sent: Friday, February 28, 2020 10:23 AM
To: Trueman, Laura (HHS/IEA) (b) (6) >; Rowell, Scott (OS/ASA)
(b) (6); Bird, Catherine (OS/OGC) (b) (6) >; Moughalian, Jen (HHS/ASFR) (b) (6); Arbes, Sarah (HHS/ASL) (b) (6)
Murphy, Ryan (OS/ASPA) <(b) (6)>; Destro, Brenda (HHS/ASPE)
(b) (6); Giroir, Brett (HHS/OASH) <(b) (6)>; Severino, Roger (HHS/OCR) (b) (6) >; Grigsby, Garrett (HHS/OS/OGA)

< (b) (6) >; Kerr, Lawrence (HHS/OS/OGA) < (b) (6) >;
Charrow, Robert (HHS/OGC) < (b) (6) >; Grimm, Christi A (OIG/IO)
< (b) (6) >; Griswold, Nancy (HHS/OMHA HQ) (b) (6) >;
Op Divs (b) (6) >; Johnson, Lynn (ACF) < (b) (6) >;
Robertson, Lance (ACL) (b) (6) >; Khanna, Gopal (AHRQ/IOD)
(b) (6) >; Redfield, Robert R. (CDC/OD) (b) (6) >; Verma, Seema
(CMS/OA) < (b) (6) >; Saxon, Bobby (CMS/CCIIO)
< (b) (6) >; Hinton, Denise (FDA/OC)
(b) (6) >; Engels, Thomas (HRSA) < (b) (6) >; Weahkee, Michael
(IHS/HQ) (b) (6) >; McCollum, Jeffrey T (IHS/HQ)
(b) (6) >; Frazier, Francis (IHS/HQ) < (b) (6) >; Collins,
Francis (NIH/OD) [E] < (b) (6) >; Fauci, Anthony (NIH/NIAID) [E]
(b) (6) >; Marston, Hilary (NIH/NIAID) [E] (b) (6) >; McCance-
Katz, Elinore (SAMHSA/OAS) (b) (6) >; Krohmer, Jon (dot.gov)
(b) (6) >
Cc: Ford-Barnes, Arwenchia (OS/ASPR/IO) (b) (6) >; Waters, Cicely
(OS/ASPR/OEA) (b) (6) >; Shuy, Bryan (OS/ASPR/IO) (b) (6) >
Subject: HHS COVID-19 Response - alignment of OPDIV/STAFDIV Efforts

Dear ASPR Colleagues,

We are at a critical juncture in our nation's response to COVID-19. As we pivot from containment of the virus to mitigation of its impacts, it is imperative that HHS moves swiftly, transparently, and in a unified manner to protect lives and save Americans. The Secretary has charged my office to lead efforts across the Department to prepare and defend our health care system during the novel coronavirus outbreak through the Health Care System Resilience Task Force.

To date, this task force has engaged with public and private sector stakeholders to broadly identify efforts that can be taken to help ensure preparedness in response to a domestic COVID-19 outbreak, and more importantly their gaps, challenges, and potential areas of need from the federal government. Now, we must build on that knowledge to expedite and execute a whole of HHS response to support protection of the health care system that spans public health, health care, and human services.

Please join Dr. Kevin Yeskey, ASPR's Principal Deputy Assistant Secretary for Preparedness and Response, and Dr. Nancy Messonnier, CDC's Director of the National Center for Immunization and Respiratory Diseases, on **Wednesday, March 4 from 9:00 AM - 10:15 AM**, at the O'Neill House Office Building for a working session to align current activities and next steps to be executed as part of a coordinated HHS response to COVID-19.

Please provide the following information to ASPR.HCSRTF@hhs.gov no later than Monday, March 2 at 12:00 PM, and be prepared to share and discuss at Wednesday's session.

- Your Designee(s) name, title, and contact information
- OPDIV/STAFFDIV name
- OPDIV/STAFFDIV current and future top five priorities related to COVID-19 (priority leads, descriptions, timelines)
- OPDIV/STAFFDIV key activities and workgroups (current and under consideration) related to COVID-19 response (include activity/workgroup leads, key purpose, timelines)
- OPDIV/STAFFDIV key areas of concern or challenges identified to date
- OPDIV/STAFFDIV core competencies or other assets it can bring to COVID-19 response efforts

We look forward to working with you on this critical effort to defend the nation's health care system. Thank you in advance for your support and participation.

Respectfully,

Bob Kadlec
ASPR

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 15:45:23 +0000
To: Zebley, Kyle (HHS/OS/OGA)
Cc: Kerr, Lawrence (HHS/OS/OGA)
Subject: RE: Current TF Agenda Draft/Request for AMA High-level Talkers
Attachments: Task Force VP Briefing 2-13-20 - with Fauci TP.docx

Kyle:

Here is a talking point for the messaging section.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Zebley, Kyle (HHS/OS/OGA) (b) (6)
Sent: Thursday, February 27, 2020 9:11 AM
To: Hall, Bill (HHS/ASPA) (b) (6); Murphy, Ryan (OS/ASPA) <(b) (6)>; Trueman, Laura (HHS/IEA) (b) (6); Johnston, Darcie (HHS/IEA) (b) (6); Arbes, Sarah (HHS/ASL) <(b) (6)>; Morse, Sara (HHS/ASL) (b) (6); Twomey, John K. (HHS/ASL) (b) (6); Pence, Laura (HHS/ASL) (b) (6)
Cc: Mango, Paul (HHS/IOS) (b) (6); Bird, Catherine (OS/OGC) <(b) (6)>; Grigsby, Garrett (HHS/OS/OGA) (b) (6); Kerr, Lawrence (HHS/OS/OGA) <(b) (6)>; Redfield, Robert R. (CDC/OD) (b) (6); McGowan, Robert (Kyle) (CDC/OD/OCS) <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Kadlec, Robert (OS/ASPR/IO) (b) (6); Shuy, Bryan (OS/ASPR/IO) (b) (6)
Subject: Current TF Agenda Draft/Request for AMA High-level Talkers
Importance: High

Good morning,

Attached, please find a current draft of an agenda for a TF Briefing for VPOTUS this afternoon. Note that this is a draft and is not final. However, in order to prepare the Secretary, can ASPA, IEA, and ASL please help with 2-3 high-level talkers each the Secretary could highlight under the External Activity/Messaging section of the agenda? Could you please send to me and Dr. Larry Kerr by **11 AM this morning**? Apologies for the quick turnaround.

Dr. Redfield, Dr. Fauci, and Dr. Kadlec, please note your presence on the agenda and please be prepared to speak to the topics assigned.

Let me know if you have any questions. Thanks for your help.

Kyle Zebley
Chief of Staff
Office of Global Affairs (OGA)
Office of the Secretary
U.S. Department of Health and Human Services
Direct: (b) (6)/Mobile: (b) (6)

Confidential and pre-decisional communication

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 20:08:22 +0000
To: Messonnier, Nancy (CDC/DDID/NCIRD/OD)
Subject: RE: mitigation in communities
Attachments: COVID-19 Targeted Layered Mitigation Strategy_Interim.022820.pdf

I assume that you are OK with the document that Garrett just sent around. See attached.


Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Messonnier, Nancy (CDC/DDID/NCIRD/OD) (b) (6) >
Sent: Sunday, March 1, 2020 2:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: FW: mitigation in communities

From: Messonnier, Nancy (CDC/DDID/NCIRD/OD)
Sent: Sunday, March 1, 2020 2:59 PM
To: Redfield, Robert R. (CDC/OD) (b) (6) >
Cc: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <(b) (6)> Schuchat, Anne MD (CDC/OD)
(b) (6) >
Subject: mitigation in communities

Here are the basic high level principles of a mitigation strategy. (b) (5)
(b) (5)



[REDACTED]

(b) (5)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 28 Feb 2020 03:02:24 +0000
To: Grigsby, Garrett (HHS/OS/OGA)
Subject: RE: [REDACTED] (b) (5)

It is a tough decision, [REDACTED] (b) (5).

From: Grigsby, Garrett (HHS/OS/OGA) [REDACTED] (b) (6) >
Sent: Thursday, February 27, 2020 5:27 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >; Kadlec, Robert (OS/ASPR/IO) [REDACTED] (b) (6); Adams, Jerome (HHS/OASH) [REDACTED] (b) (6) >
Cc: Harrison, Brian (HHS/IOS) [REDACTED] (b) (6); Zebley, Kyle (HHS/OS/OGA) [REDACTED] (b) (6) >
Subject: FW: [REDACTED] (b) (5)
Importance: High

Gentlemen,

Any problem with this – see Marty's below. Need to know asap as I'd like to forward to NSC immediately. Many thanks!

From: Cetron, Marty (CDC/DDID/NCEZID/DGMQ) [REDACTED] (b) (6)
Sent: Thursday, February 27, 2020 5:08 PM
To: Grigsby, Garrett (HHS/OS/OGA) [REDACTED] (b) (6) >
Cc: Walker, Allison Taylor. (CDC/DDID/NCEZID/DGMQ) [REDACTED] (b) (6); McGowan, Robert (Kyle) (CDC/OD/OCS) [REDACTED] (b) (6); Roohi, Shahrokh (CDC/DDID/NCEZID/DGMQ) [REDACTED] (b) (6); Elvander, Erika (OS/OGA) [REDACTED] (b) (6) >; Zebley, Kyle (HHS/OS/OGA) [REDACTED] (b) (6) >; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) [REDACTED] (b) (6)
Subject: [REDACTED] (b) (5)

Hi Garrett,

CDC intends [REDACTED] (b) (5)
[REDACTED] (b) (5)

Thanks,
Marty

[REDACTED] (b) (5)

(b) (5)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 04:31:21 +0000
To: Ms P
Subject: RE: A note from Sharon Perlman

Sharon:

Thanks for your note. It was great to hear from you. All is well with me and my family. I hope the same for you. This whole coronavirus situation is rather exhausting since I am working 24/7 with no breaks at all. However, it needs to be done since this virus is a true threat to global health.

Best regards,
Tony

From: Ms P (b) (6)
Sent: Wednesday, February 26, 2020 6:07 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: A note from Sharon Perlman

Hi Dr. Fauci,

As I was watching my favorite CNN news show starring Chris Cuomo last night, to my delight, there you were! And again, this morning with John Berman and Alisyn Camerota on New Day.

I do hope all that all is well with you and your family. We are all doing fine. My

(b) (6)

I would love to hear from you, when you have time.

With best regards,
Sharon

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 04:27:18 +0000
To: Bennett Werner
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Clinical question, Sir....

Dear Drs. Werner and Uhl:

Thank you for your note.

(b) (6)

(b) (6)

Best regards,
A.S. Fauci

-----Original Message-----

From: Bennett Werner (b) (6) >

Sent: Wednesday, February 26, 2020 6:27 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Subject: Clinical question, Sir....

Dear Dr. Fauci,

(b) (6)

By the way, we both feel you are an outstanding spokesperson and really appreciate both the work you do and your clear explanations on Public TV (and elsewhere).

Warm regards,

Bennett E. Werner, M.D. FACC FACP
Cleveland Clinic Cardiology - (b) (6)

Michelle D. Uhl, M.D.
Cleveland Clinic - medical oncology (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 04:06:03 +0000
To: Morgan Fairchild
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Covid-19

Morgan:

Thanks for the note and the offer to help. It would be great if you could tweet to your many Twitter followers that although the current risk of coronavirus to the American public is low, the fact that there is community spread of virus in a number of countries besides China and including South Korea, Japan, Italy, Iran among others poses a risk that we may progress to a global pandemic of COVID-19. If that occurs we will surely have many more cases in the USA. And so for that reason, the American public should not be frightened, but should be prepared to mitigate an outbreak in this country by measures that include social distancing, teleworking, temporary closure of schools, etc. There is nothing to be done right now since there are so few cases in this country and these cases are being properly isolated, and so go about your daily business. However, be aware that behavioral adjustments may need to be made if a pandemic occurs.

Best regards,
Tony

From: Morgan Fairchild (b) (6)
Sent: Wednesday, February 26, 2020 8:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Covid-19

Hi Dr. Fauci. I'm reaching out to see if I can help in any way to get good information out to the public, as I tried to do with AIDS. I have almost 100,000 Twitter followers and have been tweeting articles to them that I feel are helpful, but if you have any info I can help disseminate, please let me know.

Also, a great job today and this week!!

Hope you're well!

Thanks!

Best,

Morgan

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 03:00:14 +0000
To: Laura Landerman-Garber
Subject: RE: Dr Sheldon Wolff Dr Fauci NIH (b) (6)
Follow up 2/26/20

Laura:

Many thanks for your kind note. It was great to hear from you.
Warm regards,
Tony

From: Laura Landerman-Garber (b) (6) >
Sent: Wednesday, February 26, 2020 9:26 PM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6) >
Subject: Re: Dr Sheldon Wolff Dr Fauci NIH (b) (6) Follow up 2/26/20

Greetings from New Hampshire. Today I was watching the news and there you were, once again popping up in my life and making me not only smile by your kind and approachable style that I truly remember from the (b) (6), but also taken care of by your expertise. Thank you for your medical leadership during these days as the Coronavirus spreads. Please know that your legacy of research and practice will live on for generations to come!
I hope that these complex days are soon quieted for us here in the US and around the Globe

Ps (b) (6).
Amazing to think that so many of my questions were answered all those decades ago with you and Sheldon Wolff I remain forever grateful. Since I saw you last, (b) (6) who you met, moved to DC and works at American Psychological Association. (b) (6). Life marches on. I hope you and your family are well

Best,

Laura Landerman-Garber, Ph.D.

On Apr 7, 2015, at 12:18 PM, Fauci, Anthony (NIH/NIAID) [E]
(b) (6) wrote:

Laura:

Thank you so much for your beautiful note. I do remember you and am so happy that you reached out to communicate with me. I am very pleased to hear that you are doing so well. You have "made my day" by your note. I wish you and your family all the best.

Warm regards,
Tony

From: Laura Landerman-Garber (b) (6)
Sent: Tuesday, April 07, 2015 10:31 AM
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Dr Sheldon Wolff Dr Fauci NIH (b) (6) Follow up

See below please. Thank you!!

Sent from my iPhone

Begin forwarded message:

From: Laura Landerman (b) (6)
Date: April 7, 2015 at 10:06:28 AM EDT
To: "niaidnews@niaid.nih.gov" <niaidnews@niaid.nih.gov>
Subject: Dr Anthony Fauci/ NIH/ Dr SHeldon Wolff/ (b) (6)
followup
Reply-To: Laura Landerman (b) (6)>

Greetings from NH. I am trying to contact Dr Fauci after many years. I have followed his career like so many others do... (b) (6)

(b) (6)

I am not sure if this can find its way to Dr Fauci but I would so appreciate it if it could. To let him know that all those years ago,

he left n outstanding impression on [REDACTED] (b) (6)
[REDACTED]. I want to thank him from the bottom of my heart.

Sincerely,

Laura M. Landerman-Garber, Ph.D.
[REDACTED] (b) (6)

[REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 27 Feb 2020 02:57:57 +0000
To: LOUIS FORTUNATO
Subject: RE: Dear Tony: Will you take the lead in the Coronavirus problem/ we always love you/Saw you on CNN/

Lou:

I do not believe that there is a chance to republish Harrison Practice.
Best regards,
Tony

From: LOUIS FORTUNATO (b) (6)
Sent: Wednesday, February 26, 2020 9:38 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Fwd: Dear Tony: Will you take the lead in the Coronavirus problem/ we always love you/Saw you on CNN/

Begin forwarded message:

From: LOUIS FORTUNATO (b) (6) >
Subject: Fwd: Any Chance of Harrison Practice being updated and replaced on the market? I loved It Tony/ Better than Harrison's Textbook
Date: February 17, 2020 at 9:41:40 PM EST
To: (b) (6)

Dear Tony Fauci MD:

Any chance for Harrison Practice being republished again and updated with the newest Pathophysiology and Treatments?
It was better than Harrisons Textbook/More Precise and Succinct

Please email me/
I would greatly appreciate your response
either way Yes or No//

Dr Lou Fortunato

(b) (6)

Begin forwarded message:

From: LOUIS FORTUNATO [REDACTED] (b) (6) >
Subject: HERE TONY IS ANOTHER CHAPTER OF MY FUTURE NUC MED BOOK
Date: November 3, 2019 at 5:11:19 AM EST
To: [REDACTED] (b) (6)

HERE TONY IS MY NOTES IN BONE
IMAGING FOR MY FUTURE BOOK

LOU FORTUNATO

From: (b) (6)
Sent: Wed, 26 Feb 2020 20:24:59 -0500
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: [EXTERNAL] Gene-RADAR platform for Real time Mobile (POC) Coronavirus detection/ viral load monitoring/ Followup to our meeting at the ASPEN ideas festival -

Please handle.

Sent from my iPhone

Begin forwarded message:

From: "Dr. Anita Goel , M.D., Ph.D." (b) (6) >
Date: February 26, 2020 at 7:58:54 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Subject: FW: [EXTERNAL] Gene-RADAR platform for Real time Mobile (POC) Coronavirus detection/ viral load monitoring/ Followup to our meeting at the ASPEN ideas festival -

Dear Dr. Anthony Fauci,

It was a great pleasure meeting you all a couple of years ago when we were both speaking at the Aspen Ideas Festival. Some of my contacts at the CDC recently briefed me about the rapidly emerging threat of the coronavirus to the US and have been urging us to develop an app for detecting coronavirus with high sensitivity and specificity on our Gene-RADAR platform. Our platform has the ability to quantify viral loads in 'real-time' which would be a much more precise and accurate solution in deciding quarantine than the current thermometers or even the current CDC coronavirus test which has a very poor Limit of detection (ie low sensitivity).

We have a strong track record of responding to previous pandemic threats and rapidly building Gene RADAR applications for Ebola and Zika and then getting them through clinical validation as per the FDA EUA approval process. Our Gene-RADAR Zika test was FDA EUA certified right as the Zika crisis was coming to an end.

I would love to work with you to see how we can help in your efforts to rapidly respond to this deadly threat to the US and the world. Here are some of the capabilities of our platform that we believe could be an enabler for helping to stop this outbreak from becoming a full-fledged global pandemic.

- Gene-RADAR platform for Real time Mobile (POC) Coronavirus detection/ viral load monitoring
 - Highly sensitive and specific – minimize false positives and false negatives
 - With very good LOD's we could potentially start to catch people presymptomatically and enable the early detection , early quarantine would limit the spread and early intervention could lead to better outcomes
 - More precise viral load monitoring could help determine when to release people from quarantine or ICU beds
 - Our platform's ability to quantify vial loads could change clinical trial endpoints for new drug candidates or (repurposed drug formulations), thereby accelerating FDA approvals for novel therapeutic regimen
 - We already have an ISO 13485 certified manufacturing facility (currently in Boston) that we are prepared to move as fast as possible to ramp up our production

We would love to work with you to repurpose our FDA approved platform for the above coronavirus applications assay and help your noble efforts to stop this outbreak from becoming a full blown global pandemic that could costs thousands of lives and cause trillions of dollars of economic damage to the global economy.

We would love to speak with you to brief on our capabilities and discuss how we can qualify for some of the emergency funding being made available to help tackle this pandemic threat.

Happy to jump on a phone call to discuss further how we can help

How Nanobiophysics can Stop Ebola and Other Global Pandemics

- [Forbes](#)
- [Wired Magazine](#)

Best Wishes,

Dr. Anita Goel, MD, PhD
Chairman &CEO
Nanobiosym

=====

www.nanobiosym.com

email: (b) (6)

Mobile: (b) (6)

<http://www.people.fas.harvard.edu/~goel/>

email: goel@physics.harvard.edu

=====

Selected Media Links:

[Nanobiosym Gene-RADAR® X Prize Grand Prize Winner Video](#)

[Dr. Goel's Article in Scientific American Worldview](#)
[Nanobiosym Chairman &CEO Named 2018 Uber ELITE Award Winner](#)
[FDA Grants Emergency Use Authorization for Gene-RADAR® Zika Test](#)
[BBC Feature: The Genius Behind the "Tricorder that could revolutionize medicine"](#)
[Nanobiosym Selected As One Of The Top Growth Stage Ventures By The 'Unreasonable' Group](#)
[Dr. Anita Goel, MD, PhD awarded 2019 SEEMA Entrepreneur of the Year Award](#)

How Nanobiophysics can Stop Ebola and Other Global Pandemics

- [Forbes](#)
- [Wired Magazine](#)

[Nanobiosym Global Initiative Summit Website](#)
[Wall Street Journal](#)
[Washington Post](#)
[Boston Globe GameChangers](#)
[National Geographic](#)
[Forbes](#)

Nanobiosym Space News

[CBS News](#)
[Boston Business Journal](#)
[CNN](#)
[DailyMail](#)
[Space.com](#)
[Popular Mechanics](#)
[Forbes](#)
[US News and World Report](#)
[Wired](#)
[Daily Press](#)
[CBC Radio](#)
[Boston Globe STAT](#)

CONFIDENTIALITY: This email and attachments are intended for the above name only and are confidential. If you are not the intended addressee, or the person responsible for delivering it to the intended addressee, you may neither copy, disseminate, nor distribute it to anyone else or use it in any unauthorized manner. To do so is strictly prohibited and may be unlawful. If you receive this email by mistake, please advise the sender immediately by using the reply facility in your mail software and delete it from your computer.

CONFIDENTIALITY: This email and attachments are intended for the above name only and are confidential. If you are not the intended addressee, or the person responsible for delivering it to the intended addressee, you may neither copy, disseminate, nor distribute it to anyone else or use it in any unauthorized manner. To do so is strictly prohibited and may be unlawful. If you receive this email by mistake, please advise the sender immediately by using the reply facility in your mail software and delete it from your computer.

CONFIDENTIALITY: This email and attachments are intended for the above name only and are confidential. If you are not the intended addressee, or the person responsible for delivering it to the intended addressee, you may neither copy, disseminate, nor distribute it to anyone else or use it in any unauthorized manner. To do so is strictly prohibited and may be unlawful. If you receive this email by mistake, please advise the sender immediately by using the reply facility in your mail software and delete it from your computer.

CONFIDENTIALITY: This email and attachments are intended for the above name only and are confidential. If you are not the intended addressee, or the person responsible for delivering it to the intended addressee, you may neither copy, disseminate, nor distribute it to anyone else or use it in any unauthorized manner. To do so is strictly prohibited and may be unlawful. If you receive this email by mistake, please advise the sender immediately by using the reply facility in your mail software and delete it from your computer.

CONFIDENTIALITY: This email and attachments are intended for the above name only and are confidential. If you are not the intended addressee, or the person responsible for delivering it to the intended addressee, you may neither copy, disseminate, nor distribute it to anyone else or use it in any unauthorized manner. To do so is strictly prohibited and may be unlawful. If you receive this email by mistake, please advise the sender immediately by using the reply facility in your mail software and delete it from your computer.

CONFIDENTIALITY: This email and attachments are intended for the above name only and are confidential. If you are not the intended addressee, or the person responsible for delivering it to the intended addressee, you may neither copy, disseminate, nor distribute it to anyone else or use it in any unauthorized manner. To do so is strictly prohibited and may be unlawful. If you receive this email by mistake, please advise the sender immediately by using the reply facility in your mail software and delete it from your computer.

From: (b) (6)
Sent: Wed, 26 Feb 2020 19:24:48 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Interview request from WTOP [Please reply all]

Sent from my iPhone

Begin forwarded message:

From: "Anderson, Liz" <landerson@wtop.com>
Date: February 26, 2020 at 6:57:05 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Cc: "Spitalniak, Laura" <lspitalniak@wtop.com>
Subject: Interview request from WTOP [Please reply all]

Good Evening Dr. Fauci,

My name is Liz Anderson, and I'm working the editor's desk tonight at WTOP.

Are you available for a brief live interview (about 2 minutes long) about what the latest COVID-19 developments? During this evening's press conference, President Trump said you two spoke about it.

The Washington Post is also reporting that the CDC has been informed about the first coronavirus case of unknown origin confirmed in Northern California. We'd also like to talk about that and what that could mean about the spread of this virus in the states.

We have the following time slots open tonight:

9:10p

9:40p

10:10p

10:40p

11:10p

11:40p

Many thanks for your time.

Sincerely,

Liz Anderson

AE/Editor/Reporter, WTOP News

202-895-5060 (newsroom)

landerson@wtop.com

Twitter: @planetnoun

<http://wtop.com/author/landerson/>

<http://wtop.com/author/liz-anderson/>

wtop | 103.5 FM
WTOP.COM

From: (b) (6)
Sent: Wed, 26 Feb 2020 19:24:09 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Interview request from WTOP [Please reply all]

Sent from my iPhone

Begin forwarded message:

From: "Anderson, Liz" <landerson@wtop.com>
Date: February 26, 2020 at 7:01:22 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Subject: RE: Interview request from WTOP [Please reply all]

Wait-- I see you're at the press conference, too. If you have availability at one of the times listed, we'd love to have you.

Many thanks,

Liz

From: Anderson, Liz
Sent: Wednesday, February 26, 2020 6:57 PM
To: (b) (6)>
Cc: Spitalniak, Laura <lspitalniak@wtop.com>
Subject: Interview request from WTOP [Please reply all]

Good Evening Dr. Fauci,

My name is Liz Anderson, and I'm working the editor's desk tonight at WTOP.

Are you available for a brief live interview (about 2 minutes long) about what the latest COVID-19 developments? During this evening's press conference, President Trump said you two spoke about it.

The Washington Post is also reporting that the CDC has been informed about the first coronavirus case of unknown origin confirmed in Northern California. We'd also like to talk about that and what that could mean about the spread of this virus in the states.

We have the following time slots open tonight:

9:10p

9:40p

10:10p

10:40p

11:10p

11:40p

Many thanks for your time.

Sincerely,

Liz Anderson

AE/Editor/Reporter, WTOP News

202-895-5060 (newsroom)

landerson@wtop.com

Twitter: @planetnoun

<http://wtop.com/author/landerson/>

<http://wtop.com/author/liz-anderson/>

wtop | 103.5 FM
WTOP.COM

From: (b) (6)
Sent: Wed, 26 Feb 2020 19:22:28 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: AM 970 the Answer Radio Request Re: Coronavirus Response from POTUS and NIH

Sent from my iPhone

Begin forwarded message:

From: Alex Garrett <agarrett@nycradio.com>
Date: February 26, 2020 at 7:13:41 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Subject: AM 970 the Answer Radio Request Re: Coronavirus Response from POTUS and NIH

Hi Dr. Fauci,
I hope you are well ! Would love to welcome you to Kevin McCullough Radio on AM 970 the Answer tomorrow to discuss the steps the White House and the NIH are taking to combat coronavirus. Kevin is our drive-time host at 5 PM and he is nationally syndicated as well with 300+ affiliates for his broadcast!
Look forward to hearing from you. Thanks Dr. Fauci!
Alex Garrett

Producer: Kevin McCullough Radio
AM 570 the Mission WMCA: 3-4 PM
AM 970 the Answer: 5-6 PM

From: Folkers, Greg (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 21:50:05 +0000
To: Laurencot, Elizabeth;Fauci, Anthony (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Eisinger, Robert (NIH/NIAID) [E];Lane, Cliff (NIH/NIAID) [E]
Subject: RE: NEJM content proof (Fauci)

Eli,

(b) (5)

Thanks,
Tony

From: Laurencot, Elizabeth <elaurencot@nejm.org>
Sent: Wednesday, February 26, 2020 4:45 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Eisinger, Robert (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6) Folkers, Greg (NIH/NIAID) [E] (b) (6)>
Subject: RE: NEJM content proof (Fauci)

Dear Dr Fauci,

Regarding the following information--

(b) (5)

Please clarify --- thank you!

Best,
Eli

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) > **On Behalf Of** Fauci, Anthony (NIH/NIAID) [E]

Sent: Wednesday, February 26, 2020 3:48 PM

To: Laurencot, Elizabeth <elaurencot@nejm.org>; Fauci, Anthony (NIH/NIAID) [E]

(b) (6) >


Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Eisinger, Robert (NIH/NIAID) [E]

(b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6) >; Folkers, Greg (NIH/NIAID) [E] (b) (6)

Subject: RE: NEJM content proof (Fauci)

Dear Eli,

(b) (5)



Thanks,
Tony

From: Laurencot, Elizabeth <elaurencot@nejm.org>
Sent: Wednesday, February 26, 2020 9:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Eisinger, Robert (NIH/NIAID) [E] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b) (6)
Subject: RE: NEJM content proof (Fauci)

Dear Dr Fauci,

Many thanks for your quick reply and for the clear list of responses regarding the proof. I will review today and will let you know if there are any items needing further discussion.

The current plan is for publication early Friday afternoon. As I mentioned yesterday, there is a new article on Covid-19 that is also scheduled for publication that day, and the Journal editors would like you to mention it in your editorial. I expect to be able to send you a proof of that article sometime today.

Best,
Eli

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, February 26, 2020 7:37 AM
To: Laurencot, Elizabeth <elaurencot@nejm.org>
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Eisinger, Robert (NIH/NIAID) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b) (6)
Subject: RE: NEJM content proof (Fauci)

Dear Eli,
Here are my answers to your queries, and couple other minor changes:

(b) (5)



Thanks,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Laurencot, Elizabeth <elaurencot@nejm.org>
Sent: Tuesday, February 25, 2020 8:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: NEJM content proof (Fauci)
Importance: High

Dear Dr Fauci,

Attached is the content proof of your editorial. **Please read *ALL* of the following instructions and information carefully before** you begin reviewing your proofs.

First, please **stop and take a moment now** to confirm receipt, so that we can be assured that your proofs did not end up in a spam folder.

Your editorial has been edited for grammar, consistency, readability, adherence to Journal style, and clarity for nonspecialist readers. To expedite publication, we do not ask authors for specific approval of routine changes; please read the entire article to make sure your meaning has been retained. Note that we may be unable to make changes that conflict with Journal style or create grammatical or other problems. Finally, please note that a delayed or incomplete response may delay publication of your editorial.

Please read the entire proof carefully, including all queries. Please return your query replies and proof corrections ****before 12pm (US Eastern) this Friday, February 28, 2020****.

Instructions are provided below. Note that you will be reading for content only; the article will be rendered for print after the content has been finalized.

The Journal's senior medical editors will be reading your article at this stage. If they have any additional comments or queries for you, I will forward them to you in the next few days.

TO ANSWER THE QUERIES: The proof contains in-line numbered query markers and a numbered list of queries at the end. The query markers and the queries are linked, so you can jump back and forth within the file. Please respond to all the queries (see below for instructions; please do ****NOT**** use e-annotation tools) and convey any additional changes as needed.

TO RESPOND BY E-MAIL: If your corrections and your responses to the queries are straightforward, we encourage you to respond by replying to this message. Please copy and paste the list of queries into an e-mail message or a Word document and type your responses there. You may also include a list of changes (e.g., page 1, line 20, change xxx to yyy). Again, please do ****NOT**** use e-annotation tools in the PDF file; the marks are small and easy to miss, which may lead to errors in your article.

Please note that this material is confidential and embargoed until publication. If you have questions about our embargo policy, please contact NEJM Media Relations at 781-434-7847 or at Mediasupport@nejm.org.

Again, please do confirm receipt at this time. Thank you very much for your efforts with these content proofs!

Best,
Eli

Elizabeth Laurençot
Senior Manuscript Editor
New England Journal of Medicine

617-487-6547
elaurencot@nejm.org

TO READ THE PROOF: You will need Adobe Acrobat Reader software (version 4.0 or later) to view this file. Acrobat Reader is available free of charge at the Adobe Web site (<http://www.adobe.com/products/acrobat/readermain.html>).

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended

recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

From: (b) (6)
Sent: Wed, 26 Feb 2020 15:29:21 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Re: Seeking Dr. Fauci for coronavirus webinar

Let us discuss

On Feb 26, 2020, at 11:59 AM, Conrad, Patricia (NIH/NIAID) [E]
(b) (6) wrote:

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Chris Adams <cadams@nationalpress.org>
Sent: Wednesday, February 26, 2020 11:01 AM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: Seeking Dr. Fauci for coronavirus webinar

Patricia:

I hope you are doing well. Dr. Fauci has been a wonderful speaker for us in the past, and I'm reaching out to him today for a discussion on coronavirus.

When there are major news stories, we often will try to do a live webinar on the topic with a leading expert or two.

This is something we would do in our studio at our office near Dupont Circle. We normally do them for 45-60 minutes, and we take questions (via Twitter) from our audience. The audience would be reporters who cover the topic, as well as others interested in the topic. It is a way to have an in-depth, thoughtful conversation about a pressing topic.

Here are a couple we've done (the first is on Zika a few years ago):

Zika panel discussion: <https://nationalpress.org/topic/understanding-the-zika-threat/?st=0&t=&mm=Video>

Ted Koppel: <https://nationalpress.org/toolbox-topic/lights-out-risks-to-the-power-grid/?st=7042&mm=Video>

Autonomous vehicles panel discussion: <https://nationalpress.org/topic/whats-new-with-autonomous-vehicles/?st=8474&t=Automation&mm=Story>

We'd like to do one of these on coronavirus. We'd love to have Dr. Fauci as our prime guest.

We can schedule it around his demands, but would of course love to do it as soon as possible.

We know he is in demand at this moment. But he is such a singular expert on the topic we'd love to have a discussion with him – one that would help get his message out to journalists (and others) who need to be informed to best cover the topic.

Is it possible to check with Dr. Fauci to see if this is possible?

Thanks,
Chris Adams
National Press Foundation

From: (b) (6)
Sent: Wed, 26 Feb 2020 15:01:39 -0500
To: Folkers, Greg (NIH/NIAID) [E]
Cc: Eisinger, Robert (NIH/NIAID) [E]
Subject: Re: ASF and CLIFF ----- DRAFT response to Eli at NEJM

Please send this to Eli. Thanks

On Feb 26, 2020, at 12:49 PM, Folkers, Greg (NIH/NIAID) [E]
(b) (6) wrote:

Dear Eli,

(b) (5)

From: Laurencot, Elizabeth <elaurencot@nejm.org>
Sent: Wednesday, February 26, 2020 11:54 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6) >; Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Eisinger, Robert (NIH/NIAID) [E] <(b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b) (6)
Subject: RE: NEJM content proof (Fauci)
Importance: High

Dear Dr Fauci,



Thank you very much for your consideration!

Best,
Eli

From: Laurencot, Elizabeth
Sent: Wednesday, February 26, 2020 9:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6) >; Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Eisinger, Robert (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6)
Subject: RE: NEJM content proof (Fauci)

Dear Dr Fauci,

Many thanks for your quick reply and for the clear list of responses regarding the proof. I will review today and will let you know if there are any items needing further discussion.

The current plan is for publication early Friday afternoon. As I mentioned yesterday, there is a new article on Covid-19 that is also scheduled for publication that day, and the Journal editors would like you to mention it in your editorial. I expect to be able to send you a proof of that article sometime today.

Best,
Eli

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, February 26, 2020 7:37 AM
To: Laurencot, Elizabeth <elaurencot@nejm.org>
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Eisinger, Robert (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6)
Subject: RE: NEJM content proof (Fauci)

Dear Eli,
Here are my answers to your queries, and couple other minor changes:



Thanks,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Laurencot, Elizabeth <elaurencot@nejm.org>

Sent: Tuesday, February 25, 2020 8:51 AM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Subject: NEJM content proof (Fauci)

Importance: High

Dear Dr Fauci,

Attached is the content proof of your editorial. **Please read **ALL** of the following instructions and information carefully before** you begin reviewing your proofs.

First, please **stop and take a moment now** to confirm receipt, so that we can be assured that your proofs did not end up in a spam folder.

Your editorial has been edited for grammar, consistency, readability, adherence to Journal style, and clarity for nonspecialist readers. To expedite publication, we do not ask authors for specific approval of routine changes; please read the entire article to make sure your meaning has been retained. Note that we may be unable to make changes that conflict with Journal style or create grammatical or other problems. Finally, please note that a delayed or incomplete response may delay publication of your editorial.

Please read the entire proof carefully, including all queries. Please return your query replies and proof corrections ****before 12pm (US Eastern) this Friday, February 28, 2020****.

Instructions are provided below. Note that you will be reading for content only; the article will be rendered for print after the content has been finalized.

The Journal's senior medical editors will be reading your article at this stage. If they have any additional comments or queries for you, I will forward them to you in the next few days.

TO ANSWER THE QUERIES: The proof contains in-line numbered query markers and a numbered list of queries at the end. The query markers and the queries are linked, so you can jump back and forth within the file. Please respond to all the queries (see below for instructions; please do ****NOT**** use e-annotation tools) and convey any additional changes as needed.

TO RESPOND BY E-MAIL: If your corrections and your responses to the queries are straightforward, we encourage you to respond by replying to this message. Please copy and paste the list of queries into an e-mail message or a Word document and type your responses there. You may also include a list of changes (e.g., page 1, line 20, change xxx to yyy). Again, please do ****NOT**** use e-annotation tools in the PDF file; the marks are small and easy to miss, which may lead to errors in your article.

Please note that this material is confidential and embargoed until publication. If you have questions about our embargo policy, please contact NEJM Media Relations at 781-434-7847 or at Mediasupport@nejm.org.

Again, please do confirm receipt at this time. Thank you very much for your efforts with these content proofs!

Best,
Eli

Elizabeth Laurençot
Senior Manuscript Editor
New England Journal of Medicine

617-487-6547
elaurencot@nejm.org

TO READ THE PROOF: You will need Adobe Acrobat Reader software (version 4.0 or later) to view this file. Acrobat Reader is available free of charge at the Adobe Web site (<http://www.adobe.com/products/acrobat/readermain.html>).

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

<NEJMoa2002032_Guan_Content2_Author.pdf>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 17:33:08 +0000
To: Routh, Jennifer (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]; Stover, Kathy (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]
Subject: RE: remarks for White House press conference
Attachments: Fauci remarks Feb 26 - with minor edit.docx

I have made a minor tweak.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Routh, Jennifer (NIH/NIAID) [E] (b) (6) >
Sent: Wednesday, February 26, 2020 12:26 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6) >; Stover, Kathy (NIH/NIAID) [E] (b) (6) >; Conrad, Patricia (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6) >
Subject: remarks for White House press conference

Dr. Fauci,

Attached for review are proposed remarks (in bullet format) for the White House press conference.

Thanks,
Jen

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C

Bethesda, MD 20892

Direct: (b) (6)

(b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 16:49:43 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: BBC Radio

What say you?

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Paul Coletti <paul.coletti@bbc.co.uk>
Sent: Wednesday, February 26, 2020 11:47 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: BBC Radio

Dear Dr. Fauci,

Newshour on the BBC World Service is today covering the US preparedness on the Coronavirus

Would you be available for interview on this topic?

We're on air at 3pm eastern and could speak to you live at around 3:10pm or alternatively we could record a few minutes between now and then. About 8 minutes duration and we've many ways to connect to get good audio (no video as we are radio).

If there is interest from your side then I'm on + (b) (6)

Yours sincerely,

Paul Coletti
Tel: (b) (6)
Twitter: @bbeworldservice, @pcoletti
Newshour podcasts: www.bbc.co.uk/podcasts/series/newshour

BBC World Service listen live: www.bbc.co.uk/worldserviceradio/on-air

Newshour is the award-winning news and current affairs programme on BBC World Service English, the radio and online network which reaches 75 million listeners each week, including 12.5 million in the USA on National Public Radio.

Paul Coletti

Tel: (b) (6)

Twitter: @bbeworldservice, @pcoletti

Newshour podcasts: www.bbc.co.uk/podcasts/series/newshour

BBC World Service listen live: www.bbc.co.uk/worldserviceradio/on-air

Newshour is the award-winning news and current affairs programme on BBC World Service English, the radio and online network which reaches 75 million listeners each week, including 12.5 million in the USA on National Public Radio.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 16:37:50 +0000
To: Johnson, Martin S. (NIH/NIAID) [E]; Auchincloss, Hugh (NIH/NIAID) [E]; Harper, Jill (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Appropriators going to have a call at 3:30 in Larry's office with HHS Op divs on the COVID-19 Supplemental Request

Martin:

You and Hugh should be on the call.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Johnson, Martin S. (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, February 26, 2020 11:17 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] (b) (6); Harper, Jill (NIH/NIAID) [E] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: Appropriators going to have a call at 3:30 in Larry's office with HHS Op divs on the COVID-19 Supplemental Request

Tony,

Appropriators going to have a call at 3:30 in Larry's office with HHS Op Divs concerning the 2020 supplemental request.

Larry wants someone from NIAID to also be on the call. Please advise who you want to attend.

Thanks

Martin

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 16:36:36 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: SIBF inquiry

Please say no to this. Too busy.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Shannon Williams <shannon.williams@sibf.org>
Sent: Wednesday, February 26, 2020 11:10 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: SIBF inquiry
Importance: High

Dear Dr. Fauci,

I am writing to inquire about your willingness to address the Society of International Business Fellows (SIBF) as part of our webinar series. SIBF is a distinguished organization of nearly 1600 global executives and senior leaders. Our C-level global membership would appreciate getting your perspectives on the coronavirus outbreak. We are open to topics which could include....What we know and don't know...As business and community leaders what SIBF members can do to prepare and educate their employees...Safety of travel, etc.

We were thinking the webinar could be approximately 30 minutes in length (15 minutes of remarks followed by 15 minutes of Q&A). SIBF's Communications Manager could work with someone on your team to set-up the webinar. SIBF is a

non-profit, but we are able to provide a \$2k honorarium to you or a charity of your choice.

Thank you for your gracious consideration and attention to our request. It is our sincere hope that you will be able to participate.

Best regards,

Mr. Shannon George Williams | Director of Programs
Society of International Business Fellows (SIBF)
715 Peachtree Street NE, Suite 200
Atlanta, GA 30308
P: (470) 378-1151 W: www.sibf.org

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 16:27:37 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: MSNBC Guest Request 2/26

FYI. Please handle as you see fit.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hirsch, Nancy (NBCUniversal) <Nancy.Hirsch@nbcuni.com>
Sent: Wednesday, February 26, 2020 10:59 AM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: MSNBC Guest Request 2/26

Hello Dr. Fauci

I hope this finds you well and I am sure receiving numerous requests

Would you be avail to join anchor Ari Melber tonight 6 pm EST to speak to Trumps presser and the latest on Coronavirus?

Thank you for letting me know if you can join soonest possible.

Nancy

Nancy Hirsch

The Beat with Ari Melber
Mavericks with Ari Melber
Booking Producer

30 Rockefeller Plaza | New York, NY 10112

(T) 212-664-4097

(C) [REDACTED] (b) (6)



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 15:22:01 +0000
To: Eisinger, Robert (NIH/NIAID) [E]; Greg Folkers (b) (6)
Subject: FW: NEJM content proof (Fauci)

See below. I will need your help on this.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Laurencot, Elizabeth <elaurencot@nejm.org>
Sent: Wednesday, February 26, 2020 9:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Eisinger, Robert (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6)
Subject: RE: NEJM content proof (Fauci)

Dear Dr Fauci,

Many thanks for your quick reply and for the clear list of responses regarding the proof. I will review today and will let you know if there are any items needing further discussion.

The current plan is for publication early Friday afternoon. As I mentioned yesterday, there is a new article on Covid-19 that is also scheduled for publication that day, and the Journal editors would like you to mention it in your editorial. I expect to be able to send you a proof of that article sometime today.

Best,
Eli

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, February 26, 2020 7:37 AM
To: Laurencot, Elizabeth <elaurencot@nejm.org>

Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Eisinger, Robert (NIH/NIAID) [E] < (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6)>
Subject: RE: NEJM content proof (Fauci)

Dear Eli,

Here are my answers to your queries, and couple other minor changes:

(b) (5)

Thanks,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Laurencot, Elizabeth <elaurencot@nejm.org>

Sent: Tuesday, February 25, 2020 8:51 AM

To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>

Subject: NEJM content proof (Fauci)

Importance: High

Dear Dr Fauci,

Attached is the content proof of your editorial. **Please read *ALL* of the following instructions and information carefully before** you begin reviewing your proofs.

First, please **stop and take a moment now** to confirm receipt, so that we can be assured that your proofs did not end up in a spam folder.

Your editorial has been edited for grammar, consistency, readability, adherence to Journal style, and clarity for nonspecialist readers. To expedite publication, we do not ask authors for specific approval of routine changes; please read the entire article to make sure your meaning has been retained. Note that we may be unable to make changes that conflict with Journal style or create grammatical or other problems. Finally, please note that a delayed or incomplete response may delay publication of your editorial.

Please read the entire proof carefully, including all queries. Please return your query replies and proof corrections ****before 12pm (US Eastern) this Friday, February 28, 2020****.

Instructions are provided below. Note that you will be reading for content only; the article will be rendered for print after the content has been finalized.

The Journal's senior medical editors will be reading your article at this stage. If they have any additional comments or queries for you, I will forward them to you in the next few days.

TO ANSWER THE QUERIES: The proof contains in-line numbered query markers and a numbered list of queries at the end. The query markers and the queries are linked, so you can jump back and forth within the file. Please respond to all the queries (see below for instructions; please do ****NOT**** use e-annotation tools) and convey any additional changes as needed.

TO RESPOND BY E-MAIL: If your corrections and your responses to the queries are straightforward, we encourage you to respond by replying to this message. Please copy and paste the list of queries into an e-mail message or a Word document and type your responses there. You may also include a list of changes (e.g., page 1, line 20, change xxx to yyy). Again, please do ****NOT**** use e-annotation tools in the PDF file; the marks are small and easy to miss, which may lead to errors in your article.

Please note that this material is confidential and embargoed until publication. If you have questions about our embargo policy, please contact NEJM Media Relations at 781-434-7847 or at Mediasupport@nejm.org.

Again, please do confirm receipt at this time. Thank you very much for your efforts with these content proofs!

Best,
Eli

Elizabeth Laurençot
Senior Manuscript Editor
New England Journal of Medicine

617-487-6547
elaurencot@nejm.org

TO READ THE PROOF: You will need Adobe Acrobat Reader software (version 4.0 or later) to view this file. Acrobat Reader is available free of charge at the Adobe Web site (<http://www.adobe.com/products/acrobat/readermain.html>).

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 15:18:06 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: First in class, hemostatic drug - potential therapeutics for COVID-19
Attachments: NIAID EEEV - SP16_ Jan 28, 2020 - Read-Only - Read-Only.pdf, JACC manuscript Oct 2017 SP16 AMI (1).pdf, Serpin Pharma - Non-Confidential Partnering Deck v29.pdf

Please take a look at this. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Cohava Gelber (b) (6)
Sent: Tuesday, February 25, 2020 8:45 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: First in class, hemostatic drug - potential therapeutics for COVID-19
Importance: High

Dear Dr. Fauci,

(b) (4)

Please let us know how we can help.

I have attached a manuscript and company presentations for your review.

Sincerely,

Cohava

Cohava Gelber, PhD, MBA

Executive Chairperson & CEO

Serpin Pharma

www.serpinpharma.com

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 15:17:35 +0000
To: Mehta, Nehal N. (NIH/NHLBI) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]; Greg Folkers (b) (6)
Subject: RE: Guidance for users of biologics in the age of Coronavirus.

I am sorry Nehal, but I am really swamped right now and cannot make this a priority. I hope that you understand.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mehta, Nehal N. (NIH/NHLBI) [E] (b) (6) >
Sent: Tuesday, February 25, 2020 8:47 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Fwd: Guidance for users of biologics in the age of Coronavirus.

Dear Tony-

I wonder if you would be willing to participate in a short piece regarding use of biologics with looming Coronavirus for JAMA Dermatology or JAMA Internal Medicine?

Please see the email sent below to me by my colleague and collaborator Joel Gelfand from Penn.

I understand there are fierce demands on your time but we would be happy to draft for your approval.

Many thanks for your consideration!

All my best,
Nehal

Nehal N. Mehta, MD MSCE FAHA

Lasker Senior Investigator

Chief, Lab of Inflammation and Cardiometabolic Diseases

National Heart, Lung and Blood Institute

Bethesda MD 20892

Email: (b) (6)

Phone: (b) (6)

Begin forwarded message:

From: "Gelfand, Joel" (b) (6)

Date: February 25, 2020 at 8:12:48 PM EST

To: "Mehta, Nehal N. (NIH/NHLBI) [E]" (b) (6)

Subject: Guidance for users of biologics in the age of Coronavirus.

Dear Nehal,

With the coronavirus bordering on a pandemic and the expectation that it will affect the US at some point, it seems to me we should be prepared to provide guidance to patients who are on immune modulators for inflammatory disease. Specifically, many will wonder if patients should stop their biologic if the virus becomes prevalent in their community. There will also be questions about stopping biologics in the setting of acute infection with coronavirus.

Any thoughts on this? My specific interests relates to patients with psoriasis or psoriatic arthritis on biologics but it's also relevant to patients with IBD, RA and other inflammatory diseases.

Joel

Joel M. Gelfand MD, MSCE

Professor of Dermatology

Professor of Epidemiology

Vice Chair for Clinical Research (Dermatology)

University of Pennsylvania, Perelman School of Medicine

<https://www.med.upenn.edu/gelfand/>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 15:14:43 +0000
To: Stover, Kathy (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: FOR ASF REVIEW: Draft MA re: Fauci/Eisinger/Redfield COVID-19 paper

This looks fine. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stover, Kathy (NIH/NIAID) [E] (b) (6)
Sent: Tuesday, February 25, 2020 5:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: FOR ASF REVIEW: Draft MA re: Fauci/Eisinger/Redfield COVID-19 paper

Hi Dr. Fauci,

Please find attached for your review a draft media availability about your imminent NEJM paper on COVID-19. We have named you as the spokesperson in the MA.

Thanks much,
Kathy

Kathy Stover
Branch Chief
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A17F

Bethesda, MD 20892

(b) (6)

Media line: (301) 402-1663

From: (b) (6)
Sent: Wed, 26 Feb 2020 09:23:22 -0500
To: Thomas R. Frieden
Subject: Re: FYI

Thanks, Tom.

On Feb 25, 2020, at 3:41 PM, Thomas R. Frieden
<(b) (6)> wrote:

Tony,

Nothing you don't already know....

Tom

From: Tom Frieden (b) (6)>
Date: Tuesday, February 25, 2020 at 3:39 PM
To: Tom Frieden (b) (6)
Subject: A COVID-19 Pandemic is Inevitable. Now what?

Dear Colleague,

It's now clear that COVID-19 will become a pandemic. We don't know if it will be mild, moderate or severe, or how many countries it will reach.

As we shift from the initiation phase of the pandemic to the acceleration stage, I've highlighted 8 things we must do now in a new CNN OpEd:

<http://www.cnn.com/2020/02/25/health/coronavirus-pandemic-frieden/index.html>

Please share, and thank you for what you continue to do for public health.

All the best,

Tom

If you'd like to retweet, here's a [link](#).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 12:47:09 +0000
To: Collins, Francis (NIH/OD) [E]
Subject: RE: Milken outreach

Thanks, Francis. It might be better for you to make an e-mail introduction and I will take it from there.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Collins, Francis (NIH/OD) [E] (b) (6) >
Sent: Wednesday, February 26, 2020 7:32 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: RE: Milken outreach

He's at (b) (6) and (b) (6) Want to reach out directly or shall I make an e-mail introduction?

Francis

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, February 26, 2020 6:43 AM
To: Collins, Francis (NIH/OD) [E] (b) (6)
Subject: Re: Milken outreach

Francis:

Thanks for the note. Milken can help in a number of ways including directly supporting the VRC. Also, as we start looking for Pharma to step up with us, his connections could be helpful.

Tony

On Feb 25, 2020, at 12:58 PM, Collins, Francis (NIH/OD) [E] (b) (6) > wrote:

Hi Tony,

I'm sure you know Michael Milken. I've worked with him over many years, and though he is a somewhat controversial figure he has certainly helped NIH in many ways. He reached out to me last night to ask if there is anything he could do to help with the coronavirus vaccine effort. He had seen press reports that finding a pharma partner had been challenging – and wanted to volunteer his help in that regard, since he has deep connections in the private sector. He also said that he'd be glad to help with any philanthropic needs, both through his own resources and his influence over members of the Giving Pledge.

Are there useful actions that I can suggest to him?

FC

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 10:59:30 +0000
To: 辛恩波
Subject: RE: Questions about the coronavirus—Chinese Media Inquiry:

See answers below in **red**

From: 辛恩波 <xinenbo@thepaper.cn>
Sent: Wednesday, February 26, 2020 1:08 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Questions about the coronavirus—Chinese Media Inquiry:

Dear Dr Fauci,

My Name is Paul Xin, I'm a journalist from Pengpai News(ThePaper) of Shanghai, which is one of the most important new media in China. I'm Sorry to bother you as you must be very busy. I noticed your comment about coronavirus on American media, I deeply hope you could answer few of my questions. Your answers will be very helpful to me. The questions are below.

Thank you very much!

Sincerely,
Paul Xin

1/You said on CNN that US have had pandemic preparedness plan that developed in preparation for pandemic influenza. Could you provide some details of this plan? **The plan outlines the differences between containment and mitigation. It speaks of the thing that should be done if an outbreak occurs in the USA. These include social distancing, use of telecommunication and telework, temporarily closing schools, avoiding crowded places such as indoor arenas and theaters.**

2/To prepare for potential communities spread of coronavirus in US, do you think that US need take the measures similar with China? **China was in the "reactive" mode of responding to an explosion of cases in Wuhan City and Hubei province with spread throughout China. China had to resort to very dramatic measures such as shutting down cities. The USA is now in a preparative mode and not a reactive mode and so our response is much different than that of China.**



辛恩波

澎湃新闻/时事新闻中心/国际新闻部

上海市延安中路839号

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 10:46:23 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Confirmation from CNN's New Day

Got it. Thanks.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, February 26, 2020 5:40 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Fwd: Confirmation from CNN's New Day

Firm for 650 am hit today at med arts as per below.

Sent from my iPhone

Begin forwarded message:

From: "Figliola, Mike" <Mike.Figliola@turner.com>
Date: February 26, 2020 at 3:33:40 AM EST
To: "Conrad, Patricia (NIH/NIAID) [E]" <(b) (6)>, "Daniels, Ronnel (NIH/OD/ORS) [C]" <(b) (6)>, "Ryland, Ken (NIH/OD/ORS) [E]" <(b) (6)>, Jonathan Bennett <(b) (6)>, "Jackson Farrar, Joy (NIH/OD/ORS) [E]" <(b) (6)>
Subject: RE: Confirmation from CNN's New Day

Hi everyone,
This is Mike with CNN's New Day. Hope you are well.
This is to confirm Dr. Fauci will be a guest today, **Wednesday 02.26.20** at around **6:50am EST** to discuss:

6E:

Coronavirus latest – are we facing an outbreak?

You will be **solo at 6:45am EST** for the segments.

John Berman, will both be conducting today's interview.

Please arrive at the studio no later than **6:40am EST**.

Here is your studio confirmation:

SHOW MANAGER: VENDOR STUDIO #2018562

NIH Events Management (Medical Arts) Studio Info

NIH Control Room numbers are 301-827-8478 and 8479

Encompass Booking and Circuit Number:

Booking: 1-800-243-1995

Circuit: 36TBGS104492

Our IFB: 301-496-1811 (we prefer to call into the station's IFB)

Video: 1080i (59.94) - the audio is embedded.

Please call the TOC with any technical questions at 301-827-8478

Please confirm you have received this and are all set to go!

Best,

M

Mike Figliola

Editorial Producer

CNN's New Day

212-275-8161

mike.figliola@turner.com



CONFIDENTIALITY NOTICE: This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain confidential information that is legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this message is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify us by reply e-mail at mike.figliola@turner.com or by telephone at (917) 670-9410, and destroy the original transmission and its attachments without reading them or saving them to disk. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 01:32:22 +0000
To: Jon LaPook
Subject: RE: CBS Sunday Morning

Jon:

The message would have to be that the situation continues to evolve and people need to follow the news and the reports from CDC. For example, a few weeks ago if you wanted to travel to Japan or South Korea, it was fine since there were few if any cases there. Now both countries have a travel alert that says "Avoid all but essential travel". You should tell people that travel to places with few or no reported cases is fine. Only when you have community spread (person to person to person) should you be concerned about a specific travel destination. Also, you could explain to people that pandemics evolve when a new infectious disease is spreading by sustained community spread in multiple countries in different regions of the globe. Once a pandemic erupts, it is virtually impossible for any country to be free of cases. People need to understand that. You can mitigate the effects, but you cannot avoid having infections since you cannot shut off the country from the rest of the world. Also, you need to speak of the real and present danger of seasonal influenza every year. Do not let the fear of the unknown (i.e. a pandemic of a new infectious agent) distort your evaluation of the risk of the pandemic to you relative to the risks that you face every day. The only thing that we can do is to prepare as best as possible and do not yield to unreasonable fear.

Best,
Tony

-----Original Message-----

From: Jon LaPook (b) (6)>
Sent: Tuesday, February 25, 2020 6:34 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: CBS Sunday Morning

Hi Tony,

I have an unusual opportunity: the executive producer of CBS Sunday Morning has asked me to do a straight to camera shpiel about COVID-19 for this Sunday. I did something similar when people are panicking about Ebola.

You and I have spoken enough about this so that I feel comfortable with the basics. But I would love you to give some thought to whether there are any misunderstandings that you would like cleared up or information you would like disseminated.

I would love to give some logical travel advice. I know there are so many unknowns, but I have had multiple people ask me whether they should cancel their upcoming trip to ... you name it (Italy, Israel, San Francisco). I know it comes down to risk/benefit, and - as you told me during the Ebola outbreak - people have all sorts of varying levels of comfort with risk. But what do I actually SAY to the 6 million people who will be watching people? :)

Thanks,
Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

From: (b) (6)
Sent: Tue, 25 Feb 2020 19:07:15 -0500
To: McNeil Jr, Donald G
Subject: Re: thought from a kibbitzer...

You make some very good points, Donald.

On Feb 25, 2020, at 4:48 PM, McNeil Jr, Donald G <meneil@nytimes.com>wrote:

I was just watching the HHS briefing online, and thinking about an article I read this morning, and Bruce Aylward's description of what he saw in China, and a lot of [videos I've watched](#) on the South China Morning Post website (they're doing great coverage.).

In China, we in the media tend to report the horrors and the lockdown and the government's early lies...

But the truth is that a lot of average Chinese behaved incredibly heroically in the face of the virus: 25,000 doctors and nurses went into Wuhan to help, knowing they might die. Average people gave up their stockpiles of masks so they could be shipped to Wuhan. Neighborhood committees brought food to thousands of little old ladies and checked on them every day, even as they asked them to stay behind their doors for fear of infection.

Meanwhile, in America, people tend to act like selfish pigs interested only in saving themselves. How can I hoard a mask? Where's my vaccine? This morning, I read [this appalling article](#) from Alabama. Here you have Americans coming back from a horrifying experience overseas, and the President -- who is popular in Alabama -- asks Alabamans to take some of those fellow Americans in. There is zero risk because they're going to be housed on a naval base.

And yet, the answer is "No! Keep them out!" And their legislators encourage it...

I dunno -- that's the kind of behavior I expect from my fellow New Yorkers, not from Alabama.

If the virus arrives -- and we both know it will -- America is going to have to do better than that. Like the Chinese, Americans are going to have to look out for each other the way we haven't since 9/11. Or maybe since World War II.

But that's not the tone of the HHS briefings. They're an aggressive, defensive, almost smart-alecky "we got this" tone. The only time the tone was right when you

were the third to take the mike and explain things to that kid shouting from the back without a mike about "What's the real message? What do we do?"

Maybe there could be some thought given to mentally preparing Americans to work together in the face of the crisis? Quarantines are a very aggressive approach -- but they require a lot of compassion or the people quarantined suffer.

I might get around to writing an article about this, but my editors keep grabbing me for minute by minute stuff and I'm way behind.

Donald

From: (b) (6)
Sent: Tue, 25 Feb 2020 18:59:02 -0500
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: Surfactant Protein-D against coronavirus

Please handle.

Begin forwarded message:

From: Marc Salzberg <(b) (6)>
Date: February 25, 2020 at 4:42:47 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Subject: **Surfactant Protein-D against coronavirus**

Dear Dr. Fauci,

We are developing a recombinant human form of Surfactant Protein-D (AT-100), an endogenous collectin with strong immune-modulatory properties. AT-100 shows anti-inflammatory and anti-infectious properties. (b) (4)

(b) (4) There are data indicating that SP-D clears coronavirus (<https://www.ncbi.nlm.nih.gov/pubmed/19439011>). (b) (4)

While we are discussing this with a number of academic institutions, I was wondering, though, whether you and the NIH are interested to collaborate on evaluating AT-100 against coronavirus. Please let me know, if you are willing to schedule a phone call with our Chief Medical Officer Dr. Paul Kingma and I to discuss. There is obviously a sense of urgency behind this request.

Best regards,

Marc Salzberg

Airway Therapeutics, Inc.
Marc Salzberg, MD
President & CEO
1200 Johnson Ferry Rd., Suite 300
Marietta, GA 30068

Ph

(b) (6)



From: (b) (6)
Sent: Tue, 25 Feb 2020 18:33:00 -0500
To: David - Gmail
Subject: Re: David Pyrcz Reconnecting - Coronavirus Task Force

David:

Thanks for your note and your keen interest in this important challenge of coronavirus. The White House Task Force is chosen by the President upon the advice of his senior staff. I am afraid that there will not be any additional members for now. Again, thank you for your interest.

Best regards,

Tony

On Feb 25, 2020, at 5:29 PM, David - (b) (6) wrote:

Hello Dr. Fauci,

I know you are extremely busy and will get right to the point. I would like to join the coronavirus taskforce.

I worked on the Ebola task force about six years ago, which had a similar sense of urgency, and recognize that assembling a SWAT team overnight is critically important in order to monitor, contain and mitigate the spread of the coronavirus, not just for the United States, but on a worldwide basis.

I've done a significant amount of work in infectious disease vaccine development at a number of biotech firms (Vical, Inovio and Intrexon) in partnership with the NIH, Vaccine Research Center, DOD and the CDC.

I also (b) (6) we discuss preparedness on a daily basis. Those conversations clearly indicate that the knowledge and expertise is severely lacking at both the academic medical center level, as well as the community health level.

I believe my assistance can be deployed in several areas where my experience in virology, immunology, antivirals, Ebola, product development and strategic partnering could be of immediate value to research scientists, medical professionals and healthcare systems.

1. Identification of emerging therapeutics.
2. Fast track emerging therapeutics from pre-clinical to IND and fast-track clinical trials.
3. Identify opportunities to accelerate the production of commercial quantities of therapeutic material.
4. Identify unique genomic fingerprints of responders and patients undergoing treatment to guide therapeutic selection and optimize interventions.
5. Interface with public and/or institutional stakeholders on a worldwide basis (24/7) regarding safety procedures, diagnostics, therapeutic interventions, etc.
6. Other initiatives, representing areas where there is an immediate need to bring on board and deploy an individual with deep expertise, who can provide leadership, drop in and rapidly advance those initiatives.

With the urgency required, in order to provide a Navy SEAL like response, I would propose a consulting arrangement where I'm available 24/7, anywhere/anytime, for as long as needed. Please let me know your thoughts.

Here is a brief snapshot of my C.V.

1. SVP, Innovation and Chief Commercial Officer – NantKwest (gene/cell therapies, immunotherapeutics and molecular diagnostics)
2. SVP, Innovation and Chief Commercial Officer – NantHealth (AI/bioinformatics-based multi-omics based molecular diagnostics and neoantigen-based therapeutics)
3. Founder/CEO - Genomic Principles (neoantigen-based, individualized therapeutic vaccines)
4. Founder/CEO Canton Biotechnologies (DNA-based therapeutics and vaccines)
5. Chief Business Officer – Intrexon (gene/protein-based therapeutics and vaccines)
6. Chief Business Officer - Inovio (gene-based therapeutics and vaccines)
7. VP, Business Development – Vical (gene-based therapeutics and vaccines).

I know you are busy and you can feel free to forward this email to the appropriate individual. I can also be reached by cell phone (b) (6) to discuss further.

Best Wishes,

David

David Pyrcce

Cel (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 22:10:15 +0000
To: NIAID OD AM
Subject: FW: Hello from [REDACTED] (b) (6)

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Groslyn Burton <burton@theasiagroup.com>
Sent: Tuesday, February 25, 2020 10:59 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: Hello from [REDACTED] (b) (6)

Dr. Fauci -

I hope this note finds you well. [REDACTED] (b) (6)

[REDACTED] I apologize for the direct out of the blue message, however, my company The Asia Group has a podcast called Tea Leaves and we would be interested in having you as a guest to speak about the Coronavirus. I mentioned to my CEO that you are the leading expert and that I had a connection with you. We would only take about 30-45 mins of your time and would be happy to work around your schedule if this is something that you would be willing to do. Below is a short description of the podcast and a link to our episodes. If able, I'd be happy to coordinate with your assistant.

Looking forward to hearing back soon.

Thanks,
Groslyn "Foster" Burton
Vice President, Culture and Values
Executive Assistant to the Chairman
Dr. Kurt M. Campbell, Chairman and CEO
The Asia Group, LLC

202-350-3285 – Office

(b) (6) – Mobile

202-750-2944 – Fax

The Asia Group announced the launch of Tea Leaves, a new podcast that will focus on the current affairs, foreign policy, business, and arts of Asia. The podcasts' hosts, Dr. Kurt M. Campbell and Ambassador Richard Verma, will lead a series of revealing interviews with policymakers, business leaders, journalists, and artists exploring the most dynamic and consequential region in the world.

In a joint statement, Campbell and Verma said, "We wanted to share our passion for Asia with listeners, both accomplished Asia hands and those with a budding interest in the dynamic region. Our aim is to provide listeners with a greater understanding of the individuals who focus on and live in the region, and how Asia affects our world."

The hosts bring significant experience and expertise to the podcast. Campbell is CEO and Chairman of The Asia Group, and served as Assistant Secretary of State for East Asian & Pacific Affairs from 2009 to 2013. Richard Verma is Vice Chairman and Partner at The Asia Group, and served as the United States Ambassador to India from 2015 to 2017.

The first episode of Tea Leaves is now live on major podcast platforms, including iTunes, Stitcher, and Overcast. Subsequent episodes will be animated by conversations with the movers, doers, and thinkers who are driving today's Indo-Pacific. "We hope that you will subscribe and give our first episode a listen," said Campbell and Verma.

The link to the podcast is available here: <https://itunes.apple.com/us/podcast/the-tea-leaves-podcast/id1355207045>

From: (b) (6)
Sent: Tue, 25 Feb 2020 16:08:53 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: The Last Word with Lawrence O'Donnell

Let us discuss

Begin forwarded message:

From: "Shuster, Amy (NBCUniversal, MSNBC)" <amy.shuster@msnbc.com>
Date: February 25, 2020 at 3:40:25 PM EST
To: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6), "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Subject: The Last Word with Lawrence O'Donnell

Good afternoon,

I wonder if Dr. Fauci could join our program this evening at 10 pm to discuss the best measures for the government and the American people to prepare for a coronavirus pandemic.

Ali Velshi is hosting our show tonight on MSNBC.

This would be a panel discussion this evening – we're still working through details of the panel.

Interview would be from 10-10:20 pm EST.

Please let me know if anything would be possible tonight.

Many thanks,
Amy

Amy Shuster
Senior Producer
The Last Word
o. 212-664-1657
c. (b) (6)

From: (b) (6)
Sent: Tue, 25 Feb 2020 14:03:48 -0500
To: Ziady, Hanna (NE)
Subject: Re: Questions on coronavirus vaccine

45 people. It will take 3 to 4 months to complete.

On Feb 25, 2020, at 11:12 AM, Ziady, Hanna (NE)
<Hanna.Ziady@turner.com> wrote:

Thanks very much for the quick response.

Do you know at this stage when the phase 1 trial will be completed and how many people will participate in it?

Many thanks,
Hanna

Hanna Ziady
Writer | CNN Business
O: +44 207 693 1884
M: + (b) (6)
@hannaziady

From: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Date: Tuesday, 25 February 2020 at 15:58
To: "Ziady, Hanna (NE)" <Hanna.Ziady@turner.com>
Subject: RE: Questions on coronavirus vaccine

The phase 1 trial to determine safety for the mRNA vaccine platform that NIH is doing with Moderna is scheduled to start within 2 months (some time in April). However, this is just the first step in attempting to have a vaccine available for use. Even proceeding at an emergency speed, a vaccine would not be available for use for at least 1 to 1.5 years. It is characterized as a "vaccine".

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Ziady, Hanna (NE) <Hanna.Ziady@turner.com>

Sent: Tuesday, February 25, 2020 5:56 AM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >

Subject: Questions on coronavirus vaccine

Dear Dr Fauci,

Trust this mail finds you well.

I have a few questions regarding the Moderna vaccine, which it would be great to get your input on.

Is it true that trials of the possible vaccine will start in April, but that, even if the first study is positive, the vaccine might not become widely available until next year because of the need for further studies and regulatory clearances?

The company is characterizing this as a vaccine. Strictly speaking, what should it be referred to as?

If you have time for a quick telephone call this morning as soon as you're able that would be great.

Many thanks,
Hanna

Hanna Ziady
Writer, CNN Business
Office: +44 207 693 1884
Mobile: (b) (6)
@hannaziady

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please

notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

From: (b) (6)
Sent: Tue, 25 Feb 2020 13:56:38 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Re: cdc coronavirus

This does not change anything I said this AM. It is perfectly compatible with what I said. No conflict at all.

On Feb 25, 2020, at 1:32 PM, Conrad, Patricia (NIH/NIAID) [E]
(b) (6) wrote:

Pls advise

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jakaitis, Mike <mjakaitis@wtop.com>
Sent: Tuesday, February 25, 2020 1:26 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: cdc coronavirus

The CDC today alerted Americans to begin to prepare for community spread of the coronavirus.....does this changes Dr. Fauci's view on the virus? If so can he join us. If this doesn't change anything. We can use what he said this morning....or if he wants to come on and talk about the new CDC warning...we would like to speak to him.

From: (b) (6)
Sent: Tue, 25 Feb 2020 13:52:31 -0500
To: James Rae
Subject: Re: touch screens transmitting Coronavirus

Mr. Rae:

Thank you for your note.
Best regards,
A.S. Fauci

> On Feb 25, 2020, at 1:36 PM, James Rae (b) (6) > wrote:
>
> Dear Dr. Fauci-
>
> Thanks for your tv appearances to educate.
>
> Cell phone and other touch screens could be a major vector of transmission for Coronavirus.
>
> Please suggest frequent cleaning of devices with alcohol on your next tv appearance.
>
> Keep up the good work. I've watched you over the years. Your public education is much appreciated.
>
> Best regards,
>
> Jim Rae
> Boston area
> (b) (6) mobile

From: (b) (6)
Sent: Tue, 25 Feb 2020 13:09:02 -0500
To: Emanuel, Ezekiel J
Cc: (b) (6)
Subject: Re:

It may well diminish somewhat as weather gets warmer. However, there is no guarantee that this will occur. More likely that it will become seasonal and go down in our summer and resurge next winter

On Feb 25, 2020, at 12:48 PM, Emanuel, Ezekiel J (b) (6) >wrote:

To get 1 million deaths of 1957 would require 200 million infections at a death rate of 0.5%. That seems high number of infections.

But what is the worldwide seasonal flu death numbers if the USA has 50,000 deaths in a bad year and the 1957 number of deaths was 116,000? The WHO says 650,000 deaths worldwide from seasonal flu. So this could be worse but by about 40% not an order of magnitude. Okay so I should be more concerned.

And do you think it will go down in late spring with warmer weather?

Ezekiel J. Emanuel, M.D., Ph.D.

Vice Provost for Global Initiatives
Diane v.S. Levy and Robert M. Levy University Professor
Chair, Department of Medical Ethics and Health Policy (b) (6)
(b) (6)
Co-Director, Healthcare Transformation Institute
University of Pennsylvania

Phone: (b) (6)
Fax: 215-898-6567

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, February 25, 2020 12:32 PM
To: Emanuel, Ezekiel J <(b) (6) >
Subject: RE:

Zeke:

Ari is also calling me frequently. The virus has adapted itself very well to humans with considerable community transmission (certainly in China) now in other countries such as South Korea, Japan, Iran, Italy, etc. If it continues to spread via multiple generations of human to human transmission, then we will not be able to avoid considerable amounts of infections and spread in the USA. Seasonal influenza has a mortality of 0.1%. The calculated mortality of COVID-19 to about 2.5 %. It is probably lower since the denominator is likely larger than we appreciate due to asymptomatic infections. Even if the mortality goes down to 0.5%, that is still equivalent to a pandemic influenza of 1957 or 1968. In other words, it could be worse than you think.

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Emanuel, Ezekiel J (b) (6)
Sent: Tuesday, February 25, 2020 10:47 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject:

Tony,

Ari is pestering me endlessly. What is your latest update and assessment on coronavirus? I still am having a hard time seeing this as serious as everyone else. Am I blind? Yes very transmissible but low mortality like flu in many ways—the elderly, those with comorbidities, and total impact is likely to be less than flu. Also travel restrictions are delaying but not stopping virus.

Am I missing something big or small?

Thanks

Ezekiel J. Emanuel, M.D., Ph.D.

Vice Provost for Global Initiatives

Diane v.S. Levy and Robert M. Levy University Professor

Chair, Department of Medical Ethics and Health Policy ((b) (6))

Co-Director, Healthcare Transformation Institute

University of Pennsylvania

Phone: (b) (6)

Fax: 215-898-6567

From: (b) (6)
Sent: Tue, 25 Feb 2020 13:04:40 -0500
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: DDP4 Inhibitors and ACE2 Inhibitors :: Spike Protein Binding in MERS and SARS

Please handle. Thanks

Begin forwarded message:

From: Joel Meyer (b) (6) >
Date: February 25, 2020 at 12:32:24 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Subject: DDP4 Inhibitors and ACE2 Inhibitors :: Spike Protein Binding in MERS and SARS

Dear Dr. Fauci,
Is it possible that DDP4 and ACE2 inhibitors would be effective in preventing coronavirus entry and thereby 'de-rail' the infectious cycle?
Thank you for your work and guidance to NIAID!
Sincerely,
Joel R.L. Meyer

(b) (6)
(b) (6)

=====
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891363/>

"Coronavirus entry is initiated by the binding of the spike protein (S) to cell receptors, specifically, dipeptidyl peptidase 4 (DDP4) and angiotensin converting enzyme 2 (ACE2) for MERS-CoV and SARS-CoV, respectively [1–5]"

...

References

1. Masters, PS., Perlman, S. Coronaviridae in Field's Virology. Knipe, DM., Howley, PM., editors. Vol. 1. Lippincott, Williams & Wilkins; Philadelphia: 2013. p. 825-858.
2. Coleman CM, Frieman MB. Coronaviruses: important emerging human pathogens. J Virol. 2014; 88:5209–5212. [PubMed: 24600003]
3. De Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nature Rev Microbiol. 2016; 14:523–534. [PubMed: 27344959]

4. Greenberg SB. Update on human rhinovirus and coronavirus infections. *Sem Respir Crit Care Med*. 2016; 37:555–571.
5. Vijay R, Perlman S. Middle East respiratory syndrome and severe acute respiratory syndrome. *Curr Opin Virol*. 2016; 16:70–76. [PubMed: 26855039]

From: (b) (6)
Sent: Tue, 25 Feb 2020 13:02:20 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Doctor Radio followup special

Please see if this is possible. Thanks

Begin forwarded message:

From: "Siegel, Marc" <Marc.Siegel@nyulangone.org>
Date: February 25, 2020 at 12:07:19 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Cc: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)>, Beth Ameen
<beth.ameen@siriusxm.com>
Subject: Doctor Radio followup special

Hi Tony

Am wondering if you might have a few minutes to join us by phone again this
Friday between
3 and 4 on coronavirus
Would mean alot.
Marc

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 17:25:40 +0000
To: Gary Simon
Cc: Graham, Barney (NIH/VRC) [E]; Ledgerwood, Julie (NIH/NIAID) [E]; 'Chen, Grace (NIH/NIAID) [E]'; Conrad, Patricia (NIH/NIAID) [E]; Mascola, John (NIH/VRC) [E]
Subject: RE: Coronavirus vaccine

Thanks, Garry. I will pass your note on to the people who will be conducting the phase 1 vaccine trial here at NIH.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Gary Simon (b) (6) >
Sent: Tuesday, February 25, 2020 10:42 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Coronavirus vaccine

Dear Tony,

I'm not sure which email you use. (b) (4)

It would certainly expedite getting samples to NIH for immune assays.

gary

Gary L. Simon, MD, PhD, MACP
Walter G. Ross Professor of Medicine

Director, Division of Infectious Diseases
Vice-Chairman, Department of Medicine
T (b) (6)
F 202 741-2241

Confidentiality Note: This e-mail is intended only for the person or entity to which it is addressed and may contain information that is privileged, confidential or otherwise protected from disclosure. Dissemination, distribution or copying of this e-mail or the information herein by anyone other than the intended recipient, or an employee or agent responsible for delivering the message to the intended recipient, is prohibited. If you have received this e-mail in error, please call (202) 741-3636 and destroy the original message and all copies.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 17:15:43 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Collaboration proposal on [REDACTED] (b) (4)
variants
Attachments: Macrogen (Dr. Jeong-sun Seo) letter to Dr. Anthony Fauci.pdf

Please handle and respond to this person. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Ogan Gurel, MD [REDACTED] (b) (6) >
Sent: Tuesday, February 25, 2020 9:20 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Cc: Jeongsun Seo MD PhD [REDACTED] (b) (6); Changhoon Kim PhD [REDACTED] (b) (6); Moon-Young Shin [REDACTED] (b) (6)
Subject: Collaboration proposal on [REDACTED] (b) (4)

Dear Dr. Fauci,

Greetings and thank you for all your outstanding scientific and policy leadership regarding the evolving Covid-19 situation.

I am writing to you from South Korea where, as you well know, we are experiencing a very difficult phase of the epidemic. Among the several groups I have been engaged with to address this crisis, I am working with the genome sequencing company, Macrogen, which you may already be familiar with (<https://dna.macrogen.com/eng/>). Dr. Jeongsun Seo, the Chairman of Macrogen, along with other company leaders and myself have been discussing [REDACTED] (b) (4)

(b) (4)

(b) (4)

Barring the institution of any extreme travel restrictions, I am planning to visit the Bethesda area next week (Macrogen U.S. HQ is located in Rockville). I know you are extraordinarily busy but if you (or key colleagues) have time, I and other senior Macrogen colleagues would be happy to discuss the project, its necessary next steps, along with any other matters related to Korea as you wish. [Please note that I do not have any clinical symptoms or signs of Covid-19 nor any relevant contact history.]

Thank you very much for your attention to this matter and I hope that we may have a chance to advance this important project together.

Please take care and thanks again,

Ogan

(b) (6)



<http://www.linkedin.com/in/ogangurel>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 17:08:19 +0000
To: Eisinger, Robert (NIH/NIAID) [E];Greg Folkers (b) (6)
Subject: FW: NEJM content proof (Fauci)
Attachments: NEJMe2002387_Fauci_Content2_Author.pdf

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Laurencot, Elizabeth <elaurencot@nejm.org>
Sent: Tuesday, February 25, 2020 8:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: NEJM content proof (Fauci)
Importance: High

Dear Dr Fauci,

Attached is the content proof of your editorial. **Please read *ALL* of the following instructions and information carefully before** you begin reviewing your proofs.

First, please **stop and take a moment now** to confirm receipt, so that we can be assured that your proofs did not end up in a spam folder.

Your editorial has been edited for grammar, consistency, readability, adherence to Journal style, and clarity for nonspecialist readers. To expedite publication, we do not ask authors for specific approval of routine changes; please read the entire article to make sure your meaning has been retained. Note that we may be unable to make changes that conflict with Journal style or create grammatical or other problems. Finally, please note that a delayed or incomplete response may delay publication of your editorial.

Please read the entire proof carefully, including all queries. Please return your query replies and proof corrections ****before 12pm (US Eastern) this Friday, February 28, 2020****.

Instructions are provided below. Note that you will be reading for content only; the article will be rendered for print after the content has been finalized.

The Journal's senior medical editors will be reading your article at this stage. If they have any additional comments or queries for you, I will forward them to you in the next few days.

TO ANSWER THE QUERIES: The proof contains in-line numbered query markers and a numbered list of queries at the end. The query markers and the queries are linked, so you can jump back and forth within the file. Please respond to all the queries (see below for instructions; please do ****NOT**** use e-annotation tools) and convey any additional changes as needed.

TO RESPOND BY E-MAIL: If your corrections and your responses to the queries are straightforward, we encourage you to respond by replying to this message. Please copy and paste the list of queries into an e-mail message or a Word document and type your responses there. You may also include a list of changes (e.g., page 1, line 20, change xxx to yyy). Again, please do ****NOT**** use e-annotation tools in the PDF file; the marks are small and easy to miss, which may lead to errors in your article.

Please note that this material is confidential and embargoed until publication. If you have questions about our embargo policy, please contact NEJM Media Relations at 781-434-7847 or at Mediasupport@nejm.org.

Again, please do confirm receipt at this time. Thank you very much for your efforts with these content proofs!

Best,
Eli

Elizabeth Laurençot
Senior Manuscript Editor
New England Journal of Medicine

617-487-6547
elaurencot@nejm.org

TO READ THE PROOF: You will need Adobe Acrobat Reader software (version 4.0 or later) to view this file. Acrobat Reader is available free of charge at the Adobe Web site (<http://www.adobe.com/products/acrobat/readmain.html>).

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 17:07:30 +0000
To: Eisinger, Robert (NIH/NIAID) [E]; Greg Folkers (b) (6)
Subject: FW: NEJM content proof (Fauci)
Attachments: NEJMe2002387_Fauci_Content2_Author.pdf

Please take a look at this for me and proof to the extent that you can. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Laurencot, Elizabeth <elaurencot@nejm.org>
Sent: Tuesday, February 25, 2020 8:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: NEJM content proof (Fauci)
Importance: High

Dear Dr Fauci,

Attached is the content proof of your editorial. **Please read *ALL* of the following instructions and information carefully before** you begin reviewing your proofs.

First, please **stop and take a moment now** to confirm receipt, so that we can be assured that your proofs did not end up in a spam folder.

Your editorial has been edited for grammar, consistency, readability, adherence to Journal style, and clarity for nonspecialist readers. To expedite publication, we do not ask authors for specific approval of routine changes; please read the entire article to make sure your meaning has been retained. Note that we may be unable to make changes that conflict with Journal style or create grammatical or other problems. Finally, please note that a delayed or incomplete response may delay publication of your editorial.

Please read the entire proof carefully, including all queries. Please return your query replies and proof corrections ****before 12pm (US Eastern) this Friday, February 28, 2020****.

Instructions are provided below. Note that you will be reading for content only; the article will be rendered for print after the content has been finalized.

The Journal's senior medical editors will be reading your article at this stage. If they have any additional comments or queries for you, I will forward them to you in the next few days.

TO ANSWER THE QUERIES: The proof contains in-line numbered query markers and a numbered list of queries at the end. The query markers and the queries are linked, so you can jump back and forth within the file. Please respond to all the queries (see below for instructions; please do ****NOT**** use e-annotation tools) and convey any additional changes as needed.

TO RESPOND BY E-MAIL: If your corrections and your responses to the queries are straightforward, we encourage you to respond by replying to this message. Please copy and paste the list of queries into an e-mail message or a Word document and type your responses there. You may also include a list of changes (e.g., page 1, line 20, change xxx to yyy). Again, please do ****NOT**** use e-annotation tools in the PDF file; the marks are small and easy to miss, which may lead to errors in your article.

Please note that this material is confidential and embargoed until publication. If you have questions about our embargo policy, please contact NEJM Media Relations at 781-434-7847 or at Mediasupport@nejm.org.

Again, please do confirm receipt at this time. Thank you very much for your efforts with these content proofs!

Best,
Eli

Elizabeth Laurençot
Senior Manuscript Editor
New England Journal of Medicine

617-487-6547
elaurencot@nejm.org

TO READ THE PROOF: You will need Adobe Acrobat Reader software (version 4.0 or later) to view this file. Acrobat Reader is available free of charge at the Adobe Web site (<http://www.adobe.com/products/acrobat/readmain.html>).

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 15:55:19 +0000
To: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: The global health leaders call, Wednesday 26 February at 13:00 CET
Attachments: (b) (4) Swisscom Call code.pdf

Please print out for tomorrow AM.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: RYAN, Michael J. (b) (6)
Sent: Tuesday, February 25, 2020 4:10 AM
To: Redfield, Robert R. (CDC/OD) (b) (6)
(b) (6)
(b) (6) David Heymann (b) (6); Felicity Harvey
(b) (6) Chris.Elias
(b) (6); Jeremy Farrar
(b) (6) Fauci, Anthony
(NIH/NIAID) [E] (b) (6)
(b) (6) Conrad, Patricia (NIH/NIAID) [E]
(b) (6) Thomas R. Frieden (b) (6)
(b) (6); Lynn Banks (b) (6); President | Resolve to Save Lives
<president@resolvetosavelives.org> (b) (6)
(b) (6)
(b) (6)
Tarik Mohammed (b) (6)
Cc: SHOC <shoc@who.int>; Office of the Director-General <DGOOffice@who.int>; SCHWARTLANDER, Bernhard F. (b) (6); MAHJOUR, Jaouad (b) (6); FALL, Ibrahima Soce (b) (6); GREIN, Thomas <(b) (6)>; MINHAS, Raman (b) (6); COX, Paul Michael (b) (6); AL-SHORBAJI, Farah (b) (6); POOLE, Marcia (b) (6); DRURY, Patrick Anthony (b) (6); GRAAFF, Peter Jan (b) (6); Dr VAN KERKHOVE, Maria (b) (6); KABIR, Sophia

(b) (6)

Subject: The global health leaders call, Wednesday 26 February at 13:00 CET

Dear colleagues,

Dr Tedros would like to invite you to the next informal discussion about the ongoing 2019 novel coronavirus.

The teleconference will be hosted tomorrow Wednesday, 26 February at 13:00 CET and the dial-in number with a passcode is attached.

If you experience any technical difficulties joining this conference call, please contact the WHO HQ EOC operator at: +41227912490

It would be appreciated if you could kindly confirm your participation to Ms Sophia Kabir, email:

(b) (6) ; mobile no. (b) (6)

Best,

Mike

From: [REDACTED] (b) (6)
Sent: Tue, 25 Feb 2020 07:30:31 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Bloomberg Radio 2/25

Let us discuss

Begin forwarded message:

From: "Jameelah D Robinson (BLOOMBERG/ NEWSROOM:)"
<jrobinson158@bloomberg.net>
Date: February 25, 2020 at 7:25:43 AM EST
To: "NIAID NEWS (NIH/NIAID)" <NIAIDNEWS@niaid.nih.gov>
Cc: "Fauci, Anthony (NIH/NIAID) [E]" [REDACTED] (b) (6)
Subject: Bloomberg Radio 2/25
Reply-To: "Jameelah D Robinson" <jrobinson158@bloomberg.net>

Hi Dr. Fauci!

I Hope this email finds you well. I'm emailing to see if you can join Tom Keene, Bloomberg Surveillance Anchor/Editor-at-Large on his radio show tomorrow morning as a PHONER at 8:15am Et to discuss the Coronavirus. Please let me know if we can make this happen.
Many thanks!

-Jameelah

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 03:27:11 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: NIAF and coronavirus

Let us discuss.

From: Elvis Oxley <eoxley@bdo.com>
Sent: Monday, February 24, 2020 9:42 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Eric Jia-Sobota <esobota@bdo.com>
Subject: NIAF and coronavirus

Dr. Fauci, I trust this email finds you well. It has been a few years since we've seen one another on the Hill or at a NIAF event but hopefully we will rectify that soon.

I know you have a lot on your plate, especially with the coronavirus, but I am curious if you have five minutes for a call tomorrow so I can introduce you to my boss at BDO, Eric Jia-Sobota (<https://www.linkedin.com/in/eric-jia-sobota-02156036/>). Eric is an expert in cost accounting for Life Sciences companies and he wants to glean your perspective on the likely structure of the emergency coronavirus budget request so that NIH and others can maximize those research and implementation dollars at the most rapid pace. We would certainly appreciate your time.

My best, Elvis

Elvis Oxley
Managing Director
Industry Specialty Services
(b) (6) (Mobile)
703-245-8665 (Direct)
eoxley@bdo.com

BDO
Greater Washington D.C.
8401 Greensboro Drive, Suite 800
McLean, VA 22102
www.bdo.com

BDO USA, LLP, a Delaware limited liability partnership, is the U.S. member of BDO International Limited, a UK company limited by guarantee, and forms part of the international BDO network of independent member firms.

BDO is the brand name for the BDO network and for each of the BDO Member Firms.

IMPORTANT NOTICES

The contents of this email and any attachments to it may contain privileged and confidential information from

BDO USA, LLP. This information is only for the viewing or use of the intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of, or the taking of any action in reliance upon, the information contained in this e-mail, or any of the attachments to this e-mail, is strictly prohibited and that this e-mail and all of the attachments to this e-mail, if any, must be immediately returned to BDO USA, LLP or destroyed and, in either case, this e-mail and all attachments to this e-mail must be immediately deleted from your computer without making any copies hereof. If you have received this e-mail in error, please notify BDO USA, LLP by e-mail immediately.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 03:26:06 +0000
To: Tabak, Lawrence (NIH/OD) [E]
Subject: RE: Close of Day Note for 2/24/2020 re: coronavirus preparedness

No, I did not see this. You should tell Jim Gillman to copy me on everything that relates to this issue since I am the one who will be dealing with the Congress, the President and the press about all of this.

From: Tabak, Lawrence (NIH/OD) [E] (b) (6)
Sent: Monday, February 24, 2020 9:41 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: FW: Close of Day Note for 2/24/2020 re: coronavirus preparedness

Tony,
I assume you have already seen this, but just in case....
Larry

From: "Gilman, James (NIH/CC/OD) [E]" (b) (6) >
Date: Monday, February 24, 2020 at 5:50 PM
To: "Tabak, Lawrence (NIH/OD) [E]" (b) (6) >, Francis Collins
(b) (6), "Gottesman, Michael (NIH/OD) [E]" (b) (6) >
Subject: Close of Day Note for 2/24/2020 re: coronavirus preparedness

Francis / Larry / Michael:

(b) (5)

(b) (5)

Jim

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 23:38:09 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: LA Magazine / Interview request

Let us discuss.

From: jmcgahan [REDACTED] (b) (6)
Sent: Monday, February 24, 2020 6:03 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: LA Magazine / Interview request

Dear Dr. Fauci,

You and I haven't met. I'm a long-time writer for Los Angeles Magazine. We're doing a cover story for the April issue on the threat of the new coronavirus poses to the 10 million inhabitants of metropolitan Los Angeles. Would you be available for an interview on Wednesday?

Thanks,
Jason

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 22:42:57 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Welcome packet & consent form | The Coronavirus Outbreak: Tracking COVID-19 | Forum
Attachments: 3.2.20 Consent form .pdf, 3.2.20 Forum welcome document.pdf, 3.2.20 Green room agenda .pdf

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Dweck, Kristen <kdweck@hsph.harvard.edu>
Sent: Monday, February 24, 2020 5:34 PM
To: (b) (6) Lipsitch, Marc (b) (6)
Yip, Winnie Chi-Man (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: (b) (6) Osborn, Elizabeth (b) (6); Conrad, Patricia
(NIH/NIAID) [E] (b) (6); Barasch, Kimberly (NIH/NIAID) [C]
(b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Lerner, Andrea
(NIH/NIAID) [E] (b) (6)
Subject: Welcome packet & consent form | The Coronavirus Outbreak: Tracking COVID-19 | Forum
Importance: High

Good evening,

Please find attached, The Forum welcome document, green room agenda and consent form. The welcome packet includes information about our production along with what to wear while on camera. The Harvard T.H. Chan School of Public Health consent form is required for production of webcast series.

Please sign and scan a copy of the consent form back by **March 2, 2020.**

We look forward to an exciting event!

Best,
Kristen Dweck

--

Kristen A. Dweck

Digital Media and Engagement Manager, The Leadership Studio
Harvard T.H. Chan School of Public Health
677 Huntington Avenue, Kresge 329 | Boston, MA 02115
o: 617-432-1268 | f: 617-432-1780
kdweck@hsph.harvard.edu



Join the conversation:

[The Forum](#) | [Twitter](#) | [YouTube](#) | [iPhone and iPad](#)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 22:34:05 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Re:Following up on NIH visit

What is this?

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jason Gale (BLOOMBERG/ NEWSROOM:) <j.gale@bloomberg.net>
Sent: Monday, February 24, 2020 4:04 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Hoffman, Hillary (NIH/NIAID) [E] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6) Segre, Julie (NIH/NHGRI) [E] (b) (6)
Subject: RE: Re:Following up on NIH visit

Dear Hillary,
Thanks for your email.
I am indeed looking forward to my NIH visit on Friday, and am still hoping I might get some time with Dr. Fauci, though I can appreciate he might be busier than either of us expected to be back when we first scheduled my interview with him!
Warm regards,
Jason

Jason Gale, MHIthSec
Senior editor | Bloomberg News
Level 30, 120 Collins St., Melbourne VIC 3000

Tel. (landline) +61-3-9228-8783 | Mobile (b) (6)
@jwgale | LinkedIn: <http://www.linkedin.com/pub/jason-gale/6/249/a56>

From: (b) (6) At: 02/25/20 06:47:17
To: Jason Gale (BLOOMBERG/ NEWSROOM:)
Subject: RE: Re:Following up on NIH visit

Hi Jason,

Hope you have/had safe travels to DC this week! I wanted to check in to confirm that you're still planning on coming to visit us at NIH this Friday?

Currently, Dr. Myles is holding 10am and Dr. Belkaid is holding 1:30pm to discuss their microbiome-related research with you. Dr. Fauci's schedule has been very fluid lately due to the coronavirus outbreak—we'll likely need to check in with his assistant Patty Conrad on Thursday to see how his Friday calendar looks (unless you hear otherwise from Patty directly).

Best,
Hillary

Hillary Hoffman, Ph.D., Writer/Editor
Office of Communications and Government Relations, NIAID, NIH
5601 Fishers Lane #6G38
Rockville, MD 20852

(b) (6)

(b) (6)

From: Jason Gale (BLOOMBERG/ NEWSROOM:) <j.gale@bloomberg.net>
Sent: Tuesday, January 28, 2020 4:39 PM
To: Hoffman, Hillary (NIH/NIAID) [E] (b) (6)>
Subject: RE: Re:Following up on NIH visit

Sounds good. Many thanks.

----- Original Message -----

From: Hillary Hoffman (b) (6)>
To: JASON GALE
At: 29-Jan-2020 08:38:46

Sounds good – I'll ask Dr. Myles to hold 10am, so you can chat with him before you meet Dr. Fauci at 11. We can re-confirm timing closer to the date. I'll tag along, and can make sure you get where you need to – you'll get to visit several different buildings, fortunately all close by!

From: Jason Gale (BLOOMBERG/ NEWSROOM:)
<j.gale@bloomberg.net>
Sent: Tuesday, January 28, 2020 4:32 PM
To: Hoffman, Hillary (NIH/NIAID) [E] <(b) (6)>
Subject: RE: Re:Following up on NIH visit

Hi Hillary
Late night for me on 2019-nCoV...
Shall we say before DrFauci? Then I'll know better how to get to him. 😊
Thanks a lot. Jason

----- Original Message -----

From: Hillary Hoffman (b) (6)
To: JASON GALE
CC: (b) (6)
At: 29-Jan-2020 06:34:55

Hi Jason,

Great speaking with you last week. I wanted to follow up to let you know that Yasmine Belkaid and Ian Myles—whose work we discussed on host-microbe interactions and developing a bacteria-based treatment for eczema, respectively—are willing to meet with you on Feb. 28.

Here are links to some background info:

- Dr. Belkaid's [lab page](#), and recent [NIAID press release](#) about a skin microbiome study from her lab
- Dr. Myles' [lab page](#), and [NIAID press release about findings from a Ph 1/2 trial](#) assessing the *R. mucosa* treatment for eczema

Dr. Belkaid is available at 1:30pm (her building is next to the Clinical Center, where you'll be meeting with Julie Segre I believe from 12-1ish). Dr. Myles' schedule is a bit more flexible, and he's currently available to meet either in the morning before you speak with Dr. Fauci or later in the afternoon after Dr. Belkaid (Dr. Myles is in the Clinical Center, about a 5 min walk from Dr. Fauci's building) – let me know if you have a timing preference. We can firm up times a bit closer to the date, but wanted to give you an update.

Best,
Hillary

Hillary Hoffman, Ph.D., Writer/Editor
Office of Communications and Government Relations, NIAID,
NIH
5601 Fishers Lane #6G38
Rockville, MD 20852

(b) (6)

(b) (6)

From: Jason Gale (BLOOMBERG/ NEWSROOM:) <j.gale@bloomberg.net>
Sent: Thursday, January 23, 2020 4:09 PM
To: Hoffman, Hillary (NIH/NIAID) [E] <hillary.hoffman@nih.gov>
Cc: Routh, Jennifer (NIH/NIAID) [E] <jennifer.routh@nih.gov>
Subject: RE: Re:Following up on NIH visit

Sorry!! Getting on now

From: (b) (6) **At:**
01/24/20 08:07:48
To: Jason Gale (BLOOMBERG/ NEWSROOM:)
Cc: (b) (6)
Subject: RE: Re:Following up on NIH visit

Hi Jason,

Wanted to check that you're still able to join us this afternoon/morning -- and that you aren't having issues calling into the conference line. Jen and I are both on.

Thanks, and hope to talk soon!
Hillary

From: Jason Gale (BLOOMBERG/ NEWSROOM:) <j.gale@bloomberg.net>
Sent: Friday, January 17, 2020 3:02 PM
To: Hoffman, Hillary (NIH/NIAID) [E]
(b) (6)
Cc: Routh, Jennifer (NIH/NIAID) [E]

(b) (6)>
Subject: RE: Re:Following up on NIH visit

Awesome. Thanks a lot.

----- Original Message -----

From: Hillary Hoffman

(b) (6)

To: JASON GALE

CC: (b) (6)

At: 18-Jan-2020 01:31:40

Hi Jason,

Yes, 4pm next Thursday (8am Friday for you) works for us. I will send out a calendar invitation with call-in information later today.

Enjoy your time off, and looking forward to speaking with you next week!

Best,
Hillary

From: Jason Gale
(BLOOMBERG/
NEWSROOM:)
<j.gale@bloomberg.net>

Sent: Thursday, January 16, 2020 6:24 PM

To: Hoffman, Hillary
(NIH/NIAID) [E]

<(b) (6)>

Cc: Routh, Jennifer
(NIH/NIAID) [E]

(b) (6)>

Subject: RE: Re:Following up on NIH visit

Dear Hillary,
Thanks for your email.
I am on vacation Mon-

Thursday next week.
Would a 4 pm call on
Thursday Jan. 23 (8 am
Friday for me) work?
I just saw happened to
see this report, FYI:
https://medicalxpress.com/news/2020-01-gut-bacteria-parkinson.html?fbclid=IwAR2OXNzDroX9zaHhP73A22pK2zOP_2_cRQ6_YJjdQo-icbKrNKrjoPrQ9Z0
It's a good example of
the growing awareness
that the Human
Microbiome Project is
helping to provide of
the complex
interactions with
various biological
processes that underpin
health and disease.
Have a great weekend,
jason

From:

(b) (6)

At: 01/17/20 03:22:49

To: Jason Gale

(BLOOMBERG/ NEWSROOM:)

Cc:

(b) (6)

Subject: RE:

Re:Following up on NIH
visit

Hi Jason,

Great to hear of
your interest in
microbiome and flu
research. Jen and I
would be happy to
chat about what
NIAID may be able

to offer in terms of
subject matter
experts and
storylines in those
areas.

Might you be
available for a short
call next week
between 4-5pm
EST on either
Tues., Wed., or
Thurs. afternoon –
corresponding to 8-
9am Melbourne
time on Wed.,
Thurs., or Fri.
morning (assuming
I've got my time
zones correct)? If
we can't find a
mutually convenient
time, happy to
continue
discussions over
email.

Best,
Hillary

Hillary Hoffman, Ph.D.,
Writer/Editor
Office of
Communications and
Government Relations,
NIAID, NIH

(b) (6)

Media line: 301-402-
1663

From: Jason Gale
(BLOOMBERG/
NEWSROOM:)
<j.gale@bloomberg.net>
Sent: Wednesday,

January 15, 2020
11:56 PM

To: Rancourt, Anne
(NIH/NIAID) [E]

(b) (6)

Cc: Leifman, Laura
(NIH/NIAID) [E]

(b) (6)

Hoffman,
Hillary (NIH/NIAID)
[E]

(b) (6)

; Routh,
Jennifer
(NIH/NIAID) [E]

(b) (6)

Lavelle,
Judith (NIH/NIAID)
[E]

(b) (6)

Segre, Julie
(NIH/NHGRI) [E]

(b) (6)

Subject: RE:
Re:Following up on
NIH visit

Hi Anne,
Thanks a lot
for your email
and your
suggestions!
After my last
visit to NIH
(and meeting
with Lisa
Proctor and
Julie Segre
years ago), we
did the
attached story
on the gut
microbiome.
We're very
keen to look

at doing a
podcast series
on the
microbiome
(skin, gut,
other
anatomical
bits) and how
it's informing
our views on
health,
disease and
the way we
prevent and
treat
diseases.

It would be
cool to
workshop this
theme with you
and your
colleagues
before my
visit, if you
have some
time?

I cut my teeth
in medical
science
writing on
(bird) flu and
would be
interested in
the research
Jeffrey
Taubenberger's
lab is doing,
but my
understanding
(and I could
be wrong) is
that there's
still a lot of
work to be
done in
producing a
universal flu

shot. If such
vaccine
candidates are
still years
from entering
clinical
trials, we
probably would
push that
lower down the
list.
Hope that
helps, and
thanks again!
Jason

Hi Jason,

Ahead of your
visit, here
are a few labs
that are doing
innovative
work and may
present
interesting
backgrounds to
become future
stories, or
inform your
reporting. For
antimicrobial
resistance
specifically,
Dr. Fauci is
your best
source. But
the below are
exciting areas
of research at
NIAID, and may
be a fit for
Prognosis. Let
me know if any
of the below
pique your

interest and
we can share
more detail
and/or arrange
time.

- **Skin
microbiome:** NIAID
researchers
developed
[a topical
therapy
for
eczema](#)
that
involves
treating
skin with
"good"
bacteria.
If proven
effective
, this
strategy
could
offer an
inexpensive
treatment
that
requires
less
frequent
application than
many
current
eczema
medications. A
Phase 1/2
trial at
NIH
indicated

that this
novel
therapy
is safe,
and most
participa
nts
experien
ed
improvement
in
their
eczema.
NIH has
exclusively
licensed
the
technology
to
Forte
Biosciences
to
advance
this
potential
new
therapy
through
further
clinical
development.
nt.

- **Gene
therapy:**
NIAID is
developing
and
applying
gene
correction
techniques
to
treat a

variety
of
genetic
immune
disorders
. For
example,
NIAID
scientist
s co-
developed
a
lentivira
l gene
therapy
to treat
infants
with X-
SCID, a
rare and
fatal
genetic
immune
deficienc
y. In
clinical
trials,
the gene
therapy
successfu
lly
restored
the
immune
systems
of
infants
newly
diagnosed
with X-
SCID, as
well as
older
children
and young
adults
with the

condition
who
experienced
complex
medical
problems
after
receiving
standard
therapy.
Mustang
Bio is
handling
commercial
development
of the
lentiviral
gene
therapy
for X-
SCID.

- **Flu:** Dr.
Jeffrey
Taubenberger
is a
1918
influenza
expert
who
sequenced
the 1918
pandemic
viral
genome
using
archival
autopsy
specimens
from the
Armed
Forces
Institute
of

Pathology
and
frozen
lung
biopsies
from 1918
flu
victims
interred
in
permafros
t.
Learning
about
1918
pandemic
flu can
help us
better
prepare
for and
target
future
pandemic
strains.
Dr.
Taubenber
ger's lab
is
developin
g a so-
called
universal
flu
vaccine
that
includes
4
inactivat
ed
influenza
viruses
and is
expected
to
undergo
clinical

testing
soon.
Also, Dr.
Matthew
Memoli
leads
NIAID's
influenza
challenge
studies
in which
healthy
volunteer
s are
purposely
exposed
to
influenza
in a
carefully
controlle
d
environme
nt.
Challenge
studies
offer a
unique
opportuni
ty to ask
focused
questions
regarding
influenza
virus
pathogene
sis and
vaccine
efficacy
in a
controlle
d manner.

- **Mosquitoe
s:**
NIAID's

Laboratory of Malaria and Vector Research investigates disease-transmitting insects and broad areas of malaria biology and pathogenesis. Dr. Tovi Lehman studies mosquito ecology, covering broad population biology questions relevant to patterns of malaria transmission and vector control. Recently, Dr. Lehman and colleague s in Mali found that a single

mosquito
can
travel up
to 200
miles in
a single
night
with the
right
prevailin
g wind
speed.
The
research
involved
collectin
g flying
insects
using
sticky
nets on
helium-
filled
balloons
suspended
at
varying
heights.

- **Eating
for the
immune
system:**

Dr.
Yasmin
Belkaid
is
researchi
ng
connectio
ns
between
the
microbiom
e,
nutrition

, fat,
and
immunity.
This work
is early
stage,
but
potential
ly
paradigm-
shifting
as she
uncovers
connectio
ns
between
diet and
immunity,
with
implicati
ons for
using
nutrition
to boost
immune
intervent
ions,
including
vaccines.

- **RSV:**
Multiple
researche
rs are
working
to
develop
vaccines
against
respirato
ry
syncytial
virus
(RSV)—
something
most

parents
have
heard of,
but is
not
covered
by media.
RSV
usually
causes
mild
cold-like
symptoms
in
healthy
adults;
however,
RSV can
be
serious,
particula
rly for
infants
and the
elderly.
It is the
most
common
cause of
bronchiol
itis and
pneumonia
in
children
younger
than 1 in
the US.
Scientist
s have
spent
decades
trying to
develop
an
urgently
needed
safe and

effective
vaccine.
One
candidate
known as
DS-Cav1
developed
by [Dr.
Barney
Graham's](#)
team at
NIAID's
Vaccine
Research
Center
has shown
early
promise
in a
[Phase 1
clinical
trial.](#)

I'm CCing my
public affairs
colleagues who
liaise with
these topics
in case there
is follow up.
Looking
forward to
hopefully
meeting you
when you
visit.
Thanks,
Anne

From: Jason
Gale
(BLOOMBERG/
NEWSROOM:)
[<j.gale@bloomberg.net>](mailto:j.gale@bloomberg.net)

Sent:

Thursday,
December 19,
2019 4:24 PM

To: Rancourt,
Anne
(NIH/NIAID)
[E]

(b) (6)

>

Subject:

Re: Following
up on NIH
visit

Hi Anne,

Thanks for
your email and
offer to
assist with
other
interviews.

I'm "old
school," and
see merit in
building
relationships
with
researchers
and hearing
about their
work without
the
expectation of
necessarily
getting a
story.

My interests
are pretty
eclectic --
from
antimicrobial
resistance to

anesthesia. If
there's some
interesting
stuff
happening that
hasn't been
reported on in
much detail
that speaks to
the future of
health care
(that could
would for our
Prognosis
platform), I'd
be keen to
hear about it.

Many thanks
again and
happy
holidays,

Jason

Jason Gale,
HighSec
Senior editor
| Bloomberg
News
Level 30, 120
Collins St.,
Melbourne VIC
3000
Tel.
(landline)

(b) (6)

@jwgale |
LinkedIn:
[http://www.lin
kedin.com/pub/
jason-
gale/6/249/a56](http://www.linkedin.com/pub/jason-gale/6/249/a56)

From:

(b) (6)

At:

12/20/19

02:54:30

To: Jason Gale
(BLOOMBERG/
NEWSROOM:)

Subject:

Following up
on NIH visit

Hi

Jason,

I

heard
you'll
be

visiti
ng us
at NIH
on

Feb.
28 for

an
interv
iew
with
Dr.

Fauci.
Please
let me
know

if I
can
help

connec
t you
with
other
expert

s
while
you
are

here.
I'd be
happy
to
arrang
e for
you to
see
any
labs
or
hear
from
expert
s on
HIV or
other
diseas
es -
just
let me
know
what
you're
intere
sted
in
hearin
g and
seeing
.
Thanks
!
Lookin
g
forwar
d to
it.

Anne

Anne
Rancou
rt,
MPS
Sectio
n

Chief,
Office
of
Commun
icatio
ns and
Govern
ment
Relati
ons
Nation
al
Instit
ute of
Allerg
y and
Infect
ious
Diseas
es
Nation
al
Instit
utes
of
Health
Pronou
ns:
She/He
r

(b) (6)

office

(b) (6)

mobile

(b) (6)

Madonna's Secret
for Longevity Seen
Aiding Bacteria
Boom: Health
2012-05-08
21:34:07.963 GMT

By Kanoko
Matsuyama and
Jason Gale
May 9 (Bloomberg)
-- The secret to
Madonna's staying
power
may be surprisingly
simple: gardening.
What the pop star
does involves no
trowel or soil.
Thanks
to dishes of
fermented soy
beans, millet and
brown rice prepared
by her personal
chef, Mayumi
Nishimura,
Madonna practices
a form
of inner horticulture
-- cultivating her
intestinal flora in a
burgeoning
alternative
approach to health.
Studies of the
trillions of bacteria
living on and in the
body suggest the
Material Girl, 53,
may be onto
something. By
eating foods rich in
fiber and laced with
so-called good

bacteria, she may be encouraging helpful microbes to flourish in her bowel, aiding in food digestion and vitamin extraction and possibly staving off diseases from asthma to colon cancer.

"This diet that Madonna is following is very sensible," says David Topping, chief food-nutrition researcher at Australia's Commonwealth Scientific and Industrial Research Organization in Adelaide, who studied gut biology for 25 years.

"The bacteria that live inside you are fulfilling very important functions."

While scientists try to understand the ecology of the bacteria and their interactions with diet and disease, companies are looking for ways to profit.

The health benefits of gut germs have spawned a global market for products

that contain friendly bacteria, called probiotics, in the form of tablets or supplements added to foods by companies including Danone, Nestle SA, and Yakult Honsha Co. The market for supplemented dairy products such as Danone's Activia yoghurts and Yakult's fermented drinks, worth \$14.7 billion six years ago, will probably expand 32 percent to \$33.5 billion by 2016, Euromonitor International estimated last month.

Quinoa, Not Coffee

Studies published in the past year have linked certain bowel-dwelling bacteria to a stronger immune system, while others have been associated with autism and obesity. In one paper published in the journal Nature, scientists showed that a type of white blood

cell that produces antibodies only acquired its infection-fighting ability after spending time in the gut.

Nishimura, who has cooked for cancer patients before being

hired by Madonna, serves quinoa and other whole grains as

staples, along with vegetables and soy sauce, she said in a telephone interview from New York. She also tries to offer seaweed every second day -- usually sautéed or boiled.

"We eat food processed as little as possible,"

Nishimura, 55, says of her dietary approach, known as macrobiotic. She doesn't recommend meat, dairy and coffee. An agent for Madonna didn't respond to a request for comment.

Whole grains and fiber act as both food and fertilizer to the bacteria in the bowel, according to Mark Morrison, a

microbiologist with
Australia's CSIRO
in Brisbane
studying ways
to improve gut
function and health.

'Terrific Interest'

There are 10 times
as many bacteria in
the human intestinal
tract as there are
cells in the body. As
coordinator of the
Human Microbiome
Project, Lita Proctor
is helping to
organize
collaboration from
hundreds of
scientists around
the world
trying to map and
study microbial
communities living
on the skin,
in the mouth and
bowel, and in other
parts of the body.
"It's extremely
heartening and
healthy to have so
much
attention now paid
to the diet," says
Proctor, who works
at the
National Human
Genome Institute in
Bethesda,
Maryland.
Even so, Proctor
says the research is
still in its infancy,
and products based

on partial understanding may not deliver what they promise. "That's not holding up the industry," she says. "It's a very fluid, ill-defined area, but with a lot of terrific interest."

Flowers and Weeds

The term probiotic is vague and there's no accepted definition for it. Measuring results may be even more of a grey area and some supplements are destroyed by stomach acid before entering the gut, according to Proctor. Nishimura relies on fermented foods such as miso, soy sauce and tempeh to play the role of probiotics and says the benefits of her diet can be quickly noticed. "I feel better than I did 20 years ago," Madonna wrote in a preface to the cookbook her chef had published in 2010. "I am

very grateful to you
for this."

The garden analogy
is helpful when it
comes to describing
the complex
ecology of the
bacteria living on
humans, says Julie
Segre, the lead
investigator working
on the skin
microbiome at
the National Human
Genome Research
Institute.

"There are some
flowers that make it
easier for other
flowers to grow in
the same soil,"
Segre says. The
most
important thing is to
keep out the
invasive weeds, she
says.

'Transpoosions'

When the weeds
take over,
Australian
gastroenterologist
Thomas Borody has
a radical approach
to reestablishing the
balance of intestinal
flora in his patients:
he transplants
fecal germs from
disease-free
individuals directly
into the
upper reach of the
colon, in a pouch

known as the
cecum.
His Sydney clinic
has done 1,800 of
the procedures,
which
he jokingly dubs
“transpoosions,”
over 25 years.
Borody, 62,
says the treatment
has helped patients
with ailments
ranging
from autism to
pseudomembranous
colitis, a resilient
infection
that causes
abdominal pain,
loose bowel
movements and
fever.
“The next day their
diarrhea stops,” the
doctor says.
After the procedure,
he asks patients to
avoid treatments
that
may damage their
gut flora. Three
studies presented
at the
American College
of
Gastroenterology’s
meeting in October
indicate fecal
transplants can help
with bouts of
diarrhea
associated with the
bacterium
Clostridium difficile.

When Weeds Take Over

Keeping inner bugs healthy is crucial because otherwise they risk taking over more than the garden. If intestinal bacteria aren't able to survive on the food their host consumes, the germs will try to feed on what they can find -- "mucus as well as anything else," according to CSIRO's Topping. That may lead to inflammatory bowel disease, a painful condition that can evolve into colon cancer, he says. Staving off disease is one reason people have turned to Nishimura's cooking in the past. The chef, who prepared meals for cancer patients in Boston, says the diet helps with constipation, menstrual pain and body odor. When she first changed the way she ate, Nishimura says she also found that her

allergic skin rash
improved.

'So Fresh'

Typically, Nishimura
tailors her meals
each day to suit the
way her employer
feels, she says,
adding that
Madonna prefers
the chef herself to
shop for
ingredients. Popular
dishes include
seaweed in miso
soup; hijiki -- a type
of brown seaweed -
-

served with carrots
and onions and
seasoned with soy
sauce; and
cooked oats for
breakfast,
Nishimura says.
Whole grains
demand harder
work for bowel
bacteria, which
help the body
extract vitamins and
nutrients from food,
because
the insoluble fiber
they contain is only
broken down in the
lower reaches of
the digestive tract in
a fermentation
process
that delivers
different quantities
and varieties of
inflammation-

fighting short-chain fatty acids to the body's cells.

There is "solid evidence" that microbes play a role in

tuning the immune system, says Ian Lipkin, director of the

Center for Infection and Immunity at Columbia

University's Mailman School of Public Health, where scientists showed in

January that children with autism and gastrointestinal disturbances have a bacterial species not found in non-autistic children with tummy upsets.

Madonna and others making similar diet choices may not know they're pushing the science frontier.

They may just feel better.

"When you cut out animal products, white sugar and coffee

for 10 days you start to feel the difference,"

Nishimura said.

"When I first began

this diet, I
remember how my
head became
clearer, I woke up
earlier and felt so
fresh in the morning
that
I didn't want to stay
in bed."
Madonna herself
isn't lacking in
stamina. Her world
tour,
which starts in Tel
Aviv this month and
ends next March,
includes 75
concerts in Europe
and North America.
Her previous
world tour was in
2008 and 2009,
when she also
published six
children's books
and directed or
produced two
movies.

For Related News
and Information:
Most-read health-
care stories: MNI
HEA <GO>
Bloomberg's top
health stories:
HTOP <GO>
Bloomberg's top
stories on Japan:
TOPY <GO>
Bloomberg drug
database: BDRG
<GO>

--Editors: Marthe
Fourcade, Rick

Schine.

To contact the
reporters
responsible for this
story:

Kanoko Matsuyama
in Tokyo at +81-3-
3201-3490 or

[kmatsuyama2@blo
omberg.net](mailto:kmatsuyama2@bloomberg.net);

Jason Gale in
Melbourne at (b) (6)

or
[j.gale@bloomberg.n
et](mailto:j.gale@bloomberg.net)

To contact the
editor responsible
for this story:

Jason Gale at +65-
6212-1579 or

[j.gale@bloomberg.n
et](mailto:j.gale@bloomberg.net).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 22:33:02 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: FW: Virus Transmission

NIAID inquiries, please

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: DANIEL GAGNON (b) (6)
Sent: Monday, February 24, 2020 3:49 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Virus Transmission

Hi Dr. Fauci:

I have been a long time admirer of you in the field of modern medicine. This question I have relates to the current Coronavirus circulating around the world. For many years I have informed people that the ways a virus can be passed from person to person isn't always by a sneeze, cough or by touching someones face with their hands. Has anyone in your medical community though: that if someone were smoking and was an infected person that once they expel the smoke particles into the air that those micro smoke particles may contain viruses that were in the respiratory system of an infected person. Everyone I mention this to don't believe that this is possible. What are your thoughts on this matter? If so why hasn't the medical community warned the public about this possibility as I stay away from all establishments that allow smoking on their premises.

Thank you,

Daniel Gagnon
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 19:55:21 +0000
To: Conrad, Patricia (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: interview with Dr Fauci

Here is the reason for the confusion.,

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: RABIN, RONI <roni.rabin@nytimes.com>
Sent: Monday, February 24, 2020 2:51 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Re: interview with Dr Fauci

I 'm sorry -- I thought you had canceled this time this morning when you said you needed to reschedule. I'm so sorry. I'm in the middle of a meeting with editors at the Times about coronavirus coverage.

On Mon, Feb 24, 2020 at 2:42 PM Fauci, Anthony (NIH/NIAID) [E] <(b) (6)> wrote:

Hi Roni,
We just tried calling you at (b) (6) for our 2:30pm ET interview with Dr. Fauci. Please give us a call as soon as possible at (b) (6).

Thank you,
Kim

Kim Barasch [C]
Office of the Director
National Institute of Allergy & Infectious Diseases
(b) (6)
(b) (6)

From: Conrad, Patricia (NIH/NIAID) [E]

Sent: Friday, February 21, 2020 4:30 PM

To: (b) (6)

Cc: Deatrick, Elizabeth (NIH/NIAID) [C] <(b) (6)>; Robinson, Whitney (NIH/NIAID) [C] (b) (6)>

Subject: interview with Dr Fauci

Dr Fauci can be available for your interview as per below on Monday Feb 24th at 2:30 pm ET – 3:00 pm ET. Please let us know asap if that time works. The number to call for the interview will be (b) (6)

Thank you,
-patty

Roni Rabin
New York Times

(b) (6)
Roni.rabin@nytimes.com

Seeking: Phone interview

Subject: asymptomatic transmission of coronavirus

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Roni Caryn Rabin
New York Times Staff Writer
(212) 556-8314

Cell: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 18:07:33 +0000
To: Doepel, Laurie (NIH/NIAID) [E]
Subject: FW: ASF ---- measles - aerosol / contact / droplet
Attachments: 1-s2.0-S1879625717301773-main.pdf

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)
Sent: Tuesday, September 4, 2018 3:15 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Doepel, Laurie (NIH/NIAID) [E] (b) (6); Eisinger, Robert (NIH/NIAID) [E] (b) (6) Folkers, Greg (NIH/NIAID) [E] (b) (6) >; Marston, Hilary (NIH/NIAID) [E] (b) (6)
Subject: ASF ---- measles - aerosol / contact / droplet

And per CDC -- requires airborne precautions

<https://www.cdc.gov/infectioncontrol/basics/transmission-based-precautions.html>

Table 2

Overview of the evidence on transmission routes of respiratory viruses based on experimental data and the transmission route according to infection prevention guidelines

Virus	Virus family ^a	Transmission route	
		Experimental and observational data	Guidelines ^b
Measles virus	<i>Paramyxoviridae</i>	Aerosol [75–77,78*,79*]	Contact [3,110], droplet [3,109–111], aerosol [3,109–111].
Parainfluenza virus	<i>Paramyxoviridae</i>	Limited data, contact (by fomite) [83,84] ^a	Contact [3,109–111], droplet [3,109–111], aerosol [3,109].
HMPV	<i>Pneumoviridae</i>	Limited data, contact (by fomite) ^a [30]	Contact [3,110,111], droplet [3,110,111].
RSV	<i>Pneumoviridae</i>	Contact [89,88], droplet [88], aerosol [90,91**].	Contact [3,109–111], droplet [3,109,110], aerosol [109,111].
HCoV	<i>Coronaviridae</i>	Limited data, contact (by fomite) [65–67] ^a	Contact [3,110,111], droplet [3,110,111].
MERS-CoV	<i>Coronaviridae</i>	Contact [84] ^a [89] ^a [91**], droplet [89] ^c , aerosol [91**].	Contact [111], droplet [3,111].
SARS-CoV	<i>Coronaviridae</i>	Contact [70] ^a [73,79,101], droplet [73,78*,79*,117], aerosol [78,118] ^c [82] ^{c,d} .	Contact [3,110,111], droplet [3,110,111], aerosol [3,110,111].
Rhinovirus	<i>Picornaviridae</i>	Contact [35,36,42], aerosol [37,40,119].	Contact [109–111], droplet [109,111], aerosol [109–111].
Adenovirus	<i>Adenoviridae</i>	Contact [100] ^a [100,101], droplet [103], aerosol [102,103*].	Contact [3,109–111], droplet [3,109,110], aerosol [110,111].
Influenza virus	<i>Orthomyxoviridae</i>	Droplet/aerosol [55,56,57*,59]	Contact [109–111], droplet [3,109–111], aerosol [3,109–111].

^a Taxonomy was based on [62], airborne transmission is seemingly linked to:

^b WIP [108], 'Blue Book' [109], 'Red Book' [110], CDC [3] and Up-To-Date [111]. The conclusions on experimental data as presented in this table reflect the conclusions from the authors.

^c Superspreader events.

^d Aerosol-generating procedures (in a nosocomial situation).

^e Conclusions were drawn based on stability experiments.

Disclaimer: Any third-party material in this email has been shared under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 17:21:34 +0000
To: Van Hoof, Johan [JRDBE];Erbelding, Emily (NIH/NIAID) [E]
Cc: Stoffels, Paul [JJCUS]
Subject: RE: as26 based COVID-19 vaccine candidate

Johan:

Thanks for the note. I enjoyed and learned from your presentation this morning. The best way to keep in touch with NIAID would be through Emily and Barney.

Best regards,.

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Van Hoof, Johan [JRDBE] (b) (6)
Sent: Monday, February 24, 2020 11:58 AM
To: Erbelding, Emily (NIH/NIAID) [E] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6) Stoffels, Paul [JJCUS] (b) (6)
Subject: as26 based COVID-19 vaccine candidate

Dear Emily,

Dear Dr. Fauci,

First of all, I want to thank NIAID and its team for spending time with us going through the Janssen plans for Ad 26 COVID-19 vaccine development.

In follow up of our call earlier today, please find herewith the key action points I noted from our discussion. I would welcome your perspectives/comments, as well as the best way to keep in touch with NIAID.

Looking forward to your feedback,

Best regards,

Johan

Johan Van Hoof, M.D.

Managing Director, Janssen Vaccines and Prevention B.V.
Global Therapeutic Area Head IDV, Vaccines, Janssen Pharmaceuticals R&D

Phone : (b) (6) : (b) (6) Fax : +32 14 60 2841
E-mail : (b) (6)

Assistant (b) (6)
Phone : (b) (6)

-
-
Follow Up to Ad26 COVID-19 call with NIAID; February 24th 2020

(b) (4)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 16:53:04 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Subject: RE: ASF ----- NEJM commentary -- change title?

You are correct.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Sent: Monday, February 24, 2020 11:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E]
(b) (6) >
Subject: ASF ----- NEJM commentary -- change title?

(b) (5)

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 16:51:09 +0000
To: Faye Li
Cc: Billet, Courtney (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]
Subject: RE: Interview Request from China

Faye:

Thank you for your note. Please send me your questions by e-mail and I will try to answer them by e-mail.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Faye Li (b) (6) >
Sent: Monday, February 24, 2020 11:41 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Interview Request from China

Dear Dr. Fauci,

I'm Faye Li, journalist from the Portrait, a national magazine in China. My beat is science and technology. Since the outbreak of the 2019 novel coronavirus (COVID-19) in China, I'm covering feature stories about the outbreak, hoping to explain to readers what it is, especially since the virus is evolving daily at an unexpected high speed, and in so many confusing ways.

Now in China we are getting conflicting information about the new virus and thus become confused about it. For example, we are seeing more and more cases that a patient with negative test results for 2 non-continuous days, still infected with the virus and tested positive afterwards. It makes the treatment really difficult because it seems hard to determine whether the patient is fully cured or not. Since you are an experienced immunologist, I'm wondering if you could share your insights with the Chinese readers and take an interview. The Interview could be via phone or email, whichever works fine for you.

If possible, I'd love to send you the questions before we talk. Since we have time difference, I might not be available during the early afternoon (your time) but I could make it in the morning, noon and maybe late in the afternoon and evening (your time).

I'm sorry for bothering you on this subject, but we face severe difficulty in understanding this new virus and taking measures properly. We have quite limited sources and perspectives for understanding this new virus. However, as a science reporter, I believe in a crisis of public health, the information is the key for the public. They should have the opportunity to hear more perspectives from different specialists. Since you are experienced in fighting against so many viruses, especially SARS, I believe your opinions will be inspiring to the readers.

It would be of great help and great honor for us to invite you for an interview. A phone call interview would be preferred but if time doesn't work for you, is it possible for you to reply via email? I'll list all the questions in detail.

I could be reached by (b) (6) or (b) (6) I'm looking forward to your reply.

Best wishes,

Faye

The Portrait
Beijing, China

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 16:01:59 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Call for Dr. Fauci

Cristina, please.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Sent: Monday, February 24, 2020 10:46 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Barasch, Kimberly (NIH/NIAID) [C] <(b) (6)>; Haskins, Melinda (NIH/NIAID) [E] (b) (6) >
Subject: Fwd: Call for Dr. Fauci

Is this a friend or do u just want to pass to Cristina. Pls advise

Sent from my iPhone

Begin forwarded message:

From: "Haskins, Melinda (NIH/NIAID) [E]" (b) (6) >
Date: February 24, 2020 at 10:40:37 AM EST
To: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6) >
Cc: "Harris, Kara (NIH/NIAID) [E]" (b) (6) >
Subject: FW: Call for Dr. Fauci

From: Harris, Kara (NIH/NIAID) [E] (b) (6) >
Sent: Monday, February 24, 2020 10:39 AM

To: Barasch, Kimberly (NIH/NIAID) [C] (b) (6)>
Cc: Correa, Meylin (NIH/NIAID) [C] (b) (6)>; Forde, Michael (NIH/NIAID) [C] (b) (6)>; McCullough, Claire (NIH/NIAID) [E] (b) (6)>; Haskins, Melinda (NIH/NIAID) [E] (b) (6)
Subject: RE: Call for Dr. Fauci

Hi, Kim –

I spoke to Dr. Jacobs directly. He said that Dr. Michael Lockshin is a good friend/fellow Cornell graduate (Dr. Jacobs also noted he went to Cornell) and gave him Dr. Fauci's number.

Dr. Jacobs and Dr. Alexander Tarakhovsky, a virologist at The Rockefeller Institute, would like to speak to Dr. Fauci about the coronavirus. They have a theory that there may be yeast involved because it is sticky and perhaps it came from the Chinese government. They want to share their ideas and perhaps start a U.S. government effort "similar to The Manhattan Project." They do not want funding.

I thanked Dr. Jacobs for sharing his ideas and stated that I would pass along the message. Should Dr. Fauci wish to speak to them, Dr. Jacobs can be reached at the number below and Dr. Tarakhovsky can be reached at (b) (6)

Please let me know if you have any questions.

Thanks,

Kara

From: McCullough, Claire (NIH/NIAID) [E] (b) (6)
Sent: Monday, February 24, 2020 10:07 AM
To: Barasch, Kimberly (NIH/NIAID) [C] (b) (6)>
Cc: Harris, Kara (NIH/NIAID) [E] (b) (6)>; Correa, Meylin (NIH/NIAID) [C] (b) (6)>; Forde, Michael (NIH/NIAID) [C] (b) (6)>
Subject: Call for Dr. Fauci

Hi, Kim—I got some additional information from Dr. Michael Jacobs office. He is a dermatologist in New York City and said that Dr. Fauci is expecting his call. The secretary provided no further information.

Dr. Michael Jacobs

(b) (6)

Thank you.

Claire A. McCullough
Legislative Affairs and Correspondence Management Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases
National Institutes of Health
5601 Fishers Lane, Rm. 6F27 – MSC 9806
Bethesda, MD 20892
Tel: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy

and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 15:14:10 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: New England Journal of Medicine 20-02387
Attachments: Fauci-20-02387-Text.docx, Embargo-Guidelines-5.13.pdf, Production-and-proof.pdf

fyi

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: New England Journal of Medicine <onbehalfof@manuscriptcentral.com>
Sent: Monday, February 24, 2020 10:00 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Redfield, Robert R. (CDC/OD) (b) (6)
Subject: New England Journal of Medicine 20-02387

Dear Dr. Fauci,

Thank you for the article, "COVID-19 : Navigating the Uncharted," which the Journal is pleased to accept for publication.

This acceptance is made with the understanding that neither the article itself nor any part of its essential substance, tables or figures has been published or will be submitted for publication elsewhere before it appears in the Journal. The acceptance is also made with the understanding that all the authors, the data, and its presentation meet the requirements as described in the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals (www.icmje.org).

Please note that the acceptance of your commentary should be considered confidential information to be shared only with your coauthors until its final publication. To ensure that no news reports about the article appear prematurely in any form, do not speak to the media, hold press conferences, or issue news releases about your paper before the week of publication. You must receive an explicit commitment to withhold release of the information until the embargo is lifted at 5:00 p.m. (Eastern Time in the United States) on the day before the date of publication. If there are any questions about this policy, you should discuss them with the Editor.

We assume that financial relationships creating possible conflicts of interest for all authors have been fully disclosed to the Editor, including (but not limited to) any relevant relationships listed in the Open Payments database at

<https://openpaymentsdata.cms.gov/search/physicians/by-name-and-location> for physicians practicing in the United States. For information on what would qualify as a 'relevant' disclosure, please review the instructions on page 1 of your disclosure form.

Authors are reminded that all material published in the Journal is copyrighted by the Massachusetts Medical Society, that by agreeing to have their manuscript published in the Journal they grant to the Society full right and authority to secure copyright for the full term and any renewals or extensions thereof, and that permission for reprinting must be obtained in writing from the Journal.

The Journal will edit your manuscript in accordance with its established style. You will receive a proof of the edited manuscript by e-mail; the proof stage will be your next opportunity to make changes. For important information about production and proofs, see the attached document. In the meantime, please do not make any changes or send any new material to us. Thank you for your contribution to the Journal.

Sincerely yours,

Eric J. Rubin, MD, PhD
Editor-in-Chief

New England Journal of Medicine
10 Shattuck Street
Boston, MA 02115
(617) 734-9800
Fax: (617) 739-9864
<http://www.nejm.org>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 14:22:21 +0000
To: (b) (6)
Cc: Barasch, Kimberly (NIH/NIAID) [C]; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: COVID-19 Quarantine

Ming:

Thank you for your note and offer to help. I will ask my Staff Assistant, Kim Barasch, to set up a brief call for you to relate your impressions to me.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: (b) (6) >
Sent: Sunday, February 23, 2020 7:52 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: (b) (6)
Subject: COVID-19 Quarantine

Dear Dr. Fauci,

My name is Ming Lei, a Division Director at the NIGMS. I am writing to you as a private citizen, to thank you for your leadership in yet another public health emergency, and to make myself available to you if you have the time for my in-person observations of the COVID-19 caused quarantine in Hubei Province, China; the evacuation of Americans; and the quarantine in the US.

(b) (6)
As the virus still roams around, and a possibility of causing a pandemic, I want to let you know that I am willing to share with you my direct observations in case such information is of value in the developing of our responses going forward, which you will undoubtedly playing a critical role.

I will send you a reminder through my NIH email account, in case this message is put into the junk mail folder.

Sincerely,

Ming

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 14:03:36 +0000
To: Billet, Courtney (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]
Cc: Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]
Subject: RE: FOR YOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients w/ COVID-19

Looks fine to me.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6) >
Sent: Monday, February 24, 2020 8:54 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Marston, Hilary (NIH/NIAID) [E] (b) (6) >
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6) >; Conrad, Patricia (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] <(b) (6)>
Subject: FW: FOR YOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients w/ COVID-19

Renate is asking that I confirm that Dr. Collins' changes (tracked in attachments) sync with what we've been saying. They look ok to me. What say you?

From: Collins, Francis (NIH/OD) [E] <(b) (6)>
Sent: Monday, February 24, 2020 6:45:07 AM
To: Myles, Renate (NIH/OD) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Tabak, Lawrence (NIH/OD) [E] <(b) (6)>; Gilman, James (NIH/CC/OD) [E] (b) (6) >

Cc: Burklow, John (NIH/OD) [E] (b) (6)>; Hallett, Adrienne (NIH/OD) [E] (b) (6)>; Allen-Gifford, Patrice (NIH/OD) [E] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] (b) (6); Davey, Richard (NIH/NIAID) [E] (b) (6)>; Palmore, Tara (NIH/CC/OD) [E] (b) (6)>; Cohen, Justin (NIH/CC/OD) [E] (b) (6)>

Subject: RE: FOR YOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients w/ COVID-19

Hi all,

Nicely done, Renate. I made a few edits in two of the documents, see attached.

(b) (5)

FC

From: Myles, Renate (NIH/OD) [E] (b) (6)
Sent: Sunday, February 23, 2020 8:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Collins, Francis (NIH/OD) [E] (b) (6)>; Tabak, Lawrence (NIH/OD) [E] (b) (6)>; Gilman, James (NIH/CC/OD) [E] (b) (6)>
Cc: Burklow, John (NIH/OD) [E] (b) (6)>; Hallett, Adrienne (NIH/OD) [E] (b) (6)>; Allen-Gifford, Patrice (NIH/OD) [E] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] (b) (6); Davey, Richard (NIH/NIAID) [E] (b) (6)>; Palmore, Tara (NIH/CC/OD) [E] (b) (6)>; Cohen, Justin (NIH/CC/OD) [E] (b) (6)>
Subject: RE: FOR YOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients w/ COVID-19

Thanks, all. (b) (5)

(b) (5)

Latest rollout, all staff and statement are attached.

Best,
Renate

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Sent: Sunday, February 23, 2020 8:15 PM
To: Myles, Renate (NIH/OD) [E] (b) (6)>; Collins, Francis (NIH/OD) [E] (b) (6); Tabak, Lawrence (NIH/OD) [E] (b) (6)>; Gilman, James (NIH/CC/OD) [E] (b) (6)>
Cc: Burklow, John (NIH/OD) [E] (b) (6)>; Hallett, Adrienne (NIH/OD) [E]

(b) (6)>; Allen-Gifford, Patrice (NIH/OD) [E] (b) (6) Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Davey, Richard (NIH/NIAID) [E] (b) (6); Palmore, Tara (NIH/CC/OD) [E] < (b) (6); Cohen, Justin (NIH/CC/OD) [E] (b) (6)>

Subject: RE: FOR YOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients w/ COVID-19

Renate:

The rollout plan looks fine except that I would include (b) (5)

Thanks,

Tony

From: Myles, Renate (NIH/OD) [E] (b) (6)>

Sent: Sunday, February 23, 2020 7:23 PM

To: Collins, Francis (NIH/OD) [E] (b) (6); Tabak, Lawrence (NIH/OD) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Gilman, James (NIH/CC/OD) [E] (b) (6)>

Cc: Burklow, John (NIH/OD) [E] (b) (6)>; Hallett, Adrienne (NIH/OD) [E] (b) (6)>; Allen-Gifford, Patrice (NIH/OD) [E] (b) (6); Billet, Courtney (NIH/NIAID) [E] (b) (6); Davey, Richard (NIH/NIAID) [E] (b) (6)>; Palmore, Tara (NIH/CC/OD) [E] (b) (6) Cohen, Justin (NIH/CC/OD) [E] (b) (6)

Subject: FOR YOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients w/ COVID-19

Importance: High

Good evening:

Attached for your review are draft materials to communicate NIH's preparation for potential receipt of patients with COVID-19 to the NIH Clinical Center (timing TBD), including:

1. Rollout plan
2. All staff email
3. Statement

These materials were reviewed by Rick Davey, Tara Palmore, and Courtney Billet. I am developing a list of potential Qs and will work with CC and NIAID folks to develop responses, but I wanted to get these products into review in the interest of time.

Best,
Renate

Renate Myles, MBA
Deputy Director for Public Affairs
Office of Communications and Public Liaison
National Institutes of Health

Tel: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 12:59:47 +0000
To: Leggio, Lorenzo (NIH/NIDA) [E]
Subject: RE: Question from the Italian Embassy in DC re: coronavirus

Lorenzo

Thanks for the note. Unfortunately, I cannot be of any help to you since I myself have no access to this equipment. The best person to contact would be Dr. Robert Kadlec of ASPR at HHS.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Leggio, Lorenzo (NIH/NIDA) [E] (b) (6)
Sent: Monday, February 24, 2020 5:55 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: (b) (6)
Subject: Question from the Italian Embassy in DC re: coronavirus

Dear Dr. Fauci,

I apologize in advance if I write you directly to ask this question. I know you are super busy but I thought you could provide some guidance on someone I could contact about this matter.

(b) (5)

I know this seems a very technical question and I appreciate you have many other things on your plate, so I hope you don't mind if I decided to reach you out. I do know that Filippo and his team will be very grateful for any guidance that they could receive.

Thanks in advance-
Lorenzo

Lorenzo Leggio, M.D., Ph.D.
Senior Investigator (Clinical), NIDA IRP and NIAAA DICBR
Chief, [Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology](#), NIDA IRP and
NAAA DICBR
Associate Director for Clinical Research, [Medication Development Program](#), NIDA IRP
Senior Medical Advisor to the Director, NIAAA
National Institutes of Health

10 Center Drive (10CRC/15330) Room 1-5429
Bethesda, MD 20892-1108

251 Bayview Blvd, Room 01A844
Baltimore, MD 21224

Office Phone: (b) (6) (Bethesda); (b) (6) (Baltimore)
Cell: (b) (6)
E-mail: (b) (6)

Confidentiality Notice: This e-mail message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 12:42:02 +0000
To: STEWART SIMONSON
Cc: (b) (6) (NIH/CC/BEP) [E]
Subject: RE: Our story today

Thanks, Stewart. We will do it again after Cliff returns from China and finishes his 14 day self-quarantine

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: STEWART SIMONSON (b) (6) >
Sent: Monday, February 24, 2020 7:35 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Re: Our story today

Thank you—he is grateful for your help, Tony. He is in a unwindable situation but he is doing what is right and with integrity. (b) (6). As do I—(b) (6). I really appreciate it.

S

On Feb 24, 2020, at 7:23 AM, Fauci, Anthony (NIH/NIAID) [E] (b) (6) wrote:

Stewart:

Here is another article in which I strongly support Tedros.
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: John Lauerman (BLOOMBERG/ NEWSROOM:) <jlauerman@bloomberg.net>
Sent: Monday, February 24, 2020 7:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Our story today

Hi Dr. Fauci: here's our story on Tedros today, in case you haven't seen it.

<https://www.bloomberg.com/news/features/2020-02-23/coronavirus-news-who-director-general-races-against-time>

Thanks again for all your help with this one. Hope we get a chance to talk again soon.
Regards, JL

John Lauerman, Bloomberg News
3 Queen Victoria Street, London, UK
tel. +44 (0) 2035 251028 cell (b) (6)
<http://www.bloomberg.com>
<http://www.bloomberg.com/prognosis>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 12:24:01 +0000
To: John Lauerman
Subject: RE: Our story today

Thanks, John.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: John Lauerman (BLOOMBERG/ NEWSROOM:) <jlauerman@bloomberg.net>
Sent: Monday, February 24, 2020 7:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Our story today

Hi Dr. Fauci: here's our story on Tedros today, in case you haven't seen it.

<https://www.bloomberg.com/news/features/2020-02-23/coronavirus-news-who-director-general-races-against-time>

Thanks again for all your help with this one. Hope we get a chance to talk again soon.
Regards, JL

John Lauerman, Bloomberg News
3 Queen Victoria Street, London, UK
tel. +44 (0) 2035 251028 cell (b) (6)
<http://www.bloomberg.com>
<http://www.bloomberg.com/prognosis>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 11:07:01 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Cc: Erbelding, Emily (NIH/NIAID) [E]
Subject: FW: ACT Additional reading material and developments
Attachments: About ACT.Global and its Premium Purity.pdf, ATT00001.htm, ACT CleanCoat February 2020.pdf, ATT00002.htm, ACT ECA System Februar 2020.pdf, ATT00003.htm, Dr.Brill and Dr.Steinmann - ACT CleanCoat Viruzidie englisch EN 14476 08.01.2015 Logo Brill.pdf, ATT00004.htm

Cristina:

Please see if we can engage this person (Richard Tubb) and see what he has to offer. He used to be the White House physician

Thanks,

Tony

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Monday, February 24, 2020 10:42 PM
To: Biegun, Stephen E <(b) (6)>
Cc: Cassetti, Cristina (NIH/NIAID) [E] (b) (6); Erbelding, Emily (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: FW: ACT Additional reading material and developments

Steve:

Thanks for the note. I do indeed know Dr. Tubb. He sent me similar material and I am going to connect him with our program people here at NIAID to see if we can help in any way.

Best regards,

Tony

From: Biegun, Stephen E <(b) (6)>
Sent: Monday, February 24, 2020 10:33 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Fwd: ACT Additional reading material and developments

Tony,

I expect you know Dr. Richard Tubb. He and I worked closely together in the White House 18 years ago. I have a lot of confidence in his judgment, and therefore am forwarding the materials he sent me for your consideration.

I know nothing about the technologies involved, but I know this is a time to write off no good options.

Warm regards,

Steve

Sent from my iPhone

Begin forwarded message:

From: Richard Tubb [REDACTED] (b) (6) >
Date: February 24, 2020 at 8:47:23 PM EST
To: "Biegun, Stephen E" [REDACTED] (b) (6), Robert Kadke <[REDACTED] (b) (6)>
[REDACTED] (b) (6)
Subject: ACT Additional reading material and developments

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 20:22:42 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Subject: FW: chloroquine in COVID-19
Attachments: chloroquine.pdf

Let us discuss

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Gatti, Philip <(b) (6)>
Sent: Monday, February 24, 2020 2:42 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: FW: chloroquine in COVID-19

Dear Dr. Fauci,
Is there any indication/data to substantiate this claim from China (attached publication) that chloroquine/hydroxychloroquine can decrease COVID-19 infections and lung disease?

Thank you,
Philip Gatti, Ph.D.
Pharmacologist
FDA
CDER
OND
Silver Spring, MD

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 20:21:35 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Subject: FW: chloroquine in COVID-19
Attachments: Chloroquine and SARS.pdf

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Gatti, Philip <(b) (6)>
Sent: Monday, February 24, 2020 3:05 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: RE: chloroquine in COVID-19

Tony,
Thanks for the quick response. There are data from 2005 showing inhibition of SARS infection and spread from 2005. Please see attached.
Regards,
Phil

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Sent: Monday, February 24, 2020 3:00 PM
To: Gatti, Philip (b) (6)>
Cc: Lane, Henry C (NIH) (b) (6)>; Cassetti, Cristina G (NIH) (b) (6);
Erbelding, Emily J (NIH) (b) (6)>
Subject: RE: chloroquine in COVID-19

Phil:

There are no data in this brief report and so I have no way of evaluating their claim. There are a lot of these types of claims going around. I would love to see their data.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Gatti, Philip <(b) (6)>
Sent: Monday, February 24, 2020 2:42 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: chloroquine in COVID-19

Dear Dr. Fauci,
Is there any indication/data to substantiate this claim from China (attached publication) that chloroquine/hydroxychloroquine can decrease COVID-19 infections and lung disease?
Thank you,
Philip Gatti, Ph.D.
Pharmacologist
FDA
CDER
OND
Silver Spring, MD
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 19:07:38 +0000
To: Tabak, Lawrence (NIH/OD) [E]
Subject: RE: URGENT- Need your input

(b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Tabak, Lawrence (NIH/OD) [E] (b) (6)
Sent: Wednesday, February 26, 2020 2:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Hallett, Adrienne (NIH/OD) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: Re: URGENT- Need your input

Yes- that was the main thing- but any other issues that you can think of in our space?
Thanks

Get [Outlook for iOS](#)

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, February 26, 2020 2:04:38 PM
To: Tabak, Lawrence (NIH/OD) [E] (b) (6)>; Hallett, Adrienne (NIH/OD) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: RE: URGENT- Need your input

(b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Tabak, Lawrence (NIH/OD) [E] (b) (6)>
Sent: Wednesday, February 26, 2020 1:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Hallett, Adrienne (NIH/OD) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Subject: Fwd: URGENT- Need your input

I will join call- anything you want brought up?
Larry

Get [Outlook for iOS](#)

From: Pollard, Ashton (OS/IOS) (b) (6)>
Sent: Wednesday, February 26, 2020 1:44:56 PM
To: Mango, Paul (HHS/IOS) (b) (6)>; Lenihan, Keagan (FDA/OC) (b) (6)>; Tabak, Lawrence (NIH/OD) [E] (b) (6); McGowan, Robert (Kyle) (CDC/OD/OCS) (b) (6)>; Shuy, Bryan (OS/ASPR/IO) (b) (6); Zebley, Kyle (HHS/OS/OGA) (b) (6)>; Charrow, Robert (HHS/OGC) <(b) (6)>
Subject: RE: URGENT- Need your input

Hi All,

I am about to send this invite. Please confirm your attendance via email or by accepting the calendar invite.

Thank you,
Ashton

-----Original Message-----

From: Mango, Paul (HHS/IOS) (b) (6)
Sent: Wednesday, February 26, 2020 1:43 PM
To: Lenihan, Keagan (FDA/OC) (b) (6)>; Tabak, Lawrence (NIH/OD) [E] (b) (6)>; McGowan, Robert (Kyle) (CDC/OD/OCS) (b) (6)>; Shuy, Bryan

(OS/ASPR/IO) <[REDACTED] (b) (6)>; Zebley, Kyle (HHS/OS/OGA) <[REDACTED] (b) (6)>;
Charrow, Robert (HHS/OGC) [REDACTED] (b) (6)>
Cc: Pollard, Ashton (OS/IOS) <[REDACTED] (b) (6)>
Subject: URGENT- Need your input

Team- Urgent, how priority request: '[REDACTED] (b) (5)'

[REDACTED]
Ashton will invite you to a 230pm call to discuss. Please organize your responses into bullet points to discuss with the group.

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 18:25:04 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]; Stover, Kathy (NIH/NIAID) [E]
Subject: RE: Sec. Azar press briefing remarks
Attachments: 2 26 20 press briefing remarks - with Fauci edits.docx

Here are my edits.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)>
Sent: Wednesday, February 26, 2020 1:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Folkers, Greg (NIH/NIAID) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] <(b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6)>
Subject: ASF: Sec. Azar press briefing remarks

These are Sec Azar's remarks for press tonight. (Plan still evolving.)
They are asking for our comments back by 2:45 pm. New content is highlighted to make it easier on reviewers.
We're sending your talking points down there momentarily.

From: Brennan, Patrick (OS/ASPA) (b) (6)
Sent: Wednesday, February 26, 2020 1:07 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Bonds, Michelle E. (CDC/OD/OADC) (b) (6)>; Galatas, Kate (CDC/OD/OADC) (b) (6)>; Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Michael, Gretchen (OS/ASPR/OEA) <(b) (6)>; Janik, Heather (FDA/OC) (b) (6)>; Caliguiri, Laura (FDA/OC)

(b) (6)>; Lepore, Loretta (CDC/OD/OCS) < (b) (6)>; Stimson, Brian
(HHS/OGC) (b) (6)>; Arbes, Sarah (HHS/ASL) (b) (6)>; Morse, Sara
(HHS/ASL) < (b) (6)>; Pence, Laura (HHS/ASL) < (b) (6)>; Moughalian, Jen
(HHS/ASFR) (b) (6); Shuy, Caitrin (HHS/ASFR) (b) (6); Trueman,
Laura (HHS/IEA) (b) (6)>; Mango, Paul (HHS/IOS) (b) (6)>; Johnston,
Darcie (HHS/IEA) (b) (6)>; Kane, Elleen (OS/ASPR/OEA) (b) (6);
Shuy, Caitrin (HHS/ASFR) (b) (6)>; Zebbley, Kyle (HHS/OS/OGA) (b) (6)
Grigsby, Garrett (HHS/OS/OGA) (b) (6)
Cc: ASPA-Deputies (b) (6)>; Foster, Timothy (OS/ASPA) < (b) (6)>;
McGowan, Robert (Kyle) (CDC/OD/OCS) (b) (6)>
Subject: For review by 2:45 PM: Sec. Azar press briefing remarks

Hi all,

Attached is a draft of the Secretary's remarks for this evening's potential press briefing. Some of this is rote/repeated from yesterday or this morning's testimony; I have put the new content in yellow to accelerate review.

Please let me know if you have edits to this by 2:45 PM.

Thank you!

Best,
Patrick

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 15:18:25 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: RE: For review by 10:00 AM Weds: Peter Navarro coronavirus op-ed

I do not have time for this. Sorry.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)
Sent: Tuesday, February 25, 2020 10:08 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6)
Subject: Fwd: For review by 10:00 AM Weds: Peter Navarro coronavirus op-ed

This is an oped for Peter Navarro. We are asked for comments by 10am Weds.

(Complicating things a little, he was apparently just on with Tucker Carlson stating parts of it verbatim. So, hopefully this is accurate!)

From: "Brennan, Patrick (OS/ASPA)" <(b) (6)>
Date: Tuesday, February 25, 2020 at 8:27:03 PM
To: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6); "Bonds, Michelle E. (CDC/OD/OADC)" (b) (6); "Galatas, Kate (CDC/OD/OADC)" <(b) (6)>, "Billet, Courtney (NIH/NIAID) [E]" (b) (6); "Michael, Gretchen (OS/ASPR/OEA)" (b) (6); "Janik, Heather (FDA/OC)" (b) (6); "Caliguirri, Laura (FDA/OC)" (b) (6); "Lepore, Loretta (CDC/OD/OCS)" (b) (6); "Stimson, Brian (HHS/OGC)" (b) (6); "Arbes, Sarah (HHS/ASL)" (b) (6); "Morse, Sara

(HHS/ASL)" <(b) (6)>, "Pence, Laura (HHS/ASL)" <(b) (6)>, "Moughalian, Jen (HHS/ASFR)" <(b) (6)>, "Shuy, Caitrin (HHS/ASFR)" <(b) (6)>, "Trueman, Laura (HHS/IEA)" <(b) (6)>, "Mango, Paul (HHS/IOS)" <(b) (6)>, "Johnston, Darcie (HHS/IEA)" <(b) (6)>, "Kane, Elleen (OS/ASPR/OEA)" <(b) (6)>, "Shuy, Caitrin (HHS/ASFR)" <(b) (6)>, "Zebley, Kyle (HHS/OS/OGA)" <(b) (6)>, "Grigsby, Garrett (HHS/OS/OGA)" <(b) (6)>
Cc: "ASPA-Deputies" <ASPA-Deputies@hhs.gov>, "Foster, Timothy (OS/ASPA)" <(b) (6)>, "McGowan, Robert (Kyle) (CDC/OD/OCS)" <(b) (6)>

Subject: For review by 10:00 AM Weds: Peter Navarro coronavirus op-ed

Hi all,

Attached is a draft op-ed from the WH's Peter Navarro regarding the administration's coronavirus response – covering PPE, vaccines, therapeutics, and diagnostics.

There is a lot going on here so **we'd like to have edits/recommendations/affirmative clearance from FDA, CDC, NIAID, ASFR, and ASPR.**

Please send edits to me and Tim Foster by 10:00 AM tomorrow (Wednesday). Thank you!

Best,
Patrick

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 02:19:38 +0000
To: Tabak, Lawrence (NIH/OD) [E]
Subject: RE: LHHS appropriators coronavirus supplemental brief 3:30p Wednesday

Thanks, Larry!

-----Original Message-----

From: Tabak, Lawrence (NIH/OD) [E] (b) (6)
Sent: Tuesday, February 25, 2020 9:01 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: FW: LHHS appropriators coronavirus supplemental brief 3:30p Wednesday

Tony,
I will be able to do this. hopefully we can move this back in the correct direction.
Larry

On 2/25/20, 9:00 PM, "Cochran, Norris (HHS/ASFR)" (b) (6) wrote:

Correction, (b) (5). Thank you in advance.

Norris

> On Feb 25, 2020, at 8:55 PM, Cochran, Norris (HHS/ASFR) (b) (6) wrote:

>

> Dr. Tabak, Neil - would you be available to brief (b) (5)

(b) (5)
We would have CDC on the line as well. ASPR
by phone or in person. We will be in person. Please let me know either way. Thank you in advance.

>

> Norris

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 03:46:47 +0000
To: Davey, Richard (NIH/NIAID) [E]; Palmore, Tara (NIH/CC/OD) [E]
Cc: (b) (6); Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: 4 Additional COVID-19 Asymptomatic Positive Individuals Identified at Travis AFB

Rick/Tara:

Please give me a call (b) (5). If during business hours, please call my office at (b) (6). If in the evening/night call my cell phone at (b) (6). My home phone is (b) (6).

Thanks,
Tony

From: Tabak, Lawrence (NIH/OD) [E] (b) (6)>
Sent: Monday, February 24, 2020 10:40 PM
To: Kadlec, Robert (OS/ASPR/IO) (b) (6)>; Stecker, Judy (OS/IOS) <(b) (6)>
Cc: Harrison, Brian (HHS/IOS) (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Palmore, Tara (NIH/CC/OD) [E] (b) (6)>; Yeskey, Kevin (OS/ASPR/IO) (b) (6); Greene, Jonathan (OS/ASPR/EMMO) (b) (6); Lee, Scott (OS/ASPR/EMMO) (b) (6)>
Subject: Re: 4 Additional COVID-19 Asymptomatic Positive Individuals Identified at Travis AFB

thanks

From: "Kadlec, Robert (OS/ASPR/IO)" (b) (6)>
Date: Monday, February 24, 2020 at 10:37 PM
To: "Tabak, Lawrence (NIH/OD) [E]" (b) (6)>, "Stecker, Judy (OS/IOS)" (b) (6)>
Cc: "Harrison, Brian (HHS/IOS)" <(b) (6)> Anthony Fauci (b) (6); "Palmore, Tara (NIH/CC/OD) [E]" (b) (6)>, "Yeskey, Kevin (OS/ASPR/IO)" <Kevin.Yeskey@hhs.gov>, "Greene, Jonathan (OS/ASPR/EMMO)" (b) (6)>, "Lee, Scott (OS/ASPR/EMMO)" (b) (6)>
Subject: RE: 4 Additional COVID-19 Asymptomatic Positive Individuals Identified at Travis AFB

Larry would be (b) (5). Best Bob

From: Tabak, Lawrence (NIH/OD) [E] (b) (6)>
Sent: Monday, February 24, 2020 10:28 PM
To: Kadlec, Robert (OS/ASPR/IO) (b) (6)>; Stecker, Judy (OS/IOS) (b) (6)>
Cc: Harrison, Brian (HHS/IOS) (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Palmore, Tara (NIH/CC/OD) [E] (b) (6); Yeskey, Kevin

(OS/ASPR/IO) < (b) (6)>; Greene, Jonathan (OS/ASPR/EMMO)
(b) (6)>; Lee, Scott (OS/ASPR/EMMO) (b) (6)>

Subject: Re: 4 Additional COVID-19 Asymptomatic Positive Individuals Identified at Travis AFB

Any idea on timing? – please let me know (b) (5)

Thanks
Larry

From: "Kadlec, Robert (OS/ASPR/IO)" < (b) (6)>

Date: Monday, February 24, 2020 at 10:26 PM

To: "Stecker, Judy (OS/IOS)" (b) (6)>

Cc: "Harrison, Brian (HHS/IOS)" (b) (6)>, Anthony Fauci

(b) (6)>, "Tabak, Lawrence (NIH/OD) [E]" (b) (6) "Palmore,

Tara (NIH/CC/OD) [E]" (b) (6)>, "Yeskey, Kevin (OS/ASPR/IO)"

(b) (6)>, "Greene, Jonathan (OS/ASPR/EMMO)" (b) (6)>,

"Lee, Scott (OS/ASPR/EMMO)" (b) (6)>

Subject: FW: 4 Additional COVID-19 Asymptomatic Positive Individuals Identified at Travis AFB

Judy for action (b) (5)

From: Kadlec, Robert (OS/ASPR/IO)

Sent: Monday, February 24, 2020 10:19 PM

To: Harrison, Brian (HHS/IOS) (b) (6)>; Stecker, Judy (OS/IOS)

(b) (6)>; Mango, Paul (HHS/IOS) (b) (6)>; Murphy, Ryan (OS/ASPA)

(b) (6); Arbes, Sarah (HHS/ASL) (b) (6)>; Fauci, Anthony

(NIH/NIAID) [E] (b) (6)>; Tabak, Lawrence (NIH/OD) [E] (b) (6)>;

Redfield, Robert R. (CDC/OD) (b) (6); McGowan, Robert (Kyle) (CDC/OD/OCS)

(b) (6)>; Trueman, Laura (HHS/IEA) (b) (6); Moughalian, Jen (HHS/ASFR)

(b) (6)>; Johnston, Darcie (HHS/IEA) (b) (6)>

Cc: Lee, Scott (OS/ASPR/EMMO) (b) (6)>; Yeskey, Kevin (OS/ASPR/IO)

(b) (6)>; Waters, Cicely (OS/ASPR/OEA) (b) (6)>; Shuy, Bryan

(OS/ASPR/IO) (b) (6)>; Greene, Jonathan (OS/ASPR/EMMO)

(b) (6)>; Imbriale, Samuel (OS/ASPR/SIIM) (b) (6)>; Austin,

Meredith (uscg.mil) (b) (6)>; Herrmann, Jack (HHS/ASPR/OPP)

(b) (6) Ferro, Phil J. EOP/NSC

(b) (6)>; Ruggiero, Anthony J. EOP/NSC < (b) (6)>;

Cavanaugh, Brian J. EOP/NSC < (b) (6)>

Subject: 4 Additional COVID-19 Asymptomatic Positive Individuals Identified at Travis AFB

Importance: High

This evening, we were advised by the State of California that 4 passengers from the Diamond Princess tested positive by the CDC for COVID-19.

One individual who tested positive by the CDC had been tested positive in Japan and is already in hospital in CA.

We are developing the following possible Courses of Action as the State of CA cannot absorb these 3 additional asymptomatic individuals:

(b) (5)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 18:46:26 +0000
To: Moughalian, Jen (HHS/ASFR)
Subject: RE: Close Hold Review - Send comments by 1:40 pm

Jen:

I had changed the (b) (5)

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Moughalian, Jen (HHS/ASFR) (b) (6) >
Sent: Monday, February 24, 2020 1:43 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); McGowan, Robert (Kyle) (CDC/OD/OCS) (b) (6) >; Shuy, Bryan (OS/ASPR/IO) (b) (6); Kadlec, Robert (OS/ASPR/IO) (b) (6) >; Grigsby, Garrett (HHS/OS/OGA) (b) (6); Zebbley, Kyle (HHS/OS/OGA) (b) (6); Lenihan, Keagan (FDA/OC) (b) (6) >; Redfield, Robert R. (CDC/OD) (b) (6) >
Cc: Cochran, Norris (HHS/ASFR) (b) (6) >; Cabezas, Miriam (HHS/ASFR) (b) (6) >; Hittle, Taylor (HHS/ASFR) (b) (6)
Subject: RE: Close Hold Review - Send comments by 1:40 pm

Thanks for the quick response!

From: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Sent: Monday, February 24, 2020 1:42 PM
To: Moughalian, Jen (HHS/ASFR) (b) (6) >; McGowan, Robert (Kyle) (CDC/OD/OCS) (b) (6) >; Shuy, Bryan (OS/ASPR/IO) (b) (6) >; Kadlec, Robert (OS/ASPR/IO) (b) (6) >; Grigsby, Garrett (HHS/OS/OGA) (b) (6); Zebbley, Kyle (HHS/OS/OGA) (b) (6); Lenihan, Keagan (FDA/OC) (b) (6) >;

Redfield, Robert R. (CDC/OD) (b) (6)
Cc: Cochran, Norris (HHS/ASFR) (b) (6); Cabezas, Miriam (HHS/ASFR) (b) (6); Hittle, Taylor (HHS/ASFR) (b) (6)
Subject: RE: Close Hold Review - Send comments by 1:40 pm

Jen:

See my suggested edits in **red**.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Moughalian, Jen (HHS/ASFR) <(b) (6)>
Sent: Monday, February 24, 2020 1:18 PM
To: McGowan, Robert (Kyle) (CDC/OD/OCS) (b) (6); Shuy, Bryan (OS/ASPR/IO) (b) (6); Kadlec, Robert (OS/ASPR/IO) (b) (6); Grigsby, Garrett (HHS/OS/OGA) (b) (6); Zebley, Kyle (HHS/OS/OGA) <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6); Lenihan, Keagan (FDA/OC) (b) (6); Redfield, Robert R. (CDC/OD) (b) (6)
Cc: Cochran, Norris (HHS/ASFR) (b) (6); Cabezas, Miriam (HHS/ASFR) (b) (6); Hittle, Taylor (HHS/ASFR) (b) (6)
Subject: Close Hold Review - Send comments by 1:40 pm
Importance: High

Close hold. Please see below draft OMB language for a possible emergency supplemental request. Due to the fast moving nature of this process, please send comments by 1:40 PM. Numbers are still under discussion, and we will share more info in the daily update.

(b) (5)

Jen Moughalian

Assistant Secretary for Financial Resources (ASFR)

US Department of Health and Human Services

(b) (6) (Office)

(b) (6) (Cell)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 24 Feb 2020 02:00:10 +0000
To: Myles, Renate (NIH/OD) [E]
Subject: RE: FOR YOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients w/ COVID-19

(b) (5) Thanks.

From: Myles, Renate (NIH/OD) [E] <(b) (6)>
Sent: Sunday, February 23, 2020 8:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Collins, Francis (NIH/OD) [E] <(b) (6)>; Tabak, Lawrence (NIH/OD) [E] <(b) (6)>; Gilman, James (NIH/CC/OD) [E] <(b) (6)>
Cc: Burklow, John (NIH/OD) [E] <(b) (6)>; Hallett, Adrienne (NIH/OD) [E] <(b) (6)>; Allen-Gifford, Patrice (NIH/OD) [E] <(b) (6)>; Billet, Courtney (NIH/NIAID) [E] <(b) (6)>; Davey, Richard (NIH/NIAID) [E] <(b) (6)>; Palmore, Tara (NIH/CC/OD) [E] <(b) (6)>; Cohen, Justin (NIH/CC/OD) [E] <(b) (6)>
Subject: RE: FOR YOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients w/ COVID-19

Thanks, all. (b) (5)

Latest rollout, all staff and statement are attached.

Best,
Renate

From: Fauci, Anthony (NIH/NIAID) [E] <afauci@niaid.nih.gov>
Sent: Sunday, February 23, 2020 8:15 PM
To: Myles, Renate (NIH/OD) [E] <mylesr@mail.nih.gov>; Collins, Francis (NIH/OD) [E] <collinsf@od.nih.gov>; Tabak, Lawrence (NIH/OD) [E] <lawrence.tabak@nih.gov>; Gilman, James (NIH/CC/OD) [E] <james.gilman@nih.gov>
Cc: Burklow, John (NIH/OD) [E] <burklowj@od.nih.gov>; Hallett, Adrienne (NIH/OD) [E] <adrienne.hallett@nih.gov>; Allen-Gifford, Patrice (NIH/OD) [E] <patrice.allen-gifford@nih.gov>; Billet, Courtney (NIH/NIAID) [E] <billetec@niaid.nih.gov>; Davey, Richard (NIH/NIAID) [E] <rdavey@niaid.nih.gov>; Palmore, Tara (NIH/CC/OD) [E] <tpalmore@cc.nih.gov>; Cohen, Justin (NIH/CC/OD) [E] <justin.cohen@nih.gov>
Subject: RE: FOR YOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients w/ COVID-19

Renate:

The rollout plan looks fine except that I would include (b) (6)

Thanks,

Tony

From: Myles, Renate (NIH/OD) [E] (b) (6)>
Sent: Sunday, February 23, 2020 7:23 PM
To: Collins, Francis (NIH/OD) [E] (b) (6); Tabak, Lawrence (NIH/OD) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Gilman, James (NIH/CC/OD) [E] (b) (6)>
Cc: Burklow, John (NIH/OD) [E] <(b) (6)>; Hallett, Adrienne (NIH/OD) [E] (b) (6)>; Allen-Gifford, Patrice (NIH/OD) [E] (b) (6); Billet, Courtney (NIH/NIAID) [E] (b) (6); Davey, Richard (NIH/NIAID) [E] (b) (6); Palmore, Tara (NIH/CC/OD) [E] (b) (6)>; Cohen, Justin (NIH/CC/OD) [E] (b) (6)>
Subject: FOR YOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients w/ COVID-19
Importance: High

Good evening:

Attached for your review are draft materials to communicate NIH's preparation for potential receipt of patients with COVID-19 to the NIH Clinical Center (timing TBD), including:

1. Rollout plan
2. All staff email
3. Statement

These materials were reviewed by Rick Davey, Tara Palmore, and Courtney Billet. I am developing a list of potential Qs and will work with CC and NIAID folks to develop responses, but I wanted to get these products into review in the interest of time.

Best,
Renate

Renate Myles, MBA
Deputy Director for Public Affairs
Office of Communications and Public Liaison
National Institutes of Health
Tel: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 23 Feb 2020 23:14:18 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Important regarding CoronaVirus

Please handle.

From: [REDACTED] (b) (6) >
Sent: Sunday, February 23, 2020 6:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >; Fauci, Anthony (NIH/NIAID) [E]
[REDACTED] (b) (6)
Subject: Important regarding CoronaVirus

Respected Dr. Anthony

It was great to know about you and your institution, for efforts in combating any emerging infectious disease.

I am writing this email regarding our preliminary observation about the coronavirus genome.

I wish to share with you we have found 12 mirror DNA sequence within the genome of Coronavirus. We have named it (MR1 to MR12). We are highly interested in MR2 as this mirror DNA sequence is absent in the human genome. [REDACTED] (b) (4)

I wish to add here there are few studies which state that mirror DNA has the potentiality to form H-DNA and later has a potentiality to induce mutations. We strongly believe a future study on mirror DNA can answer " Why some virus mutates faster ?" "Can we stop them from mutating?" [REDACTED] (b) (4)

[REDACTED] (b) (4)
[REDACTED] I will be thankful to you, If you can give me your valuable time to discuss telephonically or through skype our ideas. I can be reached at [REDACTED] (b) (6).

I look forward to hearing from you.

with regards and Best wishes

Dr Vikash Bhardwaj (PhD JNU India)
Asst Professor Biotechnology
Starex University Gurugram India.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 23 Feb 2020 23:11:59 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: COVID-19 clinical care team

I am totally aware of all of this and have been directly involved in setting it up. You have my OK to participate to the extent that you desire.

-----Original Message-----

From: Lerner, Andrea (NIH/NIAID) [E] <(b) (6)>
Sent: Sunday, February 23, 2020 5:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: COVID-19 clinical care team

Dear Dr. Fauci,

I got a call a few minutes ago from Veronique Nussenblatt, Chief of the Clinical Center ID Consult Service, regarding me being a part of the clinical care team of COVID-19 patients if they come to the NIH.

She did not have any definitive information but said there was a chance patients could be coming from California this week— this is the first I had heard of that, and I'm guessing you may know more about it than I do.

The work would include either day or night shifts, likely a couple a week. People on the clinical care team are not instructed to separate themselves from others and will be PCR tested for the virus daily when working clinically.

I wanted to ask for your OK to do this clinical work— of course I will maintain my responsibilities in the office while doing so. Please let me know and happy to discuss further if you'd like.

Sincerely,
Andrea

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 23 Feb 2020 21:35:02 +0000
To: Haskins, Melinda (NIH/NIAID) [E]; Selgrade, Sara (NIH/NIAID) [E]; Crawford, Chase (NIH/NIAID) [E]
Cc: Marston, Hilary (NIH/NIAID) [E]; Eisinger, Robert (NIH/NIAID) [E]; Lerner, Andrea (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: Flip Cards

I have gone over the Flip cards. I note that we have only 2 cards for Coronavirus. I want to have a separate flip folder for coronavirus with a full set of cards for the specific coronavirus hearings that are coming up. You should sit down with me and also work with Hilary to prepare this set of cards. They should contain all the current epi as well as the dollar numbers for the proposed supplemental budget that we are putting together – I will get asked about that and I have clearance from the department to talk about it. Also, I want a set of cards for what we are doing in the area of research, i.e. basic research (eg animal models, etc.), diagnostics, therapeutics (remdesivir trials in China, Japan, and Nebraska), and the whole menu of vaccines. In other words, I want an entire set of cards for coronavirus. That is what I am going to get asked in both the coronavirus hearings as well as in the NIH Appropriations hearings.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 23 Feb 2020 21:22:40 +0000
To: Jon LaPook
Subject: RE: Coronavirus reality check

How about a pastrami sandwich on rye and a potato knish?

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Jon LaPook (b) (6)
Sent: Sunday, February 23, 2020 4:16 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Re: Coronavirus reality check

Thanks, Tony.

I would love you to consider my request to "tag along" with you some day - not to join you for meetings (I would wait outside unless invited in) or listen in on conference calls but to chat with you in between to give people an inside look at how seriously the government is taking the outbreak. And I could bring down a shmeat from Barney Greengrass for lunch. How could you pass that up???

Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

On Feb 23, 2020, at 4:05 PM, Fauci, Anthony (NIH/NIAID) [E] (b) (6) > wrote:

Jon:

The current appearance of community transmissions in Japan, South Korea, Italy and Iran is troublesome. As I have repeatedly said over the past couple of weeks, if and when (looks more like when now) a number of other countries besides China have sustained human to human transmissions, then we will be on the brink of a pandemic,

if not already there. The reason to say this is that when several countries have widespread transmissions, then spill-over to other countries is inevitable since one cannot shut out the rest of the world and so you can expect increasing world-wide transmissions among progressively more countries. In essence, you will be experiencing a pandemic. We are not quite there yet, but we are getting disturbingly close. It will soon be a matter of semantics regarding who would be willing to call it since it is not a mathematically precise definition. I am not so sure that WHO will have the will to declare this a "pandemic" before a number of respected epidemiologists around the world start referring publicly to it as a pandemic regardless of what WHO does or does not declare. WHO will likely be behind the curve here and will wait until it is patently obvious what we are dealing with.

Hope that this is helpful.

Best,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Jon LaPook (b) (6)

Sent: Sunday, February 23, 2020 3:47 PM

To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>

Subject: Coronavirus reality check

Hi Tony,

Why do I not think that this is a relaxing Sunday for you?

This definitely feels like an inflection point in the coronavirus outbreak - both in the unsurprising way it's spreading and the equally unsurprising misinformation and public alarm/panic we are seeing. Unsurprising but here we are. Can you give me a quick brain dump on where you think we are and how I can best inform the public?

Thanks,

Jon

P.S. please let me know whenever I can report that the outbreak is officially being called a pandemic.

Jonathan LaPook, M.D.

Chief Medical Correspondent, CBS News

Professor of Medicine

NYU Langone Health

Twitter @DrLaPook

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 23 Feb 2020 20:01:51 +0000
To: Richard Allen Johnson
Subject: RE: 2020.02.23 Sunday

Dick:

Transmission is definitely by respiratory droplet. Still unclear about aerosol transmission although there are anecdotal reports that this occurs similar to what we saw in individual episodes with SARS back in 2002-2003. Almost certainly contact transmission occurs with hand to mucosa (mouth, eyes, nasal mucosa). Unclear about fomites, doorknobs, etc. Virus can live for a couple of hours on certain inanimate objects. Virus definitely isolated from stool and urine, but not sure of role in transmission. No information about Transmission to fetus. Children have very low rate of infection. No good serologic test at this point although they are rapidly being developed.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Richard Allen Johnson (b) (6) >
Sent: Sunday, February 23, 2020 2:32 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Richard Allen Johnson
(b) (6) >
Subject: Re: 2020.02.23 Sunday

Thanks, Tony. Please continue communication with me by email. But rest your voice for a short while.

I am having trouble understanding the exact mode of transmission of COVID-19.

- Sneeze or cough produces respiratory droplet or aerosolized respiratory secretion which make contact with upper or lower respiratory mucosa, which results in infection of human cells. Seems most likely.
- What about contact transmission, contaminated hand to conjunctivae, nasal mucosa, or mouth
- Fecal/oral
- transmission to fetus
- What are the diagnostic tests to confirm diagnosis of novel coronavirus? PCR of secretions? Who in the world has these test kit; who manufactures kit.
- Are follow up serologies begin done?

Interesting questions to us and to Shelly Wolf if he were with us.

Thanks, Tony. My voice is also a little raspy.

Best,
Dick

On Sun, Feb 23, 2020 at 10:46 AM Fauci, Anthony (NIH/NIAID) [E] <(b) (6)> wrote:

Dick:

My voice is hoarse since I have been giving so many Congressional and White House briefings and TV and radio interviews. I just need to shut up for a while.

Best,
Tony

From: Richard Allen Johnson (b) (6)
Sent: Sunday, February 23, 2020 5:25 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: 2020.02.23 Sunday

Hi, Tony

I continue to follow the Cobid-19 epidemic.

What is the problem with your voice. It crackles like mine. I attribute mine to 'postnasal drip.'

WHO and Dr. Tedros are looking much better on TV. He has the WHO logo in the background. His tie show be tighter. His slouch is better. He still puts his elbows on the table in front of him.

Looking forward to lunch with you.

Best,
Dick

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 23 Feb 2020 15:56:48 +0000
To: Margolis, Leonid (NIH/NICHHD) [E]
Cc: Cassetti, Cristina (NIH/NIAID) [E]; Erbelding, Emily (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Coronavirus tissue test system: a suggestion

Thanks, Leonid. I will pass this on to appropriate associates.
Best regards,
Tony

From: Margolis, Leonid (NIH/NICHHD) [E] (b) (6) >
Sent: Sunday, February 23, 2020 5:50 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Coronavirus tissue test system: a suggestion
Importance: High

Dear Tony,

As you may know, for many years we study HIV pathogenesis in human tissues *ex vivo*. (Among my many papers, there is one, may be not the best, but that I am most proud of. This is where my co-author is Dr. Fauci 😊)

(b) (5)

Regards,
Leonid

Leonid Margolis, Ph.D.
Head,
Section of Intercellular Interactions
Eunice Kennedy-Shriver National Institute of Child Health and Human Development
Building 29B, Room 1H16D
29 Lincoln Drive
Bethesda, MD 20892
Phone: (b) (6)
Fax: 301-480-0857
e-mail: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 23 Feb 2020 15:53:48 +0000
To: john won
Subject: RE: KAMA

John:

Thank you very much for your kind note. I hope that all is well with you.
Best regards,
Tony

From: john won (b) (6) >
Sent: Sunday, February 23, 2020 9:06 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Re: KAMA

Dear Dr. Fauci,

I hope you are doing well. Your participation during our Washington DC 2017 convention was one of the most memorable events of our organization's history.

United States and the world now turns to you for your help as Coronavirus crisis is becoming pandemic. All of us here at KAMA are thinking about you and all those affected. Thank you very much for all your contributions.

Warm regards,

John Won

On Oct 24, 2017, at 10:42 AM, Fauci, Anthony (NIH/NIAID) [E] (b) (6) wrote:

John:

Thank you for your kind note. It was a pleasure to be with you.
Best regards,
Tony

From: john won (b) (6)
Sent: Tuesday, October 24, 2017 10:12 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: KAMA

Dear Dr. Fauci,

Thank you very much for speaking to us at the 43rd Annual KAMA Convention. It was a tremendous privilege for all of us. You were also so kind to stay afterwards to take pictures with all those who asked.

To be honest, having you there was very surreal. You symbolize the best of American medicine. I grew up idolizing your accomplishments as college and medical student. You saved and touched the lives of so many around the world. It is still hard to believe that I had this special opportunity to welcome you.

We will continue to do our best to serve the public and mentor medical students. I hope you can speak to us again in the near future. Thank you very much. I hope you continue in your position for another 40 years.

Warmest regards,

John H. Won

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 23 Feb 2020 15:52:06 +0000
To: Julia Belluz
Subject: RE: Comment?

Julia:

The appearance of community transmissions in Japan, South Korea, Italy and Iran is troublesome. As I have repeatedly said over the past couple of weeks, if and when (looks more like when now) a number of other countries besides China have sustained human to human transmissions, then we are on the brink of a pandemic, if not already there. The reason to say this is that when several countries have widespread transmission, then spill-over to other countries is inevitable since one cannot shut out the rest of the world and so you can expect increasing world-wide transmissions. Hence, you will be experiencing a pandemic. We are not quite there yet, but we are getting disturbingly close.

I hope that this is helpful.

Best,
Tony

From: Julia Belluz <julia.belluz@vox.com>
Sent: Sunday, February 23, 2020 4:13 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: julia.belluz@voxmedia.com; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] (b) (6)
Subject: Comment?

Dear Dr. Fauci,

Just over a week ago we talked for this story about how the outbreak is likely larger than we know now:

<https://www.google.com/amp/s/www.vox.com/platform/amp/2020/2/14/21134473/coronavirus-outbreak-singapore-us-symptoms-pandemic>

Given the developments in Singapore, Iran, Italy, and on the Diamond Princess cruise ship, I'm just wondering how your opinion about the possibility of containment and how fast we are approaching a pandemic has changed. Do these developments suggest we've entered a new phase in the outbreak?

If you have a few minutes to chat or email today, let me know. We'll be aiming to run a story on this today.

Thank you for considering.

Julia

On Feb 15, 2020, at 12:10 AM, Julia Belluz <julia.belluz@vox.com> wrote:

Thank you so much for making the time to comment at what I know is a crushingly busy time. As usual don't hesitate to ping if you have any further comments or questions! Julia

<https://www.vox.com/2020/2/14/21134473/coronavirus-outbreak-singapore-us-symptoms-pandemic>

Sent from my iPhone

On Feb 14, 2020, at 1:21 PM, Fauci, Anthony (NIH/NIAID) [E]

(b) (6) wrote:

Julia:

I just called you now (7:20 AM Washington, DC time) and got invoice mail in German that I could not understand. You can call me at (b) (6).

Thanks,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 23 Feb 2020 14:26:22 +0000
To: Theodore Li
Subject: RE: Covid-19 question

Ted:

Thanks for the note. Since she is 22 days out of Singapore she would be well beyond the 14 day quarantine used for people who are coming out of risk zones. And so although her risk is never zero, it is really very low. If she were coming from Japan or South Korea, which are experiencing an emerging outbreak, I might feel a little different, but Singapore has good infection control despite the number of cases in that country. Given her history of recent Shingrix vaccination, I would wait another day to see if her fever breaks. I agree that I would keep her at home for now. I do not think it would come to that, but if you want to get testing done, it still would have to go to the CDC via the Virginia department of health. Bottom line is that I would sit tight for now and see how she does over the next day or so. If things change, do not hesitate to call or e-mail me.

Best,
Tony

From: Theodore Li (b) (6)>
Sent: Sunday, February 23, 2020 9:11 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Covid-19 question

Hi Tony,

The wife of one of my patients received the Shingrix vaccine on Thursday 2/20 and developed fever to 101.4 the following day with malaise, headache, mild nausea (no respiratory symptoms). She's taken ibuprofen with transient temperature reduction; the fever and symptoms are the same today.

BUT . . . she and her daughter were in Singapore (b) (6) where they stayed at the (b) (6), visited (b) (6) and the (b) (6). They then flew to Colombo, Sri Lanka before returning via Europe last (b) (6) to (b) (6). So her fever began 3 weeks plus 1 day after being in Singapore.

I've told her to keep treating the fever and symptoms but to stay at home for now. The fever after Shingrix usually resolves after 2-3 days so I'd expect it to abate today or tomorrow. My question is whether there's enough of a concern, viz. the time in Singapore, for her to be tested for covid-19. If so, what's the best way to conduct the testing? Or is it okay to see if her fever breaks by tomorrow?

(You must be getting lots of these questions).

Best,
Ted

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 23 Feb 2020 04:27:10 +0000
To: Tabak, Lawrence (NIH/OD) [E]
Cc: Collins, Francis (NIH/OD) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E]
Subject: Heads Up

Larry:

I need to speak with you tomorrow (Sunday) about a request that we (NIH) will get from ASPR (Kadlec) regarding the housing of asymptomatic coronavirus positive individuals. I am copying Francis since the discussion will ultimately get to him.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 21:06:45 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Coronavirus

Please handle. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: OB Roberts (b) (6) >
Sent: Saturday, February 22, 2020 4:03 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Coronavirus

To: Dr. Fauci

FM: Oliver B Roberts



Dr. Fauci; I attended a small water seminar, put on by local (Seventh Day Adventist) medical professionals, in the mid 1970's at Elms Haven, California.

This seminar taught the participants how to eliminate the flu with the use of water treatments, ie (steam baths, etc).

I have now for these past 40 some-odd years, been taking two treatment's; one in the evening and another in the middle of the night, whenever I have contacted the flu: AND have had the facilities to do so; and each time I was well the next morning. No temperature, no symptoms whatsoever.

With the high rate that this Coronavirus is spreading, one can see what a great tool these treatments can be for medical professionals. To have those who are sick with the flu, completely free of all symptoms after two treatments would greatly ease the burden on Dr's and other medical professionals AND each facility.

Dr. I am asking for a few minutes of your time to explain this. I would like to share this with you and others. I just want to help by sharing what I learned and have been doing all these years. I feel so guilty, knowing this and not having a way to get this information to those needing it, when there so many out there sick and dying.

Note: I have been trying to reach out, hoping someone will hear me. Alas I do not have the education, pedigree nor the contacts: But you Dr. have all three! I ask not that you believe in me, but that you believe in these treatments.

Thank You for your time, please feel free to contact me via email or by phone or text or even have someone up here talk with me.

Sincerely;

OB Roberts
(Ben)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 21:04:58 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Congratulations and time to speak: Researchers Are Racing to Make a Coronavirus Vaccine. Will It Help? - The New York Times

Please set up a call with Hannah

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Valantine, Hannah (NIH/OD) [E] (b) (6)
Sent: Tuesday, February 18, 2020 10:05 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Congratulations and time to speak: Researchers Are Racing to Make a Coronavirus Vaccine. Will It Help? - The New York Times
Importance: High

Hi Tony,

I have been following this terrific work by NIAID scientists in the VRC – congratulations!

<https://www.nytimes.com/2020/01/28/health/coronavirus-vaccine.html>

As you can imagine I am delighted see Dr. Kizzmekia Corbett playing a leading role in these activities. Most importantly she is delighted with the mentorship, sponsorship and opportunity she has received at NIH, particularly from Barney Graham. (b) (6), (b) (5)

Please let me know when you might be available to speak with me.

Best,
Hannah

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 20:53:35 +0000
To: NIAID OD AM
Subject: FW: CUGH Annual Meeting

Let bus discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Thomas Quinn (b) (6)
Sent: Thursday, February 20, 2020 3:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Barasch, Kimberly (NIH/NIAID) [C] (b) (6) >; Judith Wasserheit (b) (6) >
Subject: CUGH Annual Meeting

Hi Tony,

I know how busy you are but I wanted to give you a brief update on the Annual Conference of the Consortium of Universities for Global Health (CUGH) based in Washington, DC. Here is the link to the overall CUGH meeting which provides an overview of the whole conference <https://www.cugh2020.org/program>. As we discussed months ago you agreed to be in the opening day plenary session on April 18th, entitled "Emerging Infectious Diseases and their Impact on Global Health Security". **The details and other speakers are listed below.** I may try to organize a call of all speakers in a month to coordinate talks/topics as the session is 90 minutes with 5 speakers, and a lot of ground to cover, especially with the COVID19 outbreak.

Judy Wasserheit, copied here, would also like to invite you to a special session she is organizing on the coronavirus epidemic at the same CUGH conference in a late-breaker session on Sunday, April 19 (the second day of the conference) from 8:45am-10:15am at the Washington Hilton Hotel (Monroe Room). This talk would be slightly different from the plenary session and you could expand on **COVID19 research priorities and update on progress**. We realize your schedule is very busy but your insights and knowledge on both of these topics is unparalleled. If you cannot speak at the second session we would appreciate your recommendation as to an alternative who could address this latter topic.

Thanks and all the best,
Tom

Plenary Session Details:

Session Day: Saturday, April 18, 2020

Session Time: 11:30am-1:00pm

Location: Washington Hilton Hotel, International Ballroom

Panel Title: "Emerging Infectious Diseases and their Impact on Global Health Security"

Short Panel Description: This Plenary Panel will highlight the continual threats of emerging and re-emerging infectious diseases, and their impact on global security for surveillance, detection, treatment and prevention of these diseases. Over recent decades, multiple epidemic events have underscored how highly vulnerable we are to viral threats. Our world is globally connected—and an "emerging threat" in one part of the world can pose a threat everywhere and to everyone. About 75 percent of new human diseases are caused by microbes that originate in animals. These include HIV, influenza (including pandemic H1N1, H5N1, and H7N9), Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome-Coronavirus (MERS-CoV), Ebola, Marburg, and Nipah. The recent emergence of COVID from China clearly illustrates the magnitude, rapidity

and impact that a new infectious agent can have on global health security. This panel of leading experts will discuss the emergence of these microbial threats, and our ability to detect, respond and prevent future epidemics of these pathogens.

Moderator(s) Info: Tom Quinn, Chief, NIAID, International HIV/STD Section and Man Charurat, Director, Division of Epidemiology and Prevention, Institute of Human Virology (IHV)

Speaker(s) Info:

1. Anthony Fauci, Director, NIAID

2. Chikwe Ihekweazu, Director General, Nigeria CDC

3. Peter Hotez, Dean, National School of Tropical Medicine, Baylor College of Medicine

4. Jonna Mazet, Executive Director, One Health Institute, and PI, PREDICT project, UC Davis

5. Jennifer Nuzzo, Senior Scholar, Center for Health Security, Johns Hopkins University

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 20:51:00 +0000
To: Stover, Kathy (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]
Subject: RE: FOR ASF REVIEW: Draft PR re: launch of remdesivir COVID-19 trial
Attachments: NIAID press release COVID-19 treatment trial FOG - with fauci tracked edits.docx

See my minor tracked edits. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stover, Kathy (NIH/NIAID) [E] (b) (6)
Sent: Friday, February 21, 2020 3:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Subject: FOR ASF REVIEW: Draft PR re: launch of remdesivir COVID-19 trial

Hi Dr. Fauci,

Please find attached for your review a draft press release to announce the launch of the remdesivir COVID-19 treatment trial, which enrolled its first patient today. It's been reviewed by the following individuals/groups:

- FOG
- OCGR (Kathy Stover, Courtney Billet)
- DMID: Emily Erbelding, John Beigel
- DCR: Cliff Lane, Libby Higgs
- U Nebraska (Christopher Kratochvil, Andre Kalil, comms dept)
- Awaiting comments from Gilead and WHO.

For ease of reference, the following is the quote we have drafted for your use:

(b) (5)

Thanks much,
Kathy

Kathy Stover
Branch Chief
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A17F
Bethesda, MD 20892

(b) (6)

Media line: (301) 402-1663

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 20:38:12 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Routh, Jennifer (NIH/NIAID) [E]
Subject: RE: interview request: draft responses for Greek newspaper

Good job! See my minor edits in **red**. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Friday, February 21, 2020 4:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: interview request: draft responses for Greek newspaper

Do you want to edit these..greek paper/pring?

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it

from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Routh, Jennifer (NIH/NIAID) [E] (b) (6)>
Sent: Friday, February 21, 2020 4:52 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; NIAID FOG <fog@niaid.nih.gov>
Cc: NIAID COGCORE <COGCORE@mail.nih.gov>; NIAID Media Inquiries <mediainquiries@niaid.nih.gov>
Subject: interview request: draft responses for Greek newspaper

Reporter: Theodora Tsoli
Organization: Greek newspaper To VIMA (www.tovima.gr)
Phone #(s): (b) (6), ttsoli@tovima.gr
Subject: COVID-19
Deadline: Monday 2/24

The reporter emailed questions for ASF. I have drafted proposed responses for his review, also attached.

1. **Do you believe that SARS-COV2 is capable of causing a pandemic? Are you expecting many secondary transmissions of the virus outside China?**
A pandemic is generally defined as sustained transmission of a new pathogen in multiple regions of the world. COVID-19 does not yet meet that definition, and I hope that China and other countries in Asia with some transmission are able to contain the outbreak. However, it is possible that COVID-19 could become a pandemic. It would not be surprising to see additional secondary transmissions of the virus outside of China.
2. **Chinese authorities are reporting a decline of new cases. Could we say that the virus has peaked and maybe it will slow down? When are you expecting to have a clearer picture about the evolution of this epidemic?**
Although the number of **daily** cases in China appears to have gone down, it is too early to tell if this is really a decline in the outbreak.
3. **Could the virus become endemic and give seasonal outbreaks?**
If China is not able to contain the outbreak, it is possible COVID-19 could become endemic and lead to seasonal outbreaks. However, it is too early to know the likelihood of this scenario.
4. **What about its transmissibility? Some experts say that WHO is underestimating it's transmissibility. Could the reality be different maybe because, among other things, many cases stay undetected?**
Because of the many unknowns about SARS-CoV-2, it is difficult to make any firm conclusions regarding overall transmissibility and severity. However, it appears to be much more transmissible than SARS. Also, there are likely asymptomatic COVID-19 infections that are not getting counted because people do not go to the doctor for testing or treatment if they are not sick.

5. **Do you believe that the measures taken by China and countries around the world are adequate to stop SARS-COV2 spread? There is a lot of discussion about thermal cameras and travel restrictions for example.**
China has taken extreme measures to control the outbreak. Restricting the movement of 50 million people is unprecedented. However, it might ultimately have an effect on slowing transmission. Precautions implemented in the U.S. are not intended to detect every person with COVID-19 entering the country. However, our approach has allowed us time to better plan and prepare our health system.
6. **What is the key to stop the worldwide spread of the virus?**
Though we have mobilized a rapid research response to quickly develop effective countermeasures, right now, the outbreak response remains focused on the proven public health practices of identifying cases, isolating patients and tracing contacts.
7. **In the northern hemisphere we have a flu outbreak - in Greece as well. Some experts say that this is the real danger and not the coronavirus. What is your view?**
I am always concerned about influenza. Every flu season, millions of people are at risk of getting very sick or dying. Currently people in the U.S. and most countries in the northern hemisphere are at a much higher risk of being exposed to influenza than SARS-CoV-2. However, the COVID-19 outbreak is an evolving situation and we are treating it as a very serious public health threat.
8. **Many efforts are being in process for the development of a vaccine for the new coronavirus. Are you coordinating any of them and which ones? Are there any efforts more promising than others? Which platforms of vaccine development are more promising? When do you believe that we could have a vaccine available for clinical trials and then for human use?**
NIAID is exploring multiple candidates and is on track to test an experimental messenger RNA (mRNA) vaccine in a Phase 1 clinical trial this spring. This first phase of clinical testing will involve giving the vaccine to healthy adults in the United States to see if it is safe and if it can induce an immune response in recipients. It is important to realize that the development of investigational vaccines and the clinical testing to establish their safety and effectiveness takes time. A vaccine against the novel coronavirus will likely not be widely available for **more than** a year.
9. **What about therapies? Dozens are being tried - from plasma to herbal medicines in China. Which are the most promising?**
NIAID is pursuing the development of antivirals and monoclonal antibodies for potential use against COVID-19. NIAID is preparing protocols for *in vitro* and *in vivo* studies of the antiviral remdesivir, which has shown promise against other coronaviruses in animal models. NIAID also plans to evaluate Kaletra (lopinavir/ritonavir) and interferon-beta for their activity against SARS-CoV-2. In addition, NIAID scientists are working to identify monoclonal antibodies with

therapeutic potential from stored SARS patient samples as well as COVID-19 patient samples.

10. **Are the things we know about this new virus more than the ones we don't know? Which are the main questions about it that remain to be answered?**
New data **are** published about SARS-CoV-2 every day. However, we still have a lot to learn. For example, we do not know why there are **so few cases among** children, which is uncommon for a respiratory virus.
11. **How worried should people outside China be about SARS-COV2? What is the biggest danger from this virus?**
. The risk to the general American public remains low at this time; **however, this could change and that is why we are treating the emergence of a novel coronavirus as a very serious public health threat.** We understand that people may be worried. We ask that people not let fear or panic guide their actions.
12. **Which are the protective measures anyone should take against the new virus? Do masks work?**
The vast majority of people outside of China do not need to wear a mask. A mask is more appropriate for someone who is infected than for people trying to protect against infection.

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: (b) (6)
(b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 19:41:48 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: RE: HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Cassetti, Cristina (NIH/NIAID) [E] (b) (6)>
Sent: Saturday, February 22, 2020 2:26 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Erbeling, Emily (NIH/NIAID) [E] (b) (6)>
Subject: Fwd: HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine

This is the press release from ASPR, in case you need more information on the Sanofi CoV efforts

Cristina

Begin forwarded message:

From: "Folkers, Greg (NIH/NIAID) [E]" (b) (6)
Date: February 18, 2020 at 3:07:21 PM EST
Subject: HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine

FOR IMMEDIATE RELEASE
February 18, 2020
Contact: ASPR Press Office
202-205-8117
asprmedia@hhs.gov

HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine

Racing to develop a vaccine against the 2019 novel coronavirus, the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response has engaged Sanofi Pasteur, the vaccines global business unit of Sanofi. The Biomedical Advanced Research and Development Authority (BARDA), a component of ASPR, will provide expertise and reallocated funds to support the vaccine's development. Sanofi will use its egg-free, recombinant DNA platform to produce a recombinant 2019 novel coronavirus vaccine candidate.

The technology produces an exact genetic match to proteins of the virus. The protein's DNA will be combined with DNA from a virus harmless to humans, and used to rapidly produce large quantities of antigen which stimulate the immune system to protect against the virus. The antigens will be separated and collected from these cells and purified to create working stocks of vaccine for advanced development.

"Flexibility and scalability are cornerstones of rapid response to an emerging infectious disease," said BARDA Director Rick A. Bright, Ph.D. "Using this proven technology, we can pivot immediately to address this new global health threat. Our goal is a licensed vaccine to provide long-term health security against this latest virus and prevent future coronavirus outbreaks."

BARDA has worked with Sanofi since 2004 and in 2009 began collaborating with Protein Sciences of Meridian, Connecticut, now owned by Sanofi, to develop a recombinant technology with the flexibility to make millions of doses of vaccine quickly in an influenza pandemic. In 2016, BARDA added this vaccine to the U.S. National Pre-pandemic Influenza Vaccine Stockpile. When Sanofi purchased the company and its technology in 2017, BARDA continued working with Sanofi on pandemic vaccine development, and in December 2019 the partners began focusing on increasing [manufacturing capacity](#) for recombinant influenza vaccine in the United States, in accordance with a [presidential executive order](#) to enhance national security and the public health by modernizing influenza vaccines and technologies.

This expanded collaboration with Sanofi is BARDA's second program to focus on developing a novel coronavirus vaccine candidate in the past few weeks. There is currently no approved vaccine, treatment, or diagnostic for novel coronavirus infections; however, the U.S. Food and Drug Administration has issued an emergency use authorization (EUA) to enable emergency use of a diagnostic test developed by the Centers for Disease Control and Prevention.

BARDA also is working with counterparts across the government, including within HHS and with the Department of Defense. The team is reviewing potential vaccines, treatments and diagnostics from across the public and private sectors, particularly products in development for Middle East Respiratory Syndrome (MERS) or Severe Acute Respiratory Syndrome (SARS), to identify promising candidates for development and licensure to detect, protect against or treat novel coronavirus infections.

To obtain information about any potential products in development in the private sector that could be used in responding to the novel coronavirus outbreak, the U.S. government

launched a single point-of-entry [website](#) for innovators and product developers to submit brief descriptions of their diagnostics, therapeutics, vaccines, and other products or technologies relevant to this new virus.



Federal agencies are particularly interested in identifying products and technologies that have progressed into or beyond non-clinical studies, have established large-scale commercial Good Manufacturing Practices (cGMP) manufacturing capability, and/or have utilized a platform already approved by the U.S. Food and Drug Administration (FDA). BARDA also opened an easy broad agency announcement, an [EZ-BAA](#), specific to diagnostics that utilize platforms already cleared by the FDA, with a viable plan to meet requirements for the FDA to consider Emergency Use Authorization (EUA) within 12 weeks of an award.

About HHS, ASPR, and BARDA

HHS works to enhance and protect the health and well-being of all Americans, providing for effective health and human services and fostering advances in medicine, public health, and social services. The mission of ASPR is to save lives and protect Americans from 21st century health security threats. Within ASPR, BARDA invests in innovation, advanced research and development, acquisition, and manufacturing of medical countermeasures – vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products needed to combat health security threats. To date, 54 BARDA-supported products have achieved regulatory approval, licensure or clearance. BARDA DRIVE brings together the best ideas from the medical and scientific communities, together with government and venture capital investment, to drive innovation that will strengthen our nation's health security. To learn more about preparing for and responding to public health emergencies, from new infectious diseases to natural disasters and bioterrorism, by visiting the HHS public health emergency website, www.phe.gov. For more information on partnering with BARDA on developing medical countermeasures, visit www.medicalcountermeasures.gov, and for more on DRIVE, visit drive.hhs.gov.

###

Note: All HHS press releases, fact sheets and other news materials are available at <https://www.hhs.gov/news>.

Like [HHS on Facebook](#) , follow HHS on Twitter [@HHSgov](#) , and sign up for [HHS Email Updates](#).

Last revised: February 18, 2020

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 19:41:42 +0000
To: David Willman
Subject: FW: HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine

David:

See press release below regarding BARDA and Sanofi.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Cassetti, Cristina (NIH/NIAID) [E] (b) (6)
Sent: Saturday, February 22, 2020 2:26 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Erbeling, Emily (NIH/NIAID) [E] (b) (6)
Subject: Fwd: HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine

This is the press release from ASPR, in case you need more information on the Sanofi CoV efforts

Cristina

Begin forwarded message:

From: "Folkers, Greg (NIH/NIAID) [E]" (b) (6)>
Date: February 18, 2020 at 3:07:21 PM EST
Subject: HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine

FOR IMMEDIATE RELEASE
February 18, 2020
Contact: ASPR Press Office
202-205-8117
asprmedia@hhs.gov

HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine

Racing to develop a vaccine against the 2019 novel coronavirus, the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response has engaged Sanofi Pasteur, the vaccines global business unit of Sanofi. The Biomedical Advanced Research and Development Authority (BARDA), a component of ASPR, will provide expertise and reallocated funds to support the vaccine's development. Sanofi will use its egg-free, recombinant DNA platform to produce a recombinant 2019 novel coronavirus vaccine candidate.

The technology produces an exact genetic match to proteins of the virus. The protein's DNA will be combined with DNA from a virus harmless to humans, and used to rapidly produce large quantities of antigen which stimulate the immune system to protect against the virus. The antigens will be separated and collected from these cells and purified to create working stocks of vaccine for advanced development.

"Flexibility and scalability are cornerstones of rapid response to an emerging infectious disease," said BARDA Director Rick A. Bright, Ph.D. "Using this proven technology, we can pivot immediately to address this new global health threat. Our goal is a licensed vaccine to provide long-term health security against this latest virus and prevent future coronavirus outbreaks."

BARDA has worked with Sanofi since 2004 and in 2009 began collaborating with Protein Sciences of Meridian, Connecticut, now owned by Sanofi, to develop a recombinant technology with the flexibility to make millions of doses of vaccine quickly in an influenza pandemic. In 2016, BARDA added this vaccine to the U.S. National Pre-pandemic Influenza Vaccine Stockpile. When Sanofi purchased the company and its technology in 2017, BARDA continued working with Sanofi on pandemic vaccine development, and in December 2019 the partners began focusing on increasing [manufacturing capacity](#) for recombinant influenza vaccine in the United States, in accordance with a [presidential executive order](#) to enhance national security and the public health by modernizing influenza vaccines and technologies.

This expanded collaboration with Sanofi is BARDA's second program to focus on developing a novel coronavirus vaccine candidate in the past few weeks. There is currently no approved vaccine, treatment, or diagnostic for novel coronavirus infections; however, the U.S. Food and Drug Administration has issued an emergency use authorization (EUA) to enable emergency use of a diagnostic test developed by the Centers for Disease Control and Prevention.

BARDA also is working with counterparts across the government, including within HHS and with the Department of Defense. The team is reviewing potential vaccines, treatments and diagnostics from across the public and private sectors, particularly products in

development for Middle East Respiratory Syndrome (MERS) or Severe Acute Respiratory Syndrome (SARS), to identify promising candidates for development and licensure to detect, protect against or treat novel coronavirus infections.

To obtain information about any potential products in development in the private sector that could be used in responding to the novel coronavirus outbreak, the U.S. government launched a single point-of-entry [website](#) for innovators and product developers to submit brief descriptions of their diagnostics, therapeutics, vaccines, and other products or technologies relevant to this new virus.

Federal agencies are particularly interested in identifying products and technologies that have progressed into or beyond non-clinical studies, have established large-scale commercial Good Manufacturing Practices (cGMP) manufacturing capability, and/or have utilized a platform already approved by the U.S. Food and Drug Administration (FDA). BARDA also opened an easy broad agency announcement, an [EZ-BAA](#), specific to diagnostics that utilize platforms already cleared by the FDA, with a viable plan to meet requirements for the FDA to consider Emergency Use Authorization (EUA) within 12 weeks of an award.

About HHS, ASPR, and BARDA

HHS works to enhance and protect the health and well-being of all Americans, providing for effective health and human services and fostering advances in medicine, public health, and social services. The mission of ASPR is to save lives and protect Americans from 21st century health security threats. Within ASPR, BARDA invests in innovation, advanced research and development, acquisition, and manufacturing of medical countermeasures – vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products needed to combat health security threats. To date, 54 BARDA-supported products have achieved regulatory approval, licensure or clearance. BARDA DRIVE brings together the best ideas from the medical and scientific communities, together with government and venture capital investment, to drive innovation that will strengthen our nation's health security. To learn more about preparing for and responding to public health emergencies, from new infectious diseases to natural disasters and bioterrorism, by visiting the HHS public health emergency website, www.phe.gov. For more information on partnering with BARDA on developing medical countermeasures, visit www.medicalcountermeasures.gov, and for more on DRIVE, visit drive.hhs.gov.

###

Note: All HHS press releases, fact sheets and other news materials are available at <https://www.hhs.gov/news>.

Like [HHS on Facebook](#) , follow HHS on Twitter [@HHSgov](#) , and sign up for [HHS Email Updates](#).

Last revised: February 18, 2020

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 19:39:17 +0000
To: Kevin Thurm
Subject: RE: Thanks

Kevin:

Many thanks for your kind note. Much appreciated. I hope that all is well with you.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Kevin Thurm (b) (6) >
Sent: Saturday, February 22, 2020 12:45 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Thanks

Tony

Good afternoon.

Just wanted to write and say how much I deeply appreciate your on-going public service; you've made extraordinary contributions over the course of your career and, as I've watched you on TV in the context of the current public health threat of the coronavirus, I know you're continuing to do so...

No need to respond; you have a lot going on.

From one citizen and a former colleague, extending my thanks and deep appreciation.

Best wishes.

Kevin Thurm

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 19:36:40 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Subject: RE: For review: ASM presentation for 26Feb2020
Attachments: ASM Public and Scientific Affairs Committee Meeting 2nd FINAL for 26Feb2020.pptx

I mistakenly put it into my Documents. Here it is, and I will put it into the OD now

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Sent: Saturday, February 22, 2020 2:25 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: RE: For review: ASM presentation for 26Feb2020

I don't see it in OD

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Sent: Saturday, February 22, 2020 1:49 PM
To: Schneider, Johanna (NIH/NIAID) [E] <(b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Subject: RE: For review: ASM presentation for 26Feb2020

This is now "2nd FINAL" in the OD folder. You just need to remove the instruction slides and do the required updates on several of the slides and then it is ready to go. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Schneider, Johanna (NIH/NIAID) [E] (b) (6)
Sent: Friday, February 21, 2020 4:05 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6) >; Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: For review: ASM presentation for 26Feb2020

Dr. Fauci,
Attached is the presentation to the American Society for Microbiology (ASM) Public and Scientific Affairs Committee on Wednesday Feb 26th.

The topics they have expressed interest in are:

- NIAID Budget Request FY2021
- Novel Coronavirus
- Progress on a Universal Flu Vaccine

The talk is 30 minutes plus 15-20 for discussion.

I've scheduled 30 minutes Monday morning at 10AM to review the slides with you as well.

The presentation has been uploaded to the shared drive. As indicated we will update the necessary slides on Monday afternoon before sending them to ASM on Tuesday.

Thanks,
Johanna

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 19:33:57 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: RE: Question

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Cassetti, Cristina (NIH/NIAID) [E] (b) (6)>
Sent: Saturday, February 22, 2020 2:22 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Erbeling, Emily (NIH/NIAID) [E] (b) (6)>
Subject: Re: Question

Hi Dr. Fauci,

This effort is completely driven by BARDA. DMID is not involved.

Cristina

On Feb 22, 2020, at 2:18 PM, Fauci, Anthony (NIH/NIAID) [E] <(b) (6)> wrote:

Cristina:

What is the relationship that we (DMID/NIAID) has with Sanofi in the development of a coronavirus vaccine? Are we funding them? Do we

have any agreement with them to develop a coronavirus vaccine, or is it BARDA who is dealing with them?

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 18:32:37 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: Nabel NAS nomination
Attachments: (b) (6) 2020 NAS Nomination - Section 44 - 02-22-2020.docx

Bob:

Here is (b) (6) NAS nomination. Let us touch bases on Monday to get it uploaded to the website.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 14:08:16 +0000
To: Marlene Colucci
Cc: David Rubenstein;Ginni Rometty;Donahoe, John
Subject: RE: Business Council - Dr. Anthony Fauci "fireside chat" with David Rubenstein - Thank you!

Marlene: Thanks for the note. It was my pleasure, and I never miss an opportunity to interact with David. He is an incomparable interviewer.

Best,
Tony

From: Marlene Colucci <mcolucci@businesscouncil.com>
Sent: Friday, February 21, 2020 2:40 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: David Rubenstein (b) (6); Ginni Rometty (b) (6);
Donahoe, John (b) (6)>
Subject: Business Council - Dr. Anthony Fauci "fireside chat" with David Rubenstein - Thank you!

Dr. Fauci,

We wanted to send a quick note to thank you for joining us today. Your discussion with David was so interesting and well received.

The coronavirus alone was on the minds of so many CEOs as it impacts their supply chain.

David, it goes without saying that you are the best interviewer! You make everything substantive and entertaining.

Wishing everyone an enjoyable weekend!

Warmest regards,

Marlene

Marlene Colucci

EXECUTIVE
DIRECTOR



T: 202-298-7650
C: (b) (6)
F: 202-785-0296

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 14:06:21 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: CoVid-19 In Infants

Please handle.

-----Original Message-----

From: JF K [REDACTED] (b) (6)>
Sent: Friday, February 21, 2020 2:44 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: CoVid-19 In Infants

Dr. Fauci,

Infants and children infected with CoVid-19 seem to be an anomaly. Could it be as simple as childhood vaccinations? Are Chinese children vaccinated with anti malarial drugs such as Chloroquine phosphate, which is proving effective in older patients for CoVid-19?

If infants and children are not getting severe infections, why?

Jonathan F. King

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 14:00:30 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]; Greg Folkers (GFOLKERS@niaid.nih.gov)
Subject: FW: Session Planning for COVID-19 at CROI; Tuesday March 10, at 12:10 PM Eastern Daylight Time

fyi

From: Kevin Bowen <kbowen@iasusa.org>
Sent: Friday, February 21, 2020 6:31 PM
To: Donna Jacobsen <djacobsen@iasusa.org>; Zunyou Wu (b) (6); Brooks, John T. (CDC/DDID/NCHHSTP/DHPSE) (b) (6); Baric, Ralph (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Sharon Hillier PhD (b) (6); El-Sadr, Wafaa M. (b) (6); Schooley, Robert (b) (6); Schooley, Chip (b) (6); Eron, Joseph J Jr (b) (6); Genesis Regalado (b) (6); Baric, Toni C (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: RE: Session Planning for COVID-19 at CROI; Tuesday March 10, at 12:10 PM Eastern Daylight Time

Dear CROI Speakers and Moderators:

We would like to schedule a planning call for next week to COVID-19 session at the 2020 Conference on Retroviruses and Opportunistic Infections (CROI). Please submit your availability using the poll at <http://whenisgood.net/ksy42az>. The poll should automatically adjust to your local time zone, but you can adjust the setting using the "Select your location" dropdown if needed.

We will confirm the call as soon as possible.

Regards,

Kevin Bowen
Program Director
CROI Scientific Program and IAS-USA Production

From: Donna Jacobsen
Sent: Friday, February 21, 2020 1:37 PM
To: Zunyou Wu (b) (6); John T. Brooks MD (b) (6); Baric, Ralph S (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Sharon Hillier PhD (b) (6); El-Sadr, Wafaa M. (b) (6); Kevin Bowen <kbowen@iasusa.org>; Schooley, Robert (b) (6); Robert T. Schooley, MD (b) (6); Eron, Joseph J Jr (b) (6); Kevin Bowen <kbowen@iasusa.org>; Genesis Regalado <gregalado@iasusa.org>; Baric, Toni C

(b) (6)>; Conrad, Patricia (NIH/NIAID) [E]

(b) (6)>

Subject: Session Planning for COVID-19 at CROI; Tuesday March 10, at 12:10 PM Eastern Daylight Time
Importance: High

Dear Drs Wu, Brooks, Baric, and Fauci:

It is more than incredibly impressive at how all of you, in just the past few days, have rearranged your schedules and agreed to participate in this special session in only about 2 weeks. We are all very grateful, and know this will be tremendously impactful for the CROI audience.

Below is the final list of presentations, although the order and titles may well change. We are hoping to have a conference call with the session liaisons and speakers next week if possible, to go over each of the talks to address the overall plan and discuss any overlap. Shortly we will send out a poll for availability for early morning in China, early-mid afternoon in the US West Coast, and late afternoon-evening in the US East Coast. If you can respond to the poll by Monday we would greatly appreciate it; things are moving quickly.

Many thanks again,

All of us at CROI!

SPECIAL LUNCHTIME SESSION ON COVID 19

Tue. 3/10: 12:10 PM - 1:20 PM EASTERN DAYLIGHT TIME
Auditorium

Preliminary Session Agenda (Order and talk titles to be confirmed)

1. FOCUS ON THE EPIDEMIOLOGY OF COVID-19 AND EFFORTS IN CHINA
 - a. Zunyou Wu, Chinese Center for Disease Control, China
15-minute live video (Skype or Zoom) update from China
2. FOCUS ON THE GLOBAL EPIDEMIOLOGY OF COVID-19 AND EFFORTS TO CONTROL THE OUTBREAK
 - a. John Brooks, US Centers for Disease Control, USA
15-minute update
3. FOCUS ON THE VIROLOGY OF CORONAVIRUSES OVERALL, MOLECULAR ASPECTS OF TRANSMISSION TO HUMANS, PATHOGENESIS IN MICE MODELS AND PARALLELS IN HUMANS, ETC
 - a. Ralph Baric, University of North Carolina, USA
25-minute lecture
4. FOCUS ON NIAID/NIH EFFORTS TO STUDY NOVEL CORONAVIRUSES AND DEVELOP DIAGNOSTICS, THERAPEUTICS, AND VACCINES
 - a. Anthony Fauci, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA
15-minute recorded update

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 12:13:45 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Triple E letter

Let us discuss. Likely no.

-----Original Message-----

From: Bridbord, Ken (NIH/FIC) [V] (b) (6)>
Sent: Friday, February 21, 2020 3:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Marietta Ethier (b) (6); Emily Lane <ELane@ (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: Triple E letter

Tony, my condominium community has established a program in which prominent members of the Washington area are invited to make presentations on subjects of great public interest. Shown in the email below is a description of this program. In this regard I have been asked to contact you to see, recognizing your incredibly busy schedule, if you would be interested and able to provide an update on the Coronavirus situation to our residents. Most likely you (b) (6) If you have a potential interest in sharing your great expertise on this subject with our residents could you please have your staff contact Emily Lane who is copied on this email to explore possible dates and times that would work for you. Thank you so much for your consideration of this request. Ken

On 2/21/20, 3:36 PM, "Emily Lane" <ELane@ (b) (6)> wrote:

Dear Ken,

The (b) (6) Committee greatly appreciates your willingness to approach Dr. Anthony Fauci on our behalf, asking him to address the residents of the (b) (6) on the Coronavirus. It would perhaps be helpful to Dr. Fauci, to explain who we are and what we do. (b) (6), (b) (6)

The (b) (6) Committee was formed recently to create and organize events to educate, enlighten and entertain members of the Somerset community. A few weeks ago (b) (6) spoke to a sold out crowd on impeachment. We've featured authors on a variety of topics; invited doctors with specialties of interest to our community organized trips to the Kennedy Center and theaters for attendance at ballets and plays and sponsored visits, led by experts, to various museums and the Library of Congress to view special exhibitions. An example of the latter is a tour of the Folger Library (b) (6). A presentation by Dr. Fauci on the coronavirus would be of great interest to our constituency who keep informed by reading both national and international journals. We are flexible on the date for such an appearance needing only a few days' notice to inform our residents.

I need not tell you that it would our great honor to welcome Dr. Fauci to the (b) (6).

Sincerely

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 12:08:24 +0000
To: Conrad, Patricia (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]
Cc: Marston, Hilary (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]
Subject: RE: Session Planning for COVID-19 at CROI; Tuesday March 10, at 12:10 PM Eastern Daylight Time

I totally agree. I do not want to be on a "session planning" call. Please have Hilary do this as suggested by Patty since she is preparing the talk. Thanks.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Sent: Friday, February 21, 2020 4:44 PM
To: Folkers, Greg (NIH/NIAID) [E] (b) (6) >; Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: Session Planning for COVID-19 at CROI; Tuesday March 10, at 12:10 PM Eastern Daylight Time
Importance: High

Since this is a taping for his remarks – can hilary do this call since she is doing the slides? hate to waste ASF time on this with all our other moving parts....just a thought.

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Donna Jacobsen <djacobsen@iasusa.org>
Sent: Friday, February 21, 2020 4:37 PM
To: Zunyou Wu (b) (6) >; Brooks, John T. (CDC/DDID/NCHHSTP/DHPSE) (b) (6) >; Baric, Ralph (b) (6) >; Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Sharon Hillier PhD (b) (6) ;

(b) (6) El-Sadr, Wafaa M. (b) (6) >; Kevin Bowen
(b) (6); Schooley, Robert (b) (6); Schooley, Chip
>; Eron, Joseph J Jr >; Kevin Bowen
>; Genesis Regalado (b) (6) >; Baric, Toni C
(b) (6), Conrad, Patricia (NIH/NIAID) [E] (b) (6)

Subject: Session Planning for COVID-19 at CROI; Tuesday March 10, at 12:10 PM Eastern Daylight Time
Importance: High

Dear Drs Wu, Brooks, Baric, and Fauci:

It is more than incredibly impressive at how all of you, in just the past few days, have rearranged your schedules and agreed to participate in this special session in only about 2 weeks. We are all very grateful, and know this will be tremendously impactful for the CROI audience.

Below is the final list of presentations, although the order and titles may well change. We are hoping to have a conference call with the session liaisons and speakers next week if possible, to go over each of the talks to address the overall plan and discuss any overlap. Shortly we will send out a poll for availability for early morning in China, early-mid afternoon in the US West Coast, and late afternoon-evening in the US East Coast. If you can respond to the poll by Monday we would greatly appreciate it; things are moving quickly.

Many thanks again,

All of us at CROI!

SPECIAL LUNCHTIME SESSION ON COVID 19

Tue, 3/10: 12:10 PM - 1:20 PM EASTERN DAYLIGHT TIME
Auditorium

Preliminary Session Agenda (Order and talk titles to be confirmed)

1. FOCUS ON THE EPIDEMIOLOGY OF COVID-19 AND EFFORTS IN CHINA
 - a. Zhenyou Wu, Chinese Center for Disease Control, China
15-minute live video (Skype or Zoom) update from China
2. FOCUS ON THE GLOBAL EPIDEMIOLOGY OF COVID-19 AND EFFORTS TO CONTROL THE OUTBREAK
 - a. John Brooks, US Centers for Disease Control, USA
15-minute update
3. FOCUS ON THE VIROLOGY OF CORONAVIRUSES OVERALL, MOLECULAR ASPECTS OF TRANSMISSION TO HUMANS, PATHOGENESIS IN MICE MODELS AND PARALLELS IN HUMANS, ETC
 - a. Ralph Baric, University of North Carolina, USA
25-minute lecture
4. FOCUS ON NIAID/NIH EFFORTS TO STUDY NOVEL CORONAVIRUSES AND DEVELOP DIAGNOSTICS, THERAPEUTICS, AND VACCINES
 - a. Anthony Fauci, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA
15-minute recorded update

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 12:06:10 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: DEAR TONY: CORONAVIRUS

Please handle.

From: Dr. Michael Jacobs (b) (6) >
Sent: Friday, February 21, 2020 6:14 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Alexander Tarakhovsky (b) (6); Lockshin, Michael MD (b) (6); Dr. Michael Jacobs (b) (6) >
Subject: DEAR TONY: CORONAVIRUS

dear tony:

i am a cornell medical school cumc (b) (6) graduate. i am associate professor of dermatology at weill-cornell in private practice. (b) (6)
(b) (6) alexander tarakhovsky is (b) (6) and a professor at rockefeller university. he is a virologist.

we have been following the corona virus pandemic closely, and a few days ago became alarmed at the news that the chinese government is sterilizing their paper money from hubei province.

we think that there is a possibility that the virus was released from a lab in wuhan, the biotech area of china. we also think that the virus might be complexed with another organism, such as a yeast or fungus, to make it more sticky.

we would like to discuss this with you further. we feel that immediate action must be taken by united states scientists to try to neutralize this threat.

please contact alexander and me at your earliest convenience at above emails or my mobile (b) (6) or office (b) (6) michael lockshin gave me your email.

with kind regards

michael jacobs

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 11:49:36 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: coronavirus
Attachments: Cai & Garen 1995.pdf, Cai & Garen 1996 .pdf, Cai & Garen 1997.pdf

Please handle. Thanks.

From: Garen, Alan (b) (6) >
Sent: Friday, February 21, 2020 7:46 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Garen, Alan (b) (6) >
Subject: coronavirus

Dear D. Fauci,

I want to suggest that NIAID arrange to collect serum samples from Coronavirus patients who have survived a major infection and probably have generated antiviral antibodies. My laboratory showed in the attached papers that such antibodies could be cloned from sera using a powerful technology called Phage Display. The project could be initiated in this country with as few as 2 patients.

Sincerely, Alan Garen, Yale University

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 11:39:57 +0000
To: Antoniak, Cynthia (NBCUniversal, MSNBC)
Cc: Goldner, Shannah (NBCUniversal); Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: MSNBC Reconfirming

No problem. See you then.

From: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>
Sent: Saturday, February 22, 2020 6:39 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: RE: MSNBC Reconfirming

If you could get there by 7:30am...that would be great!

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Sent: Saturday, February 22, 2020 6:38 AM
To: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>
Cc: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: [EXTERNAL] RE: MSNBC Reconfirming

I have received this e-mail and confirm 7:45 AM hit. What time do you want me at the studio?

From: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>
Sent: Saturday, February 22, 2020 5:49 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: MSNBC Reconfirming

Good Morning Dr. Fauci,

I am just reconfirming you for your segment on MSNBC this morning with Kendis Gibson and Cori Coffin.

You are hitting at 7:45am from the NBC News Bureau at 4001 Nebraska Avenue.

Topics:

-Coronavirus-infected Americans flown home against CDC advice

https://www.washingtonpost.com/health/coronavirus-diamond-princess-cruise-americans/2020/02/20/b6f54cae-5279-11ea-b119-4faabac6674f_story.html

-Decision to quarantine cruise ship—was that a misstep?

-Long term effects of decision to bring U.S. passengers back

Please reply that you got this.
Thank you!
Cyndi

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Sent: Friday, February 21, 2020 3:09 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Cc: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: RE: contact at the studio tomorrow/MSNBC intv

We absolutely will do. Thank you so much and thank you for your patience. We will be in touch first thing in the morning.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Friday, February 21, 2020 3:04 PM
To: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Cc: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: [EXTERNAL] RE: contact at the studio tomorrow/MSNBC intv

Ok – I am adding Dr Fauci to this email - please confirm to both of us in the morning. Thank you

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Sent: Friday, February 21, 2020 2:55 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Cc: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>
Subject: RE: contact at the studio tomorrow/MSNBC intv

We won't have an exact hit time until the morning BUT as of now, it's 7:30am. It might be 7:35am but that is the hit time.

Cyndi will send it to you by 5am tomorrow.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Sent: Friday, February 21, 2020 2:48 PM
To: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Cc: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>
Subject: [EXTERNAL] RE: contact at the studio tomorrow/MSNBC intv

Will you or Cyndi send exact hit time tonight? What is the approx. time we will get that?

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892

(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept

liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Sent: Friday, February 21, 2020 10:42 AM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Cc: Robinson, Whitney (NIH/NIAID) [C] (b) (6); Deatrick, Elizabeth (NIH/NIAID) [C] (b) (6); Lavelle, Judith (NIH/NIAID) [E] (b) (6)>
Subject: RE: contact at the studio tomorrow/MSNBC intv

Thank you so much

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Friday, February 21, 2020 10:35 AM
To: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Cc: Robinson, Whitney (NIH/NIAID) [C] (b) (6); Deatrick, Elizabeth (NIH/NIAID) [C] (b) (6); Lavelle, Judith (NIH/NIAID) [E] (b) (6)>
Subject: [EXTERNAL] RE: contact at the studio tomorrow/MSNBC intv

Great – thanks.

Please just let us know the exact time and we will have him arrive 20 mins prior.

His cell is (b) (6) and mine is (b) (6)

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>

Sent: Friday, February 21, 2020 10:29 AM

To: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>

Cc: Robinson, Whitney (NIH/NIAID) [C] (b) (6); Deatrick, Elizabeth (NIH/NIAID) [C] (b) (6); Lavelle, Judith (NIH/NIAID) [E] (b) (6)>

Subject: contact at the studio tomorrow/MSNBC intv

Importance: High

Patricia, hi,

The contact at the studio in the morning is Natalia Abrams. The number at the office is 202-885-4800. Also, Cyndi Antoniak will be in touch with you in the morning and send you an email about the segment and just to touch base. If you need to reach Cyndi before she reaches you, her number is 212-664- 1450 and her email is Cynthia.antoniak@nbcuni.com.

Thank you so much for making the interview work out, we appreciate it.

Shannah

From: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>

Sent: Friday, February 21, 2020 9:06 AM

To: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>

Cc: Robinson, Whitney (NIH/NIAID) [C] (b) (6); Deatrick, Elizabeth (NIH/NIAID) [C]

(b) (6)>; Lavelle, Judith (NIH/NIAID) [E]

(b) (6)>

Subject: [EXTERNAL] RE: hi and request for Dr. Fauci this weekend on MSNBC

Hi Shannah

Saturday Morning between 7:30 am ET – 8 am ET is best for Dr Fauci and will need to be from the NBC Studio at 4001 Nebraska Ave NW studio. He has a hard stop no later than 8:15 am. Please send us the onsite contact name and number and firm hit time when you can.

Thanks,
-patty

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892

(b) (6)

301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>

Sent: Thursday, February 20, 2020 4:17 PM

To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>

Cc: Barasch, Kimberly (NIH/NIAID) [C] (b) (6)>; Deatrick, Elizabeth (NIH/NIAID) [C]

(b) (6)

Subject: RE: hi and request for Dr. Fauci this weekend on MSNBC

That's terrific and yes, that studio is best if he can join us. Thank you so much. Shannah

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)

Sent: Thursday, February 20, 2020 4:16 PM

To: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>

Cc: Barasch, Kimberly (NIH/NIAID) [C] (b) (6)>; Deatrick, Elizabeth (NIH/NIAID) [C]

(b) (6)

Subject: [EXTERNAL] RE: hi and request for Dr. Fauci this weekend on MSNBC

I am sure we can make one of these work – will let you know tomorrow.
We would do from the NBC Nebraska Ave NW Studio.

thx

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Sent: Thursday, February 20, 2020 4:12 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Cc: Barasch, Kimberly (NIH/NIAID) [C] (b) (6); Deatrick, Elizabeth (NIH/NIAID) [C]
(b) (6)
Subject: hi and request for Dr. Fauci this weekend on MSNBC
Importance: High

Patricia, hi, I hope all is well with you.

Is Dr. Fauci available this weekend to be on MSNBC to discuss the latest re Corona virus -

https://www.washingtonpost.com/health/coronavirus-diamond-princess-cruise-americans/2020/02/20/b6f54cae-5279-11ea-b119-4faabac6674f_story.html

We'd like him on either on Saturday, in the 7:30am to 8am half hour, with Kendis Gibson/Cori Coffin, or on Sunday in the 12pm or 1pm hour with Alex Witt. Whatever day/hour that is good for him, we'll make work.

Thank you so much for your help in this matter.

All the best,

Shannah

Shannah Goldner
MSNBC
W: 212-664-1289
C: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 11:39:06 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: MSNBC Reconfirming

I just did reconfirm with a copy to you. Did you not get it?

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Sent: Saturday, February 22, 2020 6:38 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Fwd: MSNBC Reconfirming

You need to respond to this. It's in your on box

Sent from my iPhone

Begin forwarded message:

From: "Antoniak, Cynthia (NBCUniversal, MSNBC)" <Cynthia.Antoniak@MSNBC.COM>
Date: February 22, 2020 at 5:49:00 AM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) >
Cc: "Goldner, Shannah (NBCUniversal)" <shannah.goldner@nbcuni.com>, "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)
Subject: MSNBC Reconfirming

Good Morning Dr. Fauci,

I am just reconfirming you for your segment on MSNBC this morning with Kendis Gibson and Cori Coffin.

You are hitting at 7:45am from the NBC News Bureau at 4001 Nebraska Avenue.

Topics:

-Coronavirus-infected Americans flown home against CDC advice

https://www.washingtonpost.com/health/coronavirus-diamond-princess-cruise-americans/2020/02/20/b6f54cae-5279-11ea-b119-4faabac6674f_story.html

-Decision to quarantine cruise ship—was that a misstep?

-Long term effects of decision to bring U.S. passengers back

Please reply that you got this.

Thank you!

Cyndi

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Sent: Friday, February 21, 2020 3:09 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)

Cc: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>; Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: RE: contact at the studio tomorrow/MSNBC intv

We absolutely will do. Thank you so much and thank you for your patience. We will be in touch first thing in the morning.

From: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Sent: Friday, February 21, 2020 3:04 PM
To: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Cc: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>; Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: [EXTERNAL] RE: contact at the studio tomorrow/MSNBC intv

Ok – I am adding Dr Fauci to this email - please confirm to both of us in the morning. Thank you

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Sent: Friday, February 21, 2020 2:55 PM
To: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Cc: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>
Subject: RE: contact at the studio tomorrow/MSNBC intv

We won't have an exact hit time until the morning BUT as of now, it's 7:30am. It might be 7:35am but that is the hit time.
Cyndi will send it to you by 5am tomorrow.

From: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Sent: Friday, February 21, 2020 2:48 PM

To: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Cc: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>
Subject: [EXTERNAL] RE: contact at the studio tomorrow/MSNBC intv

Will you or Cyndi send exact hit time tonight? What is the approx. time we will get that?

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Sent: Friday, February 21, 2020 10:42 AM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Cc: Robinson, Whitney (NIH/NIAID) [C] (b) (6); Deatrick, Elizabeth (NIH/NIAID) [C] <(b) (6)>; Lavelle, Judith (NIH/NIAID) [E] (b) (6)
Subject: RE: contact at the studio tomorrow/MSNBC intv

Thank you so much

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Friday, February 21, 2020 10:35 AM
To: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Cc: Robinson, Whitney (NIH/NIAID) [C] (b) (6); Deatrick, Elizabeth (NIH/NIAID) [C] (b) (6); Lavelle, Judith (NIH/NIAID) [E] (b) (6)
Subject: [EXTERNAL] RE: contact at the studio tomorrow/MSNBC intv

Great – thanks.

Please just let us know the exact time and we will have him arrive 20 mins prior.

His cell is (b) (6) and mine is (b) (6)

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Sent: Friday, February 21, 2020 10:29 AM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Cc: Robinson, Whitney (NIH/NIAID) [C] (b) (6)>; Deatrick, Elizabeth (NIH/NIAID) [C] (b) (6); Lavelle, Judith (NIH/NIAID) [E] (b) (6)>
Subject: contact at the studio tomorrow/MSNBC intv
Importance: High

Patricia, hi,
The contact at the studio in the morning is Natalia Abrams. The number at the office is 202-885-4800.
Also, Cyndi Antoniak will be in touch with you in the morning and send you an email about the segment and just to touch base. If you need to reach Cyndi before she reaches you, her number is 212-664- 1450 and her email is Cynthia.antoniak@nbcuni.com .
Thank you so much for making the interview work out, we appreciate it.
Shannah

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Friday, February 21, 2020 9:06 AM
To: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Cc: Robinson, Whitney (NIH/NIAID) [C] <(b) (6)>; Deatrick, Elizabeth (NIH/NIAID) [C] <(b) (6)>; Lavelle, Judith (NIH/NIAID) [E]

(b) (6)

Subject: [EXTERNAL] RE: hi and request for Dr. Fauci this weekend on MSNBC

Hi Shannah

Saturday Morning between 7:30 am ET – 8 am ET is best for Dr Fauci and will need to be from the NBC Studio at 4001 Nebraska Ave NW studio. He has a hard stop no later than 8:15 am. Please send us the onsite contact name and number and firm hit time when you can.

Thanks,
-patty

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892

(b) (6)

301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>

Sent: Thursday, February 20, 2020 4:17 PM

To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)

Cc: Barasch, Kimberly (NIH/NIAID) [C] (b) (6); Deatrick, Elizabeth (NIH/NIAID) [C] (b) (6)

Subject: RE: hi and request for Dr. Fauci this weekend on MSNBC

That's terrific and yes, that studio is best if he can join us. Thank you so much. Shannah

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)

Sent: Thursday, February 20, 2020 4:16 PM

To: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>

Cc: Barasch, Kimberly (NIH/NIAID) [C] (b) (6); Deatrick, Elizabeth

(NIH/NIAID) [C] <[REDACTED] (b) (6)>

Subject: [EXTERNAL] RE: hi and request for Dr. Fauci this weekend on MSNBC

I am sure we can make one of these work – will let you know tomorrow.

We would do from the NBC Nebraska Ave NW Studio.

thx

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[REDACTED] (b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>

Sent: Thursday, February 20, 2020 4:12 PM

To: Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)>

Cc: Barasch, Kimberly (NIH/NIAID) [C] <[REDACTED] (b) (6)>; Deatrick, Elizabeth (NIH/NIAID) [C] <[REDACTED] (b) (6)>

Subject: hi and request for Dr. Fauci this weekend on MSNBC

Importance: High

Patricia, hi, I hope all is well with you.

Is Dr. Fauci available this weekend to be on MSNBC to discuss the latest re Corona virus - https://www.washingtonpost.com/health/coronavirus-diamond-princess-cruise-americans/2020/02/20/b6f54cae-5279-11ea-b119-4faabac6674f_story.html

We'd like him on either on Saturday, in the 7:30am to 8am half hour, with Kendis Gibson/Cori Coffin, or on Sunday in the 12pm or 1pm hour with Alex Witt. Whatever day/hour that is good for him, we'll make work.

Thank you so much for your help in this matter.

All the best,

Shannah

Shannah Goldner

MSNBC

W: 212-664-1289

C: [REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 02:39:22 +0000
To: Morens, David (NIH/NIAID) [E]
Subject: FW: So what do you guys think ? (I no it's not influenza, but a lot of your 2007 conclusions seem very valid now...)

David:

Please respond to this person.

Thanks,

Tony

-----Original Message-----

From: (b) (6)

Sent: Friday, February 21, 2020 9:32 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Subject: So what do you guys think ? (I no it's not influenza, but a lot of your 2007 conclusions seem very valid now...)

Dear David Morens, dear Anthony Fauci,

I realise it is not an influenza virus, but the outlook of your 2007 paper ("The 1918 Influenza Pandemic: Insights for the 21st Century") seems to me to be very valid for the current coronavirus outbreak. Or put differently - your statements and concerns from then mostly coincide with my thinking and worries now... :(.

So a question - what is your thinking now? Are the hospitals you're affiliated with hiring additional staff (yet)? Any personal preparations?

Good luck to you and all the best for those close to you, kind regards, Sean Scherer

P.S. I guess part of the the reason I'm asking is, because I (a non-institutionally affiliated biologist), am in touch with the university-hospital here (b) (6) Germany), but my concerns are so far falling on deaf ears... But also just reading the paper and seeing others come to the same conclusions - albeit on more theoretical grounds and multiple years ago - made me want to reach out. Plus I guess I'm simply curious about what you think !

From: (b) (6)
Sent: Fri, 21 Feb 2020 14:38:56 -0500
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]
Subject: Re: Work related question

You are correct. No chance that I would accept. Thanks

On Feb 21, 2020, at 2:23 PM, Billet, Courtney (NIH/NIAID) [E]
(b) (6) wrote:

In the interest of full disclosure: Stephanie (b) (6) used to work here at HHS and is now a VP with the American College of Preventive Medicine. For the life of me I couldn't see you saying yes to a weekend trip to Denver in May, and I would hate to have them waste their time sending an invite when they could be pursuing someone more likely to accept. Hope this is OK.

From: Billet, Courtney (NIH/NIAID) [E]
Sent: Friday, February 21, 2020 2:18 PM
To: Stephanie Marshall (b) (6) >
Subject: RE: Work related question

Hi – good to hear from you! I hesitate to speak definitively for him and his scheduler, but to be perfectly honest I think it's really unlikely that'd he'd be able to accept a speaking invite for Denver. The schedule is insane for the foreseeable future and isn't letting up on the weekends. He's turning invitations down left and right, unfortunately – especially those involving travel!

From: Stephanie Marshall (b) (6)
Sent: Friday, February 21, 2020 1:51 PM
To: Billet, Courtney (NIH/NIAID) [E] (b) (6) >
Subject: Work related question

Hi Courtney,

I hope you're doing well despite the ongoing craziness whether it's coronavirus or politics. Yikes, these are unsettled times.

I have a quick question for you. Our annual meeting is May 14 - 17 in Denver. Many of the sessions are in place but there's talk about doing a session around

coronavirus and inviting Dr. Fauci as the speaker. The meeting is a Thursday through Sunday and they're looking at inviting him to speak potentially on Sunday morning. Is this something he would even consider and would he commit this far out given everything that's going on? Any quick thoughts you might have would be helpful.

Thank you, thank you! Have a great weekend.

Stephanie

From: (b) (6)
Sent: Fri, 21 Feb 2020 10:40:17 -0500
To: Collins, Francis (NIH/OD) [E]
Cc: Hallett, Adrienne (NIH/OD) [E]; Tabak, Lawrence (NIH/OD) [E]
Subject: Re: FYI on Senate staff visit

Thanks, Francis.

On Feb 21, 2020, at 10:30 AM, Collins, Francis (NIH/OD) [E]
<(b) (6)>

Hi Tony,

I got asked by Alex Keenan what the NIH needs for the coronavirus response. I said that this had been looked at with great care by you and your staff. If you are asking me for technical assistance, I said, we need about (b) (5) for FY20-21, and more in the long run.

ASFR was in the room but did not have a visible seizure.

Just thought you'd want to know before you meet with the staffers later today.

FC

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 21 Feb 2020 14:31:08 +0000
To: Donna Jacobsen
Cc: Conrad, Patricia (NIH/NIAID) [E]; Greg Folkers
(b) (6); Marston, Hilary (NIH/NIAID) [E]
Subject: RE: CROI COVID 19 Session; Tuesday March 10 lunch

Donna:

Thanks for the note. I will be able to provide a 15 minute video with slides that discusses the NIH/NIAID efforts to study the novel coronavirus and to develop countermeasures in the form of diagnostics, therapeutics, and vaccines. Your team can work with Patty Conrad, Hilary Marston and Greg Folkers on the logistics. In the meantime, we will prepare the video.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Donna Jacobsen <djacobsen@iasusa.org>
Sent: Thursday, February 20, 2020 8:53 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: RE: CROI COVID 19 Session; Tuesday March 10 lunch
Importance: High

Dear Dr Fauci:

We've had a lot of discussion around our COVID-19 session today. An idea that came up was possibly having you do something remotely. Either a live feed in from your office at approximately 1:05 PM to 1:20 PM EDT on Tuesday, March 10 if you have that time available, or have you send in a video recorded presentation a day or 2 before that we can show at the session. Having some way to communicate the

high priority NIH/NIAID has on developing a vaccine and treatment would help bring the content together.

We know this is likely not possible, with the very short notice and your even more tremendously busy schedule around all of this. But it's worth the ask.

Please let me know if you think either of these is possible. And Patty, sorry for butchering your email address earlier.

Best,

Donna

Donna M. Jacobsen
Executive Director/President
International Antiviral (formerly AIDS) Society-USA
Executive Manager, CROI
131 Steuart St, Ste 500
San Francisco, CA 94105
415-544-9400

<https://www.iasusa.org>



About IAS-USA: Established in 1992, the IAS-USA is a not-for-profit, professional education organization. The mission of the IAS-USA is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV, hepatitis C virus, or other viral infections through high-quality, relevant, balanced, and needs-oriented education and information for practitioners who are actively involved in medical care. The organization's educational activities are particularly intended to bridge clinical research and patient care.

Confidentiality Notice: This e-mail and its attachments may contain privileged and confidential information intended solely for the use of the IAS-USA and the recipient(s) named above. If you are not the intended recipient, or the employee or agent responsible for delivering this message to the intended recipients, you are hereby notified that any review, dissemination, distribution, printing, or copying of this e-mail message and/or any attachments is strictly prohibited. If you have received this transmission in error, please notify the sender immediately and permanently delete this e-mail and any attachments.

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Sent: Thursday, February 20, 2020 7:12 AM

To: Donna Jacobsen <djacobsen@iasusa.org>

Cc: (b) (6); 'Elaine J. Abrams, MD (b) (6);

Sharon Hillier PhD (b) (6); Hoxie, James

(b) (6); Benson, Connie (b) (6); Kevin Bowen

<kbowen@iasusa.org>

Subject: RE: CROI COVID 19 Session; Tuesday March 10 lunch

Donna:

Thanks for the note. Unfortunately, I need to be in Washington, DC on March 10, and so I will regrettably have to decline your kind invitation. Thank you for thinking of me.

Best regards,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Donna Jacobsen <djacobsen@iasusa.org>

Sent: Tuesday, February 18, 2020 8:09 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Cc: (b) (6); 'Elaine J. Abrams, MD (b) (6)

Sharon Hillier PhD (b) (6); Hoxie, James

(b) (6); Benson, Connie (b) (6); Kevin Bowen

<kbowen@iasusa.org>

Subject: RE: CROI COVID 19 Session; Tuesday March 10 lunch

Dear Dr Fauci:

As I mentioned on the phone, we just today decided that we will have a special session on COVID 19 at CROI. It will be on Tuesday, March 10, during the lunch break; the initial general structure will be a 10- to 15- minute overview (CDC), a 25-min talk by Ralph Barac (UNC) about the virology of coronaviruses, and a 10- to 15-minute summary on what NIAID/NIH is doing and planning. We thought that this being

one of the first large medical conferences in infectious diseases this year, that we address COVID 19 at CROI

We know that this is terribly last minute, but the CROI Chairs and Foundation are hoping you are free to give the NIAID/NIH update. CROI is in Boston, March 8 to 11.

If you think you would be able to do this, we will send a more formal communication with details and work with Patty on the specifics. Thank you so much Dr Fauci; we hope you will be able to join us.

Best,

Donna

Donna M. Jacobsen
Executive Director/President
International Antiviral (formerly AIDS) Society-USA
131 Steuart St, Ste 500
San Francisco, CA 94105
415-544-9400

<https://www.iasusa.org>



About IAS–USA: Established in 1992, the IAS–USA is a not-for-profit, professional education organization. The mission of the IAS-USA is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV, hepatitis C virus, or other viral infections through high-quality, relevant, balanced, and needs-oriented education and information for practitioners who are actively involved in medical care. The organization's educational activities are particularly intended to bridge clinical research and patient care.

Confidentiality Notice: This e-mail and its attachments may contain privileged and confidential information intended solely for the use of the IAS-USA and the recipient(s) named above. If you are not the intended recipient, or the employee or agent responsible for delivering this message to the intended recipients, you are hereby notified that any review, dissemination, distribution, printing, or copying of this e-mail message and/or any attachments is strictly prohibited. If you have received this transmission in error, please notify the sender immediately and permanently delete this e-mail and any attachments.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 21 Feb 2020 13:33:20 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: FDA Request
Attachments: FDA Clearance Letter.pdf, Nepal Corona Virus Paper.pdf

Please handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeff Fischer (b) (6)
Sent: Friday, February 21, 2020 8:30 AM
To: Messonnier, Nancy (CDC/DDID/NCIRD/OD) (b) (6); Khabbaz, Rima (CDC/DDID/NCEZID/OD) (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Chris Helm (b) (6) >
Subject: FDA Request

Drs Messonnier, Khabbaz, and Fauci,

The Center for Devices and Radiological Health at the FDA suggested that we reach out to COVID-19 EUA developers to (b) (4)

(b) (4)

(b) (4)

Respectfully,

Jeff

Jeff Fischer
President
Longhorn Vaccines and Diagnostics LLC
2 Bethesda Metro Center Suite 910
Bethesda, MD 20814

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 21 Feb 2020 10:47:53 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Fwd:
Attachments: Notes for NIH.docx

Please handle.

From: RICK SAWAYA (b) (6) >
Sent: Friday, February 21, 2020 1:48 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Cassetti, Cristina (NIH/NIAID) [E]
(b) (6)
Subject: Fwd:

2202020

Dr. Fauci:

This is Dr. Rick Sawaya :

Dr. Tom Betz is (b) (6) and his training is more in line with yours than mine.
He submitted this mini-endorsement to you for me and my work. He has seen most of my works
and the NIH data protocol from 2016-2017.
I think his background gives credibility to my ideas and lends a public health opinion which I did not have
until
calling him.

Hope you enjoy this.

I have treated cancers, herpes, acne easily with this stuff and honestly and confidentially
it will do anything but your income tax.

Thanks, Rick Sawaya M.D.

(b) (6)
call between 10am and 10pm EST,

----- Forwarded message -----

From: Tom Betz (b) (6)
Date: Thu, Feb 20, 2020 at 10:32 PM
Subject: Re:
To: RICK SAWAYA (b) (6)

Rick,

I am attaching suggested notes for NIH. They may think we're both crazy but I imagine you have already
been down that road and I'm interested to see what happens. Hang in there,

Tom

On Tue, Feb 18, 2020 at 2:01 PM RICK SAWAYA <[REDACTED]> wrote:

THIS HAS THE CELL WITH LEARS SIGNATURE ABOVE IT
AND A CYSTEINE RANDOM DIAGRAM

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 21 Feb 2020 02:42:07 +0000
To: NIAID OD AM
Subject: FW: CROI COVID 19 Session; Tuesday March 10 lunch
Importance: High

Let us discuss.

From: Donna Jacobsen <djacobsen@iasusa.org>
Sent: Thursday, February 20, 2020 8:53 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Subject: RE: CROI COVID 19 Session; Tuesday March 10 lunch
Importance: High

Dear Dr Fauci:

We've had a lot of discussion around our COVID-19 session today. An idea that came up was possibly having you do something remotely. Either a live feed in from your office at approximately 1:05 PM to 1:20 PM EDT on Tuesday, March 10 if you have that time available, or have you send in a video recorded presentation a day or 2 before that we can show at the session. Having some way to communicate the high priority NIH/NIAID has on developing a vaccine and treatment would help bring the content together.

We know this is likely not possible, with the very short notice and your even more tremendously busy schedule around all of this. But it's worth the ask.

Please let me know if you think either of these is possible. And Patty, sorry for butchering your email address earlier.

Best,

Donna

Donna M. Jacobsen
Executive Director/President
International Antiviral (formerly AIDS) Society-USA
Executive Manager, CROI
131 Steuart St, Ste 500
San Francisco, CA 94105
415-544-9400

<https://www.iasusa.org>



About IAS–USA: Established in 1992, the IAS–USA is a not-for-profit, professional education organization. The mission of the IAS-USA is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV, hepatitis C virus, or other viral infections through high-quality, relevant, balanced, and needs-oriented education and information for practitioners who are actively involved in medical care. The organization's educational activities are particularly intended to bridge clinical research and patient care.

Confidentiality Notice: This e-mail and its attachments may contain privileged and confidential information intended solely for the use of the IAS-USA and the recipient(s) named above. If you are not the intended recipient, or the employee or agent responsible for delivering this message to the intended recipients, you are hereby notified that any review, dissemination, distribution, printing, or copying of this e-mail message and/or any attachments is strictly prohibited. If you have received this transmission in error, please notify the sender immediately and permanently delete this e-mail and any attachments.

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Sent: Thursday, February 20, 2020 7:12 AM
To: Donna Jacobsen <djacobsen@iasusa.org>
Cc: (b) (6); Elaine J. Abrams, MD (b) (6)
Sharon Hillier PhD (b) (6); Hoxie, James
<(b) (6)>; Benson, Connie (b) (6); Kevin Bowen
<kbowen@iasusa.org>
Subject: RE: CROI COVID 19 Session; Tuesday March 10 lunch

Donna:

Thanks for the note. Unfortunately, I need to be in Washington, DC on March 10, and so I will regrettably have to decline your kind invitation. Thank you for thinking of me.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Donna Jacobsen <djacobsen@iasusa.org>

Sent: Tuesday, February 18, 2020 8:09 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >

Cc: (b) (6) Elaine J. Abrams, MD (b) (6)

Sharon Hillier PhD (b) (6); Hoxie, James

(b) (6); Benson, Connie (b) (6); Kevin Bowen

<kbowen@iasusa.org>

Subject: RE: CROI COVID 19 Session; Tuesday March 10 lunch

Dear Dr Fauci:

As I mentioned on the phone, we just today decided that we will have a special session on COVID 19 at CROI. It will be on Tuesday, March 10, during the lunch break; the initial general structure will be a 10- to 15- minute overview (CDC), a 25-min talk by Ralph Barac (UNC) about the virology of coronaviruses, and a 10- to 15-minute summary on what NIAID/NIH is doing and planning. We thought that this being one of the first large medical conferences in infectious diseases this year, that we address COVID 19 at CROI

We know that this is terribly last minute, but the CROI Chairs and Foundation are hoping you are free to give the NIAID/NIH update. CROI is in Boston, March 8 to 11.

If you think you would be able to do this, we will send a more formal communication with details and work with Patty on the specifics. Thank you so much Dr Fauci; we hope you will be able to join us.

Best,

Donna

Donna M. Jacobsen
Executive Director/President
International Antiviral (formerly AIDS) Society-USA
131 Steuart St, Ste 500
San Francisco, CA 94105
415-544-9400

<https://www.iasusa.org>





About IAS–USA: Established in 1992, the IAS–USA is a not-for-profit, professional education organization. The mission of the IAS-USA is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV, hepatitis C virus, or other viral infections through high-quality, relevant, balanced, and needs-oriented education and information for practitioners who are actively involved in medical care. The organization's educational activities are particularly intended to bridge clinical research and patient care.

Confidentiality Notice: This e-mail and its attachments may contain privileged and confidential information intended solely for the use of the IAS-USA and the recipient(s) named above. If you are not the intended recipient, or the employee or agent responsible for delivering this message to the intended recipients, you are hereby notified that any review, dissemination, distribution, printing, or copying of this e-mail message and/or any attachments is strictly prohibited. If you have received this transmission in error, please notify the sender immediately and permanently delete this e-mail and any attachments.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 21 Feb 2020 01:47:03 +0000
To: McNeil Jr, Donald G
Subject: RE: question re the WashPost story

Donald:

You know that I always answer your calls and e-mails, but this one I want to stay away from.
Sorry.
Best,
Tony

From: McNeil Jr, Donald G <mcneil@nytimes.com>
Sent: Thursday, February 20, 2020 4:51 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: question re the WashPost story

Now that I've had a chance to read the whole story -- after editors finished whirling -- I see it also contains these grafs:

Are they accurate?

Thanks

During one call, the CDC's principal deputy director, **Anne Schuchat**, argued against taking the infected Americans on the plane, according to two participants. She noted the U.S. government had already told passengers they would not be evacuated with anyone who was infected or showed symptoms. She was also concerned about infection control. **Anthony Fauci**, head of the National Institute of Allergy and Infectious Diseases, who was also on the calls, **recalled** saying her points were valid and should be considered. But **Robert Kadlec**, assistant secretary for preparedness and response for the Department of Health and Human Services and a member of the coronavirus task force, pushed back: Officials had already prepared the plane to handle passengers who might develop symptoms on the long flight, he argued. The two Boeing 747s had 18 seats cordoned off with 10-foot-high plastic on all four sides. Infectious disease doctors would also be onboard.

On Thu, Feb 20, 2020 at 4:24 PM McNeil Jr, Donald G <mcneil@nytimes.com> wrote:

Hi, Tony:

The Washington Post has just put up a story saying that the 14 infected passengers on the buses containing 238 American passengers from the Diamond Princess were flown home AGAINST the CDC's advice. And that the States Department overruled the CDC on this.

Can you confirm whether that's true?

Thanks...

Donald

Story contains these crucial grafts:

In Washington, where it was still Sunday afternoon, a fierce debate broke out: The State Department and a top Trump administration health official wanted to forge ahead. The infected passengers had no symptoms and could be segregated on the plane in a plastic-lined enclosure. But officials at the Centers for Disease Control and Prevention disagreed, contending they could still spread the virus. The CDC believed the 14 should not be flown back with uninfected passengers.

“It was like the worst nightmare,” said a senior U.S. official involved in the decision, speaking on the condition of anonymity to describe private conversations. “Quite frankly, the alternative could have been pulling grandma out in the pouring rain, and that would have been bad, too.”

--

Donald G. McNeil Jr.
Science Correspondent
The New York Times

Tel: +1 212 556 1142
mcneil@nytimes.com

Articles: <https://www.nytimes.com/by/donald-g-mcneil-jr>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 21 Feb 2020 00:13:55 +0000
To: Richard Allen Johnson
Subject: RE: 02.20.2020 Thursday

Dick:

Thanks for the note. Always good to hear from you.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Richard Allen Johnson (b) (6)
Sent: Thursday, February 20, 2020 6:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Sandra Goldstein (b) (6)
Subject: 02.20.2020 Thursday

Hi, Tony,

(b) (6) this week.

We watched a life size ASF as you discussed and reassured us about Covid-19. You are simply the best. Were you running for president, I am sure that you would win the yote.

Don't forget our lunch in Boston.

Best,
Dick

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 20 Feb 2020 23:48:29 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]
Subject: FW: Urgent- Phone Interview Request on Coronavirus

Done!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Qi Zhang <qizhang@caixin.com>
Sent: Thursday, February 20, 2020 3:16 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Urgent- Phone Interview Request on Coronavirus

Dear Dr. Fauci,

Good afternoon. I am Olivia Zhang with Caixin Media, which is the front-liner of the Coronavirus reporting in China. We spoke at the very beginning of the virus and I wanted to talk to you regarding the latest situation, especially from test, treatment point of view. I also left you a voice message. Feel free to call me via (b) (6) whenever you're free.

I look forward to hearing from you.

Best,
Olivia

Qi ZHANG (Olivia)
U.S. Correspondent
Caixin Media Company Limited

Email: qizhang@caixin.com

Mobile: + (b) (6)

Twitter: @zhang_qiii

www.caixin.com | caixinglobal.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 20 Feb 2020 23:28:04 +0000
To: Achenbach, Joel
Subject: RE: quick question: when does an epidemic become a "pandemic" officially?

It is impossible to predict at this point if the current outbreak will progress to a true pandemic. The future of this outbreak and whether it will progress to a pandemic will be determined by two factors: 1) the degree to which China controls infections in China, which will ultimately impact how many infections leak out to other countries in the world. 2) The success or not of other countries that have received travel-related cases from China in preventing the development of sustained transmission of infections in their own country. If these other countries are successful in containing the transmissions, then a pandemic will be avoided. If a large number of countries are unsuccessful in preventing sustained multi-generation transmissions, then we could witness the next pandemic.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Achenbach, Joel <Joel.Achenbach@washpost.com>
Sent: Thursday, February 20, 2020 6:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: RE: quick question: when does an epidemic become a "pandemic" officially?

Oh....and...the big question: How likely is it that covid-19 will become a pandemic? Would love an on-the-record assessment. Thanks...joel

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Sent: Thursday, February 20, 2020 6:06 PM
To: Achenbach, Joel <Joel.Achenbach@washpost.com>
Subject: RE: quick question: when does an epidemic become a "pandemic" officially?

CAUTION: EXTERNAL SENDER

Joel:

There are many iterations of the definition of a “pandemic”. However, one that I use that is simple and understandable is as follows: An outbreak of a serious infectious disease with substantial global health consequences (usually one that has never before been experienced by the human population) that is transmitted readily from person to person and where there is sustained transmission (i.e. multiple generations of person to person to person) in multiple countries and regions of the world. In this regard, the coronavirus outbreak in China is an “epidemic” in China, but it is not yet a pandemic since there is not “sustained” person to person transmission throughout the world. There are infections in other countries (more than 25 countries), but these started as travel related cases from China and although there are several human to human infections in these other countries, these infections have not yet been “sustained”. If we start seeing sustained, multiple generations of transmissions in many countries throughout the world, then the outbreak will have progressed to fill the criteria of a true pandemic.

Hope that this is helpful.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Achenbach, Joel <Joel.Achenbach@washpost.com>

Sent: Thursday, February 20, 2020 5:51 PM

To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>

Subject: quick question: when does an epidemic become a "pandemic" officially?

Dear Tony Fauci:

Hi! Busy times. Hope you are well. Can you explain to me how we will know if and when covid-19 has become pandemic, versus whatever you'd call the current situation? Just in general, what's the definition of a pandemic?

Thank you...best, Joel

(and thanks for calling me back last weekend, sorry I missed you)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 20 Feb 2020 16:45:39 +0000
To: Michael Gerson
Subject: RE: Tony, I'm still working on this, but need your reaction
Attachments: Gerson with minor Fauci edits.docx

Mike:

Thanks for sending this. It looks good. I have copied it to a WORD document and have made some minor suggested edits for your consideration.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Michael Gerson (b) (6) >
Sent: Thursday, February 20, 2020 11:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Tony, I'm still working on this, but need your reaction

Meanwhile, on the other side of the earth, there have been 73,000 cases of coronavirus and more than 2000 deaths. This leaves American health experts hoping that the number of infections has been dramatically underreported.

That is not a typo. If the current numbers are close to accurate, it indicates a coronavirus mortality rate upwards of 2 percent. The morality rate for the seasonable flu is generally .1 percent. The mortality rate for pandemic flu is .3 percent. The particularly deadly flu pandemic of 1918 –

which took the lives of more than 100 million people around the world – had a mortality rate of 1.8 to 2 percent.

So, if 2000 deaths is the numerator, scientists hope that the denominator is actually much larger. And that is probable, given the likelihood that there are many more people who have the infection but don't know it, or are not showing symptoms.

The good news? The outbreak started in a single location and seems largely contained there. There have been several hundred cases in more than 25 countries outside of China. But the overwhelming majority have been travel related. The containment measures of Singapore, Hong Kong and Japan – which have the most cases – seem to have been successful. Of the 15 American cases (before the arrival of the cruise ship passengers), 13 are travel related. The two others are spouses of people in that group. We still have not seen widespread, sustained transmission from person to person outside of China.

The Chinese reaction to the virus has shown the weaknesses and advantages of authoritarianism. The immediate response of a system built on fear is to a problem like this one is denial and deception. No one wants to carry bad news. So local Chinese officials spent the first week of the outbreak – as the disease was spreading under the radar – insisting that the transmission of the virus was all animal to human.

But only in a society like China could you have the effective lockdown of 50 million people, including the entire city of Wuhan, to slow the spread of the disease. Public health officials in most places – who are required to balance health needs with civil liberties – would not even consider such a measure. Yet it appears to be working.

The danger? “All that is needed is for a few countries in the developing world that can't contain the coronavirus,” Tony Fauci told me. “This could be the second wave of the pandemic.”

Pandemic diseases tend to attack the weakest links – the most vulnerable health systems – in the global chain. If there is sustained transmission in those places, says Fauci, “even countries with best practices will suffer.” Countries in Africa are of particular concern. There are millions of Chinese in Africa, and many Africans study in China. Countries such as Ethiopia, Senegal and South Africa seem to be doing a good job at testing random samples for coronavirus in key cities. But Liberia? Guinea? Sierra Leone?

Seldom has there been a stronger argument for American global engagement to strengthen African health systems, which constitute part of own immune system against pandemics. Seldom has there been a better

argument to abandon “America First” posturing and to recognize that our own fate is closely tied to the fate of other nations.

Much about the future course of the disease depends on the answer to a scientific question: Is someone who has the virus but lacks symptoms – or has symptoms so mild they hardly notice – capable of transmitting the virus to others? “It looks like the answer is yes,” says Fauci. Which would make the virus far harder to control.

“We may find that the virus is highly transmissible, but less lethal than we thought in the beginning,” Fauci told me. In this case, the danger would be similar to a particularly bad influenza. And the outbreaks could be seasonal, like the flu as well. “I would not be surprised if that happened,” Fauci concluded.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 20 Feb 2020 15:15:05 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: inquiry/suggestion re Corona virus->

Please handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Alan DiCara (b) (6)
Sent: Wednesday, February 19, 2020 8:19 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: NIAID Ocpostoffice (NIH/NIAID) <OCPOSTOFFICE@niaid.nih.gov>
Subject: inquiry/suggestion re Corona virus->

2.19.2020

Dear Dr Fauci,

Thanks so much for being who you are and for dedicating your life to protecting all of us. I write because I saw your interview on PBS tonight and had a question pertaining to denominators and numerators. Please know that I profess absolutely no expertise in areas pertaining to biology nor medicine nor disease and while I understood and agree with your estimation that the fatality rate of the Corona virus to date may be somewhat inflated of the number of cases is understated, I have a related

question for you regarding info I was able to find at this site <https://www.worldometers.info/coronavirus/>

Regarding data this site reports, among many things, and as one scrolls down, that the 'number of active cases' reported today is 57,228 and the number of these that are 'serious or critical' is 12,064. In a worst case scenario, and taking the 12,064 as the numerator and dividing it by a denominator of 57,228, we get 21.08, or about 21%, much higher than the 1% based on total deaths over total cases so far. Of course this is not fair but my question is this: can we know **better** how many of the patients (cases) who are 'serious or critical' and still being treated will recover?

Thanks much for any reply-
Alan DiCara, Winsted, CT

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 20 Feb 2020 12:39:25 +0000
To: David Katz
Subject: RE: CoronaVirus Epidemic -- a Thought

David:

Thanks for the note. I hope that all is well with you. Although allogeneic/semi-allogeneic blood transfusions could be an interesting approach to serious COVID-19 disease, there are a number of existing drugs such as remdesivir (nucleotide analogue) and Kaletra (protease inhibitor) that have some pre-clinical activity against the virus and these are now being tested in randomized clinical trials.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: David Katz (b) (6)
Sent: Wednesday, February 19, 2020 6:02 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: CoronaVirus Epidemic -- a Thought

Dear Tony,

It has been some time since we last spoke, but this current catastrophe has provoked my thinking about possible therapeutic interventions that could be immediately employed -- in advance of therapies/vaccines that will take

many months to create. And I need to share those thoughts with you.

My suggestion is to treat actively-infected, and acutely ill, patients (under carefully controlled procedures) with allogeneic/ semi-allogeneic blood transfusions. The resulting GVHD response should theoretically combat, and eradicate the viral infection.

I look forward to your thoughts on this suggestion.

With best wishes to you and your family,

David

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 20 Feb 2020 10:51:23 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Marston, Hilary (NIH/NIAID) [E]
Subject: FW: GPMB: MESSAGE ON BEHALF OF THE CO-CHAIRS: PROPOSED BOARD TELECONFERENCE TODAY

FYI

From: Amelie RIOUX (b) (6)>
Sent: Thursday, February 20, 2020 2:00 AM
To: As Sy (b) (6)>; Gro Harlem Brundtland <(b) (6)>; 'Dzau Victor' (b) (6); Chris Elias (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Fore Henrietta (b) (6)>; Gao Fu (b) (6); Gashumba Diane (b) (6); Ilona Kickbusch (b) (6); Suzuki Yasuhiro (b) (6); Vega Morales Jeanette (b) (6); VijayRaghavan Krishnaswamy (b) (6)>; Skvortsova Veronika (b) (6)
Cc: (b) (6) Tore Godal (b) (6); Godal, Tore (b) (6)
Subject: GPMB: MESSAGE ON BEHALF OF THE CO-CHAIRS: PROPOSED BOARD TELECONFERENCE TODAY
Importance: High

MESSAGE ON BEHALF OF THE GPMB CO-CHAIRS DR BRUNDTLAND AND MR SY

Dear Board Members,

We would like to hold a teleconference of the Board **today, 20 February at 13:00 Geneva time.**

The agenda for the call would be as follows:

- Short update and stock taking on the coronavirus outbreak;
- Functioning of the Secretariat and improving effectiveness of the Board;
- Way forward

Please note that this call would be a **closed discussion, for Board members only.**

We would appreciate if you could confirm your participation to Amélie Rioux (at (b) (6))

We will share with you shortly the call-in details.

Thank you for your support and continued engagement. We look forward to the call.

With kind regards,

Gro and As

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 20 Feb 2020 03:43:40 +0000
To: Sharon Rockefeller
Subject: RE: This evening's broadcast

Thanks, Sharon. It is always a pleasure to be on the PBS NewsHour. They are high on honesty and integrity,
Best regards,
Tony

From: Sharon Rockefeller <srockefeller@weta.org>
Sent: Wednesday, February 19, 2020 8:33 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: This evening's broadcast

Dear Dr. Fauci,

Thank you, once again, for appearing on the PBS NewsHour and for treating so many Coronavirus patients. Your gift of calm and clear explanations to normal people is unparalleled. Please do not exhaust yourself as you help so many others. (b) (6).

Very sincerely,
Sharon

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 20 Feb 2020 00:54:10 +0000
To: Crawford, Chase (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Haskins, Melinda (NIH/NIAID) [E]; Selgrade, Sara (NIH/NIAID) [E]
Subject: RE: Requesting your assistance: Draft NIAID Insert for Upcoming Coronavirus Hearings
Attachments: Draft NIAID insert for COVID-19 hearings_to ASF - with Fauci tracked edits.docx

Here it is. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Crawford, Chase (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, February 19, 2020 6:16 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6); Haskins, Melinda (NIH/NIAID) [E] (b) (6)>; Selgrade, Sara (NIH/NIAID) [E] (b) (6)>
Subject: Requesting your assistance: Draft NIAID Insert for Upcoming Coronavirus Hearings

Dr. Fauci:

In preparation for the upcoming COVID-19 hearings of the House Committee on Energy and Commerce Health Subcommittee and the Senate Committee on Health, Education, Labor and Pensions, we have drafted the attached NIAID insert for inclusion in the combined HHS statement for the record. The Department plans to use the same combined statement for both the House and Senate hearings.

The attached draft has been reviewed by the Divisions and Drs. Harper, Eisinger, Lerner, and Marston, as well as Courtney Billet, Martin Johnson, Greg Folkers, and Laurie Doepel.

The Department has asked to receive your statement by COB tomorrow, Feb. 20th.

Thank you for your help.

Chase

Chase Crawford, D.V.M., M.S.

Public Health Analyst

Legislative Affairs and Correspondence Management Branch

Office of Communications and Government Relations

NIAID/NIH/DHHS

Bldg. 31, Room 7A17, MSC 2520

Bethesda, MD 20892-2520

(b) (6)

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 19 Feb 2020 23:03:23 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: BioCentury coverage of mAbs to treat COVID-19

Please handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Karen Tkach Tuzman <ktkach@biocentury.com>
Sent: Wednesday, February 19, 2020 5:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: BioCentury coverage of mAbs to treat COVID-19
Importance: High

Dear Dr. Fauci,

I hope all is well. BioCentury is doing a roundup of companies and institutions developing antibodies against the SARS-CoV-2 virus to treat patients with COVID-19. Since you told my colleague Steve Usdin NIAID is developing its own mAbs against the virus, we'd like to include information about that program in our roundup.

Would you or one of your colleagues be able to answer the following questions? Any information you could share by 5 PM Pacific Time on Thursday, Feb. 20 would be greatly appreciated.

1. Are your mAb candidates being developed against specific targets on SARS-CoV-2? If so, what are those targets?
2. What platforms or processes are you using to identify mAb candidates?
3. Do you have multiple mAb programs against SARS-CoV-2 proceeding in parallel, and if so, how are they distinguished?

4. What is that status of each of your mAb programs? For example, have you nominated any lead candidates, are you awaiting patient samples, etc.?
5. Do you have any metrics on lead candidates available yet, such as neutralization titers? If so, what are they?

All the best,
Karen

Karen Tkach Tuzman, Ph.D.
Head, Discovery & Preclinical Development
Associate Editor, BioCentury Inc.
650-595-5333 x 144 (office)
www.biocentury.com

Notice: This communication (including any attachments) constitutes an electronic communication within the meaning of the Electronic Communications Privacy Act, 18 USC 2510, and its disclosure is strictly limited to the recipient(s) intended by the sender of this message. This communication (including any attachments) contains proprietary information, is protected under U.S. and foreign copyright and other intellectual property law, and may contain confidential material for the sole use of the intended recipient. Any unauthorized review, use, disclosure, dissemination, copying or distribution of this communication (including any attachments), or any of their respective contents, is strictly prohibited. If you are not the intended recipient, please contact the sender by return email and destroy all copies of the original message.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 19 Feb 2020 20:27:04 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Greg Folkers (b) (6)
Subject: FW: Invitation to Speak
Attachments: Invitation_Dr. Anthony Fauci.pdf

Patty/Greg:
Let us discuss.
ASF

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Crow, Hilary <HCrow@USChamber.com>
Sent: Wednesday, February 19, 2020 12:35 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Invitation to Speak

Dear Dr. Fauci,

I'm writing to share the attached invitation with you to speak at the U.S. Chamber Foundation's program on March 10 on the future of medicine.

Our audience of CEOs, market leaders, and opinion leaders would be thrilled to learn more about your perspective on the future of medicine, current issues like the Coronavirus, and future challenges in health and medicine.

Please let me know if you have any questions. I'm happy to schedule a quick call to provide more detail over the phone with you or someone on your team.

I hope you will be able to join us.

Best,
Hilary

Hilary Crow

Executive Director, Programs

U.S. Chamber of Commerce Foundation

1615 H Street, NW | Washington, DC | 20062-2000

Office: 202.463.5710

Mobile: (b) (6)



U.S. Chamber of Commerce Foundation

www.uschamberfoundation.org



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 19 Feb 2020 16:51:27 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Handley, Gray (NIH/NIAID) [E]
Subject: RE: Invitation to the Consultation on Financing Coronavirus Disease 2019 (COVID-19) Vaccine Development | Thursday, February 20, 2020 | 9:30am to 1:30pm | World Bank Headquarters, Washington DC

If they accept two people, you should go with Gray. Obviously, you should make no commitments and when asked about policy issues, say that you will convey to me and we will get back to them.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Marston, Hilary (NIH/NIAID) [E] (b) (6)>
Sent: Wednesday, February 19, 2020 10:09 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Handley, Gray (NIH/NIAID) [E] (b) (6)
Subject: Re: Invitation to the Consultation on Financing Coronavirus Disease 2019 (COVID-19) Vaccine Development | Thursday, February 20, 2020 | 9:30am to 1:30pm | World Bank Headquarters, Washington DC

Have you had a chance to discuss this world bank conference? You, Cliff and Libby received invites. As Gray has mentioned, this is a pledging conference, so we will need to be prepared to address funding (the person that attends would need to be in sync with you on that). Obviously Cliff is on travel. Who would you like to have at the conference, if anyone?

-hilary

From: Anthony Fauci <(b) (6)>

Date: Friday, February 14, 2020 at 9:25 PM

To: NIAID AM <NIAIDODAM@niaid.nih.gov>

Subject: FW: Invitation to the Consultation on Financing Coronavirus Disease 2019 (COVID-19) Vaccine Development | Thursday, February 20, 2020 | 9:30am to 1:30pm | World Bank Headquarters, Washington DC

Let us discuss.

From: Feng Zhao <fzhao@worldbank.org>

Sent: Friday, February 14, 2020 5:22 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Cc: (b) (6); Mukesh Chawla <mchawla@worldbank.org>; Rocio Schmunis <rschmunis@worldbank.org>; Adrienne Kate Mcmanus <amcmanus@worldbank.org>; Gabrielle Lynn Williams <gwilliams1@worldbank.org>; WB Health Events <wbhealthevents@worldbank.org>; Muhammad Ali Pate <mpate@worldbank.org>

Subject: Invitation to the Consultation on Financing Coronavirus Disease 2019 (COVID-19) Vaccine Development | Thursday, February 20, 2020 | 9:30am to 1:30pm | World Bank Headquarters, Washington DC

Dear Dr. Fauci,

On behalf of the World Bank health team, in coordination with the Coalition for Epidemic Preparedness Innovations (CEPI), it is our pleasure to invite you to a half-day consultation on **Financing Coronavirus Disease 2019 (COVID-19) Vaccine Development**. The meeting is set to take place on **Thursday, February 20, 2020 from 9:30am to 1:30pm** at the **World Bank Offices in Washington DC** (located at 1818 H St NW) on **floor C2, conference room MC C2-125**.

As you know, the novel Coronavirus outbreak, which started in Wuhan, China, is evolving rapidly. As of today, the number of confirmed cases has increased significantly to over 60,000 and the virus has reached 25 countries. The outbreak, a Public Health Emergency of International Concern (PHEIC), poses a threat to countries worldwide, especially those with weak health systems and low levels of pandemic preparedness.

It is of urgent importance that we move quickly to finance the development of the appropriate countermeasures for a disease that risks becoming endemic across the globe. Two critical issues are necessary to address: i) immediate financing for the development and scale-up of a diversified portfolio of vaccines, and ii) financing the manufacturing and procurement of vaccine for global distribution.

To enhance our discussions we are working on a background paper which we will share along with an agenda at the earliest. Recognizing the short notice, we will provide remote connection details for those unable to travel for the meeting. A working lunch will also be provided.

We hope that you will be able to participate in this important meeting. Kindly confirm your participation to Ms. Gabrielle Williams, Health, Nutrition and Population Global Practice, World Bank (wbhealthevents@worldbank.org). Please do not hesitate to reach out with any questions.

Looking forward to your positive response.

Best regards,
Feng Zhao

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 19 Feb 2020 16:16:33 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Potential Speaking Engagement: Winter 2021

Please RSVP sorry no. Too busy.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Andrew Turley (b) (6)
Sent: Wednesday, February 19, 2020 10:26 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Andrew Turley (b) (6) >
Subject: Potential Speaking Engagement: Winter 2021

Dear Dr Fauci

I know things must be impossibly busy right now with the current coronavirus issues but wanted to touch base to see whether you may be interested in a speaking engagement next Spring as part of our

(b) (6)
(b) (6)

A bit about me: I am a (b) (6) Air Force Major General and retired SES from the Department of Defense. (b) (6) is an associate professor emeritus from the School of Medicine and Health Sciences at the George Washington University. We are both longtime admirers.

(b) (6) consists of people drawn from a wide variety of backgrounds, including doctors, lawyers and many from the senior tiers of the finance and corporate worlds up to and including former CEOs and other executives (and even a few retired senior government folks like me). It is an active, well-read and learned community with a keen interest in current events. As an example, we have a very active Foreign Policy Association chapter that always draws folks from across the spectrum of political and policy perspectives for interesting and well-informed discussions.

Our (b) (6) speaker series consists of presentations on a vast array of subjects, from literature and art to current events and public policy issues. Typically held on Tuesdays nights from December through April, these sessions consist of a presentation of an hour or so followed by Q&A and general discussion. We always draw standing room only crowds.

Recent and upcoming speakers have included:



The recent coronavirus outbreak has captured the interest of the nation and the world. Our folks would be extremely interested in how organizations such as NIH respond and address these incredible challenges. A presentation by you about your work on these issues, from your groundbreaking work on AIDS onward or any other topic of your choosing, would be absolutely the height of our season.

We pay transportation, lodging, an honorarium, and could even arrange for a round of golf at one of our outstanding golf courses! (Of equal importance is that we can offer you a brief respite from the cold of winter.). There are direct flights from Washington DC to West Palm Beach. We have openings in January, February and March 2021.

We would be deeply appreciative of your favorable consideration. Please feel free to contact me if I can answer any questions

F. ANDREW TURLEY

CELL: (b) (6)
HOME: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 19 Feb 2020 14:42:50 +0000
To: Greg Folkers (b) (6)
Subject: FW: Clip of Dr. Fauci on NPR

Good interview on NPR. Possible for Director's Page.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lindsey Beall <lbeall@scgcorp.com>
Sent: Wednesday, February 19, 2020 8:22 AM
To: Deatrick, Elizabeth (NIH/NIAID) [C] (b) (6); Pekoc, Ken (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Doepel, Laurie (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Hoffman, Hillary (NIH/NIAID) [E] (b) (6); Oplinger, Anne (NIH/NIAID) [E] (b) (6); Rancourt, Anne (NIH/NIAID) [E] (b) (6); Lavelle, Judith (NIH/NIAID) [E] (b) (6); Leifman, Laura (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6); NIAID OD AM <NIAIDODAM@niaid.nih.gov>; Awwad, David (NIH/NIAID) [C] (b) (6)
Cc: Osvald, Maria <mosvald@scgcorp.com>; Fabry, Cynthia (NIH/NIAID) [E] (b) (6); Meylin Correa <mcorrea@scgcorp.com>; Marcia Bache <mbache@scgcorp.com>; Megan Schartner <MSchartner@scgcorp.com>
Subject: Clip of Dr. Fauci on NPR

Good morning,

Below is a clip of Dr. Fauci discussing coronavirus on NPR's Morning Edition. This clip aired earlier this morning.

https://app.criticalmention.com/app/#!/clip/public/1b0da123-0cd7-4012-90a6-b82d27c73191?show_sentiment=false

Thanks,

Lindsey

From: Critical Mention <do-not-reply@criticalmention.com>

Sent: Wednesday, February 19, 2020 8:18 AM

To: Lindsey Beall

Subject: Critical Mention: Megan Schartner has shared a Radio Mention with you



You're always on it with Critical Mention.

***Megan Schartner* has shared a Radio
Mention with you!**

From Megan Schartner (mschartner@scgcorp.com)

[View Mention](#)

[No Program Name Available](#)



Radio

Program Name No Program Name Available

Source WLRNFM

Market DMA: 16 Miami, FL

Time Feb 19, 2020 8:07 AM EST

Clip Length 07:16.852

it's morning edition from n. p. r. news on david green in culver city california and a militant in washington d. c. good morning in china the death toll from the corona virus has hit two thousand world leaders in public health officials are trying to contain it but new infections keep showing up carl golden for example he was a passenger on the diamond princess that's the cruise ship where hundreds of people got the virus we took an aquatic clues to also alone what went wrong who knew we were going and the crew and beautiful omar here's how he ended up in omaha carl his wife jerry were quarantined on that ship for twelve days in a felt fine the whole time but then the gun on a flight back to the u. s. and carl started feeling sick or wind burke from japan to this day about two hours into the flight they woke up with a high fever after napping a little bit and the doctors on board confirmed the and then on the flight landed he tested positive for the coronavirus he's recovering now in a bio contain mean unit at the university of nebraska's medical center he's going to have to spend fourteen days there and isolation well you know working %hesitation %hesitation catering we've heard on a but one of the two days of the different doctors each day i

didn't have a clue but got a little cough still you can you might want to debate left me and i'm a little to keep but maybe also because of the jet lag in the travels and everything else on top of it no it doesn't feel any different than you know recuperating from a regular cold carl's wife jerry hasn't been diagnosed with the virus is she's being monitored in a different part of the hospital but their case is a good example of some things we know and some things we don't know about how this virus is spreading so we have called doctor anthony **fauci** he's director of the national institute of allergy and infectious diseases good morning sir good morning so carl coleman was fine all those days on the ship then he gets on a plane and he gets a fever what does that tell us about how this virus is spreading well the virus has the ability to bind it to certain cells in your body particularly in your lung so you can get anything from mild asymptomatic illness to a cough and a fever to some people about oh about twenty percent of the people come to the attention of medical than physicians in health care providers can get serious pneumonias requiring intensive care it sounds like this individual is on the %hesitation mild side of the illness because as he said it doesn't feel much more than just a common cold and as a matter of fact corona viruses in general prior to this all one of the causes of the common cold okay so what does that tell us i mean bleary often looking at the cases we're looking at a rising death toll which is tragic we look much less at the people like carly say you know my voice is raspy i had a fever had a cough the years a wide range of stuff symptoms with this virus did do we know why some people seem to be doing okay and other people are getting hit really hard well whether a couple things about that for the first thing is that any any kind of viral infection or any pathogen infection there's always a wide range of responses in the sense almost like a bell shaped curve some people get no sim is at all and we do have a symptomatic corona virus infection with this particular episode and then there's the bulk of people who get some sort of symptoms and then a small percentage of people do really really very poorly now that relates to the ability of the body to handle the virus and the one thing we know when it's not unique to this virus is that the elderly those with underlying conditions like chronic heart disease lung disease diabetes obesity they tend to get more complications much more than for example and otherwise healthy individual and that's the reason why if you look at the death rate which is around two percent for this disease at this time it is disproportionately high are among the elderly and particularly those who have underlying conditions this is interesting question carlin is wife terry presumably they work together the entire time they were quarantined right and if he gets the virus she does not did she just get lucky do some people have some sort of immune undefended don't it's a combination that's a good question it's a combination of both there is no virus that has one hundred percent attack rate even the most of infectious of all viruses like measles doesn't get a hundred percent of of %hesitation vulnerable people but respiratory viruses particularly things like influenza or the corona virus the attack rate is burying percentage and it was if he was really likely that his wife i don't think she necessarily had any on the line immune protection though that's possible the maybe some cross reaction of immune protection with other %hesitation microbes that she came into contact with but in most likely is as you suggest the luck of the draw okay interesting

and they got to patching wondered if you could clear something up because we've been hearing reports about so called super spread ours these you who spread the virus to a very high a number of other people and it sounds like a scary thing but and i just under is this a real phenomenon there that there are people who give the virus to more people than most and why is that happening well it is certainly the phenomenon of the super spreading israel we story with sars back in two thousand two and two thousand in three and they're episodes already with this particular new corona virus and it's a combination of two things it's an individual whose either at a particular moment in time shedding a very large amount of virus which makes it much easier to infect a group of people who are around him but you also see it sometimes in the hospital setting when you have a number of health care providers taking care of someone and that person is shedding a lot of virus so the short answer to your question is there are super spread is and it's a real phenomenon okay okay what we would you say at this moment is the most important or the most pressing question about this virus that we don't have answers to yet well what we don't know for sure we know that there are people who are infected will without symptoms or very minimal symptoms they hardly notice they're infected well we don't know is the extent to which people who have no symptoms are spreading it so we do know that this can occur because we have anecdotal documented cases of people who do not have symptoms who actually have infected someone usually a family member but we don't know the extent to which this cars in the broad component of this outbreak doctor anthony **fauci** the director of the national institute of allergy and infectious diseases sir thanks for joining us it was a pleasure to be with you

Critical Mention allows users to search global TV, Radio, Online News & Social from the United States, Canada, and Europe, watch video, edit and share coverage, receive real-time email alerts, build reports, and analyze coverage through word clouds and graphs.

Want to learn more about Critical Mention? Sign up for a demo [here](#).

Copyright © 2020 Critical Mention. All rights reserved.

Our mailing address is:

Critical Mention

521 5th Avenue

16th Fl

New York, NY 10175

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 19 Feb 2020 13:03:08 +0000
To: bdoherty@mms.org
Cc: lbaden@nejm.org; Fauci, Anthony (NIH/NIAID) [E]; Redfield, Robert R. (CDC/OD); Lane, Cliff (NIH/NIAID) [E]; Eisinger, Robert (NIH/NIAID) [E]
Subject: RE: New England Journal of Medicine Editorial
Attachments: H. Clifford Lane's ICMJE-2013 - For Coronavirus Editorial Fauci et al -.pdf

Briana:

Cliff Lane has separately sent his signed CTA. I am attaching his ICMJE Form. And so you should have all the forms for all 3 authors: Fauci, Lane, and Redfield. Please let me know if you have any questions.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Briana Doherty <onbehalf@manuscriptcentral.com>
Sent: Monday, February 10, 2020 11:11 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: lbaden@nejm.org
Subject: New England Journal of Medicine Editorial

Dear Dr. Fauci,

I am delighted that you have agreed to write a signed editorial to accompany the article on the initial estimates of key transmission parameters associated with nCoV-2019 virus by Li et al.

The general purpose of the Journal's editorials is to provide the reader with an authoritative interpretation or elaboration based on the substance of the article. Since this substance is usually not within the average reader's special competence, such readers will particularly benefit if the editorial avoids technical jargon, explains the article's contribution to a field of knowledge, and emphasizes, whenever possible, its clinical implications. The editorial commentary should not be concerned exclusively with the article in question but rather should use the article as a starting point for a more general discussion.

Because editorials involve interpretation and opinion, you and your potential coauthor must be free of significant relevant financial associations (including equity interest, regular consultancies, or major research support) with a company, or with a competing company, that stands to gain from the use of a product discussed in the editorial. Please contact me immediately if you are considering a coauthor, so I can ensure that your candidate meets our

criteria. Additional information about disclosure of financial and other associations appears below this letter.

Please bear in mind that your editorial represents your (and any coauthor's) personal opinion. The Journal does not include statements of grant or other support or acknowledgments with editorials.

Journal policy dictates that we must have on file a signed Copyright Transfer and Authorship Agreement from each author before a manuscript can be accepted. Therefore, the enclosed form should be signed by all authors and faxed to (781) 207-6529.

Your editorial is due at the Journal on Monday, February 17, at the very latest if the deadline imposed by our printing schedule is to be met. If the editorial is to include a figure, please submit the figure at least one week before the due date for the editorial itself.

*** Additional information about preparing and submitting your editorial is given below; please read it carefully.

The editors must reserve the right to edit (or even reject) your editorial, but whether we use it or not, the Journal currently offers a modest stipend of \$300.

Thanks again for agreeing to write this editorial for the Journal. I look forward to receiving it.

Sincerely yours,

Lindsey R. Baden, M.D.
Deputy Editor

New England Journal of Medicine
10 Shattuck Street
Boston, MA 02115
(617) 734-9800
Fax: (617) 739-9864
<http://www.nejm.org>

LENGTH OF YOUR EDITORIAL

NEJM editorials should not exceed two printed pages. This means that your word count before editing should not exceed 750 words (approximately 4500 characters). Note that we spell out trial names and most other abbreviations for our readers, and we include trial registration numbers for any clinical trials mentioned; these will lengthen your editorial if you have not included them. Please provide a title not exceeding 45 characters and a word count for the text; the entire manuscript, including references, should be double-spaced.

REFERENCES

Cite no more than 10 references, including the article you are writing about. The average collection of 10 references requires about a quarter of a printed page.

TABLE OR FIGURE

A table or a figure in your editorial will require a reduction in the number of words; because figures and tables vary in size, you may be asked to shorten the text of your editorial during the production process. A quarter-page table roughly equals 250 words, and a half-page table roughly equals 500 words.

DISCLOSURES

When completing your disclosure form, please indicate, in the "Comments" field next to the type of relationship being disclosed, the amount (in U.S. dollars) of any support you have received. Please also indicate how much of this support has been received over the past 2 years. Please e-mail your completed disclosure form to editorial@nejm.org.

In the event of publication, each author's submitted disclosure form will be posted on the Web (with any dollar amounts redacted).

COPYRIGHT TRANSFER

Each author must complete a copyright transfer agreement form. Please sign it and fax it back to 781-207-6529 as soon as possible.

TO SUBMIT YOUR EDITORIAL

*** It is important that you follow the instructions below to ensure that your article enters the correct queue. ***

When you are ready to submit your manuscript, please log in to the New England Journal of Medicine - Manuscript Central site (<http://mc05.manuscriptcentral.com/nejm>). Your case-sensitive USER ID is afauci@niaid.nih.gov. For security purposes, your password is not listed in this message. If you are unsure of your password, please visit <https://mc05.manuscriptcentral.com/nejm> and enter your e-mail address in the "Forgot Your Password?" field.

Once you are logged in, the Main Menu will be displayed. Please click on the Author Center, where you will find the manuscript listed under "Invited Manuscripts." You can click on the "Continue Submission" button to begin submitting your article.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 19 Feb 2020 12:37:58 +0000
To: Jon LaPook
Subject: RE: Coronavirus

It means that you are an outstanding and committed journalist. 😊

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Jon LaPook (b) (6)
Sent: Wednesday, February 19, 2020 7:36 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: Coronavirus

Got it. What does it mean that I'm waking up thinking about coronavirus?
:)

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine

NYU Langone Health
Twitter @DrLaPook

On Feb 19, 2020, at 7:33 AM, Fauci, Anthony (NIH/NIAID) [E]

(b) (6) wrote:

Jon:

Your hypothesis is certainly possible, but I think unlikely. In a NEJM paper for which I have just written an editorial, there were 400+ patients and none younger than 15 years old. I am certain that children from birth to 15 years were exposed to and primed by coronaviruses multiple times and so if 2nd infection enhancement were an important issue, we should have seen it in children and adolescents 15 years old and younger. Just a thought, but anything is possible.

Best,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases Building 31, Room 7A-03
31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Jon LaPook (b) (6)

Sent: Wednesday, February 19, 2020 7:26 AM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Subject: Coronavirus

Good morning, Tony,

I woke up thinking this: given the relative sparing of young people during the COVID-19 outbreak, could something similar to what happens with dengue be going on? Could a second coronavirus infection - albeit with a genetically different variant than the first - bring about worse disease than the first? And, since up to a third of the common cold is caused by a variant of coronavirus, could older people somehow have been primed by an earlier coronavirus infection?

Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 19 Feb 2020 03:41:52 +0000
To: Grigsby, Garrett (HHS/OS/OGA); Redfield, Robert R. (CDC/OD); Cetron, Marty (CDC/DDID/NCEZID/DGMQ)
Cc: Billet, Courtney (NIH/NIAID) [E]
Subject: FW: Today's report from Dr Iwata From Kobe Univ on Diamond Princess SHIP COVID-19

Folks:

You should take a look at this video (see link). The person, who is a Japanese infectious diseases specialist, is a bit inarticulate in the beginning of the video, but he provides a vivid and disturbing description of the conditions on the Diamond Princess.

Tony

From: Larry Washburn <[REDACTED] (b) (6)>
Sent: Tuesday, February 18, 2020 9:43 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Cc: Hodes, Richard (NIH/NIA) [E] [REDACTED] (b) (6)
Subject: Today's report from Dr Iwata From Kobe Univ on Diamond Princess SHIP COVID-19

Dr. Fauci,

I am living in Japan [REDACTED] (b) (6) and this morning I saw this video released by Dr. Kentaro Iwata, an infectious disease control specialist.

Please have somebody on your staff review this **ASAP** short description of Dr Iwata's 1 day visit on the ship. He has experience with Ebola, SARS, etc. He describes an alarming condition that you and CDC must be aware of. Japan has no CDC and they tend to be very bureaucratic.

<https://www.youtube.com/watch?v=vtHYZkLuKcl&feature=youtu.be>

I apologize if you already have this information.

Respectfully

Larry Washburn [REDACTED] (b) (6) Living in Japan

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 19 Feb 2020 01:32:37 +0000
To: Conrad, Patricia (NIH/NIAID) [E]; NIAID OD AM
Subject: RE: CROI COVID-19 Session; Tuesday March 10 lunch

I am not that excited about doing this. They have CDC doing the Epi, which is fun. They have Ralph Baric doing the virology, which I easily can do, and they have me talking about what NIAID is doing, which is important, but boring from a lecture standpoint.

Greg:

What say you?

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, February 18, 2020 8:22 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: Fwd: CROI COVID-19 Session; Tuesday March 10 lunch

Sent from my iPhone

Begin forwarded message:

From: Donna Jacobsen <djacobsen@iasusa.org>
Date: February 18, 2020 at 8:18:06 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) >
Cc: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6), "Elaine J. Abrams, MD" (b) (6), "Sharon Hillier PhD" (b) (6), "Hoxie, James" (b) (6) >, "Benson, Connie" (b) (6), "Kevin Bowen" (b) (6) >
<kbowen@iasusa.org>
Subject: RE: CROI COVID-19 Session; Tuesday March 10 lunch

(resending with Patty's correct email address)

Dear Dr Fauci:

As I mentioned on the phone, we just today decided that we will have a special session on COVID-19 at CROI. It will be on Tuesday, March 10, during the lunch break; the initial general structure will be a 10- to 15- minute overview of the epidemic (CDC), a 25-min talk by Ralph Barac (UNC) about the virology of coronaviruses, and a 10- to 15-minute summary on what NIAID/NIH is doing and planning. We thought that this being one of the first large medical conferences in infectious diseases this year, that it is important that we address COVID 19 at CROI.

We know that this is terribly last minute, but the CROI Chairs and Foundation are hoping you are free to give the NIAID/NIH update. CROI is in Boston, March 8 to 11.

If you think you would be able to do this, we will send a more formal communication with details and work with Patty on the specifics. Thank you so much Dr Fauci; we hope you will be able to join us.

Best,

Donna

Donna M. Jacobsen
Executive Director/President
International Antiviral (formerly AIDS) Society-USA
131 Steuart St, Ste 500
San Francisco, CA 94105
415-544-9400

<https://www.iasusa.org>



About IAS–USA: Established in 1992, the IAS–USA is a not-for-profit, professional education organization. The mission of the IAS-USA is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV, hepatitis C virus, or other viral infections through high-quality, relevant, balanced, and needs-oriented education and information for practitioners who are actively involved in medical care. The organization's educational activities are particularly intended to bridge clinical research and patient care.

Confidentiality Notice: This e-mail and its attachments may contain privileged and confidential information intended solely for the use of the IAS-USA and the recipient(s) named above. If you are not the intended recipient, or the employee or agent responsible for delivering this message to the intended recipients, you are hereby notified that any review, dissemination, distribution, printing, or copying of this e-mail message and/or any attachments is strictly prohibited. If you have received this transmission in error, please notify the sender immediately and permanently delete this e-mail and any attachments.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 19 Feb 2020 00:28:47 +0000
To: Retzlaff, Jon
Subject: RE: ACTION: Invitation to Provide Opening Remarks at the NIH-AACR Cancer, Autoimmunity, and Immunology Conference on March 23rd (on the NIH campus)

Not interested right now. Too busy. Have Hugh or someone else do this.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Retzlaff, Jon <jon.retzlaff@aacr.org>
Sent: Sunday, February 16, 2020 6:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Barasch, Kimberly (NIH/NIAID) [C] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>

Subject: ACTION: Invitation to Provide Opening Remarks at the NIH-AACR Cancer, Autoimmunity, and Immunology Conference on March 23rd (on the NIH campus)

Dear Dr. Fauci,

It's pretty clear that you have been ridiculously busy over the past month+ serving as our nation's top infectious disease doctor! Thanks so much for your leadership and dedication, Dr. Fauci!

I'm actually reaching out to you on a topic other than the coronavirus, as I am writing on behalf of the co-chairs for an important NIH-American Association for Cancer Research (AACR) conference (**the NIH-AACR Cancer, Autoimmunity, and Immunology Conference**) that will be taking place on March 23-24, 2020, on the NIH campus (in the Masur Auditorium in the NIH Clinical Center).

The co-chairs would like to invite you to be the opening speaker on Monday, March 23rd. Dr. Sharpless will be the opening speaker on Tuesday, March 24th. Please see the attached draft agenda.

Now in its third year, the Cancer, Autoimmunity, and Immunology Conference focuses on: 1) understanding the biology of immune-related adverse events which have occurred in cancer patients treated with immunotherapies and how that might inform the study of autoimmune disease, and 2) defining the potential for the study of autoimmune disease to lead to greater understanding of the treatment and management of immune-related adverse events during and following cancer therapies. The goal of this interdisciplinary conference is to bring together people who might not typically interact to promote cross-fertilization for the betterment of both research and clinical care, which is why there are four NIH ICs very much involved in the Conference, including: NCI, NIAID, NIAMS, and NIDDK.

Chairing this effort on behalf of the AACR is Julie R. Brahmer, MD, Johns Hopkins University. From the NIH, we have Elad Sharon, MD, MPH, NCI; Ravi Madan, MD, NCI; Connie Sommers, PhD, NCI; Howard Young, PhD, NCI; Katarzyna Bourcier, PhD, NCI; Marie Mancini, PhD, NIAMS; Annette Rothermel, PhD, NIAID; and Lisa Spain, PhD, NIDDK.

I know the diverse audience, including patients, researchers, clinicians, industry, regulators, and others, would be thrilled by your presence. Of course, we also know that you have participated in the previous two conference on this topic, which underscores why they would love to have you participate again!

Please let us know at your earliest convenience if you are interested and able to participate in the conference on Monday, March 23rd. If you have additional questions or concerns, you can contact me at jon.retzlaff@aacr.org or (b) (6)

Thanks again, Dr. Fauci, and I look forward to hearing from you!

Jon

Jon Retzlaff, MBA, MPA

CHIEF POLICY OFFICER
VICE PRESIDENT, SCIENCE POLICY AND GOVERNMENT AFFAIRS
Office of Science Policy and Government Affairs



American Association for Cancer Research
1401 H Street, NW, Suite 740 | Washington, DC 20005

202-898-6499 Direct | 267-765-1087 Fax | (b) (6) Cell

jon.retzlaff@aacr.org | www.AACR.org



Please note that this e-mail and any files transmitted with it may be privileged, confidential, and protected from disclosure under applicable law. This information is intended only for the person or entity to which it is addressed and may contain confidential or privileged material. Any review,

retransmission, dissemination, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is prohibited. If you received this in error, please contact the sender and delete the material from any computer.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 19 Feb 2020 00:23:40 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: New England Journal of Medicine - 20-02387

FYI. Just to keep an eye on this. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: New England Journal of Medicine <onbehalf@manuscriptcentral.com>
Sent: Tuesday, February 18, 2020 10:41 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Redfield, Robert R. (CDC/OD) (b) (6)>
Subject: New England Journal of Medicine - 20-02387

Dear Dr. Fauci,

Thank you for submitting your manuscript, "COVID-19 : Navigating the Uncharted" to the New England Journal of Medicine.

Your manuscript has been forwarded to members of our editorial staff, who will make an initial evaluation and decide whether it merits further consideration. You will be notified of the decision as soon as possible.

Your manuscript ID is 20-02387.

Please mention the above manuscript ID in all future correspondence or when calling the office for questions. If there are any changes in your street address or e-mail address, please log in to ScholarOne Manuscripts at <https://mc05.manuscriptcentral.com/nejm> and edit your user information as appropriate. You may also view the status of your manuscript at any time by checking For Authors section of the site.

We are undertaking evaluation of your manuscript with the understanding that neither the substance of the article nor the figures or tables have been published or will be submitted for publication elsewhere during the period of review.

Please provide the editors with copies of other manuscripts by you or your coauthors addressing similar or related research questions that are in preparation or under consideration at other journals. This does not apply to abstracts published in connection with scientific meetings or to news reports based on presentations at such meetings.

The Journal's policy is explained more fully at <http://www.nejm.org/page/author-center/editorial-policies>.

Please call us at 617-734-9800 if you have any questions.

Sincerely,

Eric J. Rubin, MD, PhD
Editor-in-Chief

New England Journal of Medicine
10 Shattuck Street
Boston, MA 02115
(617) 734-9800
Fax: (617) 739-9864
<http://www.nejm.org>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 23:57:32 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: draft response for NBC online

See my minor tweak

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Tuesday, February 18, 2020 2:48 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: FW: draft response for NBC online

Ok any edits? Pls advise

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Routh, Jennifer (NIH/NIAID) [E] (b) (6)
Sent: Tuesday, February 18, 2020 2:47 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6); OCPLPressTeam
<OCPLPressTeam@od.nih.gov>
Cc: NIAID COGCORE <COGCORE@mail.nih.gov>; NIAID Media Inquiries <mediainquiries@niaid.nih.gov>
Subject: draft response for NBC online

Reporter: Jacqueline Stenson
Organization: NBC online
Phone #(s): (b) (6)
Subject: COVID-19

NBC online asked, "What is NIAID's position on whether the SARS-CoV-2 is transmissible in asymptomatic people?"

I would propose that we send a response to Jacqueline attributed to ASF:

Early case reports indicate in certain circumstances SARS-CoV-2 is transmissible in asymptomatic people. We do not know the extent to which asymptomatic transmission is impacting the outbreak. However, we know that people with symptoms are usually the main driver of outbreaks of other respiratory diseases.

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: (b) (6)
(b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 23:32:19 +0000
To: Dennis Golden
Cc: Monica A Golden
Subject: RE: Coronavirus

Denny and Monica:

Many thanks for your kind note. I hope that all is well with you.
Warm regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Dennis Golden <(b) (6)>
Sent: Tuesday, February 18, 2020 4:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Monica A Golden (b) (6)
Subject: Coronavirus

Tony,

Our thoughts and prayers are with you as you professionally address the horrid coronavirus transmission.

We salute you for not "sugarcoating" or trying to be "diplomatic" about the Diamond Princess Cruises ship quarantine process.

As always, you proved yourself to be a courageous, honest and ethical man. A man who has always done the right things.

We stand with you !

In Hoc Signo Vincas,

Denny and Monica Golden

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 22:06:38 +0000
To: Selgrade, Sara (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; NIAID OCGR Leg
Subject: RE: Requesting your assistance: Draft NIAID Statement for Upcoming Appropriations Hearings
Attachments: Draft_NIAID FY2021 Statement for the Record_to ASF - with Fauci tracked edits.docx

Here it is. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Selgrade, Sara (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, February 18, 2020 4:18 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>
Subject: Requesting your assistance: Draft NIAID Statement for Upcoming Appropriations Hearings

Dr. Fauci:

In preparation for the upcoming NIH budget hearings of the House and Senate Appropriations Subcommittees on Labor, HHS, Education, and Related Agencies, we have drafted the attached NIAID statement for the record, highlighting the topics that you previously selected.

We have a firm 3-page limit for the statement. It has been reviewed by the Divisions and Drs. Harper, Eisinger, Lerner, and Marston, as well as Courtney Billet, Martin Johnson, Greg Folkers, and Laurie Doepel.

NIH OLPA has asked to receive your statement by this Wednesday, Feb. 19th. Please let us know if you would like us to request additional time for your review, given competing priorities.

Thank you for your help.

Sara

Sara Selgrade, Ph.D.
Section Chief for Legislative Activities
Legislative Affairs and Correspondence Management Branch
Office of Communications and Government Relations
NIAID/NIH/DHHS
Bldg. 31, Room 7A17, MSC 2520
Bethesda, MD 20892-2520
Phone: (b) (6)
(b) (6)

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 14:37:35 +0000
To: Venigalla B Rao
Cc: Cassetti, Cristina (NIH/NIAID) [E]
Subject: RE: Wuhan coronavirus vaccine candidates

Rao:

Best to contact Cristina Cassetti in DMID. I have copied her here.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Venigalla B Rao (b) (6)
Sent: Tuesday, February 18, 2020 9:20 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Wuhan coronavirus vaccine candidates

Dear Tony,

Good morning!

Sorry for taking your time at this very super busy time. Greatly appreciate your service and leadership!!

(b) (4)

(b) (4)

With best regards,
Rao

On Tue, May 23, 2017 at 11:03 AM Venigalla B Rao <(b) (6)> wrote:

Dear Tony,
Just a quick update.

(b) (4)

(b) (4). He has accepted both the papers and the

papers should come out back-to-back in Virology soon. I am attaching both the pdfs for your interest.

From scientific perspective, it is very satisfying to see that both the papers using completely different approaches arrived at the same virion capture model. That was not anticipated when we initiated the work 5-years ago because the reasons to develop these assays were very different. I have mentioned to Emerman to consider highlighting the papers in the journal issue, and that you and Jim might be willing to write a short piece but I have not heard about this.

With best regards,
Rao

On Mon, May 1, 2017 at 11:33 PM, Venigalla B Rao (b) (6) wrote:

Dear Tony,

(b) (4)

With best regards,
Rao

On Mon, May 1, 2017 at 9:40 PM, Fauci, Anthony (NIH/NIAID) [E] (b) (6) wrote:

Rao:

Thanks for the note and for (b) (4) (b) (4)

(b) (4)

Best regards,
Tony

From: Venigalla B Rao [mailto:(b) (6)]
Sent: Thursday, April 27, 2017 8:24 PM
To: Fauci, Anthony (NIH/NIAID) [E]
Cc: Arthos, James (NIH/NIAID) [E]; (b) (6)
Subject: Request

Dear Dr. Fauci,

This is Venigalla Rao from The Catholic University of America, Washington, DC. I have communicated with you a couple of times in the past years for different reasons. Having been involved in administrative duties (miniscule compared to yours), I can only imagine the demands on your time. I make this request despite this trepidation and I hope that you understand.

(b) (4)



Thank you for consideration.

With best regards,

Rao

Dr. Venigalla B. Rao
Professor and Chairman
Department of Biology
The Catholic University of America
620 Michigan Ave., NE
Washington, DC, 20064

<http://faculty.cua.edu/rao/>

Phone: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 14:12:48 +0000
To: Suzanne Peskin
Subject: RE: Visiting !

Suzanne:

Thanks for the note. I am very, very sorry, but I do not think that we will be able to connect on Sunday. The White House and HHS have me going 24/7 including Saturday and Sunday with the coronavirus crisis. I have seen my wife (b) (6) for a total of about 45 minutes over the past 10 days. Hopefully, we can do this at some other opportunity, but this is a very bad time. I hope that you understand.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Suzanne Peskin (b) (6)
Sent: Monday, February 17, 2020 9:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Visiting !

Hi Tony, I hope all is well with you and your family. I know you are busy these days with the Coronavirus, but was wondering if you're in town this weekend ! (b) (6) lives in DC and works for Maryland CASA as a legal fellow. I'm coming in Friday evening and was planning on taking her down memory lane. She has heard so much about (b) (6) that I would love to introduce you two. (b) (6) We are free most of Sunday if you're in town. It's been way too long. Would love to see you.

Let me know if that is at all possible.

Love,

Suzanne
Sent from my iPad

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 13:17:03 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: (b) (4) for coronavirus
Attachments: (b) (4)

Please handle. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Li, Qihong (b) (6)
Sent: Tuesday, February 18, 2020 8:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: (b) (4) for coronavirus

Dear Dr. Fauci,
I'm writing to you to seek advice on potential collaborations with NIAID-funded facilities or other private sectors to (b) (4)

(b) (4)

(b) (4)

Please feel free to contact me if you have any questions.

Best regards,
QiuHong

QiuHong Li, Ph.D,
Dept. of Ophthalmology
University of Florida
Gainesville FL
32610-0284

Phone: (b) (6)

Email: (b) (6)

From: (b) (6)
Sent: Tue, 18 Feb 2020 07:00:32 -0500
To: Collins, Francis (NIH/OD) [E]
Subject: Re: Funds for CoV

Francis:

(b) (5)

Tony

On Feb 18, 2020, at 6:22 AM, Collins, Francis (NIH/OD) [E]

(b) (6) wrote:

Hi Tony,

Larry and I will have our regular meeting with the Secretary today. (b) (5)

(b) (5)

I will see you this afternoon for our regular catch up, unless other events in our intensely busy lives intervene.

Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 11:15:14 +0000
To: Bernice Mika Huang
Subject: RE: Singapore Coronavirus Updates

Bernice:

Thank you for this important update of information.
Best regards,
Tony

From: Bernice Mika Huang (b) (6)
Sent: Tuesday, February 18, 2020 4:40 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Singapore Coronavirus Updates

Dear Dr. Anthony Fauci,

I'm Bernice (b) (6).

I had read your online discussion details on USA Today which says:

" Another thing that we don't know is why, with a respiratory-borne illness, are there virtually no children getting infected. I mean, there are no cases of kids less than 15 years old. Does that mean for some strange reason they're not getting infected, or the illness is so mild in children that we're not noticing it? It's very clear the median age is 56 or 59."

I thought it would be crucial to share updates on Singapore's coronavirus situation for your reference, because you are the expert who could help analyze the current situation. Till date, in Singapore (b) (6) have two young children who are infected:

ONE YEAR OLD

"Case 76 is a one-year-old Singaporean who was among the group evacuated from Wuhan on Feb 9. The toddler was without symptoms when he boarded the flight back to Singapore. He was put under quarantine upon landing in Singapore, and was confirmed to be infected with COVID-19 on Sunday afternoon. Advertisement He is currently warded in an isolation room at KK Women's and Children's Hospital, said MOH." Quoted from <https://www.channelnewsasia.com/news/singapore/covid19-coronavirus-singapore-update-feb-17-12441176>

SIX-MONTH OLD

" COUPLE, BABY AND MAID INFECTED The 28-year-old mother - whose infection was announced on Tuesday - works at Yong Thai Hang, a health product shop that primarily serves Chinese tourists. Her husband, a 45-year-old Singaporean tested positive on Wednesday at about 2pm, and is currently warded in an isolation room at the National Centre for Infectious Diseases (NCID). Both have no recent travel history to China. The couple's child, a six-month-old boy, tested positive at the same time and is currently warded in an isolation room at KK Women's and Children's Hospital. The family's domestic helper was one of the confirmed cases on Tuesday. MOH said in an update on Thursday that the child

was not in any infant care facility and was cared for at home, prior to being admitted to the hospital." -
Quoted from

<https://www.channelnewsasia.com/news/singapore/wuhan-virus-coronavirus-singapore-number-cases-12395928>

**Thanks, Best Regards & God Bless,
Bernice Huang**

(b) (6)

--

Best Regards, Bernice

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 11:12:55 +0000
To: Sheeley, Colin (NBCUniversal)
Subject: RE: NBC News Inquiry

I know that it is frustrating for you, but they still have not changed the official number, even though we know that it is certainly more than 44. Sorry.

From: Sheeley, Colin (NBCUniversal) <Colin.Sheeley@nbcuni.com>
Sent: Tuesday, February 18, 2020 12:26 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Chirbas, Kurt (NBCUniversal) <Kurt.Chirbas@nbcuni.com>; Varela, Jay (NBCUniversal) <jay.varela@nbcuni.com>; Santana, Cristian (NBCUniversal) <Cristian.Santana@nbcuni.com>; Mitchell, Alexander (NBCUniversal) <Alexander.Mitchell@nbcuni.com>; DiCasimirro, Gemma (NBCUniversal) <Gemma.DiCasimirro@nbcuni.com>; Studley, Joe (NBCUniversal) <Joe.Studley@nbcuni.com>; Metsch, Abigail (NBCUniversal) <Abigail.Metsch@nbcuni.com>
Subject: RE: NBC News Inquiry

Thank you Tony,

We heard this evening that there were 169 new confirmed cases aboard the cruise ship. Do you know if this changes the "official public" number at all?

Thanks,
Colin

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Sent: Monday, February 17, 2020 8:19 AM
To: Sheeley, Colin (NBCUniversal) <Colin.Sheeley@nbcuni.com>
Cc: Chirbas, Kurt (NBCUniversal) <Kurt.Chirbas@nbcuni.com>; Varela, Jay (NBCUniversal) <jay.varela@nbcuni.com>; Santana, Cristian (NBCUniversal) <Cristian.Santana@nbcuni.com>; Mitchell, Alexander (NBCUniversal) <Alexander.Mitchell@nbcuni.com>; DiCasimirro, Gemma (NBCUniversal) <Gemma.DiCasimirro@nbcuni.com>; Studley, Joe (NBCUniversal) <Joe.Studley@nbcuni.com>; Metsch, Abigail (NBCUniversal) <Abigail.Metsch@nbcuni.com>
Subject: [EXTERNAL] RE: NBC News Inquiry

Colin:

Thanks for the note. The number 44 is in flux. When I checked a couple of days ago, the "official public" number was 44. However, it was clear that there was likely more than that since the results of the tests were still coming back on some individuals. And so, it is a minimum of 44 infected from the cruise ship, but it is uncertain how many more than 44 are infected. I do not know where the Americans are staying

Best,
Tony

From: Sheeley, Colin (NBCUniversal) <Colin.Sheeley@nbcuni.com>

Sent: Monday, February 17, 2020 3:36 AM

To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>

Cc: Chirbas, Kurt (NBCUniversal) <Kurt.Chirbas@nbcuni.com>; Varela, Jay (NBCUniversal) <jay.varela@nbcuni.com>; Santana, Cristian (NBCUniversal) <Cristian.Santana@nbcuni.com>; Mitchell, Alexander (NBCUniversal) <Alexander.Mitchell@nbcuni.com>; DiCasimirro, Gemma (NBCUniversal) <Gemma.DiCasimirro@nbcuni.com>; Studley, Joe (NBCUniversal) <Joe.Studley@nbcuni.com>; Metsch, Abigail (NBCUniversal) <Abigail.Metsch@nbcuni.com>

Subject: NBC News Inquiry

Hi there,

I'm reaching out on behalf of NBC National News – would you be able to confirm that 44 Americans aboard the Diamond Princess cruises ship have tested positive for coronavirus?

Also, would you be able to say where the Americans are staying as they are being treated for the virus?

Please **REPLY ALL** with your response, or give us a call at (212) 664-5222.

Thank you,
Colin

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 11:08:19 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: CNNi Interview Request: Anthony Fauci

Let us discuss.

From: Hynds, Joanna (NE) <Joanna.Hynds@turner.com>
Sent: Tuesday, February 18, 2020 5:49 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Pfeifer, Hazel <Hazel.Pfeifer@turner.com>; Roobeek, Rosanne <Rosanne.Roobeek@turner.com>; Avramova, Nina (NE) <Nina.Avramova@turner.com>
Subject: CNNi Interview Request: Anthony Fauci

Dear Mr Fauci,

I hope this finds you well.

I'm writing to you from CNN International to see if you are available to join [Becky Anderson](#) on her prime time flagship show '[Connect the World](#)' for a live interview on today to discuss the coronavirus.

The show airs live between **10amET – 12pmET** – do you have any availability during these hours to come to a convenient bureau?

We really loved having you on the show last Sunday! As the director of the National institute of Allergy and Infectious Diseases your insight is always great for our global audience.

Might it be possible to arrange something?

Background on CNN

- CNN International reaches more than 250 million households worldwide including in the US via DIRECTV.
- CNN International is the number one international TV news channel according to all major media surveys across Europe, the Middle East and Africa, the Asia Pacific region and Latin America.
- In September 2019 [CNN.com](#) had 162 million unique readers globally per month and 114 million mobile readers a month, leading the BBC, Yahoo and New York Times.

Best,

Joanna Hynds


Planning Desk

CNN International

+ 44 207 693 1640 (office)

+ (b) (6) (cell)

joanna.hynds@turner.com



Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 10:44:58 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Confirmation from CNN's New Day

OK. Thanks.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Tuesday, February 18, 2020 5:42 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Fwd: Confirmation from CNN's New Day

Firm hit for this morning in med arts studio at 715 am

Be in studio at 7 am

Sent from my iPhone

Begin forwarded message:

From: "Steinfeld, Alix" <Alix.Steinfeld@turner.com>
Date: February 18, 2020 at 5:13:08 AM EST
To: "Figliola, Mike" <Mike.Figliola@turner.com>, Jonathan Bennett
(b) (6) >
Cc: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6) >, "Daniels, Ronnel
(NIH/OD/ORS) [C]" (b) (6) "Ryland, Ken (NIH/OD/ORS) [E]"
(b) (6) >, "Jackson Farrar, Joy (NIH/OD/ORS) [E]"
(b) (6)
Subject: RE: Confirmation from CNN's New Day

Good Morning
We have DR. ANTHONY FAUCI on New Day
Hit Time; 715aEST
IFB: 212.275.9225
PL: 212.275.9325
CONTROL: 212-275-9053
PO: 660980
Thanks
Alix

From: Figliola, Mike <Mike.Figliola@turner.com>
Sent: Tuesday, February 18, 2020 5:12 AM
To: Jonathan Bennett (b) (6) Steinfeld, Alix

<Alix.Steinfeld@turner.com>

Cc: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>; Daniels, Ronnel (NIH/OD/ORS) [C] (b) (6)>; Ryland, Ken (NIH/OD/ORS) [E] (b) (6)>; Jackson Farrar, Joy (NIH/OD/ORS) [E] (b) (6)>

Subject: RE: Confirmation from CNN's New Day

Importance: High

Adding Alix who has that info

Mike Figliola

Editorial Producer

CNN's New Day

(b) (6)

mike.figliola@turner.com



CONFIDENTIALITY NOTICE: This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain confidential information that is legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this message is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify us by reply e-mail at mike.figliola@turner.com or by telephone at (917) 670-9410, and destroy the original transmission and its attachments without reading them or saving them to disk. Thank you.

From: Jonathan Bennett (b) (6)

Sent: Tuesday, February 18, 2020 5:05 AM

To: Figliola, Mike <Mike.Figliola@turner.com>

Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Daniels, Ronnel (NIH/OD/ORS) [C] (b) (6)>; Ryland, Ken (NIH/OD/ORS) [E] (b) (6)>; Jackson Farrar, Joy (NIH/OD/ORS) [E] (b) (6)>

Subject: Re: Confirmation from CNN's New Day

Mike,

Received and noted. What are the control room and and IFB numbers?

Jonathan

On Tue, Feb 18, 2020, 3:14 AM Figliola, Mike <Mike.Figliola@turner.com> wrote:

Hi everyone,

This is Mike with CNN's New Day. Hope you are well.

This is to confirm Dr. Fauci will be a guest today, **Tuesday 02.18.20** at around **7am EST** to discuss:

7A:

Latest on Americans who tested positive after evacuation from cruise ship; What we know about how coronavirus spreads <https://www.cbsnews.com/news/transcript-dr-anthony-fauci-on-face-the-nation-february-16-2020/>

You will be **solo at 7am EST** for the segments.

Alisyn Camerota and Jim Sciutto, in for John Berman, will both be conducting today's interview.

Please arrive at the studio no later than **6:50am EST**.

Here is your studio confirmation:

STUDIO INFO 2013424

THIS INTERVIEW WILL B E FROM their NIH MED ARTS STUDIO with a direct IFB connection

Control Room numbers are 301-827-8478 and 8479

Encompass Booking and Circuit Number:

Booking: 1-800-243-1995

Circuit: 36TBGS104492

Our IFB: 301-496-1811 (we prefer to call into the station's IFB)

Video: 1080i - the audio is embedded.

Please confirm you have received this and are all set to go!

Best,

M

Mike Figliola

Editorial Producer

CNN's New Day

(b) (6)

mike.figliola@turner.com



CONFIDENTIALITY NOTICE: This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain confidential information that is legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this message is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify us by reply e-mail at mike.figliola@turner.com or by telephone at (917) 670-9410, and destroy the original transmission and its attachments without reading them or saving them to disk. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 03:08:59 +0000
To: Holland, Steven (NIH/NIAID) [E]
Subject: RE: New Coronavirus Draft Messaging

Short and sweet. Looks fine. Thanks.

From: Holland, Steven (NIH/NIAID) [E] (b) (6)
Sent: Monday, February 17, 2020 10:05 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: New Coronavirus Draft Messaging

Tony,

When you get a moment could I get your take on this most recent iteration. Apologies for the intrusions.

Thanks

Steve

--

Director, Division of Intramural Research
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Bldg. 10/11N248 MSC 1960
Bethesda, MD 20892-1960
301-402-7684 voice
(b) (6) fax
(b) (6) email

Assistant lab: Eva Portillo
(b) (6) email
(b) (6) voice

Assistant to SD: Beth Schmidt
(b) (6)
(b) (6)

From: "Bailin, Heike (NIH/OD/ORS) [E]" (b) (6)>
Date: Monday, February 17, 2020 at 10:01 PM
To: "Moss, Bradley (NIH/OD/ORS) [E]" (b) (6)
Cc: "Gottesman, Michael (NIH/OD) [E]" (b) (6), Steven Holland
(b) (6), "Schmitt, James (NIH/OD/ORS) [E]"
(b) (6) "Johnson, Alfred (NIH/OD) [E]" (b) (6),
"Palmore, Tara (NIH/CC/OD) [E]" (b) (6)>, "McGowan, Colleen

(NIH/OD/ORS) [E]" (b) (6), "Cullen, William (NIH/OD/ORS) [E]"
(b) (6)>, "Newcomer, Derek (NIH/OD/ORS) [E]"
(b) (6)>, "Tosten, Timothy (NIH/OD/ORS) [E]"
(b) (6)

Subject: Re: New Coronavirus Draft Messaging

Brad- thank you. I liked much of what you did. And thanks to all who've commented and edited. Your points are well taken.

For the sake of clarity and effectively steering folks to OMS for the proposed ICP measures I favor focusing the message even more. Please find attached OMS edits:

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 03:05:47 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: COVID 19 Diamond Princess Patients Possible Transmission by Fomites
Attachments: SARS Transmission Fomites Temperature and Humidity Variables.pdf

Please have someone respond

From: Angela Moore <[REDACTED] (b) (6)>
Sent: Monday, February 17, 2020 10:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: COVID 19 Diamond Princess Patients Possible Transmission by Fomites

I am a dermatologist but also a clinical researcher and scientist.
I was reading all of the news regarding concerns and questions on how the fellow patients are being infected.

A few questions arose, based on the NIH data on SARS Coronavirus, that has been much more studied, and most likely less virulent than the current COVID 19, which supposedly has HIV traits as well as traits to increase transmission.

I have wondered if COVID-19 is like Legionella, and possibly transmitted in the airborne water droplets in the air conditioning units of the Diamond Princess ship.

Even with the SARS Coronavirus, it was shown to be infective on fomites for up to 28 days unless 40 degrees Celsius and 80% humidity, when it was then inactivated in a few hours (see the attached article). I am wondering if the trays of food, after being passed to passengers on the ships, were then washed in suboptimal conditions (NOT at 40 degrees Celsius for several hours at 80% humidity)

I AM concerned, that based on the reinfection of those in Wuhan, China, after they returned home, on whether 14 days of quarantine is enough, based on the modeling and studies on the SARS Coronavirus, and whether 28 days of quarantine may actually be needed.

With the HIV virus component of COVID 19, one must also wonder if the T cells are being infected and passing the infection along within an infected patient. In the U.S., we may need to beware of blood transfusions from anyone infected, even asymptotically, with COVID 19.

I am sure that you have teams of clinicians and scientists working on this, and I don't know if any of the original scientists working on the SARS models are still around at Chapel Hill to perform these related studies and modeling.

Angela Moore

Angela Yen Moore, MD
Arlington Center for Dermatology
Arlington Research Center

711 East Lamar Blvd., Suite 200
Arlington, Texas 76011
phone 817-795-7546
fax 817-226-7546

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 02:48:13 +0000
To: bdoherty@mms.org
Cc: lbaden@nejm.org; Redfield, Robert R. (CDC/OD); (b) (6); Eisinger, Robert (NIH/NIAID) [E]; Greg Folkers (b) (6); Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: New England Journal of Medicine Editorial
Attachments: NEJM Editorial - Fauci et al - FINAL - 02-18-2020.docx

Briana and Lindsey:

As promised, I am attaching the invited Editorial related to the COVID-19 manuscript that we had discussed. Should I also submit it through the NEJM online website or will you take care of this? We will send in the COI and authorship forms in the next day or 2. Please let me know if you have any questions. Thank you.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Briana Doherty <onbehalf@manuscriptcentral.com>
Sent: Monday, February 10, 2020 11:11 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: lbaden@nejm.org
Subject: New England Journal of Medicine Editorial

Dear Dr. Fauci,

I am delighted that you have agreed to write a signed editorial to accompany the article on the initial estimates of key transmission parameters associated with nCoV-2019 virus by Li et al.

The general purpose of the Journal's editorials is to provide the reader with an authoritative interpretation or elaboration based on the substance of the article. Since this substance is usually not within the average reader's special competence, such readers will particularly benefit if the editorial avoids technical jargon, explains the article's contribution to a field of knowledge, and emphasizes, whenever possible, its clinical implications. The editorial commentary should not be concerned exclusively with the article in question but rather should use the article as a starting point for a more general discussion.

Because editorials involve interpretation and opinion, you and your potential coauthor must be free of significant

relevant financial associations (including equity interest, regular consultancies, or major research support) with a company, or with a competing company, that stands to gain from the use of a product discussed in the editorial. Please contact me immediately if you are considering a coauthor, so I can ensure that your candidate meets our criteria. Additional information about disclosure of financial and other associations appears below this letter.

Please bear in mind that your editorial represents your (and any coauthor's) personal opinion. The Journal does not include statements of grant or other support or acknowledgments with editorials.

Journal policy dictates that we must have on file a signed Copyright Transfer and Authorship Agreement from each author before a manuscript can be accepted. Therefore, the enclosed form should be signed by all authors and faxed to (781) 207-6529.

Your editorial is due at the Journal on Monday, February 17, at the very latest if the deadline imposed by our printing schedule is to be met. If the editorial is to include a figure, please submit the figure at least one week before the due date for the editorial itself.

*** Additional information about preparing and submitting your editorial is given below; please read it carefully.

The editors must reserve the right to edit (or even reject) your editorial, but whether we use it or not, the Journal currently offers a modest stipend of \$300.

Thanks again for agreeing to write this editorial for the Journal. I look forward to receiving it.

Sincerely yours,

Lindsey R. Baden, M.D.
Deputy Editor

New England Journal of Medicine
10 Shattuck Street
Boston, MA 02115
(617) 734-9800
Fax: (617) 739-9864
<http://www.nejm.org>

LENGTH OF YOUR EDITORIAL

NEJM editorials should not exceed two printed pages. This means that your word count before editing should not exceed 750 words (approximately 4500 characters). Note that we spell out trial names and most other abbreviations for our readers, and we include trial registration numbers for any clinical trials mentioned; these will lengthen your editorial if you have not included them. Please provide a title not exceeding 45 characters and a word count for the text; the entire manuscript, including references, should be double-spaced.

REFERENCES

Cite no more than 10 references, including the article you are writing about. The average collection of 10 references requires about a quarter of a printed page.

TABLE OR FIGURE

A table or a figure in your editorial will require a reduction in the number of words; because figures and tables vary in size, you may be asked to shorten the text of your editorial during the production process. A quarter-page table roughly equals 250 words, and a half-page table roughly equals 500 words.

DISCLOSURES

When completing your disclosure form, please indicate, in the "Comments" field next to the type of relationship being disclosed, the amount (in U.S. dollars) of any support you have received. Please also indicate how much of

this support has been received over the past 2 years. Please e-mail your completed disclosure form to editorial@nejm.org.

In the event of publication, each author's submitted disclosure form will be posted on the Web (with any dollar amounts redacted).

COPYRIGHT TRANSFER

Each author must complete a copyright transfer agreement form. Please sign it and fax it back to 781-207-6529 as soon as possible.

TO SUBMIT YOUR EDITORIAL

*** It is important that you follow the instructions below to ensure that your article enters the correct queue. ***

When you are ready to submit your manuscript, please log in to the New England Journal of Medicine - Manuscript Central site (<http://mc05.manuscriptcentral.com/nejm>). Your case-sensitive USER ID is afauci@niaid.nih.gov. For security purposes, your password is not listed in this message. If you are unsure of your password, please visit <https://mc05.manuscriptcentral.com/nejm> and enter your e-mail address in the "Forgot Your Password?" field.

Once you are logged in, the Main Menu will be displayed. Please click on the Author Center, where you will find the manuscript listed under "Invited Manuscripts." You can click on the "Continue Submission" button to begin submitting your article.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 02:09:48 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Comments on Tedros

FYI

From: John Lauerman (BLOOMBERG/ NEWSROOM:) <jlauerman@bloomberg.net>
Sent: Monday, February 17, 2020 10:20 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Comments on Tedros

BTW, I just saw that you tried me earlier and I didn't respond. I was in Geneva and evidently didn't have service. Hope we can connect this time. Best number is my desk, +44 2035 251028. Thanks again, JL

From: John Lauerman (BLOOMBERG/ NEWSROOM:) At: 02/17/20 14:37:11
To: AFAUCI@NIAID.NIH.GOV
Subject: Comments on Tedros

Hi Dr. Fauci: I'm working on a story about WHO DG Tedros and the work that he's doing to contain the coronavirus epidemic. I'm planning on discussing a number of themes, including that responding to outbreaks has become the most visible job of the DG in the past couple of decades. I'd also like to explore the issue of how important it is that countries be as open as possible about disease outbreaks, and that it's the DG's job to encourage that and move countries toward greater transparency and participation in battling outbreaks. Would you care to comment on the job that Tedros is doing in these areas? Please give me a call at +44 2035 251028 or let me know when and at what number to call you. Thanks and regards, John Lauerman, Bloomberg News

John Lauerman, Bloomberg News
3 Queen Victoria Street, London, UK
tel +44 (0) 2035 251028 cell (b) (6)
<http://www.bloomberg.com>
<http://www.bloomberg.com/prognosis>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 02:09:18 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Comments on Tedros

Please try to set up a call with John Lauerman

From: John Lauerman (BLOOMBERG/ NEWSROOM:) <jlauerman@bloomberg.net>
Sent: Monday, February 17, 2020 9:37 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Comments on Tedros

Hi Dr. Fauci: I'm working on a story about WHO DG Tedros and the work that he's doing to contain the coronavirus epidemic. I'm planning on discussing a number of themes, including that responding to outbreaks has become the most visible job of the DG in the past couple of decades. I'd also like to explore the issue of how important it is that countries be as open as possible about disease outbreaks, and that it's the DG's job to encourage that and move countries toward greater transparency and participation in battling outbreaks. Would you care to comment on the job that Tedros is doing in these areas? Please give me a call at +44 2035 251028 or let me know when and at what number to call you. Thanks and regards, John Lauerman, Bloomberg News

John Lauerman, Bloomberg News
3 Queen Victoria Street, London, UK
tel. +44 (0) 2035 251028 cell (b) (6)
<http://www.bloomberg.com>
<http://www.bloomberg.com/prognosis>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 02:02:35 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: [REDACTED] (b) (5)

Cristina:

[REDACTED] (b) (5)

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6)
Sent: Mon, 17 Feb 2020 20:56:50 -0500
To: Collins, Francis (NIH/OD) [E]
Subject: Re: (b) (5) for SARS-CoV-2

(b) (5)

On Feb 17, 2020, at 8:48 PM, Collins, Francis (NIH/OD) [E]

(b) (6) wrote:

Hi Tony,

(b) (5)

Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 00:20:01 +0000
To: Townsend, Frances
Subject: RE: This ongoing 2019 novel coronavirus, or COVID-19, outbreak has a number...

Fran:

Thanks for the note. You certainly have covered a lot of ground with your questions. I look forward to seeing you tomorrow.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Townsend, Frances <FTownsend@MAFGRP.COM>

Sent: Monday, February 17, 2020 6:55 PM

To: (b) (6); Shuy, Bryan (OS/ASPR/IO) (b) (6)

Fauci, Anthony (NIH/NIAID) [E] (b) (6) Conrad, Patricia (NIH/NIAID) [E]

(b) (6)>

Cc: Hanson, Elizabeth <ehanson@MAFGRP.COM>

Subject: This ongoing 2019 novel coronavirus, or COVID-19, outbreak has a number...

All: Below is an outline of questions for tomorrow at CFR. Sorry to get this to you late but it seems the news changes everyday. As you will see I focus mostly on coronavirus as I suspect that's where the interest will be but get to bio weapons toward the end.

I am happy to take additional questions or suggestions. These sessions go quickly and we have time for Q and A so I doubt I will get through it all but wanted you all to have something to look at.

Thanks again for doing this tomorrow.

Best

Fran

This ongoing 2019 novel coronavirus, or COVID-19, outbreak has a number of historic firsts. It's the largest quarantine in world history with China locking down over 60 million people. It's the first mass repatriation of American citizens into a quarantine, climbing over 1,000.

Let's start with some quick basics: what is coronavirus? How contagious? What is the morbidity rate?

How does it compare to SARs and MERs? More/less infectious? Lethal?

Just to put this in perspective every year here in the US we deal with the flu. How many Americans on average die each year from the flu?

But as I mentioned coronavirus has resulted in a number of historic firsts, talk about what you expect could be our scientific firsts and what roadblocks do those scientific firsts confront?

Over the years, global economic interdependence has grown in nearly every industrial sector, including health care. But that means our health care is also globally interdependent on other systems less equipped, less transparent and perhaps less responsible global actors.

China closed the wet market where the coronavirus outbreak began on 1/1, gene sequenced the virus on 1/9 so they could develop a diagnostic test but did not share the gene sequence with the global health community until 1/12.

How transparent and quick was the Chinese response? What should they have done that they failed to do? What were the consequences?

China now claims more than 70K infected and almost 1800 deaths from the virus. But it has been widely reported that the Chinese have underreported both numbers. What are countries' international obligations to report accurately? To whom? How do you know the numbers are accurate?

How does the current outbreak impact the domestic medical supply chain? What steps could or should we consider to enhance supply chain resilience?

What do the numbers suggest to you about what to expect regionally and worldwide? Have numbers peaked? Will they continue to rise? With the cruise ship there are now a total of 15 Americans infected. Do you expect additional cases? What scale? How prepared are we nationally? Locally?

Looking back over the roughly past decade, emerging infectious diseases played a recurring ominous theme. Be it from H1N1, to ebola, then Zika, and now the 2019 novel coronavirus, the threat is clearly not dissipating. When it comes to non-disease natural disasters, the Stafford Act provides a Disaster Relief Fund to enable immediate response. By comparison, there is a small Infectious Diseases Rapid Response Reserve Fund. Do we need a more Stafford Act-like mechanism to enable quicker response and research to these new threats? What other actions can we take to better prepare?

While often we see folks painting emerging infectious diseases and biodefense into separate categories, the truth is that there is significant crossover in terms of preparedness and research. Understanding that this is a sensitive topic, could you talk about how we should approach these risks in a comprehensive manner that can achieve public health and national security objectives concurrently?

I'd like to use this to transition to the topic of bio weapons which is what we originally planned to talk about. The landscape here has also transformed. When BioShield was written and the Strategic National Stockpile established we worried about State actors deploying banned weapons like smallpox; plague and hemorrhagic fever. And you

still must prepare against those things as well as new and emerging threats like the toxins we have seen deployed by Russia and North Korea in more targeted assassinations.

How do you stay ahead of these threats? Do we have the resources and surveillance that we need to stay ahead of the threat? And ensure the necessary vaccines and therapeutics?

The ebola outbreak may be an instructive example, it seems to be coming under some control despite the precarious security situation in the Democratic Republic of Congo. But the ongoing 2018 outbreak was the second largest in history following the 2013-2016 West African outbreak. As a result of these outbreaks, the United States government has pioneered new FDA-approved diagnostics and vaccines, with promising therapeutics seemingly around the approval corner too. What lessons can we draw from the ebola outbreaks? How do you work with and incentivize industry to develop what you need in the event of a catastrophic bio attack? And How do you make the best possible decisions about the stockpile?

I always worried that because we are global leaders if there was a bio attack or outbreak anywhere in the world, others would look to us and to our stockpile for the answer. Are our global allies doing enough to prepare against these threats--whether they be manmade or natural? Are they maintaining adequate stockpiles of medical countermeasures and research bases--and should they be?

Lastly (if we have time)....the FBI recently arrested a Harvard scientist for accepting undisclosed grant money from China for scientific research. It has now been reported that there are similar investigations at a number of US universities including Yale and MIT to name two and that the grant monies are in the billions. What are foreign governments looking for? Why in the US? Clearly a national security risk, is it a bio weapons concern?

DISCLAIMER: This e-mail message and any attachments are intended solely for the use of the person(s) named in the message header to whom the email is addressed and may contain information that is confidential or legally privileged. If you are not the intended recipient, you are hereby notified that any dissemination, distribution, copying, or other use of this message or its attachments is strictly prohibited. If you have received this message in error, please notify the sender immediately and permanently delete this e-mail message and any attachments (and any copies or printouts of the same).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 20:29:27 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: COVID-1
Attachments: letter to NIAID-ICIS.pdf

Please respond to them. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fitzgerald, Kate <Kate.Fitzgerald@umassmed.edu>
Sent: Monday, February 17, 2020 1:52 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Eleanor Fish <en.fish@utoronto.ca>
Subject: COVID-1

Dear Dr. Fauci,

On behalf of the International Cytokine and Interferon Society, please find attached a letter from us as clinicians and scientists committed to developing and implementing therapeutic interventions targeted against global viral infection outbreaks. We propose that high priority be given to evaluating the therapeutic antiviral activities of IFN-as/bc (clinically approved formulations) against COVID-19 which poses a potential threat to global health. Further information is detailed in the attached. The ICIS would be happy to provide the scientific and clinical expertise for this program and welcome further discussion. In particular Dr. Eleanor Fish copied above has the track record and expertise in this area.

Sincerely,

Kate A. Fitzgerald | Professor of Medicine
President | International Cytokine and Interferon Society (ICIS)

www.cytokinesociety.org

Join us @ Cytokines 2020



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 20:22:39 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Happenings Radio Q+A...

Let us discuss. She called me up today and I told her to send me an e-mail since I was on a call. (b) (5)
For discussion.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: cassidy@happeningsmag.com <cassidy@happeningsmag.com>
Sent: Monday, February 17, 2020 3:15 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Happenings Radio Q+A...

Hi there,
This is Cassidy G-D from Happenings Magazine & Radio in Kenosha, WI- we ever so briefly spoke on the phone earlier today.

I was reaching out with the hope of getting you on our radio program for a 20-30 minute Q+A in which we would talk about the Coronavirus and more specifically the impact it is having on the Diamond Princess Cruise ship along with anything you would like to talk about regarding infectious diseases and or your position as director of the National Institute of Allergy and Infectious Diseases.

Please let me know if you have any interest in being on the air with us and I would be happy to provide further details. You can also get ahold of me by our office phone at 262-564-8800.

Hope you are well and I look forward to hearing back from you, Cassidy G-D

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 19:50:25 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Cc: Erbeling, Emily (NIH/NIAID) [E]; Mascola, John (NIH/VRC) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: BMGF

Cristina:

I just spoke with Chris Carp and Trevor Mundel of the BMGF and they want to try and coordinate some of the things that they and we are doing regarding COVID-19. I told them to give you a call to set up a teleconference to discuss respective R & D agendas of NIAID and BMGF.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 18:58:46 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Info from China

Please have someone respond to this person.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Jodie Dillman <(b) (6)>
Sent: Monday, February 17, 2020 12:42 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Info from China

Dear Dr. Fauci,

It is with trepidation that I reach out to you with information that has been shared with me regarding the real status of the Coronavirus in China. My information comes to me from a (b) (6) who has correspondence from a nurse in Harbin, China.

(b) (6) is here on an H1V visa, employed for the past several years at (b) (6) in the international student program. (b) (6)

(b) (6) I have no reason to doubt the authenticity of the correspondence that she shared with me.

This correspondence shows a lung X-ray, a glass container of bloody fluid removed from an infected lung, and a map of Harbin, China depicting many areas of the coronavirus outbreaks. The written correspondence reveals that the numbers being released of confirmed deaths is drastically low due to the spread being too fast to test. Deaths in hospital hallways and of medical staff is not being shared in order to prevent panic.

Protective gear is unavailable and the nurse writing the correspondence is fearful for her life. She states that there are five levels of screenings (tests?) before a person is reported as testing positive or of being infected with the virus. If someone dies before being confirmed, these suspected deaths are covered up and not reported. Reported numbers, even of confirmed cases are grossly undercounted.

I figure you and our government realize the information and numbers coming out of China are highly inaccurate, but this correspondence on (b) (6) confirms it. I felt it was only ethical and moral to report this, despite (b) (6) plea that the two people involved in the correspondence fear governmental retribution if it was discovered that they discussed or passed on this confidential information.

I report this and swear it to be true and confidential. I am trusting it will help in some way and not just stir panic.

Jolonda Dillman

(b) (6)



Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 18:51:17 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: AI supplementation of influenza surveillance system for COVID-19 outbreak.

FYI

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Ed Peshko <esp@hedviginc.com>
Sent: Monday, February 17, 2020 1:19 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Re: AI supplementation of influenza surveillance system for COVID-19 outbreak.

ps - feel free to contact me at this address, or my personal email address, that is (b) (6).

again, I have no dog in this fight aside from wanting to avoid a large scale pandemic worldwide.

And I'm sincerely hoping that we throw the rulebook out - and develop a new one - to deal with this the same way we did when we dealt with the 1918-1919 pandemic.

On Mon, Feb 17, 2020 at 10:09 AM Ed Peshko <esp@hedviginc.com> wrote:

Dr. Fauci,

Like you, I've been watching the COVID-19 outbreak with great alarm. Given the current data, I'm almost positive at this point that it will hit the US hard at some point and as a student of history that terrifies me.

So I'm hoping that your department has contacted the Bill and Melinda Gates foundation and see if you could make the following idea national or international. It is a supplemental health system based on AI and mobile technology and consists of two planks:

First:

- train an AI to be able to detect COVID-19 by measurements that can be done by cell phone (for example pictures of patients, recordings of patient's respiratory system)

Second:

- develop and release a smart-phone application that does the following:
 - turns on location tracking so health authorities can see where the cell phone owner is.
 - allows for people to upload health measurements from their cell phone.
 - keeps TRACK of where the cell phone owner is. If that person then tests positive for COVID later on, it can then automatically figure out all the contacts of that person for the last 14 days.
 - notifies those contacts that they have been in contact with someone with COVID-19, to isolate themselves and regularly test themselves.

The goal would be to prevent hundreds of thousands of people from descending on hospitals and overwhelming them, and to allow for the CDC or other medical personnel to go OUT and get them - or isolate them for treatment in their own homes - rather than having them come in and infect everybody.

Now this all hinges on the idea that AI could detect COVID-19 based on an audio recording or a simple picture and do it reliably, but I'm fairly sure that it can based on the peer-reviewed literature. It is not a difficult AI problem assuming that the microphone can pick up sounds well enough - if not, there are already integrated stethoscopes for cell phones that could be mass produced - and once developed to enough precision it could be deployed nationally or internationally fairly easily.

For all I know something like this is already in the works but I haven't heard of anything like it - apart from the chinese app which AFAICT does not use any AI but DOES allow for automatic contact tracing.

I sincerely hope this is already in the works. Ultimately it could be used both for detection and treatment - assuming the current antivirals work out they could be distributed to the same coordinates that positive diagnoses come in, perhaps by cheap drone so that nobody actually needs to be exposed to the virus to effect treatment.

Anyways, thanks for your time and efforts. Personally I'm a software developer but I'm hoping that perspective is helpful - for I view the fight against this virus as an INFORMATIONAL fight. It's like a fire-suppression system or food safety measures. Again, I have no clue whether or not this is already being done, and I apologize in advance if I'm missing something and this all seems obvious.

I just think that in this case it is prudent for us to be safe rather than sorry.

Thanks much,

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 18:47:09 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: AI supplementation of influenza surveillance system for COVID-19 outbreak.

Please handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Ed Peshko <esp@hedviginc.com>
Sent: Monday, February 17, 2020 1:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: AI supplementation of influenza surveillance system for COVID-19 outbreak.

Dr. Fauci,

Like you, I've been watching the COVID-19 outbreak with great alarm. Given the current data, I'm almost positive at this point that it will hit the US hard at some point and as a student of history that terrifies me.

So I'm hoping that your department has contacted the Bill and Melinda Gates foundation and see if you could make the following idea national or international. It is a supplemental health system based on AI and mobile technology and consists of two planks:

First:

- train an AI to be able to detect COVID-19 by measurements that can be done by cell phone (for example pictures of patients, recordings of patient's respiratory system)

Second:

- develop and release a smart-phone application that does the following:

- turns on location tracking so health authorities can see where the cell phone owner is.
- allows for people to upload health measurements from their cell phone.
- keeps TRACK of where the cell phone owner is. If that person then tests positive for COVID later on, it can then automatically figure out all the contacts of that person for the last 14 days.
- notifies those contacts that they have been in contact with someone with COVID-19, to isolate themselves and regularly test themselves.

The goal would be to prevent hundreds of thousands of people from descending on hospitals and overwhelming them, and to allow for the CDC or other medical personnel to go OUT and get them - or isolate them for treatment in their own homes - rather than having them come in and infect everybody.

Now this all hinges on the idea that AI could detect COVID-19 based on an audio recording or a simple picture and do it reliably, but I'm fairly sure that it can based on the peer-reviewed literature. It is not a difficult AI problem assuming that the microphone can pick up sounds well enough - if not, there are already integrated stethoscopes for cell phones that could be mass produced - and once developed to enough precision it could be deployed nationally or internationally fairly easily.

For all I know something like this is already in the works but I haven't heard of anything like it - apart from the chinese app which AFAICT does not use any AI but DOES allow for automatic contact tracing.

I sincerely hope this is already in the works. Ultimately it could be used both for detection and treatment - assuming the current antivirals work out they could be distributed to the same coordinates that positive diagnoses come in, perhaps by cheap drone so that nobody actually needs to be exposed to the virus to effect treatment.

Anyways, thanks for your time and efforts. Personally I'm a software developer but I'm hoping that perspective is helpful - for I view the fight against this virus as an INFORMATIONAL fight. It's like a fire-suppression system or food safety measures. Again, I have no clue whether or not this is already being done, and I apologize in advance if I'm missing something and this all seems obvious.

I just think that in this case it is prudent for us to be safe rather than sorry.

Thanks much,

Ed

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 17:42:47 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: PBS NewsHour inquiry for today

FYI

Let us discuss after I get off the AMA call, which is going long

From: David Coles <dcoles@newshour.org>
Sent: Monday, February 17, 2020 11:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: PBS NewsHour inquiry for today

Dr. Fauci,

Might you be available to update our viewers on the latest developments in the coronavirus story today/tonight? We are particularly interested in getting your evaluation of the passengers who have been released from two cruise ships. The first, in Yokohama, Japan, where over 300 Americans released from the ship have now arrived back in the US, to go into 14 days of quarantine. 14 of those people tested positive at some point after leaving the ship, but before they boarded the plane. The second ship we want to focus on is in Cambodia. Something in the neighborhood of 1,000 passengers released from that ship have been reported to be in some state of travel to their homes, presumably around the globe. One woman who made it as far as Malaysia tested positive there and is hospitalized in Kuala Lumpur. We do know that the CDC is working with WHO and the cruise ship line to track down those traveling people.

We would very much like to hear from you what level of concern we should have over those many hundreds of people traveling right now, how well quarantine works, how important it is to maintain it, etc. We would also like to touch on the methods of containment and treatment being done inside China and how well those methods have worked.

I realize it is a holiday, and that could complicate things. But please let me know whether you could consider this, Doctor, and we will begin to work out the logistics.

Thank you.

Very best regards,
Dave

David Coles
Deputy Senior Producer, National Affairs



703 998 2104

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 16:35:20 +0000
To: Smith, Steven
Subject: Re: i've been thinking about you
Attachments: image003.png

Steven:

Thanks for the note. Much appreciated. It has been 24/7 for me for the past 4 weeks. Hope that all is well with you.

Best,

Tony

On Feb 17, 2020, at 10:39 AM, Smith, Steven <Steven.Smith@(b) (6)> wrote:

Having just come back from Australia where coronavirus is hands down a national emergency, I've been thinking about you again and all the good work you do to keep us safe.

I was with someone who's a diplomat with the Australian government who said "it's much, much worse than the Chinese would have you believe. Much worse." Melbourne and Sydney were deserted almost immediately of Chinese tourists and students. I luckily flew through DOHA.

Hang in there. It's always something.

Steven


Steven W. Smith

(b) (6)
(b) (6)

<image003.png>

This message, including attachments, is confidential and may be privileged. If you received this in error, please notify me by reply email and delete this message.

(b) (6)



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 14:14:34 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Re: Request from CNN's New Day
Attachments: image001.jpg

Thanks

On Feb 17, 2020, at 9:11 AM, Conrad, Patricia (NIH/NIAID) [E]
(b) (6)> wrote:

Working on this from med arts for tomorrow as well. Just FYI

Sent from my iPhone

Begin forwarded message:

From: "Figliola, Mike" <Mike.Figliola@turner.com>
Date: February 17, 2020 at 8:42:38 AM EST
To: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)>
Subject: RE: Request from CNN's New Day

Copy will be back soonest

M

Mike Figliola
Editorial Producer
CNN's New Day
(b) (6)
mike.figliola@turner.com

<image001.jpg>

CONFIDENTIALITY NOTICE: This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain confidential information that is legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this message is STRICTLY PROHIBITED. If you have received this transmission in error, please

immediately notify us by reply e-mail at mike.figliola@turner.com or by telephone at (917) 670-9410, and destroy the original transmission and its attachments without reading them or saving them to disk. Thank you.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Sent: Monday, February 17, 2020 8:42 AM
To: Figliola, Mike <Mike.Figliola@turner.com>
Subject: RE: Request from CNN's New Day

Between 7 am – 7:50 am ET

From: Figliola, Mike <Mike.Figliola@turner.com>
Sent: Monday, February 17, 2020 8:40 AM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: RE: Request from CNN's New Day

Working on timing – is there a preferred time?

Mike Figliola
Editorial Producer
CNN's New Day
(b) (6)
mike.figliola@turner.com

<image001.jpg>

CONFIDENTIALITY NOTICE: This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain confidential information that is legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this message is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify us by reply e-mail at mike.figliola@turner.com or by telephone at (917) 670-9410, and destroy the original transmission and its attachments without reading them or saving them to disk. Thank you.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Sent: Monday, February 17, 2020 8:40 AM
To: Figliola, Mike <Mike.Figliola@turner.com>
Subject: Re: Request from CNN's New Day

Would hit time be 1. The 7 am hour? Do I have exact time?

Sent from my iPhone

On Feb 17, 2020, at 4:16 AM, Figliola, Mike
<Mike.Figliola@turner.com> wrote:

Hi Patty,

Mike with cnn and new day here

Hope all is well

We are interested in checking Dr Fauci's availability for
Tuesday's show.

May you let me know if he is avail and what time frame works
best?

Topic is Coronavirus

Thanks!

M

Sent from my iPhone

On Jan 30, 2020, at 10:05 AM, Figliola, Mike
<Mike.Figliola@turner.com> wrote:

Hi Patty!

Morning

If we want Fauci for tomorrow, is he avail?

Barring maj breaking news we are not planning to
cancel

Thoughts?

M

Mike Figliola
Editorial Producer
CNN's New Day
(b) (6)
mike.figliola@turner.com

<image001.jpg>

CONFIDENTIALITY NOTICE: This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain confidential information that is legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this message is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify us by reply e-mail at mike.figliola@turner.com or by telephone at (917) 670-9410, and destroy the original transmission and its attachments without reading them or saving them to disk. Thank you.

From: Figliola, Mike
Sent: Thursday, January 23, 2020 10:22 AM
To: Conrad, Patricia (NIH/NIAID) [E]
(b) (6)
Subject: RE: Request from CNN's New Day

Copy thank you!

Mike Figliola
Editorial Producer
CNN's New Day
(b) (6)
mike.figliola@turner.com

<image001.jpg>

CONFIDENTIALITY NOTICE: This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain confidential information that is legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this message is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify us by reply e-mail at mike.figliola@turner.com or by telephone at (917) 670-9410, and destroy the original transmission

and its attachments without reading them or saving them to disk. Thank you.

From: Conrad, Patricia (NIH/NIAID) [E]
(b) (6)>
Sent: Thursday, January 23, 2020 10:16 AM
To: Figliola, Mike <Mike.Figliola@turner.com>
Subject: RE: Request from CNN's New Day

Per our chat just now – can have him avail between 6 am – 8:15. Hard stop at 815 am ET

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Figliola, Mike <Mike.Figliola@turner.com>
Sent: Thursday, January 23, 2020 10:02 AM
To: Conrad, Patricia (NIH/NIAID) [E]
(b) (6)
Subject: RE: Request from CNN's New Day

Ok – we wont know until 1030a meeting – is it ok to hold 6 and 7a until then?

Mike Figliola

Editorial Producer

CNN's New Day

(b) (6)

mike.figliola@turner.com

<image001.jpg>

CONFIDENTIALITY NOTICE: This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain confidential information that is legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this message is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify us by reply e-mail at mike.figliola@turner.com or by telephone at (917) 670-9410, and destroy the original transmission and its attachments without reading them or saving them to disk. Thank you.

From: Conrad, Patricia (NIH/NIAID) [E]

(b) (6)

Sent: Thursday, January 23, 2020 10:00 AM

To: Figliola, Mike <Mike.Figliola@turner.com>

Subject: RE: Request from CNN's New Day

Sorry to be a pain-if you think it will be in the 6 am hour – we might need to use a different studio...if its in the 7 am hour we can use our remote studio...

Any thoughts as to which hour again, sorry

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious
Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03

Bethesda, Maryland 20892

(b) (6)

301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Figliola, Mike <Mike.Figliola@turner.com>

Sent: Thursday, January 23, 2020 9:23 AM

To: Conrad, Patricia (NIH/NIAID) [E]

(b) (6)>

Subject: RE: Request from CNN's New Day

Copy thank you

Mike Figliola

Editorial Producer

CNN's New Day

(b) (6)

mike.figliola@turner.com

<image001.jpg>

CONFIDENTIALITY NOTICE: This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain confidential information that is legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this message is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify us by reply e-mail at mike.figliola@turner.com or by telephone at (917) 670-9410, and destroy the original transmission and its attachments without reading them or saving them to disk. Thank you.

From: Conrad, Patricia (NIH/NIAID) [E]

(b) (6)>

Sent: Thursday, January 23, 2020 9:18 AM

To: Figliola, Mike <Mike.Figliola@turner.com>

Subject: RE: Request from CNN's New Day

Checking now for all times between 6-9 will let you know soonest

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious
Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892

(b) (6)

301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Figliola, Mike <Mike.Figliola@turner.com>

Sent: Thursday, January 23, 2020 9:10 AM

To: Conrad, Patricia (NIH/NIAID) [E]

(b) (6)

Subject: RE: Request from CNN's New Day

Hi again

Could be back half of 7am but if this gets much worse we may play it higher in the hour – is there any time that doesn't work?

Mike Figliola
Editorial Producer
CNN's New Day

(b) (6)

mike.figliola@turner.com

<image001.jpg>

CONFIDENTIALITY NOTICE: This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain confidential information that is legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this message is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify us by reply e-mail at mike.figliola@turner.com or by telephone at (917) 670-9410, and destroy the original transmission and its attachments without reading them or saving them to disk. Thank you.

From: Conrad, Patricia (NIH/NIAID) [E]

(b) (6)

Sent: Thursday, January 23, 2020 8:57 AM

To: Figliola, Mike <Mike.Figliola@turner.com>

Subject: FW: Request from CNN's New Day

Hi Mike – we can make this happen.
The 7 am hour is best for us but will get back to you. do you have an idea of the hit time? need to make sure our nih studio is available.

thx

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious
Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892

(b) (6)

301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Begin forwarded message:

From: "Figliola, Mike"
<Mike.Figliola@turner.com>
Date: January 23, 2020 at 8:36:15 AM EST
To: "Fauci, Anthony (NIH/NIAID) [E]"
(b) (6)
Subject: RE: Request from CNN's New Day

Hi everyone,

This is Mike with CNN's New Day

Hope you are well

We would like to invite Dr, Fauci back to the program to discuss coronavirus

Might he be available tomorrow

We air 6-9am and happy to provide car service to and from the studio wherever you are located. John Berman and Alisyn Camerota anchor from NY.

Thoughts?

best,

M

Mike Figliola

Editorial Producer

CNN's New Day

(b) (6)

mike.figliola@turner.com

<image001.jpg>

CONFIDENTIALITY NOTICE: This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain confidential information that is legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this message is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify us by reply e-mail at mike.figliola@turner.com or by telephone at (917) 670-9410, and destroy the original transmission and its attachments without reading them or saving them to disk. Thank you.



NIH-00184.



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 13:50:10 +0000
To: Natalie Rahhal
Cc: Kadlec, Robert (OS/ASPR/IO)
Subject: FW: Comments re: 14 US passengers with coronavirus and updates

Natalie:

I sent the incorrect e-mail address for Dr. Kadlec. Here is the correct one.
Tony

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Monday, February 17, 2020 8:47 AM
To: Natalie Rahhal (b) (6) >
Cc: (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Subject: RE: Comments re: 14 US passengers with coronavirus and updates

Natalie:

Thank you for your note. Dr. Robert Kadlec, the Assistant Secretary for Preparedness and Response (ASPR) at HHS could either answer this question or point you in the direction of someone who could. I am copying him on this e-mail.

Best regards,
Tony

From: Natalie Rahhal (b) (6)
Sent: Monday, February 17, 2020 8:28 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Comments re: 14 US passengers with coronavirus and updates

Hi Dr Fauci,

I hope this note finds you well and that you've gotten a little rest over the weekend, during what I'm sure is an inordinately busy time. Would you be able to elaborate on the measures taken to keep the 14 US evacuees who have coronavirus from infecting others on board the plane? I know that remdesivir, under compassionate use, was given to at least the first American coronavirus patient, and last week NIH researchers published results early that it had preventive effects for macaques exposed to MERS. Has the US considered using this drug to protect those exposed to but not yet infected with coronavirus?

Thank you,

Natalie A Rahhal
Acting US Health Editor

Daily Mail.com

Daily Mail Online | 51 Astor Place, 9th floor, New York NY 10003

Tel: +1 212 402 9086

Mobile: (b) (6)

Twitter: <https://twitter.com/natalier78?lang=en>

Email: Natalie.rahhal@mailonline.com

Disclaimer

This e-mail and any attached files are intended for the named addressee only. It contains information, which may be confidential and legally privileged and also protected by copyright. Unless you are the named addressee (or authorised to receive for the addressee) you may not copy or use it, or disclose it to anyone else. If you received it in error please notify the sender immediately and then delete it from your system. Associated Newspapers Ltd. Registered Office: Northcliffe House, 2 Derry St, Kensington, London, W8 5TT, Registered No 84121 England.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 13:24:34 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]; Doepel, Laurie (NIH/NIAID) [E]; Eisinger, Robert (NIH/NIAID) [E]; Lerner, Andrea (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]
Subject: RE: ASF ----- attached for your review is draft abstract for Florence vaccine meeting
Attachments: Keystone abstract --transforming vaccinology -- 3-16-2020 - with minor Fauci edits.docx

Greg:

This looks great. I have made some minor edits that are tracked in the document. Please accept these and then it is ready to go. Thanks.

Best,

Tony

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, February 12, 2020 1:47 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Doepel, Laurie (NIH/NIAID) [E] (b) (6)>; Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6)>
Subject: ASF ----- attached for your review is draft abstract for Florence vaccine meeting

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 16 Feb 2020 22:28:19 +0000
To: Jon LaPook
Subject: RE: Coronavirus

Jon:

I have no idea what this guy is talking about. I have never said the R0 was close to 5 or 6. The R0 is about 2.0 to 2.2. Also, the situation is as we have discussed on several occasions. In the USA, the travel restrictions seem to be working with only 15 cases in the USA (13 travel and 2 spouses). But, as I have said, this could change. If we get substantial sustained transmission in a number of countries throughout the world, including the developing world, then sooner or later there will be significant leakage of infected individuals into the USA since you cannot restrict incoming travel from the whole world. The way we might be able to avoid a real global pandemic is if the non-China countries can contain the infections in their respective countries before there is widely distributed sustained transmissions. Once widely distributed sustained transmissions happen, a global pandemic is inevitable. What would a global pandemic mean? It depends on the true rates of morbidity and mortality. The currently reported mortality of COVID-19 is about 2%. However, there are several folds more cases than are coming to the official attention of health authorities, i.e. asymptomatic or minimally symptomatic infections. If you count these, the denominator gets much larger and the case fatality rate could drop to 1% or even 0.5 % or less. If that is the case, then this could be a very severe seasonal flu (0.2% to 0.4%; regular seasonal flu is 0.1%) or a typical pandemic like 1957 or 1968 (0.5% -0.9 %). We are not sure where it is going to land.

Hope this is helpful.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Jon LaPook (b) (6)>
Sent: Sunday, February 16, 2020 4:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Coronavirus

Hi Tony,

I thought you would be interested to see a text (below my email) I just got from a very smart Wall Street guy who has been filling me in on reaction there. I've been doing my best on air to put the current situation in perspective - communicating that the risk in the U.S. is still relatively low while letting viewers know the situation is fluid and could change. How would you sum up where we are now?

Thanks,
Jon

TEXT I JUST RECEIVED:

“Doc, total panic mode setting in . Tony Fauci talking R nought at closer to 5 or 6. Good biotech guys saying it might not die down in April. People talking about 60% of us will get it ; unstoppable in Africa. I can’t scare people but this is really bad. I hate bothering you on this but I know I need to take my cue from what you will say on CBS”

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 16 Feb 2020 21:16:02 +0000
To: Lucassen, Elisabeth B
Subject: RE: Coronavirus patient--secure

Elisabeth:

Do you have time for a quick phone call?

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lucassen, Elisabeth B <Elisabeth.Lucassen@providence.org>
Sent: Friday, February 14, 2020 1:54 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Coronavirus patient--secure
Importance: High

Dear Dr. Fauci,

(b) (6)

(b) (6)

(b) (6). Any input would be most appreciated. Many thanks in advance!

Sincerely,
Elisabeth Lucassen

This message is intended for the sole use of the addressee, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If you are not the addressee you are hereby notified that you may not use, copy, disclose, or distribute to anyone the message or any information contained in the message. If you have received this message in error, please immediately advise the sender by reply email and delete this message.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 16 Feb 2020 20:40:58 +0000
To: Redfield, Robert R. (CDC/OD)
Cc: Greg Folkers (b) (6)
Attachments: nejmoa2001316.pdf, NEJM Editorial - Fauci et al - clean with Fauci edits
accepted.docx

Bob:

As per our discussion, I am attaching the Editorial together with the NEJM paper upon which the editorial is based. Please take a look and give your approval. Of course if you have any comments or edits, they are most welcome. As mentioned, the NEJM wants the manuscript by COB tomorrow (Monday).

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 16 Feb 2020 20:20:29 +0000
To: Arthos, James (NIH/NIAID) [E]
Subject: RE: one on one

No problem. I am drowning in coronavirus and our meeting likely would have wound up being cancelled anyway. Hopefully, we will soon get back to some sort of normality in our meetings. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Arthos, James (NIH/NIAID) [E] (b) (6)
Sent: Sunday, February 16, 2020 2:18 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: one on one

Hi Tony,

I'm very sorry to bother you when you are so busy. Regarding this Tuesday, we are on your schedule for a one on one and unit head meeting. something came up last minute and I am going to be away from Tuesday through Friday, so I won't be able to make either. Sorry for the late notice.

Jim

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 16 Feb 2020 20:17:53 +0000
To: Lane, Cliff (NIH/NIAID) [E]
Cc: Greg Folkers (b) (6); Conrad, Patricia (NIH/NIAID) [E]
Subject: NEJM manuscript
Attachments: NEJM Editorial - Fauci et al - clean wuth additional Fauci edits - 02-15-2020.docx, NEJM Editorial - Fauci et al - clean with Fauci edits accepted.docx

Cliff;

I am attaching 2 documents: 1) The revised manuscript that Greg worked on in which I have added a number of tracked changes including deleting a substantial amount to get it between 800 and 900 words; and 2) A clean version where I have accepted all the tracked changes (Greg's and mine). Right now I like it the way it is and would not change it much if at all. What it needs now is references. Greg will take a shot at adding the references. If you have references, please send them to Greg and me. In the meantime, I will send it without references to Bob Redfield for his review/approval. Let us discuss by phone if you wish.

Thanks,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 16 Feb 2020 19:19:00 +0000
To: Greg Folkers (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: NEJM manuscript
Attachments: NEJM Editorial - Fauci et al - clean wuth additional Fauci edits - 02-15-2020.docx, NEJM Editorial - Fauci et al - clean with Fauci edits accepted.docx

Greg;

I am attaching 2 documents: 1) The revised manuscript that you sent to me in which I have added a number of tracked changes including deleting a substantial amount to get it between 800 and 900 words; and 2) A clean version where I have accepted all the tracked changes (yours and mine. Right now I like it the way it is and would not change it much if at all. What it needs now is references. Can you add up to 10 references? It might be easier for you to do that rather than Cliff. If not, I will send to Cliff and see if he can do it. In the meantime, I will send it without references to Bob Redfield for his review/approval. Let us discuss by phone if you wish.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 16 Feb 2020 12:12:58 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: COVID-19 therapy

Please handle.

-----Original Message-----

From: Cesare Cocchi [REDACTED] (b) (6) >
Sent: Sunday, February 16, 2020 5:18 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: COVID-19 therapy

Dear Doctor Fauci,

I am a pediatrician from [REDACTED] (b) (6) (IT).

I was wondering if high doses of vitamin A have been tried in the therapy of COVID-19.

Do you remember the cases of viral pneumonia due to measles that take place in African infants in the late seventies. It seemed to work.

Many sorry to bother you.

Have a good job!

Best regards

Cesare Cocchi MD

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 15 Feb 2020 22:21:34 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: To VIMA newspaper-Greece-interview request-coronavirus

FYI

-----Original Message-----

From: Θεοδώρα Τσώλη <thtsoli@tovima.gr>
Sent: Saturday, February 15, 2020 4:22 PM
To: NIAID NEWS (NIH/NIAID) <NIAIDNEWS@niaid.nih.gov>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: To VIMA newspaper-Greece-interview request-coronavirus

Hallo

My name is Theodora Tsoli and I am a science editor for the greek newspaper To VIMA (www.tovima.gr) one of the biggest Sunday papers in my country. I would like to have, if possible, a telephone interview with dr Fauci on the coronavirus outbreak for next Sunday's paper. If he won't be able to speak, could I send questions to which he could answer?

Looking forward to your reply

Thank you in advance

Theodora Tsoli

Στάλθηκε από το iPhone μου

Σημαντικό: Παρακαλώ δείτε την δήλωση αποποίησης ευθυνών <www.alteregomedia.org/disclaimer.html>
Important: Please read our disclaimer <www.alteregomedia.org/disclaimer.html>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 22:26:27 +0000
To: Folkers, Greg (NIH/NIAID) [E]; Billet, Courtney (NIH/NIAID) [E]; Stover, Kathy (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]; Awwad, David (NIH/NIAID) [C]
Cc: NIAID OD AM
Subject: RE: ASF RE: Dr. Fauci video request: Public Service Recognition Week
Attachments: ASF public service recognition - with tracked edits -05-05-2020.docx



See minor tracked changes.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, May 5, 2020 6:16 PM
To: Billet, Courtney (NIH/NIAID) [E] (b) (6) >; Stover, Kathy (NIH/NIAID) [E] <(b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6); Awwad, David (NIH/NIAID) [C] (b) (6) >
Cc: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: ASF RE: Dr. Fauci video request: Public Service Recognition Week

ASF –

Here is a short script for Public Service Recognition Week. We agreed to do a short video

ASF – can u tweak as needed?

David, could u record in some format that is easy? Cell phone or other I just learned they want by COB tomorrow

<< File: ASF public service recognition.docx >>

From: Seigfreid, Kim (NIH/OD) [E] (b) (6) >
Sent: Monday, April 27, 2020 4:30 PM
To: Billet, Courtney (NIH/NIAID) [E] (b) (6) >; Stover, Kathy (NIH/NIAID) [E] (b) (6) >; Routh, Jennifer (NIH/NIAID) [E] (b) (6) >
Cc: Fine, Amanda (NIH/OD) [E] (b) (6) >; Polimeni, Lydia (NIH/OD) [E] (b) (6)
Subject: Dr. Fauci video request: Public Service Recognition Week

Hi there,

Please see below. HHS is taking over the Partnership for Public Service IG account next week for Public Service Recognition Week. They asked if Dr. Fauci would be willing to do a short 30-second or less pre-recorded video thanking public servants for their work. It would be featured during the takeover, and also on NIH's other sm handles next week. It can be taken on a cell phone as sm does not require higher resolution. Let me know if you would like to accept or decline the request.

Many thanks,
Kim

Kim Seigfreid
Social Media Lead
NIH Office of Communications and Public Liaison
ph: (b) (6)
(b) (6)

From: Muhammad, Janell (HHS/ASPA) <(b) (6)>
Sent: Monday, April 27, 2020 4:10 PM
To: Seigfreid, Kim (NIH/OD) [E] (b) (6) >; Channer, Amber (OS/OASH) (b) (6) >; Foster, Timothy (OS/ASPA) (b) (6) >
Cc: Palczewski, Andrew (HHS/ASPA) <(b) (6)>; Pratt, Michael (OS/ASPA) <(b) (6)>; Sherman, Jennifer (HHS/OASH) (b) (6)
Wilker, Michael (HHS/ASPA) (b) (6); Dine, Brooke (HHS/ASPA) (b) (6)
Subject: Public Service Recognition Week

Hello All,

Hope everyone is holding up well!

OHR is taking over the Partnership for Public Service (PPS) Instagram account during Public Service Recognition Week (May 3-9, 2020). The OHR team has reached out about wanting to develop a senior leader "mashup" video — perhaps including the DepSec. T

They asked about the feasibility of this request. They also inquired about perhaps Dr. Fauci and the SG doing a pre-recorded video thanking public servants for their work.

I wanted to gather the troops so we can identify what all is being planned for this week of recognition and provide a POC for OHR if the request is feasible.

Happy to set up a call, if that is needed to discuss further.

Thanks,
Janell

Janell Muhammad

ASPA Digital Engagement (Team Lead)

U.S. Department of Health and Human Services

Email: (b) (6)

Office: (b) (6)

iPhone: (b) (6)

[HHS on Facebook](#) | [HHS on Twitter](#) | [HHSLatino](#)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 22:05:41 +0000
To: Stover, Kathy (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: FOR ASF REVIEW: Draft PR re: launch of ACTT 2 COVID treatment study

See my minor change of my comment in red.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stover, Kathy (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, May 5, 2020 1:52 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6) >; Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: FOR ASF REVIEW: Draft PR re: launch of ACTT 2 COVID treatment study

Hi Dr. Fauci,

Please find attached for your review a draft press release to announce the launch of the ACTT 2 COVID-19 treatment trial (remdesivir and baricitinib). Below is your draft quote:

“We now have solid data showing that remdesivir diminishes to a modest degree the time to recovery for people hospitalized with COVID-19,” said NIAID Director Anthony S. Fauci, M.D. “ACTT 2 will examine if adding an anti-inflammatory agent to the remdesivir regimen can provide additional benefit for patients, including improving mortality outcomes.”

The trial may start enrollment tomorrow.

Thanks much,
Kathy

Kathy Stover
Branch Chief
News and Science Writing Branch
National Institute of Allergy and Infectious Diseases (NIAID)
Office of Communications and Government Relations
National Institutes of Health/HHS
31 Center Drive, Room 7A17E
Bethesda, MD 20892
Phone: (b) (6)
E-mail: (b) (6)
NIAID Media Line: (301) 402-1663

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 22:00:53 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: COVID-19, (b) (4)
Attachments: Birman_Fauci_Azar_Adams_Hahn_letter_May_05_2020.docx

Please take a look at this.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: (b) (4)
Sent: Tuesday, May 5, 2020 2:51 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Azar, Alex M. (b) (6); Adams, Jerome M <(b) (6)>; Hahn, Stephen (FDA) (b) (6)
Subject: RE: COVID-19, (b) (4)

Dr. Anthony S. Fauci, M.D.
Director, NIAID
Mr. Alex M. Azar II
Secretary, HHS
Dr. Jerome M. Adams, M.D.
Surgeon General, HHS
Dr. Stephen M. Hahn, M.D.
Commissioner of FDA, HHS

Dear Dr. Fauci,
Dear Mr. Azar,
Dear Dr. Adams,
Dear Dr. Hahn,

(b) (4)



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 21:17:33 +0000
To: Mascola, John (NIH/VRC) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]; Erbelding, Emily (NIH/NIAID) [E]; Dieffenbach, Carl (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]; Billet, Courtney (NIH/NIAID) [E]; Graham, Barney (NIH/VRC) [E]; Marovich, Mary (NIH/NIAID) [E]
Subject: RE: D614G mutation paper

Thanks, John.

(b) (5)

(b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mascola, John (NIH/VRC) [E] (b) (6) >
Sent: Tuesday, May 5, 2020 5:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Erbelding, Emily (NIH/NIAID) [E] (b) (6); Dieffenbach, Carl (NIH/NIAID) [E] (b) (6) >; Marston, Hilary (NIH/NIAID) [E] (b) (6) >; Billet, Courtney (NIH/NIAID) [E] (b) (6); Graham, Barney (NIH/VRC) [E] (b) (6) >; Marovich, Mary (NIH/NIAID) [E] (b) (6)
Subject: FW: D614G mutation paper

Tony,

David Montefiori will be on CNN tonight related to this paper – and story in in major newspapers. I spoke with David to get some advance info. The paper is out in BioRxiv.
Few key points

John

Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2

Korber B¹, Fischer WM¹, Gnanakaran S¹, Yoon H¹, Theiler J¹, Abfalterer W¹, Foley B¹, Giorgi EE¹, Bhattacharya T¹, Parker MD³, Partridge DG⁴, Evans CM⁴, de Silva TI^{4,5}, on behalf of the Sheffield COVID-19 Genomics Group[#], LaBranche CC², and Montefiori DC²

Summary

We have developed an analysis pipeline to facilitate real-time mutation tracking in SARS-CoV-2, focusing initially on the Spike (S) protein because it mediates infection of human cells and is the target of most vaccine strategies and antibody-based therapeutics. To date we have identified fourteen mutations in Spike that are accumulating. Mutations are considered in a broader phylogenetic context, geographically, and over time, to provide an early warning system to reveal mutations that may confer selective advantages in transmission or resistance to interventions. Each one is evaluated for evidence of positive selection, and the implications of the mutation are explored through structural modeling. The mutation Spike D614G is of urgent concern; it began spreading in Europe in early February, and when introduced to new regions it rapidly becomes the dominant form. Also, we present evidence of recombination between locally circulating strains, indicative of multiple strain infections. These findings have important implications for SARS-CoV-2 transmission, pathogenesis and immune interventions.

From: David Montefiori, Ph.D. (b) (6)

Sent: Tuesday, May 5, 2020 1:23 PM

To: Mascola, John (NIH/VRC) [E] (b) (6)

Subject: RE: D614G

John,

I thought you should know that the D614G story is getting a lot of press attention today. I story came out in the LA Times this morning that probably started it all. It will likely be on CNN tonight, and maybe other networks.

Just a heads-up.

David

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 20:43:39 +0000
To: Billet, Courtney (NIH/NIAID) [E]; NIAID OD AM
Subject: RE: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards
Attachments: Script to honor Avi Schiffmann - 05-05-2020.docx

Here is my tracked version of the Schiffmann script.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)>
Sent: Tuesday, May 5, 2020 3:06 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: FW: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards

OK – so this is the ask from the Webby awards: a short recorded video message. They have sent a proposed script below -- just an example – obviously we're free to change it. Avi is a pretty extraordinary kid. 17 years old!

Here is the site he created, back in early January. He's aggregating data from WHO, CDC, and other sources: <https://ncov2019.live/>

NBC Today story: <https://www.today.com/parents/17-year-old-built-website-track-coronavirus-t175245>

New Yorker article about him: <https://www.newyorker.com/magazine/2020/03/30/the-high-schooler-who-became-a-covid-19-watchdog>

From: lesley lesleycahillroy.com <lesley@lesleycahillroy.com>
Sent: Tuesday, May 5, 2020 2:32 PM

To: Billet, Courtney (NIH/NIAID) [E] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: Re: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards

Hi Courtney,

This would be a pre-recorded message with Dr Fauci solo. He would set up Avi's award and help to celebrate his Webby moment for him. Avi will be sending us his 5 word Webby speech which will then follow Dr. Fauci's intro. Below is a draft of the introduction for him, let us know if he would like to make any edits/changes. I've also attached the format for taping on his phone/computer. Please let me know if you need any additional information and hoping we can make it work.

Thank you so much

Best

Lesley

DR. FAUCI:

I'm Dr. Anthony Fauci. Unfortunately, you've seen a lot of me lately. But thankfully, I'm here to present some good news and I'm excited for the opportunity to shine some light on one of the many young people who have stepped up and helped us throughout a difficult time.

The 24th Annual Webby Awards would like to honor Avi Schiffmann as the 2020 Person of the Year to recognize his creation of ncov2019.live to track the spread of COVID-19 across the world.

As we collectively navigate the severe impact of COVID-19, including the difficult, but critical calls for nationwide social distancing, the Internet has become the lifeblood of people looking for accurate information about the novel coronavirus and the necessary steps to combat it.

Since launching the site on December 29th, Schiffmann's tracking tool has been an invaluable resource that sounded the alarm on the virus and its spread, notably calling attention to its severity long before many global officials.

At a time when the spread of misinformation can be so detrimental to our efforts, the site has provided over 600 million visitors with accurate real-time data. Schiffmann has helped people around the globe understand COVID-19 and the necessity of upgrades to current health care systems and the importance of measures to flatten the curve.

For having the foresight to track the global spread of COVID-19 and for creating an essential website to provide real-time data about the virus to people everywhere, it is my great privilege to honor Avi Schiffmann as the 2020 Webby Person of the Year.

Thank you

Best

Lesley

Begin forwarded message:

From: Lesley Cahill Roy <lesley@lesleycahillroy.com>
Subject: Re: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards
Date: May 1, 2020 at 12:13:10 PM EDT
To: (b) (6)

Hi Dr Fauci

I just wanted to follow up on below regarding Avi and The Webby Awards.
Would be wonderful if you could be a part of this moment for him.

Thanks so much

Lesley

On Apr 20, 2020, at 1:57 PM,
lesley lesleycahillroy.com<lesley@lesleycahillroy.com> wrote:

<6EDD370A-6106-4603-B557-7AAEE9A9EF79.png>

Dear Dr. Fauci,

I hope you and the family are all safe and healthy during these challenging times. Hailed by The New York Times as "the Internet's highest honor," The Webby Awards has been the premiere award for online excellence for over two decades, honoring the companies and people who have critically shaped digital technology and culture.

This year, due to the impact of the coronavirus The Webby Awards are moving their renowned award show to an online experience. On May 19th, 2020, the 24th Annual Webby Awards will bring together Webby Winners from around the world in an Internet Celebration which will showcase the artists,

organizations, and creators using their platforms to imagine a better tomorrow through information, education, movement, comedy, all while inspiring audiences to take action to enact positive change.

The 24th Annual Webby Awards are proud to honor Avi Schiffmann as the 2020 Person of the Year to recognize his creation of ncov2019.live to track the spread of COVID-19 across the world. We would be honored if Dr. Fauci would “virtually” present Avi with his award.

As we collectively navigate the severe impact of COVID-19 on the world and late calls for nation-wide social distancing, the Internet has become the lifeblood for people looking for accurate information about the novel coronavirus. Since launching the site on December 29th, Avi Schiffmann’s tracking site was a necessary tool that sounded the alarm on the novel coronavirus and its spread, notably calling attention to its severity long before many global officials. By providing over 100 million visitors with real-time data on the virus’ spread, Schiffmann has helped people around the globe understand COVID-19 and the necessity of upgrades to current health care systems and measures to flatten the curve.

For having the foresight to track the global spread of COVID-19 and for creating a website to provide real-time data about the virus to people everywhere, it is our great privilege to honor Avi Schiffmann as the 2020 Webby Person of the Year. The celebration will highlight the important work Avi and his fellow winners are doing, and will mark his hallmark Webby 5-Word acceptance speech in Internet history. Dr. Fauci’s presenter speech could be recorded on his phone and we can send you through a script for him to review, edit and details for format and deadline.

This year’s Webby Awards will also take action, the impact of COVID-19 and government responses around the world, has brought the importance of voting into sharp focus. The Webby Awards has partnered with Vote.or and aim to check the voter registration status of 1 million voters in the United States, promoting the importance of voting to help ensure voter turnout this November is the highest it has ever been. This partnership will integrate into all elements of this year’s online celebration.

Our thoughts are with all of you in this difficult time.

Best

Lesley Cahill Roy

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 19:49:36 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]
Subject: FW:

unlikely

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Konstantin Vulkov <kv@egoist.bg>
Sent: Tuesday, May 5, 2020 3:42 PM
To: NIAID NEWS (NIH/NIAID) <NIAIDNEWS@niaid.nih.gov>
Cc: NIAID Ocpostoffice (NIH/NIAID) <OCPOSTOFFICE@niaid.nih.gov>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Harper, Jill (NIH/NIAID) [E] (b) (6)>
Subject:

Dear Sir/Madam,

My name is Konstantin Vulkov and I am Program director of the biggest Bulgarian private radio station, Darik radio (www.darikradio.bg). This is a news/talk radio station. I am a regular contributor to Bulgarian National TV as well as several online and print publications, editor-in-chief of egoist.bg as well as editor-in-chief of the biannual Darik-owned publication called Dolce Far Niente.

I am a document photographer as well, focusing mainly on portraits.

I am covering the coronavirus pandemic extensively - visiting COVID-19 units across the country, making my daily radio programme "Mind games", writing stories for our websites www.darikradio.bg, www.dnews.bg and egoist.bg.

It would be an honour if I can make a short telephone interview with Mr. Anthony S. Fauci, M.D.

Please let me know if I can call and make the interview. I promise I won't take more than 10 minutes of Mr. Fauci's time.

Your help is much appreciated.

Best,

Konstantin

Konstantin Vulkov
Program Director
Darik Radio
82, Dondukov blvd.
Sofia 1504
Bulgaria

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 19:48:10 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: RE: AUSTRIA - Try to support - COVID 19 - Strategy

Looks fine.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lerner, Andrea (NIH/NIAID) [E] (b) (6)
Sent: Tuesday, May 5, 2020 3:37 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Re: AUSTRIA - Try to support - COVID 19 - Strategy

Dr. Fauci,

I will respond. Here is what I propose to say (in addition to thanking him). Let me know if you'd change anything:

(b) (5)



Sincerely,

Andrea

From: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Date: Tuesday, May 5, 2020 at 10:40 AM
To: "Lerner, Andrea (NIH/NIAID) [E]" (b) (6)
Subject: Fwd: AUSTRIA - Try to support - COVID 19 - Strategy

Not a crazy note. Please respond on my behalf. Thanks

Begin forwarded message:

From: (b) (6)
Date: May 5, 2020 at 8:19:48 AM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Subject: AUSTRIA - Try to support - COVID 19 - Strategy

Dear – highly respected – Dr. Fauci

Why do I try to childishly support a respected expert and personally highly honored Gentleman like you – Dr. Fauxi ?

Because for me – it is heartbreaking and unbelievably disturbing, what was and is going on in the course of the last 4 months in the USA.


I talk about the USA, that relieved my country - AUSTRIA - 75 years ago from the hell of the NAZI-Regime – with American Lives and Blood.

With all my respect, my hopes, my passion, my tears, my mourning – May Grace and Blessing be with You and the USA.



After running the numbers available on COVID 19 pandemic data – my experiences as an Economist led to following analysis and proposed strategy:

**COVID 19 is a true threat for humans >65 years of age with pre-existing illnesses,
but nearly influenza-like for humans < 65 years of age and humans > 65 years of age without pre-existing illnesses**

AUSTRIA: Deaths by age



Deaths as of 100.000 inhabitants by age




**Germany – Death by age – men and women
– mortality rate in %**

Comparison – Italy and China

Coronavirus Mehr Männer unter den Toten

Die Auswertung des Robert-Koch-Instituts (RKI) basiert auf mehr als 149.000 Coronavirus-Fällen in Deutschland. Unter den mehr als 5000 erfassten Covid-19-Todesfällen finden sich über fast alle Altersgruppen hinweg auffallend mehr Männer als Frauen.

■ Männer ■ Frauen



(Anzahl verstorbenen Covid-19-Patienten nach Alter und Geschlecht, Altersgruppen-Einteilung laut RKI, Stand: 23. April 2020)

Quelle: WDR / Martin Mörzow / Quelle: RKI

ntv

Italien: mehr Covid-19-Tote als in China

Mortalitätsrate in Prozent der Erkrankten

Altersgruppen	ITALIEN	CHINA
0-9	0	0
10-19	0	0,2
20-29	0	0,2
30-39	0,3	0,2
40-49	0,4	0,4
50-59	1,0	1,3
60-69	3,5	3,6
70-79	12,8	8,0
≥ 80	20,2	14,8

Anteil der Verstorbenen über 80 Jahre



Proposed Strategy

1. Keep the virus 100% (totally) away from people older than 60 with pre-existing illnesses

Identify, Testing, Shelter, Preserve from contact with virus, Preserve from Hospitalization and ICU

2. **Minimize possible contact with virus for people older than 60 without pre-existing illnesses**

Identify, Testing, Partial Stay at Home, Social Distancing, , Preserve from Hospitalization and ICU

Once 1 and 2 are warranted:

3. **Handle the rest of the population with care, but keep them going and working – as you would do in an influenza-season**

The critical factor for further intervention is the capacity of the regionally available ICU-capacity

Interventions: Social Distancing, Masks, Testing, Tracing, Stay at home when ill, Quarantine at home when ill

Respectfully Yours
Gerald Glockenstein

Mag. Gerald Glockenstein

(b) (6)



From: (b) (6)
Sent: Tue, 5 May 2020 10:47:11 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: request of interview by Giuseppe Sarcina, corriere della Sera

Please try to get clearance. This is the top newspaper in Italy

Begin forwarded message:

From: Sarcina Giuseppe <gsarcina@res.it>
Date: May 5, 2020 at 8:03:29 AM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Subject: Re: request of interview by Giuseppe Sarcina, corriere della Sera

Inviato da iPhone

Dear Doc. Fauci,
this is Giuseppe Sarcina, the us correspondent of Corriere della Sera,
the main italian newspaper.
I understood that you are looking at the italian case with great
attention.
I wonder if you can grant me a short interview.
I have sent an email march 21. But then I saw that you spoke with an
other italian newspaper. So I would like to have a chance to have your
voice for our Readers as well. Corriere della Sera is a newspaper based
in Milano, Lombardy, The region most affected by the coronavirus.
Thank you
Warm Regards
Giuseppe Sarcina
Washington dc

(b) (6)

Oggetto: request of interview by Giuseppe Sarcina, corriere della Sera

Dear Doc. Fauci,

this is Giuseppe Sarcina, the us correspondent of Corriere della Sera,
the main italian newspaper.

I understood that you are looking at the italian case with great
attention.

I wonder if you can grant me a short interview.

That would be really helpful for our readers

Thank you

Warm Regards

Giuseppe Sarcina

Washington dc

From: (b) (6)
Sent: Tue, 5 May 2020 10:43:37 -0400
To: NIAID OD AM
Subject: Fwd: Invitation to Participate in Book Project on COVID-19

Let us discuss. (b) (5)

Begin forwarded message:

From: Dawinder Sidhu <dss@umbc.edu>
Date: May 5, 2020 at 8:14:12 AM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Subject: Invitation to Participate in Book Project on COVID-19

Dr. Fauci,

I hope this email finds you well. I am a professor at the University of Maryland, an elected term member in the Council on Foreign Relations, and a former fellow at the Supreme Court of the United States.

I am writing because I am preparing a book, tentatively entitled "Rebuilding America: A Blueprint for Post-COVID-19 America," consisting of essays by leading figures on (1) how COVID-19 has impacted their particular field, and (2) how that field should be reimagined in light of the crisis. The essays will reconsider all sectors of society, including law, education, healthcare, fashion, music, etc., and collectively will be the first comprehensive guide for post-coronavirus reconstruction efforts.

I am very hopeful that you may be willing to contribute a short essay on how the current coronavirus has impacted public health policy, and how such policies can and should evolve moving forward.


Only 50 industry leaders are being asked to contribute. Commitments have been secured from an impressive group, including a retired four-star general and a preeminent constitutional scholar. I very much hope you will take part in this innovative project given your historic and unparalleled contributions to the public's understanding of the current crisis.

With respect to logistics, I am hoping to receive commitments from all authors this month, with essays due within one month, and with the

essays available through Amazon's expedited publishing platform roughly one month after that. Each essay should be no more than 1,000 words, and I may offer light edits for the author's final approval. A final note: all proceeds from the sale of the book will be donated.

I am very hopeful that you will give every serious consideration to this invitation, and will lend your voice towards reimagining and revitalizing a new America.

Best,
Dave

Dawinder S. Sidhu
University of Maryland
 (b) (6)

dss@umbc.edu

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 13:00:29 +0000
To: Lipkin, Ian W.
Subject: RE: SARS-CoV-2

Thanks, Ian. I hope that you are well.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lipkin, Ian W. (b) (6)
Sent: Tuesday, May 5, 2020 8:39 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Fwd: SARS-CoV-2

Tony,

(b) (4) This prompted the letter I sent to him last evening to which he responded this morning. I don't expect a response but wanted to keep you updated. We deeply appreciate your efforts in steering and messaging.

All my best,
Ian

Ps. Skoll just invested \$5M in piloting the GIDEoN international capacity building and surveillance network that includes Cliff and others in your intramural team.

Begin forwarded message:

From: ZhuChen (b) (6) >
Subject: Re:SARS-CoV-2
Date: May 5, 2020 at 8:16:23 AM EDT
To: Lipkin, Ian W. (b) (6) >

Dear Ian,
Thank you for your email detailing the

(b) (4)

(b) (4)

(b) (4). I shall keep you informed of any

progress in the coming weeks.
Best,
Zhu

----- Original -----

From: "Lipkin, Ian W. (b) (6)";
Date: Tue, May 5, 2020 06:06 AM
To: "ZhuChen" (b) (6) >;
Subject: SARS-CoV-2

Dear Zhu,
The COVID-19 pandemic poses an unprecedented threat not only to global public health but also to economic and political stability. Uncertainty about the origin of COVID-19 pandemic is causing friction worldwide, particularly between China and the United States. There is agreement that the causative agent, SARS-CoV-2 originated in a bat. There is also a high level of confidence that the virus was not deliberately modified in any laboratory. What we do not know is the answers to two questions: (1) whether a precursor virus circulated in the human population before it evolved to become a pandemic virus and (2) whether a precursor virus adapted to humans by first passing through another animal. (b) (4)

With great affection,
Ian

W. Ian Lipkin, MD
John Snow Professor of Epidemiology and Director
Center for Infection and Immunity
Mailman School of Public Health

Professor of Pathology and Neurology
College of Physicians & Surgeons
Columbia University
722 West 168th Street, 17th Floor
New York, NY 10032

Voice: (b) (6)

Fax: (212) 342-9044

Email: (b) (6)

Administrative Coordinator

(b) (6)

www.cii.columbia.edu

Follow CII on Twitter: CII_Columbia | Facebook: CII.Columbia

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 12:40:52 +0000
To: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: VP slides
Attachments: VP brief VRC 5may2020v2.pptx

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mascola, John (NIH/VRC) [E] (b) (6)
Sent: Monday, May 4, 2020 7:07 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: VP slides



Tony, here are slides, including changes we discussed. Patty and all have them.
John

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 12:06:24 +0000
To: Harris, Mary (NIH/NIAID) [E]
Subject: RE: Thank you , Dr. Fauci, Thank you so very much!

Mary:

Many thanks for your kind note. It is much appreciated. Stay well.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Harris, Mary (NIH/NIAID) [E] (b) (6)>
Sent: Tuesday, May 5, 2020 8:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Thank you , Dr. Fauci, Thank you so very much!

Dr. Fauci,

I wanted to personally thank you for being the voice of reason, security, comfort and insight. (b) (6)
(b) (6) As much
as I miss being in the office, I am grateful to say my Director is Dr. Anthony Fauci and share with my family, friends, and church that if you said it, it's gospel. They can bank on it! You have given comfort to my family and myself. You will never know how much! I want you and those who in researchers who are hard at work without much rest but tons of sacrifice including that of your families to find a vaccine, give the Nation a sense of safety and security in this unprecedented time are greatly appreciated. My family, friend and myself are send our prayers for your continued strength. Thank you doesn't seem like enough. I couldn't be prouder to work at NIAID and specifically on the 7th floor of Building 31.

Simply Grateful,

Mary Harris
NIAID Travel Policy Specialist
NIAID Travel Card Coordinator

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 00:37:21 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: CORONA and BACTERIAL SUPERINFECTION
Attachments: 1918 influenza insight- fauci.pdf, ESP el arroz epidemol.pdf, Infection and Immunity-2015-Rynda-Apple-3764.full.pdf, JClinsightco-infection.pdf, lancet.png, Mail Esp.pdf, mail germany 1.pdf, piramide.png, PLEASE FORWARD THIS MESSAGE TO error.pdf, portugal.pdf, Predominant Role of Bacterial Pneumonia as a Cause of Death in Pandemic Influenza - Dr Fauci.pdf, press usa.pdf, Recuperados.pdf, spanish flu 1918 - eng original.pdf, tyska pres mail.pdf, US error message.pdf, Us mail 0408.pdf, WHO-2019-nCoV-clinical-2020.4-eng.pdf, virus piramdie eng.png

Please take a look and decide. Thanks.

From: Ola Melhus [REDACTED] (b) (6)
Sent: Monday, May 4, 2020 12:25 PM
To: [REDACTED] (b) (6) Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
[REDACTED]
Subject: CORONA and BACTERIAL SUPERINFECTION

Dear Doctors,

I don't know if you have got this information.

A truly deadly virus

cannot spread very far. Why? Because people quickly get sick and die. In other words, they cannot spread the virus further, which is a prerequisite for a large spread like corona. Covid-19 has spread throughout the world.

The premise is that it is not very dangerous, it causes mild symptoms for most people, many do not even notice that they were sick. But the virus has different phases in the body, after a while it goes into a resting phase, you feel better, but the virus is still present and can pass on. Covid-19 is an optimally developed virus that spreads rapidly around the world. But if it were really deadly, almost everyone would die.

So far in our 4 billion long history, there have been **no airborne** viruses or bacteria. Yes, in the hollywood movie "outbreak" there was, but it was a movie. Why hasn't it?

If it had existed, this planet would have been a dead planet without life. It would have killed all living. It is possible that there is somewhere else in the universe, but not here on planet Earth. Not now. Remember, this is not the first time a new virus is spreading in the world. What is happening now has happened earlier in our long history.

But people are die you say. Yes, but the virus don't kill them. The virus open a "door" in the cell wall thats allows for bacterias, how always are present, to invade the body and create an aggressiv bacterial superinfection. That's what kills them. See,

1. Influenza and Bacterial Superinfection: Illuminating the Immunologic Mechanisms of Disease.




FIG 1 Common pathways of susceptibility to postinfluenza bacterial superinfections. Early after influenza virus infection, mice show reduced susceptibility to superinfection that is at least in part due to increased production of IL-13. This IL-13-rich environment does not permit IFN- γ production, allowing unaltered phagocytosis and clearance of bacteria. The role for either neutrophils or macrophages (phagocytes) in bacterial clearance early during influenza virus infection has not been fully investigated. Progression of influenza virus infection results in increased susceptibility to secondary infection. Type I IFN (or IL-27) signaling initiated in response to influenza virus infection results in downregulated production of IL-1 β and IL-23 and impaired type 17 immune responses. Inhibition of IL-17 and IL-22 reduces production of antimicrobial peptides. Type I IFN signaling also reduces levels of neutrophil chemoattractants Cxcl1 and Cxcl2 and can induce formation of NETs. IL-27 induced during influenza virus infection further suppresses IL-17 production but stimulates production of regulatory cytokine IL-10, which contributes to increased susceptibility to superinfection, presumably by alteration of the anti-influenza inflammatory response. IAV, influenza A virus infection.

and this reports:

2. Deaths from Bacterial Pneumonia during 1918–19 Influenza Pandemic

3. The 1918 Influenza Pandemic: Insights for the 21st Century

4. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness

5. Survival during influenza-associated bacterial superinfection improves following viral- and bacterial-specific monoclonal antibody treatment

6. Predominant Role of Bacterial Pneumonia as a Cause of Death in Pandemic Influenza: Implications for Pandemic Influenza Preparedness

How can this happen? How can the doctors be so blind. I have a theory about this and here it comes:

My (b) (6) was a psychologist. May she rest in peace in heaven.

It seems that the corona virus has affected the brain more in a certain group in society, namely politicians, doctors, journalists and other with power and positions in the society. The virus is not dangerous for this group, but it's opens a door in the brain's cell wall that allows it to enter the fear center of the brain.

This door has been closed for many years. We haven't had any major wars and nothing has threatened them. They have felt invulnerable. Convinced of their own superior ability and greatness. Not only can they control the people, they can now control the climate by turning the carbon dioxide tap. If they close it, the temperature drops, if they open it the temperature goes up. They don't know that the sun is 109 times as big as our planet. 109 times. It seems so small when we look up in the sky. They thought they could control everything.

Then came the VIRUS, they receive an abrupt awakening. They get scared. Politicians get sick and die. Doctors die. The brain is attacked by fear virus. They can no longer think clearly and logically. The panic is near, they are reminded of their own mortality. Just like a virus in a computer. It's slows it down and it becomes unusable. That's what happens when a fear virus attacks the brain.

Here where I live, there are panic over 1600 confirmed cases. The television is talking "infected persons" when there is "confirmed laboratory cases". It's two different things. Misleading the people. Why panic over 1 600 infected? Closing all not necessary business, all schools, all except for supermarket, gas station, banks. You can't go out after 5.00 pm. If you do, you get arrested.

Why? They are scared. Because the ruling class is afraid. Everyone with this masks. Doctors crying on television. The President with mask. They are scared. Doctors. Journalists. Polices.

2020. The year when the world got completely crazy.

You have an medical obligation to inform the world about the truth.

Kind regards,

Ola Melhus

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 00:36:13 +0000
To: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Therapeutics and vax
Attachments: NIAID SARS-CoV-2 Tx and Vax overview.docx

Please print out and put in folder labelled "COVID-19 Therapeutics and Vaccines"

From: Marston, Hilary (NIH/NIAID) [E] (b) (6)
Sent: Monday, May 4, 2020 12:32 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C]
<(b) (6)>
Subject: Therapeutics and vax

For your Therapeutics discussion later today


From: (b) (6)
Sent: Mon, 4 May 2020 19:52:45 -0400
To: Troye, Olivia EOP/NSC
Cc: Hurst, Natalie R. EOP/OVP; Mascola, John (NIH/VRC) [E]; Graham, Barney (NIH/VRC) [E]; Francis Collins
Subject: Re: Email connecting us

Here they are. Thanks

On May 4, 2020, at 7:46 PM, Troye, Olivia EOP/NSC
(b) (6)

Hi Dr. Fauci,
Per our conversation, sending you a note. I'm copying Natalie who will help get them cleared in.
Thank you!
Olivia

Olivia Troye
Special Advisor to the Vice President for
Homeland Security, Counterterrorism, and North America
Office of the Vice President, National Security Affairs
White House Coronavirus Task Force
O: (b) (6) | M: (b) (6) (Does not receive texts)
(b) (6)





From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 4 May 2020 21:05:39 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Invitation to join (virtually) the ACTIV Leadership Meeting 5/6

Please see me about this.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Collins, Francis (NIH/OD) [E] (b) (6) >
Sent: Monday, May 4, 2020 11:18 AM
To: ICDDIR-L@LIST.NIH.GOV
Cc: Parker, Ashley (NIH/OD) [E] (b) (6); Wholley, David (FNIH) [T]
(b) (6) >; Melencio, Cheryl (FNIH) [T] (b) (6) >
Subject: Invitation to join (virtually) the ACTIV Leadership Meeting 5/6

Dear Colleagues,

As you may be aware, the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership has been moving forward rapidly to address the global pandemic. We held our initial ACTIV leadership meeting on April 3rd including, NIH, FDA, BARDA, EMA, and industry heads of research and development. Four working groups were formed out of this meeting to focus on preclinical therapeutics, clinical therapeutics, clinical trial capacity, and vaccines.

Although some ICs have representatives participating in the working groups, we recognize there is a need to keep everyone looped in to the various activities and progress of the partnership, particularly in view of all of the concurrent IC projects about COVID-19. The ACTIV working groups will be delivering their second report to the **ACTIV Leadership Group on Wednesday, May 6, from 3:30-5:00pm**. I am writing to invite the ICDs to listen-in on this meeting. There will be a lot to cover during the meeting and the members of the Leadership Group will be asking the questions. But to give a chance for us NIHers to

discuss what has been presented, I am scheduling a separate ICD call for 5:05-5:30pm, immediately following the ACTIV leadership meeting.

If you are available to take part, please send your responses to David Wholley and Cheryl Melencio of FNIH (cc'd here) by noon tomorrow, May 5th. Once you confirm your attendance, Cheryl will send you a calendar invite for both the ACTIV leadership meeting and the ICD follow-up call.

Best regards,
Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 4 May 2020 15:28:08 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Need your help Covid-19 CAS-10685

I do not know this person. We should refer him to Brett Giroir.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Sent: Monday, May 4, 2020 10:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: FW: Need your help Covid-19 CAS-10685

Do you know this person?

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept

liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Harris, Kara (NIH/NIAID) [E] (b) (6) >
Sent: Friday, May 1, 2020 8:38 AM
To: Conrad, Patricia (NIH/NIAID) [E] <(b) (6) >
Cc: Auchincloss, Hugh (NIH/NIAID) [E] (b) (6) >; Billet, Courtney (NIH/NIAID) [E] (b) (6) >; Haskins, Melinda (NIH/NIAID) [E] (b) (6) >
Subject: FW: Need your help Covid-19 CAS-10685

Hi, Patty –

This individual states that he previously worked with Dr. Fauci and that he knows him. Please let me know if you would like Public Inquiries to handle.

Thanks,
Kara

From: Ray Rosa (b) (6) >
Sent: Thursday, April 30, 2020 5:58 PM
To: NIAID Ocpostoffice (NIH/NIAID) <OCPOSTOFFICE@niaid.nih.gov>
Subject: Need your help Covid-19

I am working with a group of physicians whom need your guidance on Serum Covid-19 tests. I need someone to call me so I can ask specific questions. I worked with Dr Fauci back in 1998 when I was in the Air Force. So he does know me. Ray Rosa is the name. Can you please call me.

(b) (6) cell

Sent from AOL Mobile Mail
Get the new AOL app: mail.mobile.aol.com

From: Auchincloss, Hugh (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 4 May 2020 14:00:23 +0000
To: NIAID OD AM
Subject: FW: inquiry

Another one that he will probably want to do.

From: Augustine M. K. Choi [REDACTED] (b) (6)
Sent: Monday, May 4, 2020 9:21 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: inquiry

Hi Tony,

I can only imagine your schedule. Thank you for all you are doing for the country in our fight against this virus.

Weill Cornell would like to invite you for a 3 min remarks to the Class of 2020 at their upcoming graduation if your schedule allows. The virtual graduation is on May 28th. We can tape your remarks at any time which fits your schedule, from now or up to right before May 28.

If you able to accept this invitation, please let me know. If not, totally understandable and we would love to have you back again after covid subsides.

Thanks again!

Augustine M.K. Choi, M.D.
Stephen and Suzanne Weiss Dean, Weill Cornell Medicine
Provost for Medical Affairs, Cornell University

Weill Cornell Medicine
1300 York Avenue, Suite F-113 Box 83 | New York, NY 10065
Telephone: 212-746-6005
Fax: 212-746-8424
Email: amc2056@med.cornell.edu

From: Anthony Fauci <[REDACTED] (b) (6)>
Date: Monday, March 30, 2020 at 12:19 PM
To: Augustine Choi [REDACTED] (b) (6)
Subject: [EXTERNAL] RE: all wearing masks

My work with the Coronavirus Task Force and the large volume of incoming emails precludes me or my staff from answering each individual message. I would encourage you to visit www.coronavirus.gov for the latest information and guidance related to COVID-19.

Thank you, and best regards.

Anthony S. Fauci, M.D.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 4 May 2020 12:28:04 +0000
To: Corey, Larry
Subject: FW: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

As an FYI for the 9:00 AM meeting.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Dolsten, Mikael (b) (6) >
Sent: Monday, May 4, 2020 8:15 AM
To: Collins, Francis (NIH/OD) [E] (b) (6) >
Cc: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Mascola, John (NIH/VRC) [E] (b) (6) >; Lane, Cliff (NIH/NIAID) [E] (b) (6) >; Lowy, Douglas (NIH/NCI) [E] (b) (6) >; Jansen, Kathrin (b) (6) >
Subject: Re: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

Francis
Thanks for the response

We appreciate the federal initiative and opportunity to influence it's design . I know Kathrin Jansen (ccd here) from PFE is working w the team on this.

(b) (4)
(b) (4) It's great to be collaborating w NIH-FDA for the best of our nation and global health .

In the master protocol , I hope the working committee is discussing (b) (5)
(b) (5)

(b) (5)

These are just two examples we can discuss on Wednesday in the leadership meeting of times permits .

(b) (5)

I look forward to the meeting

Best
Mikael
Sent from my iPhone

On May 4, 2020, at 04:26, Collins, Francis (NIH/OD) [E] (b) (6) wrote:

Hi Mikael,

Wow, sounds like you are making fantastic progress with the vaccine program, and we would certainly not want to do anything to slow you down! I understand that you are evaluating several mRNA formats with BioNTech. If one of those turned out to be ready for phase II/III in late June, we would be most interested in the possibility of including that in the master protocol. Please keep Tony and me in touch with Pfizer's progress, including which mRNA format you choose to move into advanced development.

Hope to hear your voice at the ACTIV Leadership Group meeting on Wednesday. There will be a lot to talk about!

Best, Francis

From: Dolsten, Mikael [REDACTED] (b) (6) >

Sent: Sunday, May 3, 2020 6:26 PM

To: Collins, Francis (NIH/OD) [E] [REDACTED] (b) (6) >

Subject: Re: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

Hi Francis

We certainly enjoy taking part in ACTIV

I will check if we did get our drugs on the lists below



I will discuss w Kathrin Jansen if we may have an option to add one of our several vaccine formats that is less advanced or a refined format of our most advanced in the master protocol etc

If we can agree about shared key endpoints , we can include that cross all studies Whether master protocol or more advanced sponsor trials which helps comparison

Happy to discuss w you and welcome your advice
Mikael

Mikael Dolsten, M.D., Ph.D.
Chief Scientific Officer and President,
Worldwide Research, Development and Medical
Pfizer Inc.
235 East 42nd Street
New York, NY 10017

On May 3, 2020, at 5:16 PM, Collins, Francis (NIH/OD) [E]

[REDACTED] (b) (6) > wrote:

Mats

Hi Mikael,

Thanks for your note and this update on exciting progress on several fronts. ACTIV is moving forward with gratifying speed and commitment. With regard to vaccines, tomorrow the ACTIV vaccines WG will be discussing a master protocol for a phase II/III trial with adaptive design, multiple arms, and a shared placebo arm, aiming to launch on or about July 1. FDA is strongly supportive. The Moderna, Sanofi, and JnJ vaccines are likely to be included – might Pfizer also join?

(b) (4) – I trust that compound is on the list of therapeutic candidates that the Clinical Therapeutics WG of ACTIV is reviewing? They are supposed to put forward a tentative list for the Wednesday Leadership Group meeting. Ditto with the (b) (4) option!

Looking forward to catching up soon!

Best, Francis

From: Dolsten, Mikael (b) (6) >
Sent: Sunday, May 3, 2020 12:06 PM
To: Collins, Francis (NIH/OD) [E] (b) (6) >
Subject: Re: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

Hi Francis

I trust you are well but likely working too many hours as we all experience in the difficult Covid times.

In the vaccine space we have progressed rapidly and are already in phase 1/2 studies dose escalation phase testing multiple format of mRNA vaccine . Key for us is (b) (4) .

In the anti-viral areas we are (b) (4)

(b) (4)

(b) (4)

We also want to start (b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

How are things going w ACTIV.
Any issues to discuss ?

I hope our PFE representatives in ACTIV are helping out well

Pls let me know if there is anything particular to discuss or I can help you with

Best personal regards
Mikael

Sent from my iPhone

On May 3, 2020, at 10:49, Collins, Francis (NIH/OD) [E]

(b) (6) > wrote:

Hi Morten,

Thanks for your note. It would be great to have this connection – but let me suggest that you start with David Wholley (cc'd here), as he oversees all four of the ACTIV working groups. Joe is the program lead for the group on preclinical therapeutics/repurposing.

Best, Francis

From: Sogaard, Morten (b) (6)

Sent: Sunday, May 3, 2020 10:46 AM

To: Collins, Francis (NIH/OD) [E] (b) (6)

Cc: Dolsten, Mikael (b) (6); Prof Trevor M Jones CBE FMedSci (b) (6); Sogaard, Morten (b) (6) >

Subject: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

Francis,

I hope you are having a good weekend.

Quick question: Would you be OK if I/we reached out to Joe Menetski, who I understand leads many of the ACTIV efforts. We have come to know Joe very well as a great collaborator on the AMP gene therapy initiative and It would be very easy I think working informally with Joe to look a bit more under the hood and identify/ map opportunities for alignment with the other initiatives.

All the Best,
Morten

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 4 May 2020 10:53:14 +0000
To: Haskins, Melinda (NIH/NIAID) [E]
Subject: RE: EOP/OMB Alert: May Hearing Guidance

What does this mean for the May 12 Senate Hearing?

From: Haskins, Melinda (NIH/NIAID) [E] (b) (6)
Sent: Monday, May 4, 2020 6:20 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] <(b) (6)>
Subject: EOP/OMB Alert: May Hearing Guidance

I have highlighted in yellow the fundamentals of the OMB guidance below.

Melinda


From: Hallett, Adrienne (NIH/OD) [E] (b) (6)>
Sent: Sunday, May 3, 2020 9:54 PM
To: OD-OLPA-Leg Contacts <OD-OLPA-LegContacts@OD.NIH.GOV>
Subject: Fwd: May Hearing Guidance


FYI. New OMB hearing guidance.

From: Yaworske, Jason A. EOP/OMB (b) (6)>
Sent: Sunday, May 3, 2020 9:06 PM
Cc: Ueland, Eric M. EOP/WHO <(b) (6)>; Hodgson, Christopher (ovp.eop.gov) <(b) (6)>
Subject: May Hearing Guidance
Importance: High

Agency legislative affairs teams,

(b)(5) - PCP





Thank you, and please let us know if you have any questions.

Jason

Jason Yaworske
Associate Director for Legislative Affairs
Office of Management and Budget

(b) (6) (o)

(b) (6) (c)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 4 May 2020 00:50:18 +0000
To: Collins, Francis (NIH/OD) [E]; Mascola, John (NIH/VRC) [E]; Lane, Cliff (NIH/NIAID) [E]
Cc: Tabak, Lawrence (NIH/OD) [E]; Parker, Ashley (NIH/OD) [E]
Subject: RE: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

We need to find out precisely what he is talking about when he says “vaccine formats” and “refined formats”. I really do not know what he is talking about. (b) (4), (b) (5)

[REDACTED]

[REDACTED]

John/Cliff:
Let us discuss this at our morning meeting.

Thanks,
Tony

From: Collins, Francis (NIH/OD) [E] (b) (6) >
Sent: Sunday, May 3, 2020 8:03 PM
To: Mascola, John (NIH/VRC) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Tabak, Lawrence (NIH/OD) [E] (b) (6); Parker, Ashley (NIH/OD) [E] (b) (6)
Subject: FW: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

Hi John, Cliff, and Tony,

See note below, where Mikael Dolsten indicates Pfizer is planning to (b) (4). He intends to discuss our master protocol possibility with Kathrin Jensen. I am not quite sure what he means by “several vaccine formats”.

Does this timetable sound realistic?

Any suggestion about a response?

Francis

From: Dolsten, Mikael (b) (6)
Sent: Sunday, May 3, 2020 6:26 PM
To: Collins, Francis (NIH/OD) [E] (b) (6)

Subject: Re: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/collaboration on ACTIV activities?

Hi Francis

We certainly enjoy taking part in ACTIV

I will check if we did get our drugs on the lists below



I will discuss w Kathrin Jansen if we may have an option to add one of our several vaccine formats that is less advanced or a refined format of our most advanced in the master protocol etc

If we can agree about shared key endpoints , we can include that cross all studies Whether master protocol or more advanced sponsor trials which helps comparison

Happy to discuss w you and welcome your advice
Mikael

Mikael Dolsten, M.D., Ph.D.
Chief Scientific Officer and President,
Worldwide Research, Development and Medical
Pfizer Inc.
235 East 42nd Street
New York, NY 10017

On May 3, 2020, at 5:16 PM, Collins, Francis (NIH/OD) [E] <[REDACTED]> (b) (6) wrote:
Mats

Hi Mikael,

Thanks for your note and this update on exciting progress on several fronts. ACTIV is moving forward with gratifying speed and commitment. With regard to vaccines, tomorrow the ACTIV vaccines WG will be discussing a master protocol for a phase II/III trial with adaptive design, multiple arms, and a shared placebo arm, aiming to launch on or about July 1. FDA is strongly supportive. The Moderna, Sanofi, and JnJ vaccines are likely to be included – might Pfizer also join?

(b) (4)– I trust that compound is on the list of therapeutic candidates that the Clinical Therapeutics WG of ACTIV is reviewing? They are supposed to put forward a tentative list for the Wednesday Leadership Group meeting. Ditto with the (b) (4) option!

Looking forward to catching up soon!

Best, Francis

From: Dolsten, Mikael (b) (6)

Sent: Sunday, May 3, 2020 12:06 PM

To: Collins, Francis (NIH/OD) [E] (b) (6)

Subject: Re: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

Hi Francis

I trust you are well but likely working too many hours as we all experience in the difficult Covid times.

In the vaccine space we (b) (4)

(b) (4)

In the anti-viral areas we are (b) (4)

(b) (4)

(b) (4)

How are things going w ACTIV.
Any issues to discuss ?

I hope our PFE representatives in ACTIV are helping out well

Pls let me know if there is anything particular to discuss or I can help you with

Best personal regards
Mikael

Sent from my iPhone

On May 3, 2020, at 10:49, Collins, Francis (NIH/OD) [E] [REDACTED] (b) (6) wrote:

Hi Morten,

Thanks for your note. It would be great to have this connection – but let me suggest that you start with David Wholley (cc'd here), as he oversees all four of the ACTIV working groups. Joe is the program lead for the group on preclinical therapeutics/repurposing.

Best, Francis

From: Sogaard, Morten [REDACTED] (b) (6) >
Sent: Sunday, May 3, 2020 10:46 AM
To: Collins, Francis (NIH/OD) [E] [REDACTED] (b) (6) >
Cc: Dolsten, Mikael [REDACTED] (b) (6); Prof Trevor M Jones CBE FMedSci [REDACTED] (b) (6); Sogaard, Morten [REDACTED] (b) (6)
Subject: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

Francis,

I hope you are having a good weekend.

Quick question: Would you be OK if I/we reached out to Joe Menetski, who I understand leads many of the ACTIV efforts. We have come to know Joe very well as a great collaborator on the AMP gene therapy initiative and It would be very easy I think working informally with Joe to look a bit more under the hood and identify/ map opportunities for alignment with the other initiatives.

All the Best,
Morten

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 21:45:43 +0000
To: Greg Folkers ([REDACTED] (b) (6)); Doepel, Laurie (NIH/NIAID) [E]
Subject: Pitt and INC
Attachments: Commencement Remarks, generic 30-sec for UPitt and UNC SOM, - FINAL - for 5-08-2020 (videos).docx

See attachment with remarks for UPitt and UNC . I have left the tracked changes showing so that you can see what I have done. Please accept these and then proof it. It is now marked FINAL (tracking needs to be accepted) in the OD folder. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 21:28:33 +0000
To: Greg Folkers (b) (6); Doepel, Laurie (NIH/NIAID) [E]
Subject: USUHS
Attachments: Commencement Remarks, USUHS 2-min -FINAL - for 5-16-2020 (Video).docx

See attachment with USUHS remarks . I have left the tracked changes showing so that you can see what I have done. Please accept these and then proof it. It is now marked FINAL (tracking needs to be accepted) in the OD folder. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 21:21:04 +0000
To: Greg Folkers (b) (6); Doepel, Laurie (NIH/NIAID) [E]
Subject: AMA
Attachments: Commencement Remarks, AMA 3-min - FINAL - for May 2020 (Video).docx

See attachment with AMA remarks . I have left the tracked changes showing so that you can see what I have done. Please accept these and then proof it. It is now marked FINAL (tracking needs to be accepted) in the OD folder. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 20:58:32 +0000
To: Doepel, Laurie (NIH/NIAID) [E]; Greg Folkers (b) (6)
Subject: UCSF
Attachments: Commencement Remarks, UCSF SOM - FINAL - for May 2020 (Video).docx

Greg/Laurie:

I am attaching the UCSF 3 minute talk. I labeled it as "FINAL" and it is in the OD folder. However, I have left in the tracked changes for you to see what I did. Please accept the changes and then go over it one last time. I like it the way it is and so please no trivial corrections.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 20:11:08 +0000
To: Doepel, Laurie (NIH/NIAID) [E]; Greg Folkers (b) (6)
Subject: Holy Cross
Attachments: Commencement Remarks, Holy Cross - FINAL - for 05-22-2020 (video).docx

The Holy Cross video script is in the OD File marked as "FINAL". I have left the tracked changes showing so that you will know what I have done. Please accept the changes and take a final look. I am also attaching for your look.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 18:34:28 +0000
To: Tromberg, Bruce (NIH/NIBIB) [E]; 'Sharpless, Ned
(b) (6)'
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: 2 quick points

Thanks, Bruce.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Tromberg, Bruce (NIH/NIBIB) [E] (b) (6)>
Sent: Sunday, May 3, 2020 2:28 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); 'Sharpless, Ned
(b) (6)'
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: Re: 2 quick points

Hi Tony,

Thanks! Hope you are doing well.

This is basically exactly what we are working to facilitate with our RADx and digital health (app) platform initiatives...greatly expanding testing and creating a digital backbone to provide people with ways to access tests and interpret results. For expanding testing platforms, see <https://www.nibib.nih.gov/news-events/newsroom/nih-mobilizes-national-innovation-initiative-covid-19-diagnostics> We have >700 applications that have been started in just a few days. For the digital health (e.g. app) platform we've put a lot of thought into the design and are hoping a contractor will be able to launch a pilot study of healthcare workers soon. Ned and I plan on issuing additional calls in this area with multiple institutes as stakeholders in the coming weeks.

Best,
Bruce

Bruce J. Tromberg, Ph.D.

Director
National Institute of Biomedical Imaging and Bioengineering
National Institutes of Health
Building 31, Room 1C14
Bethesda, MD 20892-2281
(b) (6)
301-480-0679 - FAX
(b) (6)
<http://www.nibib.nih.gov>

From: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Date: Sunday, May 3, 2020 at 1:55 PM
To: "'Sharpless, Ned (b) (6)>
"Tromberg, Bruce (NIH/NIBIB) [E]" (b) (6)>
Cc: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)
Subject: FW: 2 quick points

Ned/Bruce:

I thought that I would pass this on to you in case you have interest. Thanks.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Eric Ottesen (b) (6)>
Sent: Saturday, May 2, 2020 8:23 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: 2 quick points

Dear Tony,

1. I had planned to write to thank you for giving an interview (b) (6) for the Washington Post last month. Your generosity with time was 'all Tony,' and I did appreciate it. I was waiting for the chaos around you to subside before writing but.....
2. Last evening I was asked to forward the message below to you. You might already know Jack Warren, Professor of Medicine and Infectious Diseases at U. Maryland (b) (6). As his email says, (b) (6) with Samsung's venture capital group, which has an idea for a future, comprehensive surveillance system for COVID-19 (b) (4). It is interesting, but all I know is what I read in the power-point attached. I cannot imagine you would have time to look at it yourself, but perhaps it could be shared with other systems-oriented individuals working towards 'opening up' responsibly.

Pardon me for stepping out of my normal NTD 'swim lane' but I did want to help out (b) (6), and certainly nothing is more important these days than COVID-19 and the outstanding work you are doing to manage it.

All the very best,

-Eric

From: Warren, John [mailto:(b) (6)]
Sent: Thursday, April 30, 2020 6:52 PM
To: (b) (6)
Subject: Jack Warren

Eric

A voice from the past. Covid-19 prevented us from meeting up (b) (6) but I'm writing because it might yet bring at least the two of us together.

(b) (6) Samsung's venture capital group and his team has what I think is an incredibly useful idea for contact tracing for covid-19 as well as actually opening the economy up again. The idea is contained within the attachment.

I wonder if you still have any contacts with Anthony Fauci. Is so, could you see your way clear to forwarding the attachment to him? The group has identified some appropriate test manufacturers but is at the point where they need to know the spectrum so as to focus on the optimal ones. The thought was that Tony Fauci might be the best person to know what tests are in development stage.

What are your thoughts?

Don't worry about confidentiality; they want to widely share this idea so as to get it out as quickly as possible.

Thanks

Jack Warren MD
Professor of Medicine
Division of Infectious Diseases
University of Maryland School of Medicine
Baltimore MD 21201

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 17:56:39 +0000
To: NIAID OD AM
Subject: RE: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards

????? Who is this person?

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Auchincloss, Hugh (NIH/NIAID) [E] (b) (6) > On Behalf Of Fauci, Anthony (NIH/NIAID) [E]
Sent: Sunday, May 3, 2020 1:55 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: FW: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards

From: lesley lesleycahillroy.com <lesley@lesleycahillroy.com>
Sent: Friday, May 1, 2020 12:13 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards

Hi Dr Fauci

I just wanted to follow up on below regarding Avi and The Webby Awards. Would be wonderful if you could be a part of this moment for him.

Thanks so much

Lesley

On Apr 20, 2020, at 1:57 PM, lesley lesleycahillroy.com <lesley@lesleycahillroy.com> wrote:

<6EDD370A-6106-4603-B557-7AAEE9A9EF79.png>

Dear Dr. Fauci,

I hope you and the family are all safe and healthy during these challenging times. Hailed by The New York Times as “the Internet’s highest honor,” The Webby Awards has been the premiere award for online excellence for over two decades, honoring the companies and people who have critically shaped digital technology and culture.

This year, due to the impact of the coronavirus The Webby Awards are moving their renowned award show to an online experience. On May 19th, 2020, the 24th Annual Webby Awards will bring together Webby Winners from around the world in an Internet Celebration which will showcase the artists, organizations, and creators using their platforms to imagine a better tomorrow through information, education, movement, comedy, all while inspiring audiences to take action to enact positive change.

The 24th Annual Webby Awards are proud to honor Avi Schiffmann as the 2020 Person of the Year to recognize his creation of ncov2019.live to track the spread of COVID-19 across the world. We would be honored if Dr. Fauci would “virtually” present Avi with his award.

As we collectively navigate the severe impact of COVID-19 on the world and late calls for nation-wide social distancing, the Internet has become the lifeblood for people looking for accurate information about the novel coronavirus. Since launching the site on December 29th, Avi Schiffmann’s tracking site was a necessary tool that sounded the alarm on the novel coronavirus and its spread, notably calling attention to its severity long before many global officials. By providing over 100 million visitors with real-time data on the virus’ spread, Schiffmann has helped people around the globe understand COVID-19 and the necessity of upgrades to current health care systems and measures to flatten the curve.

For having the foresight to track the global spread of COVID-19 and for creating a website to provide real-time data about the virus to people everywhere, it is our great privilege to honor Avi Schiffmann as the 2020 Webby Person of the Year. The celebration will highlight the important work Avi and his fellow winners are doing, and will mark his hallmark Webby 5-Word acceptance speech in Internet history. Dr. Fauci's presenter speech could be recorded on his phone and we can send you through a script for him to review, edit and details for format and deadline.

This year’s Webby Awards will also take action, the impact of COVID-19 and government responses around the world, has brought the importance of voting into sharp focus. The

Webby Awards has partnered with Vote.or and aim to check the voter registration status of 1 million voters in the United States, promoting the importance of voting to help ensure voter turnout this November is the highest it has ever been. This partnership will integrate into all elements of this year's online celebration.

Our thoughts are with all of you in this difficult time.

Best

Lesley Cahill Roy

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 17:55:14 +0000
To: 'Sharpless, Ned' (b) (6); Tromberg, Bruce (NIH/NIBIB) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: 2 quick points
Attachments: covid contact tracing.pdf

Ned/Bruce:

I thought that I would pass this on to you in case you have interest. Thanks.
Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Eric Ottesen (b) (6)
Sent: Saturday, May 2, 2020 8:23 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: 2 quick points

Dear Tony,

1. I had planned to write to thank you for giving an interview (b) (6) for the Washington Post last month. Your generosity with time was 'all Tony,' and I did appreciate it. I was waiting for the chaos around you to subside before writing but.....
2. Last evening I was asked to forward the message below to you. You might already know Jack Warren, Professor of Medicine and Infectious Diseases at U. Maryland (b) (6). As his email says (b) (6) Samsung's venture capital group, which has an idea for a future, comprehensive surveillance system for COVID-19 (b) (4). It is interesting, but all I know is what I read in the power-point attached. I cannot imagine you would have time

to look at it yourself, but perhaps it could be shared with other systems-oriented individuals working towards 'opening up' responsibly.

Pardon me for stepping out of my normal NTD 'swim lane' but I did want to help out (b) (6) and certainly nothing is more important these days than COVID-19 and the outstanding work you are doing to manage it.

All the very best,

-Eric

From: Warren, John [mailto:(b) (6)]
Sent: Thursday, April 30, 2020 6:52 PM
To: (b) (6)
Subject: Jack Warren

Eric

A voice from the past. Covid-19 prevented us from meeting up (b) (6) but I'm writing because it might yet bring at least the two of us together.

(b) (6) Samsung's venture capital group and his team has what I think is an incredibly useful idea for contact tracing for covid-19 as well as actually opening the economy up again. The idea is contained within the attachment.

I wonder if you still have any contacts with Anthony Fauci. Is so, could you see your way clear to forwarding the attachment to him? The group has identified some appropriate test manufacturers but is at the point where they need to know the spectrum so as to focus on the optimal ones. The thought was that Tony Fauci might be the best person to know what tests are in development stage.

What are your thoughts?

Don't worry about confidentiality; they want to widely share this idea so as to get it out as quickly as possible.

Thanks

Jack Warren MD
Professor of Medicine
Division of Infectious Diseases
University of Maryland School of Medicine
Baltimore MD 21201

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 17:53:55 +0000
To: Eric Ottesen
Subject: RE: 2 quick points

Eric:

Thanks for your note. No problem. I will forward this to people here at NIH who are pursuing such approaches. I hope that all is well with you.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Eric Ottesen (b) (6)>
Sent: Saturday, May 2, 2020 8:23 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: 2 quick points

Dear Tony,

1. I had planned to write to thank you for giving an interview (b) (6) for the Washington Post last month. Your generosity with time was 'all Tony,' and I did appreciate it. I was waiting for the chaos around you to subside before writing but....
2. Last evening I was asked to forward the message below to you. You might already know Jack Warren, Professor of Medicine and Infectious Diseases at U. Maryland (b) (6). As his email says, (b) (6) Samsung's venture capital group, which has an idea for a future, comprehensive surveillance system for COVID-19 (b) (4). It is interesting, but all I know is what I read in the power-point attached. I cannot imagine you would have time to look at it yourself, but perhaps it could be shared with other systems-oriented individuals working towards 'opening up' responsibly.

Pardon me for stepping out of my normal NTD 'swim lane' but I did want to help out (b) (6), and certainly nothing is more important these days than COVID-19 and the outstanding work you are doing to manage it.

All the very best,

-Eric

From: Warren, John [mailto:(b) (6)]
Sent: Thursday, April 30, 2020 6:52 PM
To: (b) (6)
Subject: Jack Warren

Eric

A voice from the past. Covid-19 prevented us from meeting up (b) (6) but I'm writing because it might yet bring at least the two of us together.

(b) (6) Samsung's venture capital group and his team has what I think is an incredibly useful idea for contact tracing for covid-19 as well as actually opening the economy up again. The idea is contained within the attachment.

I wonder if you still have any contacts with Anthony Fauci. Is so, could you see your way clear to forwarding the attachment to him? The group has identified some appropriate test manufacturers but is at the point where they need to know the spectrum so as to focus on the optimal ones. The thought was that Tony Fauci might be the best person to know what tests are in development stage.

What are your thoughts?

Don't worry about confidentiality; they want to widely share this idea so as to get it out as quickly as possible.

Thanks

Jack Warren MD
Professor of Medicine
Division of Infectious Diseases
University of Maryland School of Medicine
Baltimore MD 21201
(b) (6)

From: Auchincloss, Hugh (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 17:52:37 +0000
To: NIAID OD AM
Subject: FW: INVITE- American College of Cardiology
Importance: High

From: Kim, Jonathan Ho-Youn (b) (6)
Sent: Friday, May 1, 2020 3:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Ryan Meyer (b) (6) Robyn Snyder (b) (6)
Subject: Re: INVITE- American College of Cardiology
Importance: High

Dr. Fauci- Of course, I appreciate how busy you are, so just reaching out again on behalf of the American College of Cardiology as noted below. We were hopeful we could steal just an hour of your time in June for an important discussion on COVID-19 and exercise training. This is part of a virtual agenda for one of our national conferences (Care of the Athletic Heart) with outreach around the world given this is a part of the ACC educational platform.

We hope this is something you have the bandwidth for, and simply appreciate your consideration. I hope to hear from you and thank you for all your service once again.

My best, Jonathan Kim

Jonathan H. Kim MD, MSc, FACC
Chief of Sports Cardiology
Department of Medicine, Division of Cardiology
Department of Orthopedics
Emory University
Adjunct Assistant Professor
Division of Applied Physiology
Georgia Institute of Technology
Team Cardiologist for Emory Athletics, Georgia Tech Athletics, Atlanta Falcons, Atlanta Hawks, Atlanta Braves, and Atlanta Dream
Office Phone: (b) (6)
Research Profile: <http://medicine.emory.edu/cardiology/emory-first-faculty-directory/profile.html?f=JKIM10>
Email: (b) (6)

From: Kim, Jonathan Ho-Youn
Sent: Thursday, April 16, 2020 3:46 PM

To: (b) (6)
Cc: Ryan Meyer (b) (6); Rcbyn Snyder (b) (6)>
Subject: INVITE- American College of Cardiology

Dr. Fauci-

On behalf of the American College of Cardiology (ACC), first I would like to thank you for your tremendous service throughout your incredible career and certainly during these present and challenging times. We are indebted to your service and thankful everyday we have you to help guide public health measures through the COVID-19 pandemic.

I am a member of the Sports and Exercise Council for the ACC and the Course Chair for our annual ACC Care of the Athletic Heart Conference. Originally scheduled June 18-20, 2020 at ACC Heart House in Washington DC. I am also faculty at Emory University and direct our sports cardiology program in Atlanta.

Of course, we have made the difficult decision to cancel our live meeting in June, but myself along with the staff at ACC are working very hard transitioning the course to a virtual course and agenda. This course will be a much shorter version and the agenda will all be pre-recorded and distributed as a 'live simulated version' on June 20, 2020.

With the impact of COVID-19 on all aspects of life and society, in our academic world of sports cardiology, we are dealing with how COVID has impacted exercise and athletes. As you can imagine, there are a multitude of different issues and questions that colleagues are raising.

One new session for our virtual agenda that we think will generate a lot of interest and is of high importance will be a panel discussion on sports, exercise, and COVID-19. We would like to get additional expertise on the panel from the ID/public health and Sports Medicine arenas, in addition to sports cardiology. Of course, there is no one that carries the expertise you do from the ID and public health perspective and we would be extremely honored if you could be a part of this one session and join our faculty for the course.

Before getting into more details and a formal invite from the ACC, I wanted to first see if you had the bandwidth for this. Understanding you are as busy, if not busier, than anyone in the world right now. This session would be pre-recorded and we would certainly work to be flexible with anytime you had for this in early June to record.

I hope this is something that could work- again we would be honored to host you virtually.

Many thanks for considering, and hope to hear from you soon. Best, Jonathan Kim

Jonathan H. Kim MD, MSc, FACC
Chief of Sports Cardiology

Department of Medicine, Division of Cardiology

Department of Orthopedics

Emory University

Adjunct Assistant Professor

Division of Applied Physiology

Georgia Institute of Technology

Team Cardiologist for Emory Athletics, Georgia Tech Athletics, Atlanta Falcons, Atlanta Hawks, Atlanta Braves, and Atlanta Dream

Office Phone: (b) (6)

Research Profile: <http://medicine.emory.edu/cardiology/emory-first-faculty-directory/profile.html?f=JKIM10>

Email: (b) (6)

This e-mail message (including any attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this message (including any attachments) is strictly prohibited.

If you have received this message in error, please contact the sender by reply e-mail message and destroy all copies of the original message (including attachments).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 17:50:45 +0000
To: Jon LaPook
Subject: RE: Today's segment on CBS Sunday Morning

Jon:

Terrific piece on "No time to abandon science"! Keep up this great work. We need to stay on course.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Jon LaPook (b) (6)
Sent: Sunday, May 3, 2020 1:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Today's segment on CBS Sunday Morning

Dear Tony,

I hope (though would not bet my life that) you are getting at least a modicum of down time today.

Here's a link to the segment I told you about. No commercial!

<https://www.youtube.com/watch?v=0jCohlBICg0>

[<http://img.youtube.com/vi/0jCohlBICg0/0.jpg>]<<https://www.youtube.com/watch?v=0jCohlBICg0>>

Dr. Jon LaPook: No time to abandon science - YouTube<<https://www.youtube.com/watch?v=0jCohlBICg0>>
www.youtube.com

As we reach a point in the COVID-19 pandemic when some states are tempted to open sooner than health experts say they should, Dr. Jon LaPook notes that this ...

Jon

Jonathan LaPook, M.D.

Chief Medical Correspondent, CBS Evening News Professor of Medicine NYU Langone Health



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 17:23:12 +0000
To: Paola Dama
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: White House Coronavirus Task Force

Dr. Dama:

Thank you for your note. I am attaching a slide of the members of the USA Task Force and as you can see, Dr. Antonio Giordano is not a member.

Best regards,

A.S. Fauci

White House Coronavirus Task Force – Announced Jan. 29, 2020

Chair: VP Mike Pence

Response Coordinator: Deborah Birx

■ Jerome Adams	■ Stephen Hahn
■ Alex Azar	■ Derek Kan
■ Stephen Biegun	■ Larry Kudlow
■ Robert Blair	■ Chris Liddell
■ Ben Carson	■ Steven Mnuchin
■ Ken Cuccinelli	■ Robert O'Brien
■ Kelvin Droegemeier	■ Matthew Pottinger
■ Anthony Fauci	■ Robert Redfield
■ Joe Grogan	■ Joel Szabat



■ Seema Verma
■ Robert Wilkie

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Paola Dama (b) (6) >
Sent: Sunday, May 3, 2020 10:55 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: White House Coronavirus Task Force

Dear Dr. Fauci,

I hope to find you well with this email.
I take the liberty to write you because I have some concern about the misinformation that can discredit your task and honors.
On many occasions in tv and press, Antonio Giordano, Director of Sbarro Institute in Philadelphia, Keeps saying that he is a member of the USA Task Force.
I'm wondering if it's true.

I work in UK, but I'm originally from Naples (Italy).
I held my PhD in Carlo Croce's lab at OSU and I specialized in immunotherapy at University of Chicago.
Currently I'm a research fellow at University of Sussex.

I apologize if you find this email inopportune, the time is unfortunate, I grant you.
I don't like the idea that some people might take advantage of this very unpleasant moment for all the world.
So I wish that I made a mistake this time.

I'm also wondering if you are willing to release a brief interview.
I stand with you and USA that I miss very much

I really appreciate your time
Thank you
Kind Regards
Ciao ☺

Paola Dama, Ph D
Molecular Oncology and Pharmacology

University of Sussex
School of Life Sciences
John Maynard Smith (JMS) Building
Room 4B13
Falmer, Brighton BN1 9QG

cell. (b) (6) (Italia) / (b) (6) (USA)
(b) (6)

Email: (b) (6)
Skype: (b) (6)
website www.taskforcepandora.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 15:44:23 +0000
To: [REDACTED] (b) (6)
[REDACTED]
Subject: Great photo of Mommy and me in this article

<https://www.usatoday.com/story/news/nation/2020/05/03/coronavirus-white-house-expert-dr-anthony-fauci-americans-trust/3042991001/>

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [REDACTED] (b) (6)
Sent: Sun, 3 May 2020 10:30:04 -0400
To: Collins, Francis (NIH/OD) [E]
Cc: Mascola, John (NIH/VRC) [E]; Lane, Cliff (NIH/NIAID) [E]; Wholley, David (FNIH) [T]; Tabak, Lawrence (NIH/OD) [E]; Denny, Joshua (NIH/OD) [E]; Gebo, Kelly (NIH/OD) [G]; Lowy, Douglas (NIH/NCI) [E]; Devaney, Stephanie (NIH/OD) [E]; Adam, Stacey (FNIH) [T]; Santos, Michael (FNIH) [T]; Freire, Maria (FNIH) [T]
Subject: Re: crazy idea

[REDACTED] (b) (5)

On May 3, 2020, at 9:47 AM, Collins, Francis (NIH/OD) [E]
[REDACTED] (b) (6) wrote:

Hi John, Cliff, and Tony,

As we contemplate ways to stand up a master protocol that could enroll 50 – 100K participants in a multi-arm COVID-19 trial this summer, I wondered if [REDACTED] (b) (5)

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

See below - [REDACTED] (b) (5). What do you think?

Francis

From: Denny, Joshua (NIH/OD) [E] [REDACTED] (b) (6) >
Sent: Saturday, May 2, 2020 11:22 PM
To: Collins, Francis (NIH/OD) [E] <[REDACTED] (b) (6)>
Cc: Tabak, Lawrence (NIH/OD) [E] [REDACTED] (b) (6) >
Subject: Re: crazy idea

Hi Francis,

This is exciting to hear! Fabulous to hear we may be approaching such a trial. [REDACTED] (b) (5)

[REDACTED]
[REDACTED]

(b) (5)

Best,
Josh

Sent from my iPhone

On May 2, 2020, at 8:34 PM, Collins, Francis (NIH/OD) [E]

(b) (6) wrote:

Hi Josh,

Developments over the last week (b) (5)

(b) (5)

Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 12:31:13 +0000
To: Handley, Gray (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: form Jorge Perez IPK Cuba

Thanks.

From: Handley, Gray (NIH/NIAID) [E] (b) (6)
Sent: Saturday, May 2, 2020 11:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: RE: form Jorge Perez IPK Cuba

Will send a reply tomorrow morning.

I have spoken to State Department and have approved response. Someone will listen in.

Will copy you.

Gray

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Sent: Saturday, May 2, 2020 3:18 PM
To: Handley, Gray (NIH/NIAID) [E] <(b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: FW: form Jorge Perez IPK Cuba

Gray:

Would you please handle this.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any

other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Pérez Avila, Jorge <(b) (6)>
Sent: Friday, May 1, 2020 12:13 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: form Jorge Perez IPK Cuba

Dear Dr. Fauci

Hello from Cuba.

Have been a long time we haven't been in touch.

Now the whole world is facing a new epidemic and in Cuba we are working in order to controlling. We will like to re-new our contact regarding this disease Covid 19, we prepare a telephone conference in order to exchange ideas to have a better understanding to control the epidemic. This conference will be held from Cuba next tuesday 05/05/2020 at 4:30pm Cuban time. In clouse I am sending the topics. We will like to have you and Dr. Handley in this activity if it is possible to attend this conference. If you are in agreement we will like to know by answering this email and them we will you any other detail.

If you have any other person to contact in order to participate will be helpfull for us.

Waiting for your answer.

Dr. Jorge Perez
IPK
Cuba

Preliminary program

Objectives:

- Updating COVID-19 situation at global, regional and mainly in Cuba and USA
- To sharing data of how our two countries are facing this emergency including research studies, etc

Topics for the discussion:

- The main strategies that both countries are developing to face COVID-19.
- Diagnostic strategy
- Clinical management in adults and children
- Innovative Cuban biotechnology products incorporated into the treatment models used in the different stages of treatment
- Some other research studies
- Discussion

Events and courses at the following address:

<http://instituciones.sld.cu/ipk/>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 20:17:31 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: RE:

Thanks

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Cassetti, Cristina (NIH/NIAID) [E] (b) (6) >
Sent: Saturday, May 2, 2020 4:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Erbeling, Emily (NIH/NIAID) [E] (b) (6) >; Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Subject: RE:

Hi,

I already reached out to Dr. Bolognesi and some of us in Program have a call scheduled with him to discuss this proposal.

I will let you know the outcome.

Kind regards,

Cristina

From: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Sent: Saturday, May 2, 2020 3:39 PM
To: Cassetti, Cristina (NIH/NIAID) [E] (b) (6) >
Cc: Erbeling, Emily (NIH/NIAID) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: RE:
Importance: High

Cristina:

It would be a good idea for you to show this to a couple of other NIAID people for their opinion, and then out of courtesy to get back to Dr. Bolognesi one way or another.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Cassetti, Cristina (NIH/NIAID) [E] <(b) (6)>
Sent: Thursday, April 30, 2020 11:36 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Erbelding, Emily (NIH/NIAID) [E] (b) (6)>
Subject: RE:

Dear Dr. Fauci,

I reviewed this proposal (b) (5)

(b) (5), (b) (4)

(b) (5) informative

to discuss the project directly with them. Would you like for me to put together a small group at NIAID (with reps from DMID and DAIDS) to talk with Dr. Bolognesi and his colleagues?

Kind regards,

Cristina

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Sent: Thursday, April 30, 2020 7:58 PM
To: Cassetti, Cristina (NIH/NIAID) [E] <(b) (6)>
Cc: Erbeling, Emily (NIH/NIAID) [E] <(b) (6)>
Subject: FW:
Importance: High

Cristina:

Please take a good look at this. It is from Dani Bolognesi, one of our top HIV/AIDS investigators from a few years back. He is a serious scientist. Let me know what you think.

Thanks,

Tony

From: Eisinger, Robert (NIH/NIAID) [E] (b) (6) > **On Behalf Of** Fauci, Anthony (NIH/NIAID) [E]
Sent: Monday, April 27, 2020 6:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW:

Email from Dani Bolognesi.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email: (b) (6)

From: Dani Bolognesi, Ph.D. (b) (6)
Sent: Monday, April 27, 2020 6:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Barasch, Kimberly (NIH/NIAID) [C]
<(b) (6)>
Subject: FW:

Kimberly: Please see that this reaches Tony as per our call today.

TX in advance.

Dani

Hi Tony:

In advance of getting together with you and your team, I am forwarding a short presentation for you guys to look at. The key elements are follows:



We are prepared to discuss this with you and your team at any time that is convenient for you. As you may know, we are locked down here in the Research Triangle until May 15. If it makes sense, we could arrange a WebEx as an initial step.

Many thanks for the opportunity to share this with you!

All the very best,

Dani

(b) (6)

Best,

Dani

Sent from Dani Bolognesi

From: "Dani Bolognesi, Ph.D." (b) (6)

Date: Monday, April 27, 2020 at 2:53 PM

To: "Matthias Gromeier, M.D." (b) (6) >

Subject: Please review this draft email to Tony--TX

Matthias: Please review and edit the proposed email to Tony.

Dani

Hi Tony: In advance of getting together with you and your team, I am forwarding a short presentation for you guys to look at. The key elements are follows:



We are prepared to discuss this with you and your team at any time that is convenient for you. As you may know, we are locked down here in the Research Triangle until May 15. If it makes sense, we could arrange a WebEX as an initial step.

All the best,

Dani

Best,

Dani

Sent from Dani Bolognesi

The information in this electronic mail is sensitive, protected information intended only for the addressee(s). Any other person, including anyone who believes he/she might have received it due to an addressing error, is requested to notify the sender immediately by return electronic mail, and to delete it without further reading or retention. The information is not to be forwarded to or shared unless in compliance with Duke Health policies on confidentiality and/or with the approval of the sender.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 19:08:58 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Validated precise prediction of remdesivir's clinical efficacy on SARS-CoV-2 viral load

Please take a look at this and respond if appropriate.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Idonae Lovetrue (b) (6) >
Sent: Friday, May 1, 2020 2:25 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Beigel, John (NIH) [E] (b) (6); Booth, Mason (NIH/NIAID) [C]
(b) (6) Kim, Sonnie (NIH/NIAID) [E] (b) (6)
Subject: Validated precise prediction of remdesivir's clinical efficacy on SARS-CoV-2 viral load

Dear Dr. Fauci,

I'd like to share with you that the recent clinical trial results on remdesivir have validated our prediction of the remdesivir-specific post-treatment viral rebound in human COVID-19 patients. More details can be found in our official announcement <https://bit.ly/RRemdesivir>.

This prediction of remdesivir's clinical efficacy on viral load made on Feb. 23 2020 (b) (4)

(b) (4)

(b) (4)

We appreciate and respect all the efforts your have made towards the COVID-19 pandemic.

Best regards,
Idonae

Idonae Lovetrue | CEO, Demiurge Technologies AG, Switzerland

www.demiurge.technology

This email and any attachments thereto may contain private, confidential, and privileged material for the sole use of the intended recipient. Any review, copying, or distribution of this email (or any attachments thereto) by others is strictly prohibited. If you are not the intended recipient, please contact the sender immediately and permanently delete the original and any copies of this email and any attachments thereto. This email is intended for information purposes only and is provided without any warranty of any kind, either expressed or implied. While some information used on this document may have been obtained from various published and unpublished sources considered to be reliable, Demiurge Technologies AG neither guarantees its accuracy or completeness nor accepts liability for any direct or consequential losses arising from its use. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 19:00:06 +0000
To: Fetalvo, Ninio J. EOP/OVP
Subject: RE: Back to CMS

Ninio:

Thanks for all your good work in the White House. Stay safe and well.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fetalvo, Ninio J. EOP/OVP (b) (6)
Sent: Friday, May 1, 2020 3:12 PM
To: (b) (6); Fetalvo, Ninio (CMS/OC) (b) (6)
Subject: Back to CMS

All,

Today is my last day on detail to the Office of the Vice President. I am heading back to CMS to continue supporting the Trump Administration's response to the coronavirus. It has been an incredible honor serving the Vice President and the Coronavirus Task Force, and a pleasure working alongside all of you. I look forward to our ongoing work together.

Best,
Ninio

—

Ninio J.H. Fetalvo

Personal: (b) (6) | (b) (6)
CMS: (b) (6) | (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 18:27:23 +0000
To: Johnson, Martin S. (NIH/NIAID) [E]; Auchincloss, Hugh (NIH/NIAID) [E]; NIAID OCGR Leg; McGowan, John J. (NIH/NIAID) [E]; Erbelding, Emily (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]; Rotrosen, Daniel (NIH/NIAID) [E]; Crum, Wayne (NIH/NIAID) [E]; Harper, Jill (NIH/NIAID) [E]
Cc: Eisinger, Robert (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]; Lerner, Andrea (NIH/NIAID) [E]; Doepel, Laurie (NIH/NIAID) [E]; Gilles, Sharon (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]; Stover, Kathy (NIH/NIAID) [E]; Law, Kim (NIH/NIAID) [E]; Lee, Kun-Lin (NIH/NIAID) [E]; Bushar, Nicholas (NIH/NIAID) [E]; Schneider, Johanna (NIH/NIAID) [E]
Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 4/24/20

Thanks, Martin.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Johnson, Martin S. (NIH/NIAID) [E] (b) (6)
Sent: Friday, May 1, 2020 7:40 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] (b) (6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] (b) (6); Erbelding, Emily (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Rotrosen, Daniel (NIH/NIAID) [E] (b) (6); Crum, Wayne (NIH/NIAID) [E] <wcrum@niaid.nih.gov>; Harper, Jill (NIH/NIAID) [E] (b) (6)
Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] (b) (6); Doepel, Laurie (NIH/NIAID) [E] (b) (6); Gilles, Sharon (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Law, Kim (NIH/NIAID) [E] (b) (6); Lee, Kun-Lin (NIH/NIAID) [E] (b) (6); Bushar, Nicholas (NIH/NIAID) [E] (b) (6) v>;

Schneider, Johanna (NIH/NIAID) [E] (b) (6)

Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 4/24/20

Tony,

YTD spending is \$110.8M, increasing \$24.1M from last week.

Spending driven by implementation of 3 epidemiological studies, ramp up of resources necessary for vaccine candidate testing and vaccine candidate development.

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]

Sent: Friday, April 24, 2020 7:11 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] (b) (6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] (b) (6); Erbelding, Emily (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Rotrosen, Daniel (NIH/NIAID) [E] <(b) (6)>; Crum, Wayne (NIH/NIAID) [E] (b) (6); Harper, Jill (NIH/NIAID) [E] (b) (6)

Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] (b) (6); Doepel, Laurie (NIH/NIAID) [E] (b) (6); Gilles, Sharon (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Law, Kim (NIH/NIAID) [E] (b) (6); Lee, Kun-Lin (NIH/NIAID) [E] <(b) (6)>; Bushar, Nicholas (NIH/NIAID) [E] (b) (6); Schneider, Johanna (NIH/NIAID) [E] (b) (6)

Subject: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 4/24/20

Tony,

YTD spending is \$86.7M, an increase of \$8.3M from last week.

Spending driven by foundational research including the characterization of factors associated with severe disease, transmission dynamics, structural analysis of SARS-CoV-2 proteins. Small awards to support vaccine and therapeutic discovery.

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]

Sent: Friday, April 17, 2020 6:15 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] (b) (6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] (b) (6); Erbelding, Emily (NIH/NIAID) [E] <(b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b) (6); Rotrosen, Daniel

(NIH/NIAID) [E] (b) (6)>; Crum, Wayne (NIH/NIAID) [E] (b) (6)>;
Harper, Jill (NIH/NIAID) [E] (b) (6)>
Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E]
<(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Marston,
Hilary (NIH/NIAID) [E] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E]
(b) (6); Doepel, Laurie (NIH/NIAID) [E] (b) (6); Gilles, Sharon
(NIH/NIAID) [E] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6)
Stover, Kathy (NIH/NIAID) [E] (b) (6); Law, Kim (NIH/NIAID) [E] (b) (6)>;
Lee, Kun-Lin (NIH/NIAID) [E] <(b) (6)>; Bushar, Nicholas (NIH/NIAID) [E]
(b) (6)>; Schneider, Johanna (NIH/NIAID) [E] (b) (6)>

Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 4/17/20

Tony,

YTD spending is \$78.4M, an increase of \$10.9M from last week including costs to evaluate therapeutics in humans and NHPs, manufacture of a prototype virus-like vaccine candidate developed by Taubenberger/Memoli, and spending to accelerate discovery of new therapeutics, vaccines and diagnostics.

(b) (5)

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Friday, April 10, 2020 8:22 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] (b) (6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] (b) (6); Erbelding, Emily (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Rotrosen, Daniel (NIH/NIAID) [E] <(b) (6)>; Crum, Wayne (NIH/NIAID) [E] (b) (6); Harper, Jill (NIH/NIAID) [E] (b) (6)
Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] (b) (6); Doepel, Laurie (NIH/NIAID) [E] (b) (6); Gilles, Sharon (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Law, Kim (NIH/NIAID) [E] (b) (6); Lee, Kun-Lin (NIH/NIAID) [E] (b) (6); Bushar, Nicholas (NIH/NIAID) [E] (b) (6); Schneider, Johanna (NIH/NIAID) [E] (b) (6)
Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 4/10/20

Tony,

YTD spending is \$67.5M, unchanged* from last week. A summary is attached.

I have also attached an updated budget plan reflecting our projected spending by research category by fiscal year. We are updating this weekly as we receive updates from the divisions on the timing of clinical trials, observational studies, natural history studies and research resource needs.

We will report mid-week on our YTD spending which will be in sync with the data the Dept. extracts.

Martin

-
-
- The reason that we have reported no weekly increase is to match our reported spending with the financial information that the Department is now extracting from our accounting system. We have always included spending from our regular appropriation, as directed by the Department. Now the guidance from the Dept. has been updated to report only spending from the supplemental COVID-19 appropriations.

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Friday, April 3, 2020 8:54 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Auchincloss, Hugh (NIH/NIAID) [E]

(b) (6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] <(b) (6)>; Erbelding, Emily (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Rotrosen, Daniel (NIH/NIAID) [E] <(b) (6)>; Crum, Wayne (NIH/NIAID) [E] (b) (6); Harper, Jill (NIH/NIAID) [E] (b) (6)>
Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] (b) (6); Doepel, Laurie (NIH/NIAID) [E] (b) (6); Gilles, Sharon (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Law, Kim (NIH/NIAID) [E] (b) (6); Lee, Kun-Lin (NIH/NIAID) [E] (b) (6); Bushar, Nicholas (NIH/NIAID) [E] (b) (6); Schneider, Johanna (NIH/NIAID) [E] (b) (6)>
Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 4/3/20

Tony,

YTD spending is \$67.5M , a weekly increase of \$45.9M mostly for initial funding for set-up of clinical trials for evaluation of remdesivir in patients with early disease stage and a placebo-controlled clinical trial of intravenous hyperimmune immunoglobulin (IVIG) in patients with COVID-19.

I've provided a summary spending plan the team worked on and a table for the \$1.532B that we have received in supplemental appropriations

- \$826M NIAID received 3/5/20 - the Coronavirus Preparedness and Response Supplemental Appropriations Act
- \$706M NIAID received 3/25/20 - the Coronavirus Aid, Relief, and Economic Security (CARES) Act

In the last document I've also included narrative summarizing activities funded by the \$249M Other NIH Institutes received in the CARES Act

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Friday, March 27, 2020 7:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] (b) (6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] (b) (6); Harper, Jill (NIH/NIAID) [E] <(b) (6)>; Crum, Wayne (NIH/NIAID) [E] <(b) (6)>; Erbelding, Emily (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Rotrosen, Daniel (NIH/NIAID) [E] (b) (6)>
Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Marston,

Hilary (NIH/NIAID) [E] <(b) (6)>; Lerner, Andrea (NIH/NIAID) [E]
(b) (6)>; Doepel, Laurie (NIH/NIAID) [E] (b) (6)>; Gilles, Sharon
(NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6)>;
Stover, Kathy (NIH/NIAID) [E] <(b) (6)>; Law, Kim (NIH/NIAID) [E] (b) (6)>;
Lee, Kun-Lin (NIH/NIAID) [E] (b) (6)>; Bushar, Nicholas (NIH/NIAID) [E]
(b) (6); Schneider, Johanna (NIH/NIAID) [E] (b) (6)>

Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 3/26/20

Tony,

YTD spending is \$21.6M , a weekly increase of \$4.0M for clinical trial site set-up for therapeutics, further vaccine development, small animal development, and therapeutic development (mAbs) and basic research.

Most of the \$50M-\$60M we listed last week we expect to be awarded before March 31. In many cases contractors have begun work without the award so as to not stall work.

Early next week I'll provide a summary spending plan for the additional \$706M that NIAID received in the supplemental appropriation signed by the President today.

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]

Sent: Friday, March 20, 2020 4:54 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Auchincloss, Hugh (NIH/NIAID) [E]
(b) (6)>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J.
(NIH/NIAID) [E] (b) (6)>; Harper, Jill (NIH/NIAID) [E] (b) (6)>; Crum,
Wayne (NIH/NIAID) [E] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E]
(b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b) (6)>

Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E]
(b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Marston, Hilary
(NIH/NIAID) [E] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E] <(b) (6)>;
Doepel, Laurie (NIH/NIAID) [E] <(b) (6)>; Gilles, Sharon (NIH/NIAID) [E]
<(b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6)>; Stover, Kathy
(NIH/NIAID) [E] (b) (6)>; Law, Kim (NIH/NIAID) [E] (b) (6)>; Lee, Kun-Lin
(NIH/NIAID) [E] (b) (6)>; Bushar, Nicholas (NIH/NIAID) [E] (b) (6)
Schneider, Johanna (NIH/NIAID) [E] (b) (6)>

Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 3/19/20

Tony,

YTD spending is \$17.6M , a weekly increase of \$3.5M for clinical trial site set-up, therapeutic development (mAbs) and basic research.

We greatly appreciate all your hard work.

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]

Sent: Friday, March 13, 2020 6:45 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] (b) (6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] <(b) (6)>; Harper, Jill (NIH/NIAID) [E] (b) (6); Crum, Wayne (NIH/NIAID) [E] (b) (6); Erbeling, Emily (NIH/NIAID) [E] (b) (6)>

Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] (b) (6); Doepel, Laurie (NIH/NIAID) [E] (b) (6); Gilles, Sharon (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Law, Kim (NIH/NIAID) [E] (b) (6); Lee, Kun-Lin (NIH/NIAID) [E] (b) (6); Bushar, Nicholas (NIH/NIAID) [E] (b) (6); Schneider, Johanna (NIH/NIAID) [E] (b) (6)>

Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 3/12/20

Tony,

Since we our last report we have increased spending on the COVID-19 response by \$1.5M for a total YTD spending of \$14.1M.

The \$1.5M increase is for the following:

\$1.0M awarded to set-up clinical sites at Emory and U. Washington Seattle for adaptable RCT of remdesivir.

\$0.4M supported data analysis of rhesus animal model and grant to gain understanding of the host pathways that regulate viral gene expression and viral subversion of the host immune system.

\$0.1M funded vaccine development at VRC and DIR

(b) (5)

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]

Sent: Friday, March 6, 2020 5:31 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] (b) (6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] (b) (6); Harper, Jill (NIH/NIAID) [E] (b) (6);

Crum, Wayne (NIH/NIAID) [E] (b) (6)

Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E]

(b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E]

(b) (6); Doepel, Laurie (NIH/NIAID) [E] (b) (6); Gilles, Sharon (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6);

Stover, Kathy (NIH/NIAID) [E] (b) (6); Law, Kim (NIH/NIAID) [E] (b) (6); Lee, Kun-Lin (NIH/NIAID) [E] (b) (6)

Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 3/5/20

Tony,

Since our last report we have increased spending on the COVID-19 response by \$0.2M for a total YTD spending of \$12.6M.

The \$0.2M increase is for vaccine candidate development at NIAID Intramural Labs including RML. Costs are mostly for staffing and overhead and include a preclinical immunogenicity

study designed to test the mRNA-1273 nCoV vaccine two-dose schedule in mice. The study will measure the immune response to this vaccine in an animal model in anticipation of clinical test in humans.

(b) (5)

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Friday, February 28, 2020 11:57 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] (b) (6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] <(b) (6)>; Harper, Jill (NIH/NIAID) [E] (b) (6); Crum, Wayne (NIH/NIAID) [E] (b) (6)>
Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] (b) (6); Gilles, Sharon (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Law, Kim (NIH/NIAID) [E] (b) (6); Lee, Kun-Lin (NIH/NIAID) [E] (b) (6)
Subject: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 2/27/20

Tony,

Since we our last report we have increased spending on the COVID-19 response by \$2.3M for a total YTD spending of \$12.4M.

A recap of the \$2.3 million spent in the last week is as follows:

- \$1.9M to set-up a Phase I trial (45 subjects) of the VRC/Moderna mRNA platform candidate at Kaiser Permanente Washington Health Research Institute (One of the VTEUs)

- \$0.3M that supported University of Hong Kong researchers in the development of a RT-PCR test to detect SARSCoV2 from human samples. The group has now shared the tests and relevant reagents with over 30 labs globally to enable diagnosis of COVID-19.
- \$0.1M vaccine candidate development at NIAID Intramural Labs

(b) (5)

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]

Sent: Friday, February 14, 2020 3:56 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] (b) (6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] (b) (6); Harper, Jill (NIH/NIAID) [E] (b) (6); Crum, Wayne (NIH/NIAID) [E] (b) (6)

Cc: Eisinger, Robert (NIH/NIAID) [E] <(b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] (b) (6); Gilles, Sharon (NIH/NIAID) [E] (b) (6)

Subject: FY 2020 - COVID-19 - Actual and Forecasted Spending as of 2/13/20

Dr. Fauci,

Attached is a narrative we are updating weekly for NIAID's COVID-19 response.

The accompanying spreadsheet summarizes the figures and includes a summary of our supplemental request.

We'll provide an update by Thursday of next week.

Martin

Resource Planning and Mission Integration Branch (RPMIB) – NIAID
NIH Bldg. 31 Room 7A47

Tel: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 18:22:37 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Cc: (b) (6)
Subject: RE: RE:

Zeke:

Thanks for your note. (b) (6) and I would love to get together with you all for dinner. Let us try to do so within a reasonably soon time frame.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Eisinger, Robert (NIH/NIAID) [E] (b) (6) > **On Behalf Of** Fauci, Anthony (NIH/NIAID) [E]
Sent: Saturday, May 2, 2020 7:24 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: FW: RE:

Email from Zeke Emanuel.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email: (b) (6)

From: Emanuel, Ezekiel J (b) (6) >
Sent: Friday, May 1, 2020 8:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: (b) (6) >
Subject: Re: RE:

Tony

You are national--international --treasure. And we are depending upon your sanity and smarts.

We can have you and (b) (6) over for dinner on the porch and order in from (b) (6) or something. Anytime you are ready.

Ezekiel J. Emanuel, M.D., Ph.D.

Vice Provost of Global Initiatives

Chair, Department of Medical Ethics and Health Policy (b) (6)

Levy University Professor

Co-Director, Healthcare Transformation Institute

Perelman School of Medicine and The Wharton School

University of Pennsylvania

Phone: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Sent: Friday, May 1, 2020 6:55 PM
To: Emanuel, Ezekiel J < (b) (6) >
Cc: (b) (6)
Subject: RE: RE:

Zeke:

Thanks for the note. Indeed, we do agree. (b) (6)

(b) (6) I look forward to chatting with you some time soon.

Best,

Tony

From: Emanuel, Ezekiel J <(b) (6)>

Sent: Thursday, April 30, 2020 6:37 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>

Subject: Re: RE:

Sorry for misreading what you said--I think maybe I overintepreted--lots of finance people called and seemed like I was a downer compared to you. But I think we agree.

Are you and (b) (6) doing okay?

Ezekiel J. Emanuel, M.D., Ph.D.

Vice Provost of Global Initiatives

Chair, Department of Medical Ethics and Health Policy (b) (6)

Levy University Professor

Co-Director, Healthcare Transformation Institute

Perelman School of Medicine and The Wharton School

University of Pennsylvania

Phone: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>

Sent: Thursday, April 30, 2020 5:33 PM

To: Emanuel, Ezekiel J (b) (6)>

Subject: RE:

Zeke:

I did not "strongly" endorse it. I specifically said that it was not a knockout drug and was only a baby step in the direction of developing more and better drugs. I said that it was important because it proved in a well-powered, randomized, placebo-controlled clinical trial that one can suppress the virus enough to see a clinical effect, as modest as the effect was. I do not think I forced anything.

Happy to chat with you about it.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Emanuel, Ezekiel J (b) (6) >
Sent: Thursday, April 30, 2020 2:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject:

Tony,

I hope you and (b) (6) are doing well. You are doing an amazing job under difficult circumstances. And just know we prefer the "real" Tony to the Brad Pitt version!!!

I am a bit perplexed by your seeming strong endorsement of remdesivir. Was it just a bit forced?

My reading was the data were weak and in normal times for normal disease it is not enough to approve. And very unlikely to really impact COVID-19 disease pattern--regardless of supply issues.

Stay safe

Ezekiel J. Emanuel, M.D., Ph.D.

Vice Provost of Global Initiatives

Chair, Department of Medical Ethics and Health Policy (b) (6)

Levy University Professor

Co-Director, Healthcare Transformation Institute

Perelman School of Medicine and The Wharton School

University of Pennsylvania

Phone: (b) (6)


From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 18:00:31 +0000
To: Hurst, Natalie R. EOP/OVP
Subject: RE: Update - White House Coronavirus Task Force Meeting

Thanks, Natalie!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

(b)(5) - PCP



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 17:57:11 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Greetings from India

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Prof. Chirantan Chatterjee <(b) (6)>
Sent: Saturday, May 2, 2020 11:47 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Deepak Bhatt Manager - Communications (b) (6)
Subject: Greetings from India

Dear Dr Fauci,

My greetings from India. I am a health economist and management professor at the Indian Institute of Management, Ahmedabad, India's premier management school. Also, i am a avid fan of your work even from pre-covid19 days.

I write to you requesting some time if possible to do a podcast of 45 minutes with you over zoom. The science and policy ecosystem in India i think would immensely benefit if you can offer your thoughts on what should be India's 12-month strategy going forward for COVID-19.

We have done some recent podcasts relatedly and they are listed her
(<https://m.soundcloud.com/healthcastbycmhs/>).

If you agree, and we are flexible all of May, my communication head Mr. Deepak marked in the email will arrange the zoom logistics and make it as seamless as possible for you.

We will also go per your time zone conveniences and do this over webex/hangout/skype or phone call if that helps.

It would be a delight Dr. Fauci if you can join us in the conversation, looking forward to hearing from you. Our respectful namaste 🙏 from India for all the brave work you are doing.

My best, Chirantan

Chirantan Chatterjee (PhD, Carnegie Mellon) || Associate Professor (Economics & Business Policy) & ICICI Bank Chair in Strategic Management || Chairperson, Center for Management of Health Services at IIMA || 2019-2020 Visiting Fellow, 2018-2019 Campbell & Edward Teller National Fellow, Hoover Institution, Stanford University || Office Address: Wing 15F, Indian Institute of Management || Ahmedabad, 380 015 Gujarat, India || Skype:

(b) (6) || Email: (b) (6) or (b) (6) || [Hoover Institution Website](#) | [IIMA Official Website](#)

What is laid down, ordered, factual is never enough to embrace the whole truth: life always spills over the rim of every cup. – Boris Pasternak in *Bridges to Infinity* : The Human Side of Mathematics (1983) by Michael Guillen

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 12:08:00 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]; Haskins, Melinda (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Congresswoman Sheila Jackson Lee invites your participation in a Virtual Town Hall meeting hosted by ABC affiliate Channel 13 in Houston, Texas on Thursday, May 7, 2020 at 7:00 PM CDT
Attachments: Dr. Anthony Fauci - Town Hall Invite.pdf

Please take a look at this. We obviously will have to get clearance through HHS and White House Leg. This is for Thursday and so we would need to submit soon.

From: Coney, Lillie (b) (6) >
Sent: Friday, May 1, 2020 11:23 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Rushing, Glenn (b) (6); Coney, Lillie (b) (6)
Subject: Congresswoman Sheila Jackson Lee invites your participation in a Virtual Town Hall meeting hosted by ABC affiliate Channel 13 in Houston, Texas on Thursday, May 7, 2020 at 7:00 PM CDT

May 1, 2020

Dr. Anthony Fauci, M.D.
Director of the National Institute of Allergy and Infectious Diseases
Department of Health and Human Services
5601 Fishers Lane
Bethesda, MD 20892-9806

Dear Dr. Fauci:

Thank you for your tremendous steadfast leadership during this pandemic and health crisis. Our nation has not faced a crisis of this magnitude since the 1918 Spanish Flu, but we will travel this journey together and defeat this virus. In the end, the nation will become stronger and more prepared.

Your participation is requested in a Virtual Town Hall meeting hosted by ABC affiliate Channel 13 in Houston, Texas on Thursday, May 7, 2020 at 7:00 PM CDT. This town hall meeting will focus on testing and guidelines for re-opening our nation. It is scheduled to last an hour with 2 or 3 guests including yourself. Houston is the fourth largest city in the country and your knowledge and expertise would be most helpful in our fight to keep our infection and fatality rates low for this entire region and the State of Texas.

My office has been pushing testing and setting up testing sites since the first notification of the coronavirus. We currently have seven active testing sites and expanding each week to get to the mass testing necessary to flatten the infection rate.

Thank you for your consideration of this request and I look forward to participating with you in the Virtual Town Hall meeting. Again, thank you for your leadership. Please RSVP or if you have questions regarding this request with Glenn Rushing, my Chief of Staff at (b) (6) and Lillie Coney, my Chief Policy Advisor at (b) (6).

Very truly yours,

J

Sheila Jackson Lee
Member of Congress

Regards,
Lillie Coney
Policy Director
Congresswoman Sheila Jackson Lee (TX-18)
2079 Rayburn HOB
Washington, DC 20515

(b) (6)



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 12:01:04 +0000
To: [REDACTED] (b) (6)
Subject: FW: RE:

Let us try to do this next weekend.

From: Eisinger, Robert (NIH/NIAID) [E] [REDACTED] (On Behalf Of Fauci, Anthony (NIH/NIAID) [E])
Sent: Saturday, May 2, 2020 7:24 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: FW: RE:

Email from Zeke Emanuel.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: [REDACTED] (b) (6)
Email: [REDACTED] (b) (6)

From: Emanuel, Ezekiel J [REDACTED] (b) (6) >
Sent: Friday, May 1, 2020 8:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Cc: [REDACTED] (b) (6) >
Subject: Re: RE:

Tony

You are national--international --treasure. And we are depending upon your sanity and smarts.

We can have you and [REDACTED] (b) (6) over for dinner on the porch and order in from [REDACTED] (b) (6) or something. Anytime you are ready.

Ezekiel J. Emanuel, M.D., Ph.D.

Vice Provost of Global Initiatives

Chair, Department of Medical Ethics and Health Policy (b) (6)

Levy University Professor

Co-Director, Healthcare Transformation Institute

Perelman School of Medicine and The Wharton School

University of Pennsylvania

Phone: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6) v>

Sent: Friday, May 1, 2020 6:55 PM

To: Emanuel, Ezekiel J (b) (6) >

Cc: (b) (6) >

Subject: RE: RE:

Zeke:

Thanks for the note. Indeed, we do agree. (b) (6)

(b) (6) I look forward to chatting with you some time soon.

Best,

Tony

From: Emanuel, Ezekiel J (b) (6) >

Sent: Thursday, April 30, 2020 6:37 PM

To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>

Subject: Re: RE:

Sorry for misreading what you said--I think maybe I overintepreted--lots of finance people called and seemed like I was a downer compared to you. But I think we agree.

Are you and (b) (6) doing okay?

Ezekiel J. Emanuel, M.D., Ph.D.

Vice Provost of Global Initiatives

Chair, Department of Medical Ethics and Health Policy (b) (6)

Levy University Professor

Co-Director, Healthcare Transformation Institute

Perelman School of Medicine and The Wharton School

University of Pennsylvania

Phone: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >

Sent: Thursday, April 30, 2020 5:33 PM

To: Emanuel, Ezekiel J (b) (6) >

Subject: RE:

Zeke:

I did not "strongly" endorse it. I specifically said that it was not a knockout drug and was only a baby step in the direction of developing more and better drugs. I said that it was important because it proved in a well-powered, randomized, placebo-controlled clinical trial that one can suppress the virus enough to see a clinical effect, as modest as the effect was. I do not think I forced anything.

Happy to chat with you about it.

Best,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Emanuel, Ezekiel J (b) (6)

Sent: Thursday, April 30, 2020 2:12 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Subject:

Tony,

I hope you and (b) (6) are doing well. You are doing an amazing job under difficult circumstances. And just know we prefer the "real" Tony to the Brad Pitt version!!!

I am a bit perplexed by your seeming strong endorsement of remdesivir. Was it just a bit forced?

My reading was the data were weak and in normal times for normal disease it is not enough to approve. And very unlikely to really impact COVID-19 disease pattern--regardless of supply issues.

Stay safe

Ezekiel J. Emanuel, M.D., Ph.D.

Vice Provost of Global Initiatives

Chair, Department of Medical Ethics and Health Policy (b) (6)

Levy University Professor

Co-Director, Healthcare Transformation Institute

Perelman School of Medicine and The Wharton School

University of Pennsylvania

Phone: [REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 02:04:00 +0000
To: Selgrade, Sara (NIH/NIAID) [E]
Cc: NIAID OCGR Leg;Billet, Courtney (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Requesting your assistance: Draft NIAID Statement for May 12 Senate HELP Hearing
Attachments: 2020.05.12 NIAID Senate HELP testimony COVID 19 - with Fauci tracked changes.docx

I am attaching the document with minor tracked edits. Nice job! Thanks.

From: Selgrade, Sara (NIH/NIAID) [E] (b) (6)>
Sent: Thursday, April 30, 2020 5:24 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: Requesting your assistance: Draft NIAID Statement for May 12 Senate HELP Hearing

Dr. Fauci:

In preparation for the upcoming May 12th COVID-19 hearing of the Senate Health, Education, Labor, and Pensions Committee (Chair: Sen. Lamar Alexander, R-TN), we have drafted the attached NIAID testimony, building on your prior testimony on COVID-19. Drs. Giroir, Hahn, and Redfield also have been invited to the hearing.

We expect that your testimony will be included as an insert to an HHS-wide testimony. At the request of NIH OD, we have incorporated into the draft COVID-19 activities across NIH.

The testimony has been reviewed by the Divisions and Drs. Lane, Harper, Marston, and Lerner, as well as Courtney Billet, Greg Folkers, Martin Johnson, and Laurie Doepel.

NIH OLPA has asked to receive your testimony for clearance by tomorrow, if possible.

Thank you for your help.

Sara

Sara Selgrade, Ph.D.

Section Chief for Legislative Activities

Legislative Affairs and Correspondence Management Branch

Office of Communications and Government Relations

NIAID/NIH/DHHS

Bldg. 31, Room 7A17, MSC 2520

Bethesda, MD 20892-2520

Phone: (b) (6)

(b) (6)

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 1 May 2020 15:28:23 +0000
To: Routh, Jennifer (NIH/NIAID) [E]
Subject: RE: clips

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Routh, Jennifer (NIH/NIAID) [E] (b) (6) >
Sent: Friday, May 1, 2020 8:56 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E]
(b) (6) >; Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Subject: RE: clips

Dr. Fauci –

I have requested the full clips from our clipping service. I found the following online in the meantime:

Today Show:

<https://www.today.com/video/dr-anthony-fauci-remdesivir-is-a-very-important-first-step-in-fighting-coronavirus-82800197863>

CNN Town Hall (clip discussing federal “reopening” guidelines):

<https://twitter.com/CNN/status/1256023483638669313>

CNN Town Hall (clip discussing vaccines):

<https://twitter.com/CNN/status/1256044817093558272>

Thanks,
Jen

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: (b) (6)
(b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Sent: Friday, May 1, 2020 7:44 AM
To: Routh, Jennifer (NIH/NIAID) [E] (b) (6)>
Subject: clips

Jen:

Can we please make sure that I get the lips from yesterday from NBC Today Show and CNN Town Hall with Sanjay and Anderson.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 1 May 2020 12:26:55 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: [REDACTED] (b) (4)

Another email from Andre Kalil.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone [REDACTED] (b) (6)
Email: [REDACTED] (b) (6)

From: Kalil, Andre C [REDACTED] (b) (6) >
Sent: Thursday, April 30, 2020 8:12 PM
To: Beigel, John (NIH) [E] [REDACTED] (b) (6); Dodd, Lori (NIH/NIAID) [E] [REDACTED] (b) (6);
Davey, Richard (NIH/NIAID) [E] <[REDACTED] (b) (6)>; Lane, Cliff (NIH/NIAID) [E]
[REDACTED] (b) (6)>; Proschan, Michael (NIH/NIAID) [E] [REDACTED] (b) (6)>; Marston, Hilary
(NIH/NIAID) [E] [REDACTED] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: RE: [REDACTED] (b) (4)

[REDACTED] (b) (4)

Thanks,

Andre

Andre Kalil, MD, MPH, FACP, FIDSA, FCCM

Professor

Department of Internal Medicine

Division of Infectious Diseases

Director, Transplant ID Program

Associate Editor, CMI, Official Journal of ESCMID

Editorial Board, CCM, Official Journal of SCCM



University of Nebraska Medical Center

985400 Nebraska Medical Center, Omaha, NE 68198-5400

(b) (6) | fax 402.559-5581

(b) (6)

[UNMC](#) | [Facebook](#) | [Twitter](#) | [YouTube](#) | [Flickr](#)

"Lucky? Obviously you haven't heard anything I've said. It was a matter of applying Bayes' Theorem to estimate the conditional probabilities. Giving due weight to the prior probabilities..."

Robert Ludlum - The Ambler Warning

From: Beigel, John (NIH) [E] (b) (6) >

Sent: Thursday, April 30, 2020 5:25 AM

To: Dodd, Lori (NIH/NIAID) [E] (b) (6) >; Kalil, Andre C (b) (6) >; Davey, Richard (NIH/NIAID) [E] <(b) (6)>; Lane, Cliff (NIH/NIAID) [E] <(b) (6)>; Proschan, Michael (NIH/NIAID) [E] (b) (6) >; Marston, Hilary (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6) >

Subject: Re: (b) (4)

Non-UNMC email

(b) (4)

--

John Beigel, M.D.

Associate Director for Clinical Research

Division of Microbiology and Infectious Diseases

National Institute of Allergy and Infectious Diseases (NIAID)

Phone: (b) (6)

email: (b) (6)

From: Lori Dodd (b) (6)>

Date: Thursday, April 30, 2020 at 6:05 AM

To: John Beigel (b) (6)>, Andre Kalil (b) (6)>, Richard Davey (b) (6)>, Cliff Lane <(b) (6)>, Michael Proschan (b) (6)>, Hilary Marston (b) (6)>, "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)

Subject: RE: (b) (4)

Andre-

I like what you wrote, and particularly like the first two sentences.

From: Beigel, John (NIH) [E] (b) (6)>

Sent: Thursday, April 30, 2020 5:53 AM

To: Kalil, Andre C (b) (6)>; Davey, Richard (NIH/NIAID) [E] <(b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b) (6)>; Dodd, Lori (NIH/NIAID) [E] <(b) (6)>; Proschan, Michael (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>

Subject: Re: (b) (4)

Andre,

(b) (4)

We too are open for further edits

John

--

John Beigel, M.D.

Associate Director for Clinical Research

Division of Microbiology and Infectious Diseases

National Institute of Allergy and Infectious Diseases (NIAID)

Phone: (b) (6)

email: (b) (6)

From: Andre Kalil (b) (6) >
Date: Thursday, April 30, 2020 at 3:19 AM
To: John Beigel (b) (6) >, Richard Davey (b) (6) >, Cliff Lane (b) (6), Lori Dodd (b) (6) >, Michael Proshan (b) (6) >, Hilary Marston < (b) (6) >, "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) >
Subject: (b) (4)



Please let me know your thoughts and suggestions.

Andre

Andre Kalil, MD, MPH, FACP, FIDSA, FCCM

Professor

Department of Internal Medicine

Division of Infectious Diseases

Director, Transplant ID Program

Associate Editor, CMI, Official Journal of ESCMID

Editorial Board, CCM, Official Journal of SCCM



University of Nebraska Medical Center

985400 Nebraska Medical Center, Omaha, NE 68198-5400

(b) (6) | fax 402.559-5581

[UNMC](#) | [Facebook \[facebook.com\]](#) | [Twitter \[twitter.com\]](#) | [YouTube \[youtube.com\]](#) | [Flickr \[flickr.com\]](#)

"Lucky? Obviously you haven't heard anything I've said. It was a matter of applying Bayes' Theorem to estimate the conditional probabilities. Giving due weight to the prior probabilities..."

Robert Ludlum - The Ambler Warning

The information in this e-mail may be privileged and confidential, intended only for the use of the addressee(s) above. Any unauthorized use or disclosure of this information is prohibited. If you have received this e-mail by mistake, please delete it and immediately contact the sender.

The information in this e-mail may be privileged and confidential, intended only for the use of the addressee(s) above. Any unauthorized use or disclosure of this information is prohibited. If you have received this e-mail by mistake, please delete it and immediately contact the sender.

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 1 May 2020 12:25:50 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW:

Email from Dani Bolognesi.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email: (b) (6)

From: Dani Bolognesi, Ph.D. (b) (6)
Sent: Thursday, April 30, 2020 8:13 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: RE:

TX Tony. Nice touch reminding folks of how AZT propelled the pharmas and great to see things moving with this beast!

Sei un campione!

Dani

From: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Sent: Thursday, April 30, 2020 7:58 PM
To: Cassetti, Cristina (NIH/NIAID) [E] (b) (6)>
Cc: Erbelding, Emily (NIH/NIAID) [E] (b) (6)
Subject: FW:

Cristina:

Please take a good look at this. It is from Dani Bolognesi, one of our top HIV/AIDS investigators from a few years back. He is a serious scientist. Let me know what you think.
Thanks,
Tony

From: Eisinger, Robert (NIH/NIAID) [E] (b) (6)> **On Behalf Of** Fauci, Anthony (NIH/NIAID) [E]
Sent: Monday, April 27, 2020 6:57 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: FW:

Email from Dani Bolognesi.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email: (b) (6)

From: Dani Bolognesi, Ph.D. (b) (6) >
Sent: Monday, April 27, 2020 6:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Barasch, Kimberly (NIH/NIAID) [C]
(b) (6) >
Subject: FW:

Kimberly: Please see that this reaches Tony as per our call today.

TX in advance.

Dani

Hi Tony:

In advance of getting together with you and your team, I am forwarding a short presentation for you guys to look at. The key elements are follows:



(b) (4), (b) (5)

We are prepared to discuss this with you and your team at any time that is convenient for you. As you may know, we are locked down here in the Research Triangle until May 15. If it makes sense, we could arrange a WebEx as an initial step.

Many thanks for the opportunity to share this with you!

All the very best,

Dani

(b) (6)

Best,

Dani

Sent from Dani Bolognesi

From: "Dani Bolognesi, Ph.D." <(b) (6)>

Date: Monday, April 27, 2020 at 2:53 PM

To: "Matthias Gromeier, M.D." (b) (6)

Subject: Please review this draft email to Tony--TX

Matthias: Please review and edit the proposed email to Tony.

Dani

Hi Tony: In advance of getting together with you and your team, I am forwarding a short presentation for you guys to look at. The key elements are follows:

We are prepared to discuss this with you and your team at any time that is convenient for you. As you may know, we are locked down here in the Research Triangle until May 15. If it makes sense, we could arrange a WebEX as an initial step.

All the best,

Dani

Best,

Dani

Sent from Dani Bolognesi

The information in this electronic mail is sensitive, protected information intended only for the addressee(s). Any other person, including anyone who believes he/she might have received it due to an addressing error, is requested to notify the sender immediately by return electronic mail, and to delete it without further reading or retention. The information is not to be forwarded to or shared unless in compliance with Duke Health policies on confidentiality and/or with the approval of the sender.

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 1 May 2020 12:10:09 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: ACTT publication
Importance: High

Another email from Andre Kalil.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email: (b) (6)

From: Kalil, Andre C (b) (6) >
Sent: Friday, May 1, 2020 2:59 AM
To: Beigel, John (NIH) [E] (b) (6) >; Davey, Richard (NIH/NIAID) [E]
(b) (6) >; Lane, Cliff (NIH/NIAID) [E] (b) (6); Dodd, Lori (NIH/NIAID) [E]
(b) (6) >; Proschan, Michael (NIH/NIAID) [E] (b) (6) Marston, Hilary
(NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: ACTT publication
Importance: High

Not my first choice, but I want to share the invitation email below with you.
Andre

Andre Kalil, MD, MPH, FACP, FIDSA, FCCM
Professor
Department of Internal Medicine
Division of Infectious Diseases
Director, Transplant ID Program
Associate Editor, CMI, Official Journal of ESCMID
Editorial Board, CCM, Official Journal of SCCM



University of Nebraska Medical Center
985400 Nebraska Medical Center, Omaha, NE 68198-5400
(b) (6) | fax 402.559-5581
(b) (6)

[UNMC](#) | [Facebook](#) | [Twitter](#) | [YouTube](#) | [Flickr](#)

"Lucky? Obviously you haven't heard anything I've said. It was a matter of applying Bayes' Theorem to estimate the conditional probabilities. Giving due weight to the prior probabilities..."

Robert Ludlum - The Ambler Warning

From: [REDACTED] (b) (4)

Sent: Thursday, April 30, 2020 1:03 PM

To: Kalil, Andre C [REDACTED] (b) (6)

Subject: ACTT publication

Importance: High

Non-UNMC email

Dear Dr. Kalil,

(b) (4)



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 1 May 2020 11:38:53 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: interview request by Greek newspaper Ethnos

FYI

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Γιώργος Σκαφιδάς <gs kafidas@ethnos.gr>
Sent: Friday, May 1, 2020 6:07 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: interview request by Greek newspaper Ethnos

Dear Dr. Fauci,

my name is George Skafidas and I'm a journalist working for the Greek national weekly ETHNOS (www.ethnos.gr).

We would be very much interested in doing an interview with you, to be published in the Sunday edition of the paper, regarding the developments surrounding the COVID-19 pandemic.

Best regards

ΕΘΝΟΣ

George Skafidas

Senior editor, World Affairs

tel: +30 210 6510550

mob: [REDACTED] (b) (6)

Οι πληροφορίες που περιέχονται σε αυτό το μήνυμα ηλεκτρονικού ταχυδρομείου (e-mail) καθώς και σε τυχόν συνημμένα είναι εμπιστευτικές και προορίζονται για χρήση αποκλειστικά από το συγκεκριμένο παραλήπτη (-ες). Οι πληροφορίες αυτές μπορεί να καλύπτονται από επιχειρησιακό ή άλλα απόρρητα ή άλλους νόμους και δεν επιτρέπεται να ανακοινωθούν σε οποιονδήποτε τρίτο. Σε περίπτωση που δεν είστε ο παραλήπτης του μηνύματος ή το πρόσωπο που είναι αρμόδιο για την παράδοσή του στον παραλήπτη, απαγορεύεται να το ανακοινώσετε, αντιγράψετε, διανείμετε ή διατηρήσετε εν όλων ή εν μέρει.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 1 May 2020 11:38:08 +0000
To: (b) (6)
Subject: RE: Coronavirus: Covid 19

Ato:

Thank you for your note. We will know soon whether hydroxychloroquine has any beneficial effects as the results of randomized, controlled trials become available. The pathogenesis of COVID-19 is still an open question. You are correct in that there is a more recent tendency to use ventilators only as a very last resort since oxygenation rather than ventilation appears to be key to recovery.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: gabriel stephens (b) (6)
Sent: Friday, May 1, 2020 4:53 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Coronavirus: Covid 19

Hi Dr Fauci,

Please find an audio attached of a doctor describing the experience with regards to covid 19 in the hospital. She seems to suggest covid 19 is a virus that rather attacks the blood cell, leading to respiratory and other organ complications, hence they need to look at treatment in a different light. In the UK some hospitals have moved away from using ventilators due to the high death rate of those on ventilators, and are rather using ventilators for sleep apnea, as they are less invasive, and the results are much much better compared to invasive ventilators

There are some anecdotal observations I have also made. The infection rate in most African countries seem to be comparatively low, which could possibly be due to the rate of testing being conducted. However the death rates are also comparatively very low. From initial information with regards to

hydroxychloroquine and some antimalaria drugs usage, it was suggested that those who were alleged to have had some benefits had mild symptoms of covid 19. I know some clinical trials have shown hydroxychloroquine not to be effective in the treatment of covid 19 in very ill patients. However, my hypothesis is, are the low death rates in Africa linked to the fact that malaria is very prevalent in Africa, and lots of Africans take antimalarial drugs, making them less susceptible to covid 19, hence the low death rate. Is there a similar trend in other countries where malaria is prevalent? Is there an unintended benefit of taking antimalarial drug (or other medication) before covid infection, or at the onset, making people less susceptible to covid19.

As I said, this is based on anecdotal observations.

Yours sincerely

Ato Stephens

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 23:58:07 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Cc: Erbeling, Emily (NIH/NIAID) [E]
Bcc: Dani Bolognesi, Ph.D.
Subject: FW:
Attachments: Brown et al submitted.pdf, NIH Presentation final.pptx, preprints202002.0147.v2 (1).pdf, Mosaheb et al 2020.pdf

Cristina:

Please take a good look at this. It is from Dani Bolognesi, one of our top HIV/AIDS investigators from a few years back. He is a serious scientist. Let me know what you think.
Thanks,
Tony

From: Eisinger, Robert (NIH/NIAID) [E] (b) (6) > **On Behalf Of** Fauci, Anthony (NIH/NIAID) [E]
Sent: Monday, April 27, 2020 6:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: FW:

Email from Dani Bolognesi.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone (b) (6) 9
Email (b) (6)

From: Dani Bolognesi, Ph.D. (b) (6) >
Sent: Monday, April 27, 2020 6:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Barasch, Kimberly (NIH/NIAID) [C] (b) (6) >
Subject: FW:


Kimberly: Please see that this reaches Tony as per our call today.

TX in advance.

Dani

Hi Tony:

In advance of getting together with you and your team, I am forwarding a short presentation for you guys to look at. The key elements are follows:



We are prepared to discuss this with you and your team at any time that is convenient for you. As you may know, we are locked down here in the Research Triangle until May 15. If it makes sense, we could arrange a WebEx as an initial step.

Many thanks for the opportunity to share this with you!

All the very best,

Dani

(b) (6)

Best,

Dani

Sent from Dani Bolognesi

From: "Dani Bolognesi, Ph.D." (b) (6) >
Date: Monday, April 27, 2020 at 2:53 PM
To: "Matthias Gromeier, M.D." (b) (6) >
Subject: Please review this draft email to Tony--TX

Matthias: Please review and edit the proposed email to Tony.

Dani

Hi Tony: In advance of getting together with you and your team, I am forwarding a short presentation for you guys to look at. The key elements are follows:



We are prepared to discuss this with you and your tea at any time that is convenient for you. As you may know, we are locked down here in the Research Triangle until May 15. If it makes sense, we could arrange a WebEX as an initial step.

All the best,

Dani

Best,

Dani

Sent from Dani Bolognesi

The information in this electronic mail is sensitive, protected information intended only for the addressee(s). Any other person, including anyone who believes he/she might have received it due to an addressing error, is requested to notify the sender immediately by return electronic mail, and to delete it without further reading or retention. The information is not to be forwarded to or shared unless in compliance with Duke Health policies on confidentiality and/or with the approval of the sender.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 22:35:34 +0000
To: Jeremy Farrar;Dzau, Victor J.;George GAO
Cc: Richard [REDACTED];Hannon, Emma;Conrad, Patricia (NIH/NIAID) [E];Teresa Miller de Vega; [REDACTED];Rebeka Yasmin - CEPI;ben.tinker@cnn.com;Amanda.Sealy@cnn.com;Neel.Khairzada@turner.com;Tia.Miller@turner.com [REDACTED];McGinnis, J. Michael;Balatbat, Celynn;Mun, Jenny; [REDACTED];Redfield, Robert R. (CDC/OD)
Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Jeremy:

Many thanks for the update. Please continue to keep me informed.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED]
FAX: (301) 496-4409
E-mail: [REDACTED]

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar [REDACTED]
Sent: Tuesday, April 28, 2020 10:39 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED]; Dzau, Victor J. <VDzau@nas.edu>; George GAO [REDACTED]
Cc: Richard Hatchett [REDACTED]; [REDACTED]; Hannon, Emma <EHannon@nas.edu>; Conrad, Patricia (NIH/NIAID) [E] [REDACTED]; Teresa Miller de Vega [REDACTED]; [REDACTED]; Rebeka Yasmin - CEPI [REDACTED]; ben.tinker@cnn.com; Amanda.Sealy@cnn.com; Neel.Khairzada@turner.com; Tia.Miller@turner.com; [REDACTED]; McGinnis, J. Michael [REDACTED]; [REDACTED]; Mun, Jenny <JMun@nas.edu> [REDACTED]; Redfield, Robert R. (CDC/OD) [REDACTED]
Subject: Re: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Quick update

Update in confidence

European network from this morning:

16 Paris, 2 Geneva, few Madrid last 10 days - nothing like this usually seen even with seasonal KD or TSS

Barcelona have slightly different experience of 6 'Kawasaki' in last 2 weeks - couple now who have large coronary aneurysms, as have one child South London and one in Bristol.

Most UK PICU have 1-2 of these type of cases

Phenotype seems Diarrhoea and abdominal pain, refractory shock then various degrees of heart involvement and inflammation ++ - several have had their normal appendix whipped out
Most negative respiratory and stool PCR for anything, some positive resp PCR COVID - GOSH early case has seroconverted, but had immunoglobulin

We are establishing database UK and Europe and trying to define what the clinician features are and agree investigations.

Notably, none in US reported (just D/W Boston childrens who have been running shared international COVID experience web calls) and none in Rome, unsure about rest of Italy yet
Does seem BAME preponderance -?? immune related or social phenomenon, in terms of deprivation prevalence and ability to isolate

From: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>

Date: Monday, 27 April 2020 at 12:36

To: Jeremy Farrar <(b) (6)>, Victor Dzau <VDzau@nas.edu>, George Gao <(b) (6)>

Cc: Richard Hatchett <(b) (6)>

(b) (6)
"Hannon, Emma" <EHannon@nas.edu>, "Conrad, Patricia (NIH/NIAID) [E]" <(b) (6)>, Teresa de Vega <(b) (6)>, Rebeka Yasmin - CEPI <(b) (6)>, "ben.tinker@cnn.com" <ben.tinker@cnn.com>, "Amanda.Sealy@cnn.com" <Amanda.Sealy@cnn.com>, "Neel.Khairzada@turner.com" <Neel.Khairzada@turner.com>, "Tia.Miller@turner.com" <Tia.Miller@turner.com>, (b) (6) "McGinnis, J. Michael" <MMcGinnis@nas.edu>, (b) (6)>, "Mun, Jenny" <JMun@nas.edu>, (b) (6)>, "Redfield, Robert R. (CDC/OD)" <(b) (6)>

Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Jeremy:

Thanks for the heads up. Is there any more detailed description of the precise clinical manifestations? They describe a "multisystem inflammatory state". It is vasculitis or anything more specific? Could be an infectious agent that has nothing to do with SARS-CoV-2 infection even though some children are circumstantially infected with SARS-CoV-2 or it could be a post-SARS-CoV-2 inflammatory syndrome, perhaps a Kawasaki syndrome-like disease. Please keep me informed if you hear any further information.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar (b) (6)>

Sent: Monday, April 27, 2020 7:13 AM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Dzaou, Victor J. <VDzaou@nas.edu>; George GAO (b) (6)>

Cc: Richard Hatchett (b) (6)

(b) (6); Hannon, Emma <EHannon@nas.edu>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Teresa Miller de Vega <(b) (6)>; Rebeka Yasmin - CEPI (b) (6)>; ben.tinker@cnn.com; Amanda.Sealy@cnn.com; Neel.Khairzada@turner.com; Tia.Miller@turner.com; (b) (6) McGinnis, J. Michael <JMcGinnis@nas.edu>; (b) (6)>; Mun, Jenny <JMun@nas.edu>; (b) (6)

Subject: Re: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

To be aware of – news over night so a huge amount of uncertainty – important for COVID19 now, and a potential concern for how we view immunity, protection, post-infectious immunopathology.

<https://www.hsj.co.uk/acute-care/exclusive-national-alert-as-coronavirus-related-condition-may-be-emerging-in-children/7027496.article>

<https://t.co/Bj6YHJ8zi>

From: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Date: Sunday, 26 April 2020 at 19:52
To: Victor Dzau <VDzau@nas.edu>, George Gao <(b) (6)>
Cc: Jeremy Farrar <(b) (6)>, Richard Hatchett <(b) (6)>
<(b) (6)>, "Hannon, Emma" <EHannon@nas.edu>, "Conrad, Patricia (NIH/NIAID) [E]" <(b) (6)>, Teresa de Vega <(b) (6)>, Rebeka Yasmin - CEPI <(b) (6)>, "ben.tinker@cnn.com" <ben.tinker@cnn.com>, "Amanda.Sealy@cnn.com" <Amanda.Sealy@cnn.com>, "Neel.Khairzada@turner.com" <Neel.Khairzada@turner.com>, "Tia.Miller@turner.com" <Tia.Miller@turner.com>, <(b) (6)> "McGinnis, J. Michael" <MMcGinnis@nas.edu>, <(b) (6)> "Mun, Jenny" <JMun@nas.edu>, <(b) (6)>
Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

It was a real pleasure to join all of you on this important session. Many thanks for inviting me.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: <(b) (6)>
FAX: (301) 496-4409
E-mail: <(b) (6)>

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Dzau, Victor J. <VDzau@nas.edu>
Sent: Saturday, April 25, 2020 3:59 PM

To: George GAO (b) (6) >

Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

(b) (6) Hannon,
Emma <EHannon@nas.edu>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)

(b) (6); rebeka.yasmin@cepi.net; ben.tinker@cnn.com;

Amanda.Sealy@cnn.com; Neel.Khairzada@turner.com; Tia.Miller@turner.com; (b) (6)

McGinnis, J. Michael <MMcGinnis@nas.edu>; (b) (6); Mun, Jenny
(b) (6); haja.bally@cepi.net

Subject: Re: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear Jeremy, Tony, Sanjay, George, Susan and Richard,

Thank you so much for your superb contributions. It was a spectacular session- a truly inspiring one. I am grateful to all of you.

Hope to see you soon.

Warmest regards,

Victor

On Apr 25, 2020, at 1:22 PM, George GAO (b) (6) wrote:

I am waiting for being connected and will use slides which were sent to your office
George

发自我的iPhone

在 2020年4月24日, 01:49, Dzau, Victor J. <VDzau@nas.edu>
写道 :

Dear Jeremy, Tony, Sanjay, George, Susan, and Richard,

I'm really looking forward to this panel on COVID-19 at the NAS Annual Meeting on Saturday, April 25th at 2:00-3:30 pm ET. There is tremendous excitement and enthusiasm, and registration is through the roof.

I am sending this note to do a last minute check to see if there is anything you need from me. I also want to check whether you are planning to use slides. Will you be sending your slides to us to project or use the share screen feature to advance your own slides? Regardless, it would be helpful to me if you could send me your slides for my preparation.

I would greatly appreciate it if you would respond to this email.

Best,
Victor

PS, (b) (6), my special assistant, will be sending you additional information about the session logistics shortly.

From: Dzau, Victor J. <VDzau@nas.edu>

Sent: Thursday, April 9, 2020 11:01 AM

To: Mun, Jenny <JMun@nas.edu>; (b) (6)

(b) (6)

Cc: (b) (6) Hannon, Emma

<EHannon@nas.edu>; (b) (6)

; 'ben.tinker@cnn.com' <ben.tinker@cnn.com>;

'Amanda.Sealy@cnn.com' <Amanda.Sealy@cnn.com>;

'Neel.Khairzada@turner.com' <Neel.Khairzada@turner.com>;

'Tia.Miller@turner.com' <Tia.Miller@turner.com>; (b) (6)

Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear all,

Thank you for agreeing to participate in a special late breaking session on the COVID-19 pandemic at the NAS annual meeting. Knowing how busy you are, I am sending this email in lieu of a call to prepare for the session.

As you know, this is a 90 minute session which aims to provide our audience with deeper insights into the latest developments in the COVID-19 response. I plan to hold an engaging discussion that covers the whole experience on dealing with this pandemic – from US to international, to preparedness and response, the biology of the virus, the state of diagnostic, treatment and vaccine development, and the importance of communication.

I will begin the session by providing brief (~3 min) opening remarks describing the circumstances of the pandemic. Then, I will introduce the panelists and you will each have 7 minutes to provide remarks. You

may use a limited number of slides for illustration. I hope that each panelist will provide their own perspective and speak to the issues proposed below.

- Jeremy Farrar will discuss the global response to the pandemic, drawing from his experience as a global leader, the chair of the Scientific Advisory Group for the WHO's R&D Blueprint and as a member of the Global Preparedness Monitoring Board.
- Tony Fauci will discuss the US pandemic and provide his perspective as a member of the White House Coronavirus Task Force addressing the 2019–20 coronavirus pandemic.
- George Gao will discuss China's response to the pandemic and lessons learned for the rest of the globe.
- Susan Weiss will discuss the viral characteristics of SARS COV2 , insights into its pathobiology, immunity and development of a pan-CoV antiviral.
- Richard Hatchett will discuss the development of new vaccines and treatments against COVID-19.
- Sanjay Gupta will comment on the health system response to the pandemic and challenges related to communication and public engagement in responding to COVID-19.

Following remarks from each panelist, we will have a moderated discussion amongst ourselves – I will ask you a set of questions (15 mins) and then we will take questions from the web (25 mins). To prepare me to be your moderator, please send me any questions you would like me to ask you. For those of you who would like to have a prep call, please let me know and I will set it up.

Best,
Victor

From: Mun, Jenny

Sent: Wednesday, April 8, 2020 10:56 AM

To: [REDACTED] (b) (6)

Cc: Dzau, Victor J. ; [REDACTED] (b) (6) ; Mun, Jenny ; Hannon, Emma ;

[REDACTED] (b) (6)
[REDACTED] ben.tinker@cnn.com' ; 'Amanda.Sealy@cnn.com'
; 'Neel.Khairzada@turner.com' ; 'Tia.Miller@turner.com'

Subject: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear Speakers:

I am the logistical contact for the COVID-19 session that will be held as part of the Annual Meeting (online) program on Saturday, April 25 at 2:00 pm EDT. Thank you for agreeing to participate in this session. To help you with your planning, I have provided additional details below.

Please note that the session will be live webcast and the general public will also be able to watch the session. Video from the session will also be uploaded on the NAS YouTube channel (<https://www.youtube.com/user/theNASciences>) after the meeting. We will need to obtain signed speaker release forms for your participation in this session. I have attached the speaker release form for your review and submission. **Please return the signed speaker release form by Monday, April 13.**

Session speakers are asked to connect 30 minutes prior to the session start time (**by Saturday, April 25 at 1:30 pm EDT**) to allow the technical staff to check connections and prepare for the session. Details on how to connect will be sent before the meeting.

We will list you in our promotional materials as noted below. If this is incorrect, please let me know.

Anthony S. Fauci, Director, National Institute of Allergy and Infectious Diseases

Jeremy Farrar, Director, Wellcome Trust

George F. Gao, Director-General, Chinese Center for Disease Control & Prevention

Sanjay Gupta, Chief Medical Correspondent, CNN

Richard J. Hatchett, CEO, Coalition for Epidemic Preparedness Innovations

Susan R. Weiss, Professor of Microbiology, Perelman School of Medicine, University of Pennsylvania

Since many of us have moved to remote work environments, you may already be proficient with Zoom and other online meeting/collaboration applications. I am attaching a 'speaker guidelines' file in case you have any questions on how best to prepare for and stage your remote talk. We have technical staff available to help you become familiar with Zoom and its settings – such as “sharing your screen” (if you have slide presentations that need to be shown during your talk). We can arrange for a training session this week or next week. If you would like to schedule a session, please let me know as soon as possible.

Dr. Dzau's office will be in touch regarding the agenda for this session. If you have any other questions, please let me know.

Regards, Jenny

Jenny Mun
Membership Director
National Academy of Sciences

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 22:19:19 +0000
To: Alexander Patterson
Subject: RE: (b) (6) made a Video Game of Yo: "Fauci's Revenge"

Thanks, Alex! Much appreciated.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Alexander Patterson <alex.patterson@beatthebomb.com>
Sent: Thursday, April 30, 2020 11:26 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Daniel Lahart <dlahart@regis.org>
Subject: (b) (6) made a Video Game of Yo: "Fauci's Revenge"

Dear Dr. Fauci -

My name is Alex Patterson and I'm (b) (6) I made a video game about you called **Fauci's Revenge**. Link to play: <https://beatthebomb.com/beatthevirus>

We are streaming the Finals of a tournament live tonight at 8 PM EST on Twitch, FB, and YouTube.
Twitch Stream Link (free to watch): <https://www.twitch.tv/beatthebomb1000>

Also available on:

Facebook: <https://www.facebook.com/BeatTheBomb/>

YouTube: <https://www.youtube.com/channel/UC0yh7vo1knuKuaaCKUssAzA>

Please watch the Twitch Stream if you can! Otherwise I will follow up tomorrow with a video!

Media coverage of the Fauci's Revenge in the News:

- [NBC New York](#)
[Spectrum NY1 News](#)
[Timeout New York](#)
[News 12 New York](#)
[Bushwick Daily](#)
[Fox 5 Good Day New York](#)

To date we've raised over \$6,150 for New York City's Public Health System ([NYC Health + Hospitals](#)). We've created limited edition t-shirts (including a Fauci's Revenge one). We've donated 6,150 [Protective Suits](#) and 4,500 [Gloves](#) to the NYC Mayor's Office and face shields to Maimonides Medical Center. Men for others!

Looking forward to being back in the halls soon at a Jug Night or Career Day. Enjoy the game!

Best,

Alex Patterson (b) (6)

--

Alex Patterson

CEO BEAT THE BOMB

www.beatthebomb.com

Follow us on instagram: @beatthebomb

247 Water Street, Suite 106, Brooklyn, 11201

work: 718-643-0200 // cell: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 22:18:45 +0000
To: [REDACTED] (b) (6)
Subject: FW: [REDACTED] (b) (6) Grad made a Video Game of Yo: "Fauci's Revenge"
Attachments: Fauci's Revenge Game Logo.png

Yikes!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Alexander Patterson <alex.patterson@beatthebomb.com>
Sent: Thursday, April 30, 2020 11:26 AM
To: Fauci, Anthony (NIH/NIAID) [E] <afauci@niaid.nih.gov>
Cc: Daniel Lahart <dlahart@regis.org>
Subject: [REDACTED] (b) (6) made a Video Game of Yo: "Fauci's Revenge"

Dear Dr. Fauci -

My name is Alex Patterson and I'm [REDACTED] (b) (6) I made a video game about you called **Fauci's Revenge**. Link to play: <https://beatthebomb.com/beatthevirus>

We are streaming the Finals of a tournament live tonight at 8 PM EST on Twitch, FB, and YouTube.
Twitch Stream Link (free to watch): <https://www.twitch.tv/beatthebomb1000>

Also available on:

Facebook: <https://www.facebook.com/BeatTheBomb/>

YouTube: <https://www.youtube.com/channel/UC0yh7vo1knuKuaaCKUssAzA>

Please watch the Twitch Stream if you can! Otherwise I will follow up tomorrow with a video!

Media coverage of the Fauci's Revenge in the News:

- NBC New York
Spectrum NY1 News
Timeout New York
News 12 New York
Bushwick Daily
Fox 5 Good Day New York


To date we've raised over \$6,150 for New York City's Public Health System (NYC Health + Hospitals). We've created limited edition t-shirts (including a Fauci's Revenge one). We've donated 6,150 Protective Suits and 4,500 Gloves to the NYC Mayor's Office and face shields to Maimonides Medical Center. Men for others!

Looking forward to being back in the halls soon at a Jug Night or Career Day. Enjoy the game!

Best,
Alex Patterson (b) (6)

--

Alex Patterson
CEO BEAT THE BOMB
www.beatthebomb.com
Follow us on instagram: @beatthebomb
247 Water Street, Suite 106, Brooklyn, 11201
work: 718-643-0200 // cell: (b) (6)





BEAT THE BOMB

PRESENTS

FAUCI'S REVENGE

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 22:14:57 +0000
To: (b) (6)
Cc: Tromberg, Bruce (NIH/NIBIB) [E]; Sharpless, Norman (NIH/NCI) [E]; Birx, Deborah L. EOP/NSC; Redfield, Robert R. (CDC/OD); Collins, Francis (NIH/OD) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Stanford National Daily Health Survey for COVID - "Open Up America Again"
Attachments: 4.28.20 NDHS Overview Slides-Rusty-Fauci _ 1.pptx

Rod:

Great to hear from you. Thanks very much for sending this. Very impressive! I will forward this to Bruce Tromberg and Ned Sharpless who have been working on COVID-related apts. In addition, I have cc'd Deb Birx (Coordinator of the White House COVID-19 Task Force) as well as CDC Director Bob Redfield and Francis Collins. I hope that all is well with you. Stay well and safe,

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Pettigrew, Roderic I
Sent: Thursday, April 30, 2020 4:20 AM
To: Anthony S. Fauci (NIH/NIAID) (b) (6)
Subject: Stanford National Daily Health Survey for COVID - "Open Up America Again"

Hi Tony,

Greetings from Houston, where the number of cases peaked ~2 weeks ago, dropped 35-40% and seemed to have plateaued since. Great to see you on TV and see the nation (including Brad

Pitt😊) get to know the rigorously informed, keenly rationale and consistently clear Tony your colleagues have long known.

(b) (4), (b) (5)

Thank you, Tony. Very proud to know you. Kind regards to (b) (6).

Rod

Roderic I Pettigrew, PhD, MD

CEO EnHealth | Health Science Center and College of Engineering

Robert A Welch Professor and Executive Dean EnMed | Colleges of Medicine, Engineering and Houston Methodist Hospital

Texas A&M University ALKEK Building|Suite 1103

2121 W Holcombe Blvd | Houston, TX 77030

www.enmed.tamu.edu

Ph: (b) (6) | (b) (6)

MAKING WHAT IF POSSIBLE | whatif.tamu.edu

From: Hofmann, Lawrence, M.D. <[REDACTED]> (b) (6)

Sent: Tuesday, April 28, 2020 11:19 AM

To: Pettigrew, Roderic I [REDACTED] (b) (6)

Cc: Pelc, Norbert J [REDACTED] (b) (6)

Subject: [EXTERNAL]National Daily Health Survey for COVID - "Open Up America Again"

(b) (4), (b) (5)



Best,

R

Lawrence "Rusty" Hofmann, MD

Professor and Chief, Interventional Radiology

Medical Director, Digital Health Integration

Medical Director, Cardiac and Interventional Services

@rustyhofmannMD

(m) [REDACTED] (b) (6)

Assistant: [REDACTED] (b) (6)

[REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 22:05:19 +0000
To: Barillas, Carolina (NIH/NIAID) [E]
Cc: Auchincloss, Hugh (NIH/NIAID) [E]
Subject: RE: [REDACTED] (b) (5)

Carolina:

Thanks for sending this [REDACTED] (b) (5)

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Barillas, Carolina (NIH/NIAID) [E] [REDACTED] (b) (6)
Sent: Thursday, April 30, 2020 11:25 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Cc: Auchincloss, Hugh (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: [REDACTED] (b) (5)

Dear Tony,

[REDACTED] (b) (5)

All the best,
Carolina



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 21:47:05 +0000
To: (b) (6)
Subject: FW: Autopsy data supporting Remdesivir trial
Attachments: (b) (4)

Take a look at the Figures in the manuscript. (b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Timothy Schacker (b) (6)
Sent: Thursday, April 30, 2020 1:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Autopsy data supporting Remdesivir trial

Tony,

(b) (4)

Stay well (please) and thank you for all you are doing!

Tim

Timothy Schacker, M.D.
Vice Dean for Research, Medical School
Director, Program in HIV Medicine
University of Minnesota


Mail:
MMC 250
420 Delaware Street SE
Minneapolis, MN 55455


FedEx/UPS:
Mayo C688
420 Delaware Street SE
Minneapolis, MN 55455

Phone: (b) (6)

Fax: 612-626-5599

email: (b) (6)





From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 14:17:43 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]
Subject: FW: May the Official Nobel documentary program at Swedish Television get an interview with you Dr Fauci about Covid-19 before May 7th please?

Please get clearance and set it up if possible.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Johan Bergendorff <johan.bergendorff@svt.se>
Sent: Thursday, April 30, 2020 9:56 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: NIAID NEWS (NIH/NIAID) <NIAIDNEWS@niaid.nih.gov>; Barasch, Kimberly (NIH/NIAID) [C] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6)
Subject: May the Official Nobel documentary program at Swedish Television get an interview with you Dr Fauci about Covid-19 before May 7th please?

Dear Dr. Fauci,

I had the honor to interview you in april 2016 about the zika epidemic at your office for a program for national Swedish radio as their global health correspondent. I hope I may have the honor again now Sir?

I am now working as science correspondent for the national Swedish Television (non commercial public service, half the population as daily viewers) in our official Nobel prize laureate documentary program "Vetenskapens Värld" (the World of Science) and wonder if you have any chance to give us a 10 minute interview by web video before May 7th please?

I would like to ask you two questions: What is most crucial now to succeed with an covid-19 pandemic exit in the US? How do you find the Swedish strategy against Covid-19 so far (Dr. Mike Ryan praised it yeasterday at the WHO press conference as a model for an exit strategy, what is your view)?

In this one hour program aired on May 11th we will have other prominent scientists as well talking about exit strategies, among others Nobel prize winner prof. Paul Krugman, prof. Bengt Holmström MIT, prof. Angus Deaton Princeton, as well as Prof Gabriel Leung Dean University Hongkong etc.

Here you can see the reports I did from my earlier interview with you about the zika epidemic in 2016 (in Swedish). News report: <https://sverigesradio.se/artikel/6420891> 20 min
documentary: <https://sverigesradio.se/avsnitt/712016>

One option is that I send you a link for a web video Conference call. Another option is that I call you on the phone and your media department may have the oportunity to record a video of your anseers with HD quality that is better to air.

Please let me know if you are available and when.

Best regards,

Johan Bergendorff
Science correspondent, Swedish Television

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 13:31:50 +0000
To: Julie.Steenhuysen@thomsonreuters.com
Cc: Greg Folkers (b) (6)
Subject: FW: Fauci says leak concerns fueled his White House revelation of Gilead drug results

Julie:

You did a good job in reporting our conversation last night. Thanks.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)>
Sent: Thursday, April 30, 2020 8:59 AM
To: NIAID COGCORE <COGCORE@mail.nih.gov>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: Fauci says leak concerns fueled his White House revelation of Gilead drug results

Health News

April 30, 2020 / 1:07 AM / Updated 4 hours ago

Fauci says leak concerns fueled his White House revelation of Gilead drug results

Julie Steenhuysen

5 Min Read

CHICAGO (Reuters) - Concerns over leaks compelled the top U.S. infectious disease official to reveal data on Gilead Sciences Inc's experimental drug remdesivir, the first in a scientifically rigorous clinical trial to show benefit in treating COVID-19.



National Institute of Allergy and Infectious Diseases Director Dr. Anthony Fauci attends a coronavirus response meeting between U.S. President Donald Trump and Louisiana Governor John Bel Edwards in the Oval Office at the White House in Washington, U.S., April 29, 2020. REUTERS/Carlos Barria

The dramatic announcement by Dr Anthony Fauci in the Oval Office on Wednesday prompted concerns among scientists that the Trump administration was raising hopes about a coronavirus treatment before sharing the full data with researchers.

As a cautionary example of inflating the potential value of a therapy, some pointed to President Donald Trump's repeated endorsements of malaria drug hydroxychloroquine as a treatment, with no evidence that it works.

Newer data suggests the malaria treatments may carry significant risks for some sufferers of the respiratory disease caused by the virus.

Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), which is running the trial, said he took the first opportunity to get the word out that patients taking a dummy treatment or placebo should be switched to remdesivir in hopes of benefiting from it.

He expressed concern that leaks of partial information would lead to confusion. Since the White House was not planning a daily virus briefing, Fauci said he was invited to release the news at a news conference with Louisiana Gov. John Bel Edwards(D). "It was purely driven by ethical concerns," Fauci told Reuters in a telephone interview.

"I would love to wait to present it at a scientific meeting, but it's just not in the cards when you have a situation where the ethical concern about getting the drug to people on placebo dominates the conversation."

An independent data safety and monitoring board, which had looked at the preliminary results of the NIAID trial, determined it had met its primary goal of reducing hospital stays.

On Tuesday evening, that information was conveyed in a conference call to scientists studying the drug globally.

"There are literally dozens and dozens of investigators around the world," Fauci said. "People were starting to leak it." But he did not give details of where the unreported data was being shared.

Several scientists interviewed by Reuters felt the White House setting seemed inappropriate for the release of highly anticipated government-funded trial data on the Gilead therapy.

They had expected it to be presented simultaneously in a detailed news release, a briefing at a medical meeting or in a scientific journal, allowing researchers to review the data.

Information from various trials of remdesivir has been leaked to media in recent weeks. In a statement on Wednesday, Gilead said the NIAID's much anticipated trial had met its primary goal, but gave no details.

Data in a separate NIAID statement after Fauci spoke detailed preliminary results showing that patients who got the drug had a 31 percent faster time to recovery than those who got a placebo, cutting hospital stays by four days.

The trial also came close to showing the drug helped people survive the disease, but the data fell just short of statistical significance.

"I want to see the full data. I want to understand the statistics. I want to understand the benefit and risk. I want to understand the structure of the study, and all of it," said Dr. Steven Nissen, the chief academic officer at the Cleveland Clinic.

"Am I encouraged from what I've heard? Yes, I'm encouraged. But I want to get a full understanding of what happened here, and not get it via a photo opportunity from the Oval Office."

Data Gilead released on its own trial of remdesivir drew less attention, as it did not compare outcomes between those receiving therapy and those who did not.

Results from a third study in China suggesting remdesivir failed to help COVID-19 patients were released in the British medical journal the Lancet after review by a peer group of scientists.

"That's the only thing I'll hang my hat on, and that was negative," said Dr. Eric Topol, director and founder of the Scripps Research Translational Institute in La Jolla, California.

He was unimpressed by remdesivir's modest benefit.

"It was expected to be a whopping effect," Topol added. "It clearly does not have that."

At the Oval Office news conference, Fauci compared the study findings to AZT, the first drug to show any benefit against HIV, decades ago.

"We know that was an imperfect drug. It was the first step," Fauci said in the interview.

"Similar to AZT, it's (remdesivir) the first baby step towards what hopefully will be a number of better drugs that will come in and be able to treat people with COVID-19."

(This story has been refiled to correct spelling of "clinical" in paragraph one)

Reporting by Julie Steenhuysen; Editing by Michele Gershberg and Clarence Fernandez

Our Standards:[The Thomson Reuters Trust Principles.](#)

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 10:20:32 +0000
To: STEWART SIMONSON (b) (6)
Cc: Masur, Henry (NIH/CC/CCMD) [E]; STEWART SIMONSON
Subject: RE: COVID-19 and Haiti

Bill:

(b) (6) Work with him. As per our prior conversation and as you know better than anyone, Haiti is struggling and I know that Stewart will do whatever he can to assist you.

Warm regards,

Tony

From: STEWART SIMONSON (b) (6)
Sent: Thursday, April 30, 2020 5:44 AM
To: (b) (6)
Cc: Fauci, Anthony (NIH/NIAID) [E]; (b) (6) Masur, Henry (NIH/CC/CCMD) [E]; (b) (6); STEWART SIMONSON (b) (6)
Subject: COVID-19 and Haiti

Dear Dr. Pape:

I lead the World Health Organization (WHO) delegation to the United Nations and know of you through Tony Fauci and Henry Masur, (b) (6). For nearly 5 years immediately preceding my appointment at WHO,, I was an technical advisor at Hôpital Sacré-Cœur in Milot and remain in close contact with institution. Because of this, PAHO leadership asked me to join their COVID-19 planning discussions related to Haiti. I understand from Henry that you have been appointed by MSPP to coordinate COVID-19 preparedness and response activities. If you have some time available on Friday, it would be good to talk via Zoom or Webex. I can arrange this and would plan to have the PAHO deputy director as well as other PAHO officials on the line. Would you be available Friday afternoon for such a discussion? If not Friday, anytime over the weekend would also likely work on our end.

Thanks so much for considering this.

With best regards,

Stewart Simonson

STEWART SIMONSON
Washington, DC/New York
(b) (6) or
(b) (6)
(b) (6)S)
IS)
(Switzerland)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 01:24:46 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Has anyone tried palivizumab (Synagis)

Please respond.

From: Rich May (b) (6)
Sent: Wednesday, April 29, 2020 10:21 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Has anyone tried palivizumab (Synagis)

Good morning Dr. Fauci,

Has anyone tried palivizumab (Synagis) on any new COVID-19 patients?

Thank you for your time,
Richard May, MD, PhD, D.H.Sc (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 22:42:24 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: NAD repletion for Covid-19

Please take a look and respond if appropriate

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mel Cohen (b) (6)
Sent: Wednesday, April 29, 2020 1:52 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: NAD repletion for Covid-19
Importance: High

Dear Dr. Fauci,

Recent research has shown that SARS-CoV-2 plays havoc with NAD function within cells.

Coronavirus Infection and PARP Expression Dysregulate the NAD Metabolome: A Potentially Actionable Component of Innate Immunity:
<https://www.biorxiv.org/content/10.1101/2020.04.17.047480v3>

The Molecular Story of COVID-19; NAD+ Depletion Addresses All Questions in this Infection:
<https://www.preprints.org/manuscript/202003.0346/v1>

Other research has shown that NAD+ levels decline from aging and obesity, both significant factors in Covid-19 severity. But it has also been demonstrated that NAD levels can be replenished through oral administration of nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). NR in particular has had several human studies demonstrating its safety and efficacy, and roughly 50 human studies listed on clinicaltrials.gov for all manner of disorders.

There is at least one anecdotal report of dramatic improvement in a Covid-19 patient after

administration of NMN.

NMN shows great promise in case studies of humans with COVID-19:

https://alivebynature.com/nmn-shows-promise-for-treatment-of-covid-19-in-case-studies/?utm_campaign=NMN%20for%20covid%20%28TqFTyz%29&utm_medium=email&utm_source=Main%20List&ke=eyJrbF9lbWFpbCI6ICJtZWxhZGlzdHJpYnV0ZWwuY2EiLCAia2xfY29tcGFueV9pZCI6ICJsbWROWFoifQ%3D%3D

That article begins with the disclaimer, "*There are no human trials that prove effectiveness of any NAD+ boosting supplements for preventing or curing COVID-19.*"

That is a problem. When I see the resources that have been wasted pursuing hydroxychloroquine, I am saddened to learn that there are no clinical trials of nicotinamide riboside as part of a treatment regimen for Covid-19. Can you do anything about getting such a study done?

Regards,
Mel Cohen

Disclaimer: [REDACTED] (b) (6)

[REDACTED]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 22:01:22 +0000
To: Folkers, Greg (NIH/NIAID) [E]; NIAID OD AM
Subject: RE: ASF----- slides for Business Roundtable, Friday 5-1-2020, 12-1 / FOR REVIEW IN OD

Now FINAL in the OD folder. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Sent: Wednesday, April 29, 2020 5:03 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: ASF----- slides for Business Roundtable, Friday 5-1-2020, 12-1 / FOR REVIEW IN OD

- This is a zoom call.
- I think you will be able to use slides.
- I have put in OD a draft "curtain-raiser" set that you could show to kick things off – or use them as TPs if you prefer.
- I will update any epi or other numbers tomorrow night
- The "ask" is below

From: Silverberg, Kristen <KSilverberg@brt.org>
Sent: Tuesday, April 14, 2020 4:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: invitation from BRT

Dr. Fauci,

First, thank you for everything you are doing. I have always been grateful for your public service, but feel particularly indebted to you these days.

To add to the debt...Josh and I wanted to see if you would be willing to join a call with Business Roundtable CEOs. We have been doing COVID-19 calls with them every Friday at 1:30pm. Typically, about 100-125 CEOs of large, U.S.-based firms will join. They are all managing and planning for difficult issues around employee and customer safety. They would love to hear from you directly and to ask a few questions. It might also be a good place to deliver any messages you want them to hear.

We completely understand if it isn't doable, of course. If you are able, we would love to host you sometime between 1:30pm-2:30pm this Friday (or any Friday on which your schedule would allow it).

Best,

Kristen

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 15:09:44 +0000
To: Anthony Fauci
Subject: FW: Potential slides for Remdesivir presentation
Attachments: Remdesivir bullet slides - FAUCI - FINAL.pptx

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wednesday, April 29, 2020 11:02 AM
To: Short, Marc T. EOP/OVP (b) (6); 'Miller, Katie R. EOP/OVP'
(b) (6) >
Subject: Potential slides for Remdesivir presentation

Marc/Katie:

Here are 3 slides that I might use in the press briefing. If necessary, I could make the presentation without them, but it might be clearer to have them just in case.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 14:18:44 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: RE: two things

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, April 29, 2020 9:16 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6)
Subject: ASF: two things

Talked to FDA. They have written (and cleared with Gilead) a new sentence in place of what we had in there about an EUA. Our release has been updated (attached) with the sentence highlighted below.

ALSO: Bill Hall called me to ask if you had alerted the Secretary to this (so the press release clearance process isn't the way he first learns of it). I told him I wasn't sure. If you haven't done so, perhaps you wish to now?

As part of the U.S. Food and Drug Administration's commitment to expediting the development and availability of potential COVID-19 treatments, the agency has been engaged in sustained and ongoing discussions with Gilead Sciences regarding making remdesivir available to patients as quickly as possible, as appropriate.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 10:45:24 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]; Stover, Kathy (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]; Erbeling, Emily (NIH/NIAID) [E]
Subject: RE: please read, Gilead statement

Looks fine. Thanks.

From: Billet, Courtney (NIH/NIAID) [E] <billetc@niaid.nih.gov>
Sent: Wednesday, April 29, 2020 6:43 AM
To: Fauci, Anthony (NIH/NIAID) [E] <afauci@niaid.nih.gov>
Cc: Folkers, Greg (NIH/NIAID) [E] <gfolkers@niaid.nih.gov>; Conrad, Patricia (NIH/NIAID) [E] <conradpa@niaid.nih.gov>; Marston, Hilary (NIH/NIAID) [E] <hilary.marston@nih.gov>; Routh, Jennifer (NIH/NIAID) [E] <jennifer.routh@nih.gov>; Stover, Kathy (NIH/NIAID) [E] <kathy.stover@nih.gov>; Lane, Cliff (NIH/NIAID) [E] <clane@niaid.nih.gov>; Erbeling, Emily (NIH/NIAID) [E] <emily.erbeling@nih.gov>
Subject: ASF: please read, Gilead statement

FYI – this will go out before markets open this morning:

GILEAD SCIENCES STATEMENT ON POSITIVE DATA EMERGING FROM NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES' STUDY OF REMDESIVIR

Foster City, Calif., April 29, 2020 – Gilead Sciences, Inc. (Nasdaq: GILD) is aware of the positive data emerging from the National Institute of Allergy and Infectious Diseases' (NIAID) study of remdesivir. We understand that the trial has met its primary endpoint and that NIAID will provide detailed information at an upcoming briefing.

In addition to the NIAID trial, Gilead expects to share additional remdesivir data from the company's open-label Phase 3 SIMPLE trial in patients with severe COVID-19 disease shortly. This study will provide information on whether a shorter, 5-day duration of therapy may have similar efficacy and safety as the 10-day treatment course evaluated in the NIAID trial and other ongoing trials. Gilead expects data at the end of May from the second SIMPLE study evaluating the 5- and 10-day dosing durations of remdesivir in patients with moderate COVID-19 disease.

Gilead will continue to discuss with regulatory authorities the growing data set regarding remdesivir as a potential treatment for COVID-19.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 03:09:03 +0000
To: Berkowitz, Avrahm J. EOP/WHO
Subject: RE: Jared Kushner Defends Dr. Fauci After Fox News Host Criticises Top Coronavirus Task Force Expert

Thanks, Avi.

-----Original Message-----

From: Berkowitz, Avrahm J. EOP/WHO (b) (6)
Sent: Tuesday, April 28, 2020 10:00 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Jared Kushner Defends Dr. Fauci After Fox News Host Criticises Top Coronavirus Task Force Expert

Just wanted to share an article- all the best!
Avi

<https://www.newsweek.com/jared-kushner-defends-dr-fauci-fox-news-host-little-tough-1500339>

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 03:08:36 +0000
To: Billet, Courtney (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]; Erbelding, Emily (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: DRAFT NIAID statement on remdesivir, ACTT 2
Attachments: SHORTENED NIAID statement NEW NEW - with Fauci edits.docx

See my minor edits. (b) (5)

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)>
Sent: Tuesday, April 28, 2020 10:40 PM
To: Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6); Erbelding, Emily (NIH/NIAID) [E] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: RE: DRAFT NIAID statement on remdesivir, ACTT 2

OK – here's a re-do. (b) (5)
(b) (6)
(b) (6)
(b) (6)
(b) (6)

From: Billet, Courtney (NIH/NIAID) [E]
Sent: Tuesday, April 28, 2020 10:02 PM
To: Folkers, Greg (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: RE: DRAFT NIAID statement on remdesivir, ACTT 2

(not sure what happened with spacing). Cliff – I got your suggestion too. I'll blend yours, mine, and Gregs and send a clean new one shortly.

From: Billet, Courtney (NIH/NIAID) [E]
Sent: Tuesday, April 28, 2020 10:01 PM
To: Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6)>

Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)

Subject: RE: DRAFT NIAID statement on remdesivir, ACTT 2

I took a crack at a revision as well. We can blend these.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)

Sent: Tuesday, April 28, 2020 9:57 PM

To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Routh, Jennifer (NIH/NIAID) [E]

(b) (6)>; Billet, Courtney (NIH/NIAID) [E] <(b) (6)>; Erbelding, Emily

(NIH/NIAID) [E] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] <(b) (6)>; Marston,

Hilary (NIH/NIAID) [E] (b) (6)>

Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>

Subject: RE: DRAFT NIAID statement on remdesivir, ACTT 2

Here is my suggested edit to the short version.

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>

Sent: Tuesday, April 28, 2020 9:21 PM

To: Routh, Jennifer (NIH/NIAID) [E] (b) (6)>; Billet, Courtney (NIH/NIAID) [E]

(b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Erbelding, Emily

(NIH/NIAID) [E] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] <(b) (6)>; Marston,

Hilary (NIH/NIAID) [E] <(b) (6)>

Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>

Subject: FW: DRAFT NIAID statement on remdesivir, ACTT 2

Importance: High

Thanks for all your work. (b) (5)

(b) (5)

(b) (5). Please change

this.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)

Sent: Tuesday, April 28, 2020 7:29 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>

Cc: Routh, Jennifer (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E]

(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>; Folkers, Greg

(NIH/NIAID) [E] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] (b) (6)>;

Lane, Cliff (NIH/NIAID) [E] <(b) (6)>; Marston, Hilary (NIH/NIAID) [E]

(b) (6)

Subject: ASF: DRAFT NIAID statement on remdesivir, ACTT 2

Importance: High

There are two versions for your consideration here, as discussed.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 01:53:28 +0000
To: Lane, Cliff (NIH/NIAID) [E]
Subject: RE: Bullets
Attachments: Rendesivir bullet slides - FAUCI.pptx

I added another bullet.

From: Lane, Cliff (NIH/NIAID) [E] (b) (6)
Sent: Tuesday, April 28, 2020 9:51 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: Bullets

Graph inserted.

From: Anthony Fauci (b) (6)>
Date: Tuesday, April 28, 2020 at 9:47 PM
To: "Lane, Cliff (NIH/NIAID) [E]" (b) (6)>
Subject: RE: Bullets

I made some minor changes

From: Lane, Cliff (NIH/NIAID) [E] (b) (6)
Sent: Tuesday, April 28, 2020 9:27 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Bullets

For comment

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 01:50:16 +0000
To: Lane, Cliff (NIH/NIAID) [E]
Subject: RE: DRAFT NIAID statement on remdesivir, ACTT 2
Attachments: ACTT 2 NIAID statement CB KS EE HM HCL1 - with minor edits.docx

(b) (5) I made some minor edits.

From: Lane, Cliff (NIH/NIAID) [E] (b) (6)>
Sent: Tuesday, April 28, 2020 9:44 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: DRAFT NIAID statement on remdesivir, ACTT 2

Attached for consideration.

From: Anthony Fauci (b) (6)>
Date: Tuesday, April 28, 2020 at 9:21 PM
To: "Routh, Jennifer (NIH/NIAID) [E]" (b) (6)>, "Billet, Courtney (NIH/NIAID) [E]" (b) (6)>, "Folkers, Greg (NIH/NIAID) [E]" (b) (6), "Erbelding, Emily (NIH/NIAID) [E]" (b) (6), "Lane, Cliff (NIH/NIAID) [E]" (b) (6)>, Hilary Marston (b) (6)>
Cc: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)>
Subject: FW: DRAFT NIAID statement on remdesivir, ACTT 2

Thanks for all your work. (b) (5)

(b) (5)
(b) (5). Please change this.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)>
Sent: Tuesday, April 28, 2020 7:29 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Routh, Jennifer (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6)
Subject: ASF: DRAFT NIAID statement on remdesivir, ACTT 2
Importance: High

There are two versions for your consideration here, as discussed.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 01:21:27 +0000
To: Routh, Jennifer (NIH/NIAID) [E]; Billet, Courtney (NIH/NIAID) [E]; Greg Folkers (GFOLKERS@niaid.nih.gov); Erbelding, Emily (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: DRAFT NIAID statement on remdesivir, ACTT 2
Attachments: ACTT 2 NIAID statement CB KS EE HM.docx, SHORTENED NIAID statement.docx

Thanks for all your work. However, (b) (5)
(b) (5)
(b) (5). Please change this.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)
Sent: Tuesday, April 28, 2020 7:29 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Routh, Jennifer (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Erbelding, Emily (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6)
Subject: ASF: DRAFT NIAID statement on remdesivir, ACTT 2
Importance: High

There are two versions for your consideration here, as discussed.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 00:56:02 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Coronavirus info about a program that can help.
Attachments: BCA_id_V1 (wecompress.com).pdf

Please take a look and respond if appropriate

-----Original Message-----

From: Alex Holbus (b) (6)
Sent: Tuesday, April 28, 2020 6:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Coronavirus info about a program that can help.

Dear Dr Fauci

It's a pleasure to send you this email my name is Alex Holbus I am from the UK I currently live in Serbia or ex Yugoslavia.
I am a Economist and Humanitarian. I can talk about my Biography but at this time the subject I want to share with you I much more important.

In January 2016 I sent a letter to Mr Trump (b) (6) telling him that I was happy that he will bring change to America and the world and that if he needed my expertise that I would help your country and the world. As I have not got any responses from him nor his people I can see that he might not be interested. But as I have been following you over the media and be reading about your carrier as a Doctor I believe you know what your doing and would like to take this opportunity to help you and your country at this time when it's the worst then ever before in the modern world. I have a program that can help with the coronavirus in the way of identifying people and following there movement that can help you collect data faster and more sufficient. The program is based on an app so every one can use it. Countries in Europe are starting to use it by the end of May the Europe Union has made it mandatory that all member states need to use it and the future members like Serbia. So you will see attached a presentation about the program and if you or your country is interested please let me know and I will put you in contact with the company making this program. I did not send this email to you so we make money on people it's to help I just wanted to help. I will be contacting my contacts in the USA from Thursday morning but first I wanted to talk with you and give you the opportunity to see if Mr Trump would interested in this program for your country. If nothing comes back from you anyway my friend and contact in the USA will talk with the white house but I wanted to do it the proper way by talking to you as you are the main medical person in the USA for the coronavirus.

Anyway wish you and your country all the best and that the world will become a better place after this epidemic is over.

It's one life one world one human we are all one on this planet no one is bigger or better the all of us as humanity as one.

Kind regards

Alex Holbus

Director at Real Five Company.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Apr 2020 17:41:52 +0000
To: [REDACTED] (b) (6)
Subject: RE: worrisome

Yes. Please call to their attention. [REDACTED] (b) (6) It is merely a nasal swab

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [REDACTED] (b) (6)
Sent: Tuesday, April 28, 2020 10:32 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: worrisome

From today's Medscape.

https://www.medscape.com/viewarticle/929407?nlid=135287_5653&src=wnl_newsairt_daily_200427_MSCPEDIT&uac=71367AK&impID=2361940&faf=1

Older adults with COVID-19, the illness caused by the coronavirus, have several "atypical" symptoms, complicating efforts to ensure they get timely and appropriate treatment, according to physicians. COVID-19 is typically signaled by three symptoms: a fever, an insistent cough and shortness of breath. But older adults — the age group most at risk of severe complications or death from this condition — may have none of these characteristics.

Instead, seniors may seem "off" — not acting like themselves — early on after being infected by the coronavirus. They may sleep more than usual or stop eating. They may seem unusually apathetic or confused, losing orientation to their surroundings. They may become dizzy and fall. Sometimes, seniors stop speaking or simply collapse.

[REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Apr 2020 17:39:34 +0000
To: Janet Tobias; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Riding along tomorrow am

OK

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Janet Tobias <janet@ikanamedia.com>
Sent: Tuesday, April 28, 2020 12:46 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Subject: Riding along tomorrow am

Hi Tony and Patty:

Would it be ok to do the 6:45 am ride to NIH tomorrow? We would also get there early to do one more paper throw. And last night was great!

Janet

From: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Date: Sunday, April 26, 2020 at 4:30 PM
To: Janet Tobias <janet@ikanamedia.com>
Subject: RE: Quick question

My work with the Coronavirus Task Force and the large volume of incoming emails precludes me or my staff from answering each individual message. I would

encourage you to visit www.coronavirus.gov for the latest information and guidance related to COVID-19.

Thank you, and best regards.

Anthony S. Fauci, M.D.

From: Auchincloss, Hugh (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Apr 2020 15:50:24 +0000
To: NIAID OD AM
Subject: FW: Invitation from the Investment Community
Attachments: Letter of invitation_Dr. Anthony Fauci from UBS Investment Bank (1).pdf

I don't think so.

From: Elizabeth Haenle (b) (6) >
Sent: Tuesday, April 28, 2020 11:36 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Invitation from the Investment Community

Dear Dr. Fauci,

I am the co-founder of SAGE Worldwide, a global speaker and consulting company. I am reaching out on behalf of one of my partners, Robert Karofsky, Co-President of UBS Investment Bank, with an invitation to join the UBS Global response to Covid-19 in a live streaming moderated discussion on May 18. Alternatively your conversation could be pre-recorded to accommodate your busy schedule. At this critically important time in our nation's history, the investment community wants to help our nation fight Covid-19 and use our country's economic engine to find a cure and solutions for Covid-19. They also are thinking through how to help our nation's businesses going forward. Your expertise is important to this conversation.

By way of background, I served in the White House for eight years in the Bush Administration as the Social Secretary to Vice President Cheney. In that capacity, I had the privilege of curating a range of discussions with global thinkers and thought leaders on the world's most pressing topics. At SAGE, we bring that level of excellence to our business partners as we help curate discussions that have an impact on public awareness and investor sentiment, which is particularly important as the U.S. responds to Covid-19.

Additionally, (b) (6)

Participants at the UBS Global Healthcare Conference provide critical funding to pharmaceuticals and healthcare research and are the businesses on the frontline of the Covid-19 healthcare response.

Attached please find an invitation from UBS with further details of the event. I welcome the opportunity to hear from you at your earliest convenience, and thank you for your important work and dedication to our country's well being over the course of your distinguished career and service at NIAID.

Warmest regards,
Elizabeth Haenle
Co-Founder, SAGE Worldwide
Phone: (b) (6)
Attachment 1

--

Elizabeth Haenle 戴丽翠

Co-founder and President

M: [REDACTED] (b) (6)

E: [REDACTED] (b) (6)

W: SAGEworldwide.com



This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you have received this email in error please notify the system manager. This message contains confidential information and is intended only for the individual named. If you are not the named addressee you should not disseminate, distribute or copy this e-mail. Please notify the sender immediately by e-mail if you have received this e-mail by mistake and delete this e-mail from your system. If you are not the intended recipient you are notified that disclosing, copying, distributing or taking any action in reliance on the contents of this information is strictly prohibited.

From: Auchincloss, Hugh (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Apr 2020 14:46:56 +0000
To: NIAID OD AM
Subject: FW: HIGH SCHOOL MUN CONFERENCE

For discussion

From: Dane Cohn (b) (6) >
Sent: Tuesday, April 28, 2020 10:44 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Barasch, Kimberly (NIH/NIAID) [C]
(b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Fauci,
Anthony (NIH/NIAID) [E] (b) (6) >
Subject: HIGH SCHOOL MUN CONFERENCE

Dear Dr. Anthony Fauci,

My name is Dane Cohn, and I am an (b) (6). I have often listened to your inspiring words on the news and followed your assiduous work to help us through this pandemic. Our school participates in Model UN, an event in which high school students represent various countries in debates on international issues from the past and present. Colorado's final Model UN conference was canceled, so our school ((b) (6)) decided to host an online conference for the whole state of Colorado and beyond. Our team would like to formally invite you to give a short address (be it pre-recorded or live online) to the students during our opening ceremony.

We hope that our conference will inspire the youth of our nation and the world to stand up and fight for our future rather than resign their aspirations to lockdown. We host this conference because we see the importance of keeping our academic passions going while staying safe within the confines of our homes. We host this conference because we want to contribute to the fight against COVID-19 — money raised from our conference will go towards buying masks, food, and other resources for those who need it most.

This is why we ask you, a hero during this troubling time, to speak to the students of our conference, who not only include the youth of Colorado, but also the youth of our country and world. Any type of address would be greatly and wholeheartedly appreciated. If your address is pre-recorded, we would appreciate it if we could receive it by May 1st, as our conference is the morning of May 2nd. We believe you can bring true inspiration into our hearts and minds. We know you are very busy, but if it were at all possible to share with us even a short 2-3 minute pre-recorded greeting and message to the students participating in this Model UN conference, it would be truly inspirational. Thank you so much for your time, we hope to hear from you soon.

Most Respectfully,
Dane Cohn and the entire (b) (6) Model UN Team

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Apr 2020 11:25:09 +0000
To: Haskins, Melinda (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Please advise LHHS Hearing w/ Dr. Fauci -- Wednesday, May 6

8:30 AM would be good. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Haskins, Melinda (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, April 28, 2020 7:08 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Subject: RE: Please advise LHHS Hearing w/ Dr. Fauci -- Wednesday, May 6

Let me know when you'd like me to call please.

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, April 28, 2020 7:04 AM
To: Haskins, Melinda (NIH/NIAID) [E] (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Subject: Re: Please advise LHHS Hearing w/ Dr. Fauci -- Wednesday, May 6

Let us chat by phone this morning

On Apr 28, 2020, at 5:51 AM, Haskins, Melinda (NIH/NIAID) [E] <(b) (6)> wrote:

We do not know if the DeLauro hearing would be remote. The Senate HELP one would be in person with some form of social distancing.

Sent from my iPhone

On Apr 27, 2020, at 10:36 PM, Fauci, Anthony (NIH/NIAID) [E]

(b) (6) > wrote:

E should make sure that we schedule it at a time of day that does not conflict with the COS visit.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >

Sent: Monday, April 27, 2020 8:20 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Subject: Fwd: Please advise LHHS Hearing w/ Dr. Fauci -- Wednesday, May 6

This is the day of the VIP visit—whoever it is. VP or COS. Pls advise. And not sure if these are 1 person or not. I suspect remote right??

Sent from my iPhone

Begin forwarded message:

From: "Haskins, Melinda (NIH/NIAID) [E]"

(b) (6)

Date: April 27, 2020 at 8:10:52 PM EDT

To: "Conrad, Patricia (NIH/NIAID) [E]"

(b) (6) >

Cc: NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>, "Billet, Courtney (NIH/NIAID) [E]" (b) (6) >, "Harper, Jill (NIH/NIAID) [E]" (b) (6)

Subject: Please advise LHHS Hearing w/ Dr. Fauci --
Wednesday, May 6

Patty,

See below. Another hearing.

Thank you,
Melinda

Sent from my iPhone

Begin forwarded message:

From: "Hallett, Adrienne (NIH/OD) [E]"

(b) (6)

Date: April 27, 2020 at 7:57:36 PM EDT

To: "Haskins, Melinda (NIH/NIAID) [E]"

(b) (6)>, "Selgrade, Sara
(NIH/NIAID) [E]" <(b) (6)>,
"LaMontagne, Karen (NIH/OD) [E]"
(b) (6)>, "Higgins, Lauren
(NIH/OD) [E]" (b) (6)>
**Subject: Fwd: LHHS Hearing w/ Dr. Fauci --
Wednesday, May 6**

Guess they really are coming back.

Begin forwarded message:

From: "Steigleder, Stephen"
(b) (6)
>
Date: April 27, 2020 at 7:41:56 PM
EDT
To: "Hallett, Adrienne (NIH/OD) [E]"
(b) (6)>
**Subject: LHHS Hearing w/ Dr. Fauci -
- Wednesday, May 6**

Hi Adrienne,

I hope you're doing well.

I'm reaching out because Chair
DeLauro would like to invite Dr. Fauci
to a hearing next Wednesday, May 6,
with the House LHHS appropriations
subcommittee. The focus of the
hearing, not surprisingly, would be
COVID-19. Members of the
subcommittee would very much like
to hear from Dr. Fauci on anything
related to COVID-19, but I think the
main topics would be:

- Mitigation and Testing; and
- Progress on vaccines,
therapeutics, and
diagnostics, as well as
necessary preparations to
manufacture and
disseminate a vaccine once it
is ready.

Chair DeLauro is flexible about a starting time for the hearing on Wednesday, so she would be happy to accommodate a time that works for Dr. Fauci's schedule.

Please let me know as soon as possible, so we can plan accordingly.

Thanks so much,

Stephen

.....
Stephen Steigleder
House Appropriations Committee
Labor/HHS/Education Subcommittee

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Apr 2020 00:22:50 +0000
To: (b) (6)
Subject: FW: Remdesivir--good news
Attachments: 20-0006_DSMB_primary_analysis_report_for_DMID.pdf

From: Erbelding, Emily (NIH/NIAID) [E] (b) (6) >
Sent: Monday, April 27, 2020 8:05 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Remdesivir--good news

Tony,

(b) (5)

Emily

Emily Erbelding, M.D., M.P.H.
Director, Division of Microbiology and Infectious Diseases
NIAID/NIH
5601 Fishers Lane
Rockville, MD 20852
Tel: (b) (6)

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 22:56:59 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW:
Attachments: Brown et al submitted.pdf, NIH Presentation final.pptx, preprints202002.0147.v2 (1).pdf, Mosaheb et al 2020.pdf

Email from Dani Bolognesi.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email: (b) (6)

From: Dani Bolognesi, Ph.D. (b) (6)>
Sent: Monday, April 27, 2020 6:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Barasch, Kimberly (NIH/NIAID) [C] (b) (6)
Subject: FW:

Kimberly: Please see that this reaches Tony as per our call today.

TX in advance.

Dani

Hi Tony:

In advance of getting together with you and your team, I am forwarding a short presentation for you guys to look at. The key elements are follows:



We are prepared to discuss this with you and your team at any time that is convenient for you. As you may know, we are locked down here in the Research Triangle until May 15. If it makes sense, we could arrange a WebEx as an initial step.

Many thanks for the opportunity to share this with you!

All the very best,

Dani

(b) (6)

Best,

Dani

Sent from Dani Bolognesi

From: "Dani Bolognesi, Ph.D." (b) (6) >

Date: Monday, April 27, 2020 at 2:53 PM

To: "Matthias Gromeier, M.D." (b) (6)

Subject: Please review this draft email to Tony--TX

Matthias: Please review and edit the proposed email to Tony.

Dani

Hi Tony: In advance of getting together with you and your team, I am forwarding a short presentation for you guys to look at. The key elements are follows:



We are prepared to discuss this with you and your tea at any time that is convenient for you. As you may know, we are locked down here in the Research Triangle until May 15. If it makes sense, we could arrange a WebEX as an initial step.

All the best,

Dani

Best,

Dani

Sent from Dani Bolognesi

The information in this electronic mail is sensitive, protected information intended only for the addressee(s). Any other person, including anyone who believes he/she might have received it due to an addressing error, is requested to notify the sender immediately by return electronic mail, and to delete it without further reading or retention. The information is not to be forwarded to or shared unless in compliance with Duke Health policies on confidentiality and/or with the approval of the sender.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 22:17:19 +0000
To: Folkers, Greg (NIH/NIAID) [E]; NIAID OD AM
Subject: RE: COVID/Transportation Impacts

Ok. Let us discuss forwarding to CDC>

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)
Sent: Monday, April 27, 2020 6:15 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: RE: COVID/Transportation Impacts

this seems like CDC issue

They address some of the issues here:

What Rideshare, Taxi, Limo, and other Passenger Drivers-for-Hire Need to Know about COVID-19
<https://www.cdc.gov/coronavirus/2019-ncov/community/organizations/rideshare-drivers-for-hire.html>

Communication Toolkit for Transportation Partners to Inform Road Travelers Monday, April 27, 2020
<https://www.cdc.gov/coronavirus/2019-ncov/travelers/transportation-toolkit.html>

Cleaning and Disinfection for Non-emergency Transport Vehicles Tuesday, April 14, 2020
<https://www.cdc.gov/coronavirus/2019-ncov/community/organizations/disinfecting-transport-vehicles.html>

-----Original Message-----

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6) > On Behalf Of Fauci, Anthony (NIH/NIAID) [E]
Sent: Monday, April 27, 2020 6:05 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: FW: COVID/Transportation Impacts

-----Original Message-----

From: Anthony Foxx [REDACTED] (b) (6)>
Sent: Monday, April 27, 2020 4:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: COVID/Transportation Impacts

Dr. Fauci:

This is Anthony Foxx, immediate former US Transportation Secretary, and I greatly enjoyed our interactions (brief thoughts they were) during my time in the last Administration.

I write to request your help in advising the transportation community about how to manage through the present crisis, particularly as some areas are easing restrictions. I would welcome an opportunity to join you in a Q/A, which could be valuable for rideshare companies [REDACTED] (b) (6), transit agencies, airlines etc. I would think that a 10-15 minute chat would do wonders. That said, I know you are terribly busy and have so many things to do but would appreciate any opportunity to help you get important information out.

This could be pulled together rapidly and done within the next week or so.

Thanks for your attention to this matter. All my best,

Anthony.
Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 22:00:13 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Update - White House Coronavirus Task Force Meeting - 4.28.20

FYI

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

(b)(5) - PCP

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 21:57:57 +0000
To: Lusso, Paolo (NIH/NIAID) [E]
Subject: RE: Covid thrombi

Thanks, Paolo.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lusso, Paolo (NIH/NIAID) [E] (b) (6)
Sent: Monday, April 27, 2020 12:34 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Kovacs, Joseph (NIH/CC/CCMD) [E] (b) (6); Masur, Henry (NIH/CC/CCMD) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6) >
Subject: Re: Covid thrombi

Dear Tony,

I talked with Dr. Viecca this morning who shared additional information about his protocol. They started from the pathological observation that all patients dying of Covid-19 pneumonia had diffuse pulmonary microthrombosis. Since they detected almost exclusively white thrombi, they reasoned that they had to block platelet activation/aggregation, while heparin would be ineffective at that stage. Thus, they treated a first group of five critical patients with potent anti-aggregant therapy (Tirofiban/Aggrastat) and apparently in all of them the pO2 started to rise within less than 2 hours, they got off the ventilators and went on to full recovery. Viecca is an interventional cardiologist (b) (4)

I sent copy of his protocol and contact information to Joe.

Let me know if I can be of any further help. All the best,

Paolo

Paolo Lusso, M.D., Ph.D.
Chief, Section of Viral Pathogenesis
Laboratory of Immunoregulation
Bldg. 10, Rm. 6A11
NIAID, NIH
Bethesda, MD 20892

Phone: (b) (6) (personal)

(b) (6) (lab)

Fax: (301) 480-5291

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 21:57:23 +0000
To: Collins, Francis (NIH/OD) [E] (b) (6)
Cc: Mascola, John (NIH/VRC) [E]
Subject: FW: Revised Slides
Attachments: Vaccine Development Slides Revised Draft 042720.pptx

Pleas respond for both of us. I already cc'd you on an email that I sent to John with a minor comment about slide #2.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Marks, Peter (b) (6)
Sent: Monday, April 27, 2020 1:14 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Collins, Francis (NIH/OD) [E]
(b) (6)
Cc: Mascola, John (NIH/VRC) [E] (b) (6)>
Subject: Revised Slides

Dear Francis and Tony,

Apologize that the prior slides were too busy. John conveyed that message. Please see these versions that may be more along the lines that you are looking for. (b) (5)

Best Regards,
Peter

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 21:54:37 +0000
To: Schwetz, Tara (NIH/OD) [E]
Subject: RE: Flagging NIH Media Product for Release Tomorrow

You could play the role in the movie of my medical school girl friend, which would give you the possibility of working with Brad Pitt 😊

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Schwetz, Tara (NIH/OD) [E] (b) (6)
Sent: Monday, April 27, 2020 5:49 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: Flagging NIH Media Product for Release Tomorrow

Now, you also have the answer to who would play you in a movie! 😊

Tara A. Schwetz, PhD
Acting Director, NINR
Associate Deputy Director, NIH
A: Building 1, Room 138
P: (b) (6) | M: (b) (6)

From: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Date: Monday, April 27, 2020 at 5:46 PM
To: Tara Schwetz (b) (6)
Subject: RE: Flagging NIH Media Product for Release Tomorrow

Thanks, Tara. Pitt was amazing. One reviewer of the SNL show said that Pitt looked "exactly like me". That statement made my year. 😊

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Schwetz, Tara (NIH/OD) [E] (b) (6) >
Sent: Monday, April 27, 2020 5:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Marston, Hilary (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Barasch, Kimberly (NIH/NIAID) [C] (b) (6) Myles, Renate (NIH/OD) [E] (b) (6); Walsh, Elizabeth (NIH/OD) [E] (b) (6)
Subject: Flagging NIH Media Product for Release Tomorrow

Tony,

Please see below and attached a time-sensitive COVID-19 item for your awareness and sharing with the remainder of the Task Force, as appropriate. The plan is to release this tomorrow.

Item 1: Title: Rapid Acceleration of Diagnostics (RADx) Initiative

Activity Type: Funding of new research program

Summary: With a (b) (5) investment from federal stimulus funding, RADx initiative will infuse funding into early innovation technologies to speed development of rapid and widely accessible COVID-19 testing. At the same time, NIH will seek opportunities to move more advanced diagnostic technologies swiftly through the development pipeline toward commercialization and broad availability. As part of the initiative, NIH is urging scientists and inventors with a rapid testing technology to compete in a national COVID-19 testing challenge for a share of up to \$500 million over all phases for further development. The goal is to add tens of millions per month of accurate and easy-to-use tests to all Americans by Fall 2020.

Impact on COVID-19 Pandemic Response: RADx will accelerate the development, validation, and commercialization of innovative new testing methods that can be deployed in point-of-care and home settings. These technologies are urgently needed to guide and inform safe return to work, school, and life activities.

Office: National Institute of Biomedical Imaging and Bioengineering

Action Date: Solicitation announcement April 28, 2020

Type of Action: Research Program Award

Potential for Press Coverage: Mainstream Press

Press Release in Development?: Yes

Do let me know if you have any questions.

(Also, Brad Pitt?! Wow, that was a really nice shout out/thank you.)

Best,

Tara A. Schwetz, PhD

Acting Director, NINR

Associate Deputy Director, NIH

A: Building 1, Room 138

P: (b) (6) | **M:** (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 21:48:46 +0000
To: Birx, Deborah L. EOP/NSC
Cc: Redd, Stephen (CDC/DDPHSIS/OD); Hahn, Stephen
Subject: Flagging NIH Media Product for Release Tomorrow
Attachments: 2020-04-27_COVID-19WeeklyReport_NIBIB OD_tas.docx

Deb:

As an FYI. This is an initiative from NIBIB/NIH on development of POC diagnostics for SARS-CoV-2.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 21:39:57 +0000
To: Stover, Kathy (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: FOR ASF REVIEW: Draft PR re: SARS-CoV-2 incidence in children

Looks fine. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stover, Kathy (NIH/NIAID) [E] (b) (6) >
Sent: Monday, April 27, 2020 4:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6) >
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6) >; Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Subject: FOR ASF REVIEW: Draft PR re: SARS-CoV-2 incidence in children

Hi Dr. Fauci,

Please find attached for your review a draft release about the launch of the Human Epidemiology and Response to SARS-CoV-2 (HEROS) study, which is intended to help determine the percentage of children infected with SARS-CoV-2 and the percentage of infected children who develop COVID. In addition, the study will examine whether rates of SARS-CoV-2 infection differ between children who have asthma or other allergic conditions and children who do not. Your draft quote is as follows:

“One interesting feature of this novel coronavirus pandemic is that very few children have become sick with COVID-19 compared to adults,” said NIAID Director Anthony S. Fauci, M.D. “Is this because children are resistant to infection with SARS-CoV-2, or because they are

infected but do not develop symptoms? The HEROS study will help us begin to answer these and other key questions.”

Thanks much,
Kathy

Kathy Stover
Branch Chief
News and Science Writing Branch
National Institute of Allergy and Infectious Diseases (NIAID)
Office of Communications and Government Relations
National Institutes of Health/HHS
31 Center Drive, Room 7A17E
Bethesda, MD 20892
Phone: (b) (6)
E-mail: (b) (6)
NIAID Media Line: (301) 402-1663

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 21:04:24 +0000
To: Auchincloss, Hugh (NIH/NIAID) [C] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E]; Jean W Pape
Subject: (b) (4)
Attachments: (b) (4)

Hugh:

(b) (6), (b) (4)

(b) (6) Please take care of it.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6)
Sent: Monday, April 27, 2020 3:01 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: (b) (4)

Tony,

(b) (4), (b) (6)

Best,

Bill

JEAN WILLIAM PAPE, MD

Howard and Carol Holtzmann Professor of Clinical Medicine,
Center for Global Health, Division of Infectious Diseases, Department of Medicine,
Weill Cornell Medical College, New York, New York, USA
402 East 67th Street, New York, NY 10065
Tel (Office) (b) (6)

Director,
Les Centres GHESKIO,
33, Blvd. Harry Truman, Port-au-Prince, Haïti.
Tel (Office): (b) (6)
Voip: (b) (6)

From: Conrad, Patricia (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 16:09:04 +0000
To: NIAID OD AM
Subject: FW: The National Organization of Italian Americans in Film & Television (NOIAFT) - Interview Request

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Taylor Taglianetti <taylor@noiaft.org>
Sent: Monday, April 27, 2020 12:03 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: The National Organization of Italian Americans in Film & Television (NOIAFT) - Interview Request

Dear Dr. Fauci,

I hope this email finds you well. My name is Taylor Taglianetti and I am the founder of the National Organization of Italian Americans in Film & Television (NOIAFT).

Our organization is so very proud of the work you are doing for our country and sends tremendous thanks for the hope and reassurance you have instilled during these trying times.

It would be an honor to conduct a short interview with you. Our organization includes many young Italian Americans breaking into the entertainment industry and with the coronavirus dramatically impacting our field, I'd love to ask you a few questions about what the future of the entertainment business looks like. We'd be happy to send the questions in advance for your approval. If you don't have time for a phone call, the questions can be answered via email at your leisure.

Thank you for your time and consideration.

Sincerely,

Taylor Taglianetti


Founder, *The National Organization of Italian Americans in Film & Television (NOIAFT)*

(347) 686-4968

www.noiaft.org

taylor@noiaft.org







From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 14:19:38 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Media query: CNN, re: ASF's NAS web briefing on Saturday

I was referring only to animal (macaque) models. I never said that it looked good in humans. Human clinical trials are ongoing to answer that question. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Monday, April 27, 2020 9:30 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Fwd: Media query: CNN, re: ASF's NAS web briefing on Saturday

Pls advise

Sent from my iPhone

Begin forwarded message:

From: "Leifman, Laura (NIH/NIAID) [E]" (b) (6)>
Date: April 27, 2020 at 9:27:13 AM EDT
To: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)>, NIAID FOG
<fog@niaid.nih.gov>
Cc: NIAID COGCORE <COGCORE@mail.nih.gov>, NIAID Media Inquiries
<mediainquiries@niaid.nih.gov>
Subject: Media query: CNN, re: ASF's NAS web briefing on Saturday

Elizabeth Cohen

CNN

Elizabeth.Cohen@turner.com

Topic: Statement by ASF during Saturday NAS web briefing

Deadline: urgent

Hi Patty,

Elizabeth would like to clarify something that Dr. Fauci apparently said about remdesivir during his NAS web briefing on Saturday. The transcribed segment of the talk that she is focused on says:

"Remdesivir is the one that's gotten the most publicity. It is interesting that if you look at it in a prophylactic therapeutic model in MERS coronavirus infection, it looked pretty good. There was clinical benefits just reported a couple of weeks ago of SARS coronavirus 2 in rhesus macaques."

She wants to clarify what Dr. Fauci meant by looking at remdesivir "in a prophylactic therapeutic model in MERS"—whether this means in an animal model or something else. It sounds like that phrase is referring to the RML study in which remdesivir successfully prevented disease in MERS-infected rhesus macaques, as reported in the Feb. 13 NIAID media availability pasted below. Is that correct?

Best,

Laura

Remdesivir Prevents MERS Coronavirus Disease in Monkeys

Results Support Testing Antiviral Against 2019 Novel Coronavirus

February 13, 2020

The experimental antiviral remdesivir successfully prevented disease in rhesus macaques infected with Middle East respiratory syndrome coronavirus (MERS-CoV), according to a new study from National Institutes of Health scientists. Remdesivir prevented disease when administered before infection and improved the condition of macaques when given after the animals already were infected.

The new report from NIH's National Institute of Allergy and Infectious Diseases (NIAID) appears in the *Proceedings of the National Academy of Sciences*.

MERS-CoV is closely related to the 2019 novel coronavirus (SARS-CoV-2, previously known as 2019-nCoV) that has grown to be a global public health emergency since cases were first detected in Wuhan, China, in December.

Remdesivir has previously protected animals against a variety of viruses in lab experiments. The drug has been shown experimentally to effectively treat monkeys infected with Ebola and Nipah viruses. Remdesivir also has been investigated as a treatment for Ebola virus disease in people.

The current study was conducted at NIAID's Rocky Mountain Laboratories in Hamilton, Montana. The work involved three groups of animals: those treated with remdesivir 24

hours before infection with MERS-CoV; those treated 12 hours after infection (close to the peak time for MERS-CoV replication in these animals); and untreated control animals. The scientists observed the animals for six days. All control animals showed signs of respiratory disease. Animals treated before infection fared well: no signs of respiratory disease, significantly lower levels of virus replication in the lungs compared to control animals, and no lung damage. Animals treated after infection fared significantly better than the control animals: disease was less severe than in control animals, their lungs had lower levels of virus than the control animals, and the damage to the lungs was less severe.

The scientists indicate that the promising study results support additional clinical trials of remdesivir for MERS-CoV and COVID-19, the disease that SARS-CoV-2 causes. Several clinical trials of remdesivir for COVID-19 are under way in China, and other patients with COVID-19 have received the drug under a compassionate use protocol.

The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services, also provided support for this study. Gilead Sciences, Inc., developed remdesivir, also known as GS-5734, and collaborated in the research.

MERS-CoV emerged in Saudi Arabia in 2012. Through December 2019, the World Health Organization had confirmed 2,499 MERS-CoV cases and 861 deaths (or about 1 in 3). Because about one-third of MERS-CoV cases spread from infected people being treated in healthcare settings, the scientists suggest that remdesivir could effectively prevent disease in other patients, contacts of patients, and healthcare workers. They also note the drug might help patients who are diagnosed with MERS or COVID-19 if given soon after symptoms start.

ARTICLE:

E de Wit *et al.* Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. *PNAS* DOI: 10.1073/pnas.1922083117.

WHO:

NIAID Director Anthony S. Fauci, M.D., and Emmie de Wit, Ph.D., a principal investigator in NIAID's Laboratory of Virology, are available to comment on this study.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 14:11:59 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Coronavirus Antigen Microarray

Please take a look and handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Anderson, Cassandra (NIH/NIDDK) [E] (b) (6)>
Sent: Monday, April 27, 2020 8:17 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: FW: Coronavirus Antigen Microarray

Good morning Dr. Fauci,

I work in NIDDK in bldg. 50 in the Laboratory Endocrinology and Receptor Biology.

Thank you for all the information you have provided to our nation. I also want to say you are doing a terrific job in handling the COVID-19 virus, without you and your staff I don't know where our country would be.

I received the email below this morning from Jiang Yufei from Sino Biological. Not sure why I was sent this email, but I thought of you and your staff. Please see the email below.

Thank you again for all that you are doing to help keep us safe!

Stay safe!

Cassandra Anderson
Administrative Professional
Bldg. 50 Room 4133
301-402-7845

From: Yufei Jiang <yufei.jiang@sinobiological.info>

Sent: Monday, April 27, 2020 8:04 AM

To: Anderson, Cassandra (NIH/NIDDK) [E] (b) (6)>

Subject: Coronavirus Antigen Microarray

Hi Cassandra,

Happy Day! I am excited to let you know that Sino Biological just released Coronavirus antigen Microarray (CoVAM) which belongs to our Sinommune™ Multiplex Antigen Microarray product line. You may get more details from the following link:

<https://www.sinobiological.com/research/virus/coronavirus-array>

Currently the standard pre-printed CoVAM array is sold in the unit of slide, 16 arrays/slide. In each array there are 65 antigens related to the viruses that can cause upper respiratory tract infections including the most recent SARS-CoV-2. The list price is \$3,200/slide. Please contact me for how to place the order if you are interested or need more information.

So far, this array has mainly been used for two purposes: 1) Sero-surveillance studies of COVID-19 infection, and 2) Evaluating antibody reactivity in animals (monkeys and mice) after vaccination. Please be advised that our array is for research use only (RUO), not for the diagnostic purpose which needs the FDA approval.

After you run the samples on the slide, you may read the slide on the following compatible machines:

<https://www.innopsys.com/en/lifesciences-products/microarrays/innoscan>

<https://www.moleculardevices.com/products/additional-products/genepix-microarray-systems-scanners#ref>

<https://www.agilent.com/en/product/cgh-cgh-snp-microarray-platform/cgh-cgh-snp-microarray-scanners-equipment/surescan-microarray-scanner-228493>

Thanks.

-Yufei

Yufei Jiang, PhD

Manager, NY, MD, DC, VA

Sales & Business Development

Sino Biological US Inc.

1400 Liberty Ridge Dr., Suite 101

Wayne, PA 19087

Cell: (b) (6)

Email: yufei_jiang@sinobiological.com

www.sinobiological.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 14:11:06 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Otto e Mezzo - Italian Show

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Torchia Patrizia <Patrizia.Torchia@la7.it>
Sent: Monday, April 27, 2020 8:05 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Otto e Mezzo - Italian Show

Dear Mr. Fauci,

I'm Patrizia Torchia, I'm a journalist and I am a member of the team on the Italian show *Otto e Mezzo*, hosted daily by journalist Lilli Gruber on La7 channel.

I'm reaching out to invite you in our show. Mrs. Gruber would be honored to have you, Dr. Fauci explore in more depth the challenges Coronavirus has forced the world to face. Can make this happen?

Below is Lilli Gruber's bio and a brief description of the show.

WHO:

Lilli Gruber is the editor-in-chief and host of Italy's most influential political daily talk show, "Otto e mezzo", airing on prime-time on La7 TV. She's received Italy's most prestigious journalism awards for her work and was the first woman to ever conduct the prime-time News broadcast in Italy (RAI TV, 1987). As a foreign correspondent she covered most of last 30 years' major world events, from the fall of the Berlin wall to 9/11 to the Iraq war. Beside her television work, Ms. Gruber wrote eleven bestseller books including "Eredità", which was top seller for 20 weeks and ran 14 reprints. In 2004, Ms. Gruber

won a head-to-head campaign against Silvio Berlusconi by a large margin of votes and was elected to the European Parliament. There, among other appointments, she was the Head of the EU Delegation to the Gulf States and Yemen and a member of the EU Delegation to Iran.

"Otto e mezzo"

Italy's most influential political daily talk show shown on prime-time on La7 TV. Through interviews with elected political figures and candidates for office, commentators, and journalists, the show focuses on international political news and economy with a special focus on Italy and Europe. Beginning in 2008 "*Otto e Mezzo*" became Lilli Gruber's way to keep her commitment to holding those in power accountable by asking questions and touching on topics citizens are curious about. ***Otto e Mezzo*** airs Monday to Saturday from 8:35pm to 9:10pm. Within this time-frame Paolo Pagliaro's news column "Il Punto" stands out for accuracy and thoughtfulness by pulling the thread on the highest rated issues in an agenda. During the current season *Otto e Mezzo* has become Italy's most watched political talk show reaching an average of 7.3% of share with 2.5 million viewers per day.

Production location(s): La7 studios, via Umberto Novaro 32, Rome, Italy

Presented by: Lilli Gruber

Original network: La7

Executive producers: Stefania Bucciarelli

Directed by: Lorenzo Fontana

www.live.la7.it

www.ottoemezzo.la7.it

Twitter: @OttoemezzoTW)

Facebook: OttoemezzoLa7)

Thank you in advance for the considering. Looking forward to hearing from you.

Patty Torchia

Otto e Mezzo

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 14:08:24 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Fauci and PayPal

Not really.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Monday, April 27, 2020 9:54 AM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: FW: Fauci and PayPal

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fetalvo, Ninio J. EOP/OVP [REDACTED] (b) (6)
Sent: Monday, April 27, 2020 9:51 AM
To: Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: FW: Fauci and PayPal

FYI—Defer to you on this.

From: Miller, Amanda <amanmiller@paypal.com>
Sent: Monday, April 27, 2020 9:18 AM
To: Fetalvo, Ninio J. EOP/OVP [REDACTED] (b) (6)
Cc: Walters, Lindsay <Lindsay.Walters@edelman.com>
Subject: [EXTERNAL] Re: Fauci and PayPal

Hi Ninio,

We are wondering if Dr. Fauci would like to have a taped Skype conversation with PayPal CEO and President Dan Schulman to talk about safety measures, health and science tied to COVID-19. We would air the conversation during a global employee all hands to our 23,000 employees and then we could syndicate parts of it externally on our social channels.

Thanks for any help in reaching Fauci's team.

Thanks,
Amanda

Amanda Christine Miller
Senior Director, Corporate Communications
408.219.0563
[@PayPalNews](#)


From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 14:07:40 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: RE: [REDACTED] (b) (4)

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lerner, Andrea (NIH/NIAID) [E] [REDACTED] (b) (6)>
Sent: Monday, April 27, 2020 10:05 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: Re: [REDACTED] (b) (4)

I will make sure they get a response!

From: "Fauci, Anthony (NIH/NIAID) [E]" [REDACTED] (b) (6)>
Date: Sunday, April 26, 2020 at 8:43 PM
To: "Lerner, Andrea (NIH/NIAID) [E]" [REDACTED] (b) (6)>
Subject: FW: Update: [REDACTED] (b) (4)

Please respond to this person. Thanks.

From: Kircheis Dr. Ralf <RKircheis@syntacoll.de>
Sent: Wednesday, April 22, 2020 9:41 AM
To: Coomes, Stephanie (NIH/NIAID) [E] [REDACTED] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E]
[REDACTED] (b) (6)
Cc: [REDACTED] (b) (6); Kircheis Dr. Ralf <RKircheis@syntacoll.de>
Subject: Update: [REDACTED] (b) (4)
Importance: High

Dear Dr. Fauci,
dear Dr. Coomes,

thank you for your reply from 13. April with the notice that the information has been shared with NIAID's COVID-19 research team.

Has the project already been initially evaluated by the team?

Are there any questions or need for additional information?



Looking forward to hearing from you.

Kind regards,

Ralf

Mit freundlichen Grüßen / Kind regards

Dr. Ralf Kircheis

Director R&D

Research & Development

Mail: RKircheis@syntacoll.de

Phone: +49 9441 686048

syntacoll

Syntacoll GmbH, Donaustasse 24, D-93342 Saal a. d. Donau

Tel: +49 9441 / 68 60 0, Fax: +49 9441 / 68 60 30

Handelsregister: Amtsgericht Regensburg - HRB 1612

USt-IdNr. DE 128580796

Geschäftsführerin: Dr. Alexandra Dietrich

Unsere Hinweise zum Datenschutz, insbesondere zu den Ihnen zustehenden Rechten, finden Sie unter:

www.syntacoll.de/datenschutz

Von: Coomes, Stephanie (NIH/NIAID) [E] (b) (6)]

Gesendet: Montag, 13. April 2020 02:37

An: Kircheis Dr. Ralf <RKircheis@syntacoll.de>

Betreff: RE: (b) (4), (b) (5)

Dear Dr. Kircheis,

Thank you for your recent email to Dr. Anthony Fauci. Your message was forwarded to the Division of Microbiology and Infectious Diseases (DMID) at the National Institute of Allergy and Infectious Diseases (NIAID). As a member of DMID's Office of Scientific Coordination and Program Operations, I am pleased to respond.

I want to thank you for reaching out to share this information and let you know that your message has been shared with NIAID's COVID-19 research team.

Sincerely,
Stephanie

Stephanie M. Coomes, Ph.D.
Health Scientist Administrator
Office of Scientific Coordination and Program Operations
Division of Microbiology and Infectious Diseases
National Institute of Allergy and Infectious Diseases
National Institutes of Health
5601 Fishers Lane, Room 7G68
Rockville, MD 20892

(b) (6)

(b) (6)

Disclaimer: The information in this email and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the originally intended recipient. If you have received this email in error, please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of NIAID by one of its representatives.

From: Kircheis Dr. Ralf <(b) (6)>

Sent: Wednesday, April 8, 2020 2:49 AM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] (b) (6)>; NIAID Ocpstoffice (NIH/NIAID) <OCPOSTOFFICE@niaid.nih.gov>

Cc: Fischer, Elizabeth (NIH/NIAID) [E] (b) (6)>; Foster, Erin (NIH/NIAID) [E] (b) (6)>; Foster, Sarah (NIH/NIAID) [E] (b) (6)>; Vasilenko, Olga (NIH/NIAID) [E] (b) (6)>; Vasquez, Aurelio (NIH/NIAID) [E] (b) (6)>; Vostal, Alexander (NIH/VRC) [F] (b) (6)>; Vazquez-Maldonado, Nancy (NIH/NIAID) [E] (b) (6)>; Austin, James (NIH/NIAID) [E] (b) (6)>; Agulto, Liane (NIH/NIAID) [E] (b) (6)>; Deckhut, Alison (NIH/NIAID) [E] (b) (6)>

Kircheis Dr. Ralf <RKircheis@syntacoll.de>

Subject: WG: [REDACTED] (b) (4), (b) (5)

Importance: High

[REDACTED] (b) (4), (b) (5)

Dear Dr. Fauci,
dear Madams/Sirs,

I want to bring to your attension some potentially important experimental data and a new proposal for treatment of COVID-19 patients with acute respiratory distress syndrome and organ failure. Sorry for the broad distribution but I wanted to make sure that my message reaches you.

[REDACTED] (b) (4), (b) (5)

Please forward this mail to the colleagues you consider relevant for evaluation, discussion and consideration for your clinical strategy for COVID-19.

Please let me know if additional informations are necessary.

To my person: I have MD PhD degree and have many years experience in pharmaceutical development (Boehringer Ingelheim), Biotech (Igeneon, Aphton, Virologik GmbH) (for reference see also PubMed Kircheis r) currently leading R&D activities at Syntacoll (part of Innocoll). I am providing this information personally in order to help to find a treatment for COVID-19 patients.

Looking forward to getting feedback from you,

With kind regards,

Ralf Kircheis (MD PhD)

(b) (6)

rkircheis@syntacoll.de

(b) (6)

Mit freundlichen Grüßen / Kind regards

Dr. Ralf Kircheis

Director R&D

Research & Development

Mail: RKircheis@syntacoll.de

Phone: +49 9441 686048

syntacoll

Syntacoll GmbH, Donaustrasse 24, D-93342 Saal a. d. Donau
Tel: +49 9441 / 68 60 0, Fax: +49 9441 / 68 60 30
Handelsregister: Amtsgericht Regensburg - HRB 1612
USt-IdNr. DE 128580796

Geschäftsführerin: Dr. Alexandra Dietrich

Unsere Hinweise zum Datenschutz, insbesondere zu den Ihnen zustehenden Rechten, finden Sie unter:
www.syntacoll.de/datenschutz



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 12:33:44 +0000
To: Jeremy Farrar
Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Thanks, Jeremy. I saw the report in the Post from Saturday. These children had mostly respiratory disease and diarrhea. I will check with the docs at DC Children's Hospital about the presence of "multisystem inflammatory state". This could just be the advanced stage of their disease compatible with advanced SARS-COV-2

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar (b) (6)
Sent: Monday, April 27, 2020 7:38 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Dzaou, Victor J. <VDzaou@nas.edu>; George GAO (b) (6)>
Cc: Richard Hatchett (b) (6); Hannon, Emma <EHannon@nas.edu>; Conrad, Patricia (NIH/NIAID) [E] (b) (6); Teresa Miller de Vega (b) (6); Rebeka Yasmin - CEPI (b) (6); ben.tinker@cnn.com; Amanda.Sealy@cnn.com; Neel.Khairzada@turner.com; Tia.Miller@turner.com; (b) (6) McGinnis, J. Michael <MMcGinnis@nas.edu>; (b) (6) Mun, Jenny <JMun@nas.edu>; (b) (6) Redfield, Robert R. (CDC/OD) (b) (6)>
Subject: Re: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Thanks Tony – have asked for that and will share as soon as I can.

I believe there have been reports in the Washington Post.

https://www.washingtonpost.com/local/new-dc-hospital-numbers-suggest-kids-do-face-some-risk-of-coronavirus-hospitalization/2020/04/25/5e78c268-86fe-11ea-878a-86477a724bdb_story.html

From: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>

Date: Monday, 27 April 2020 at 12:36

To: Jeremy Farrar <(b) (6)>, Victor Dzau <VDzau@nas.edu>, George Gao <(b) (6)>

Cc: Richard Hatchett <(b) (6)>

"Hannon, Emma" <EHannon@nas.edu>, "Conrad, Patricia (NIH/NIAID) [E]" <(b) (6)>, Teresa de Vega <(b) (6)>, Rebeka Yasmin - CEPI <(b) (6)>

<(b) (6)> "ben.tinker@cnn.com" <ben.tinker@cnn.com>, "Amanda.Sealy@cnn.com" <Amanda.Sealy@cnn.com>, "Neel.Khairzada@turner.com" <Neel.Khairzada@turner.com>, "Tia.Miller@turner.com" <Tia.Miller@turner.com>, <(b) (6)> "McGinnis, J. Michael" <MMcGinnis@nas.edu>, <(b) (6)> "Mun, Jenny" <JMun@nas.edu>, <(b) (6)> "Redfield, Robert R. (CDC/OD)" <(b) (6)>

Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Jeremy:

Thanks for the heads up. Is there any more detailed description of the precise clinical manifestations? They describe a "multisystem inflammatory state". It is vasculitis or anything more specific? Could be an infectious agent that has nothing to do with SARS-CoV-2 infection even though some children are circumstantially infected with SARS-CoV-2 or it could be a post-SARS-CoV-2 inflammatory syndrome, perhaps a Kawasaki syndrome-like disease. Please keep me informed if you hear any further information.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: <(b) (6)>

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar (b) (6)>

Sent: Monday, April 27, 2020 7:13 AM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Dzaou, Victor J. <VDzaou@nas.edu>; George GAO (b) (6)>

Cc: Richard Hatchett (b) (6)

(b) (6) Hannon, Emma <EHannon@nas.edu>; Conrad, Patricia (NIH/NIAID) [E] (b) (6) Teresa Miller de Vega (b) (6); (b) (6); Rebeka Yasmin - CEPI (b) (6)>; ben.tinker@cnn.com; Amanda.Sealy@cnn.com; Neel.Khairzada@turner.com; Tia.Miller@turner.com; (b) (6); McGinnis, J. Michael <MMcGinnis@nas.edu>; (b) (6); Mun, Jenny <JMun@nas.edu>; (b) (6)

Subject: Re: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

To be aware of – news over night so a huge amount of uncertainty – important for COVID19 now, and a potential concern for how we view immunity, protection, post-infectious immunopathology.

<https://www.hsj.co.uk/acute-care/exclusive-national-alert-as-coronavirus-related-condition-may-be-emerging-in-children/7027496.article>

<https://t.co/Bj6YHLJ8zi>

From: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>

Date: Sunday, 26 April 2020 at 19:52

To: Victor Dzaou <VDzaou@nas.edu>, George Gao (b) (6)>

Cc: Jeremy Farrar (b) (6)>, Richard Hatchett (b) (6)

(b) (6) "Hannon, Emma" <EHannon@nas.edu>, "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)>, Teresa de Vega (b) (6)>, Rebeka Yasmin - CEPI (b) (6)>, "ben.tinker@cnn.com" <ben.tinker@cnn.com>, "Amanda.Sealy@cnn.com" <Amanda.Sealy@cnn.com>, "Neel.Khairzada@turner.com" <Neel.Khairzada@turner.com>, "Tia.Miller@turner.com" <Tia.Miller@turner.com>, (b) (6) "McGinnis, J. Michael" <MMcGinnis@nas.edu>,

(b) (6)>, "Mun, Jenny" <JMun@nas.edu>,
(b) (6)>

Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

It was a real pleasure to join all of you on this important session. Many thanks for inviting me.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Dzau, Victor J. <VDzau@nas.edu>

Sent: Saturday, April 25, 2020 3:59 PM

To: George GAO (b) (6)

Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

(b) (6); Hannon, Emma <EHannon@nas.edu>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)

(b) (6) ben.tinker@cnn.com;

Amanda.Sealy@cnn.com; Neel.Khairzada@turner.com; Tia.Miller@turner.com; (b) (6)

McGinnis, J. Michael <MMcGinnis@nas.edu>; (b) (6); Mun, Jenny

(b) (6); haja.bally@cepi.net

Subject: Re: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear Jeremy, Tony, Sanjay, George, Susan and Richard,

Thank you so much for your superb contributions. It was a spectacular session- a truly inspiring one. I am grateful to all of you.

Hope to see you soon.

Warmest regards,

Victor

On Apr 25, 2020, at 1:22 PM, George GAO (b) (6) wrote:

I am waiting for being connected and will use slides which were sent to your office
George

发自我iPhone

在 2020年4月24日, 01:49, Dzau, Victor J. <VDzau@nas.edu>
写道 :

Dear Jeremy, Tony, Sanjay, George, Susan, and Richard,

I'm really looking forward to this panel on COVID-19 at the NAS Annual Meeting on Saturday, April 25th at 2:00-3:30 pm ET. There is tremendous excitement and enthusiasm, and registration is through the roof.

I am sending this note to do a last minute check to see if there is anything you need from me. I also want to check whether you are planning to use slides. Will you be sending your slides to us to project or use the share screen feature to advance your own slides? Regardless, it would be helpful to me if you could send me your slides for my preparation.

I would greatly appreciate it if you would respond to this email.

Best,
Victor

PS, (b) (6) my special assistant, will be sending you additional information about the session logistics shortly.

From: Dzau, Victor J. <VDzau@nas.edu>

Sent: Thursday, April 9, 2020 11:01 AM

To: Mun, Jenny <JMun@nas.edu>; (b) (6)

(b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6)

Cc: (b) (6) Hannon, Emma

<EHannon@nas.edu>; (b) (6)

(b) (6)
(b) (6)

(b) (6); 'ben.tinker@cnn.com' <ben.tinker@cnn.com>;
'Amanda.Sealy@cnn.com' <Amanda.Sealy@cnn.com>;
'Neel.Khairzada@turner.com' <Neel.Khairzada@turner.com>;
'Tia.Miller@turner.com' <Tia.Miller@turner.com>; 'hujr@chinacdc.cn'

(b) (6)

Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information
regarding your Saturday April 25 participation

Dear all,

Thank you for agreeing to participate in a special late breaking session on the COVID-19 pandemic at the NAS annual meeting. Knowing how busy you are, I am sending this email in lieu of a call to prepare for the session.

As you know, this is a 90 minute session which aims to provide our audience with deeper insights into the latest developments in the COVID-19 response. I plan to hold an engaging discussion that covers the whole experience on dealing with this pandemic – from US to international, to preparedness and response, the biology of the virus, the state of diagnostic, treatment and vaccine development, and the importance of communication.

I will begin the session by providing brief (~3 min) opening remarks describing the circumstances of the pandemic. Then, I will introduce the panelists and you will each have 7 minutes to provide remarks. You may use a limited number of slides for illustration. I hope that each panelist will provide their own perspective and speak to the issues proposed below.

- Jeremy Farrar will discuss the global response to the pandemic, drawing from his experience as a global leader, the chair of the Scientific Advisory Group for the WHO's R&D Blueprint and as a member of the Global Preparedness Monitoring Board.
- Tony Fauci will discuss the US pandemic and provide his perspective as a member of the White House Coronavirus Task Force addressing the 2019–20 coronavirus pandemic.
- George Gao will discuss China's response to the pandemic and lessons learned for the rest of the globe.
- Susan Weiss will discuss the viral characteristics of SARS COV2, insights into its pathobiology, immunity and development of a pan-CoV antiviral.
- Richard Hatchett will discuss the development of new vaccines and treatments against COVID-19.
- Sanjay Gupta will comment on the health system response to the pandemic and challenges related to communication and public engagement in responding to COVID-19.

Following remarks from each panelist, we will have a moderated discussion amongst ourselves – I will ask you a set of questions (15 mins) and then we will take questions from the web (25 mins). To prepare me to be your moderator, please send me any questions you would like me to ask you. For those of you who would like to have a prep call, please let me know and I will set it up.

Best,
Victor

From: Mun, Jenny

Sent: Wednesday, April 8, 2020 10:56 AM

To: [REDACTED] (b) (6)

Cc: Dzau, Victor J. ; [REDACTED] (b) (6) ; Mun, Jenny ; Hannon, Emma ;

[REDACTED] (b) (6)
[REDACTED] 'ben.tinker@cnn.com' ; 'Amanda.Sealy@cnn.com'
; 'Neel.Khairzada@turner.com' ; 'Tia.Miller@turner.com'

Subject: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear Speakers:

I am the logistical contact for the COVID-19 session that will be held as part of the Annual Meeting (online) program on Saturday, April 25 at 2:00 pm EDT. Thank you for agreeing to participate in this session. To help you with your planning, I have provided additional details below.

Please note that the session will be live webcast and the general public will also be able to watch the session. Video from the session will also be uploaded on the NAS YouTube channel (<https://www.youtube.com/user/theNASciences>) after the meeting. We will need to obtain signed speaker release forms for your participation in this session. I have attached the speaker release form for your review and submission. **Please return the signed speaker release form by Monday, April 13.**

Session speakers are asked to connect 30 minutes prior to the session start time (**by Saturday, April 25 at 1:30 pm EDT**) to allow the technical staff to check connections and prepare for the session. Details on how to connect will be sent before the meeting.

We will list you in our promotional materials as noted below. If this is incorrect, please let me know.

Anthony S. Fauci, Director, National Institute of Allergy and Infectious Diseases

Jeremy Farrar, Director, Wellcome Trust

George F. Gao, Director-General, Chinese Center for Disease Control & Prevention

Sanjay Gupta, Chief Medical Correspondent, CNN

Richard J. Hatchett, CEO, Coalition for Epidemic Preparedness Innovations

Susan R. Weiss, Professor of Microbiology, Perelman School of Medicine, University of Pennsylvania

Since many of us have moved to remote work environments, you may already be proficient with Zoom and other online meeting/collaboration applications. I am attaching a 'speaker guidelines' file in case you have any questions on how best to prepare for and stage your remote talk. We have technical staff available to help you become familiar with Zoom and its settings – such as “sharing your screen” (if you have slide presentations that need to be shown during your talk). We can arrange for a training session this week or next week. If you would like to schedule a session, please let me know as soon as possible.

Dr. Dzau's office will be in touch regarding the agenda for this session. If you have any other questions, please let me know.

Regards, Jenny

Jenny Mun

Membership Director

National Academy of Sciences

jmun@nas.edu

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 18:45:27 +0000
To: [REDACTED] (b) (6)
Subject: SNL review

OKAY, so here is something even better than having Brad Pitt portray me on SNL. It is a recent review of Pitt's performance in which the TV reviewer said :

"Kicking things off, the Oscar winner dropped jaws during the cold open with his monologue about President Donald Trump's recent (and concerning) comments about COVID-19.

"Good evening, I'm Dr. Anthony Fauci," Pitt began his monologue and looked nearly identical to the director of the National Institute of Allergy and Infectious Diseases."

Someone said Pitt looked "nearly identical" to me. Yikes!! 😊

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 18:37:57 +0000
To: Barnes, Freddie
Subject: RE: Appreciation

Freddie:

Many thanks for your kind note. It is much appreciated.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Barnes, Freddie <freddie.barnes@ncdps.gov>
Sent: Sunday, April 26, 2020 10:48 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Appreciation

Dr. Fauci I just wanted to express my profound appreciation to you for your work during this COVID-19 pandemic. I especially appreciate how you have spent considerable time and capital reaching out to the Black and brown communities. I saw exerts of your snapchat with Will Smith and saw nearly all of your interview on the Breakfast Club. I regret I have to send an email to you re this matter. But this is the day we live in. Minority communities continue to be over-looked in crises and the impact of such crises on their respective communities. For you to be intentional about keeping the minority communities in the loop is commendable, especially since these communities will be absorbing the disproportionate share of the sicknesses and deaths coming from COVID-19.

Thanks for all of what your are doing in keeping the nation informed. Thanks for informing based on the facts, data, and truth.

Take care and "Cover your six."

Email correspondence to and from this address may be subject to the North Carolina Public Records Law and may be disclosed to third parties by an authorized state official.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 13:29:53 +0000
To: Adams, Jerome (HHS/OASH); (b) (6); Giroir, Brett
(HHS/OASH)
Cc: (b) (6)
Subject: RE: High touch points

(b) (5)

From: Adams, Jerome (HHS/OASH); (b) (6) >
Sent: Sunday, May 3, 2020 7:37 AM
To: Fauci, Anthony (NIH/NIAID) [E]; (b) (6) >; (b) (6); Giroir, Brett
(HHS/OASH); (b) (6) >
Cc: (b) (6)
Subject: Fwd: High touch points

Please see short thread below. Senator Young reached out to me about this and I forwarded to CDC. As I mention (b) (5)

(b) (5)

Thoughts?

Jerome

VADM Jerome Adams
20th US Surgeon General

Begin forwarded message:

From: "Adams, Jerome (HHS/OASH)" (b) (6) >
Date: May 3, 2020 at 7:32:46 AM EDT
To: "Jernigan, Daniel B. (CDC/DDID/NCIRD/ID)" (b) (6) >
Cc: "Schuchat, Anne MD (CDC/OD)" (b) (6)
Subject: Re: High touch points

Thank you. (b) (5) (b) (5)

(b) (5)

Please keep me posted. And should I refer the senator to you or someone at CDC to close the loop?

Thanks!

J

VADM Jerome Adams
20th US Surgeon General

On May 2, 2020, at 7:08 PM, Jernigan, Daniel B. (CDC/DDID/NCIRD/ID)

(b) (6) > wrote:

ADM Adams:

Thanks for sending this. There has been a lot of guidance on disinfection and cleaning, notably some very recent collaborative work we have done with EPA (<https://www.cdc.gov/coronavirus/2019-ncov/community/reopen-guidance.html>). Attached are two documents focused on re-opening America with emphasis on cleaning and disinfection, including high-touch surfaces. Also below are a number of websites that address cleaning and disinfection which point out the importance of disinfecting high-touch locations like doorknobs. They give guidance how to clean them, but they don't address methods for using a paper towel or Kleenex to first turn the knob and then discard the towel. (b) (5)

Thanks

Dan.

Daniel B. Jernigan, MD MPH
Director, Influenza Division; HHS CDC Lead, FEMA-HHS COVID-19 Response
Captain, USPHS (RET)
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
1600 Clifton Rd NE, Atlanta, GA 30329
Phone (b) (6), Cell (b) (6)
(b) (6) www.cdc.gov/flu

<https://www.cdc.gov/coronavirus/2019-ncov/community/disinfecting-building-facility.html>

<https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/disinfecting-your-home.html>

<https://www.cdc.gov/coronavirus/2019-ncov/community/disinfecting-building-facility-H.pdf>

From: Adams, Jerome (HHS/OASH) (b) (6) >

Sent: Friday, May 1, 2020 5:35 PM

To: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) (b) (6) >

Cc: Schuchat, Anne MD (CDC/OD) <(b) (6)>

Subject: High touch points

Dr. Jernigan,

I got a message from a Senator asking why we didn't have specific reopening recommendations for "high touch" points like door knobs/ handles/ elevator buttons. The Senator stated that (b) (5)

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED] I told him I'd follow up with CDC, (b) (5)
[REDACTED]
[REDACTED] Would appreciate your feedback on this.

Jerome

VADM Jerome Adams, MD, MPH
20th U.S. Surgeon General

<Reopening_America_Guidance.pdf>

<ReOpening_America_Cleaning_Disinfection_Decision_Tool.pdf>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 22:37:05 +0000
To: Hahn, Stephen;Debi Birx;Redfield, Robert R. (CDC/OD);Verma, Seema (CMS/OA)
Subject: RE: Serology Studies in Germany

Thanks, Steve!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hahn, Stephen (b) (6)>
Sent: Thursday, April 30, 2020 6:34 PM
To: Debi Birx (b) (6)>; Redfield, Robert R. (CDC/OD) (b) (6),
Seema (CMS/OA) <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E]
(b) (6)
Subject: Fwd: Serology Studies in Germany

Interesting information from Germany

From: Shuren, Jeff <(b) (6)>
Date: April 30, 2020 at 5:46:27 PM EDT
To: Hahn, Stephen <(b) (6)>, Shah, Anand (b) (6)>, Lenihan, Keagan
(b) (6)>, Guram, Jeet <(b) (6)>, Rom, Colin
(b) (6)>
Subject: Serology Studies in Germany

FYSA regarding serology studies being conducted in Germany, including status of tests to be used for those studies. This is the follow up to what I sent you last week. (b) (5)

(b) (5)

(b) (5)

From: Hoshi, Ryan <(b) (6)>

Sent: Thursday, April 30, 2020 3:17 PM

To: Shuren, Jeff (b) (6)

Cc: Nalubola, Ritu (b) (6); Louati, Claudia (FSN)* (b) (6);

O'Leary, Brendan (b) (6); Torres, Melissa A (b) (6);

Stenzel, Timothy (b) (6)

Subject: FW: PLEASE REVIEW >> Meeting Notes - Call with (b) (5)

(b) (5)

(b) (5)

Thank you,
Ryan

Ryan A. Hoshi, Ph.D.

International Policy Analyst | Center for Devices and Radiological Health | (b) (6) | phone

(b) (6) | mobile (b) (6)



Excellent customer service is important to us.

Please take a moment to provide feedback regarding the customer service you have received.

[click here for survey](#)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 14:14:36 +0000
To: Halkovich, Townshend Connie
Subject: RE: Appreciation to my hero--Dr. Fauci--our country's voice of reason in these unsettling, uncertain times--We NEED YOU!!!! Please don't leave us now when we need you most!!!

Connie:

Many thanks for your kind note. Much appreciated.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Halkovich, Townshend Connie (b) (6)
Sent: Monday, April 27, 2020 9:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Halkovich, Townshend Connie (FDA/OC) (b) (6)
Subject: RE: Appreciation to my hero--Dr. Fauci--our country's voice of reason in these unsettling, uncertain times--We NEED YOU!!!! Please don't leave us now when we need you most!!!

Where is Dr. Fauci?

I know where Dr. Fauci is—I saw him on SNL—remarkably he looked like Brad Pitt—except [to many of us] Dr. Fauci is better looking. Smile, wink *Why? We look with our hearts*
I remember someone asked Dr. Fauci [in jest] who would he like to represent him in a movie...Dr. F. said Brad Pitt. Well—Dr. F. Your dream suggestion came true. But, in many of our hearts—NO ONE can take the place of our beloved, well respected, honored Dr. Anthony Fauci!!!!

God Bless America, God Bless Dr. Fauci !!!

From: Halkovich, Townshend Connie <(b) (6)>
Sent: Friday, March 13, 2020 11:06 AM

To: 'anthony.fauci@nih.gov' (b) (6)
Cc: Halkovich, Townshend Connie <Constance.Halkovich@fda.hhs.gov>
Subject: Appreciation

Dear Dr. Fauci:

1st & foremost—please keep yourself healthy....get more rest than 3 hrs/night. ☺ Why? We need you!
THANK YOU for all your very informative updates. YOU are voice of reason...in time of coronavirus
fear...you give us hope...saying that action is what is needed...not fear!
You are someone we can be proud of...you provide service we can count on!!!!
God bless You & Your Family!!!

Warmest Regards from:

Connie Leigh Townshend Halkovich, Management Analyst, 410-867-0878,

#FDA/OIMT/DIO Proud: People & Service you can count on! ☺

(b) (6)

My Wish 4 U: Peace, Love, Laughter —blessed 2 work with U ALL! Abe Lincoln: "folks are as happy as they choose 2 be"—B
happy all circumstances—Hope all well with you, yours—if not, pretend it is.

FDA Mission: Responsible for protecting public health by ensuring safety, efficacy/security of human & vet. drugs, biol. products, med.
devices, our nation's food supply, cosmetics, & products that emit radiation.

DIO Mission: Provide excellent implementation, operation, maintenance of IT [equipment, services] to promote FDA's Public
Health Mission.

DIO Vision: Provide state-of-the-art IT services-inclusive of surrounding policy, planning, customer service, integration, &
oversight necessary to make the mission successful & sustainable.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 22:26:27 +0000
To: Folkers, Greg (NIH/NIAID) [E]; Billet, Courtney (NIH/NIAID) [E]; Stover, Kathy (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]; Awwad, David (NIH/NIAID) [C]
Cc: NIAID OD AM
Subject: RE: ASF RE: Dr. Fauci video request: Public Service Recognition Week
Attachments: ASF public service recognition - with tracked edits -05-05-2020.docx



See minor tracked changes.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, May 5, 2020 6:16 PM
To: Billet, Courtney (NIH/NIAID) [E] (b) (6) >; Stover, Kathy (NIH/NIAID) [E] <(b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6); Awwad, David (NIH/NIAID) [C] (b) (6) >
Cc: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: ASF RE: Dr. Fauci video request: Public Service Recognition Week

ASF –

Here is a short script for Public Service Recognition Week. We agreed to do a short video

ASF – can u tweak as needed?

David, could u record in some format that is easy? Cell phone or other I just learned they want by COB tomorrow

<< File: ASF public service recognition.docx >>

From: Seigfreid, Kim (NIH/OD) [E] (b) (6) >
Sent: Monday, April 27, 2020 4:30 PM
To: Billet, Courtney (NIH/NIAID) [E] (b) (6) >; Stover, Kathy (NIH/NIAID) [E] (b) (6) >; Routh, Jennifer (NIH/NIAID) [E] (b) (6) >
Cc: Fine, Amanda (NIH/OD) [E] (b) (6) >; Polimeni, Lydia (NIH/OD) [E] (b) (6)
Subject: Dr. Fauci video request: Public Service Recognition Week

Hi there,

Please see below. HHS is taking over the Partnership for Public Service IG account next week for Public Service Recognition Week. They asked if Dr. Fauci would be willing to do a short 30-second or less pre-recorded video thanking public servants for their work. It would be featured during the takeover, and also on NIH's other sm handles next week. It can be taken on a cell phone as sm does not require higher resolution. Let me know if you would like to accept or decline the request.

Many thanks,
Kim

Kim Seigfreid
Social Media Lead
NIH Office of Communications and Public Liaison
ph: (b) (6)
(b) (6)

From: Muhammad, Janell (HHS/ASPA) <(b) (6)>
Sent: Monday, April 27, 2020 4:10 PM
To: Seigfreid, Kim (NIH/OD) [E] (b) (6) >; Channer, Amber (OS/OASH) (b) (6) >; Foster, Timothy (OS/ASPA) (b) (6) >
Cc: Palczewski, Andrew (HHS/ASPA) <(b) (6)>; Pratt, Michael (OS/ASPA) <(b) (6)>; Sherman, Jennifer (HHS/OASH) (b) (6)
Wilker, Michael (HHS/ASPA) (b) (6); Dine, Brooke (HHS/ASPA) (b) (6)
Subject: Public Service Recognition Week

Hello All,

Hope everyone is holding up well!

OHR is taking over the Partnership for Public Service (PPS) Instagram account during Public Service Recognition Week (May 3-9, 2020). The OHR team has reached out about wanting to develop a senior leader "mashup" video — perhaps including the DepSec. T

They asked about the feasibility of this request. They also inquired about perhaps Dr. Fauci and the SG doing a pre-recorded video thanking public servants for their work.

I wanted to gather the troops so we can identify what all is being planned for this week of recognition and provide a POC for OHR if the request is feasible.

Happy to set up a call, if that is needed to discuss further.

Thanks,
Janell

Janell Muhammad

ASPA Digital Engagement (Team Lead)

U.S. Department of Health and Human Services

Email: (b) (6)

Office: (b) (6)

iPhone: (b) (6)

[HHS on Facebook](#) | [HHS on Twitter](#) | [HHSLatino](#)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 21:58:55 +0000
To: Adams, Jerome (HHS/OASH)
Subject: RE: Update on Sara Alert

What do you mean by [REDACTED] (b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Adams, Jerome (HHS/OASH) [REDACTED] (b) (6) >
Sent: Tuesday, May 5, 2020 2:49 PM
To: Birx, Deborah L. EOP/NSC <[REDACTED] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E]
[REDACTED] (b) (6) >
Subject: FW: Update on Sara Alert
Importance: High

[REDACTED] (b) (5)

Jerome

VADM Jerome Adams, MD, MPH
20th U.S. Surgeon General

From: Jarris, Paul [REDACTED] (b) (6) >
Sent: Friday, May 1, 2020 7:29 PM
To: Adams, Jerome (HHS/OASH) [REDACTED] (b) (6) >
Cc: Wright, Janet (HHS/OASH) [REDACTED] (b) (6)

Subject: Update on Sara Alert

Importance: High

Dear Jerome,

I hope you are well. Thank you for all you are doing to represent public health and our nation. It is very comforting knowing you are informing the nations COVID-19 response.

I wanted to give you an update on called Sara Alert, the software program I am leading at MITRE. Sara Alert is being provided free of any costs and deployed in state, tribal, and local health departments to support public health in contact tracing and active monitoring of individuals in isolation and quarantine. We are engaged with ASTHO, NACCHO, CSTE, and the application is hosted live on APHL's AIMS platform. Sara Alert officially launched on April 3 and is currently supporting multiple jurisdictions including Commonwealth of the Northern Mariana Islands, Danbury, CT, and the State of Arkansas. It is also being rolled out in Washington, Arizona, Pennsylvania, Virginia, Maine and Vermont. We are getting ready to launch in additional jurisdictions over the next couple of weeks.

We have recently responded to questions we were told came from the White House so I wanted to make sure you have background materials. I imagine you are the person that the President and Vice President would turn to for information. I am happy to arrange any briefing materials or demo that would be helpful for you to respond.

As I mentioned previously, Sara Alert is a standards-based, open source tool that automates the process of monitoring individuals exposed to or infected with COVID-19 (or any disease, it's configurable) – and will serve as an enduring national resource to contain disease. Sara Alert is free for use by public health organizations.

Best wishes to you. Stay healthy for all of us.

Paul

ABOUT SARA ALERT

In response to the COVID-19 pandemic, the MITRE Corporation, a not-for-profit that works in the public interest, developed Sara Alert, a standards-based, open source tool in partnership with national public health organizations. Sara Alert **automates the process of monitoring** individuals exposed to or infected with COVID-19 (or any disease, it's configurable) – and will serve as an **enduring national resource** to contain disease. **Sara Alert is free for use by public health organizations.**

- Sara Alert allows public health officials to import and enroll individuals (or households) at risk of developing or infected with COVID-19.
- Individuals enter their symptoms daily via web, text, email or phone, allowing public health officials to focus on high risk and non-reporting individuals.
- The web-based tool enables increased efficiency in tracking cases, leading to earlier containment of the virus and reduction of burden on public health resources.
- Sara Alert is a national system and allows transferal of monitorees across jurisdictions for tighter contact tracing.

Sara Alert launched on April 3 and **is now supporting multiple jurisdictions.**

Sara Alert YouTube Video: <https://youtu.be/IQxAuNsg-RA>

Paul E. Jarris, MD, MBA
Chief Medical Advisor
Health Transformation Center
MITRE Corporation

(b) (6)

(b) (6) Office

(b) (6) Mobile

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 17:45:26 +0000
To: Lane, Cliff (NIH/NIAID) [E]; Collins, Francis (NIH/OD) [E]
Cc: Lowy, Douglas (NIH/NCI) [E]; Mascola, John (NIH/VRC) [E]
Subject: RE: Gallo and OPV

(b) (5).

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lane, Cliff (NIH/NIAID) [E] (b) (6) >
Sent: Sunday, May 3, 2020 1:22 PM
To: Collins, Francis (NIH/OD) [E] (b) (6) >
Cc: Lowy, Douglas (NIH/NCI) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E]
(b) (6) >; Mascola, John (NIH/VRC) [E] (b) (6) >
Subject: Re: Gallo and OPV

Francis,

(b) (5)

Cliff

On May 3, 2020, at 12:55 PM, Collins, Francis (NIH/OD) [E] (b) (6) wrote:

Hi all,

I'm a bit at a loss to know how to respond to Bob Gallo. (b) (5)

Francis

From: Gallo, Robert (b) (6) >
Sent: Sunday, May 3, 2020 12:07 PM
To: Collins, Francis (NIH/OD) [E] (b) (6)
Subject: RE: Your query to Dr. Kadlec

Dear Francis,

It was a pleasure to hear from you, and yes, it has been a long time since we met or even spoke. Moons ago I was set to write to you after reading your wonderful book, but I ended up instead speaking with others about it. I should add at this point that I did not quickly respond to your email of a few days ago because I simply missed it.

It is true that I strongly suggest that OPV be quickly (already it is not quickly) brought forward for induction of a strong innate immune response to prevent or markedly reduce SARS-CoV-2 infection and/or severity until the field obtains a proven safe and efficacious vaccine producing a long lasting, adaptive immunity. OPV is very safe (notably for OPV 1 and 3 as bOPV which we will use and completely safe in a vaccinated population), simple, cheap, rather obvious, yet unique among the massive number of vaccines many (maybe most) of which are the same or at least if not exactly the same aiming at the same mechanism (targeting the spike and searching for the putative correlate of neutralizing Abs.).

OPV should work for a few months and possibly longer. Also it should be working multiple times so I think could cover more than a few months, giving us time for a proven vaccine of adaptive immunity, which might be very long lasting as is hoped.

In the main the WHO comments are correct. Of course we sought and have letters of support from them as well as from many others. Though they are again supportive in their notes to you, there is one item that surprises me. They add that there was no clinical efficacy results as yet. They know or certainly should know that there is plenty of clinical data for this concept with BCG, OPV, and live Measles vaccine. Needless to say this is what turned me on during our regular Global Virus Network (GVN) conference calls. (Incidentally GVN is an organization I have thought of bringing to your attention. I think you would find it impressive and useful). I would be happy to share with you the clinical observations with OPV if you wish.

I would like to take a small diversion, but I suspect you are aware of these things. My colleagues and I respect the WHO because of its representation and because we have colleagues/friends there as well. However, sometimes bureaucracy of a massive degree leads to inaction or even much worse-- political expediency. I won't bother you with details of these unless you ask, but I had such experiences with HTLV-1 which we discovered in 1980 as the 1st human retrovirus and which cause not only the highest incidence of cancer (% of infections) of any virus and other fatal diseases as well but mainly in less developed countries (plus Japan) and again with HIV in 1984. Behavior was not beneficial. Perhaps it will be of relevance in the future because a few at WHO took a position to remove OPV (Sabin) in favor of IPV (Salk) in their polio eradication scheme. It was a huge failure. As my FDA collaborator, Konstantin Chumakov, says "Blessed be Bill Gates" because he saved OPV and saved the day and in so doing has produced a still better OPV.

There is indeed data also for BCG as well as live Measles though I know less of the latter. BCG is less available, requires injection, harder to make, not as safe, and we think unlikely to be as effective as OPV. Nonetheless, we favor its use too. The mechanisms will be similar.

You asked whether monkey trials are planned. For several reasons definitely not -- though we are planning some monkey experiments, but not large enough for "clinical" conclusions. The main reasons are: 1) cost; 2) that billions not thousands or millions have received OPV safely and in our collective view (and we know the studies pretty well) protection has been clinically shown; 3) In a pandemic we wished to move quickly (so far we must say that has not been achieved). A typical monkey vaccine study will take time, but 4) in this case it would be a huge amount of lost time as monkeys require great doses of polio for infection and monkeys have to be trained to drink their orange juice. It would be hard to imagine that such studies would even give us useful information.

On a final digression Francis I have had 36 years of on/off experiences with glycosylated spike proteins—their analyses immunologically and especially regarding use in vaccines and developing neutralizing Abs. I believe it will be a mistake to put most eggs in that basket. The risks: shortened antibody half life; 2) protection NOT correlating with neutralizing Abs; 3) sometimes hazards from them. Admittedly, they might work, but I trust and hope that not everything is going in this bag. If you wish to discuss this again I will be available.

Finally, I had no idea you were into vaccines or SARS-2 nor any part of CoVID-19 disease, but I am very happy to learn this.

Thanks.

Bob Gallo

From: Collins, Francis (NIH/OD) [E] (b) (6) >
Sent: Thursday, April 30, 2020 5:00 PM
To: Gallo, Robert (b) (6) >
Cc: Disbrow, Gary (OS/ASPR/BARDA) <(b) (6)>; Kadlec, Robert (OS/ASPR/IO) (b) (6) >; Tabak, Lawrence (NIH/OD) [E] <(b) (6)>; Shuy, Bryan (OS/ASPR/IO) (b) (6) >; Johnson, Robert (OS/ASPR/BARDA) (b) (6) >; Mascola, John (NIH/VRC) [E] (b) (6) >; Lane, Cliff (NIH/NIAID) [E] (b) (6) >
Subject: Your query to Dr. Kadlec

CAUTION: This message originated from a non UMB, UMSOM, FPI, or UMMS email system. Whether the sender is known or not known, hover over any links before clicking and use caution opening attachments.

Dear Bob,

It's been quite a while since we've chatted. Bob Kadlec asked me to respond to your query about the possible use of OPV to activate innate immunity and provide COVID-19 protection. Has this been tested in a non-human primate model? I note the recommendation below that says a clinical trial is planned – can you tell me more about that?

As you can imagine, we are all flat out on the vaccine development pathway!

Francis

The use of oral polio vaccine (OPV) to prevent SARS-CoV2 (Polio Eradication Campaign)

There is no evidence that oral poliovirus vaccine (OPV) protects people against infection with COVID-19 virus.

A clinical trial addressing this question is planned in the USA, and WHO will evaluate the evidence when it is available.

In the absence of evidence, WHO does not recommend OPV vaccination for the prevention of COVID-19. WHO continues to recommend OPV as part of essential immunization services to prevent poliomyelitis and as part of global polio eradication efforts.

There are experimental signals from various studies over the years that OPV has non-specific effects on the immune system. These effects have not been well characterized and their clinical relevance is unknown. Such non-specific effects may

not be limited to OPV, as other live vaccines have also been associated with non-specific protective effects (such as BCG vaccine against tuberculosis). Nonlive vaccines in contrast do not seem to have the same effects.

The exact mechanism of non-specific protection induced by live vaccines needs to be elucidated further. Clinical studies could begin immediately because the vaccines in question are licensed and have an excellent safety record. Clinical trials involving off-label use of various drugs licensed for other indications are currently underway. The existing scientific rationale suggests that the same should be done for OPV and other live vaccines. A study is currently being discussed with various partners and vaccine manufacturers, including the US FDA, the outcomes of which will be carefully assessed to determine potential use in the context of the spread of SARS-CoV2 until the time when specific vaccines and antiviral therapies are ready.

From: Kadlec, Robert (OS/ASPR/IO) (b) (6)
Sent: Thursday, April 30, 2020 10:28 AM
To: Gallo, Robert (b) (6); Collins, Francis (NIH/OD) [E]
<(b) (6); Tabak, Lawrence (NIH/OD) [E] (b) (6)>; Shuy, Bryan (OS/ASPR/IO) (b) (6)>
Subject: Re: Response

Dr Gallo thank you for your note and I appreciate you reaching out to me. I have copied Dr Collins and Dr Tabak to consider the ACTIV forum they have created to bring industry academia and government to consider scientific base approaches That you have described. Dr Collins has organized a vaccine group and I assess could be the best and fastest place to discuss your concept. I am sure they will connect with you soonest

Best

Bob Kadlec.

Sent from my iPhone

On Apr 30, 2020, at 10:02 AM, Gallo, Robert (b) (6) > wrote:

Dear Dr. Kaldec,

I have not heard from you in over a week. You mentioned getting back to me in a day or two. Time is passing. I am asking you to look at OPV 1 plus 3 serotypes as a bivalent, completely safe vaccine with powerful stimulation of innate immunity lasting several weeks , which can be given a second or third time, and with a historical track record of

preventing other infections from entirely different RNA viruses (such as protecting against influenza). Therefore, it should be really helpful for some months, and I think get us past a second wave of SARS-CoV-2, and help people return to work safely. I don't understand delays or apparent lack of interest. Who can possibly be against this? If you hear of hypothetical problems we can show you that these are false. Just ask the questions, and we can give you the evidence.

However, no answer from you suggests no interest and must quickly make alternative pathways. I am though quite surprised and fear you are receiving "fake news" if you will pardon the expression. Some have been against this who defend their old and failed position on polio eradication with their promotion of the use of the inactivated polio virus vaccine. Please note that in the US between 1962 and 1985 we received (safely) the oral polio (OPV). Moreover, if vaccinated already there has not been a single case of a complication and BILLIONS have received it. No it will not last long as innate immunity is short lived, but we strongly believe that we can break the back of the SARS-CoV-2 spread. Also note that this is what Bill Gates is doing now in India and much of the Eastern hemisphere.

There are countries outside the US wanting to move fast on this. We are waiting for your reply.

Robert Gallo
Director, Institute of Human Virology,
Professor of Medicine and Professor of Microbiology,
UMB, School of Medicine, Baltimore,

And
Co-founder and International Science Advisor of the Global Virus
Network (GVN)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 15:17:01 +0000
To: Collins, Francis (NIH/OD) [E]; Mascola, John (NIH/VRC) [E]; Lane, Cliff (NIH/NIAID) [E]
Cc: Tabak, Lawrence (NIH/OD) [E]
Subject: RE: Response

Francis:

Thanks for the note. I will let Cliff speak for himself, (b) (5)

(b) (5)

(b) (5) but I will let him speak for himself. We can discuss further if you wish.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Collins, Francis (NIH/OD) [E] (b) (6) >
Sent: Thursday, April 30, 2020 10:58 AM
To: Mascola, John (NIH/VRC) [E] (b) (6) >; Lane, Cliff (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Tabak, Lawrence (NIH/OD) [E] (b) (6) >
Subject: FW: Response

Hi John, Cliff, and Tony,

Ignore the silly part of the message below, where (b) (5)
(b) (5). But let me ask you guys whether (b) (5)
(b) (5)
(b) (5)

Francis

From: Collins, Francis (NIH/OD) [E]
Sent: Thursday, April 30, 2020 10:55 AM
To: Kadlec, Robert (OS/ASPR/IO) (b) (6)
Cc: Tabak, Lawrence (NIH/OD) [E] (b) (6) >; Shuy, Bryan (OS/ASPR/IO) (b) (6); Disbrow, Gary (OS/ASPR/BARDA) (b) (6) >; Johnson, Alfred (NIH/OD) [E] (b) (6)
Subject: RE: Response

Bob,

Dropping Bob Gallo from the thread, but adding Gary and Robert. (b) (5)
(b) (5)
(b) (5)
(b) (5) Please advise.

Francis

From: Kadlec, Robert (OS/ASPR/IO) (b) (6)
Sent: Thursday, April 30, 2020 10:28 AM
To: Gallo, Robert (b) (6) >; Collins, Francis (NIH/OD) [E] (b) (6); Tabak, Lawrence (NIH/OD) [E] (b) (6) >; Shuy, Bryan (OS/ASPR/IO) (b) (6)
Subject: Re: Response

Dr Gallo thank you for your note and I appreciate you reaching out to me. I have copied Dr Collins and Dr Tabak to consider the ACTIV forum they have created to bring industry academia and government to consider scientific base approaches That you have described. Dr Collins has organized a vaccine group and I assess could be the best and fastest place to discuss your concept. I am sure they will connect with you soonest

Best

Bob Kadlec.

Sent from my iPhone

On Apr 30, 2020, at 10:02 AM, Gallo, Robert (b) (6) > wrote:

Dear Dr. Kadlec,

I have not heard from you in over a week. You mentioned getting back to me in a day or two. Time is passing. I am asking you to look at OPV 1 plus 3 serotypes as a bivalent, completely safe vaccine with powerful stimulation of innate immunity lasting several weeks, which can be given a second or third time, and with a historical track record of preventing other infections from entirely different RNA viruses (such as protecting against influenza). Therefore, it should be really helpful for some months, and I think get us past a second wave of SARS-CoV-2, and help people return to work safely. I don't understand delays or apparent lack of interest. Who can possibly be against this? If you hear of hypothetical problems we can show you that these are false. Just ask the questions, and we can give you the evidence.

However, no answer from you suggests no interest and must quickly make alternative pathways. I am though quite surprised and fear you are receiving "fake news" if you will pardon the expression. Some have been against this who defend their old and failed position on polio eradication with their promotion of the use of the inactivated polio virus vaccine. Please note that in the US between 1962 and 1985 we received (safely) the oral polio (OPV). Moreover, if vaccinated already there has not been a single case of a complication and BILLIONS have received it. No it will not last long as innate immunity is short lived, but we strongly believe that we can break the back of the SARS-CoV-2 spread. Also note that this is what Bill Gates is doing now in India and much of the Eastern hemisphere.

There are countries outside the US wanting to move fast on this. We are waiting for your reply.

Robert Gallo
Director, Institute of Human Virology,
Professor of Medicine and Professor of Microbiology,
UMB, School of Medicine, Baltimore,

And

Co-founder and International Science Advisor of the Global Virus Network (GVN)

From: (b) (6)
Sent: Wed, 29 Apr 2020 13:39:44 -0400
To: Billet, Courtney (NIH/NIAID) [E]
Subject: Fwd: ASF: For review ASAP: draft Sec. Azar Remdesivir statement
Attachments: 4 29 20 remdesivir.docx, ATT00001.htm

Cannot do right now. Go without me

Begin forwarded message:

From: "Billet, Courtney (NIH/NIAID) [E]" (b) (6)
Date: April 29, 2020 at 1:11:19 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Cc: "Routh, Jennifer (NIH/NIAID) [E]" <(b) (6)>, "Stover, Kathy (NIH/NIAID) [E]" (b) (6) "Lane, Cliff (NIH/NIAID) [E]" (b) (6)>, "Marston, Hilary (NIH/NIAID) [E]" (b) (6)>, "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)>, "Folkers, Greg (NIH/NIAID) [E]" (b) (6)>
Subject: ASF: For review ASAP: draft Sec. Azar Remdesivir statement

From: Fritz, Craig (NIH/OD) [E] (b) (6)
Sent: Wednesday, April 29, 2020 10:38 AM
To: Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6) Routh, Jennifer (NIH/NIAID) [E] (b) (6)>
Cc: Burklow, John (NIH/OD) [E] (b) (6); Myles, Renate (NIH/OD) [E] (b) (6); Fine, Amanda (NIH/OD) [E] (b) (6)>; Wojtowicz, Emma (NIH/OD) [E] (b) (6)>; NIH News Clearance (NIH/OD) <NIHNewsClearance@mail.nih.gov>
Subject: FW: For review ASAP: draft Sec. Azar Remdesivir statement
Importance: High

Hi all – please let us know if you have any comments to the attached.

Thanks!
Craig

From: Brennan, Patrick (OS/ASPA) (b) (6)>
Sent: Wednesday, April 29, 2020 10:33 AM
To: Fritz, Craig (NIH/OD) [E] (b) (6)>; Burklow, John (NIH/OD) [E] (b) (6)>; Myles, Renate (NIH/OD) [E] (b) (6)>; Fine, Amanda (NIH/OD) [E] (b) (6)>; Wojtowicz, Emma (NIH/OD) [E] (b) (6)>; Charrow, Robert (HHS/OGC) (b) (6)>
Cc: Pence, Laura (HHS/ASL) (b) (6)>; Hall, Bill (HHS/ASPA) (b) (6)>; Pratt, Michael (OS/ASPA) (b) (6)>; Blakeman, Scott (OS/ASPA) <(b) (6)>
Subject: For review ASAP: draft Sec. Azar Remdesivir statement

NIH and Mr. Charrow,

Below and in the attached is a draft statement from the Secretary regarding the Remdesivir trial – please let me know as soon as you can if this looks OK. (I pulled the frontmatter from the NIH press release.) Thank you!

- Patrick



Patrick Brennan
Director of Speechwriting
Department of Health and Human Services
Office: (b) (6) | Cell (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 01:56:42 +0000
To: (b) (6)v
Subject: FW: DRAFT document for WH Briefing Tomorrow
Attachments: Development-Medical-Countermeasures-WH-Briefing 29 April.pptx

Here it is.

From: Collins, Francis (NIH/OD) [E] (b) (6)>
Sent: Tuesday, April 28, 2020 8:08 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: FW: DRAFT document for WH Briefing Tomorrow

Hi Tony,

I called Paul to (b) (5)
(b) (5)
(b) (5)
(b) (5)
(b) (5)
(b) (5)

Francis

From: Mango, Paul (HHS/IOS) <(b) (6)>
Sent: Tuesday, April 28, 2020 7:26 PM
To: Collins, Francis (NIH/OD) [E] (b) (6)>; Kadlec, Robert (OS/ASPR/IO) (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Marks, Peter (FDA/CBER) (b) (6); Woodcock, Janet (FDA/CDER) (b) (6)>; Tromberg, Bruce (NIH/NIBIB) [E] (b) (6)
Subject: DRAFT document for WH Briefing Tomorrow

Thank you all for your timely responses for contributions to this today. Please give this a look and let us know if there is anything glaringly out of place. We will have time to address edits during and after our 930am check in tomorrow. The Secretary may or may not use page 1 during his introductory remarks.



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 18:14:04 +0000
To: Gibbons, Gary (NIH/NHLBI) [E]
Cc: Koroshetz, Walter (NIH/NINDS) [E]; (b) (6); Auchincloss, Hugh (NIH/NIAID) [C]; (b) (6); Collins, Francis (NIH/OD) [E]; (b) (6); Tabak, Lawrence (NIH/OD) [E]; Conrad, Patricia (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]
Subject: Thrombotic phenomena in COVID-19

Gary:

In follow-up of our recent conversation regarding the growing evidence that the extremely catastrophic course of many patients with COVID-19 seems to me pathogenically associated with the findings of microthrombi in the lungs and often a multisystem process resembling DIC. In addition, there have been growing numbers of cases of individuals (some young and otherwise healthy) who have had unexplained strokes, only to find out that they actually have COVID-19. (b) (5)

(b) (5)

(b) (5) Thanks.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Auchincloss, Hugh (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 17:42:12 +0000
To: NIAID OD AM
Subject: FW: Invitation to Webinar as keynote speaker.

I wouldn't think so.

From: Secretary ARP (b) (6) >
Sent: Saturday, April 25, 2020 2:07 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Invitation to Webinar as keynote speaker.

To,
Anthony S. Fauci,
Office of the Director,
National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 9000 Rockville Pike, Bldg 31, Room 7A03,
Bethesda MD 20892

Subject: Invitation to Webinar as keynote speaker.

Dear Sir,

On behalf of ASSOCIATION OF REGISTERED PHARMACIST (An association working for Pharmacy Profession and having more than 2000 members) in collaboration with Divine International, Gwalior (A Pioneer Pharmacy Institute) I am pleased to invite you to our Webinar having THEME "CHALLENGES AND OPPORTUNITIES FOR PHARMACIST IN THE PRESENT EPIDEMIC COVID-19" that will be held from 2nd May 2020 to 3rd May 2020. This Webinar is the get together of Pharma professionals through the web. The vision of this Webinar is to Aware, Prepare and strengthen our Pharmacy professionals in our country to this epidemic COVID-19 for present and future aspect and exports more realistic ideas and present scenario of this epidemic COVID-19.

You are one of the legends of Pharma Expert of our country, it is a great privilege for us to see if you share your experience with us, we really expect and want that you join our Webinar and share with us the great experience of your life, we want to learn something from you so that we can create a great ideas, opportunity, and roll of Pharma professional for our country in the present scenario.

We would be pleased to have you present at this point at this webinar to listen to what the role and importance in the Pharmacist advancement and their impact on our society and daily life we would also love to hear your thoughts and opinion about the Pharma professional that is a dream of our pharmacy fraternity.

Therefore you are requested to send your recorded Lecture/presentation of 30-40 min

Sincerely,

--
Thanks

Rajesh Singh Jadon
Secretary (National)
Association of Registered Pharmacists
Gwalior MP
Mob: [REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 15:43:25 +0000
To: (b) (6)
Subject: RE (b) (6), (b) (4)
Attachments: (b) (6), (b) (4)

From: (b) (6) >
Sent: Sunday, April 26, 2020 11:32 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: (b) (6), (b) (4)

To work on at home

From: Ulrich, Connie M (b) (6)
Sent: Saturday, April 25, 2020 2:35 PM
To: Cynda Rushton (b) (6) >; (b) (6)
Subject: (b) (6), (b) (4)

Hi Christine and Cynda,

I finished my section and unfortunately have to keep changing the COVID numbers! I will add some thoughts to the last section. Not sure how much we can add there but maybe some reflections would be helpful. Enjoy the sunshine today!!

Best.
Connie

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 02:57:31 +0000
To: Collins, Francis (NIH/OD) [E]
Cc: Tabak, Lawrence (NIH/OD) [E]
Bcc: Mascola, John (NIH/VRC) [E] (b) (6)
Subject: RE: agenda for Kadlec et al., Sun noon meeting

Francis:

Sorry that I took so long to respond.

(b) (5)

(b) (5)

(b) (5) Let us connect

by phone first thing in the AM>

Thanks,

Tony

From: Collins, Francis (NIH/OD) [E] <(b) (6)>
Sent: Saturday, April 25, 2020 2:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Tabak, Lawrence (NIH/OD) [E]
(b) (6)>
Subject: RE: agenda for Kadlec et al., Sun noon meeting

(b) (5)

From: Collins, Francis (NIH/OD) [E]
Sent: Saturday, April 25, 2020 2:49 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Tabak, Lawrence (NIH/OD) [E]
(b) (6)
Subject: agenda for Kadlec et al., Sun noon meeting

Hi Tony and Larry,

For the meeting tomorrow at noon (currently invitees are Kadlec, Disbrow, Johnson, Woodcock, Marks, and us three), I would propose the following framework:

(b) (5)

(b) (5)

Thoughts? Tony, should

(b) (5)

Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 01:22:21 +0000
To: Corey MD, Larry
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: [REDACTED] (b) (6)

Let us talk tomorrow (Sunday). I am sorry that I did not get back to you today.

From: Corey MD, Larry [REDACTED] (b) (6)
Sent: Saturday, April 25, 2020 5:36 PM
To: Mascola, John (NIH/VRC) [E] [REDACTED] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6); Collins, Francis (NIH/OD) [E]
[REDACTED] (b) (6)
Subject: Re: [REDACTED] (b) (6)

Agree. [REDACTED] (b) (6)

Sent from my iPhone

On Apr 25, 2020, at 1:59 PM, Mascola, John (NIH/VRC) [E] <[REDACTED] (b) (6)> wrote:

[REDACTED] (b) (6) seem reasonable

Sent from my iPhone


On Apr 25, 2020, at 15:54, Corey MD, Larry [REDACTED] (b) (6) wrote:

A do have to say I am surprised . but ok

From: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Sent: Saturday, April 25, 2020 12:53 PM
To: Corey MD, Larry [REDACTED] (b) (6); Mascola, John (NIH/VRC) [E]
[REDACTED] (b) (6)>
Cc: Collins, Francis (NIH/OD) [E] [REDACTED] (b) (6)>
Subject: Fwd: New England Journal of Medicine 20-13479

Let us discuss next steps

Begin forwarded message:



(b) (6)

From: (b) (6)
Sent: Sat, 25 Apr 2020 13:05:04 -0400
To: Collins, Francis (NIH/OD) [E]
Cc: Tabak, Lawrence (NIH/OD) [E]
Subject: Re: White House Task Force Briefing Monday

(b) (5)

On Apr 25, 2020, at 11:42 AM, Collins, Francis (NIH/OD) [E]

<(b) (6)>.

Judy Stecker called. Said there's a separate (b)(5) - PCP

(b) (5)

(b) (5)

(b) (5)

FC

From: Collins, Francis (NIH/OD) [E]
Sent: Saturday, April 25, 2020 10:36 AM
To: (b) (6) (OS/IOS) (b) (6)
Cc: Tabak, Lawrence (NIH/OD) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Pence, Laura (HHS/ASL) <(b) (6)>; Harrison, Brian (HHS/IOS) (b) (6)>; Wood, Gretchen (NIH/OD) [E] (b) (6) McManus, Ayanna (NIH/OD) [E] (b) (6)
Subject: FW: White House Task Force Briefing Monday

Hi Mr. Secretary,


Please see below for a (b)(5) - PCP


(b) (5) Glad to speak with you about how best to handle, if you have advice. (b) (6)

Francis

(b)(5) - PCP







From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Apr 2020 14:25:16 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Italy Covid-19

La Stampa is one of the two most important newspapers in Italy.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mastrolilli Paolo <Paolo.MASTROLILLI@lastampa.it>
Sent: Friday, April 24, 2020 10:08 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Italy Covid-19

Dear Doctor Fauci,

My name is Paolo Mastrolilli, I am the US Bureau Chief for the Italian daily La Stampa.

I am writing because we would appreciate very much the opportunity to have a phone or written Q&As interview with you to discuss the Covid 19 pandemic. Considering the difficult situation Italy is experiencing, the help President Trump is sending to Italy, and the plan to open America again, it would be very helpful for Italy to hear from your experience and competence to address the Covid 19. We think that your advices would be very helpful to help our country and our citizens in dealing with the pandemic.

We understand that you are very busy and this request has no deadline.

La Stampa is a leading Italian daily, it is owned by the Agnelli Elkann family, owner of Fiat Chrysler as well.

I am also a contributor for the Vatican Radio and the official news portal of the Holy See, I would share the interview with them as well, if you like.

My cellphone number is (b) (6)

Please let me know if you need any further information.

Best regards

Paolo Mastrolilli

Il presente messaggio (inclusi gli allegati) contiene informazioni riservate esclusivamente al destinatario/ai destinatari indicato/i nel messaggio, ed è protetto dalla legge. La diffusione, distribuzione e/o la copia del contenuto del presente messaggio da parte di qualsiasi soggetto diverso dal destinatario è severamente vietata ai sensi dell'art. 616 c.p. e delle vigenti normative in materia di protezione dei dati personali. Se non siete i destinatari del presente messaggio, vi preghiamo di distruggerlo e di darcene immediata comunicazione inviando un messaggio di ritorno all'indirizzo e-mail del mittente.

This message (including any attachments) contains confidential information intended only for the recipient(s) named above, and is protected by law. Any disclosure, distribution and/or copying of this message by any subject different from the named recipient(s) is strictly prohibited according to art. 616 c.p. and to the applicable data protection laws. If you are not the intended recipient, please delete this message and inform us immediately about the deletion by sending a message to the sender's e-mail address.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Apr 2020 10:33:49 +0000
To: Holland, Steven (NIH/NIAID) [E]
Cc: Marston, Hilary (NIH/NIAID) [E]; Lerner, Andrea (NIH/NIAID) [E]
Subject: RE: Successful Submission of a Manuscript to Science (abc4208)

Thanks, Steve.

-----Original Message-----

From: Holland, Steven (NIH/NIAID) [E] (b) (6)
Sent: Thursday, April 23, 2020 11:48 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Marston, Hilary (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] (b) (6)
Subject: FW: Successful Submission of a Manuscript to Science (abc4208)

This is the acalabrutinib paper today submitted to Science. NEJM was interested but wanted a month delay to be sure about the results but some of the authors (Not the NIAID one) balked and have gone elsewhere. Just keeping you in the loop.

Steve

--

Director, Division of Intramural Research National Institute of Allergy and Infectious Diseases National Institutes of Health
Bldg. 10/11N248 MSC 1960
Bethesda, MD 20892-1960
(b) (6) voice
301-480-4507 fax
(b) (6)

Assistant lab: Eva Portillo

(b) (6)
(b) (6) voice

Assistant to SD: Beth Schmidt

(b) (6)
(b) (6) voice

On 4/23/20, 1:59 PM, "Lionakis, Michail (NIH/NIAID) [E]" (b) (6) wrote:

Attached the submitted paper, which will be deposited to MedRxiv.org today I think.
Mihalis

On 4/23/20, 1:34 PM, "science_editors@aaas.org" <science_editors@aaas.org> wrote:

Manuscript Title: Inhibition of Bruton Tyrosine Kinase in Patients with Severe Covid-19
Author: Lionakis
Manuscript Number: abc4208

Dear Dr. Lionakis:

You are listed as a coauthor on the above manuscript, which has recently been submitted to Science.

According to Science policy, all authors must have seen and approved the submission of their manuscript. If you have seen the manuscript and approved its submission, no action is necessary.

If you have not read this paper or do not approve its submission to Science, please let us know as soon as possible. Please refer to the manuscript number listed above in any correspondence (you can just reply to this message).

You can see the status of your manuscript at any time by logging into your account at the Science Journals Submission and Information Portal at <https://cts.sciencemag.org>.

If you do not yet have an account, please go to <https://cts.sciencemag.org/scc/#/forgot-password> and use the email at which you received this correspondence because that is linked to your manuscript. Then, follow the prompts to set your password and login. After login, you can access your manuscript and monitor its status.

Once you are registered, we encourage you to link your account to your ORCID ID, an identifier that facilitates the correct attribution of your publications to you. To learn more about ORCID or to obtain an ORCID ID, visit their site at: <http://orcid.org>.

Your manuscript is now undergoing an initial screening to determine whether it will be sent for in-depth review. If the manuscript is sent to review, its status will change to "To Review".

Sincerely,
The Editors
Science

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Apr 2020 01:58:36 +0000
To: Greg Folkers (b) (6)
Subject: FW: HIVR4P postponed to 17-21 January 2021

FYI. See yellow highlighted request.

From: HIVR4P - Secretariat <secretariat@hivr4p.org>
Sent: Thursday, April 23, 2020 11:23 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Dieffenbach, Carl (NIH/NIAID) [E] (b) (6) >
Subject: HIVR4P postponed to 17-21 January 2021



Dear Dr. Fauci,

As the research community responds to the global challenges of the COVID-19 pandemic, HIV prevention science matters as much as ever. Our priority as organizers of the HIV Research for Prevention (HIVR4P) conference remains the safety and wellbeing of all participants.

After careful consideration, we have decided to postpone the HIVR4P conference to **17-21 January 2021**. Updated details for the session(s) are listed below:

Session title:	HIV prevention 2020 – Where are we now and where are we going?
Session type:	Opening plenary
Suggested presentation title/topic:	Much accomplished; Much to do – An overview on HIV prevention research
Session description:	Today's plenary sets the stage for the conference week ahead, outlining the big-picture challenges we face in research, product development and access to prevention. Speakers will provide diverse perspectives on the state of the field today, the opportunities and obstacles ahead and priorities for action moving forward.
Session date and time:	Monday, 18 January 2021 - 16:00-18:00

Meet the Experts lunches

We invite you to host an informal table discussion at a Meet the Experts lunch on **20 January 2021, 12:00-13:00**. Daily meet the experts lunches provide early-career investigators and community advocates with valuable opportunities for informal, in-depth exchange with experts representing a cross-section of research issues, implementation challenges and HIV-affected communities.

Please reply to this email by Wednesday, 6 May if you are still available to deliver this important presentation and, if so, please also include a photo and a brief biography.

We are acutely aware many researchers and research organizations with critical studies and submissions to HIVR4P are now also heavily engaged in the COVID-19 response. Our hope is that postponing the conference, rather than presenting it virtually in October, will allow for the broadest participation to foster knowledge-exchange, debate and direction-setting in the field of HIV prevention research that HIVR4P is known for.

Thank you for your consideration.

Sincerely,

HIVR4P - Secretariat

HIV Research for Prevention

W: (b) (6)

Avenue de France 23 | CH-1202 Geneva | Switzerland

HIVR4P Conference | 17-21 January 2021 | Cape Town, South Africa



HIVR4P.org



[@HIVR4Px](https://twitter.com/HIVR4Px)



[/HIVR4P](https://facebook.com/HIVR4P)

From: HIVR4P - Secretariat

Sent: 21 February 2020 16:57

To: (b) (6)

Cc: Bargavi Thyagarajan (b) (6)

Subject: HIVR4P 2020 - Invitation to present



**HIV RESEARCH
FOR PREVENTION**

CAPE TOWN, SOUTH AFRICA • 11-15 OCTOBER 2020

Dear Dr. Fauci,

We are writing with great pleasure to invite you to present at the 4th HIV Research for Prevention Conference ([HIVR4P 2020](#)) in Cape Town, South Africa, from 11-15 October 2020. HIV Research for Prevention is the only global scientific conference focused exclusively on the challenging and fast-growing field of HIV prevention research. HIVR4P fosters interdisciplinary knowledge-exchange on HIV vaccines, microbicides, PrEP, treatment as prevention and biomedical interventions as well as their related social and behavioural implications.

Details for the session(s) are listed below:

Session title:	HIV prevention 2020 – Where are we now and where are we going?
Session type:	Opening plenary
Suggested presentation title/topic:	Much accomplished; Much to do – An overview on HIV prevention research
Session description:	Today's plenary sets the stage for the conference week ahead, outlining the big-picture challenges we face in research, product development and access to prevention. Speakers will provide diverse perspectives on the state of the field today, the opportunities and obstacles ahead and priorities for action moving forward.
Session date and time:	Monday, 12 October 2020 - 16:00-18:00

Meet the Experts lunches

We invite you to host an informal table discussion at a Meet the Experts lunch on **14 October 2020, 12:00-13:00**. Daily meet the experts lunches provide early-career investigators and community advocates with valuable opportunities for informal, in-depth exchange with experts representing a cross-section of research issues, implementation challenges and HIV-affected communities.

As an invited-speaker, you would be eligible to receive:

- Complimentary conference registration;
- Roundtrip economy airfare arranged through the HIVR4P travel agency; and
- Accommodation at one of the hotels pre-blocked by the conference secretariat.

To accept this invitation, please reply to this email by **Thursday, 27 February** and include a photo and a brief biography. Please find also attached for your record the official invitation signed by the HIVR4P 2020 Co-Chairs.

We ask that you please send any questions to the HIVR4P Secretariat at secretariat@hivr4p.org.

Thank you for your consideration. We look forward to you joining us in Cape Town!

Sincerely,

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Apr 2020 01:30:49 +0000
To: blonda quirico
Subject: RE: estimation of dynamics of COVID-19 in USA new simulations at 23 April 2020

Thanks.

From: blonda quirico <(b) (6)>
Sent: Thursday, April 23, 2020 5:02 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; COPPIETERS'T WALLANT Yves
(b) (6)>
Subject: estimation of dynamics of COVID-19 in USA new simulations at 23 April 2020

Tony,

We send you our simulations.

Best regards.

Quirico

Le mercredi 22 avril 2020 à 00:09:50 UTC+2, Fauci, Anthony (NIH/NIAID) [E] (b) (6)> a écrit :

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: blonda quirico (b) (6)
Sent: Tuesday, April 21, 2020 11:18 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); COPPIETERS'T WALLANT Yves (b) (6)>
Subject: Re: estimation of dynamics of COVID-19 in USA new simulations at 21 April 2020

Tony,

Professor COPPIETERS and I, we send you our new simulations :

In summary, the USA COVID-19 epidemic model says :

- the final size of epidemic = more than 850610 people infected and detected;
- date of epidemic peak = +/- 7 April 2020 with theoretical new cases - in one day during this peak - about +/- 35520;
- end of epidemic = +/- 19-28 June 2020 (we use two methods);
- mortality at the end of epidemic :
 - ** if death rate 5% = +/- 42.530 deceased people (for the moment the death rate = 5%)
 - ** if death rate 10% = +/- 85.060 deceased people

You reached 91,1 % of the theoretical logistic curve.

Best regards.

Quirico

00 32 475 48 68 42

Le dimanche 19 avril 2020 à 15:57:50 UTC+2, Fauci, Anthony (NIH/NIAID) [E] (b) (6)> a écrit :

Quirico:

Thanks again! Please keep this information coming to me.

Best regards,

Tony

From: blonda quirico (b) (6)>
Sent: Sunday, April 19, 2020 5:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; COPPIETERS'T WALLANT Yves (b) (6)
Subject: Re: estimation of dynamics of COVID-19 in USA new simulations at 18 April 2020

Tony,

We send you our new simulations.

In summary, the USA COVID-19 epidemic model says :

- the final size of epidemic = more than 779000 people infected and detected;
- date of epidemic peak = +/- 7 April 2020 with theoretical new cases - in one day during this peak - about +/- 35063;
- end of epidemic = +/- 4-13 June 2020 (we use two methods);

- mortality at the end of epidemic :

** if dead rate 5% = +/- 40000 deceased people

** if dead rate 10% = +/- 80.000 deceased people

You reached 87.5 % of the theoretical logistic curve.

Best regards.

Quirico

00 32 475 48 68 42

Le lundi 6 avril 2020 à 03:32:35 UTC+2, Fauci, Anthony (NIH/NIAID) [E] (b) (6)> a écrit :

Dr. Blonda:

Thank you for sending me this information. I appreciate it.

Best regards,

Tony

From: blonda quirico (b) (6)
Sent: Sunday, April 5, 2020 9:23 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; COPPIETERS'T WALLANT Yves (b) (6)>
Subject: estimation of dynamics of COVID-19 in USA

Professor Anthony FAUCY,

Sorry to disturb during the COVID-19 in USA.

But I would you inform about the COVID-19 in USA.

I'm medical doctor in Belgium.

With my teacher Professor Yves COPPIETERS (Ecole de santé publique - ULB - Brussels), we make simulations about the COVID-19 for many countries.

In summary, the USA COVID-19 epidemic model says :

- the final size of epidemic = +/- 462760 people infected and detected;
- date of epidemic peak = +/- 1- 2 April 2020 with theoretical new cases - in one day during this peak - about +/- 28390;
- end of epidemic = +/- 15 May 2020;
- mortality :
 - ** if dead rate 5% = +/- 23140 deceased people
 - ** if dead rate 10% = +/- 46275 deceased people

If you are interested by our simulations, you can contact us.

Best regards.

Dr Quirico BLONDA

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Apr 2020 00:50:12 +0000
To: [REDACTED] (b) (6)
Subject: FW: The Tablet I find myself thinking back to his father, Stephen Fauci, whose drugstore our family relied on back in the 1950s.

You have got to read this!!!

From: Folkers, Greg (NIH/NIAID) [E] [REDACTED] (b) (6) >
Sent: Thursday, April 23, 2020 7:21 PM
To: NIAID COG CORE <COG CORE@mail.nih.gov>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: The Tablet I find myself thinking back to his father, Stephen Fauci, whose drugstore our family relied on back in the 1950s.

<https://thetablet.org/only-in-print-dr-faucis-roots-in-dyker-heights/>

[ADVERTISE](#) | [CLASSIFIEDS](#) | [CONTACT US](#)

THE TABLET

Search **GO**

NEWS

OPINION

PARISHES

SCHOOLS

SPORTS

AROUND THE DIOCESE

SYNOPSIS

CORONAVIRUS

Only in Print: Dr. Fauci's Roots in Dyker Heights

April 8, 2020



Dr. Anthony Fauci meets with Regis High School students and the school's president, Father Daniel Lahart, S.J., in 2019. Fauci (whose family owned a neighborhood pharmacy in Dyker Heights) is a 1958 graduate of the Jesuit school. (Photo: courtesy of Fauci family)

CATHOLIC NEWS SERVICE

Religious education continues in different format during pandemic

Bishops in Amazon urge Peru to guard indigenous needs during pandemic

April 15, 2020
Volume 15

From the Neighborhood by Frank Derosa

Frank DeRosa retired as Associate Publisher of The Tablet and director of the Diocesan Public Information Office in 2008

When I see Dr. Anthony Fauci on the TV screen explaining expertly everything we need to know about the coronavirus pandemic, I find myself thinking back to his father, Stephen Fauci, whose drugstore our family relied on back in the 1950s.

Steve Fauci was the neighborhood pharmacist.

The Fauci Pharmacy stood on the southwest corner of 13 th Ave. and 83 rd St., in the Dyker Heights section of Brooklyn, diagonally across from the Shrine Church of St. Bernadette. We lived two blocks away on 85 th .

Long ago parishioners like me remember what the store looked like, the soda fountain that ran along the right wall, the telephone booths at the left close to the entrance and the counter straight ahead down the center.

Whenever my mother sent me there, Mr. Fauci would be behind the counter, but it was a family enterprise. They lived in an apartment above the store, and if the patriarch wasn't serving you, his wife, Eugenia, or daughter, Denise, was there. Young Anthony, I've since learned, pitched in too, his father sending him out on his bike to deliver items to customers.

I've never met the man who has become the most important medical voice in the country. Nor have former parishioners that I've spoken to about him in recent days, like boyhood pals Anthony LoFrisco, from 80th St., now in Connecticut, and Bob Orlando, who lived on 84th, now a New Jersey resident, as well as Bishop Gerald Barbarito of the Palm Beach Diocese, from 11th Ave. But each remembers the pharmacy as a Dyker Heights institution.

While we don't know him personally, in a sense he's become everyone's friend. With his steady television presence, he's imparted his vast knowledge and straightforward advice in a trademark, sometimes gravelly or raspy, Brooklyn accent that has endeared him to people far and wide. You can't be anything but proud of someone of his prominence who came from the parish.

Anthony became known as Tony, as he tells it, when Father Flanagan, principal of Regis High School, decided to call him that on his first day as a freshman. The name stuck.

Tony took buses and trains to the Jesuit school in Manhattan, including the old Sea Beach Express. He traveled 70 minutes each way, did three hours of homework, captained the basketball team and excelled in the classroom.

I remember hearing that when Tony was a high schooler, he had a part-time job working in St. Bernadette's rectory, answering the phone and doing whatever else parishioners wanted him to do to put them in touch with one of the parish priests. In those days, the rectory had a priestly bonanza. There

were four of them.

Because St. Bernadette's School had not yet been established, Tony went to Our Lady of Guadalupe School, where he was taught by Dominican Sisters. It was, and is, St. Bernadette's neighboring parish.

Like most kids, he loved sports. He played CYO baseball and basketball. At Dyker Park on 86th St., he and his friends developed skills in imitation of their heroes. A Yankee follower living in the midst of Brooklyn Dodgers fans who adored The Boys of Summer, he's said his favorite players were Joe DiMaggio and Mickey Mantle.

Tony's father and mother married at 18, after they graduated from New Utrecht High School. Steve went on to Columbia to study pharmacy.

Sometime after he opened his pharmacy, he became friends with Father Al Varriale, one of St. Bernadette's beloved parish priests. At one point, Steve, as a parent, and the priest known as Father V, who directed the parish's robust CYO sports program for youths, shared a concern. It was the easy availability of indecent

and immoral publications that they knew was a threat to the moral development of young people.

So, with the approval and support of the Diocese of Brooklyn, together they formed a diocesan commission against pornography. Both men are now long gone, and so is the commission, but it was a good idea, though it did not survive them.

Remarkably, just a few houses up the block from where Steve established his pharmacy, lived the Pellegrinos, another family of St. Bernadette's parishioners that produced a renowned medical professional. The eldest son, Edmund, became a bioethicist, a "preeminent" one, as one newspaper described him after he died. But he was more. He helped develop medical programs at Kentucky, Stony Brook and Tennessee Universities. Later, he took on the presidency of The Catholic University of America. Then, after completing his tenure there, he became, as physician and philosopher, the director of the Kennedy Institute of Ethics at Georgetown University.

Though years apart in age, both Dr. Fauci and Dr. Pellegrino became Hippocratic stars, nurtured on the same block.

Only in Brooklyn, I say, not without bias.

Steve Fauci was known by members of his extended family and friends for his personality, kindness, sense of humor and wit, and for telling good stories. So they said in comments after he died in 2008.

Tony appears to have inherited Steve's gene for lightheartedness. His daughter once told the Washington Post that her dad could be a "goofball. . .he works hard and does his thing, but he comes home and he's singing opera in the kitchen and dancing around."

That kind of calm can help a man maintain his balance as he deals with the pressure of talking to millions of people every day about the complexity of a global pandemic.

As one newsman said, "When Fauci appears on the screen, you turn up the volume."

He once said the Jesuits at Regis and Holy Cross College taught him the importance of "precision of thought and economy of expression."

That's what he delivers every day: accurate information given concisely.

That's Tony Fauci, now a national treasure. And to think, he came from the neighborhood.

Dr. Anthony Fauci



He graduated from Regis High School and the College of Holy Cross. He graduated number one in his class at Cornell Medical School in 1966.

He completed his medical residency at New York Hospital. In 1984, he became director of National Institute of Allergy and Infectious Diseases, a position he holds today.



Front row, kneeling



Stephen A. Fauci
 New Utrecht High School
 Dante Circle
 Vox Populi

Steve was once known as the champ-city sprinter, now he excels as the class great jester. A regular fellow with a ready smile and full of spirit. You could always count on Steve being present at every class and school affair.



Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Apr 2020 00:35:33 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Another Possible Tool in The Fight Against SARS-CoV-2 ?

Pleas take a look and figure out where to send it.

From: Gary Radin <GRadin@dhs.lacounty.gov>
Sent: Thursday, April 23, 2020 8:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Another Possible Tool in The Fight Against SARS-CoV-2 ?

Dr. Fauci---Forgive the crude and unsolicited manner in which I am attempting to reach out to you but I don't really KNOW any other way !

I am not a medical doctor nor am I a principle investigator. I am just a Cytologist employed in the Anatomic Pathology department at LA County-USC Medical Center here in Southern California.

But I have been reading a lot--- and in my own exploration I have come across several articles which suggest the possibility of using a class of agents called SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS in combination with antivirals like oseltamivir (or perhaps Remdesivir?) to treat both the viral pathogen responsible for the current pandemic as well as the runaway immune response of the host leading to the oft fatal cytokine storms.

Apparently these compounds have been approved for flare-ups of multiple sclerosis, and have even been tried on Alzheimer's patients. The commonly known drug is FINGOLIMOD. But these papers that I have cited for you below seem to indicate that structural analogs of this compound could be important in damping down the dysregulated pro-inflammatory cascades which seem to be leading to DIC, alveolar exudates and diffuse alveolar damage, capillary leak syndrome and ultimately the multiple organ failure that is killing an unacceptably high number of people.

The fly in the ointment Dr. Fauci here is that these S-1-PR agonists have only been demonstrated to be effective in non-human primates and other mammals. And much of these studies on these compounds has been done not on coronaviruses but on influenza viruses. So it would be a gamble. But is that not how we have learned much about human health and disease is by the gracious sacrifice of our animal cousins ? And might it not be a general effect that these sphingosine derivatives have on viral sepsis so that maybe what works for influenza might work for the coronavirus?

In the dire situation that many of the most critically ill COVID 19 patients find themselves, it seems they are on the precipice of a rapid demise once they begin to show certain key laboratory results---(spikes in D-DIMER, C-Reactive Protein, Serum Ferritin, prolongation of

prothrombin and APTT, increased cardiac troponin 1, surges in IL-6, IL-7, monocytic and macrophage chemo-attractant cytokines etc).

With patients isolated by these aberrant lab values, the window may be narrow but it may be a time where application of antiviral compounds in combination with these inflammatory modulators could have a striking impact on mortality? Indeed maybe even TWO different antivirals with differing mechanisms of action in combination with these S1-PR Agonists would even be better. And the possibilities of other combinations of course would be there for further exploration.

Fully cognizant of the Hippocratic Oath to 'first do no harm' I still believe that at least the medical rationale is sound for the inclusion of these agents into the possible arsenal of therapeutics for the more severe COVID 19 patients.

Please refer below to the studies I found particularly helpful or promising. Perhaps you can put together some 'teams' to further explore investigate these options ??

We all appreciate everything you have done, and continue to do !

Gary Radin

<https://www.sciencedirect.com/science/article/pii/S0140673620303056>

<https://www.pnas.org/content/108/29/12018>

<https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S0042682214000063?returnurl=https:%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0042682214000063%3Fshowall%3Dtrue&referrer=>



Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus | PNAS

Human pandemic H1N1 2009 influenza virus rapidly infected millions worldwide and was associated with significant mortality. Antiviral drugs that inhibit influenza virus replication are the primary therapy used to diminish disease; however, there are two significant limitations to their effective use: (i) antiviral drugs exert selective pressure on the virus, resulting in the generation of ...

www.pnas.org

[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)30566-3/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30566-3/fulltext)

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
- The Lancet

The potential risk factors of older age, high SOFA score, and d-dimer greater than 1 µg/mL could help clinicians to identify patients with poor prognosis at an early stage. Prolonged viral shedding provides the rationale for a strategy of isolation of infected patients and optimal antiviral interventions in the future.

www.thelancet.com

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3176439/>



Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection - PubMed Central (PMC)

Cytokine storm during viral infection is a prospective predictor of morbidity and mortality, yet the cellular sources remain undefined. Here, using genetic and chemical tools to probe functions of the S1P 1 receptor, we elucidate cellular and signaling mechanisms important in initiating cytokine storm. While S1P 1 receptor is expressed on endothelial cells and lymphocytes within lung tissue ...

www.ncbi.nlm.nih.gov

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 22:47:07 +0000
To: Billet, Courtney (NIH/NIAID) [E]; Greg Folkers (b) (6); Conrad, Patricia (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Sammies recognition this year – congratulations
Attachments: AFauci, NIH.pcf

Please take a look at this and let us discuss. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Max Stier <mstier@ourpublicservice.org>
Sent: Thursday, April 23, 2020 2:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Barasch, Kimberly (NIH/NIAID) [C] (b) (6); Sammies <Sammies@ourpublicservice.org>
Subject: Sammies recognition this year – congratulations

Dr. Fauci:

I hope you are healthy and well. The [Partnership for Public Service](#) is honored to inform you that we have selected you as a finalist for the 2020 Samuel J. Heyman [Service to America Medals](#), otherwise known as the Oscars of government service.

You were nominated by Francis Collins for your outstanding career at NIAID and the work you are currently doing on behalf of the American people to prepare, inform and protect lives in our country and around the world during this uncertain time. Your work truly embodies the best of government that we strive to recognize through the Sammies program.

Attached, I've included the profile we have drafted to summarize your work and accomplishments – both for recognizing you as a finalist and for having the selection committee vote for the award

recipients. Should you have any edits or wish to add a personal quote, please send those to us at your convenience. We will be releasing your profile publicly with the rest of the finalists on Sunday, May 3.

Again, thank you for the work you do on behalf of the NIH and our country.

Best,

Max Stier
President and CEO
Partnership for Public Service

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 22:37:35 +0000
To: Greg Folkers (b) (6); Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

FYI

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Dzau, Victor J. <VDzau@nas.edu>
Sent: Thursday, April 23, 2020 1:49 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
(b) (6)
(b) (6)
(b) (6)
Cc: Hannon, Emma <EHannon@nas.edu>; Conrad, Patricia (NIH/NIAID) [E] (b) (6);
(b) (6)
(b) (6) 'ben.tinker@cnn.com' <ben.tinker@cnn.com>;
'Amanda.Sealy@cnn.com' <Amanda.Sealy@cnn.com>; 'Neel.Khairzada@turner.com'
<Neel.Khairzada@turner.com>; 'Tia.Miller@turner.com' <Tia.Miller@turner.com>; (b) (6)
>; McGinnis, J. Michael <MMcGinnis@nas.edu>; (b) (6)
(b) (6); Mun, Jenny <JMun@nas.edu>; (b) (6)
Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear Jeremy, Tony, Sanjay, George, Susan, and Richard,

I'm really looking forward to this panel on COVID-19 at the NAS Annual Meeting on Saturday, April 25th at 2:00-3:30 pm ET. There is tremendous excitement and enthusiasm, and registration is through the roof.

I am sending this note to do a last minute check to see if there is anything you need from me. I also want to check whether you are planning to use slides. Will you be sending your slides to us to project or use the share screen feature to advance your own slides? Regardless, it would be helpful to me if you could send me your slides for my preparation.

I would greatly appreciate it if you would respond to this email.

Best,
Victor

PS, (b) (6), my special assistant, will be sending you additional information about the session logistics shortly.

From: Dzau, Victor J. <VDzau@nas.edu>

Sent: Thursday, April 9, 2020 11:01 AM

To: Mun, Jenny <JMun@nas.edu>; (b) (6)

Cc: (b) (6); Hannon, Emma <EHannon@nas.edu>;

'conradpa@niaid.nih.gov' (b) (6); 'T.MillerdeVega@wellcome.ac.uk'

(b) (6); 'jsi@cepi.net' (b) (6) 'rebeka.yasmin@cepi.net'

(b) (6); 'ben.tinker@cnn.com' <ben.tinker@cnn.com>; 'Amanda.Sealy@cnn.com'

<Amanda.Sealy@cnn.com>; 'Neel.Khairzada@turner.com' <Neel.Khairzada@turner.com>;

'Tia.Miller@turner.com' <Tia.Miller@turner.com>; (b) (6)

Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear all,

Thank you for agreeing to participate in a special late breaking session on the COVID-19 pandemic at the NAS annual meeting. Knowing how busy you are, I am sending this email in lieu of a call to prepare for the session.

As you know, this is a 90 minute session which aims to provide our audience with deeper insights into the latest developments in the COVID-19 response. I plan to hold an engaging discussion that covers the whole experience on dealing with this pandemic – from US to international, to preparedness and response, the biology of the virus, the state of diagnostic, treatment and vaccine development, and the importance of communication.

I will begin the session by providing brief (~3 min) opening remarks describing the circumstances of the pandemic. Then, I will introduce the panelists and you will each have 7 minutes to provide remarks. You may use a limited number of slides for illustration. I hope that each panelist will provide their own perspective and speak to the issues proposed below.

- Jeremy Farrar will discuss the global response to the pandemic, drawing from his experience as a global leader, the chair of the Scientific Advisory Group for the WHO's R&D Blueprint and as a member of the Global Preparedness Monitoring Board.
- Tony Fauci will discuss the US pandemic and provide his perspective as a member of the White House Coronavirus Task Force addressing the 2019–20 coronavirus pandemic.
- George Gao will discuss China's response to the pandemic and lessons learned for the rest of the globe.
- Susan Weiss will discuss the viral characteristics of SARS COV2 , insights into its pathobiology, immunity and development of a pan-CoV antiviral.
- Richard Hatchett will discuss the development of new vaccines and treatments against COVID-19.
- Sanjay Gupta will comment on the health system response to the pandemic and challenges related to communication and public engagement in responding to COVID-19.

Following remarks from each panelist, we will have a moderated discussion amongst ourselves – I will ask you a set of questions (15 mins) and then we will take questions from the web (25 mins). To prepare me to be your moderator, please send me any questions you would like me to ask you. For those of you who would like to have a prep call, please let me know and I will set it up.

Best,
Victor

From: Mun, Jenny

Sent: Wednesday, April 8, 2020 10:56 AM

To: [REDACTED] (b) (6)

Cc: Dzau, Victor J. ; [REDACTED] (b) (6) ; Mun, Jenny ; Hannon, Emma ; [REDACTED] (b) (6) ; [REDACTED] (b) (6) 'ben.tinker@cnn.com' ; 'Amanda.Sealy@cnn.com' ; 'Neel.Khairzada@turner.com' ; 'Tia.Miller@turner.com'

Subject: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear Speakers:

I am the logistical contact for the COVID-19 session that will be held as part of the Annual Meeting (online) program on Saturday, April 25 at 2:00 pm EDT. Thank you for agreeing to participate in this session. To help you with your planning, I have provided additional details below.

Please note that the session will be live webcast and the general public will also be able to watch the session. Video from the session will also be uploaded on the NAS YouTube channel (<https://www.youtube.com/user/theNASciences>) after the meeting. We will need to obtain signed speaker release forms for your participation in this session. I have attached the speaker release form for your review and submission. **Please return the signed speaker release form by Monday, April 13.**

Session speakers are asked to connect 30 minutes prior to the session start time (**by Saturday, April 25 at 1:30 pm EDT**) to allow the technical staff to check connections and prepare for the session. Details on how to connect will be sent before the meeting.

We will list you in our promotional materials as noted below. If this is incorrect, please let me know.

Anthony S. Fauci, Director, National Institute of Allergy and Infectious Diseases
Jeremy Farrar, Director, Wellcome Trust
George F. Gao, Director-General, Chinese Center for Disease Control & Prevention
Sanjay Gupta, Chief Medical Correspondent, CNN
Richard J. Hatchett, CEO, Coalition for Epidemic Preparedness Innovations
Susan R. Weiss, Professor of Microbiology, Perelman School of Medicine, University of Pennsylvania

Since many of us have moved to remote work environments, you may already be proficient with Zoom and other online meeting/collaboration applications. I am attaching a 'speaker guidelines' file in case you have any questions on how best to prepare for and stage your remote talk. We have technical staff available to help you become familiar with Zoom and its settings – such as “sharing your screen” (if you have slide presentations that need to be shown during your talk). We can arrange for a training session this week or next week. If you would like to schedule a session, please let me know as soon as possible.

Dr. Dzau's office will be in touch regarding the agenda for this session. If you have any other questions, please let me know.

Regards, Jenny

Jenny Mun
Membership Director
National Academy of Sciences
jmun@nas.edu

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 22:36:33 +0000
To: Casetti, Cristina (NIH/NIAID) [E]; Lerner, Andrea (NIH/NIAID) [E]; (b) (6); Conrad, Patricia (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]
Subject: FW: New sheet
Attachments: COVID.docx

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Dani Bolognesi, Ph.D. <(b) (6)>
Sent: Thursday, April 23, 2020 1:01 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Subject: FW: New sheet

Hi Tony:

I hesitate to bother you with this as I am sure that you are inundated with requests of this sort over and above everything else you are doing which is truly magnificent. I believe that there is something of potential importance in what is communicated below but you are in the best position to tell me whether it could fit in the toolbox you are assembling for COVID 19 in both the short and longer term. I have to acknowledge our friend Bob Gallo for triggering this

(b) (4)

Reaching out to you to see if you think this approach has merit. Since your time is so precious, I do not expect you to review this but perhaps you can forward to one of your trusted colleagues.

PPS. Loved the interview with Coach K!

Con un forte abbraccio!

Dani

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 22:25:14 +0000
To: [REDACTED] (b) (6)
Subject: FW: MSNBC: See Dr. Fauci's Stunning Pandemic Warning – Long Before Trump Minimized Coronavirus | MSNBC <https://bit.ly/2yynEPf>

I may have already sent this to you, but I do not think so. It is short (6 minutes) but it has a segment that shows me 37 years ago. Yikes!!! You will get a chuckle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Barasch, Kimberly (NIH/NIAID) [C] [REDACTED] (b) (6)
Sent: Thursday, April 23, 2020 9:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: FW: MSNBC: See Dr. Fauci's Stunning Pandemic Warning – Long Before Trump Minimized Coronavirus | MSNBC <https://bit.ly/2yynEPf>

Kim Barasch [C]
Office of the Director
National Institute of Allergy & Infectious Diseases
[REDACTED] (b) (6)
[REDACTED] (b) (6)

From: Folkers, Greg (NIH/NIAID) [E] [REDACTED] (b) (6)>
Sent: Tuesday, April 21, 2020 11:06 PM
Subject: MSNBC: See Dr. Fauci's Stunning Pandemic Warning – Long Before Trump Minimized Coronavirus | MSNBC <https://bit.ly/2yynEPf>



Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 22:14:31 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: A proposal to stop COVID-19 and reopen our schools and businesses
Attachments: Scientists_to_Stop_COVID19_2020_04_23_FINAL.pdf

Email below from David Liu.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone (b) (6)
Email: (b) (6)

From: David Liu (b) (6)
Sent: Thursday, April 23, 2020 6:01 PM
To: Collins, Francis (NIH/OD) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6)>; Austin, Christopher (NIH/NCATS) [E] (b) (6)>; Wholley, David (FNIH) [T] (b) (6)>; Freire, Maria (FNIH) [T] (b) (6); Tabak, Lawrence (NIH/OD) [E] (b) (6)>
Cc: Michael Rosbash (b) (6)>; Ramnik Xavier (b) (6)>; EDWARD SCOLNICK (b) (6); Stuart Schreiber (b) (6)>; Michael Z Lin (b) (6)>; Ben Cravatt (b) (6)>; Thomas Cahill (b) (6)
R. Scott Kemp (b) (6)
Subject: Re: A proposal to stop COVID-19 and reopen our schools and businesses

Dear Francis, Anthony, Cliff, Christopher, David, Maria, and Lawrence,

I hope you are all well. Attached is the updated set of four proposals on:

- 1) Rapid repurposing of antiviral drugs to treat COVID-19;
- 2) Expedited development of neutralizing monoclonal antibodies to treat COVID-19;
- 3) Rapid COVID-19 vaccine development;
- 4) Risk-reduced ways to reopen schools and businesses, and the healthcare system changes that are needed to enable them.

We hope you find these updated proposals useful, and would be happy to engage in any way that could be helpful.

Sincerely yours,

Ben Cravatt (Scripps), Lynn Goldman (GWU), Akiko Iwasaki (Yale), Scott Kemp (MIT), Michael Lin (Stanford), David Liu (Harvard/Broad), Michael Rosbash (Brandeis), Stuart Schreiber (Harvard/Broad), Ed Scolnick (Broad), Jonathan Simons (PCF), and Ramnik Xavier (MGH/Broad)

David R. Liu
Richard Merkin Professor and Director of the Merkin Institute
of Transformative Technologies in Healthcare
Director of the Chemical Biology and Therapeutic Sciences Program
Core Institute Member and Vice-Chair of the Faculty, Broad Institute
Investigator, Howard Hughes Medical Institute
Thomas Dudley Cabot Professor of the Natural Sciences
and Professor of Chemistry & Chemical Biology, Harvard University
75 Ames Street
Cambridge, MA 02142

On Apr 19, 2020, at 8:48 PM, Collins, Francis (NIH/OD) [E] (b) (6) wrote:

Dear David et al.,

Thanks for forwarding this very thoughtful document, which presents a series of important recommendations – most of which I agree with. I don't know if you saw Friday's announcement (attached) of the new public private partnership called ACTIV (for Accelerating COVID-19 Therapeutic Interventions and Vaccines), but it has taken on most of the points you raise in sections 1 – 3 of your letter. I share your hopes that remdesivir will show benefit, and the current large NIH-sponsored RCT has completed enrollment and should reveal results in about a month. But of course we want to test multiple other interventions – both small molecules and antibody-based therapies, so we need our trial system to be optimized like never before. I will share your letter with the leaders of ACTIV, who are working with unprecedented speed to prioritize the next set of therapeutic candidates as well as pushing vaccine development programs to adopt exceptionally creative trial designs to test safety and efficacy (with full engagement by FDA).

Best regards, Francis

From: David Liu (b) (6)
Sent: Sunday, April 19, 2020 5:20 PM
To: OD Labc (NIH/OD) (b) (6); Collins, Francis (NIH/OD) [E] (b) (6)
Cc: Michael Rosbash (b) (6); Ramnik Xavier (b) (6); EDWARD SCOLNICK (b) (6); Stuart Schreiber <(b) (6)>; Michael Z Lin (b) (6); Ben Cravatt (b) (6)
Subject: A proposal to stop COVID-19 and reopen our schools and businesses

Dear Francis,

I hope you are well.

I write on behalf of a group of citizen-scientists, most or all of whom you know. Motivated solely by our desire to help defeat the serious threat our nation and the world now faces, we wrote a set of four actionable, non-partisan proposals (attached) to produce safe and effective COVID-19 therapeutics and vaccines in the shortest possible timeframe, and to reopen our society in a manner that reduces the risk of future COVID-19 outbreaks.

We hope you find these ideas interesting, and might be willing to share this set of proposals with Dr. Tony Fauci, along with our willingness to discuss any part of the proposals with him if we can be helpful. We understand from our efforts to contact Dr. Fauci through email routes that his standard inbox may be too overwhelmed for our proposal to reach him.

The four proposals attached describe: (1) How to rapidly repurpose an antiviral drug to treat COVID-19 patients; (2) How to expedite the development of human antibody drugs to treat patients and to provide short-term protection for healthy individuals; (3) How to develop COVID-19 vaccines on an expedited time scale; and (4) How to reopen our businesses and schools in a manner that reduces the risk of future outbreaks and deaths.

Thank you for any help or thoughts you might be able to provide.

Sincerely yours,

Ben Cravatt (Scripps), Lynn Goldman (GWU), Akiko Iwasaki (Yale), Scott Kemp (MIT), Michael Lin (Stanford), David Liu (Harvard/Broad), Michael Rosbash (Brandeis), Stuart Schreiber (Harvard/Broad), Ed Scolnick (Broad), Jonathan Simons (PCF), and Ramnik Xavier (MGH/Broad)

David R. Liu
Richard Merkin Professor and Director of the Merkin Institute
of Transformative Technologies in Healthcare
Director of the Chemical Biology and Therapeutic Sciences Program
Core Institute Member and Vice-Chair of the Faculty, Broad Institute
Investigator, Howard Hughes Medical Institute
Thomas Dudley Cabot Professor of the Natural Sciences
and Professor of Chemistry & Chemical Biology, Harvard University
75 Ames Street
Cambridge, MA 02142

<NIH_ACTIV_Release_041720.docx>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 21:47:13 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: White House Coronavirus Task Force Meeting - 4.24.20

FYI

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

(b)(5) - PCP


From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 21:40:33 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Update: White House Coronavirus Task Force Meeting

Heads-up! Change in schedule for tomorrow.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

(b)(5) - PCP



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 21:29:50 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: MSNBC: See Dr. Fauci's Stunning Pandemic Warning – Long Before Trump Minimized Coronavirus | MSNBC <https://bit.ly/2yynEPf>

<https://bit.ly/2yynEPf>

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Barasch, Kimberly (NIH/NIAID) [C] (b) (6)
Sent: Thursday, April 23, 2020 9:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: FW: MSNBC: See Dr. Fauci's Stunning Pandemic Warning – Long Before Trump Minimized Coronavirus | MSNBC <https://bit.ly/2yynEPf>

Kim Barasch [C]
Office of the Director
National Institute of Allergy & Infectious Diseases
(b) (6)
(b) (6)

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, April 21, 2020 11:06 PM
Subject: MSNBC: See Dr. Fauci's Stunning Pandemic Warning – Long Before Trump Minimized Coronavirus | MSNBC <https://bit.ly/2yynEPf>



Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: (b) (6)
Sent: Thu, 23 Apr 2020 14:34:36 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Thank you, and...
Attachments: image002.png, ATT00001.htm, PasstheMic Expert Outreach.pdf, ATT00002.htm

Let us discuss

Begin forwarded message:

From: Gayle Smith <gayle.smith@one.org>
Date: April 23, 2020 at 1:49:04 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Cc: Tom Hart <tom.hart@one.org>
Subject: Thank you, and...

Dear Tony,

I have always felt reassured when the good Dr. Fauci speaks, and now more than ever. As an American, a former colleague, a long-time admirer and student of your wisdom – thank you. We are all safer because of you, and the world will be a better place because of you. Again.

As you know, I am now leading the ONE Campaign. We've been quite active with the ONEWorld Campaign, dedicated to the fight against this newest virus, and focused on Africa. We've made some progress on debt, and next up is a focus on ensuring that a vaccine, when it comes, is available to everyone.

One of the things we want to do is educate people, in all of the places we work. It won't surprise you that of particular urgency amongst our partners in Africa is that facts and information get to people across the continent, but we also know that more facts are needed everywhere. So next month we are going to launch #PassTheMic, where every day for 19 days we will ask a celebrity to turn his or her social media channels over to an expert on COVID-19 for one day. So Julia Roberts might turn her Twitter account to you to talk about the critical elements needed to flatten the curve and slow the spread. Or Idris Elba could give up his Instagram to the head of the African CDC so that he can illustrate the impact COVID-19 will have across Africa and what that means for the rest of the world.

We know artists want to be helpful right now, but that it is hard to know what to do. And we know there are experts like you out there who have the answers. We've thought about this a lot at ONE and wanted to do something we felt would truly have an impact. As we look ahead we know COVID-19 does not know borders and until it is beaten everywhere

we are not in the clear. We need a global response plan and we need it now. By turning over their platforms for the day, celebrity influencers will be donating one of their biggest assets – their followers – to YOU, giving you the platform you need (and we all need) to tell the world why a global response is critical. Because none of us are safe until all of us are safe.

We will work with each expert/celebrity pair to personalize the content to our and our celebrity partners' audiences – in North America, Europe and Africa, and help create content that both parties are happy with. We are now confirming our talent partners, and so far are getting a terrific response.

We know you're a busy man, so we've planned it so that the amount of time on your end would be minimal. But the impact would be maximal.

I'm attaching more information about the campaign. Please let me know what you think and if you have questions. Ideally we would like to get this off the ground in early May, so are hoping to confirm folks by April 28th at the latest. Our team will be in touch with your office to follow up.

Thanks as always for everything you do. All my best to you, Gayle



Gayle Smith | President & Chief Executive Officer | (b) (6)

[ONE.ORG](#) | [Twitter](#) | [Facebook](#) | [Instagram](#)

ONE is a global movement campaigning to **end extreme poverty and preventable disease by 2030** so that everyone, everywhere can lead a life of dignity and opportunity.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 18:25:56 +0000
To: Simmons-Butler, Kirk (NIH/NIAID) [C]
Subject: Re: Thank you Dr. Fauci!
Attachments: image001.png, image002.gif

Kirk:

Thank you for your kind note. Much appreciated.
Best regards,
Tony

On Apr 23, 2020, at 2:16 PM, Simmons-Butler, Kirk (NIH/NIAID) [C]
(b) (6) wrote:

Greetings Dr. Fauci,

I just wanted to take a moment to personally thank you for all of your support and leadership during these unprecedented times. I am proud to be a part of the NIAD family and you represent us and the country well! God continue to bless and keep you and your family! Thank you again sir!

Regards,
Kirk

Kirk D. Simmons-Butler, M.S.
Assistant Facility Manager 14DNR, Charles River Laboratories Inc.
NIH/NIAID
(Office) (b) (6)
(Fax) (301) 761-6013
Charles River website - www.criver.com

<image001.png>

<image002.gif>

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it

from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Disease (NIAID) shall not accept liability for any statement made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Sent: Friday, March 27, 2020 11:55 AM
To: NIAID Announcements <NIAID-announce@niaid.nih.gov>
Subject: Platelet Donations Down are Down Amid Coronavirus Outbreak – Please Donate

Dear Colleagues:

The NIH Platelet Donor Center has an urgent need for healthy individuals to give lifesaving platelets to patients. The need for platelet donations is especially acute now with the coronavirus pandemic. While social distancing and increased telework are necessary to contain and slow the spread of coronavirus, we have seen a marked decline in platelet and blood donations for our patients.

To alleviate this shortage, NIAID and the Department of Transfusion Medicine (DTM) are co-sponsoring a two-week Platelet Drive from March 30 – April 10. Platelet collections, as well as whole blood and Double Red Cell donations, can only be made at the NIH Blood Bank on campus in Building 10, Room 1C713 Monday through Friday from 8:00 am to 5:00 pm. The Platelet Center at Fishers Lane is temporarily closed and platelet collections are now on the main campus through at least the next 30 days. This move helps to ensure that blood donors are protected by visitor screening, minimizing possible exposure to individuals at risk.

What is a double red cell donation? A double red cell donation enables donors to donate two units of red blood cells in one visit. During a procedure called apheresis, whole blood is separated through a cell separator and red blood cells are collected. The remainder of the blood components are returned to the donor along with saline to replace the lost volume.

I encourage participation of all employees who are eligible to provide a donation to benefit our NIH patients. I understand employees may be hesitant to participate under the current conditions, but I would like to reassure you that blood donation is a safe process.

Additional precautions have been put in place at our Blood Bank to help prevent the spread of infection and protect the health of donors and staff.

Thank you to all who support our quarterly platelet drives. Your efforts provide a lifeline for our patients. Those who participated in the last drive are now eligible to help once again. In appreciation of your dedication to helping others, NIAID grants administrative leave to any NIAID federal employee who donates platelets at the NIH Blood Bank. Specifically, you will be granted 4 hours of administrative leave to be used immediately following your platelet donation appointment. As always with such activities, please notify your supervisor for approval prior to donating at the NIH Platelet Center.. Contractor employees should speak directly to their contract companies to determine what leave

options are available. Please contact the Donor Center at [301-496-4321](tel:301-496-4321) to schedule your appointment. Let the Donor Center staff know you are with the NIAID Platelet/Double Red Cell Drive. They will answer eligibility questions and provide information about the donation process.

Thank you for considering donating during this stressful time. Best regards.

Sincerely,
A.S. Fauci

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.





From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 17:39:48 +0000
To: Auchincloss, Hugh (NIH/NIAID) [C] (b) (6)
Subject: FW: Wellness Initiative Proposal
Attachments: Wellness Initiative_POC_Sundar.zip, Wellness Initiative Proposal_Sundar.pdf, Managing Anxiety Around COVID-19 March 27 (007).pdf

Please take a look at this and handle.

From: Sundar, Sachin (NIH/NIAAA) [F] (b) (6) >
Sent: Thursday, April 23, 2020 1:05 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Wellness Initiative Proposal

Dear Dr. Fauci,

I have an idea regarding science communication and wellness. Here's a rough proposal and proof of concept. At full effect, I think it could have noteworthy potential. (b) (5)

(b) (5)
(b) (5)
(b) (5)

Thank you for your time.

Respectfully,
Sachin Sundar

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 13:25:22 +0000
To: Stephen L. Hoffman
Subject: RE: Follow Up Thanks

Thanks, Steve. I appreciate your note.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stephen L. Hoffman <slhoffman@sanaria.com>
Sent: Wednesday, April 22, 2020 9:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Follow Up Thanks

Dear Tony,

I hear continuously from people from all walks of life how grateful they are for your presence on the COVID-19 team. You are performing an incredible service to our country and the world.

Thanks again,

Steve

Stephen L. Hoffman, M.D.
Chief Executive and Scientific Officer
Sanaria Inc.
9800 Medical Center Dr. ste 209a
Rockville MD 20850
tel: (b) (6) (work)

tel: (b) (6) (mobile)

fax: 301-770-5554

E-Mail: slhoffman@sanaria.com

www.sanaria.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 13:00:55 +0000
To: Redfield, Robert R. (CDC/OD)
Cc: Allison Arwady;David Barr;Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Dr. Fauci asked me to send Chicago question
Attachments: Workforce_Proposal_Chicago_April2020.pdf

Bob:

Please take a look at this. This question evolved from a teleconference that I had 2 nights ago with people "in the trenches" including Alison Arwady (Chicago). The question is what will be the relationship between the public health workforces at the federal and local levels. Youi had spoken of the CDC people that will be assigned locally and that will help build up a local workforce. How will CDD interact and relate to the locals. Is there any possibility of Federal funding of their proposal (see attachment). If not, do you have any suggestions for them? I can discuss this with you today at the Task Force meeting. Thanks.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Sent: Wednesday, April 22, 2020 3:53 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: Dr. Fauci asked me to send Chicago question

Pls advise.

From: Allison Arwady <(b) (6)>
Sent: Wednesday, April 22, 2020 3:42 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: Dr. Fauci asked me to send Chicago question

Dear Patty,

Last night on his call with public health leaders from cities across the country, Dr. Fauci asked me to send him/you my follow-up question from Chicago:

How will the necessary public health workforce expansion (e.g. for wide-scale case investigation, contact tracing, linkage to care, community testing, and vaccination) be supported at the federal level?

Our understanding is that state or local jurisdictions will be able to develop their own workforces rather than supporting a single workforce at the federal level, and we agree with this approach, but it would be very helpful to understand next steps and potential timelines, particularly as the reopening drumbeat gets louder.

For example, Chicago has developed a local plan/proposal (attached) that would meet our local needs, help address some of our underlying race and economic equity concerns, and build on our existing community and clinical partnerships. We have shared it with some partners, but it is not at all clear how/whether/when/how much funding might be available. Given the need to quickly expand our workforce and plan ahead, it would be very helpful to get a sense of:

- a. How much funding/support might be available, and how that will be determined
- b. Whether funding might come through HHS/CDC (our preferred mechanism), FEMA, or another mechanism
- c. Will support be available in weeks or months...and for how long—we are strongly advocating for 5 years, similar to what was done for Ebola
- d. Any other information about how our local or state plans need to be adapted to fit into federal thinking on this approach

Thank you so much; I deeply appreciate Dr. Fauci taking the time to meet with us directly and hear our concerns.

Allison

Allison Arwady, MD, MPH
Commissioner
Chicago Department of Public Health
(b) (6)



From: David Barr (b) (6)
Sent: Wednesday, April 22, 2020 8:47 AM
To: Allison Arwady (b) (6); Percak, Jeffrey M (b) (6); Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Demetre Daskalakis (b) (6)>; Mushatt, David M (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] <(b) (6)>; Iyengar, Preetha (DOH) (b) (6)
Duchin, Jeff (b) (6)
Subject: Notes from call with Dr. Fauci

Hello - Thanks for all for a very informative and sobering discussion last night. I've provided bullets below to capture the main points. Please add or change as needed. I've kept this relatively short but can supply a full recording of the call if you want it.

We will have another call next Tuesday.

David

PPE supplies:

- while hospitals are in better shape than a few weeks ago, significant shortages remain at long-term care facilities, skilled nursing facilities, outpatient settings like doctors' offices and urgent care clinics, shelters, prisons. Gowns are the biggest problem, but gloves, masks and shields are also short. Doctors offices are closing for lack of PPE.
- each city is trying to solve these shortages in a short-term, piecemeal way. They need a longer-term solution to stabilize availability. Outpatient settings are looking to health departments to provide supplies, something HDs are not set up to do.
- testing in most places still requires PPE use (e.g. no availability of anterior nasal swabs) and the PPE shortages are severely limiting testing scale up.
- even at hospitals, supply limitations make re-opening elective surgeries and other procedures impossible at this stage.
- If considering re-opening businesses, this will drastically increase PPE needs to a whole new sector.

TESTING challenges:

- Each city reported that, despite improvements, a very limited number of tests are being performed compared to need.
- Supply shortages are the biggest challenge: swabs, PPE, sample kits, reagents are the biggest obstacles. Not clear where this is going to come from or who is responsible for addressing problems.
- Private labs limit number of sample kits distributed each week. In places where public labs are available, there is a push to get providers to use the public labs. But many places don't have public labs.
- There is no clear guidance on how to prioritize who gets tested first. So, in some places, that means that people at lower-risk are being testing but people at greater risk (due to symptoms,

exposure, high-risk living/work environment, etc) are not being testing. Guidelines are needed to help prioritize where testing resources are used first.

- Public testing produces skewed results. Testing becomes available only to those who can make an appointment and who can drive to the site. This means many lower-priority people get tested but high-priority people do not. This skews understanding of positivity rates.

- Some labs are underutilized - but the reason is that there are breakdowns in the supply chain that make it difficult to test people and get tests to the labs. (e.g.) (b) (4)

- Reimbursement is an obstacle. CMS offering to cover test costs (\$100 per test) would help get labs to do more testing. It would not solve the problem, but it would help.

- Proliferation of unvalidated antibody tests is causing confusion. High rates of false results, misinterpretation of what results mean (e.g. telling people who test antibody positive that they must quarantine for two weeks). Chicago spends a lot of time shutting down these testing sites as they make things harder and use up supplies.

- there is increasing pressure to reach a target number of tests performed each day in order to get to 're-opening'. But the number needed is contextual based on the environment, population - there isn't one 'right' number for everywhere.

- Need better public messaging on difference between virology and serologic tests.

- Current testing capacity is nowhere near what is needed to make informed decisions about re-opening.

TESTING: reporting challenges

- Current PoC tests have no link to provide results to health departments. Many outpatient facilities and SNFs have no system for reporting test results to HDs. Need electronic link for reporting PoC test results.

- While aggregate positive tests may be reported, negative results are not.

- Impossible to really understand population levels of infection because (1) number of tests performed is too low and (2) not testing the 'right' people

- Every one is pushing for rapid scale up of antibody tests, but we still don't know what the results of these tests mean and how to apply them to policy development.

- CDC and NIH will each coordinate sero-surveys. No details on CDC approach yet. NIH study is up. Still not clear how to use the results of these studies, but useful to collect data now and apply it as knowledge grows. Locally-coordinate sero-surveys can be helpful but only if tests are highly validated.

The Future:

- How many tests should we be doing? How much PPE/testings/beds/staff will be needed in the coming year? Next winter, we will face dual flu and COVID outbreaks, without stable testing capacity, how will we differentiate between the two?

- What are the plans for contact tracing? Who will recruit and train? Is there a federal plan or guidelines for this? How will it be paid for? What do we do to effectively isolate those infected?

This e-mail, and any attachments thereto, is intended only for use by the addressee(s) named herein and may contain legally privileged and/or confidential information. If you are not the intended recipient of this e-mail (or the person responsible for delivering this document to the intended recipient), you are hereby notified that any dissemination, distribution, printing or copying of this e-mail, and any attachment thereto, is strictly prohibited. If you have received this e-mail in error, please respond to the individual sending the message, and permanently delete the original and any copy of any e-mail and printout thereof.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 12:53:24 +0000
To: Stover, Kathy (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: FOR ASF REVIEW: Draft PR re: launch of hydroxychloroquine/azithromycin study

Looks fine.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stover, Kathy (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, April 22, 2020 3:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Subject: FOR ASF REVIEW: Draft PR re: launch of hydroxychloroquine/azithromycin study

Hi Dr. Fauci,

Please find attached for your review a draft press release describing the launch of the ACTG hydroxychloroquine/azithromycin study for COVID-19. NIAID will issue the release after the first participant(s) has enrolled, which is currently anticipated around May 1.

The following is the quote we have drafted for you:

"We urgently need a safe and effective treatment for COVID-19. Repurposing existing drugs is an attractive option because these medications have undergone extensive testing, allowing them to move quickly into clinical trials and accelerating their potential approval for COVID-19 treatment," said NIAID Director Anthony S. Fauci, M.D. "Although there is anecdotal evidence

that hydroxychloroquine and azithromycin may benefit people with COVID-19, we need solid data from a large randomized, controlled clinical trial to determine whether this experimental treatment is safe and can improve clinical outcomes.”

Thanks much,
Kathy

Kathy Stover
Branch Chief
News and Science Writing Branch
National Institute of Allergy and Infectious Diseases (NIAID)
Office of Communications and Government Relations
National Institutes of Health/HHS
31 Center Drive, Room 7A17E
Bethesda, MD 20892
Phone: (b) (6)
E-mail: (b) (6)
NIAID Media Line: (301) 402-1663

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 11:54:41 +0000
To: Corey MD, Larry (b) (6); Mascola, John (NIH/VRC) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]
Subject: NEJM manuscript
Attachments: COVID vaccine editorial_prefinal April21_7pm fsc - with minor Fauci edits.docx

Larry/John:

I have gone over the changes that Francis has inserted and I have edited some of them. Please accept his changes and my edits of them (or any additional edits that you have) and then it is OK to send in. Please let me know if you have any questions.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 11:13:29 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: seeking your advice on a COVID-19 question

Email from Pardis Sabeti.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email: (b) (6)

From: Pardis Sabeti (b) (6)
Sent: Wednesday, April 22, 2020 9:47 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Collins, Francis (NIH/OD) [E] (b) (6)
Subject: Re: seeking your advice on a COVID-19 question

Awe, thank you, here for you two any time, and grateful for the enormous positive impact you have on the world, Pardis

On Wed, Apr 22, 2020 at 9:43 PM Fauci, Anthony (NIH/NIAID) [E] <(b) (6)> wrote:

Thanks, Pardis. It was great to spend time with you and your colleagues. We learned a lot.
Warm regards,
Tony

From: Collins, Francis (NIH/OD) [E] (b) (6) >
Sent: Wednesday, April 22, 2020 8:44 PM
To: Pardis Sabeti <(b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: RE: seeking your advice on a COVID-19 question

Hey there Pardis,

You are much too kind – but we are grateful for YOU and your team!

It was fun to talk science for a little while. 😊

Best, Francis

From: Pardis Sabeti [REDACTED] (b) (6)>
Sent: Wednesday, April 22, 2020 8:38 PM
To: Collins, Francis (NIH/OD) [E] [REDACTED] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: Re: seeking your advice on a COVID-19 question

Dear Francis and Tony,

Thank you for a great conversation. Jacob, Bronwyn, and I stayed on a moment after you left and talked about how inspired we are by each of you and by the camaraderie between you two. Jacob added those two are national treasures, and Bronwyn and I wholeheartedly agreed.

Grateful for you both,

Pardis

On Wed, Apr 22, 2020 at 8:21 AM Collins, Francis (NIH/OD) [E] [REDACTED] (b) (6)> wrote:

Hi Pardis,

See attached paper that argues there may be a significant difference in virulence of the COVID-19 clade that predominates on the west coast compared to the east coast. Tony Fauci and I would like to know [REDACTED] (b) (5)

Also attached is a MedRxiv preprint that describes major differences in pathogenicity of different viral strains. I just got this [REDACTED] (b) (5)

Can I talk with you later today after you have a chance to review this?

Thanks, Francis

--

Pardis Sabeti, MD, DPhil
Professor, Harvard University & Harvard T.H. Chan School of Public Health
Broad Institute of MIT and Harvard
Howard Hughes Medical Institute

Assistant: [REDACTED] (b) (6)
Phone: [REDACTED] (b) (6)
Website: www.sabetilab.org

--
Pardis Sabeti, MD, DPhil

Professor, Harvard University & Harvard T.H. Chan School of Public Health

Broad Institute of MIT and Harvard

Howard Hughes Medical Institute

Assistant [REDACTED] (b) (6)>

Phone: [REDACTED] (b) (6)

Website: www.sabetilab.org

From: (b) (6)
Sent: Thu, 23 Apr 2020 07:09:44 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: invitation to New Zealand conversation

Sent from my iPhone

Begin forwarded message:

From: Pat Brittenden <info@blindfish.media>
Date: April 23, 2020 at 12:02:13 AM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Subject: invitation to New Zealand conversation

Good afternoon Dr Fauci,

We are interested in seeing if you would be available for a chat via Zoom to New Zealand about COVID-19

The US is an essential part of the NZ economy contributing between \$1.5 and \$2 billion dollars annually from tourism alone and we would love to have a conversation about where the US is at, how COVID-19 is being dealt with, and the future of things that could lead up to opening our borders again.

We're happy to have you for any length of time, but if you have 10-20 minutes that would be amazing.

Thank you for what you are doing in this global event, I hope we can connect sometime soon

Sincerely,

--

Pat Brittenden
www.theDOC.nz
www.patbrittenden.com/about
(b) (6)

From: (b) (6)
Sent: Thu, 23 Apr 2020 07:08:26 -0400
To: Barasch, Kimberly (NIH/NIAID) [C]
Subject: Fwd: Global Health Leaders Call, Thursday, 23 April, 14:30 CET

Sent from my iPhone

Begin forwarded message:

From: "KABIR, Sophia" (b) (6) >
Date: April 23, 2020 at 6:54:46 AM EDT
To: SHOC <shoc@who.int>, Office of the Director-General <DGO@who.int>, "Redfield, Robert R. (CDC/OD)" (b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6)
David Heymann
(b) (6), "Felicity Harvey"
(b) (6), "Chris.Elias"
(b) (6),
(b) (6)
"Fauci, Anthony (NIH/NIAID) [E]"
(b) (6)
(b) (6)
"GREIN, Thomas"
(b) (6),
(b) (6), "COX, Paul Michael"
(b) (6), "MINHAS, Raman"
(b) (6)
"Conrad, Patricia (NIH/NIAID) [E]"
(b) (6) >, "MAHJOUR, Jaouad"
(b) (6), "FALL, Ibrahima Soce"
(b) (6), "Thomas R. Frieden"
(b) (6)
Lynn Banks
(b) (6), President | Resolve to Save Lives
(b) (6), "Amadou.SALL"
(b) (6) "AL-SHORBAJI, Farah"
(b) (6)
Robynn Leidig
(b) (6),
"DRURY, Patrick Anthony"
(b) (6) >, "Dr VAN KERKHOVE, Maria"
(b) (6)
(b) (6)
"GRAAFF, Peter Jan"

(b) (6)>, "POOLE, Marcia" < (b) (6), Tarik Mohammed
(b) (6) Carlos
Navarro Colorado (b) (6)
, Ryan Morhard (b) (6)>,
"BRIAND, Sylvie" (b) (6), "MORGAN, Oliver" (b) (6)
"Harries, Jenny" (b) (6)>, "Awwad, David (NIH/NIAD)
[C]" (b) (6)>, "SIMONSON, Stewart" (b) (6)
"SINGER, Peter Alexander" < (b) (6), "Jayatunga, Wikum"
(b) (6)
"Julie.HALL" (b) (6) Amelie
RIOUX (b) (6)
, "SHIN, Young-Soo" (b) (6)
(b) (6), Feng Ding
(b) (6)
"SMITH, Ian Michael" (b) (6), "AYLWARD,
Raymond Bruce J." (b) (6)

Cc: SHOC <shoc@who.int>, Office of the Director-General <DGOOffice@who.int>,
"SCHWARTLANDER, Bernhard F." < (b) (6) "MAHJOUR,
Jaouad" (b) (6), "FALL, Ibrahima Soce" (b) (6), "GREIN,
Thomas" (b) (6)>, "MINHAS, Raman" (b) (6), "COX, Paul
Michael" (b) (6)>, "AL-SHORBAJI, Farah" (b) (6)>,
"POOLE, Marcia" (b) (6)>, "DRURY, Patrick Anthony"
(b) (6)>, "GRAAFF, Peter Jan" (b) (6)>, "Dr VAN
KERKHOVE, Maria" (b) (6), "FARES, Christine Youssef"
(b) (6)>

Subject: RE: Global Health Leaders Call, Thursday, 23 April, 14:30 CET

Dear colleagues,

Apologies for the mistake in the below subject line.

The meeting starts at **14.30 CET**, as mentioned in the email.

Kind regards,

Sophia

From: KABIR, Sophia

Sent: Thursday, April 23, 2020 10:51 AM

To: SHOC <shoc@who.int>; Office of the Director-General <DGOOffice@who.int>;

(b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6); Felicity Harvey (b) (6)
(b) (6); Chris Elias (b) (6)
(b) (6) Jeremy Farrar
(b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6); GREIN, Thomas (b) (6); COX, Paul Michael
(b) (6); SCHWARTLANDER, Bernhard F. (b) (6); MINHAS,
Raman (b) (6)
(b) (6); MAHJOUR, Jaouad (b) (6); FALL, Ibrahima Soce
(b) (6); 'Thomas R. Frieden' (b) (6); 'Elhadj SY'
(b) (6); 'Lynn Banks' (b) (6); 'President |
Resolve to Save Lives' (b) (6)
(b) (6) AL-
SHORBAJI, Farah (b) (6)
(b) (6); 'Robynn Leidig' (b) (6); DRURY,
Patrick Anthony (b) (6) Dr VAN KERKHOVE, Maria (b) (6)
(b) (6)
(b) (6)
(b) (6); 'Cheryl Cohen' (b) (6); GRAAFF, Peter
Jan (b) (6); POOLE, Marcia (b) (6) 'Tarik Mohammed'
(b) (6)
(b) (6)
(b) (6); 'Ryan Morhard' < (b) (6); BRIAND,
Sylvie (b) (6); MORGAN, Oliver (b) (6); 'Harries, Jenny'
(b) (6); 'Awwad, David (NIH/NIAID) [C]' (b) (6);
SIMONSON, Stewart (b) (6); SINGER, Peter Alexander (b) (6);
'Jayatunga, Wikum' (b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6); SHIN, Young-Soo (b) (6)
(b) (6) 'Feng Ding'
(b) (6)
(b) (6)
(b) (6)

(b) (6) SMITH, Ian Michael (b) (6);
AYLWARD, Raymond Bruce J. (b) (6)

Cc: SHOC <shoc@who.int>; Office of the Director-General <DGO@who.int>;
SCHWARTLANDER, Bernhard F. (b) (6); MAHJOUR, Jaouad
(b) (6); FALL, Ibrahima Soce (b) (6); GREIN, Thomas
(b) (6); MINHAS, Raman (b) (6); COX, Paul Michael
(b) (6); AL-SHORBAJ, Farah (b) (6); POOLE, Marcia
(b) (6); DRURY, Patrick Anthony (b) (6); GRAAFF, Peter Jan
(b) (6); Dr VAN KERKHOVE, Maria <(b) (6)>; FARES,
Christine Youssef (b) (6)

Subject: Global Health Leaders Call, Thursday, 23 April, 14:00 CET

Dear colleagues,

Ahead of the Global Health Leaders Call at 14.30 CET today, please find an epidemiological update and analysis attached, in addition to the "Considerations in adjusting public health and social measures in the context of COVID-19" interim guidance document, which was published on the WHO website on 16 April.

Please find below, the key questions for your consideration and input.

1. What is your view on the latest epidemiology, virus transmission and severity in affected countries ?
2. What are the emerging issues/challenges that you see as important ?
3. What should be the priorities for the 1-2 weeks?
4. Any other issues you see as important?

You will be able to connect via the Webex connection below. If you experience any technical difficulties, please contact the WHO HQ EOC operator at: +41 22 79 15 533 or via email: shoc@who.int.

Best,

Sophia

Meeting number (access code): (b) (6), (b) (4)

Meeting password (b) (6), (b) (4)

Thursday, April 23, 2020

2:00 pm | (UTC+02:00) Brussels, Copenhagen, Madrid, Paris |

Join meeting

Join by phone

Tap to call in from a mobile device (attendees only)

(b) (6) TZERLAND Toll

JS Toll

Global call-in numbers

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 02:16:12 +0000
To: Alice Park
Subject: FW: Time follow up
Attachments: MedRxiv_Mutations impact pathogenicity SARS-CoV-2_ Lanjuan Li et al.
2020.04.14..pdf

Alice:
Here is another manuscript.
Tony

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 02:11:27 +0000
To: Lou Ignarro
Subject: RE: Greetings- NOT urgent

Lou:

Thank you for your kind note. It is much appreciated. I hope that you are well.
Best regards,
Tony

From: Lou Ignarro (b) (6)
Sent: Tuesday, April 21, 2020 5:38 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Greetings- NOT urgent

Hi Tony,

This is Lou Ignarro from UCLA. You and I shared the stage in the "Shoe" at the Ohio State University a few years ago, where you gave the Graduation Address to the undergraduate seniors. I was on stage with you, to receive an award for my basic biomedical research which resulted in my being awarded the Nobel Prize in Medicine in 1998. I recall the nice conversations we were enjoying with Sanjay Gupta while robing for the event.

Thanks for the truly spectacular job you are doing, regarding the coronavirus pandemic. We Nobel Laureates especially regard your work as the most important during our lifetime. Thank you and God bless.

My best wishes,

Lou Ignarro

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 01:50:03 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: letter from the Governor of Puerto Rico
Attachments: Dr. Anthony S. Fauci, MD[2].pdf

Heads up for a call from the Puerto Rican Health Minister.

From: Pablo L. Peña Antonmarchi <ppena@fortaleza.pr.gov>
Sent: Wednesday, April 22, 2020 5:24 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Barasch, Kimberly (NIH/NIAID) [C] (b) (6) >; Jennifer M. Storipan <jstoripan@prfaa.pr.gov>; Juan L. Negrón <jnegron@prfaa.pr.gov>; Maria del C Reyes Crespo <mreyes@fortaleza.pr.gov>; Antonio L. Pabon Batlle <apabon@fortaleza.pr.gov>
Subject: letter from the Governor of Puerto Rico
Importance: High

Dear Dr. Anthony Fauci:

I am sending you for your attention a letter from the Governor of Puerto Rico Hon. Wanda Vázquez Garced.

Cordially,

Pablo L. Peña Antonmarchi
Executive Assistant
Lcdo. Antonio Pabón Batlle
Chief of Staff Office
La Fortaleza
San Juan, Puerto Rico



NOTA DE CONFIDENCIALIDAD: Esta transmisión electrónica contiene información perteneciente a la Oficina del Gobernador, que es confidencial, privilegiada y/o privada bajo las leyes aplicables. Solamente podrá ser utilizada por la persona o entidad a la cual se dirige. Si usted no es el destinatario intencional, se le notifica que se prohíbe cualquier uso, disseminación o copia de esta comunicación. Si usted recibe esta comunicación por error, favor de notificar al remitente y eliminar este correo electrónico de su sistema.

CONFIDENTIALITY NOTE: This electronic transmission contains information belonging to the Governor's Office, which is confidential, privileged and exempt from disclosure under the applicable law. It is intended solely for the use of the individual or entity to which it is addressed. If you are not the intended recipient, you are hereby notified that any use, dissemination, or copying of the communication is strictly prohibited. If you have received this communication by error, please notify the sender and delete this e-mail from your system.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 01:40:52 +0000
To: Alice Park; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Time follow up
Attachments: Viral Clades Brufsky 42020 Accepted Final.pdf

Alice:

It was great working with you today. Here is the reference. I believe that it will be in the Journal of Medical Virology. It has been accepted, but is not yet in print.

Best regards,

Tony

From: Alice Park <alice.park@time.com>
Sent: Wednesday, April 22, 2020 6:30 PM
To: Fauci, Anthony (NIH/NIAID) [E] <AFAUCI@niaid.nih.gov>; Conrad, Patricia (NIH/NIAID) [E] <conradpa@niaid.nih.gov>
Subject: Time follow up

Dear Dr. Fauci -- many thanks for your time today; we are thrilled to have you as part of the TIME 100 Talks, which will go live tomorrow.

In the meantime, I wanted to double check the reference to the study you mentioned about the east and west coast strains and their potential difference in virulence. Realize it's preliminary, so just wanted to confirm any references we make to it. I checked the biorxiv and medrxiv but didn't find the citation. Would appreciate the journal if it was published. Many thanks! Alice

PLEASE NOTE NEW PHONE NUMBER

Alice Park
TIME

(b) (6)
alice.park@time.com
@aliceparkny

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Apr 2020 16:29:19 +0000
To: Collins, Francis (NIH/OD) [E] (b) (6)
Cc: Corey MD, Larry (b) (6); Mascola, John (NIH/VRC) [E]
Subject: FW: "final draft"
Attachments: COVID vaccine editorial_prefinal April21_7pm.docx

Francis:

Here is the paper that I mentioned to you and that we are planning to submit to the *NEJM*. I have put your name on it as the senior author. If you are comfortable with that, we will go with it. Please take a look at the manuscript and make any comments or edits that you see fit.

Thanks,

Tony

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Apr 2020 14:41:09 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Greg Folkers (b) (6); Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Request for Dr. Fauci + Ryan Zimmerman Pros For Heroes | COVID-19 Relief Fund

I was thinking the very same thing.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, April 21, 2020 8:43 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Subject: RE: Request for Dr. Fauci + Ryan Zimmerman Pros For Heroes | COVID-19 Relief Fund

Ps – what do you want to bet you get invited to throw a first pitch next year?

From: Billet, Courtney (NIH/NIAID) [E]
Sent: Tuesday, April 21, 2020 8:38 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Subject: FW: Request for Dr. Fauci + Ryan Zimmerman Pros For Heroes | COVID-19 Relief Fund

We're a "go" on this. I'll circle back with his rep tomorrow.

On Apr 21, 2020, at 6:50 PM, Billet, Courtney (NIH/NIAID) [E] (b) (6) wrote:

Hi guys— as a huge Nats fan, Dr. Fauci very much wants to do this chat with Ryan Zimmerman. Can I get a green light to work on this with them? I'll get the q's but it will be the same general theme as with Steph Curry, YES Network, etc.

From: Judee Ann Williams <judeeann.williams@caa.com>
Sent: Tuesday, April 21, 2020 5:54 PM
To: Billet, Courtney (NIH/NIAID) [E] (b) (6)
Cc: Christine Lancman <christine.lancman@caa.com>; Routh, Jennifer (NIH/NIAID) [E] (b) (6)
Subject: Re: Request for Dr. Fauci + Ryan Zimmerman Pros For Heroes | COVID-19 Relief Fund

Absolutely! We would 100% be able to work around that and avoid any association of fundraising.
We would set this up however he will be most comfortable, seed questions in advance, etc. and shed a light on what is most helpful.
Will wait to hear and if you need anything else just let us know. Thank you so much!

From: "Billet, Courtney (NIH/NIAID) [E]" (b) (6)
Date: Tuesday, April 21, 2020 at 4:41 PM
To: Judee Williams <judeeann.williams@caa.com>
Cc: Christine Lancman <christine.lancman@caa.com>, "Routh, Jennifer (NIH/NIAID) [E]" (b) (6)
Subject: RE: Request for Dr. Fauci + Ryan Zimmerman Pros For Heroes | COVID-19 Relief Fund

External Sender

Hi – thanks for your message – we will check and someone will get back to you in the next few days. One caveat is that as a Federal official, Dr. Fauci cannot be associated with fundraising in any way. Please confirm that is something you would be able to work around?

From: Judee Ann Williams <judeeann.williams@caa.com>

Sent: Monday, April 20, 2020 5:21 PM

To: Routh, Jennifer (NIH/NIAID) [E] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] (b) (6)>

Cc: Christine Lancman <christine.lancman@caa.com>

Subject: Request for Dr. Fauci + Ryan Zimmerman Pros For Heroes | COVID-19 Relief Fund

Jennifer & Courtney-

Hello! Our friends from Steph Curry's team passed along your contact information to us and we work at CAA where we represent World Series Champion, Ryan Zimmerman.

Ryan wanted to express his gratitude first & foremost to Dr. Fauci, the entire team and all those behind the scenes working around the clock.

Ryan recently launched the Pros for Heroes Covid-19 Fund last week, with more than 30 professional athletes supporting and over \$300,000 raised across 1,400 separate donations. (>www.prosforheroes.org<). Since its launch last Tuesday, contributions from the Pros For Heroes Fund have gone directly towards PPE needs throughout the Inova hospital network throughout the mid-Atlantic and have helped provide meals to those critical care front-line workers – keeping these front-line heroes covered at work and comfortable at home.

If Dr. Fauci was up to it, Ryan would love to host either a short 15 minute Q&A on his Facebook to continue raising awareness for how we need to be responding to the ongoing crisis. Or even simply thank Dr. Fauci for the tireless work he is doing and shine a light on how folks can support these critical frontline workers.

We are also open to what you think would work best! Would there any openings that would work best?

We know Dr. Fauci is big baseball fan, and of course we are all huge fans of his! If we can ever be supportive or help navigate anything in the world of pop culture, please do not hesitate to ask.

Warmest wishes,

Judee Ann

Judee Ann Williams | Co-Head, CAA Social Impact
T: 212-277-5294 | M: (b) (6) | Washington, DC

NEW YORK - LONDON - NASHVILLE - MUNICH - LOS ANGELES - BEIJING - SHANGHAI

[>https://www.caa.com/<](https://www.caa.com/)

Pros For Heroes

"Teamwork is the ability to come together towards a common goal. We are looking forward to attracting as many supporters to help join this cause and give back as much as we can to those who have given us so much," said Washington National All-Star, Ryan Zimmerman, the fund's founder.

Social Links:

[>https://www.instagram.com/prosforheroes/<](https://www.instagram.com/prosforheroes/)

[>https://twitter.com/prosforheroes<](https://twitter.com/prosforheroes)

Today Show:

[>https://www.today.com/video/ryan-zimmerman-talks-pros-for-heroes-fund-for-feeding-health-care-workers-82202693577<](https://www.today.com/video/ryan-zimmerman-talks-pros-for-heroes-fund-for-feeding-health-care-workers-82202693577)

Washington Post Launch Article:

[>https://www.washingtonpost.com/sports/2020/04/14/nationals-ryan-zimmerman-starts-fund-health-care-workers-with-100k-gift/<](https://www.washingtonpost.com/sports/2020/04/14/nationals-ryan-zimmerman-starts-fund-health-care-workers-with-100k-gift/)

This e-mail and any files transmitted with it are intended solely for the use of the individual or entity to whom they are addressed. If the reader of this e-mail is not the intended recipient or the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any use dissemination, forwarding, printing or copying of this e-mail is strictly prohibited. CAA is committed to ensuring that clients are free to do their best work without experiencing harassment and want to ensure they have the relevant resources they need. Clients can go to [>https://www.caa.com/legal/sexual-harassment-guidelines-caa-clients<](https://www.caa.com/legal/sexual-harassment-guidelines-caa-clients) to learn more about their rights, and how to report violations.

This e-mail and any files transmitted with it are intended solely for the use of the individual or entity to whom they are addressed. If the reader of this e-mail is not the intended recipient or the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any use dissemination, forwarding, printing or copying of this e-mail is strictly prohibited. CAA is committed to ensuring that clients are free to do their best work without experiencing harassment and want to ensure they have the relevant resources they need. Clients can go to [>https://www.caa.com/legal/sexual-harassment-guidelines-caa-clients<](https://www.caa.com/legal/sexual-harassment-guidelines-caa-clients) to learn more about their rights, and how to report violations.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Apr 2020 00:29:33 +0000
To: Collins, Francis (NIH/OD) [E] (b) (6)
Subject: FW: SCMP: Coronavirus's ability to mutate has been vastly underestimated, and mutations affect deadliness of strains, Chinese study finds

More on mutations

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tuesday, April 21, 2020 1:58 PM
To: Graham, Barney (NIH/VRC) [E] (b) (6)
Subject: FW: SCMP: Coronavirus's ability to mutate has been vastly underestimated, and mutations affect deadliness of strains, Chinese study finds

Not peer reviewed, but what do you think?

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] <(b) (6)>
Sent: Monday, April 20, 2020 1:53 PM
Subject: SCMP: Coronavirus's ability to mutate has been vastly underestimated, and mutations affect deadliness of strains, Chinese study finds

[China / Science](#)

Coronavirus's ability to mutate has been vastly underestimated, and mutations affect deadliness of strains, Chinese study finds

- The most aggressive strains of Sars-CoV-2 could generate 270 times as much viral load as the least potent type
- New York may have a deadlier strain imported from Europe, compared to less deadly viruses elsewhere in the United States



Stephen Chen in Beijing

Published: 10:41pm, 20 Apr, 2020

Updated: 1:33am, 21 Apr, 2020



A team led by Professor Li Lanjuan has studied how the novel coronavirus mutates and possible implications for the pandemic. Photo: EPA-EFE

A new study by one of China's top scientists has found the ability of the new coronavirus to mutate has been vastly underestimated and different strains may account for different impacts of the disease in various parts of the world.

Professor Li Lanjuan and her colleagues from Zhejiang University found within a small pool of patients many mutations not previously reported. These mutations included changes so rare that scientists had never considered they might occur.

They also confirmed for the first time with laboratory evidence that certain mutations could create strains deadlier than others.

"Sars-CoV-2 has acquired mutations capable of substantially changing its pathogenicity," Li and her collaborators wrote in a non-peer reviewed paper released on preprint service medRxiv.org on Sunday. Li's study provided the first hard evidence that mutation could affect how severely the virus caused disease or damage in its host.

Li took an unusual approach to investigate the virus mutation. She analysed the viral strains isolated from 11 randomly chosen Covid-19 patients from Hangzhou in the eastern province of Zhejiang, and then tested how efficiently they could infect and kill cells.

The deadliest mutations in the Zhejiang patients had also been found in most patients across Europe, while the milder strains were the predominant varieties found in parts of the United States, such as Washington state, according to their paper.

A separate study had found that New York strains had been imported from Europe. The death rate in New York was similar to that in many European countries, if not worse.

But the weaker mutation did not mean a lower risk for everybody, according to Li's study. In Zhejiang, two patients in their 30s and 50s who contracted the weaker strain became severely ill. Although both survived in the end, the elder patient needed treatment in an intensive care unit.

This finding could shed light on differences in regional mortality. The pandemic's infection and death rates vary from one country to another, and many explanations have been proposed.

Genetic scientists had noticed that the dominant strains in different geographic regions were inherently different. Some researchers suspected the varying mortality rates could, in part, be caused by mutations but they had no direct proof.

The issue was further complicated because survival rates depended on many factors, such as age, underlying health conditions or even blood type.

In hospitals, Covid-19 has been treated as one disease and patients have received the same treatment regardless of the strain they have. Li and her colleagues suggested that defining mutations in a region might determine actions to fight the virus.

“Drug and vaccine development, while urgent, need to take the impact of these accumulating mutations ... into account to avoid potential pitfalls,” they said.

Li was the first scientist to propose the Wuhan lockdown, according to state media reports. The government followed her advice and in late January, the city of more than 11 million residents was shut down overnight.

The sample size in this most recent study was remarkably small. Other studies tracking the virus mutation usually involved hundreds, or even thousands, of strains.

Li’s team detected more than 30 mutations. Among them 19 mutations – or about 60 per cent – were new.

They found some of these mutations could lead to functional changes in the virus’ spike protein, a unique structure over the viral envelope enabling the coronavirus to bind with human cells. Computer simulation predicted that these mutations would increase its infectivity.

To verify the theory, Li and colleagues infected cells with strains carrying different mutations. The most aggressive strains could generate 270 times as much viral load as the weakest type. These strains also killed the cells the fastest.

It was an unexpected result from fewer than a dozen patients, “indicating that the true diversity of the viral strains is still largely underappreciated,” Li wrote in the paper.



Professor Li Lanjuan is a leading Chinese epidemiologist. Photo: Xinhua

The mutations were genes different from the earliest strain isolated in Wuhan, where the virus was first detected in late December last year.

The coronavirus changes at an average speed of about one mutation per month. By Monday, more than 10,000 strains had been sequenced by scientists around the globe, containing more than 4,300 mutations, according to the China National Centre for Bioinformation.

Most of these samples, though, were sequenced by a standard approach that could generate a result quickly. The genes were read just once, for instance, and there was room for mistakes.

Li's team used a more sophisticated method known as ultra-deep sequencing. Each building block of the virus genome was read more than 100 times, allowing the researchers to see changes that could have been overlooked by the conventional approach.

The researchers also found three consecutive changes – known as tri-nucleotide mutations – in a 60-year-old patient, which was a rare event. Usually the genes mutated at one site at a time. This patient spent more than 50 days in hospital, much longer than other Covid-19 patients, and even his faeces were infectious with living viral strains.

"Investigating the functional impact of this tri-nucleotide mutation would be highly interesting," Li and colleagues said in the paper.

Professor Zhang Xuegong, head of the bioinformatics division at the National Laboratory for Information Science and Technology at Tsinghua University, said ultra-deep sequencing could be an effective strategy to track the virus' mutation.

"It can produce some useful information," he said.

But this approach could be much more time consuming and costly. It was unlikely to be applied to all samples.

"Our understanding of the virus remains quite shallow," Zhang said. Questions such as where the virus came from, why it could kill some healthy young people while generating no detectable symptoms in many others still left scientists scratching their heads.

"If there is a discovery that overturns the prevailing perception, don't be surprised."

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Apr 2020 00:16:44 +0000
To: Collins, Francis (NIH/OD) [E] (b) (6)
Subject: FW: For your attention
Attachments: COVAX2020 - A GLOBAL EFFORT for the ACCELERATED DEVELOPMENT, PRODUCTION and EQUITABLE ACCESS to COVID-19 VACCINES_16Apr2020_DRAFT.docx

See attachment that Hilary sent me. (b) (5)

From: Marston, Hilary (NIH/NIAID) [E] (b) (6)
Sent: Tuesday, April 21, 2020 7:44 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Re: For your attention

(b) (5)

From: Anthony Fauci (b) (6)>
Date: Tuesday, April 21, 2020 at 7:30 PM
To: Hilary Marston <(b) (6)v>
Subject: FW: For your attention

Have you heard of this on any of the calls where you represent me??

From: Collins, Francis (NIH/OD) [E] (b) (6)
Sent: Tuesday, April 21, 2020 7:28 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Tabak, Lawrence (NIH/OD) [E] (b) (6); Freire, Maria (FNIH) [T] <mfreire@fnih.org>; Wholley, David (FNIH) [T] <dwholley@fnih.org>
Subject: FW: For your attention

Hi all,

See note below from Victor Dzau about a global effort on COVID-19. I can't tell if this is more than a fund-raising effort. I know we have Gates reps on our ACTIV working groups – has any of this plan come up, David?

Francis

From: Dzau, Victor J. <VDzau@nas.edu>
Sent: Tuesday, April 21, 2020 4:10 PM
To: Collins, Francis (NIH/OD) [E] <(b) (6)>
Cc: Kanarek, Morgan <MKanarek@nas.edu>
Subject: For your attention

Dear Francis,

Congratulations on your launch of Public Private Partnership to speed COVID 19 vaccine and treatment options. This is very timely and much needed. Kudos to your leadership.

I am sure you are aware of a global coordinating effort to accelerate vaccines, diagnostics and therapeutics. I have been part of the conversation and planning along with Jeremy Farrar, Richard Hatchett, Seth Berkley, Chris Elias, Paul Stoffels etc. Recently WHO, Gates Foundation and European Commission have been leading the planning. This has advanced rapidly and is in the final stages in development that will be soon announced. It has involved European Commission, Germany, Japan, UK, Norway, France, Saudi as well as Gates Foundation, WHO, World Bank, Wellcome Trust, GAVI, Global Fund, CEPI, GPMB and private sector industry. The initiative will begin with a Pledge conference for \$8B as a starting point. This will be led by President von der Leyen and is co-chaired by the above country leaders. This will occur on May 4. In addition by the end of this week or early next week there will be an announcement on the global coordinating structure with will involve Gates, WHO etc.

I am writing to be sure that you and the White House are aware of these upcoming events. Can you share this information with the White House? Besides you, who else should I share this information with? I will be happy to send you background documents if you wish.

Please call me anytime.

Best,

Victor

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 23:10:36 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: Consideration of IM COVID Immune Globulin for Prevention of COVID-19 Infection
Attachments: Prophylactic Intramuscular COVID-IG - Oxman.pdf, FURTHER ARGUMENTS IN FAVOR OF INTRAMUSCULAR COVID-IG Version 4 - Oxman.pdf

Email from Gary Noble, advisor to Bob Windom in the 1980s.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email: (b) (6)

From: Gary Noble (b) (6)
Sent: Tuesday, April 21, 2020 4:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: McGowan, John J. (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Oxman, Michael (b) (6)
Subject: Consideration of IM COVID Immune Globulin for Prevention of COVID-19 Infection

Dear Tony,

I will always remember our amazing collaboration during the HIV/AIDS days in the 1980s, when I served as AIDS Advisor to Bob Windom, the DHHS Assistant Secretary for Health during President Reagan's administration. And now, I am delighted and amazed to watch you so adroitly maneuver the COVID-19 scientific policies and keep them front and center in the current White House!!

(b) (6), Michael Oxman, has worked with John Zaia at City of Hope, and a Mayo/Hopkins/Michigan State consortium for a trial of IM COVID-IG as a preferred method for treatment and prevention of COVID-19.

This week, Mike expects to complete the protocol for a placebo (normal IG)-controlled trial of IM COVID-IG prophylaxis in at-risk healthcare workers

who are engaged in direct patient care at UCSD, but they need a modicum of support. Mike asked if I would reach out to see if NIAID might provide of support for this effort, using IM, as opposed to IV, COVID-IG.

I've copied Mike, who has provided the attached background information.

Tony, with all my respect and admiration for what you are doing for the U.S. and for all of us.

Gary

Gary R. Noble, MD, MPH, MA (Oxon)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 22:14:24 +0000
To: NIAID OD AM
Subject: FW: Invitation to Speak at UC Berkeley COVID-19 Hackathon

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Saahil Chadha <saahil@calhacks.io>
Sent: Tuesday, April 21, 2020 11:00 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Invitation to Speak at UC Berkeley COVID-19 Hackathon

Dear Dr Fauci,

My name is Saahil, and I'm a director at Cal Hacks, a student organization at the University of California, Berkeley. This upcoming weekend, we will be hosting [hack:now](#), a 36-hour global online hackathon to foster innovative and technical solutions to tackle the challenges faced around the current COVID-19 pandemic. We're projected to have 1,500 participants from around the world. I'm reaching out to invite you to be our opening ceremony speaker.

Specifically, this Friday night, April 24, from 7-8pm Pacific Daylight Time, we're going to be hosting the opening ceremony of our event. At this time, we want to inspire our hackers to help solve global challenges related to health and community. **We would be absolutely honored if you would join us to speak at our opening ceremony for just a few minutes to share your experiences with and response to the COVID-19 pandemic.** Your unique perspective and expanse of knowledge makes you the most qualified person, and we would be humbled to include you as our opening ceremony speaker. Please let us know if you are able to accept this invitation.

Stay safe,

Saahil Chadha

(b) (6)

Calhacks.io

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 22:06:57 +0000
To: Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Message for Dr Anthony FAUCI

OK. Please take care of this. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)
Sent: Tuesday, April 21, 2020 11:31 AM
To: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: RE: Message for Dr Anthony FAUCI

I would be extremely grateful to you if you can provide me with the most recent and pertinent scientific and population data concerning covid-19. I know how extremely busy you are but maybe a collaborator of yours whether he can send me the data via e-mail (b) (6).

Not exactly sure what he wants but I can send him some links that will get him the latest CoV info from pubmed, preprints, CDC etc

From: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Sent: Tuesday, April 21, 2020 11:16 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6)
Subject: FW: Message for Dr Anthony FAUCI

Can we direct her somewhere? Gray?

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jean-Louis Touraine (b) (6) >
Sent: Tuesday, April 21, 2020 11:06 AM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: Potential SPAM:Message for Dr Anthony FAUCI

I would be very grateful to you if you can forward the following mail to Dr Anthony FAUCI.

Many thanks.
Sincerely yours,

Pr Jean-Louis TOURAINE, Lyon and Paris, France.

Dear Tony,

You may remember, that we have met repeatedly and worked in parallel and in association, during the early years of the HIV epidemic.

You and I have been trained in immunology. Both of us are much sollicitated to help facing and fighting the covid-19 epidemic.

During the past years , as well as recently, I have followed with great interest and respect your accomplishments and your advices in the fights against epidemics. I would be extremely grateful to you if you can provide me with the most recent and pertinent scientific and population data concerning covid-19. I know how extremely busy you are but maybe a collaborator of yours whether he can send me the data via e-mail (b) (6) This will allow me to give more documented informations to the French President and Government. Cooperation between countries will be crucial against covid-19 as it has been against HIV and other agents.

I look forward to seeing you again in quieter times.
Many thanks and very best personal regards.

Jean-Louis TOURAINE, M.D., Ph. D., M.P.

Ce message, ainsi que les pièces jointes, sont établis, sous la seule responsabilité de l'expéditeur, à l'intention exclusive de ses destinataires ; ils peuvent contenir des informations confidentielles. Toute publication, utilisation ou diffusion doit être autorisée préalablement.

Ce message a fait l'objet d'un traitement anti-virus.

Il est rappelé que tout message électronique est susceptible d'altération au cours de son acheminement sur Internet.

Vous pouvez consulter le site de l'Assemblée nationale à l'adresse suivante : <http://www.assemblee-nationale.fr>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 21:39:30 +0000
To: Collins, Francis (NIH/OD) [E] (b) (6)
Cc: Myles, Renate (NIH/OD) [E]; Burklow, John (NIH/OD) [E]; Billet, Courtney (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: STAT: Director of U.S. agency key to helping vaccine development leaves role suddenly amid coronavirus pandemic <https://bit.ly/2XRZqKa>

(b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, April 21, 2020 3:01 PM
Subject: STAT: Director of U.S. agency key to helping vaccine development leaves role suddenly amid coronavirus pandemic <https://bit.ly/2XRZqKa>

Director of U.S. agency key to helping vaccine development leaves role suddenly amid coronavirus pandemic

By [Nicholas Florko](#) @NicholasFlorko
April 21, 2020



Rick Bright HHS

WASHINGTON — Rick Bright, one of the nation's leading vaccine development experts and the director of the Biomedical Advanced Research and Development Authority, is no longer leading the organization, officials told STAT.

The shakeup at the agency, known as BARDA, couldn't come at a more inopportune time for the office, which invests in drugs, devices, and other technologies that help address infectious disease outbreaks and which has been at the center of the government's coronavirus pandemic response.

Bright, whose departure was confirmed by three industry sources and two current Trump administration sources, will instead move into a narrower role at the National Institutes of Health overseeing a similar but limited public-private partnership aimed at vaccine development. Gary Disbrow, Bright's former deputy at BARDA, will serve as the acting director of the office, an HHS spokesperson confirmed to STAT.

BARDA was expected to play an even larger role in the coming months; Congress more than tripled BARDA's budget in the most recent coronavirus stimulus package. Already, the office has a role in some of the splashiest Covid-19 projects, including partnerships with Johnson & Johnson and Moderna Therapeutics, both of which are developing potential Covid-19 treatments.

Related:

This tiny federal agency was built to respond to a crisis like coronavirus. Now that it's here, is BARDA ready?

BARDA has been plagued with management issues virtually since its creation in 2006, with much of the criticism aimed at a contracting department that some say is unresponsive to industry partners. The office has only had two permanent directors since its creation in 2006. Bright has led the organization since 2016.

None of the sources articulated the reason for Bright's departure, though several mentioned recent chafing between Bright and Bob Kadlec, the HHS Assistant Secretary for Preparedness and Response, which has oversight over BARDA.

An HHS spokesperson confirmed that Bright will work on a recently announced NIH public-private partnership with 16 drug makers aimed at developing vaccines and treatments for Covid-19.

"Dr. Rick Bright will transfer the skills he has applied as Director of the [BARDA] to the [NIH]. ... Dr. Bright brings extensive experience and expertise in facilitating powerful public-private partnerships that advance the health and well-being of the American people," the spokesperson said.

Bright did not immediately respond to requests for comment.

Bright's career has largely centered around vaccine and drug development. His work at the Centers for Disease Control and Prevention focused on influenza viruses, antiviral drugs and tests. He has also worked in the biotechnology industry and served as an advisor to the World Health Organization. Before becoming BARDA director, he led the agency's Influenza and Emerging Infectious Diseases Division.

Lev Facher contributed reporting.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 21:18:24 +0000
To: Crawford, Chase (NIH/NIAID) [E]; Auchincloss, Hugh (NIH/NIAID) [E]; McGowan, John J. (NIH/NIAID) [E]; Harper, Jill (NIH/NIAID) [E]; Gilles, Sharon (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]; Johnson, Martin S. (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]; Billet, Courtney (NIH/NIAID) [E]
Cc: Haskins, Melinda (NIH/NIAID) [E]; Selgrade, Sara (NIH/NIAID) [E]
Subject: RE: Attention: COVID-19 legislative package bill text released

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Crawford, Chase (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, April 21, 2020 3:27 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Auchincloss, Hugh (NIH/NIAID) [E] (b) (6) >; McGowan, John J. (NIH/NIAID) [E] (b) (6) >; Harper, Jill (NIH/NIAID) [E] (b) (6) >; Gilles, Sharon (NIH/NIAID) [E] (b) (6) >; Lane, Cliff (NIH/NIAID) [E] (b) (6) >; Johnson, Martin S. (NIH/NIAID) [E] (b) (6) >; Marston, Hilary (NIH/NIAID) [E] (b) (6) >; Billet, Courtney (NIH/NIAID) [E] (b) (6) >
Cc: Haskins, Melinda (NIH/NIAID) [E] (b) (6) >; Selgrade, Sara (NIH/NIAID) [E] (b) (6) >
Subject: Attention: COVID-19 legislative package bill text released
Importance: High

Good Afternoon,

At 4p.m. today (4/21), the U.S. Senate is expected to hold a vote by unanimous consent on the "Paycheck Protection Program and Health Care Enhancement Act" (bill text attached). In particular please note that the legislative package includes

the following supplemental appropriations for diagnostic testing (pages 13-15 of attached):

- **NIH/OD** – not less than **\$1B** to develop, validate, improve, and implement testing and associated technologies; to accelerate research, development, and implementation of point of care and other rapid testing; and for partnerships with governmental and non-governmental entities to research, develop, and implement the activities outlined in this proviso.
 - funds in the preceding proviso may be transferred to the accounts of the Institutes and Centers of the National Institutes of Health for the purposes specified in the preceding proviso
 - the transfer authority provided in the preceding proviso is in addition to all other transfer authority available to the NIH
- **NCI** – not less than **\$306M** to develop, validate, improve, and implement serological testing and associated technologies for the purposes specified under this paragraph in this Act:
- **NIBIB** – not less than **\$500M** to accelerate research, development, and implementation of point of care and other rapid testing related to coronavirus:
- **CDC** – not less than **\$1B** for surveillance, epidemiology, laboratory capacity expansion, contact tracing, public health data surveillance and analytics infrastructure modernization, disseminating information about testing, and workforce support necessary to expand and improve COVID–19 testing
- **BARDA** – not less than **\$1B** for necessary expenses of advanced research, development, manufacturing, production, and purchase of diagnostic, serologic, or other COVID–19 tests or related supplies, and other activities related to COVID–19 testing at the discretion of the Secretary
- **FDA** – **\$22M** to support activities associated with diagnostic, serological, antigen, and other tests, and related administrative activities

We will keep you updated on any developments related to this legislation. Please let us know if you have any questions.

Thanks,
Chase

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 21:01:27 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: RE: Ryan Zimmerman

If cleared, I would love to. (b)(5) - PCP

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b)(6)
FAX: (301) 496-4409
E-mail: (b)(6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] (b)(6)
Sent: Tuesday, April 21, 2020 4:43 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b)(6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b)(6); Routh, Jennifer (NIH/NIAID) [E] (b)(6); Stover, Kathy (NIH/NIAID) [E] (b)(6); Folkers, Greg (NIH/NIAID) [E] (b)(6)
Subject: Ryan Zimmerman

Would you be interested in doing something with Ryan Zimmerman? Format TBD. We'll pursue further discussion if you give the green light.

From: Billet, Courtney (NIH/NIAID) [E]
Sent: Tuesday, April 21, 2020 4:41 PM
To: Judee Ann Williams <judeeann.williams@caa.com>
Cc: Christine Lancman <christine.lancman@caa.com>; Routh, Jennifer (NIH/NIAID) [E] (b)(6)
Subject: RE: Request for Dr. Fauci + Ryan Zimmerman Pros For Heroes | COVID-19 Relief Fund

Hi – thanks for your message – we will check and someone will get back to you in the next few days. One caveat is that as a Federal official, Dr. Fauci cannot be associated with fundraising in any way. Please confirm that is something you would be able to work around?

From: Judee Ann Williams <judeeann.williams@caa.com>

Sent: Monday, April 20, 2020 5:21 PM

To: Routh, Jennifer (NIH/NIAID) [E] (b) (6); Billet, Courtney (NIH/NIAID) [E] (b) (6)>

Cc: Christine Lancman <christine.lancman@caa.com>

Subject: Request for Dr. Fauci + Ryan Zimmerman Pros For Heroes | COVID-19 Relief Fund

Jennifer & Courtney-

Hello! Our friends from Steph Curry's team passed along your contact information to us and we work at CAA where we represent World Series Champion, Ryan Zimmerman.

Ryan wanted to express his gratitude first & foremost to Dr. Fauci, the entire team and all those behind the scenes working around the clock.

Ryan recently launched the Pros for Heroes Covid-19 Fund last week, with more than 30 professional athletes supporting and over \$300,000 raised across 1,400 separate donations. (www.prosforheroes.org). Since its launch last Tuesday, contributions from the Pros For Heroes Fund have gone directly towards PPE needs throughout the Inova hospital network throughout the mid-Atlantic and have helped provide meals to those critical care front-line workers - keeping these front-line heroes covered at work and comfortable at home.

If Dr. Fauci was up to it, Ryan would love to host either a short 15 minute Q&A on his Facebook to continue raising awareness for how we need to be responding to the ongoing crisis. Or even simply thank Dr. Fauci for the tireless work he is doing and shine a light on how folks can support these critical frontline workers.

We are also open to what you think would work best! Would there any openings that would work best?

We know Dr. Fauci is big baseball fan, and of course we are all huge fans of his! If we can ever be supportive or help navigate anything in the world of pop culture, please do not hesitate to ask.

Warmest wishes,

Judee Ann

Judee Ann Williams | Co-Head, CAA Social Impact

T: 212-277-5294 | M (b) (6) | Washington, DC

NEW YORK - LONDON - NASHVILLE - MUNICH - LOS ANGELES - BEIJING - SHANGHAI

<https://www.caa.com/>

Pros For Heroes

“Teamwork is the ability to come together towards a common goal. We are looking forward to attracting as many supporters to help join this cause and give back as much as we can to those who have given us so much,” said Washington National All-Star, Ryan Zimmerman, the fund’s founder.

Social Links:

<https://www.instagram.com/prosforheroes/>

<https://twitter.com/prosforheroes>

Today Show:

<https://www.today.com/video/ryan-zimmerman-talks-pros-for-heroes-fund-for-feeding-health-care-workers-82202693577>

Washington Post Launch Article:

<https://www.washingtonpost.com/sports/2020/04/14/nationals-ryan-zimmerman-starts-fund-health-care-workers-with-100k-gift/>

This e-mail and any files transmitted with it are intended solely for the use of the individual or entity to whom they are addressed. If the reader of this e-mail is not the intended recipient or the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any use dissemination, forwarding, printing or copying of this e-mail is strictly prohibited. CAA is committed to ensuring that clients are free to do their best work without experiencing harassment and want to ensure they have the relevant resources they need. Clients can go to <https://www.caa.com/legal/sexual-harassment-guidelines-caa-clients> to learn more about their rights, and how to report violations.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 20:44:40 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]; clane@niaid.nih.gov
Subject: RE: urgent: CNN request

Cliff should do this.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Sent: Tuesday, April 21, 2020 4:41 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Fwd: urgent: CNN request

Sent from my iPhone

Begin forwarded message:

From: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)>
Date: April 21, 2020 at 4:31:46 PM EDT
To: "Billet, Courtney (NIH/NIAID) [E]" (b) (6)>
Subject: Fwd: urgent: CNN request

Sent from my iPhone

Begin forwarded message:

From: "Billet, Courtney (NIH/NIAID) [E]" <(b) (6)>
Date: April 21, 2020 at 2:49:39 PM EDT
To: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)
Cc: "Routh, Jennifer (NIH/NIAID) [E]" (b) (6)
Subject: FW: urgent: CNN request

Patty – can you please check with Dr. Fauci if he'd like to speak to Elizabeth Cohen about the treatment guidelines.

From: Lane, Cliff (NIH/NIAID) [E] (b) (6)>
Sent: Tuesday, April 21, 2020 2:48 PM
To: Billet, Courtney (NIH/NIAID) [E] (b) (6); Pau, Alice (NIH/NIAID) [E] (b) (6)>
Cc: Doepel, Laurie (NIH/NIAID) [E] (b) (6); Masur, Henry (NIH/CC/CCMD) [E] (b) (6); Myles, Renate (NIH/OD) [E] (b) (6)>
Subject: Re: urgent: CNN request

I think Dr. Fauci would want the option of first refusal. He has anticipated he will be asked about these.

From: "Billet, Courtney (NIH/NIAID) [E]" (b) (6)
Date: Tuesday, April 21, 2020 at 1:35 PM
To: "Pau, Alice (NIH/NIAID) [E]" (b) (6)>
Cc: Laurie Doepel (b) (6)>, "Masur, Henry (NIH/CC/CCMD) [E]" (b) (6), "Lane, Cliff (NIH/NIAID) [E]" (b) (6), "Myles, Renate (NIH/OD) [E]" (b) (6)>
Subject: RE: urgent: CNN request

Hi Alice – thanks for sending this along. We will confer about how best to handle media requests about the guidelines – we're calling them NIH guidelines and the press release came from NIH, so I'd like to involve the NIH media office in this, hence I've cc'd Renate Myles. I think it's sort of an unsettled question as to who the spokespeople will be. Drs. Lane and Masur – do you have a preference?

Also, who is Claire? (The person who forwarded the CNN request to you and Dr. Masur. Would be good to have a last name so we can confer with her as needed going forward.)

From: Pau, Alice (NIH/NIAID) [E] (b) (6)>
Sent: Tuesday, April 21, 2020 1:24 PM

To: Billet, Courtney (NIH/NIAID) [E] (b) (6)
Cc: Doepel, Laurie (NIH/NIAID) [E] (b) (6) Masur, Henry (NIH/CC/CCMD) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6)>

Subject: FW: urgent: CNN request

Hi Courtney,

Please see below the request from CNN. Per Laurie, I will forward other requests to you.

Thanks, Alice

From: COVID19 Treatment Guidelines
<COVID19TreatmentGuidelines@nih.gov>
Date: Tuesday, April 21, 2020 at 1:06 PM
To: Henry Masur (b) (6), Alice Pau (b) (6)>
Subject: Fw: urgent: CNN request

Hi Henry and Alice,

I am not sure how we want to handle interview requests like this. Would someone on the Panel want to/be allowed to speak to the press about the guidelines?

I am happy to politely decline if we want to handle it that way.

It is nice to see that we are being picked up by the press already though. I am glad people are already expressing interest.

Just let me know!
Claire

From: Nigam, Minali <Minali.Nigam@turner.com>
Sent: Tuesday, April 21, 2020 4:03 PM
To: COVID19 Treatment Guidelines <COVID19TreatmentGuidelines@nih.gov>
Cc: Cohen, Elizabeth <Elizabeth.Cohen@turner.com>; Fine, Amanda (NIH/OD) [E] (b) (6)>
Subject: urgent: CNN request

To the NIH Covid-19 Treatment Guideline Team:

My name is Minali Nigam and I work with Elizabeth Cohen at CNN Health. We wanted to reach out and request to speak with someone over the phone involved with the NIH treatment guidelines for covid-19. Please let us know as soon as possible for an available time today.


We appreciate your help, as we inform our viewers of important health information.


Best,
Minali

Dr. Minali Nigam
CNN Health


(b) (6)
















From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 19:42:03 +0000
To: Birx, Deborah L. EOP/NSC;Hahn, Stephen;Redfield, Robert R. (CDC/OD)
Subject: FW: SCMP: Coronavirus's ability to mutate has been vastly underestimated, and mutations affect deadliness of strains, Chinese study finds

See below

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-2263
FAX: (301) 496-4409
E-mail: afauci@niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)
Sent: Monday, April 20, 2020 1:53 PM
Subject: SCMP: Coronavirus's ability to mutate has been vastly underestimated, and mutations affect deadliness of strains, Chinese study finds

China / Science

Coronavirus's ability to mutate has been vastly underestimated, and mutations affect deadliness of strains, Chinese study finds

- The most aggressive strains of Sars-CoV-2 could generate 270 times as much viral load as the least potent type
- New York may have a deadlier strain imported from Europe, compared to less deadly viruses elsewhere in the United States



Stephen Chen in Beijing

Published: 10:41pm, 20 Apr, 2020

Updated: 1:33am, 21 Apr, 2020



A team led by Professor Li Lanjuan has studied how the novel coronavirus mutates and possible implications for the pandemic. Photo: EPA-EFE

A new study by one of China's top scientists has found the ability of the new coronavirus to mutate has been vastly underestimated and different strains may account for different impacts of the disease in various parts of the world.

Professor Li Lanjuan and her colleagues from Zhejiang University found within a small pool of patients many mutations not previously reported. These mutations included changes so rare that scientists had never considered they might occur.

They also confirmed for the first time with laboratory evidence that certain mutations could create strains deadlier than others.

"Sars-CoV-2 has acquired mutations capable of substantially changing its pathogenicity," Li and her collaborators wrote in a non-peer reviewed paper released on preprint service medRxiv.org on Sunday. Li's study provided the first hard evidence that mutation could affect how severely the virus caused disease or damage in its host.

Li took an unusual approach to investigate the virus mutation. She analysed the viral strains isolated from 11 randomly chosen Covid-19 patients from Hangzhou in the eastern province of Zhejiang, and then tested how efficiently they could infect and kill cells.

The deadliest mutations in the Zhejiang patients had also been found in most patients across Europe, while the milder strains were the predominant varieties found in parts of the United States, such as Washington state, according to their paper.

A separate study had found that New York strains had been imported from Europe. The death rate in New York was similar to that in many European countries, if not worse.

But the weaker mutation did not mean a lower risk for everybody, according to Li's study. In Zhejiang, two patients in their 30s and 50s who contracted the weaker strain became severely ill. Although both survived in the end, the elder patient needed treatment in an intensive care unit.

This finding could shed light on differences in regional mortality. The pandemic's infection and death rates vary from one country to another, and many explanations have been proposed.

Genetic scientists had noticed that the dominant strains in different geographic regions were inherently different. Some researchers suspected the varying mortality rates could, in part, be caused by mutations but they had no direct proof.

The issue was further complicated because survival rates depended on many factors, such as age, underlying health conditions or even blood type.

In hospitals, Covid-19 has been treated as one disease and patients have received the same treatment regardless of the strain they have. Li and her colleagues suggested that defining mutations in a region might determine actions to fight the virus.

"Drug and vaccine development, while urgent, need to take the impact of these accumulating mutations ... into account to avoid potential pitfalls," they said.

Li was the first scientist to propose the Wuhan lockdown, according to state media reports. The government followed her advice and in late January, the city of more than 11 million residents was shut down overnight.

The sample size in this most recent study was remarkably small. Other studies tracking the virus mutation usually involved hundreds, or even thousands, of strains.

Li's team detected more than 30 mutations. Among them 19 mutations – or about 60 per cent – were new.

They found some of these mutations could lead to functional changes in the virus' spike protein, a unique structure over the viral envelope enabling the coronavirus to bind with human cells. Computer simulation predicted that these mutations would increase its infectivity.

To verify the theory, Li and colleagues infected cells with strains carrying different mutations. The most aggressive strains could generate 270 times as much viral load as the weakest type. These strains also killed the cells the fastest.

It was an unexpected result from fewer than a dozen patients, "indicating that the true diversity of the viral strains is still largely underappreciated," Li wrote in the paper.



Professor Li Lanjuan is a leading Chinese epidemiologist. Photo: Xinhua

The mutations were genes different from the earliest strain isolated in Wuhan, where the virus was first detected in late December last year.

The coronavirus changes at an average speed of about one mutation per month. By Monday, more than 10,000 strains had been sequenced by scientists around the globe, containing more than 4,300 mutations, according to the China National Centre for Bioinformation.

Most of these samples, though, were sequenced by a standard approach that could generate a result quickly. The genes were read just once, for instance, and there was room for mistakes.

Li's team used a more sophisticated method known as ultra-deep sequencing. Each building block of the virus genome was read more than 100 times, allowing the researchers to see changes that could have been overlooked by the conventional approach.

The researchers also found three consecutive changes – known as tri-nucleotide mutations – in a 60-year-old patient, which was a rare event. Usually the genes mutated at one site at a time. This patient spent more than 50 days in hospital, much longer than other Covid-19 patients, and even his faeces were infectious with living viral strains.

"Investigating the functional impact of this tri-nucleotide mutation would be highly interesting," Li and colleagues said in the paper.

Professor Zhang Xuegong, head of the bioinformatics division at the National Laboratory for Information Science and Technology at Tsinghua University, said ultra-deep sequencing could be an effective strategy to track the virus' mutation.

"It can produce some useful information," he said.

But this approach could be much more time consuming and costly. It was unlikely to be applied to all samples.

"Our understanding of the virus remains quite shallow," Zhang said. Questions such as where the virus came from, why it could kill some healthy young people while generating no detectable symptoms in many others still left scientists scratching their heads.

"If there is a discovery that overturns the prevailing perception, don't be surprised."

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 18:01:06 +0000
To: Jim Yong Kim
Subject: RE: My article

Jim:

Very nice paper! Thanks for sending it.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jim Yong Kim <Jim.Yong.Kim@global-infra.com>
Sent: Monday, April 20, 2020 3:00 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: My article

Tony,

Hope you're well and thank you again for all that you are doing. I got this out today in the New Yorker and I'll be talking to most of the Democratic caucus today about what we're doing in Mass and the developing world.

Hang in there and let me know if there is anything more I can do. Mass is tough but we're going to have a 1000 contact tracers very soon. Every day we learn so much, which is why it's so important for everyone to get started.

Jim

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 17:43:21 +0000
To: EDWARD SCOLNICK
Cc: Mascola, John (NIH/VRC) [E]; Cassetti, Cristina (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]
Subject: RE: for your consideration
Attachments: Scientists_to_Stop_COVID19_2020_04_15_FINAL.pdf

Ed:

Thank you for your note and for sending this. The outline that you provide is exactly in sync with what we are already doing and have definitive plans to do with regard to classic antivirals, monoclonal antibodies, and a variety of vaccine candidates. As you know, the candidate developed here at NIH in collaboration with Moderna is well into phase 1 trials and at least 2 others are entering into phase 1 trials.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: EDWARD SCOLNICK (b) (6)
Sent: Sunday, April 19, 2020 5:18 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: David R. Liu (b) (6); Schreiber, Stuart (b) (6); Michael Rosbash (b) (6); Ramnik Xavier (b) (6)
Subject: for your consideration

Tony . I hope your mail box is not so full that there is room for this. A group of concerned scientists from different parts of the country was organized to try to encapsulate and focus the national effort against Covid. This document has been shared with the White House although we are not sure if it has had any effect on their plans. It has also been shared with The Gates Foundation and a few other business and academic leaders. We think we have been fairly comprehensive in our considerations and recommendations. I hope you will find this helpful. We would greatly appreciate a conversation with you after you have had an opportunity to digest the content of the proposal. If there is anything else we can do to help you in this National emergency, we stand ready to help. When I was at Merck ,we led the successful effort to make HIV a manageable disease and we dramatically lowered the death rate as a result of the drugs we made ,and the first triple therapy trial during the HIV pandemic. We hope we can help do the same for The Covid Pandemic Best wishes Ed scolnick

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 15:12:29 +0000
To: Grady, Christine (NIH/CC/BEP) [E]
Subject: FW: Thank you

See part about you. 😊

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, April 21, 2020 11:07 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: Thank you

This is a cute note...you can skip most of it and see highlight - that is the cute part

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: JOAN HUSSEY (b) (6)
Sent: Tuesday, April 21, 2020 9:34 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Thank you

Dear Dr. Fauci,

I just wanted to say thank you for everything you are doing to educate us in this country, and keep us safe during this horrendous coronavirus pandemic. I can't even begin to imagine how difficult it is to maintain your composure and persevere with your focus, being constantly in the public eye and also trying to expertly guide a president who seems more preoccupied with his own image (and sound of his own voice), and political aspirations than with the actual well being of his country's citizens.

By now, it should be perfectly clear to us that we can't have a healthy economy without a healthy population.

(b) (6)

(b) (6) We all have been diligent about staying at home (b) (6)

(b) (6) ordering food and other things to be delivered to our house (we all wash our hands 'religiously'). (b) (6) is the only one of us who occasionally goes to a grocery store or drug store if necessary and then, he always wears a mask, gloves, and keeps at least six feet between himself and anyone else, and gets in and out as quickly as possible. In addition, (b) (6) are so intent on keeping me well and alive, we haven't even, any of us, physically visited with each other, in person, inside our house for months.

In the past two months, I've been outside only four times - twice on our deck and twice in my car, dropping off a couple of shopping bags at a friend's house and at (b) (6) group home - both times leaving the bags in the driveway, and then driving right back home.

I'm so thankful for FaceTime, but we miss hugs and kisses. I know all this must sound extreme, and it is, but I'm terrified of becoming a statistic so we're doing whatever we can to stay healthy for ourselves and one another.

(b) (6)

(b) (6) My family is hearing what you're saying and taking your advice. I'm sorry this email is so long but my intention, more than anything, is to thank you for your wisdom and advice, both grounded in years of experience.

I worked at NIH for about 25 years - in the CC, in NCI, and in Human Genome. I met you once, briefly, about 40 years ago (+/-) in Bldg. 31's fitness room. I had been working in the CC, in the Patient Activities Dep't. (on the POB out- and in-patient units) at the time. I was incorrectly using a piece of equipment and you were kind enough to come over and show me the correct way to use it. I recognized you immediately, and have never forgotten that experience and how gracious you were.

I'm well aware from the news that you are up against some very tough people and some very tough times but please know you also have an army of grateful followers in this country who are completely convinced that what you are advising is in their very best interest.

Thank you again for all you've done for all of us over the years. My family and I are more grateful than I can express.

PS I read all about your wife who sounds amazing also. You two make an "All-Star" team.

Be well.

Gratefully, Joan ("Joanie") Hussey

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 15:11:29 +0000
To: (b) (6)
Subject: FW: Thank you

Joanie:

Many thanks for your kind note. It is much appreciated. Stay safe!

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: JOAN HUSSEY (b) (6)
Sent: Tuesday, April 21, 2020 9:34 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Thank you

Dear Dr. Fauci,

I just wanted to say thank you for everything you are doing to educate us in this country, and keep us safe during this horrendous coronavirus pandemic. I can't even begin to imagine how difficult it is to maintain your composure and persevere with your focus, being constantly in the public eye and also trying to expertly guide a president who seems more preoccupied with his own image (and sound of his own voice), and political aspirations than with the actual well being of his country's citizens.

By now, it should be perfectly clear to us that we can't have a healthy economy without a healthy population.

(b) (6)

(b) (6). We all have been diligent about staying at home (b) (6)

(b) (6), ordering food and other things to be delivered to our house (we all wash our hands 'religiously'). (b) (6) is the only one of us who occasionally goes to a grocery store or drug store if necessary and then, he always wears a mask, gloves, and keeps at least six feet between himself and anyone else, and gets in and out as quickly as possible. In addition, (b) (6) are so intent on keeping me well and alive, we haven't even, any of us, physically visited with each other, in person, inside our house for months. In the past two months, I've been outside only four times - twice on our deck and twice in my car, dropping off a couple of shopping bags at a friend's house and at (b) (6) - both times leaving the bags in the driveway, and then driving right back home. I'm so thankful for FaceTime, but we miss hugs and kisses. I know all this must sound extreme, and it is, but I'm terrified of becoming a statistic so we're doing whatever we can to stay healthy for ourselves and one another.

(b) (6)

(b) (6) My family is hearing what you're saying and taking your advice. I'm sorry this email is so long but my intention, more than anything, is to thank you for your wisdom and advice, both grounded in years of experience. I worked at NIH for about 25 years - in the CC, in NCI, and in Human Genome. I met you once, briefly, about 40 years ago (+/-) in Bldg. 31's fitness room. I had been working in the CC, in the Patient Activities Dep't. (on the POB out- and in-patient units) at the time. I was incorrectly using a piece of equipment and you were kind enough to come over and show me the correct way to use it. I recognized you immediately, and have never forgotten that experience and how gracious you were.

I'm well aware from the news that you are up against some very tough people and some very tough times but please know you also have an army of grateful followers in this country who are completely convinced that what you are advising is in their very best interest.

Thank you again for all you've done for all of us over the years. My family and I are more grateful than I can express.

PS I read all about your wife who sounds amazing also. You two make an "All-Star" team.

Be well.

Gratefully, Joan ("Joanie") Hussey

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 14:52:49 +0000
To: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: White House Coronavirus Task Force PowerPoint - 4.21.20
Attachments: PowerPoint April 21.pptx

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

(b)(5) - PCP

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 02:52:55 +0000
To: Corey, Larry
Subject: manuscript
Attachments: COVID vaccine editorial_prefinal April20 wfigure -with Fauci tracked edits.docx

Here it is.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6)
Sent: Mon, 20 Apr 2020 19:24:58 -0400
To: Mascola, John (NIH/VRC) [E]
Subject: Fwd: COVID-19 vaccine

Let us discuss. I am not sure how to answer Adrian,

Begin forwarded message:

From: Adrian Hill (b) (6)
Date: April 20, 2020 at 6:16:30 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Cc: Hildegund Ertl (b) (6)>, Sarah Gilbert (b) (6)
Subject: FW: COVID-19 vaccine

Dear Dr Fauci

(b) (4)



Thank you for your consideration of this at an exceptionally busy time.

Yours sincerely

Adrian Hill

Professor Adrian V. S. Hill

Director, The Jenner Institute
Nuffield Department of Medicine
University of Oxford
Old Road Campus Research Building
Oxford OX3 7DQ

Tel: (b) (6)

Email: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Apr 2020 20:43:18 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Update: White House Coronavirus Meeting - 4.21.20

Yikes..... That would make 4 days in a row without a Press Conference for me – Saturday, Sunday, Monday and tomorrow 😊😊

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hurst, Natalie R. EOP/OVP (b) (6)
Sent: Monday, April 20, 2020 4:38 PM
Subject: Update: White House Coronavirus Meeting - 4.21.20
Importance: High

All -

There will be **no White House Coronavirus Task Force Meeting** on Tuesday, April 21st.

Enjoy your evening,

Natalie Hurst
Operations Coordinator, White House Coronavirus Task Force
Executive Assistant to the Chief of Staff
The Office of the Vice President
(b) (6)

From: (b) (6)
Sent: Mon, 20 Apr 2020 13:29:37 -0400
To: Charles McCall
Cc: Rotrosen, Daniel (NIH/NIAID) [E];Cassetti, Cristina (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E]
Subject: Re: Tony and Dan, this is Cash. I seek your advice.

Dan:

Please bring this to the attention of appropriate NIAID people.

Thanks,

Tony

> On Apr 19, 2020, at 10:34 PM, Charles McCall <(b) (6)> wrote:

>

> Dear Tony and Dan,

>

>

>

(b) (4)

> Thank you for considering this idea. Be safe.

>

>

>

> Cash

>

>

>

> Sent from iPad

> Charles (Cash) McCall, MD

> Professor of Internal Medicine, Translational Sciences, Microbiology & Immunology


> Wake Forest University School of Medicine

> Wake Forest Biotech Place, suite 350, room 3W-007

> 575 N. Patterson Avenue

> Winston-Salem, NC 27101

>



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Apr 2020 15:03:51 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: A National Testing Action Plan by the Rockefeller Foundation: Embargoed till midnight Monday April 20
Attachments: RF National COVID-19 Testing Action Plan_LAST FINAL_04.20.2020.docx

Set up

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: O'Connor, Eileen <EOConnor@rockfound.org>
Sent: Monday, April 20, 2020 7:47 AM
To: Fauci, Anthony (NIH/NIAID) [E] <AFAUCI@niaid.nih.gov>; Anthony.s.fauci@nih.gov; AFAURCI@niaid.nih.gov
Subject: A National Testing Action Plan by the Rockefeller Foundation: Embargoed till midnight Monday April 20

Dear Tony:

Thank you for all you are doing. Not sure you remember me (b) (6)
(b) (6) we talked a lot when I was at CNN. I have not wanted to bother you but wanted to make sure you had the National Testing Action Plan that we have put together with top researchers from all the various roadmaps, etc. I joined The Rockefeller Foundation after working in Afghanistan and Pakistan with State and coerced Christy Feig to join me. We would be happy to get on a call today with Raj and Jonathan Quick and other authors like Mike Pellini and Mark McLellan and Rick Klausner.

Given our history with public health and our ability to convene, we hoped we could help by working out a consensus plan. I have been briefing Caleb McCarry at the White House. We have worked with industry to also figure out the solutions to the supply chain issues and the

other logistical issues. We are going to put \$10 million into helping this standup. This plan doesn't just say what we need but the steps to get it done to open more safely.

Please let me know if you would like a call.

Regards
Eileen

Eileen O'Connor
Senior Vice President
Communications, Policy and Advocacy
The Rockefeller Foundation
Office: 212 852 8436
Mobile: (b) (6)

eoconnor@rockfound.org

www.rockfound.org

(For scheduling purposes, please contact my assistant, (b) (6), at
(b) (6))

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Apr 2020 14:22:57 +0000
To: Anderson, Jennifer (NIH/NIAID) [E]
Subject: FW: Potential Postbac IRTA Fellowship
Attachments: CV 4.19.pdf

Please handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6)
Sent: Monday, April 20, 2020 9:00 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Potential Postbac IRTA Fellowship

(b) (6)



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Apr 2020 11:58:51 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: RE: ASF: Today's YES Network interview

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6) >
Sent: Monday, April 20, 2020 7:55 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E]
(b) (6) >
Subject: ASF: Today's YES Network interview

You have an interview today with Jack Curry of the YES Network (Yankees). Just last night, The NY Post ran a story that includes Jack among the many sports broadcasting stars that have come out of Fordham (b) (6); Jack and I have talked about this). Thought you might like to see it. Parts of your interview are also going to run on Michael Kay's show, and Kay also features prominently in this piece.

How Fordham has produced a generation of sports media stars

April 19, 2020 | 4:04pm | [Updated April 19, 2020 | 9:16pm](#)



John Giannone, Michael Kay and Mike Breen; Chris Carrino Courtesy of Michael Kay, Chris Carrino

Long before he was an electee to the Basketball Hall of Fame, Mike Breen was an intimidated 18-year-old freshman attending a workshop at Fordham's renowned college radio station, WFUV, in the fall of 1979.

Breen felt sheepish next to the juniors and seniors leading the seminar and contemplated delaying the start of his broadcasting training. Soon, a couple of upperclassmen, including future NBA writer Dave D'Alesandro, made him feel more comfortable.

But he still didn't have any friends until one day on campus he saw a confident sophomore trying to sweet talk a young woman. "I know you like me," he said. "I can see it in your eyes."

The woman responded by saying she would not date him if he were the last man on earth. She essentially was saying, "See ya" ... to Michael Kay.

That is how Breen first became friends with Kay.

"For him to have the confidence to do this in front of everybody with this beautiful student, I thought, 'Man, this guy has a great sense of humor,'" Breen said.

Four decades later, Breen and Kay are still good friends.



Michael Kay and Mike Breen Courtesy of Michael Kay

Fordham, the private Jesuit university in The Bronx that launched the legendary Vin Scully, for decades has been a powerhouse sportscasting pipeline, especially in New York. And the school ties that first united Breen and Kay are webbed throughout the industry.

Fordham is the alma mater for the voice of the NBA Finals/Knicks (Breen, Class of 1983), the Yankees' lead TV play-by-player/ESPN New York afternoon radio host (Kay, '82), the voice of the Giants (Bob Papa, '86), the radio voice of the Nets (Chris Carrino, '92) MSG's John Giannone ('86), YES' Jack Curry ('86), WFAN's Paul Dottino ('86) and YES/ESPN's Ryan Ruocco ('08). And that's just New York-based sportscasters.

For good measure, the school produced CBS' Spero Dedes ('01), ESPN's Tony Realì ('00) and the Washington Nationals' Charlie Slowes ('83). There are many more, and not just in front of the camera. If you need a field producer, Jim Johnson ('86) works for ESPN. A radio engineer? WFAN's Chris Majkowski ('89) will set things up. Media relations? Louis Barricelli ('09) is leading things at MLB Network.

Like everyone else, they are all dealing with the halt of sports due to the coronavirus pandemic. It is a jarring timeout for people so used to being on the run.



Ryan Ruocco, Mike Breen Courtesy of Ryan Ruocco

Take Carrino, who has done so much to raise money and awareness for facio scapulo humeral dystrophy (FSHD), a form of muscular dystrophy that afflicts him. A fundraising event was supposed to take place in March at a Nets game at Barclays Center. His 10th annual fundraising dinner, corresponding with his 50th birthday, was slated for August, and now is in question.

“I don’t know if it is going to be safe to have people together still,” Carrino said. “Are the restrictions going to be there in terms of how many people can gather in one place? The other aspect of it for me is: How comfortable am I asking people for money when I know the economy and certain businesses are affected so badly?”

Ruocco was supposed to get married in Italy in June. He and his fiancée, Andrea Ferzoco, are now going to punt the wedding until June 2021.

“It sucks,” Ruocco said. “Andrea and I were so excited and so were our guests. We have been feeling all the joy leading us to this. There are people dealing with much more dire circumstances than rescheduling a wedding. That is kind of the perspective we have tried to take.”

While most of the successful sports media alumni are worried about the current direction of Fordham and WFUV because of a de-emphasis on sports during the pandemic, to a man they say how Fordham molded them and led them to where they are today.

They were helped by famous names such as the legendary Marty Glickman, a mentor, and Stan Fischler, who taught classes. Then there were the less famous, equally instrumental figures in the program, such as Bob Ahrens, who ran WFUV as its executive producer during many of these notable students’ formative years.



John Giannone punting at Fordham Courtesy of John Giannone

The experiences that they shared forged many of them, such as Breen and Kay, into close friends.

Giannone went to Fordham after being recruited to be a punter on the football team. During training camp his freshman year, he quickly figured out the third-string punter would never see the field. He went to Kay, then the WFUV sports director as a senior, to try to help on the station. Kay said Giannone could do stats for him during the football season.

Kay went on to work at The Post, and later helped Giannone land an entry-level position at the paper. When Giannone transferred into television at CNN/Sports Illustrated, it was through a Kay connection. And Giannone landed at MSG Network after Kay left to become the TV voice of the Yankees when YES Network began.

When it was Giannone's turn as WFUV sports director, he made Papa and Curry a play-by-play and an analyst when they were sophomores.

WFUV also got its staff access to locker rooms at places like Yankee Stadium and Madison Square Garden to learn the craft next to professionals at the highest level. That remains largely true today.

"WFUV allowed you to believe you were a professional broadcaster before you really were," Curry said. "We were in the heart of New York City, and, even if we weren't Marv Albert, we felt as if what Marv Albert was doing for the Knicks, we were doing for Fordham."

There is a lineage that unites. Carrino learned how to describe the geography of a basketball court from Glickman. Later, Carrino returned to Fordham and taught Ruocco the same lessons. These days, at some Nets games, Ruocco is on TV, sitting next to Carrino, calling the game on the radio.



Jack Curry Courtesy of Jack Curry

Papa also was mentored by Glickman. Papa and Carrino each were told by their fathers that if they majored in communications, they would have to pay for school themselves. Both ended up in the Business School, but had their eyes on WFUV the whole time.

Carrino ended up working as a producer for Papa, beginning when Papa hosted a tailgate show on WFAN. Carrino eventually followed Papa as the radio voice of the Nets.

The Fordham sports alums want everyone to be safe during this time — and they can't wait to get back to what they love to do.

"I'm desperate to get back to work," Breen said. "I'm hoping there is NBA basketball. This is the best time of the year."

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Apr 2020 11:14:21 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: the Strategy document
Attachments: COVID vaccine editorial_prefinal April19 wfigure.docx

Email below is from Larry Corey.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email: (b) (6)

From: Corey MD, Larry (b) (6) >
Sent: Sunday, April 19, 2020 11:45 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Cc: Mascola, John (NIH/VRC) [E] (b) (6) >; Miner PhD, Mindy <(b) (6)>
Subject: the Strategy document

Here is the working draft of the article for the NEJM . It , in my opinion, reads really well . I have embellished it today with a figure that conceptually outlines what we are talking about ; the old axiom that a picture is worth a thousand words .

The editorial guidelines of the NEJM has 2 potential categories . One is Perspectives which is 1200 words an 5 references . We are at 1750 words and I think losing 500 words takes away a lot from the message . The other category is a special report which is over 2500 words and allows lots of references (40) I think this is best and was one reason I thought about adding the conceptual figure which does outline in a single picture what we are talking about .

Tony , If you feel its best to have Francis on this paper we both support it . Your call . I do however lean on including Francis . I would say politicly to achieve our goal and bring all these companies into the tent while you are away at the White House having him buy into this plan through the ACTIV program seems important to us . I think we get to our goal if he is out there publicly embracing this; using the NIAID networks labs DSMB and the correlates programs . This type of granularity really puts him deep into understanding what we are doing . If this means you are first and he is last author we are ok with that , For me I need to have him use me for interfacing with the company in defining these collaborations . If you were present all the time this would be unnecessary , but as he will be the link with BARDA linking him to John and I increases the likelihood of success.

Ok enough ... as they say on the news Goodnight ..

Larry

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Apr 2020 02:39:49 +0000
To: 'Thomas Quinn'
Subject: FW: Fauci photo
Attachments: Fauci ISSTD 1983.pdf

Thanks, Tom!

From:
From: Thomas Quinn [REDACTED] (b) (6) >
Sent: Sunday, April 19, 2020 6:28 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Cc: Hunter Handsfield <hhh@uw.edu>
Subject: FW: Fauci photo

Hi Tony,
It was great to see you and present our work to you this last Friday. I really enjoyed our discussion and feedback.
As I said on zoom, we all really appreciate your leadership in the COVID-19 crisis. Thank you for providing the guiding way through this.

[REDACTED] (b) (4)
[REDACTED].

In the meantime, your photos are getting passed around and Hunter Handsfield wanted you to have this one (from the HIV archives—1983 in Seattle).

All the best,
Tom

p.s. [REDACTED] (b) (6)
[REDACTED] Stay healthy!

From: Hunter Handsfield <hhh@uw.edu>
Date: Sunday, April 19, 2020 at 3:52 PM
To: Thomas Quinn [REDACTED] (b) (6)
Subject: Fauci photo

Hi, Tom. Going through old boxes I came across this, from 5th ISSTD, Seattle 1983. Give Tony my greetings if you forward to him.

Cheers— Hunter

H. Hunter Handsfield, MD
Professor Emeritus of Medicine
Center for AIDS and STD
University of Washington

Phone +1 206 935-5225

Mobile (b) (6)



From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Apr 2020 01:58:31 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: Fauci photo
Attachments: Fauci ISSTD 1983.pdf

Email from Tom Quinn to you.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email: (b) (6)

From: Thomas Quinn (b) (6)
Sent: Sunday, April 19, 2020 6:28 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Hunter Handsfield <hhh@uw.edu>
Subject: FW: Fauci photo

Hi Tony,
It was great to see you and present our work to you this last Friday. I really enjoyed our discussion and feedback.
As I said on zoom, we all really appreciate your leadership in the COVID-19 crisis. Thank you for providing the guiding way through this.

(b) (4)
(b) (6)

In the meantime, your photos are getting passed around and Hunter Handsfield wanted you to have this one (from the HIV archives—1983 in Seattle).

All the best,
Tom

p.s. (b) (6)
(b) (6) - Stay healthy!

From: Hunter Handsfield [REDACTED] (b) (6)

Date: Sunday, April 19, 2020 at 3:52 PM

To: Thomas Quinn [REDACTED] (b) (6) >

Subject: Fauci photo

Hi, Tom. Going through old boxes I came across this, from 5th ISSTD, Seattle 1983. Give Tony my greetings if you forward to him.

Cheers— Hunter

H. Hunter Handsfield, MD
Professor Emeritus of Medicine
Center for AIDS and STD
University of Washington

Phone + [REDACTED] (b) (6)
Mobile [REDACTED]



From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Apr 2020 01:56:21 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: A proposal to stop COVID-19 and reopen our schools and businesses

Email from David Liu to FC with a cc to you.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email: (b) (6)

From: David R. Liu (b) (6)
Sent: Sunday, April 19, 2020 9:08 PM
To: Collins, Francis (NIH/OD) [E] (b) (6)>
Cc: Michael Rosbash (b) (6)>; Ramnik Xavier (b) (6)>;
EDWARD SCOLNICK (b) (6)>; Stuart Schreiber (b) (6)>; Michael Z Lin
(b) (6)>; Ben Cravatt (b) (6)>; Fauci, Anthony (NIH/NIAID) [E]
(b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b) (6)>; Austin, Christopher
(NIH/NCATS) [E] (b) (6)>; Wholley, David (FNIH) [T] (b) (6)>; Freire, Maria
(FNIH) [T] (b) (6)>; Tabak, Lawrence (NIH/OD) [E] (b) (6)>; Thomas Cahill
(b) (6)>
Subject: Re: A proposal to stop COVID-19 and reopen our schools and businesses

Thank you, Francis, for your speedy reply. Please let us know if we can help ACTIV, Fauci, or any other leaders who might want to engage.

Best,
David

David R. Liu
Richard Merkin Professor and Director of the Merkin Institute
of Transformative Technologies in Healthcare
Broad Institute Core Institute Member and Vice-Chair of the Faculty
Director of the Chemical Biology and Therapeutic Sciences Program
Howard Hughes Medical Institute Investigator
Harvard University Professor of Chemistry and Chemical Biology
75 Ames Street
Cambridge, MA 02142

On Apr 19, 2020, at 8:48 PM, Collins, Francis (NIH/OD) [E] (b) (6)> wrote:

Dear David et al.,

Thanks for forwarding this very thoughtful document, which presents a series of important recommendations – most of which I agree with. I don't know if you saw Friday's announcement (attached) of the new public private partnership called ACTIV (for Accelerating COVID-19 Therapeutic Interventions and Vaccines), but it has taken on most of the points you raise in sections 1 – 3 of your letter. I share your hopes that remdesivir will show benefit, and the current large NIH-sponsored RCT has completed enrollment and should reveal results in about a month. But of course we want to test multiple other interventions – both small molecules and antibody-based therapies, so we need our trial system to be optimized like never before. I will share your letter with the leaders of ACTIV, who are working with unprecedented speed to prioritize the next set of therapeutic candidates as well as pushing vaccine development programs to adopt exceptionally creative trial designs to test safety and efficacy (with full engagement by FDA).

Best regards, Francis

From: David Liu (b) (6)>

Sent: Sunday, April 19, 2020 5:20 PM

To: OD Labc (NIH/OD) (b) (6)>; Collins, Francis (NIH/OD) [E]

<(b) (6)>

Cc: Michael Rosbash (b) (6)>; Ramnik Xavier

(b) (6)>; EDWARD SCOLNICK (b) (6)>; Stuart

Schreiber (b) (6) Michael Z Lin <(b) (6)>; Ben Cravatt

(b) (6)

Subject: A proposal to stop COVID-19 and reopen our schools and businesses

Dear Francis,

I hope you are well.

I write on behalf of a group of citizen-scientists, most or all of whom you know. Motivated solely by our desire to help defeat the serious threat our nation and the world now faces, we wrote a set of four actionable, non-partisan proposals (attached) to produce safe and effective COVID-19 therapeutics and vaccines in the shortest possible timeframe, and to reopen our society in a manner that reduces the risk of future COVID-19 outbreaks.

We hope you find these ideas interesting, and might be willing to share this set of proposals with Dr. Tony Fauci, along with our willingness to discuss any part of the

proposals with him if we can be helpful. We understand from our efforts to contact Dr. Fauci through email routes that his standard inbox may be too overwhelmed for our proposal to reach him.

The four proposals attached describe: (1) How to rapidly repurpose an antiviral drug to treat COVID-19 patients; (2) How to expedite the development of human antibody drugs to treat patients and to provide short-term protection for healthy individuals; (3) How to develop COVID-19 vaccines on an expedited time scale; and (4) How to reopen our businesses and schools in a manner that reduces the risk of future outbreaks and deaths.

Thank you for any help or thoughts you might be able to provide.

Sincerely yours,

Ben Cravatt (Scripps), Lynn Goldman (GWU), Akiko Iwasaki (Yale), Scott Kemp (MIT), Michael Lin (Stanford), David Liu (Harvard/Broad), Michael Rosbash (Brandeis), Stuart Schreiber (Harvard/Broad), Ed Scolnick (Broad), Jonathan Simons (PCF), and Ramnik Xavier (MGH/Broad)

David R. Liu

Richard Merkin Professor and Director of the Merkin Institute
of Transformative Technologies in Healthcare

Director of the Chemical Biology and Therapeutic Sciences Program
Core Institute Member and Vice-Chair of the Faculty, Broad Institute
Investigator, Howard Hughes Medical Institute

Thomas Dudley Cabot Professor of the Natural Sciences
and Professor of Chemistry & Chemical Biology, Harvard University
75 Ames Street
Cambridge, MA 02142

<NIH_ACTIV_Release_041720.docx>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Apr 2020 01:25:42 +0000
To: bgertz@washingtontimes.com
Cc: Miller, Katie R. EOP/OVP; Short, Marc T. EOP/OVP
Subject: Scientific paper on origin of coronavirus

Bill:

Here are the links to the scientific papers and a commentary about the scientific basis of the origins of SARS-CoV-2.

The proximal origin of SARS-CoV-2. Andersen KG, Rambaut A, Lipkin WI, **Holmes** EC, Garry RF. Nat Med. 2020 Apr;26(4):450-452. doi: 10.1038/s41591-020-0820-9. No abstract available.

A Genomic Perspective on the Origin and Emergence of SARS-CoV-2. Zhang YZ, **Holmes** EC. Cell. 2020 Apr 16;181(2):223-227. doi: 10.1016/j.cell.2020.03.035. Epub 2020 Mar 26.

Also this statement from Eddie Holmes

<https://bit.ly/2ym1UGe>

Best regards,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

On Apr 19, 2020, at 2:21 PM, Bill Gertz <bgertz@washingtontimes.com> wrote:

Katie,

Dr. Fauci on Friday said he would share a scientific paper with the press on the origin of the coronavirus. Can you please help me get a copy of that paper? Thanks in advance.

Bill Gertz

National Security Correspondent
@BillGertz | direct 202-636-3274
TheGertzFile.com

<twtdlogo.jpg>

3600 New York Ave NE | Washington DC, 20002

The information contained in this electronic transmission is intended for the exclusive use of the individuals to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is prohibited by law. If the reader of this transmission is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. In addition, any unauthorized copying, disclosure or distribution of the material in this e-mail and any attachments is strictly forbidden.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Apr 2020 01:22:40 +0000
To: Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: RE: IMPORTANT

Thanks Greg.

Patty:

Please respond to Dr. Dzau's questions.

Thanks,

Tony

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Sent: Sunday, April 19, 2020 7:06 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Fauci, Anthony (NIH/NIAID) [E]
(b) (6)
Cc: Barasch, Kimberly (NIH/NIAID) [C] (b) (6)
Subject: RE: IMPORTANT

Patty I had spoken to ASF about using a few slides and he said yes / I will have them done short;y

- V Dzau: I will begin the session by providing brief (~3 min) opening remarks describing the circumstances of the pandemic. Then, I will introduce the panelists and you will each have 7 minutes to provide remarks. You may use a limited number of slides for illustration. I hope that each panelist will provide their own perspective and speak to the issues proposed below.
- Jeremy Farrar will discuss the global response to the pandemic, drawing from his experience as a global leader, the chair of the Scientific Advisory Group for the WHO's R&D Blueprint and as a member of the Global Preparedness Monitoring Board.

- Tony Fauci will discuss the US pandemic and provide his perspective as a member of the White House Coronavirus Task Force addressing the 2019–20 coronavirus pandemic.
- George Gao will discuss China's response to the pandemic and lessons learned for the rest of the globe.
- Susan Weiss will discuss the viral characteristics of SARS COV2 , insights into its pathobiology, immunity and development of a pan-CoV antiviral.
- Richard Hatchett will discuss the development of new vaccines and treatments against COVID-19.
- Sanjay Gupta will comment on the health system response to the pandemic and challenges related to communication and public engagement in responding to COVID-19.

From: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Sent: Sunday, April 19, 2020 7:01 PM
To: Folkers, Greg (NIH/NIAID) [E] <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] <(b) (6)>
Subject: FW: IMPORTANT

We need to discuss tomorrow on our daily meeting/call – do you want to do slides.

Again this event is on a Saturday and is tentative as we do not know when the TF meeting will be scheduled that day.

So – if you can do it - will you use slides?

So if you cant do this – do you want a surrogate and who?

I will make sure David is on board for zoom.

From: Dzau, Victor J. <VDzau@nas.edu>

Sent: Sunday, April 19, 2020 3:11 PM

To: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >

Cc: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; (b) (6)
Mun, Jenny <JMun@nas.edu>

Subject: IMPORTANT

Dear Patty,

I hope this finds you well. I know how terribly busy Tony is and I hate to trouble him, however, the NAS Annual Meeting panel on COVID-19 is less than a week away and my team needs answers to the questions below. Can you call this to his attention or assist him in providing the signed form and requested information? We hope to have this by Tuesday (4/23) morning, if possible.

- Please provide a **cell number** where you can be reached in case you do not connect in time (if you prefer, you can provide the number of your assistant if they will be able to reach you directly by cell or at home).
- Will you have slides to display during your talk?
- Are you able to use Zoom 'share your screen' to show the slides directly during your talk or do you need someone from NAS to show your slides for you?
- Will you need a test session with our Zoom techs? Please let me know as soon as possible as staff are available to hold training sessions through Monday, April 20 (9 AM to 5 PM EDT).
- If you would like to promote your participation in our meeting on social media, please let me know the contact of your social media contact from your institution.

Finally, because this is going to be a remote meeting, we would like panelists to log into Zoom 30 minutes before the session starts – that is at 1:30 pm ET to go over the technology and any last minute speaker prep. So far, more than 800 Academy members have registered for the meeting and there will be additional members of the public and possibly the press tuning in.

Best,
Victor



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 19 Apr 2020 03:29:42 +0000
To: Peter Daszak
Subject: RE: Thank you for your public comments re COVID-19's origins

Peter:

Many thanks for your kind note.
Best regards,
Tony

From: Peter Daszak (b) (6)
Sent: Saturday, April 18, 2020 9:43 PM
To: Morens, David (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Stemmy, Erik (NIH/NIAID) [E] (b) (6) >; Erbelding, Emily (NIH/NIAID) [E] (b) (6) >; Aleksei Chmura (b) (6)
Subject: Thank you for your public comments re COVID-19's origins
Importance: High

Tony (cc'ing David so that you might pass this on to Tony once he has a spare second)

As the PI of the R01 grant publicly targeted by Fox News reporters at the Presidential press briefing last night, I just wanted to say a personal thankyou on behalf of our staff and collaborators, for publicly standing up and stating that the scientific evidence supports a natural origin for COVID-19 from a bat-to-human spillover, not a lab release from the Wuhan Institute of Virology.


(b) (7)(A)

From my perspective, your comments are brave, and coming from your trusted voice, will help dispel the myths being spun around the virus' origins.

Once this pandemic's over I look forward thanking you in person and let you know how important your comments are to us all.

Cheers,

Peter



From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 19 Apr 2020 01:23:00 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: cotton swabs

Followup email from Jake Tapper.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email: (b) (6)

From: Jake Tapper (b) (6)
Sent: Saturday, April 18, 2020 4:53 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Re: cotton swabs

Got it
Thanks

On Sat, Apr 18, 2020 at 4:52 PM Fauci, Anthony (NIH/NIAID) [E] (b) (6) > wrote:

This is what I was referring to. They are not ready for prime time, since they have to get the right media and wrapping.

Subject: Qtip announcement

<https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-gates-foundation-unitedhealth-group-quantigen-and-us-cotton>

Coronavirus (COVID-19) Update: FDA, Gates Foundation, UnitedHealth Group, Quantigen, and U.S. Cotton Collaborate to Address Testing Supply Needs

The U.S. Food and Drug Administration announced a further expansion of COVID-19 testing options through the recognition that spun synthetic swabs – with a design similar to Q-tips – could be used to test patients by collecting a sample from the front of the nose.

As part of this effort, U.S. Cotton, the largest manufacturer of cotton swabs and a subsidiary of Parkdale-Mills, developed a polyester-based Q-tip-type swab that is fully synthetic for compatibility with COVID-19 testing. Harnessing its large-scale U.S.-based manufacturing capabilities, U.S. Cotton plans to produce these new polyester swabs in large quantities to help meet the needs for coronavirus diagnostic testing.

“This action today demonstrates the ingenuity that results from the FDA working in partnership with the private sector. The Trump Administration has been working side-by-side with our industry partners to fight this pandemic, and today is a great example of that work. We appreciate work by UnitedHealth Group, Quantigen, and the Gates Foundation to perform and support the clinical studies necessary for this advancement. We also want to acknowledge U.S. Cotton’s efforts to manufacture a new type of swab for COVID-19 testing that can be produced at scale. We appreciate the work of these collaborators to consider how these test supplies could be broadly distributed to meet not only the testing needs of the United States but also global needs around the pandemic. All of these actions by these American organizations will help continue to expand our testing capability,” said FDA Commissioner Stephen M. Hahn, M.D.

This finding that spun synthetic swabs could be used for COVID-19 testing is based on results from a clinical investigation that represents a collaboration between the FDA, UnitedHealth Group, the Gates Foundation, and Quantigen. The type of testing at the front of the nose used in this study is notable because it allows self-collection by patients thereby limiting exposure of healthcare providers; it is more comfortable for patients and it can be performed by a swab that is more readily available and manufacturable at scale.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 22:21:02 +0000
To: Corey MD, Larry; Conrad, Patricia (NIH/NIAID) [E]
Cc: Mascola, John (NIH/VRC) [E]
Subject: RE: (b) (6)
Attachments: COVID vaccine editorial_16April 7pm - with Fauci edits.docx

Larry:

I have gone over the manuscript and have made a number of edits that are tracked into the attached document. Please take a look, accept the changes (unless you have issues with them), add the references and then let us discuss next steps, i.e. add or not Francis to authors and where in the order.

John:

Please also give it another good look.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Corey MD, Larry (b) (6) >
Sent: Saturday, April 18, 2020 12:34 AM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Fauci, Anthony (NIH/NIAID) [E]
(b) (6) >
Cc: Mascola, John (NIH/VRC) [E] (b) (6) >
Subject: working draft of NEJM

Here is the working draft . My manuscript typist too tired to work tonight so it reflects several changes I made tonight ; it should be readable ;

Larry

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 20:40:34 +0000
To: Auchincloss, Hugh (NIH/NIAID) [C] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E]; Greg Folkers (b) (6)
Subject: FW: You are a Hero

Please see me about this on Monday. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Kathy Ireland (b) (6)
Sent: Tuesday, April 7, 2020 4:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: You are a Hero

Dear Dr. Fauci,

Thank you for everything you're doing for America and the world. I'm writing to you today, rather than calling, because it's impossible to imagine the degree to which leading science during this COVID-19 pandemic is impacting your life and your family. Please know, that your wisdom and passion brings so much comfort to millions, including our family and me, specifically. You may recall from our previous talks, that (b) (6)

(b) (6) What a vicious virus, Dr. Fauci ... unlike anything I've ever seen.

In addition to my work as Ambassador for the Elizabeth Taylor AIDS Foundation, it is also an honor and responsibility to serve as International Youth Chair for the National Pediatric Cancer Foundation. In that position, people approach with questions for our government that I am uncomfortable giving opinions on in ignorance. So reluctant to bother you - I'm seeking to learn who at the NIH I should bring this to?

The question comes from my associate (b) (6), (b) (4)

(b) (4)

Thank you so much for all that you do.

Always,

Kathy

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 20:21:32 +0000
To: [REDACTED] (b) (6)
[REDACTED] (b) (6)
Subject: FW: article and bb rim
Attachments: The Mentor Who Made Dr. Anthony Fauci - WSJ - large text.pdf

This article about my relationship with Shelly Wolff is worth reading

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Barton Haynes, M.D. <barton.haynes@duke.edu>
Sent: Thursday, April 16, 2020 12:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: article and bb rim

Hi tony:

Glad this worked out. Wonderful article. Great tribute to both you and Shelly. But the socks in the last picture.....

On another note, [REDACTED] (b) (6)
[REDACTED]
[REDACTED]

[REDACTED] (b) (6)
[REDACTED] So when the pandemic is over or when you are down there and want a break, I can put you in touch with him to see the Regis bb goal.

He has been following your career for many years. Very nice fellow.

Thanks for all you are doing Tony, it only sounds like it is getting more and more difficult. But you are doing an amazing job....

So proud of you and that [REDACTED] (b) (6)

Best Bart

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 20:12:02 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Greg Folkers (b) (6); Billet, Courtney (NIH/NIAID) [E]
Subject: FW: From Jack Curry/ YES Network (Yankees)

Have we decided to set this up. Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)
Sent: Thursday, April 16, 2020 1:45 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6)>
Subject: ASF: From Jack Curry/ YES Network (Yankees)

Jack Curry (broadcaster with the YES Network, which is like MASN, but for the Yankees) is appealing to you as a New Yorker and lifelong Yankees fan for a 10-minute interview via Zoom. Jack covered the Yankees for 22 years at the NYT. The interview would run on YES (largest regional sports network in the country) as the focus of one of the original shows they are producing 3x/week called "YES, WE'RE HERE." It would be run across all of their social media platforms (reach of over 1M). They would also air clips on the Michael Kay Radio Show (TV play-by-play announcer for the Yankees), which is simulcast on YES and is the highest-rated drive time talk show in New York.

Questions below, including a few at the end about your lifelong baseball fandom. Is this something you'd be willing to do? If so we will seek clearance.

POSSIBLE QUESTIONS

DOCTOR FAUCI, I KNOW YOUR DAYS ARE FILLED WITH OFFERING ADVICE AND COUNSEL TO SO MANY PEOPLE ABOUT THE CORONAVIRUS. WITH THE SOBERING POSITION WE HAVE BEEN IN FOR A WHILE, WHAT WOULD BE YOUR MOST URGENT MESSAGE TO AMERICANS?

THE PHRASE 'FLATTENING THE CURVE' HAS BECOME COMMONPLACE IN OUR VERNACULAR IN RECENT WEEKS. HOW MUCH CLOSER ARE WE GETTING TO FLATTENING THE CURVE?

YOU'VE SAID SEVERAL TIMES THAT THE VIRUS IS THE CLOCK. WHAT IS THE VIRUS TELLING YOU ABOUT THAT TIME FRAME?

AS THE COUNTRY TRIES TO WORK ITS WAY BACK, THERE HAS BEEN SPECULATION ABOUT HOW PROFESSIONAL SPORTS CAN RETURN. WHAT ARE YOUR THOUGHTS ON HOW, FOR INSTANCE, MAJOR LEAGUE BASEBALL WOULD BE ABLE TO START ITS SEASON?

BASEBALL IS A SPORT IN WHICH SHAKING HANDS IS AS COMMON AS BALLS AND STRIKES. NOT JUST IN BASEBALL, OBVIOUSLY, BUT IN LIFE OVERALL, HOW MUCH DO YOU ADVOCATE NOT SHAKING HANDS ANYMORE?

THE NEW YORK TIMES REFERRED TO YOU AS THE EXPLAINER-IN-CHIEF IN COMPLIMENTING YOUR ABILITY TO SPEAK BLUNTLY AND TRUTHFULLY. SO HOW SHOULD AMERICANS PLAN ON BEHAVING AS WE MOVE FORWARD IN THESE UNCERTAIN TIMES?

AND...IF DR FAUCI WAS COMFORTABLE WITH IT, A COUPLE OF QUESTIONS ABOUT HIS BASEBALL FANDOM...

WITH ALL THAT'S HAPPENING AROUND US AND YOUR IMPORTANT ROLE IN IT, IT MIGHT SEEM TRITE TO DISCUSS BASEBALL. BUT I KNOW YOU'VE BEEN A YANKEE FAN FOR MORE THAN 70 YEARS. AND I WOULD LIKE TO ASK YOU A FEW BASEBALL QUESTIONS.

WHEN AND HOW DID YOUR YANKEE FANDOM BEGIN?

YOU WERE A YOUNGSTER WHEN THE YANKEES WON 5 STRAIGHT WORLD SERIES TITLES FROM 1949-1953, THE ONLY TIME THAT'S EVER HAPPENED IN BASEBALL HISTORY. WHAT ARE YOUR MEMORIES OF THOSE YEARS?

HOW HAS YOUR BACKGROUND IN SPORTS HELPED YOU IN YOUR ROLE WITH THE NIAID?

AND, FINALLY, YOU'VE SPOKEN ABOUT HOW NEW YORK IS THE EPICENTER OF THE VIRUS. FOR NEW YORKERS WHO ARE LOOKING FOR SOME LIGHT AT THE END OF THE TUNNEL, WHAT WOULD YOU SAY TO THEM?

From: (b) (6)
Sent: Mon, 27 Apr 2020 07:00:08 -0400
To: Barasch, Kimberly (NIH/NIAID) [C]
Subject: Fwd: The global health leaders call, THURSDAY 30 April at 14.30 CET

FYI

Begin forwarded message:

From: "RYAN, Michael J." (b) (6) <>
Date: April 27, 2020 at 5:34:56 AM EDT
To: SHOC (b) (6) <>, Office of the Director-General <DGOOffice@who.int>, "Redfield, Robert R. (CDC/OD)" (b) (6)
(b) (6)
(b) (6) David Heymann
(b) (6) <>, "Felicity Harvey" (b) (6)
(b) (6) "Chris.Elias" (b) (6)
(b) (6)
(b) (6) <>, "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
(b) (6)
(b) (6) "COX, Paul Michael" (b) (6) <>, "GREIN, Thomas"
(b) (6) <>, "MINHAS, Raman" (b) (6)
(b) (6) <>, "Conrad, Patricia (NIH/NIAID) [E]" (b) (6) <>, "MAHJOUR, Jaouad" (b) (6) <>, "FALL, Ibrahima Soce" (b) (6) <>, "Thomas R. Frieden" (b) (6)
Lynn Banks <> (b) (6) <>, President | Resolve to Save Lives <president@resolvetosavelives.org>, "Amadou.SALL"
(b) (6) "AL-SHORBAJI, Farah" (b) (6)
(b) (6) <>, Robynn Leidig (b) (6) <>
(b) (6) <>, "DRURY, Patrick Anthony" (b) (6) <>, "Dr VAN KERKHOVE, Maria" (b) (6)
(b) (6)
(b) (6) "POOLE, Marcia" (b) (6) <>, "GRAAFF, Peter Jan" (b) (6) <>, Tarik Mohammed

(b) (6) Carlos
Navarro Colorado (b) (6)
Ryan Morhard (b) (6)>
"BRIAND, Sylvie" (b) (6), "MORGAN, Oliver" (b) (6)
"Harries, Jenny" (b) (6), "Awwad, David (NIH/NIAID)"
[C]" (b) (6), "SIMONSON, Stewart" (b) (6)
"SINGER, Peter Alexander" (b) (6) "Jayatunga, Wikum"
(b) (6)
"Julie.HALL" (b) (6)>, Amelie
RIOUX (b) (6)>, "KABIR, Sophia" (b) (6)
(b) (6)
, "SHIN, Young-Soo" (b) (6)
Feng Ding (b) (6)
ASMA, Samira" (b) (6)>
Cc: SHOC <shoc@who.int>, Office of the Director-General <DGOoffice@who.int>,
"SCHWARTLANDER, Bernhard F." (b) (6)>, "MAHJOUR,
Jaouad" (b) (6), "FALL, Ibrahima Soce" (b) (6)>, "GREIN,
Thomas" (b) (6), "MINHAS, Raman" (b) (6)>, "COX, Paul
Michael" (b) (6)>, "AL-SHORBAJI, Farah" (b) (6),
"POOLE, Marcia" (b) (6)>, "DRURY, Patrick Anthony"
(b) (6)>, "GRAAFF, Peter Jan" (b) (6)>, "Dr VAN
KERKHOVE, Maria" (b) (6)>, "KABIR, Sophia"
(b) (6)>, "FARES, Christine Youssef" (b) (6),
"AYLWARD, Raymond Bruce J." (b) (6)>, "SMITH, Ian Michael"
(b) (6)

Subject: The global health leaders call, THURSDAY 30 April at 14.30 CET

Dear colleagues,

Dr Tedros would like to invite you to the next informal discussion about the ongoing 2019 novel coronavirus.

The teleconference will be hosted on **THURSDAY, 30 April** at **14:30 CET** and **Zoom details** are copied below.

If you experience any technical difficulties joining this conference call, please contact the WHO HQ EOC operator at: +41227915533

It would be appreciated if you could kindly confirm your participation to Ms Sophia Kabir, email (b) (6); mobile no. (b) (6)

The agenda and background documents will be shared ahead of the call.

Best,

Mike

Join Zoom Meeting

[https://who.zoom.us/j/\(b\)\(6\),\(b\)\(4\)](https://who.zoom.us/j/(b)(6),(b)(4))

Meeting ID: (b) (6), (b) (4)

Password: (b) (6), (b) (4)

Dial by your location

+41 43 210 71 08 Switzerland

+41 43 210 70 42 Switzerland

0 800 561 252 Switzerland Toll-free

0 800 002 622 Switzerland Toll-free

+1 253 215 8782 US (Tacoma)

+1 213 338 8477 US (Los Angeles)

888 475 4499 US Toll-free

877 853 5257 US Toll-free

+33 7 5678 4048 France

+33 1 7095 0350 France

0 800 944 049 France Toll-free

0 800 940 415 France Toll-free

Meeting ID: (b) (6), (b) (4)

Find your local number: <https://who.zoom.us/j/aeFZfwUgUc>

Join by SIP

(b) (6), (b) (4)@zoomcrc.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 10:54:50 +0000
To: Duchin, Jeff
Subject: RE: High Praise

Jeff:

Well-deserved recognition of your fine work. Keep it up.
Best regards,
Tony

From: Duchin, Jeff (b) (6)
Sent: Sunday, April 26, 2020 11:58 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: High Praise

Tony - in a recent shoddy "investigative journalism" piece about our work here in Seattle (<https://www.seattletimes.com/seattle-news/times-watchdog/why-the-seattle-sounders-game-went-on-despite-coronavirus-emergency/>) the reporter referred to me as being to the Seattle area what Anthony Fauci would become to the country. So despite the crappy reporting he bestowed upon me the highest of praise and reminded me again of the incredible service you are doing for our country. Hang in there and take care of your self. We need you. Jeff



Why the Seattle Sounders
game March 7 went on
despite coronavirus
emergency

As virus fears grew, public officials and sports execs debated health risks — and PR messages — but let 33,000 into a March 7 Sounders match. At what cost?

www.seattletimes.com

Jeffrey S. Duchin, MD (he/him)
Health Officer and Chief, Communicable Disease Epidemiology & Immunization Section
Public Health - Seattle and King County
Professor in Medicine, Division of Infectious Diseases, University of Washington
Adjunct Professor, School of Public Health
401 5th Ave, Suite 1250, Seattle, WA 98104
Tel: (206) 296-4774; Direct (b) (6); Fax: (206) 296-4803
E-mail: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 02:47:49 +0000
To: Shapiro, Neil (NIH/OD) [E]; Collins, Francis (NIH/OD) [E]; Tabak, Lawrence (NIH/OD) [E]; Johnson, Alfred (NIH/OD) [E]; Hallett, Adrienne (NIH/OD) [E]
Subject: RE: NIAID facilities in the CARES Act spend plan

I suggest that [REDACTED] (b) (6)

From: Shapiro, Neil (NIH/OD) [E] [REDACTED] (b) (6) >
Sent: Sunday, April 26, 2020 10:32 PM
To: Collins, Francis (NIH/OD) [E] [REDACTED] (b) (6) >; Tabak, Lawrence (NIH/OD) [E] [REDACTED] (b) (6) >; Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6); Johnson, Alfred (NIH/OD) [E] [REDACTED] (b) (6) >; Hallett, Adrienne (NIH/OD) [E] <[REDACTED] (b) (6)>
Subject: NIAID facilities in the CARES Act spend plan
Importance: High

Francis and Tony,

I have been working to get OMB/ASFR clearance for the 3rd Supplemental spend plan, and have encountered a hitch with OMB concerning the VRC/RML proposal. They say they [REDACTED] (b) (3)

[REDACTED]

I raised the issue to Norris, and he asked me to [REDACTED] (b) (3)

[REDACTED]

[REDACTED] (b) (3) Thanks,

Neil

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 02:46:32 +0000
To: Collins, Francis (NIH/OD) [E]
Subject: RE: New England Journal of Medicine 20-13479

Yes, please.

From: Collins, Francis (NIH/OD) [E] (b) (6) >
Sent: Sunday, April 26, 2020 10:32 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: FW: New England Journal of Medicine 20-13479

Want me to call (b) (6) ?

From: Corey MD, Larry (b) (6) >
Sent: Sunday, April 26, 2020 1:44 PM
To: Collins, Francis (NIH/OD) [E] (b) (6) >; Fauci, Anthony (NIH/NIAID) [E] (b) (6); Mascola, John (NIH/VRC) [E] (b) (6) >
Subject: RE: New England Journal of Medicine 20-13479

I think it would be very helpful , I see no downside ...

From: Collins, Francis (NIH/OD) [E] (b) (6) >
Sent: Sunday, April 26, 2020 6:38 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Mascola, John (NIH/VRC) [E] (b) (6); Corey MD, Larry (b) (6) >
Subject: RE: New England Journal of Medicine 20-13479

If it would be helpful, I'd be glad to do the outreach to Holden Thorp – Tony and I can discuss.

Francis

From: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Sent: Sunday, April 26, 2020 8:37 AM
To: Mascola, John (NIH/VRC) [E] (b) (6) >; Corey MD, Larry (b) (6) >; Collins, Francis (NIH/OD) [E] (b) (6) >
Subject: RE: New England Journal of Medicine 20-13479

All good options. Let us go with *Science* first. If they do not want it, I am certain that *Science Translational Medicine* will take it. I will discuss with Francis and John.

From: Mascola, John (NIH/VRC) [E] (b) (6) >
Sent: Saturday, April 25, 2020 5:59 PM
To: Corey MD, Larry <(b) (6)>; Collins, Francis (NIH/OD) [E] (b) (6)

Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Subject: RE: New England Journal of Medicine 20-13479

In looking at NEJM, they have had 4 COVID-19 perspectives in last 6 weeks, and they may have impacted their thinking.

Agree with talking to editors. If interest in Science or Nature, suggestions below.

Priscilla Kelly, editor at science emailed me a while about their interest in papers. So if interest in Science, we could check with her.

If Nature, Ursula Weiss.

John

From: Corey MD, Larry (b) (6) >

Sent: Saturday, April 25, 2020 5:50 PM

To: Collins, Francis (NIH/OD) [E] (b) (6) >

Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Mascola, John (NIH/VRC) [E] (b) (6) >

Subject: Re: New England Journal of Medicine 20-13479

You and Tony decide. Science or Nature accomplish the same but it seems we need a discussion with the editor first to explain the importance of the manuscript.

Sent from my iPhone

On Apr 25, 2020, at 2:18 PM, Collins, Francis (NIH/OD) [E] (b) (6) > wrote:

Very surprised.

Do you want me to push back?

Francis

From: Corey MD, Larry <(b) (6)>

Sent: Saturday, April 25, 2020 3:55 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Mascola, John (NIH/VRC) [E] (b) (6) >

Cc: Collins, Francis (NIH/OD) [E] <(b) (6)>

Subject: RE: New England Journal of Medicine 20-13479

A do have to say I am surprised . but ok

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Sent: Saturday, April 25, 2020 12:53 PM
To: Corey MD, Larry (b) (6)>; Mascola, John (NIH/VRC) [E]
(b) (6)>
Cc: Collins, Francis (NIH/OD) [E] (b) (6)
Subject: Fwd: New England Journal of Medicine 20-13479

Let us discuss next steps

Begin forwarded message:

From: New England Journal of Medicine
<onbehalf@manuscriptcentral.com>
Date: April 25, 2020 at 12:31:26 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" <afauci@niaid.nih.gov>
Subject: New England Journal of Medicine 20-13479
Reply-To: "editorial@nejm.org" <editorial@nejm.org>

Dear Dr. Fauci,

I am sorry to inform you that your submission, "A Strategic Approach to Successful COVID-19 Vaccine Development," has not been accepted for publication in the Journal. It was evaluated by members of our editorial staff. After considering its focus, content, and interest, we made the editorial decision not to consider your submission further. We are informing you of this promptly so that you can submit it elsewhere.

Thank you for the opportunity to consider your submission.

Sincerely yours,

Eric Rubin, M.D., Ph.D.
Editor-in Chief

New England Journal of Medicine
10 Shattuck Street
Boston, MA 02115
(617) 734-9800
Fax: (617) 739-9864
<http://www.nejm.org>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 00:48:28 +0000
To: Adrian Hill
Cc: Hildegund Ertl; Sarah Gilbert; Redfield, Robert R. (CDC/OD)
Subject: RE: COVID-19 vaccine

Adrian:

Thank you for your note. Sorry that I took a few days to get back to you, but I have been swamped. It is good to know of your work on the chimpanzee adenoviral vectors. The biosafety classification of viral vectors in the U.S. is within the purview of the CDC, and so I have copied CDC Director Bob Redfield on this e-mail. He would be able to point you in the right direction.


Best regards,

Tony

From: Adrian Hill (b) (6)
Sent: Monday, April 20, 2020 6:16 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Hildegund Ertl (b) (6); Sarah Gilbert (b) (6) >
Subject: FW: COVID-19 vaccine

Dear Dr Fauci

(b) (4)



Thank you for your consideration of this at an exceptionally busy time.

Yours sincerely

Adrian Hill

Professor Adrian V. S. Hill
Director, The Jenner Institute
Nuffield Department of Medicine
University of Oxford
Old Road Campus Research Building
Oxford OX3 7DQ

Tel: + (b) (6)

Email (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 00:45:21 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: 260 County Models of COVID-19 Outbreaks across the US

Please see me or give me a call about this. Thanks.

From: Rubin, David M (b) (6)>
Sent: Tuesday, April 21, 2020 9:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Offit, Paul (b) (6); Tasian, Gregory E (b) (6)>; Huang, Jing (b) (6)>
Subject: 260 County Models of COVID-19 Outbreaks across the US

Hi Dr. Fauci,

Jon Yewdell suggested I contact you directly to expedite a briefing on the new county-level models that our center, PolicyLab, at CHOP, will be releasing tomorrow. He shared with us your note below about including Ambassador Birx and Bob Redfield as well. We'd be happy to do so, and had been in touch with Ambassador Birx last week. We have also stayed in contact with the analytics team led by Irum Zaidi and Chuck Vitek. I am also tasked to Governor Wolf's crisis team in Pennsylvania and shared the data with the Governor today.

Let us know next steps for arranging a video conference. Will arrange our schedule at your convenience. Will have Drs. Paul Offit, Greg Tasian, and Jing Huang join from our team.

Best,

Dave

David Rubin, MD MSCE

Director of Population Health Innovation
Director of PolicyLab

Children's Hospital of Philadelphia

Office: (b) (6)

Cell: (b) (6)

www.policylab.chop.edu | [@PolicyLabCHOP](https://twitter.com/PolicyLabCHOP)



Professor of Pediatrics
Perelman School of Medicine
University of Pennsylvania



From: "Yewdell, Jon (NIH/NIAID) [E]" (b) (6)
Date: Tuesday, April 21, 2020 at 8:55 PM
To: "Rubin, David M" (b) (6) >
Cc: Paul Offit (b) (6) >
Subject: <no subject>

David,
At this point, I think it is best to contact Tony directly. He's at
(b) (6),

Good luck!

jon

Jonathan Yewdell MD, PhD
Chief, Cellular Biology Section
Laboratory of Viral Diseases
NIAID, NIH

[Truth Wins: A Practical Guide to Succeeding in Biomedical Research](#)
[free eBook download](#) of my book

[Link to Ohio State Science Sunday video on scientific method](#)

From: Rubin, David M <(b) (6)>
Sent: Tuesday, April 21, 2020 8:43 PM
To: Yewdell, Jon (NIH/NIAID) [E] (b) (6)
Cc: Offit, Paul (b) (6)
Subject: FW: Heads up from Paul Offit and David Rubin on policy memorandum to reopen economy

Hi Jon,

Paul forwarded me your email back to him. Our team would be happy to present to him, Ambassador Birs, and Bob Redfield. We have shared the models with Governor Wolf in Pennsylvania today, and they are informing strategy here. The 260 county models will post to our PolicyLab website tomorrow. Of

note, Paul and I had spoken to Ambassador Birx in the last couple of weeks, and we have been in contact with Irum Zaidi, Chuck Vitek, and the analytics team.

Let us know how would be best to set up a group webinar to present the information. Or feel free to connect us directly with their schedulers. Think the models illustrate the low margin of error in the large cities for resurgence risk, even as other less densely populated counties may be tolerant to reopening strategies.

Dave

David Rubin, MD MSCE

Director of Population Health Innovation
Director of PolicyLab

Children's Hospital of Philadelphia

Office: (b) (6)

Cell: (b) (6)

www.policylab.chop.edu | [@PolicyLabCHOP](https://twitter.com/PolicyLabCHOP)



Professor of Pediatrics
Perelman School of Medicine
University of Pennsylvania



From: Paul Offit (b) (6) >

Date: Tuesday, April 21, 2020 at 5:46 PM

To: "Rubin, David M" (b) (6)

Subject: Fw: Heads up from Paul Offit and David Rubin on policy memorandum to reopen economy

Tony has seen our memo. His response is below.

From: Yewdell, Jon (NIH/NIAID) [E] (b) (6) >

Sent: Tuesday, April 21, 2020 5:45 PM

To: Offit, Paul

Subject: FW: Heads up from Paul Offit and David Rubin on policy memorandum to reopen economy

Tony never ceases to amaze me....

See immediate reply below

Jonathan Yewdell MD, PhD

Chief, Cellular Biology Section

Laboratory of Viral Diseases

NIAID, NIH

Truth Wins: A Practical Guide to Succeeding in Biomedical Research
free eBook download of my book

Link to Ohio State Science Sunday video on scientific method

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >

Sent: Tuesday, April 21, 2020 5:06 PM

To: Yewdell, Jon (NIH/NIAID) [E] (b) (6) >

Cc: Shaffer, Meredith (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Barasch, Kimberly (NIH/NIAID) [C]

(b) (6) >

Subject: RE: Heads up from Paul Offit and David Rubin on policy memorandum to reopen economy

Jon:

Thanks for the note. It would be even better if they could present not only to me, but to Deb Birx and Bod Redfield.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Yewdell, Jon (NIH/NIAID) [E] (b) (6)
Sent: Tuesday, April 21, 2020 4:29 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Shaffer, Meredith (NIH/NIAID) [E] (b) (6)
Subject: Heads up from Paul Offit and David Rubin on policy memorandum to reopen economy

Tony,

Paul and David asked me to pass this on to you.

Forwarded message from David:

"I think the time has come, with our models on 260 counties across the country releasing in the next 48 hours, to offer Tony Fauci, and potentially other task force members, a preview of the work. Our models have incorporated local area differences due to weather, population and social distancing. They reveal that the large, densely populated cities will struggle to re-open, and are not well aided by weather effects given their density. However, in less densely populated areas, in which case counts are lower, weather has been a mitigating factor. These latter counties may

have better success when they re-open assuming they are smart about workplace safety and have testing and surveillance strategies in place”

Dave

David Rubin, MD MSCE

Director of Population Health Innovation
Director of PolicyLab

Children's Hospital of Philadelphia

Office: (b) (6)

Cell: (b) (6)

www.policylab.chop.edu | [@PolicyLabCHOP](https://twitter.com/PolicyLabCHOP)



Professor of Pediatrics
Perelman School of Medicine
University of Pennsylvania



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 00:43:24 +0000
To: Young, Neal S (NIH/NHLBI) [E]
Subject: RE: Lambris

Thanks, Neal.
Best regards,
Tony

From: Young, Neal S (NIH/NHLBI) [E] (b) (6) >
Sent: Wednesday, April 22, 2020 8:07 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: FW: Lambris

Dear Tony

'Forwarding to you at the request of two colleagues, experts in anti-complement therapies.

Thanks, and 'stay healthy.

Neal

From: "John D. Lambris" (b) (6) >
Date: Tuesday, April 21, 2020 at 2:43 PM
To: Skype (b) (6)
Cc: Antonio M Risitano (b) (6)
Subject: Lambris

Hi Neal,

I hope all is well and you are staying healthy.

(b) (4)

Could you please bring us in contact with Antony Fauci to see if he can help our program?

All the best and Stay Healthy

John

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 00:42:34 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Update: Inhibit cytokine storm in COVID-19 patients by Proteasome Inhibitors
Attachments: (b) (4)

Please respond to this person. Thanks.

From: Kircheis Dr. Ralf <RKircheis@syntacoll.de>
Sent: Wednesday, April 22, 2020 9:41 AM
To: Coomes, Stephanie (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: (b) (6); Kircheis Dr. Ralf <RKircheis@syntacoll.de>
Subject: Update: Inhibit cytokine storm in COVID-19 patients by Proteasome Inhibitors
Importance: High

Dear Dr. Fauci,
dear Dr. Coomes,

thank you for your reply from 13. April with the notice that the information has been shared with NIAID's COVID-19 research team.

Has the project already been initially evaluated by the team?

Are there any questions or need for additional information?

- I have summed up the relevant data regarding the use of proteasome inhibitors for treatment of COVID-19 patients with acute lung and systemic organ failure in a position paper, please find a Preview draft attached.
- With regard to currently ongoing trials with monoclonal antibodies against the IL-6 receptor, i.e. tocilizumab or sarilumab: These approaches go into the same direction as the present suggestion, however, inhibition of NF- κ B by proteasome inhibitors could provide the unique potential to inhibit the release of multiple cytokines simultaneously, in particular strongly pro-inflammatory cytokines including IL-1, IL-6, TNF α and chemokines, such as MIP-1 and CXCL1.
- This simultaneous inhibition of multiple cytokines/chemokine seems to be advantageous compared to single target approaches (as with the mAb) to compensate for redundant and synergistic effects of multiple cytokines released during highly pathogenic CoV or H5N1 infection.

Looking forward to hearing from you.

Kind regards,

Ralf

Mit freundlichen Grüßen / Kind regards

Dr. Ralf Kircheis

Director R&D

Research & Development

Mail: RKircheis@syntacoll.de

Phone: +49 9441 686048

syntacoll

Syntacoll GmbH, Hennastrasse 24, D-93342 Saalaa, d. Donau
Tel: +49 9441 / 68 60 0, Fax: +49 9441 / 68 60 30
Handelsregister: Amtsgericht Regensburg - HRB 1612
USt-IdNr. DE 128580796
Geschäftsführerin: Dr. Alexandra Dietrich

Unsere Hinweise zum Datenschutz, insbesondere zu den Ihnen zustehenden Rechten, finden Sie unter:
www.syntacoll.de/datenschutz

Von: Coomes, Stephanie (NIH/NIAID) [E] (b) (6)

Gesendet: Montag, 13. April 2020 02:37

An: Kircheis Dr. Ralf <RKircheis@syntacoll.de>

Betreff: RE: Inhibit cytokine storm in COVID-19 patients by Velcade Bortezomib

Dear Dr. Kircheis,

Thank you for your recent email to Dr. Anthony Fauci. Your message was forwarded to the Division of Microbiology and Infectious Diseases (DMID) at the National Institute of Allergy and Infectious Diseases (NIAID). As a member of DMID's Office of Scientific Coordination and Program Operations, I am pleased to respond.

I want to thank you for reaching out to share this information and let you know that your message has been shared with NIAID's COVID-19 research team.

Sincerely,
Stephanie

Stephanie M. Coomes, Ph.D.
Health Scientist Administrator
Office of Scientific Coordination and Program Operations
Division of Microbiology and Infectious Diseases
National Institute of Allergy and Infectious Diseases
National Institutes of Health
5601 Fishers Lane, Room 7G68
Rockville, MD 20892

(b) (6)

(b) (6)

Disclaimer: The information in this email and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the originally intended recipient. If you have received this email in error, please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of NIAID by one of its representatives.

From: Kircheis Dr. Ralf <RKircheis@syntacoll.de>

Sent: Wednesday, April 8, 2020 2:49 AM

To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Billet, Courtney (NIH/NIAID) [E]

<(b) (6)>; NIAID Ocpstoffice (NIH/NIAID) <OCPOSTOFFICE@niaid.nih.gov>

Cc: Fischer, Elizabeth (NIH/NIAID) [E] <(b) (6)>; Foster, Erin (NIH/NIAID) [E]

<(b) (6)>; Foster, Sarah (NIH/NIAID) [E] <(b) (6)>; Vasilenko, Olga

(NIH/NIAID) [E] <(b) (6)>; Vasquez, Aurelio (NIH/NIAID) [E]

<(b) (6)>; Vostal, Alexander (NIH/VRC) [F] <(b) (6)>; Vazquez-

Maldonado, Nancy (NIH/NIAID) [E] <(b) (6)>; Austin, James (NIH/NIAID) [E]

<(b) (6)>; Agulto, Liane (NIH/NIAID) [E] <(b) (6)>; Deckhut, Alison

(NIH/NIAID) [E] <(b) (6)>; Kircheis Dr. Ralf <RKircheis@syntacoll.de>

Subject: WG: Inhibit cytokine storm in COVID-19 patients by Velcade Bortezomib

Importance: High

Inhibition of cytokine storm in COVID-19 patients with acute respiratory distress syndrom by PROTEASOME INHIBITORS e.g. Velcade (Bortezomib)

Dear Dr. Fauci,

dear Madams/Sirs,

I want to bring to your attention some potentially important experimental data and a new proposal for treatment of COVID-19 patients with acute respiratory distress syndrome and organ failure. Sorry for the broad distribution but I wanted to make sure that my message reaches you.

Similarly as has been described earlier for SARS-CoV, MERS-CoV (Channappanavar & Perlman, 2017), H5N1 and some heavy H1N1 Influenza A infections, also COVID-19 patients have been reported to show significantly increased systemic cytokine release (i.e. cytokine storm), particularly those patients with lung failure or systemic organ failure (*Chaolin Huang et al. Lancet vol 395, 2020, ref 1*).

Previous studies at **Virologik GmbH, Erlangen, Germany**, in collaboration with the **Friedrich-Loeffler-Institut, Tuebingen, Germany** have shown, that H5N1 (or alternatively LPS) -induced Cytokine storm *in vivo* can be inhibited by application of Proteasome Inhibitors (*E. Haasbach et al, Antiviral Res. 91, 2011, ref. 2*), via the inhibition of translocation of the NF- κ B transcription factor to the nucleus (see **Fig. below**). The mechanism of NF- κ B inhibition by proteasome inhibitors is well described, and works via the inhibition of the proteasomal degradation of the cytosolic inhibitor I κ B, this way keeping NF- κ B bound in the cytosol and thereby inhibiting the otherwise induced (by cytokine or LPS- or RNA virus) translocation of NF- κ B to the nucleus where it would initiate the transcription of many cytokines. This effect of proteasome inhibitors seems to work in most cell types, we could demonstrate this effect in several different cell types (including macrophages) after stimulation with TNF α in vitro and in H5N1 (or LPS) treated mice in vivo (see manuscript and Figs. attached).

Inhibition of NF- κ B by proteasome inhibitors provides the unique potential to inhibit the release of many cytokines simultaneously, in particular strongly proinflammatory cytokines IL-1 α , IL-6, TNF α , MIP-1 β ... (whereas some other cytokines involved in antiviral immune response, such as IFN γ probably seem to be not/less affected (because of different transcription pathway)).

Importantly, beside the anti-inflammatory activity, proteasome inhibitors showed also significant anti-fibrotic activity (Lueftenegger et al., manuscript and figs attached), which may be also important in the treatment of COVID-19 patients with heavy lung disease.

Furthermore, there have been several publications showing that in particular early phases of the replication cycle of Corona virus seem to be dependent on interaction with the ubiquitin-proteasomal system (UPS) of the host cell, and were effectively inhibited by selective 20S proteasome inhibitors (such as Velcade) (Wang et al. *Virology J* 2010, 7:99 (ref. 3); M. Raaben et al. *J. Virology*, 84(15), 2010, ref. 4).

There are several registered proteasome inhibitors (Bortezomib (Velcade®) e.g. produced by Millennium Pharmaceuticals (i.e Takeda Oncology); Carfilzomib (Kyprolis®), Ixazomib (Ninlaro®)) for treatment of multiple myeloma and Mantel cell lymphoma, i.e. there are registered drugs with well known side effects available to be tested in small clinical studies for evaluation of their therapeutic efficacy in COVID-19 patients with heavy lung disease and other organ failure. **Noteworthy:** in contrast to the chronical oncological indications where up to 8 treatment cycles (and sometimes even more) are applied, it seems plausible that just one or two treatment cycles of proteasome inhibitors might be sufficient to downregulate the cytokine storm in COVID-19 patients, which would be associated also with much lower side effects.

Early first experience on efficacy could be gained from compassionate use applications in heavily ill COVID-19 patients very quickly. Beside the registered application forms, i.e. infusions, probably also inhalative application should be tested as well, because it may be better suited to reach the respective target cells in the lung, i.e. alveolar epithelial cell and alveolar macrophages. There are multiple inhalative devices available, e.g. the Handihaler by Boehringer Ingelheim used for Spiriva (for COPD treatment).

Although there are still many open questions, the potential to control the cytokine storm-induced heavy lung and other organ failure by using already registered drugs, ie. proteasome inhibitors may be a real chance to get an additional treatment option, hopefully decreasing the cases necessary for artificial aeration.

Please forward this mail to the colleagues you consider relevant for evaluation, discussion and consideration for your clinical strategy for COVID-19.

Please let me know if additional informations are necessary.

To my person: I have MD PhD degree and have many years experience in pharmaceutical development (Boehringer Ingelheim), Biotech (Igeneon, Aphton, Virologik GmbH) (for reference see also PubMed Kircheis r) currently leading R&D activities at Syntacoll (part of Innocoll). I am providing this information personally in order to help to find a treatment for COVID-19 patients.

Looking forward to getting feedback from you,


With kind regards,

Ralf Kircheis (MD PhD)

(b) (6)

rkircheis@syntacoll.de

PIs inhibit TNF α induced nuclear NF κ B translocation



- PI inhibit TNF α induced nuclear NF κ B translocation in a variety of cells, including tumor cells, stellate cells and macrophages

Antiviral Res. 2011 Sep;91(3):304-13. doi: 10.1016/j.antiviral.2011.07.006. Epub 2011 Jul 13.

Antiviral activity of the proteasome inhibitor VL-01 against influenza A viruses.

Haasbach E¹, Pauli EK, Spranger R, Mitzner D, Schubert U, Kircheis R, Planz O.

Author information

Abstract

The appearance of highly pathogenic avian influenza A viruses of the H5N1 subtype being able to infect humans and the 2009 H1N1 pandemic reveals the urgent need for new and efficient countermeasures against these viruses. The long-term efficacy of current antivirals is often limited, because of the emergence of drug-resistant virus mutants. A growing understanding of the virus-host interaction raises the possibility to explore alternative targets involved in the viral replication. In the present study we show that the proteasome inhibitor VL-01 leads to reduction of influenza virus replication in human lung adenocarcinoma epithelial cells (A549) as demonstrated with three different influenza virus strains, A/Puerto Rico/8/34 (H1N1) (EC₅₀ value of 1.7 μ M), A/Regensburg/D6/09 (H1N1v) (EC₅₀ value of 2.4 μ M) and A/Mallard/Bavaria/1/2006 (H5N1) (EC₅₀ value of 0.8 μ M). In in vivo experiments we could demonstrate that VL-01-aerosol-treatment of BALB/c mice with 14.1 mg/kg results in no toxic side effects, reduced progeny virus titers in the lung ($1.1 \pm 0.3 \log_{10}$ pfu) and enhanced survival of mice after infection with a 5-fold MLD₅₀ of the human influenza A virus strain A/Puerto Rico/8/34 (H1N1) up to 50%. Furthermore, treatment of mice with

VL-01 reduced the cytokine release of IL- α/β , IL-6, MIP-1 β , RANTES and TNF- α induced by LPS or highly pathogen avian H5N1 influenza A virus. The present data demonstrates an antiviral effect of VL-01 in vitro and in vivo and the ability to reduce influenza virus induced cytokines and chemokines.

Copyright © 2011 Elsevier B.V. All rights reserved.

PMID:21777621

DOI: [10.1016/j.antiviral.2011.07.006](https://doi.org/10.1016/j.antiviral.2011.07.006)

[Indexed for MEDLINE]

Mit freundlichen Grüßen / Kind regards

Dr. Ralf Kircheis

Director R&D

Research & Development

Mail: RKircheis@syntacoll.de

Phone: +49 9441 686048

syntacoll

Syntacoll GmbH, Donaustrasse 24, D-93342 Saal a. d. Donau
Tel: +49 9441 / 68 60 0, Fax: +49 9441 / 68 60 30
Handelsregister: Amtsgericht Regensburg - HRB 1612
USt-IdNr. DE 128580796
Geschäftsführerin: Dr. Alexandra Dietrich

Unsere Hinweise zum Datenschutz, insbesondere zu den Ihnen zustehenden Rechten, finden Sie unter www.syntacoll.de/datenschutz

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 00:40:50 +0000
To: Xizhong, Cui (NIH/CC/CCMD) [E]
Subject: RE: remdesivir and Present's words on disinfectant

Brian:

Thank you for your note. [REDACTED] (b) (5)

Best regards,
Tony

From: Xizhong, Cui (NIH/CC/CCMD) [E] [REDACTED] (b) (6) >
Sent: Sunday, April 26, 2020 8:36 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: remdesivir and Present's words on disinfectant

Dear Dr. Fauci,

I am an investigator in CCMD, CC, National Institutes of Health, I am studying coronavirus infection in animal models on preclinical treatment. I was a doctor when I was in China, now I am just a preclinical investigator on infectious diseases.

[REDACTED] (b) (5)

[REDACTED] (b) (6), (b) (5)

Best wish to you and be safe. Thanks your efforts to all Americans!!

Brian X. Cui, MD, Ph.D
Critical Care Medicine Department
Clinical Center
National Institutes of Health
Phone: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 23:13:59 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Subject: Re: Keynote Speaker- Keystone Vaccinology eSymposia (directions to record & upload talk)
Attachments: image001.png, image002.png, image003.png, image004.png, image005.png

Agree.

On Apr 26, 2020, at 6:38 PM, Folkers, Greg (NIH/NIAID) [E]
<[REDACTED]> wrote:

I think Hilary is closest to this and should get the assignment

From: Fauci, Anthony (NIH/NIAID) [E] [REDACTED]
Sent: Sunday, April 26, 2020 5:12 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: FW: Keynote Speaker- Keystone Vaccinology eSymposia (directions to record & upload talk)

Greg and team:

Let us discuss.

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED]
FAX: (301) 496-4409
E-mail: [REDACTED]

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Kristina Horton <kristinah@keystonesymposia.org>
Sent: Friday, April 24, 2020 4:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: rino.r.rappuoli@gsk.com; Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Subject: Keynote Speaker- Keystone Vaccinology eSymposia (directions to record & upload talk)

Greetings Dr. Fauci:

Thank you for agreeing to participate as the keynote speaker for the Keystone eSymposia: **Vaccinology in the Age of Pandemics: Strategies Against COVID-19 & Other Global Threats**, a virtual conference which will be held on, **Monday, June 15 and Tuesday, June 16, 2020**.

Understanding how busy you are right now, we would like to make this process as easy as possible. We are hoping to receive pre-recorded talks by Monday, May 18. Please keep us apprised on your timeline and we will work with your schedule. Here are the details on next steps.

Next Steps:

- **Keynote Talk Title:** Transforming Vaccinology: COVID-19 Emergency and Considerations for the Next Decade
 - **Please review your talk title and return any changes.** Changes can be made up to two-weeks prior to the event.
- **Please follow this link to upload your talk recording, by Monday, May 18.** Click here to learn more about recording your presentation. Our media team can assist you with recording on your personal computer.
 - Similar to the face-to-face conference, we envision approximately 50-60 minutes for the keynote lecture.

For questions about the scientific programming of this meeting, please contact Dr. Rappuoli at rino.r.rappuoli@gsk.com and I will serve as the administrative/logistics contact at KristinaH@KeystoneSymposia.Org.

Best,
Kristina

Kristina H. Richardson, MS
Scientific Advisory Board Coordinator
Administrative Assistant: CSO & Global Development
+ (b) (6) | kristinah@keystonesymposia.org

<image001.png>

970.262.1230 | 800.253.0685 | www.keystonesymposia.org
Visit virtual.keystonesymposia.org to view our digital content.

<image002.png>

<image003.png>

<image004.png>

<image005.png>

KEYSTONE  SYMPOSIA™
on Molecular and Cellular Biology
Accelerating Life Science Discovery

INCLUDE
DIVERSITY IN THE SCIENTIFIC WORKFORCE



KEYSTONE SYMPOSIUM on Molecular and Cellular Biology

Accelerating Life Science Discovery

INCLUDE

DIVERSITY IN THE SCIENTIFIC WORKFORCE







From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 23:13:04 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]; Folkers, Greg (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]
Subject: Re: Thank you, and...
Attachments: image002.png

Gayle (b) (6) and so I would like to do it if they clear it

On Apr 26, 2020, at 7:08 PM, Conrad, Patricia (NIH/NIAID) [E]
(b) (6) wrote:

You sent this to me on Friday but we have not had a chance to discuss.

(b)(5) - PCP

Please advise if you want to do this – again, adding others here as well..

-p

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Sent: Sunday, April 26, 2020 5:44 PM
To: Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Cc: Barasch, Kimberly (NIH/NIAID) [C] (b) (6)
Subject: FW: Thank you, and...

Have we discussed this already? Gayle (b) (6)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Gayle Smith <gayle.smith@one.org>

Sent: Thursday, April 23, 2020 1:48 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>

Cc: Tom Hart <tom.hart@one.org>

Subject: Thank you, and...

Dear Tony,

I have always felt reassured when the good Dr. Fauci speaks, and now more than ever. As an American, a former colleague, a long-time admirer and student of your wisdom – thank you. We are all safer because of you, and the world will be a better place because of you. Again.

As you know, I am now leading the ONE Campaign. We've been quite active with the ONEWorld Campaign, dedicated to the fight against this newest virus, and focused on Africa. We've made some progress on debt, and next up is a focus on ensuring that a vaccine, when it comes, is available to everyone.

One of the things we want to do is educate people, in all of the places we work. It won't surprise you that of particular urgency amongst our partners in Africa is that facts and information get to people across the continent, but we also know that more facts are needed everywhere. So next month we are going to launch #PassTheMic, where every day for 19 days we will ask a celebrity to turn his or her social media channels over to an expert on COVID-19 for one day. So Julia Roberts might turn her Twitter account to you to talk about the critical elements needed to flatten the curve and slow the spread. Or Idris Elba could give up his Instagram to the head of the African CDC so that he can illustrate the impact COVID-19 will have across Africa and what that means for the rest of the world.

We know artists want to be helpful right now, but that it is hard to know what to do. And we know there are experts like you out there who have the answers. We've thought about this a lot at ONE and wanted to do something we felt would truly have an impact. As we look ahead we know COVID-19 does not know borders and until it is beaten everywhere we are not in the clear. We need a global response plan and we need it now. By turning over their platforms for the day, celebrity influencers will be donating one of their biggest assets – their followers – to YOU, giving you the platform you need (and we all need) to tell the world why a global response is critical. Because none of us are safe until all of us are safe.

We will work with each expert/celebrity pair to personalize the content to our and our celebrity partners' audiences – in North America, Europe and Africa, and help create content that both parties are happy with. We are now confirming our talent partners, and so far are getting a terrific response.

We know you're a busy man, so we've planned it so that the amount of time on your end would be minimal. But the impact would be maximal.

I'm attaching more information about the campaign. Please let me know what you think and if you have questions. Ideally we would like to get this off the ground in early May, so are hoping to confirm folks by April 28th at the latest. Our team will be in touch with your office to follow up.

Thanks as always for everything you do. All my best to you, Gayle

<image002.png>

Gayle Smith | President & Chief Executive Officer | (b) (6)
ONE.ORG | [Twitter](#) | [Facebook](#) | [Instagram](#)

ONE is a global movement campaigning to **end extreme poverty and preventable disease by 2030** so that everyone, everywhere can lead a life of dignity and opportunity.

<PasstheMic Expert Outreach.pdf>



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 21:50:57 +0000
To: Broas, Timothy
Cc: Grady, Christine (NIH/CC/BEP) [E]
Subject: RE: Greetings

Tim:

Thank you for your kind note. It was great to hear from you. I hope that all is well with you and your family and that we get a chance to re0connect when the situation begins to return to some form of normality..

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Broas, Timothy <timothy.broas@bclplaw.com>
Sent: Thursday, April 23, 2020 10:26 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Greetings

Dear Tony:

It's been a long time. Honestly, I can't remember when we last saw each other. I recall that wonderful day we went to the Nats game together, although I cannot remember who else came with us. And of course I will always remember when you came to my Partners in Health fundraiser and introduced Paul Farmer. I will never forget your speech (and neither will Paul!).

Once (b) (6)

I apologize for dropping out of touch.

Those events were so many years ago, (b) (6) no? So much has happened and changed since then, and now, seeing you and listening to your wise words and advice every day, I am reminded that we need to reconnect, when it's safe and you have time. We have so much to catch up on! I have been meaning to write to you or call you, but I had misplaced your email address and phone numbers. I hope this address works and this message reaches you.

Meantime, thank you for your service to our country, indeed the world. You have been a solid, wise, steady voice, Tony, and, despite all the naysayers and fools on social media, you have earned the respect of billions of people. I am very proud of you, and am humbled and honored that I can call you my friend.

I hope you and your family are well, and staying safe. The Broas family is doing well, thanks in no small part to your daily advice and objective analysis. Thank you! Please let me know if there is anything I can do for you or your family.

Looking forward to seeing you on the other side of this, and having a good catch up. Who knows, maybe at a Nats game?

Best regards,

Tim

BRYAN
CAVE
LEIGHTON
PAISNER **RLP**

AMBASSADOR (RET) TIMOTHY M. BROAS

timothy.broas@bcplaw.com

T: +1 202 508 6115 M: (b) (6)

BRYAN CAVE LEIGHTON PAISNER LLP.
1155 F Street NW, Washington, DC 20004-1357

bcplaw.com

COVID-19 / CORONAVIRUS RESOURCES



This electronic message is from a law firm. It may contain confidential or privileged information. If you received this transmission in error, please reply to the sender to advise of the error and delete this transmission and any attachments.

We may monitor and record electronic communications in accordance with applicable laws and regulations. Where appropriate we may also share certain information you give us with our other offices (including in other countries) and select third parties. For further information (including details of your privacy rights and how to exercise them), see our updated Privacy Notice at www.bcplaw.com.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 21:44:20 +0000
To: Greg Folkers (b) (6); Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Thank you, and...
Attachments: PasstheMic Expert Outreach.pdf

Have we discussed this already? Gayle (b) (6).

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Gayle Smith <gayle.smith@one.org>
Sent: Thursday, April 23, 2020 1:48 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Tom Hart <tom.hart@one.org>
Subject: Thank you, and...

Dear Tony,

I have always felt reassured when the good Dr. Fauci speaks, and now more than ever. As an American, a former colleague, a long-time admirer and student of your wisdom – thank you. We are all safer because of you, and the world will be a better place because of you. Again.

As you know, I am now leading the ONE Campaign. We've been quite active with the ONEWorld Campaign, dedicated to the fight against this newest virus, and focused on Africa. We've made some progress on debt, and next up is a focus on ensuring that a vaccine, when it comes, is available to everyone.

One of the things we want to do is educate people, in all of the places we work. It won't surprise you that of particular urgency amongst our partners in Africa is that facts and information get to people across the continent, but we also know that more facts are needed everywhere. So next month we are going to launch #PassTheMic, where every day for 19 days we will ask a celebrity to turn his or her social media channels over to an expert on COVID-19 for one day. So Julia Roberts might turn her Twitter

account to you to talk about the critical elements needed to flatten the curve and slow the spread. Or Idris Elba could give up his Instagram to the head of the African CDC so that he can illustrate the impact COVID-19 will have across Africa and what that means for the rest of the world.

We know artists want to be helpful right now, but that it is hard to know what to do. And we know there are experts like you out there who have the answers. We've thought about this a lot at ONE and wanted to do something we felt would truly have an impact. As we look ahead we know COVID-19 does not know borders and until it is beaten everywhere we are not in the clear. We need a global response plan and we need it now. By turning over their platforms for the day, celebrity influencers will be donating one of their biggest assets – their followers – to YOU, giving you the platform you need (and we all need) to tell the world why a global response is critical. Because none of us are safe until all of us are safe.

We will work with each expert/celebrity pair to personalize the content to our and our celebrity partners' audiences – in North America, Europe and Africa, and help create content that both parties are happy with. We are now confirming our talent partners, and so far are getting a terrific response.

We know you're a busy man, so we've planned it so that the amount of time on your end would be minimal. But the impact would be maximal.

I'm attaching more information about the campaign. Please let me know what you think and if you have questions. Ideally we would like to get this off the ground in early May, so are hoping to confirm folks by April 28th at the latest. Our team will be in touch with your office to follow up.

Thanks as always for everything you do. All my best to you, Gayle



Gayle Smith | President & Chief Executive Officer | (b) (6)

[ONE.ORG](https://one.org) | [Twitter](#) | [Facebook](#) | [Instagram](#)

ONE is a global movement campaigning to **end extreme poverty and preventable disease by 2030** so that everyone, everywhere can lead a life of dignity and opportunity.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 21:36:37 +0000
To: Lusso, Paolo (NIH/NIAID) [E]
Subject: RE: Potential treatment breakthrough from Milan

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lusso, Paolo (NIH/NIAID) [E] <(b) (6)>
Sent: Sunday, April 26, 2020 5:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Lane, Cliff (NIH/NIAID) [E] <(b) (6)>
Subject: Re: Potential treatment breakthrough from Milan

Dear Tony:

I am trying to reach the PI of the study, but on a Sunday afternoon/evening I doubt I will be successful. I should be able to get more information tomorrow morning and pass it on to you, Cliff and Joe Kovacs.

All the best,

Paolo

Paolo Lusso, M.D., Ph.D.
Chief, Section of Viral Pathogenesis
Laboratory of Immunoregulation
Bldg. 10, Rm. 6A11
NIAID, NIH
Bethesda, MD 20892

Phone: (b) (6) (personal)

(b) (6) (lab)

Fax: (301) 480-5291

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)

Date: Sunday, April 26, 2020 at 3:47 PM

To: "Lusso, Paolo (NIH/NIAID) [E]" (b) (6)

Cc: "Lane, Cliff (NIH/NIAID) [E]" (b) (6)

Subject: RE: Potential treatment breakthrough from Milan

Thanks, Paolo. (b) (5)

(b) (5)

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lusso, Paolo (NIH/NIAID) [E] (b) (6)

Sent: Sunday, April 26, 2020 12:22 PM

To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)

Subject: Potential treatment breakthrough from Milan

Dear Tony:

[REDACTED] (b) (5)

Congratulations to Brad Pitt for impersonating you! All the best,

Paolo

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 21:17:22 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Washington Post story re: Sammies finalists

Please set up an interview as requested below. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Davidson, Joe <joe.davidson@washpost.com>
Sent: Friday, April 24, 2020 12:58 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: (b) (6)
Subject: Washington Post story re: Sammies finalists

Hello Tony,

Congratulations on being a Career Achievement finalist for the Samuel J. Heyman Service to America Medals (Sammies). I'm writing a Federal Insider column about the finalists and would like arrange a telephone interview with you for the story.

My questions include:

Why did you join the federal service?

Is there one example or anecdote that makes you particularly proud of your work?

What do you like most about your job?

What do you like least about your job?

Why would you recommend, or not, your agency and/or the federal government to those seeking career advice?

I know this is an incredibly busy time for you. I appreciate that the life and death issues related to the coronavirus are more important than any award. Nonetheless, I hope you

can spare 10 or 15 minutes for a telephone interview on Tuesday or Wednesday, April 28 or 29. I can also make other days that week work.

Thank you.

Best,
Joe

Joe Davidson, columnist

The Washington Post

1301 K Street, NW

Washington, DC 20071

202.334.6415 – work

(b) (6) – cell

joe.davidson@washpost.com

Twitter: @JoeDavidsonWP

Website: wapo.st/JoeDavidson

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 21:14:32 +0000
To: Greg Folkers (b) (6)
Cc: (b) (6); Grady, Christine (NIH/CC/BEP) [E]
Subject: FW: COG - Helen Branswell/STAT request / challenge studies

Please have her speak with Chris and/or Cliff. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Sent: Friday, April 24, 2020 3:04 PM
To: NIAID COGCORE <COGCORE@mail.nih.gov>
Cc: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: COG - Helen Branswell/STAT request / challenge studies

Helen would like to speak with someone (ASF, Cliff, C Grady?) to discuss current thinking here on challenge studies for COVID-19. Not sure of deadline.

(b) (6)
helen.branswell@statnews.com

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 21:12:06 +0000
To: NIAID OD AM
Subject: FW: Keynote Speaker- Keystone Vaccinology eSymposia (directions to record & upload talk)
Attachments: Vaccinology eSymposia_DRAFT Program Description & Schedule.pdf

Greg and team:
Let us discuss.
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Kristina Horton <kristinah@keystonesymposia.org>
Sent: Friday, April 24, 2020 4:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: rino.r.rappuoli@gsk.com; Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: Keynote Speaker- Keystone Vaccinology eSymposia (directions to record & upload talk)

Greetings Dr. Fauci:

Thank you for agreeing to participate as the keynote speaker for the Keystone eSymposia: **Vaccinology in the Age of Pandemics: Strategies Against COVID-19 & Other Global Threats**, a virtual conference which will be held on, **Monday, June 15 and Tuesday, June 16, 2020.**

Understanding how busy you are right now, we would like to make this process as easy as possible. We are hoping to receive pre-recorded talks by Monday, May 18. Please keep us apprised on your timeline and we will work with your schedule. Here are the details on next steps.

Next Steps:

- **Keynote Talk Title:** Transforming Vaccinology: COVID-19 Emergency and Considerations for the Next Decade
 - **Please review your talk title and return any changes.** Changes can be made up to two-weeks prior to the event.
- **Please follow this [link](#) to upload your talk recording, by Monday, May 18.** Click [here](#) to learn more about recording your presentation. Our media team can assist you with recording on your personal computer.
 - Similar to the face-to-face conference, we envision approximately 50-60 minutes for the keynote lecture.

For questions about the scientific programming of this meeting, please contact Dr. Rappuoli at rino.r.rappuoli@gsk.com and I will serve as the administrative/logistics contact at KristinaH@KeystoneSymposia.Org.

Best,
Kristina

Kristina H. Richardson, MS
Scientific Advisory Board Coordinator
Administrative Assistant: CSO & Global Development
+ (b) (6) | kristinah@keystonesymposia.org

KEYSTONE SYMPOSIA™
on Molecular and Cellular Biology
Accelerating Life Science Discovery

INCLUDE
DIVERSITY IN THE SCIENTIFIC WORKFORCE

PO Box 1630 | Silverthorne | CO 80498 | USA (regular mail only)
160 US Highway 6, Ste. 200 | Silverthorne | CO 80498 | USA (courier only)
970.262.1230 | 800.253.0685 | www.keystonesymposia.org
Visit virtual.keystonesymposia.org to view our digital content.



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 21:11:15 +0000
To: Hahn, Stephen
Subject: FW: Thank You! (FDA Submission: EUA200258)
Attachments: 2AML - COVID-19_ACCREDITATION 1 PAGER.PDF, IMG-20200330-WA0002.jpg

Steve:

They have contacted me, but have you seen this? I am sure that it is one of many that you see.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Eli J. Safdieh (b) (6) >
Sent: Friday, April 24, 2020 4:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: Thank You! (b) (4)

Dear Dr. Fauci,

Hope all is well. Since this crisis has begun, I have been working (b) (4)

[REDACTED]

[REDACTED] (b) (4)

[REDACTED]

I look forward to your positive response.

Best Regards,

Eli J. Safdieh

From: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6) > on behalf of "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Date: Thursday, March 19, 2020 at 10:59 AM
To: Eli Safdieh (b) (6) >
Subject: RE: Thank You!

Dr. Fauci wanted me to thank you for you note.

Best regards,

Patricia L. Conrad

Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Eli J. Safdieh (b) (6) >
Sent: Thursday, March 19, 2020 5:13 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Thank You!

Hi Dr.,

Hope all is well with you and your family.

You are a symbol of integrity, nationalism, humanity, brilliance and perseverance. God bless you in all that you do for our country, for human beings and society.

We are praying for your success in mitigating and destroying this epidemic!

Best Regards,

Eli J. Safdieh

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 21:06:30 +0000
To: Dieffenbach, Carl (NIH/NIAID) [E]
Subject: RE: Documents as discussed

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Dieffenbach, Carl (NIH/NIAID) [E] (b) (6)
Sent: Friday, April 24, 2020 6:13 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: FW: Documents as discussed

Dr. Fauci,

I feel compelled to let you know directly when ever I talk to or correspond with an IC Director. I know you asked him to reach out. Just closing the loop.

Carl

-----Original Message-----

From: Dieffenbach, Carl (NIH/NIAID) [E]
Sent: Friday, April 24, 2020 6:11 PM
To: Singer, Dinah (NIH/NCI) [E] (b) (6)>; Sharpless, Norman (NIH/NCI) [E]
(b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6) Auchincloss, Hugh (NIH/NIAID) [E]
(b) (6)>; Erbelding, Emily (NIH/NIAID) [E] (b) (6)>; Casseffi, Cristina
(NIH/NIAID) [E] (b) (6)>
Subject: Documents as discussed

Dinah and Ned,

It was a pleasure talking to you about what you are considering. As we discussed, here is the NIAID Strategic Plan that was just published, and two models of funding opportunity announcements for you to consider as models. I also think the Cancer Centers have aspects of collaboration, shared facilities, and research focus that you can borrow. So much of what NIAID has built is modeled on the Cancer Centers.

NIAID strategic plan for COVID-19

<https://www.niaid.nih.gov/sites/default/files/NIAID-COVID-19-Strategic-Plan-2020.pdf>

Current Centers for AIDS Research FOA

<https://grants.nih.gov/grants/guide/pa-files/pa-20-106.html>

This is a very old RFA. I am sending it because it was NIAID's first attempt to build research capacity for the Level 3 and Level 4 pathogens after the Anthrax events. The current versions of the RFAs have been limited competitions and are a less relevant.

<https://grants.nih.gov/grants/guide/rfa-files/rfa-ai-04-032.html>

With best regards,

Carl

Carl W. Dieffenbach, Ph.D.

Director

Division of AIDS, NIAID

5601 Fishers Lane, Room 8D34

(he, him, his)

Rockville, MD 20852-9831

Phone: (b) (6)

Cell: (b) (6)

Fax: (240) 627-3466

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The NIAID shall not accept liability for any statement made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 21:05:18 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Interview - john lauermann

Yes.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Sent: Friday, April 24, 2020 7:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Subject: FW: Interview - john lauermann
Importance: High

Ok to schedule? This is cleared

From: John Lauerman (BLOOMBERG/ NEWSROOM:) At: 04/14/20 18:46:16
To: (b) (6)
Cc: (b) (6), (b) (6), (b) (6)
Subject: RE: Interview

Hi Jennifer et al: Here are a few questions for Dr. Fauci.

Scientists from the University of Bristol found that the coronavirus has unexpected tendency to large mutations in the spike protein when its grown in monkey cells. This had been seen

before as a virus that was unwilling to mutate. Does this create any concerns about vaccine design and effectiveness?

It now appears that some people who recover from Covid have no antibodies to the SARS-Cov2. What are the possible explanations for this? Has it occurred in other viral diseases? Does it have any implications for the effectiveness of vaccines? Is NIAID investigating this? Is there a possibility that the virus sequesters in cells?

Another feature of coronaviruses appears to be rapidly waning immunity. Has this been seen in any NIAID experiments? What does this suggest about the virus's ability to evade the immune system?

A laboratory at Oxford has suggested that, if all goes well, they may be finished with phase 3 trials in 5000 people by the fall, which could mean as early as September. Does that sound realistic to you?

Some companies are asking regulators to make sure that safety standards are upheld for makers of Covid vaccines, and that corners aren't cut. Is it worth cutting some safety corners to get a Covid vaccine ready for distribution?

How many people should the Moderna vaccine be tested in in phase 3? How long would you expect those trials to take?

Thanks very much, hope we can set this up soon. All best, JL +44 2035 251028

From: (b) (6) At: 04/12/20 22:38:36
To: John Lauerman (BLOOMBERG/ NEWSROOM:)
Cc: (b) (6), (b) (6),
(b) (6)
Subject: RE: Interview

Hi John – sorry we are still trying to get something arranged. Could you send your questions.

Thanks,
Jen

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations

National Institute of Allergy and Infectious Diseases (NIAID)

NIH/HHS

31 Center Drive Room 7A17C

Bethesda, MD 20892

Direct: [REDACTED] (b) (6)

[REDACTED] (b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 21:00:27 +0000
To: Conrad, Patricia (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]
Subject: RE: BOLIVIAN COVID-19 GUIDELINES

I cannot co-author anything with them. Make sure they do not slip my name in.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Sent: Saturday, April 25, 2020 7:20 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Subject: Fwd: BOLIVIAN COVID-19 GUIDELINES

Sent from my iPhone

Begin forwarded message:

From: Quispe Cornejo Armin Alvaro (b) (6) >
Date: April 25, 2020 at 5:30:30 AM EDT
To: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6) >, "Barasch, Kimberly (NIH/NIAID) [C]" (b) (6) >
Cc: ' (b) (6) >
(b) (6) >, Armin Quispe Cornejo (b) (6) >, (b) (6) >
Subject: BOLIVIAN COVID-19 GUIDELINES

Dear Ms. Patricia Conrad

Dear Ms. Kimberly Marie Barasch

I hope you are well despite the current devastating world pandemic.

The **Bolivian Society of Intensive Care** together with the **Bolivian Healthcare Ministry** are writing the national guidelines for the management of COVID-19 in the critically ill patient, an issue that is an emergency worldwide and may become **disastrous** in the low-middle income countries of Latin America if not managed since the beginning with precise, accurate and uniform approaches.

With our team in Erasme University Hospital in Brussels, Belgium, together with Professors **Jean - Louis Vincent, Fabio Taccone, Jean Charles Preiser, Jacques Creteur**, etc., we are preparing the material with other Bolivian and Mexican intensivists, internists, infectologists, imagenologists.

I wonder if Dr. Anthony Fauci would honor us coauthoring and reviewing our last version of some chapters of our guidelines.

Best regards,

AAQC

--



SPE - CORNEJO,

Medicine PhD fellow (Fell.)

M/MX] — Internista

*critica [UNAM] —
[A]*

abetología — Educación

— SIZ member

8177



Hôpital
Erasme



ULB

Cliniques universitaires d
Route de Lennik 808 - B -
S www.erasme.ulb.ac.be



Cliniques universitaires de Bruxelles
Route de Lennik 808 - B - 1070 Bruxelles
S www.erasme.ulb.ac.be

[Lien vers Disclaimer](#)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 20:12:51 +0000
To: Alberti Saverio
Subject: RE: spreading determinants of SARS-CoV-2

Thank you!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Alberti Saverio (b) (6)
Sent: Sunday, April 26, 2020 9:10 AM
To: Auchincloss, Hugh (NIH/NIAID) [E] (b) (6)
Subject: spreading determinants of SARS-CoV-2

Dear Tony,

we are all witnessing the great effort your collaborators and yourself are investing over this pandemic emergency.

As you well know, in Europe and Italy we had the unfortunate privilege of having been first hit hard by the pandemic, after China.

We had the opportunity of meta-analyzing data from 170.000 patients in European countries, for associated determinants of the spreading force of COVID-19.

If this may provide a useful, albeit non gratifying, contribution for the US and other countries, we would feel we had done our job.

best wishes

Saverio

--
Prof. Saverio Alberti

Genetica Medica

Dipartimento di Scienze Biomediche

Università di Messina

Policlinico "G. Martino"

via Consolare Valeria

98125 Messina

(b) (6)

(b) (6)

Skype: (b) (6)i

email: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 19:58:06 +0000
To: (b) (6)
Subject: RE: Covid 19 Double Mechanism. By Dr Brogna Carlo

Thank you for sending this.
Best regards,
AS Fauci

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: c.brogna@libero.it (b) (6)
Sent: Friday, April 17, 2020 7:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Covid 19 Double Mechanism. By Dr Brogna Carlo

Dear Dr A. Fauci,

we don't know each other. I was born (b) (6) I am a simple doctor in Medicine and live in a remote Italian region. I am no one. I trust in God that you can read my paper, being published. I send it to you to anticipate the exit times because I trust that we can really understand what Covid 19 is. Being nobody, I did what nobody would have done. I used the few tools I had available and questioned all the papers and data published so far. I describe what the dual mechanism of the Covid-19 can be. I anticipate that the result conclusion is not to my credit but I have been helped. I wish you a good read. May God bless us.

Sincerely with love,

Dr. Carlo Brogna M.D.

(b) (6)

Italia

Avellino-Isernia

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 19:56:13 +0000
To: Goletti Delia
Cc: Fabrizio Cantini; (b) (6) Lerner, Andrea (NIH/NIAID) [E]; Cassetti, Cristina (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]; Greg Folkers (b) (6)
Subject: RE: impact of baricitinib in COVID-19-an off label study CONFIDENTIAL

Thank you, Delia. I appreciate the information.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Goletti Delia (b) (6) >
Sent: Friday, April 17, 2020 8:03 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Fabrizio Cantini (b) (6)
Subject: impact of baricitinib in COVID-19-an off label study CONFIDENTIAL

dear dr Fauci, good morning. I hope you are fine.

Apologies to disturb you but it may be of your interest. I saw in the web that you (NIAID/Fauci)(
<https://investor.lilly.com/news-releases/news-release-details/lilly-begins-clinical-testing-therapies-covid-19>)
will be support a trial using Baricitinib as part of the ACTT trial...

I collaborated with Fabrizio Cantini (he reads in cc), a reumathologist of Prato to write a letter to J Infection (pdf attached). He conducted an off- label study in patients with mild-moderate pneumonia with COVID-19 [(SpO2) >92% at room-air, and ratio arterial oxygen partial pressure/fractional inspired oxygen (PaO2/FiO2) 100-300 mmHg] to evaluate the impact of baritinib (tablet 4 mg/day) in terms of safety, clinical respiratory improvements , discharge, ICU transfer in 2 weeks; these patients received also lopinavir/ritonavir therapy. The last consecutive patients with moderate COVID-19 pneumonia receiving standard of care therapy (lopinavir/ritonavir and hydroxychloroquine) admitted before the date of the first baricitinib-treated patient served as controls.

The results of this off-label study, with the limit of not been a RCT, are encouraging:

1. Safety: only 1/12 case of transaminase elevation at day 10, likely due to lopinavir ritonavir co-administration because baricitinib is mainly renal secreted
2. Respiratory Improvement: SpO2 and ratio arterial oxygen partial pressure/fractional inspired oxygen (PaO2/FiO2) significantly improved;
3. Discharge in 7/12 vs 1/12
4. ICU transfer (0/12 vs 4/12)

I do hope it may be a useful, although I am aware that it is a very preliminary info for you.

Thank you for your attention.

All the best

Delia

Da: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Inviato: giovedì 16 aprile 2020 00:02

A: Goletti Delia (b) (6)

Oggetto: RE: Italian press...for you!

Delia:

Thank you very much for sending these.

Best regards,

Tony

From: Goletti Delia (b) (6) >

Sent: Wednesday, April 15, 2020 2:51 PM

To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>

Subject: Italian press...for you!

Dear dr Fauci, I disturb you only to let you know that the Italian press is with you!

Dr Ippolito asked me to contribute to prepare a document in support of you which I did with all my heart. I gave my very minor contribution in supporting the scientific journalist, but with a lot of proud for you.

If you do not have it, below are the some of the links in your favor.

<https://apnews.com/27feaca21519a5eaf555c01313d33b91>

<https://apnews.com/b59d0a2c4c53f1c63a074b0d375fec23>

<https://www.nytimes.com/aponline/2020/04/15/world/europe/ap-eu-virus-outbreak-italy-fauci.html>

<https://www.nytimes.com/aponline/2020/04/15/business/ap-virus-outbreak-the-latest.html>

https://www.washingtonpost.com/world/europe/italian-virus-hospital-offers-fauci-work-if-trump-fires-him/2020/04/15/9b9afac0-7f16-11ea-84c2-0792d8591911_story.html

<https://abcnews.go.com/Health/wireStory/italian-virus-hospital-offers-fauci-work-trump-fires-70160122>

<https://www.ilfattoquotidiano.it/2020/04/15/coronavirus-direttore-spallanzani-scrive-a-mattarella-e-conte-il-licenziamento-di-fauci-sarebbe-un-disastro-e-non-solo-per-usa/5770793/>

https://www.repubblica.it/salute/medicina-e-ricerca/2020/04/15/news/per_favore_non_silurate_anthony_fauci-254087254/
<https://www.sanitainformazione.it/politica/emergenza-covid-19-negli-usa-anthony-fauci-rischia-il-licenziamento-lappello-di-ippolito-spallanzani/>
https://www.adnkronos.com/fatti/cronaca/2020/04/15/coronavirus-pazienti-dimessi-dallo-spallanzani_puDuaZKkoJNyLCZ1IDlgPN.html

all the best
Delia

Da: Goletti Delia

Inviato: domenica 12 aprile 2020 19:57

A: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>

Oggetto: R: all my gratitude and an update

Thank you for your time!
Best regards

Da: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>

Inviato: domenica 12 aprile 2020 19:53

A: Goletti Delia (b) (6)

Oggetto: RE: all my gratitude and an update

Delia:

Many thanks for your kind note. It is much appreciated. I am pleased to see that you are getting involved in COVID-19 work. Keep up your excellent work.

Best regards,
Tony

From: Goletti Delia (b) (6)

Sent: Sunday, April 12, 2020 11:02 AM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>

Subject: all my gratitude and an update

dear dr Fauci, apologies to write you in these busy days. It is only to express **all my gratitude** for what you have done in your life to fight infectious diseases and what you are doing now for COVID-19. **Your efforts and achievement are in front of the whole world** and for me it is a great honor to have been with you in 1992-1996 at the time of HIV fight. As I told you many times, **you are a model of excellence!**

Only to keep you updated in my life, I am fine, and I mainly work as an ID specialist and scientist at the same place in Rome, the National Institute for Infectious Diseases L. Spallanzani. I am doing 2 days a week outpatients TB clinic and I run a small laboratory on TB research. However, given the pandemia, I shifted the lab activities on COVID-19, in particular on:

1. the role of coinfection (COVID-19 coinfection with tuberculosis, or COVID-19 coinfection with HIV) on the modulation of the in vitro immune specific-response to SARS-CoV-2, or M. tuberculosis or HIV in cells from COVID-19 patients at different clinical stage

2. in vitro evaluation of the immunological and virological effect of baricinib, an anti-JAK1 and –JAK2 drugs, used in reumathoid arthritis, that has shown using BenevolentAI's proprietary artificial intelligence-derived knowledge graph, as an agent that reduces the SARS-CoV-2 endocytosis into target cells potentially inhibiting the entry.

Moreover, I would be happy to contribute in any activity you may think I am useful.

I wish you a happy Easter in this blessed day.

Thank you for your attention and for **having had the possibility of working with you that has been crucial in my personal and professional life.**

All the best
Delia

Delia Goletti, MD, PhD

Clinical Investigator, Laboratorio del Vecchio, Room 13

Head of Translational Research Unit

Department of Epidemiology and Preclinical Research National Institute for Infectious Diseases L. Spallanzani

Via Portuense 292, Roma 00149 Italy

Tel: (b) (6), Fax: +39-06-5582-825

E-mail address (b) (6)

http://www.inmi.it/ricerca_traslazionale.htm; http://www.inmi.it/ricerca_traslazionale_english.html

Professor of Pathology,
Unicamillus University
Rome, Italy

Visiting Professor,
Centre for Immunobiology,
Bizard Institute,
Queen Mary University of London, UK

Top Italian Women Scientist



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Apr 2020 14:41:51 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: RE: Expert U.S. panel develops NIH treatment guidelines for COVID-19

Please send me our press release related to the guidelines

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)>
Sent: Tuesday, April 21, 2020 8:46 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Lane, Cliff (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: FW: Expert U.S. panel develops NIH treatment guidelines for COVID-19

Your thoughts on Cliff et al doing a COCA call about the new guidelines?
(COCA= CDC's Clinician Outreach and Communication Activity)

From: Billet, Courtney (NIH/NIAID) [E]
Sent: Tuesday, April 21, 2020 8:37 PM
To: Lane, Cliff (NIH/NIAID) [E] (b) (6)>; Masur, Henry (NIH/CC/CCMD) [E] (b) (6)
Cc: Pau, Alice (NIH/NIAID) [E] (b) (6)>; Doepel, Laurie (NIH/NIAID) [E] (b) (6)
Subject: RE: Expert U.S. panel develops NIH treatment guidelines for COVID-19

(b) (5)

(b) (5) We don't have to decide this tonight....

From: Lane, Cliff (NIH/NIAID) [E] (b) (6)
Sent: Tuesday, April 21, 2020 8:20 PM
To: Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Masur, Henry (NIH/CC/CCMD) [E]
(b) (6)>
Cc: Pau, Alice (NIH/NIAID) [E] (b) (6); Doepel, Laurie (NIH/NIAID) [E]
(b) (6)>
Subject: Re: Expert U.S. panel develops NIH treatment guidelines for COVID-19

(b) (5)

From: "Billet, Courtney (NIH/NIAID) [E]" (b) (6)
Date: Tuesday, April 21, 2020 at 3:49 PM
To: "Lane, Cliff (NIH/NIAID) [E]" <(b) (6)>, "Masur, Henry (NIH/CC/CCMD) [E]"
(b) (6)>
Cc: "Pau, Alice (NIH/NIAID) [E]" (b) (6), Laurie Doepel (b) (6)
Subject: FW: Expert U.S. panel develops NIH treatment guidelines for COVID-19

Please advise?

From: Hall, Bill (HHS/ASPA) (b) (6)>
Sent: Tuesday, April 21, 2020 3:46 PM
To: Billet, Courtney (NIH/NIAID) [E] <(b) (6)>
Subject: FW: Expert U.S. panel develops NIH treatment guidelines for COVID-19

Would Cliff and company want to participate in a COCA call that CDC could put on?

From: Bonds, Michelle E. (CDC/OD/OADC) (b) (6)>
Sent: Tuesday, April 21, 2020 2:44 PM
To: Hall, Bill (HHS/ASPA) (b) (6)
Subject: FW: Expert U.S. panel develops NIH treatment guidelines for COVID-19

I see the NIH treatment guidelines news release is out. Are you still interested in hosting a COCA call on these guidelines?

Subject: FW: Expert U.S. panel develops NIH treatment guidelines for COVID-19

Just out, press release from NIH:


Expert U.S. panel develops NIH treatment guidelines for COVID-19

04/21/2020 11:30 AM EDT

"Living document" expected to be updated often as new clinical data accrue.

Expert U.S. panel develops NIH treatment guidelines for COVID-19

“Living document” expected to be updated often as new clinical data accrue.



Colorized scanning electron micrograph of an apoptotic cell (green) infected with SARS-COV-2 virus particles (orange), isolated from a patient sample. Image captured at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. *NIAID*

A panel of U.S. physicians, statisticians, and other experts has developed treatment guidelines for coronavirus disease 2019 (COVID-19). These guidelines, intended for healthcare providers, are based on published and preliminary data and the clinical expertise of the panelists, many of whom are frontline clinicians caring for patients during the rapidly evolving pandemic. The guidelines are posted online (covid19treatmentguidelines.nih.gov) and will be updated often as new data are published in peer-reviewed scientific literature and other authoritative information emerges.

The guidelines consider two broad categories of therapies currently in use by healthcare providers for COVID-19: antivirals, which may target the coronavirus directly, and host modifiers and immune-based therapies, which may influence the immune response to the virus or target the virus.

The panel's conclusions about treating COVID-19 with various agents that fall into these two classes of therapies are distilled in summary recommendations. Subsequently, the document provides background information about each agent—such as clinical data about its use, ongoing clinical trials, and known interactions with other drugs—that forms the basis for the Recommendation. Tables briefly outline the same information.

The guidelines also describe the evaluation and stratification of patients based on their risk of infection and severity of illness. Recommendations in this section address best practices for managing patients at different stages of infection, for example:

- Outpatients who are either asymptomatic or who have mild to moderate symptoms and are self-isolating
- Inpatients with severe illness or critical disease

Special considerations for pregnant women and for children who are infected are also included.

A comprehensive section of the guidelines addresses a range of considerations for clinicians caring for the most critically ill hospitalized patients. This section includes multiple

recommendations for patients needing critical care, including infection control procedures, hemodynamic and ventilatory support, and drug therapy.

Finally, the guidelines include recommendations concerning the use of concomitant medications. These include statins; corticosteroids; non-steroidal anti-inflammatory drugs; and certain drugs used to control hypertension, known as ACE inhibitors and ARBs.

The treatment guidelines panel is co-chaired by Roy M. Gulick, M.D., chief of the Infectious Disease Division at Weill Medical Hospital of Cornell University, New York City; H. Clifford Lane, M.D., clinical director of the National Institute of Allergy and Infectious Diseases, National Institutes of Health; and Henry Masur, M.D., chief of the Critical Care Medicine Department at the NIH Clinical Center. Members of the guidelines panel, appointed by the co-chairs, were chosen based on their clinical experience and expertise in patient management, translational and clinical science, and/or the development of treatment guidelines. They include 30 experts drawn from U.S. healthcare and academic organizations, federal agencies, and professional societies.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

From: National Institutes of Health (NIH) <nih.ocpl@service.govdelivery.com>

Sent: Tuesday, April 21, 2020 12:32 PM

To: Bedrosian, Sara (CDC/OD/OADC) (b) (6)

Subject: Expert U.S. panel develops NIH treatment guidelines for COVID-19

Having trouble viewing this email? [View it as a Web page.](#)



You are receiving this message because you are subscribed to News Releases for National Institutes of Health (NIH).

Expert U.S. panel develops NIH treatment guidelines for COVID-19

04/21/2020 11:30 AM EDT

“Living document” expected to be updated often as new clinical data accrue.

[Update Your E-mail Address](#) | [Add Subscriptions](#) | [Unsubscribe](#)

If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. For all other inquiries about NIH programs and activities, please contact [Ask NIH](#). Before writing, please view our [Frequently Asked Questions](#) page, our [Health Information](#) page, or [Search](#) our website.

This service is provided to you by the [National Institutes of Health](#).

NIH...Turning Discovery Into Health[®]



This email was sent to eri7@cdc.gov using GovDelivery Communications Cloud on behalf of: National Institutes of Health (NIH) · 9000 Rockville Pike · Bethesda MD 20892 · 301-496-4000 / TTY 301-402-9612

■

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Apr 2020 01:11:10 +0000
To: Marks, Peter; Collins, Francis (NIH/OD) [E]
Cc: Mascola, John (NIH/VRC) [E]; Disbrow, Gary (OS/ASPR/BARDA); Conrad, Patricia (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]; (b) (6)
Subject: RE: Vaccine Development
Attachments: Warp Speed Brief Deck 0800 042220.pptx

Peter:

Happy to discuss at your convenience – sooner rather than later. Let us make sure that we

(b) (5)

(b) (5). Happy to discuss this in detail with you.

Best regards,
Tony

From: Marks, Peter (b) (6)>
Sent: Thursday, April 23, 2020 5:50 PM
To: Collins, Francis (NIH/OD) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Mascola, John (NIH/VRC) [E] (b) (6); Disbrow, Gary (OS/ASPR/BARDA) (b) (6)
Subject: Vaccine Development

Dear Francis and Tony,

I know that you have heard murmuring about Project Warp Speed. We had a call today with John Mascola, Carl Dieffenbach, Hilary Marston, Mary Marovich and Emily Erbelding to go through the proposal and discuss how it could feed into the ACTIV effort. (b) (5)

They suggested that I contact you to try to set up a brief call to go over the plan. I am attaching a slide deck that provides an overview and am happy to find the time whenever you are available.

Thanks so much for considering,
Peter

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Apr 2020 00:29:08 +0000
To: Collins, Francis (NIH/OD) [E] (b) (6)
Subject: Viral Clades Brufsky 42020 Accepted Final.pdf
Attachments: Viral Clades Brufsky 42020 Accepted Final.pdf

Here is the paper from Pittsburg on the mutations. I will send on separate e-mail the commentary from China on another study

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tuesday, April 21, 2020 3:43 PM
To: Graham, Barney (NIH/VRC) [E] (b) (6)>
Cc: Mascola, John (NIH/VRC) [E] (b) (6)
Subject: FW: Viral Clades Brufsky 42020 Accepted Final.pdf

This is really getting interesting. See attachment.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hahn, Stephen (b) (6)>
Sent: Tuesday, April 21, 2020 3:28 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) Redfield, Robert R. (CDC/OD)
<(b) (6)>; Debi Birx (b) (6)>
Subject: Viral Clades Brufsky 42020 Accepted Final.pdf

Sorry for all of the emails. I spoke to Adam who is an oncologist. I thought this might be of interest.
Steve

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 20:29:10 +0000
To: Birx, Deborah L. EOP/NSC
Subject: RE: Serology Test Calculator

(b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Birx, Deborah L. EOP/NSC (b) (6)>
Sent: Tuesday, April 21, 2020 4:06 PM
To: Hahn, Stephen (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6);
Redfield, Robert R. (CDC/OD) (b) (6)>; Giroir, Brett (OS) <(b) (6)>
Subject: Re: Serology Test Calculator

(b) (5) Deb

From: "Hahn, Stephen" (b) (6)>
Date: Tuesday, April 21, 2020 at 3:23 PM
To: "Birx, Deborah L. EOP/NSC" <(b) (6)>, "Fauci, Anthony S (NIH)"
(b) (6)>, "Redfield, Robert R (CDC)" (b) (6)>, "Giroir, Brett (OS)"
(b) (6)
Subject: Fwd: Serology Test Calculator

From: Shuren, Jeff <(b) (6)>
Date: April 20, 2020 at 6:26:14 PM EDT
To: Hahn, Stephen (b) (6)>, Lenihan, Keagan (b) (6)>, Shah, Anand

(b) (6) >, Rom, Colin

(b) (6)

Subject: Serology Test Calculator

Attached is a very rudimentary calculator that you are welcome to share with the WHTF/HHS serology WG to calculate the positive predictive value and negative predictive value of individual serology tests and the use of two tests by plugging in the known or estimated sensitivity, specificity, and population prevalence of COVID-19.

(b) (5)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 20:28:43 +0000
To: (b) (6)
Subject: FW: Serology Test Calculator
Attachments: Calculator for PPV and NPV for individual tests and combined protected.xlsx

I will call you about this.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hahn, Stephen (b) (6)>
Sent: Tuesday, April 21, 2020 3:23 PM
To: Debi Birx (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Redfield, Robert R. (CDC/OD) (b) (6)>; Giroir, Brett (OS) (b) (6)>
Subject: Fwd: Serology Test Calculator

From: Shuren, Jeff (b) (6)>
Date: April 20, 2020 at 6:26:14 PM EDT
To: Hahn, Stephen (b) (6), Lenihan, Keagan (b) (6)>, Shah, Anand (b) (6), Rom, Colin (b) (6)>
Subject: Serology Test Calculator

Attached is a very rudimentary calculator that you are welcome to share with the WHTF/HHS serology WG to calculate the positive predictive value and negative predictive value of individual serology tests and the use of two tests by plugging in the known or estimated sensitivity, specificity, and population prevalence of COVID-19. (b) (5)

Calculator for Positive Predictive Value (PPV) and Negative Predictive Value (NPV) for individual tests and combined

Test 1

Sen1	Sp1
97.0%	93.2%

Test 2

Sen2	Sp2
88.0%	96.0%

Prevalence	5.0%				
Test 1					
%Pos1 (Test1=pos)	PPV1 for (Test1=pos)	%Neg1 (Test1=neg)	NPV1 for (Test1=neg)		
11.3%	42.9%	88.7%	99.8%		
Test 2					
%Pos2 (Test2=pos)	PPV2 for (Test2=pos)	%Neg2 (Test2=neg)	NPV2 for (Test2=neg)		
8.2%	53.7%	91.8%	99.3%		
Combined					
%Pos (Test1=pos, Test2=pos)	PPV for (Test1=pos, Test2=pos)	%Discordant (Test1=pos, Test2=neg)	NPV for (Test1=pos, Test2=neg)	%Neg (Test1=neg)	NPV for (Test1=neg)
4.5%	94.3%	6.8%	91.4%	88.7%	99.8%

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 22:21:37 +0000
To: Hahn, Stephen
Cc: Birx, Deborah L. EOP/NSC; Redfield, Robert R. (CDC/OD); Kadlec, Robert (OS/ASPR/IO); Caliguiri, Laura (FDA/OC); Lenihan, Keagan (FDA/OC); Shuren, Jeff (FDA/CDRH); Lane, Cliff (NIH/NIAID) [E]; Shah, Anand (FDA/OC)
Subject: RE: medRxiv: COVID-19 Antibody Seroprevalence in Santa Clara County, California

Great idea!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hahn, Stephen (b) (6)>
Sent: Saturday, April 18, 2020 6:19 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Birx, Deborah L. EOP/NSC (b) (6)>; Redfield, Robert R. (CDC/OD) (b) (6); Kadlec, Robert (OS/ASPR/IO) (b) (6); Caliguiri, Laura (FDA/OC) (b) (6); Lenihan, Keagan (FDA/OC) (b) (6); Shuren, Jeff (FDA/CDRH) (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Shah, Anand (FDA/OC) (b) (6)
Subject: RE: medRxiv: COVID-19 Antibody Seroprevalence in Santa Clara County, California

Team,
Anand Shah, Deputy Commissioner, reached out to the Stanford investigators on our behalf. Very interesting information regarding their research and the test that they are using. They are interested in partnering with us. I'll let Anand give the details.

Anand will be reaching out to the MGH folks, as well. (b) (5)

Steve

From: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Date: April 18, 2020 at 3:38:39 PM EDT
To: Hahn, Stephen (b) (6)
Cc: Birx, Deborah L. EOP/NSC (b) (6)>, Redfield, Robert R (CDC) (b) (6)
Kadlec, Robert P (OS) (b) (6), Caliguiri, Laura (b) (6),
Lenihan, Keagan (b) (6)>, Shuren, Jeff <(b) (6)>, Lane, Henry
C (NIH) (b) (6)>
Subject: RE: medRxiv: COVID-19 Antibody Seroprevalence in Santa Clara County, California

Steve:

John Ioannidis is the one that most of us know. He is the person one of your people could reach out to.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hahn, Stephen (b) (6)
Sent: Saturday, April 18, 2020 3:25 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Birx, Deborah L. EOP/ (b) (6)>; Redfield, Robert R. (CDC/OD) (b) (6)>; Kadlec, Robert (OS/ASPR/IO) (b) (6)>; Caliguiri, Laura (FDA/OC) (b) (6)>; Lenihan, Keagan (FDA/OC) (b) (6); Shuren, Jeff (FDA/CDRH) (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6)
Subject: RE: medRxiv: COVID-19 Antibody Seroprevalence in Santa Clara County, California

We can certainly work with them. Does anyone know any of these folks?

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Date: April 18, 2020 at 10:51:33 AM EDT

To: Hahn, Stephen (b) (6)
Cc: Birx, Deborah L. EOP/NSC (b) (6), Redfield, Robert R (CDC) (b) (6)>, Kadlec, Robert P (OS) (b) (6), Caliguiri, Laura (b) (6)>, Lenihan, Keagan <(b) (6)>, Shuren, Jeff (b) (6)>, Lane, Henry C (NIH) (b) (6)
Subject: RE: medRxiv: COVID-19 Antibody Seroprevalence in Santa Clara County, California

Steve:

Thanks for the quick reply. The data from the Stanford group (b) (5)

(b) (5)
(b) (5)
(b) (5)

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hahn, Stephen (b) (6)>
Sent: Saturday, April 18, 2020 10:31 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Birx, Deborah L. EOP/NSC (b) (6)>; Redfield, Robert R. (CDC/OD) (b) (6)>; Kadlec, Robert (OS/ASPR/IO) (b) (6)>; Caliguiri, Laura (FDA/OC) (b) (6)>; Lenihan, Keagan (FDA/OC) <(b) (6)>; Shuren, Jeff (FDA/CDRH) (b) (6)
Subject: Re: medRxiv: COVID-19 Antibody Seroprevalence in Santa Clara County, California

Tony,

(b) (5)

(b) (5)

(b) (5).

Steve

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Date: April 18, 2020 at 10:03:32 AM EDT
To: Hahn, Stephen (b) (6)
Cc: Birx, Deborah L. EOP/NSC (b) (6), Redfield, Robert R (CDC) (b) (6)
Kadlec, Robert P (OS) (b) (6) >
Subject: FW: medRxiv: COVID-19 Antibody Seroprevalence in Santa Clara County, California

Steve:

(b) (5)

Thanks,
Tony

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)
Sent: Friday, April 17, 2020 5:44 PM
Subject: medRxiv: COVID-19 Antibody Seroprevalence in Santa Clara County, California

COVID-19 Antibody Seroprevalence in Santa Clara County, California

Eran Bendavid, Bianca Mulaney, Neeraj Sood, Soleil Shah, Emilia Ling, Rebecca Bromley-Dulfano, Cara Lai, Zoe Weissberg, Rodrigo Saavedra, James Tedrow, Dona Tversky, Andrew Bogan, Thomas Kupiec, Daniel Eichner, Ribhav Gupta, John Ioannidis, Jay Bhattacharya

doi: <https://doi.org/10.1101/2020.04.14.20062463>

- [Abstract](#)
- [Info/History](#)
- [Metrics](#)
- [Preview PDF](#)

Abstract

Background Addressing COVID-19 is a pressing health and social concern. To date, many epidemic projections and policies addressing COVID-19 have been designed without seroprevalence data to inform epidemic parameters. We measured the seroprevalence of antibodies to SARS-CoV-2 in Santa Clara County. **Methods** On 4/3-4/4, 2020, we tested county residents for antibodies to SARS-CoV-2 using a lateral flow immunoassay. Participants were recruited using Facebook ads targeting a representative sample of the county by demographic and geographic characteristics. We report the prevalence of antibodies to SARS-CoV-2 in a sample of 3,330 people, adjusting for zip code, sex, and race/ethnicity. We also adjust for test performance characteristics using 3 different estimates: (i) the test manufacturer's data, (ii) a sample of 37 positive and 30 negative controls tested at Stanford, and (iii) a combination of both. **Results** The unadjusted prevalence of antibodies to SARS-CoV-2 in Santa Clara County was 1.5% (exact binomial 95CI 1.11-1.97%), and the population-weighted prevalence was 2.81% (95CI 2.24-3.37%). Under the three scenarios for test performance characteristics, the population prevalence of COVID-19 in Santa Clara ranged from 2.49% (95CI 1.80-3.17%) to 4.16% (2.58-5.70%). These prevalence estimates represent a range between 48,000 and 81,000 people infected in Santa Clara County by early April, 50-85-fold more than the number of confirmed cases. **Conclusions** The population prevalence of SARS-CoV-2 antibodies in Santa Clara County implies that the infection is much more widespread than indicated by the number of confirmed cases. Population prevalence estimates can now be used to calibrate epidemic and mortality projections.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 03:05:43 +0000
To: clane@niaid.nih.gov
Subject: FW: FYI - "Coronavirus Disease 2019 (COVID-19) Treatment Guidelines"

Go for it. Congratulations!!! 😊

From: Hall, Bill (HHS/ASPA) (b) (6)>
Sent: Monday, April 20, 2020 10:07 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Myles, Renate (NIH/OD) [E] (b) (6); Burklow, John (NIH/OD) [E] (b) (6)
Subject: Re: FYI - "Coronavirus Disease 2019 (COVID-19) Treatment Guidelines"

Hi Tony,

(b) (5) PCP. I've told John B/Renate/Courtney that everything can post first thing tomorrow morning.

Best regards,
Bill

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Sent: Monday, April 20, 2020 11:53 AM
To: Miller, Katie R. (ovp.eop.gov) (b) (6); Short, Marc T. EOP/OVP (b) (6)>
Cc: Birx, Deborah L. EOP/NSC (b) (6)>; Redfield, Robert R. (CDC/OD) (b) (6)>; Billet, Courtney (NIH/NIAID) [E] (b) (6); Hall, Bill (HHS/ASPA) (b) (6)>; O'Malley, Devin M. EOP/OVP (b) (6); (b) (6) (b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b) (6); Myles, Renate (NIH/OD) [E] (b) (6)
Subject: FYI - "Coronavirus Disease 2019 (COVID-19) Treatment Guidelines"

Katie/Marc:

Just as an FYI - "The Coronavirus Disease 2019 (COVID-19) Treatment Guidelines" that were developed here at NIH, and a copy of which I provided to Deb Birx and ultimately to Mark Meadows is moving forward. Mark Meadows

(b) (5)

(b) (5). Press release

will come from NIH with clearance through the appropriate channels (see attachment as an FYI). I anticipate that this will happen in the next day or two.

Thanks.

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Apr 2020 23:05:49 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Subject: RE: ask to highlight the incredible work of key federal workers

Correct again.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Sent: Monday, April 20, 2020 5:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Billet, Courtney (NIH/NIAID) [E] (b) (6) >; NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Cc: Stover, Kathy (NIH/NIAID) [E] <(b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6)
Subject: RE: ask to highlight the incredible work of key federal workers

(b) (5)

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Sent: Monday, April 20, 2020 4:52 PM
To: Folkers, Greg (NIH/NIAID) [E] (b) (6) >; Billet, Courtney (NIH/NIAID) [E] (b) (6) >; NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Cc: Stover, Kathy (NIH/NIAID) [E] (b) (6) >; Routh, Jennifer (NIH/NIAID) [E] (b) (6)
Subject: RE: ask to highlight the incredible work of key federal workers

I agree.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6) 3
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] <gfolkers@niaid.nih.gov>
Sent: Monday, April 20, 2020 4:52 PM
To: Billet, Courtney (NIH/NIAID) [E] <billetc@niaid.nih.gov>; NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Cc: Stover, Kathy (NIH/NIAID) [E] <kathy.stover@nih.gov>; Routh, Jennifer (NIH/NIAID) [E] <jennifer.routh@nih.gov>
Subject: RE: ask to highlight the incredible work of key federal workers

(b) (5)

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)
Sent: Monday, April 20, 2020 4:40 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Cc: Stover, Kathy (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6)>
Subject: FW: ask to highlight the incredible work of key federal workers

Let us discuss. (b) (5)
(b) (5) Any suggestions?

From: Boyse, Natalie (OS/ASPA) (b) (6)>
Sent: Monday, April 20, 2020 4:28 PM
To: Billet, Courtney (NIH/NIAID) [E] (b) (6); Myles, Renate (NIH/OD) [E] (b) (6); Burklow, John (NIH/OD) [E] (b) (6)>
Cc: Bird, Catherine (OS/OGC) <(b) (6)>; Brennan, Patrick (OS/ASPA) (b) (6)>
Subject: FW: ask to highlight the incredible work of key federal workers

Hi John, Renate and Courtney –

(b) (5)

Let me know if you have any questions re: this request. I am available and happy to chat this afternoon.
Thanks,
Natalie

Natalie Boyse
Special Assistant, Immediate Office of the Secretary
U.S. Department of Health & Human Services
M ([REDACTED])
b

From: Baldwin, Brittany L. EOP/WHO <([REDACTED]) (b) (6)>
Sent: Monday, April 20, 2020 3:00 PM
To: Boyse, Natalie (OS/ASPA) ([REDACTED]) (b) (6)
Subject: ask to highlight the incredible work of key federal workers

Hi Natalie – great talking just now.

(b) (5)

(b) (5)



Please do not hesitate to reach out with questions!

Brittany L. Baldwin
Special Assistant to the President
Speechwriter

O: (b) (6)

C: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Apr 2020 12:01:43 +0000
To: Collins, Francis (NIH/OD) [E]; Mascola, John (NIH/VRC) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]; McManus, Ayanna (NIH/OD) [E]; Wood, Gretchen (NIH/OD) [E]; Tabak, Lawrence (NIH/OD) [E]; Barasch, Kimberly (NIH/NIAID) [C]
Subject: RE: Pursuant to My Email on Friday

I agree. Let us do it another time.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Collins, Francis (NIH/OD) [E] (b) (6) >
Sent: Monday, April 20, 2020 4:59 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Mascola, John (NIH/VRC) [E] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); McManus, Ayanna (NIH/OD) [E] (b) (6) >; Wood, Gretchen (NIH/OD) [E] (b) (6); Tabak, Lawrence (NIH/OD) [E] (b) (6) >; Barasch, Kimberly (NIH/NIAID) [C] (b) (6)
Subject: RE: Pursuant to My Email on Friday

With apologies, I just realized that the ACTIV Vaccines working group (which involves John in a significant way, and will be joined today by Tal Zaks from Moderna) meets this morning from 9 – 10 am. Probably we need to pick another time for this pow-wow about the CVP?

Francis

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Sent: Sunday, April 19, 2020 9:41 PM
To: Collins, Francis (NIH/OD) [E] (b) (6) >; Mascola, John (NIH/VRC) [E] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; McManus, Ayanna (NIH/OD) [E] (b) (6) >; Wood, Gretchen (NIH/OD) [E] (b) (6); Tabak, Lawrence (NIH/OD) [E] (b) (6); Barasch, Kimberly (NIH/NIAID) [C] (b) (6) >
Subject: RE: Pursuant to My Email on Friday

Patty:

Please see if we can incorporate this call into our regularly scheduled 9:00 AM call that actually includes some of the same cast of people.

Thanks,

Tony

From: Collins, Francis (NIH/OD) [E] (b) (6) >
Sent: Sunday, April 19, 2020 9:38 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Mascola, John (NIH/VRC) [E] <(b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>; McManus, Ayanna (NIH/OD) [E] (b) (6) >; Wood, Gretchen (NIH/OD) [E] (b) (6) >; Tabak, Lawrence (NIH/OD) [E] (b) (6) >
Subject: RE: Pursuant to My Email on Friday

Got it, (b) (5)

(b) (5)

Can we have a phone call about this tomorrow at 9:15 am? Anyone else to include (Emily? Cliff?)

Francis

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Sent: Sunday, April 19, 2020 9:30 PM
To: Mascola, John (NIH/VRC) [E] (b) (6) >; Collins, Francis (NIH/OD) [E] (b) (6)

Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)

Subject: RE: Pursuant to My Email on Friday

Francis:

(b) (5)

Best,

Tony

From: Mascola, John (NIH/VRC) [E] (b) (6)

Sent: Sunday, April 19, 2020 4:24 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Collins, Francis (NIH/OD) [E]

(b) (6)

Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)

Subject: FW: Pursuant to My Email on Friday

<< File: Cov Vaccine Program HHS (draft) 19April20.pptx >>

Tony, Francis,

(b) (5)

Happy to discuss.

John

(b) (6)

From: Kadlec, Robert (OS/ASPR/IO) (b) (6)
Sent: Sunday, April 12, 2020 8:59 PM
To: Hassell, David (Chris) (OS/ASPR/IO) (b) (6); Collins, Francis (NIH/OD) [E] (b) (6); Mascola, John (NIH/VRC) [E] (b) (6); Bright, Rick (OS/ASPR/BARDA) (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Disbrow, Gary (OS/ASPR/BARDA) (b) (6); Patrick, Vanessa (OS/ASPR/BARDA) (CTR) (b) (6); Moughalian, Jen (HHS/ASFR) (b) (6); Redfield, Robert R. (CDC/OD) (b) (6); Messonnier, Nancy (CDC/DDID/NCIRD/OD) (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Marks, Peter (FDA/CBER) (b) (6); Yeskey, Kevin (OS/ASPR/IO) (b) (6)
Cc: Harrison, Brian (HHS/IOS) <(b) (6)>; Dareshori, Zack (HHS/IOS) (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Stecker, Judy (OS/IOS) (b) (6); Shuy, Bryan (OS/ASPR/IO) (b) (6); Wolinetz, Carrie (NIH/OD) [E] (b) (6)
Subject: Pursuant to My Email on Friday

I want to share with you the product of the BCG team who drafted the attached briefing and Decision Memo drafted for the Secretary's review tomorrow. I want to thank all those who contributed over this holiday weekend to offer their ideas and concepts that is represented in these products. This represents just a first step of many steps that first outlines a concept that will then be operationalized into a historic effort for not only the Department and agencies who will contribute to it, but to our Nation. Again, thank you for your contributions and commitment. Best Bob

<< File: Vaccine strategy-200411-v 13.pptx >> << File: Secretary Determination Memorandum-
Project Warp Speed-041120 1825 draft.doc >>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Apr 2020 01:34:55 +0000
To: Mascola, John (NIH/VRC) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Pursuant to My Email on Friday

OK. Let us discuss tomorrow.

From: Mascola, John (NIH/VRC) [E] (b) (6) >
Sent: Sunday, April 19, 2020 6:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] <(b) (6) >
Subject: FW: Pursuant to My Email on Friday

Tony,

One key point that may be easier to review with 5 min call, whenever you get the chance.

John

From: Mascola, John (NIH/VRC) [E]
Sent: Sunday, April 19, 2020 5:13 PM
To: Collins, Francis (NIH/OD) [E] (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E]
(b) (6) >
Subject: RE: Pursuant to My Email on Friday

Francis,

(b) (5)

If still not so clear, feel free to call.

John

(b) (6)

From: Collins, Francis (NIH/OD) [E] (b) (6)

Sent: Sunday, April 19, 2020 5:04 PM

To: Mascola, John (NIH/VRC) [E] (b) (6) >

Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Fauci, Anthony (NIH/NIAID) [E]
(b) (6) >

Subject: RE: Pursuant to My Email on Friday

Hi John,

Thanks for your thoughtful note.

(b) (5)

(b) (5)

Francis

From: Mascola, John (NIH/VRC) [E] <(b) (6)>

Sent: Sunday, April 19, 2020 4:24 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Collins, Francis (NIH/OD) [E]
(b) (6)>

Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>

Subject: FW: Pursuant to My Email on Friday

<< File: Cov Vaccine Program HHS (draft) 19April20.pptx >>

Tony, Francis,



Happy to discuss.

John

(b) (6)

From: Kadlec, Robert (OS/ASPR/IO) (b) (6)
Sent: Sunday, April 12, 2020 8:59 PM
To: Hassell, David (Chris) (OS/ASPR/IO) (b) (6); Collins, Francis (NIH/OD) [E] (b) (6); Mascola, John (NIH/VRC) [E] (b) (6); Bright, Rick (OS/ASPR/BARDA) (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Disbrow, Gary (OS/ASPR/BARDA) (b) (6); Patrick, Vanessa (OS/ASPR/BARDA) (CTR) (b) (6); Moughalian, Jen (HHS/ASFR) (b) (6); Redfield, Robert R. (CDC/OD) (b) (6); Messonnier, Nancy (CDC/DDID/NCIRD/OD) (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Marks, Peter (FDA/CBER) (b) (6); Yeskey, Kevin (OS/ASPR/IO) (b) (6)
Cc: Harrison, Brian (HHS/IOS) (b) (6); Dareshori, Zack (HHS/IOS) (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Stecker, Judy (OS/IOS) (b) (6); Shuy, Bryan (OS/ASPR/IO) (b) (6); Wolinetz, Carrie (NIH/OD) [E] (b) (6)
Subject: Pursuant to My Email on Friday

I want to share with you the product of the BCG team who drafted the attached briefing and Decision Memo drafted for the Secretary's review tomorrow. I want to thank all those who contributed over this holiday weekend to offer their ideas and concepts that is represented in these products. This represents just a first step of many steps that first outlines a concept that will then be operationalized into a historic effort for not only the Department and agencies who will contribute to it, but to our Nation. Again, thank you for your contributions and commitment. Best Bob

<< File: Vaccine strategy-200411-v 13.pptx >> << File: Secretary Determination Memorandum-Project Warp Speed-041120 1825 draft.doc >>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Apr 2020 14:55:57 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Coronavirus Questions for the Office of the Surgeon General

Please make sure that I call this person tomorrow [REDACTED] (b) (6).

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [REDACTED] (b) (6) MEDCOM (USA) [REDACTED] (b) (6)
Sent: Tuesday, April 21, 2020 9:58 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: RE: Coronavirus Questions for the Office of the Surgeon General

Dr. Fauci,

Thank you for responding to my request for information. Please be safe.

[REDACTED] (b) (6)
[REDACTED] (b) (6) My cell phone number is
[REDACTED] (b) (6).

r/
[REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Sent: Tuesday, April 21, 2020 12:49 PM
To: [REDACTED] (b) (6) MEDCOM (USA) [REDACTED] (b) (6)
Cc: Lerner, Andrea (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: [Non-DoD Source] FW: Coronavirus Questions for the Office of the Surgeon General

All active links contained in this email were disabled. Please verify the identity of the sender, and confirm the authenticity of all links contained within the message prior to copying and pasting the address to a Web browser.

(b) (6)

Thank you for your note. Shown below are my answers to your questions. I hope that you find them helpful.

1. How do you recommend I reassure our staff on dealing with the stressors of COVID-19?

This is indeed an unprecedented and stressful time. Stress can often come from the unknown. In times of stress it is critical to take care of one's physical health, by eating well, getting enough sleep, and exercising. In addition, maintaining connections with family and friends (via phone calls, email, or video chatting) while physically socially distancing is very important.

2. Can COVID-19 be contracted from a corpse?

Infection control measures should be undertaken when dealing with deceased individuals with known or suspected COVID-19. The CDC provides guidance on this issue here; Caution-<https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-postmortem-specimens.html> < Caution-<https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-postmortem-specimens.html> >

3. If someone has been a user of Hydroxychloroquine for years, are they susceptible to contracting COVID-19?

Clinical trials are underway to determine if hydroxychloroquine is effective in preventing COVID-19 in exposed persons. Until we know the answer to this question, persons who take hydroxychloroquine on a daily basis for another medical condition should consider themselves vulnerable to COVID-19 and take appropriate and recommended measures to protect themselves.

4. Are masks and gloves truly effective, if so, why are so many medical professionals contracting the virus?

I believe that infection control strategies which include proper use of personal protective equipment (PPE) as recommended by the CDC are effective.

Caution-https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-recommendations.html?CDC_AA_refVal=https%3A%2F%2FCaution-www.cdc.gov%2Fcoronavirus%2F2019-ncov%2Finfection-control%2Fcontrol-recommendations.html < Caution-https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-recommendations.html?CDC_AA_refVal=https%3A%2F%2FCaution-www.cdc.gov%2Fcoronavirus%2F2019-ncov%2Finfection-control%2Fcontrol-recommendations.html >

In cases where inadequate PPE is worn, or if is not put on/taken off according to proper procedure, the risk of contracting COVID is increased. In addition, healthcare workers on the front lines can be exposed if they encounter a patient who is not initially suspected of having COVID-19 without PPE, especially if they are exposed to aerosol generating processes.

5. What is the most important thing we should be doing, other than social distancing?

Social distancing is key in order to avoid coming into contact with someone with COVID-19, but washing one's hands often (or using an alcohol-based hand sanitizer) and avoiding touching one's face with unwashed hands are critical as well, especially when coming into contact with surfaces that may have been touched by others or public places.

6. Finally, what keeps you up at night, regarding COVID-19?

I have said in the past that what keeps me up at night is the possibility of a pandemic respiratory infection. We are in that reality now, and what keeps me up at night is the response, a major part of which is the development of an effective vaccine and treatments for COVID-19.

Best regards,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-

(b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6) MEDCOM (USA) (b) (6) -
(b) (6) > >

Sent: Tuesday, April 14, 2020 9:13 AM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) > >

Subject: Coronavirus Questions for the Office of the Surgeon General

Dr. Fauci,

I am (b) (6), the antiterrorism and insider threat officer for the Office of the Surgeon General (Army) / U.S. Army Medical Command. I have been in government for nearly thirty-four years, and this is new to me. I see and hear the concerns of many people. You are the voice of reason for millions of concerned citizens. I have a few questions for you:

1. How do you recommend I reassure our staff on dealing with the stressors of COVID-19?

2. Can COVID-19 be contracted from a corpse?
3. If someone has been a user of Hydroxychloroquine for years, are they susceptible to contracting COVID-19?
4. Are masks and gloves truly effective, if so, why are so many medical professionals contracting the virus?
5. What is the most important thing we should be doing, other than social distancing?

Finally, what keeps you up at night, regarding COVID-19?

Thank you for your time and please be safe.

r/

(b) (6) Antiterrorism and Insider Threat Officer
Office of the Surgeon General and U.S. Army Medical Command
Mission Assurance and Protection Division
Fort Sam Houston, TX 78234
Cell phone: (b) (6)



(b) (6)

✉ NIPRNet: (b) (6)

✉ SIPRNet: (b) (6)

Level I Antiterrorism Awareness Training:

Caution-<http://jko.jten.mil/courses/at1/launch.html> < Caution-
<http://jko.jten.mil/courses/at1/launch.html> >

Organizational Mailbox:

(b) (6) < Caution-
mailto: (b) (6) >

To submit contracts for AT/OPSEC review:

Caution- (b) (6) Caution-
(b) (6) >

"Not on My Watch"

CONFIDENTIALITY NOTE: This electronic transmission, including all attachments, is directed in confidence solely to the person(s) to whom it is addressed, or an authorized recipient, and may not otherwise be distributed, copied or disclosed. The contents of the transmission may also be subject to intellectual property rights and all such rights are expressly claimed and are not waived. If you received this transmission in error, please notify the sender immediately by returning the electronic transmission and then immediately delete this transmission, including all attachments, without copying, distributing or disclosing same.

"PRIVACY ACT INFORMATION"

In compliance with the Privacy Act of 1974, this information is Personal Data and must be protected from public disclosure.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 17:48:36 +0000
To: (b) (6)
Cc: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Coronavirus Questions for the Office of the Surgeon General

(b) (6)

Thank you for your note. Shown below are my answers to your questions. I hope that you find them helpful.

1. **How do you recommend I reassure our staff on dealing with the stressors of COVID-19?**
This is indeed an unprecedented and stressful time. Stress can often come from the unknown. In times of stress it is critical to take care of one's physical health, by eating well, getting enough sleep, and exercising. In addition, maintaining connections with family and friends (via phone calls, email, or video chatting) while physically socially distancing is very important.
2. **Can COVID-19 be contracted from a corpse?**
Infection control measures should be undertaken when dealing with deceased individuals with known or suspected COVID-19. The CDC provides guidance on this issue here:
<https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-postmortem-specimens.html>
3. **If someone has been a user of Hydroxychloroquine for years, are they susceptible to contracting COVID-19?**
Clinical trials are underway to determine if hydroxychloroquine is effective in preventing COVID-19 in exposed persons. Until we know the answer to this question, persons who take hydroxychloroquine on a daily basis for another medical condition should consider themselves vulnerable to COVID-19 and take appropriate and recommended measures to protect themselves.
4. **Are masks and gloves truly effective, if so, why are so many medical professionals contracting the virus?**
I believe that infection control strategies which include proper use of personal protective equipment (PPE) as recommended by the CDC are effective.
https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-recommendations.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Finfection-control%2Fcontrol-recommendations.html
In cases where inadequate PPE is worn, or if is not put on/taken off according to proper procedure, the risk of contracting COVID is increased. In addition, healthcare workers on the front lines can be exposed if they encounter a patient who is not initially suspected of having COVID-19 without PPE, especially if they are exposed to aerosol generating processes.
5. **What is the most important thing we should be doing, other than social distancing?**
Social distancing is key in order to avoid coming into contact with someone with COVID-19, but washing one's hands often (or using an alcohol-based hand sanitizer) and avoiding touching one's face with unwashed hands are critical as well, especially when coming into contact with surfaces that may have been touched by others or public places.

6. Finally, what keeps you up at night, regarding COVID-19?

I have said in the past that what keeps me up at night is the possibility of a pandemic respiratory infection. We are in that reality now, and what keeps me up at night is the response, a major part of which is the development of an effective vaccine and treatments for COVID-19.

Best regards,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6) MEDCOM (USA) (b) (6)

Sent: Tuesday, April 14, 2020 9:13 AM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >

Subject: Coronavirus Questions for the Office of the Surgeon General

Dr. Fauci,

I am (b) (6) the antiterrorism and insider threat officer for the Office of the Surgeon General (Army) / U.S. Army Medical Command. I have been in government for nearly thirty-four years, and this is new to me. I see and hear the concerns of many people. You are the voice of reason for millions of concerned citizens. I have a few questions for you:

1. How do you recommend I reassure our staff on dealing with the stressors of COVID-19?
2. Can COVID-19 be contracted from a corpse?
3. If someone has been a user of Hydroxychloroquine for years, are they susceptible to contracting COVID-19?
4. Are masks and gloves truly effective, if so, why are so many medical professionals contracting the virus?
5. What is the most important thing we should be doing, other than social distancing?

Finally, what keeps you up at night, regarding COVID-19?

Thank you for your time and please be safe.

r/

(b) (6), Antiterrorism and Insider Threat Officer
Office of the Surgeon General and U.S. Army Medical Command
Mission Assurance and Protection Division
Fort Sam Houston, TX 78234
Cell phone: (b) (6)



(b) (6)

✉ NIPRNet: (b) (6)

✉ SIPRNet:

Level I Antiterrorism Awareness Training:

<http://jko.iten.mil/courses/at11/launch.html>

Organizational Mailbox:

(b) (6)

To submit contracts for AT/OPSEC review:

(b) (6)

"Not on My Watch"

CONFIDENTIALITY NOTE: This electronic transmission, including all attachments, is directed in confidence solely to the person(s) to whom it is addressed, or an authorized recipient, and may not otherwise be distributed, copied or disclosed. The contents of the transmission may also be subject to intellectual property rights and all such rights are expressly claimed and are not waived. If you received this transmission in error, please notify the sender immediately by returning the electronic transmission and then immediately delete this transmission, including all attachments, without copying, distributing or disclosing same.

"PRIVACY ACT INFORMATION"

In compliance with the Privacy Act of 1974, this information is Personal Data and must be protected from public disclosure.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 20:35:32 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]; Greg Folkers (b) (6)
Subject: FW: Coronavirus Questions for the Office of the Surgeon General

Please fashion some responses to his questions for me to send back to him
Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6) USARMY MEDCOM (USA) (b) (6) >
Sent: Tuesday, April 14, 2020 9:13 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Coronavirus Questions for the Office of the Surgeon General

Dr. Fauci,

I am (b) (6) the antiterrorism and insider threat officer for the Office of the Surgeon General (Army) / U.S. Army Medical Command. I have been in government for nearly thirty-four years, and this is new to me. I see and hear the concerns of many people. You are the voice of reason for millions of concerned citizens. I have a few questions for you:

1. How do you recommend I reassure our staff on dealing with the stressors of COVID-19?
2. Can COVID-19 be contracted from a corpse?
3. If someone has been a user of Hydroxychloroquine for years, are they susceptible to contracting COVID-19?
4. Are masks and gloves truly effective, if so, why are so many medical professionals contracting the virus?
5. What is the most important thing we should be doing, other than social distancing?

Finally, what keeps you up at night, regarding COVID-19?

Thank you for your time and please be safe.

r/

(b) (6), Antiterrorism and Insider Threat Officer
Office of the Surgeon General and U.S. Army Medical Command
Mission Assurance and Protection Division
Fort Sam Houston, TX 78234
Cell phone: (b) (6)



(b) (6)

✉ NIPRNet: (b) (6)

✉ SIPRNet:

Level I Antiterrorism Awareness Training:
<http://jko.jten.mil/courses/at11/launch.html>

Organizational Mailbox:

(b) (6)

To submit contracts for AT/OPSEC review:

(b) (6)

"Not on My Watch"

CONFIDENTIALITY NOTE: This electronic transmission, including all attachments, is directed in confidence solely to the person(s) to whom it is addressed, or an authorized recipient, and may not otherwise be distributed, copied or disclosed. The contents of the transmission may also be subject to intellectual property rights and all such rights are expressly claimed and are not waived. If you received this transmission in error, please notify the sender immediately by returning the electronic transmission and then immediately delete this transmission, including all attachments, without copying, distributing or disclosing same.

"PRIVACY ACT INFORMATION"

In compliance with the Privacy Act of 1974, this information is Personal Data and must be protected from public disclosure.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 19:51:12 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: COVID-19 - Potential Treatment

Please take a look and handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Benoit Ponton <bponton@cpa-qc.ca>
Sent: Friday, April 17, 2020 8:57 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Contact (b) (6)
Subject: COVID-19 - Potential Treatment

COVID-19 – Potential Treatment

April 17, 2020

National Institute of Allergy and Infectious Diseases,
National Institutes of Health
31 Center Drive MSC 2520
Building 31, Room 7A03
Bethesda, MD 20892-2520

C/O Anthony S. Fauci, M.D.

Hello Dr. Fauci,

In the current state of medical knowledge and research in the pharmaceutical industry, there is no short- or medium-term solution to prevent disease or cure patients with SARS-Cov-2 (COVID-19).

With this letter, I would like to make you aware of the preventive and curative potential of essential oils (EOs); **lives could be saved.**

Scientific aromatherapy: use of aromatic compounds extracted from plants – essential oils – for medical purposes; ‘hard’ science of nature, based among other things, on in-depth knowledge of organic chemistry. We are not talking about perfumery or occult sciences.

According to Mr. Dominique BAUDOUX, an internationally known Belgian pharmacist and “aromatologist”: ***there is a multitude of research on the antiviral properties of essential oils. The results are impressive and indisputable. Here are some viruses for which we have real data:***

- Severe acute respiratory syndrome virus SARS-Cov (it is a coronavirus)
- The H1N1 flu virus
- Avian influenza virus type H5N1 and subtypes H7N3 and H9N2
- The anti-infectious bronchitis virus (IBV)
- Herpes simplex virus HSV
- Dengue virus DEN
- Newcastle disease virus NDV
- Junin virus (an arena virus responsible for hemorrhagic fever)

Source : <https://www.pranarom.com/blog/guide-des-huiles-essentielles/les-huiles-essentielles-efficaces-contre-lecoronavirus-vrai-ou-faux>: See references 1 to 28 below.

To add meat to the bone, if you visit the **National Center for Biotechnology Information (U.S.)** :

- You will find nearly **225 000 references** on “essential oil.”
See : <https://www.ncbi.nlm.nih.gov/search/all/?term=essential%20oil>
- You will find approximately **22 000 references** on “essential oil + viral.”
See : <https://www.ncbi.nlm.nih.gov/search/all/?term=essential%20oil%20+%20viral>

In addition, according to a brief email exchange with Mr. Pierre FRANCHOMME, a French researcher, one of the leading experts in the field of medicinal essential oils, he informed me that: ***a recent Indian study (March 31) highlights the potential activity of 1,8 cineole (eucalyptol) on SARS-Cov-2, as I suspected from my experience on other enveloped viruses.***

Note: the molecule 1,8 cineole is found in high concentration in eucalyptus EOs.

- Sharma, A.D.; Kaur, I. **Eucalyptol (1,8 cineole) from Eucalyptus Essential Oil a Potential Inhibitor of COVID 19 Corona Virus Infection by Molecular Docking Studies** . Preprints 2020, 2020030455 (doi: 10.20944/preprints202003.0455.v1).
Source : <https://www.preprints.org/manuscript/202003.0455/v1>

Another study (2008) provided by Mr. Franchomme, shows a high antiviral activity of bay laurel/leaf essential oil (*Laurus nobilis*) on SARS-Cov, which appeared in November 2002 in Guangdong province, China and which prevailed until 2004.

- Loizzo, M. R., Saab, A. M., Tundis, R., Statti, G. A., Menichini, F., Lampronti, I., ... Doerr, H. W. (2008). **Phytochemical Analysis and in vitro Antiviral Activities of the Essential Oils of Seven Lebanon Species**. Chemistry & Biodiversity, 5(3), 461–470. doi :10.1002/cbdv.200890045
Source : <https://onlinelibrary.wiley.com/doi/abs/10.1002/cbdv.200890045>

Since SARS-Cov and SARS-Cov-2 (COVID-19) are close relatives, it is quite possible that *Laurus nobilis* essential oil will be as effective on SARS-Cov-2.

Here are two other studies that should be of interest to researchers, according to Mr. FRANCHOMME:

- See reference 20 below **Efficacy of cineole in patients suffering from acute bronchitis: a placebo-controlled double-blind trial**. Cough 9, 25 (2013).
Source : <https://doi.org/10.1186/1745-9974-9-25>

Conclusions of this study : *The effects of Cineole in the treatment of acute bronchitis were clearly measurable and could be proven after a treatment period of merely 4 days. This study corroborates the fact that cineole actively and significantly reduces cough frequency after four days. Therefore it has been shown to have a great socioeconomic impact.*

- See also reference 22 below.

Also, according to Mr. FRANCHOMME, **a clinical study on the treatment of essential oils in patients with COVID-19 has just been undertaken in a hospital setting (100 patients), double blind against placebo**. I will know the results at the same time as everyone else and will inform you.

Here is a summary of Mr. FRANCHOMME's analysis:



The scientific community is launched in search of a miracle drug in the basket of molecules already known for other indications. Our design is to trust the plant world, a great provider of remarkable molecules.

CONCLUSION

We need to think outside the box of allopathic medicine and synthetic drugs that offer no solution and put pressure on our leaders to **release funds for clinical research** on the treatment of patients suffering from COVID-19 using essential oils, as advocated by Mr. Franchomme.

To this end, M. FRANCHOMME confirmed to me this: *I am at the disposal of your authorities to provide and explain a protocol based on essential oils.*

His email address is : [REDACTED] (b) (6)

In terms of a double-blind placebo clinical study, there is, as of today, a huge cohort of hospitalized patients, a significant portion of whom I suspect would be enthusiastic about voluntary enrolment.

For patients in critical care with a life-threatening prognosis, it is undoubtedly possible, given the circumstances, to bypass the usual research protocols and offer a last-resort treatment to these patients in an attempt to save their lives, with their permission or that of their legal representatives in case of temporary or permanent incapacity.

Even if it doesn't work, I don't think patients or their loved ones will blame your government for trying everything, but if you don't, I wouldn't like to be in your shoes!

Cordially,

Benoit Ponton
BP/bp

CC: M. Pierre FRANCHOMME

2150, rue Marianne-Baby
Chambly, QC, Canada J3L 0A3
Office (450) 447-4872
Cell phone [REDACTED] (b) (6)
Email bponton@cpa-qc.ca

SCIENTIFIC PUBLICATIONS

Source : <https://www.pranarom.com/blog/guide-des-huiles-essentielles/les-huiles-essentielles-efficaces-contre-lecoronavirus-vrai-ou-faux>

1. Garozzo, A., Timpanaro, R., Bisignano, B., Furneri, P. M., Bisignano, G., & Castro, A. (2009). **In vitro antiviral activity of Melaleuca alternifolia essential oil.** Letters in applied microbiology, 49(6), 806-808.
<https://sfamjournals.onlinelibrary.wiley.com/doi/full/10.1111/j.1472-765X.2009.02740.x>
2. Reichling, J., Schnitzler, P., Suschke, U., & Saller, R. (2009). **Essential oils of aromatic plants with antibacterial, antifungal, antiviral, and cytotoxic properties—an overview.** Complementary Medicine Research, 16(2), 79-90.
<https://www.karger.com/Article/Abstract/207196>

3. Schnitzler, P., Schon, K. and Reichling, J. (2001) **Antiviral activity of Australian tea tree oil and eucalyptus oil against herpes simplex virus in cell culture.** Pharmazie 56, 343–347. <https://www.ncbi.nlm.nih.gov/pubmed/11338678>
4. Mohammad, A., & Mehmood, D. **In Vivo Anti-Viral Effect of Melaleuca alternifolia (Tea Tree Oil) and Olea europaea (Olive Leaf Extract) on Vero Cell Adapted Avian Influenza Virus.** Human Journals. Research Article December 2018 Vol.:14, Issue:1 Citation: Mohammad Danish Mehmood et al. Ijppr.Human, 2018; Vol. 14 (1): 7-19. https://www.researchgate.net/publication/331149520_In_Vivo_Anti-Viral_Effect_of_Melaleuca_alternifolia_Tea_Tree_Oil_and_Olea_europaea_Olive_Leaf_Extract_on_Vero_Cell_Adapted_Avian_Influenza_Virus
5. Usachev, E. V., Pyankov, O. V., Usacheva, O. V., & Agranovski, I. E. (2013). **Antiviral activity of tea tree and eucalyptus oil aerosol and vapour.** Journal of aerosol science, 59, 22-30. <https://www.sciencedirect.com/science/article/pii/S0021850213000086>
6. Ankita, S., Chandra, S. S., & Arti, T. (2013). **Phytochemical study and antimicrobial activities of cinnamomum camphora.** World Journal of Pharmaceutical research Volume 3, Issue 2, 2287-2294. <https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&ved=2ahUKEwildfj5OHOAhUEZN8KHZDjBdMQFjABegQIBBAB&url=https%3A%2F%2Fwjpr.net%2Fdownload%2Farticle%2F1400323946.pdf&usq=AOvVaw0WLdK22oqsjVQCt6bqmXeb>
7. Astani, A., & Schnitzler, P. (2014). **Antiviral activity of monoterpenes beta-pinene and limonene against herpes simplex virus in vitro.** Iranian journal of microbiology, 6(3), 149. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4393490/>
8. Astani, A., Reichling, J., & Schnitzler, P. (2010). **Comparative study on the antiviral activity of selected monoterpenes derived from essential oils.** Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives, 24(5), 673-679. <https://onlinelibrary.wiley.com/doi/abs/10.1002/ptr.2955>
9. Bisignano, B. (2009). **Attività antivirale e studio del meccanismo d'azione di estratti di melaleuca alternifolia nei confronti del virus dell'influenza A.** Area 06 – Scienze mediche. <http://hdl.handle.net/10761/1767>
10. Blanchard, J. M. (2007). **Cinnamomum camphora à cinéole (ravintsara), une plante au service de la prévention des infections nosocomiales en milieu hospitalier?.** Phytothérapie, 5(1), 15-20.
11. Carson, C.F., Ashton, L., Dry, L., Smith, D.W. and Riley, T.V. (2001) **Melaleuca alternifolia (tea tree) oil gel (6%) for the treatment of recurrent herpes labialis.** J Antimicrob Chemother 48, 450–451. <https://academic.oup.com/jac/article/48/3/450/736091>

12. Carson, C.F., Smith, D.W., Lampacher, G.J. and Riley, T.V. (2008) **Use of deception to achieve double-blinding in a clinical trial of *Melaleuca alternifolia* (tea tree) oil for the treatment of recurrent herpes labialis.** *Contemp Clin Trials* 29, 9–12.
[https://www.contemporaryclinicaltrials.com/article/S1551-7144\(07\)00053-5/fulltext](https://www.contemporaryclinicaltrials.com/article/S1551-7144(07)00053-5/fulltext)
13. Galan, D. M., Ezeudu, N. E., ..., & Malcolm, B. J. (2020). **Eucalyptol (1, 8-cineole): an underutilized ally in respiratory disorders?** *Journal of Essential Oil Research*, 1-8.
<https://www.tandfonline.com/doi/abs/10.1080/10412905.2020.1716867?journalCode=tjeo20>
14. Garozzo, A., Timpanaro, R., Stivala, A., Bisignano, G., & Castro, A. (2011). **Activity of *Melaleuca alternifolia* (tea tree) oil on Influenza virus A/PR/8: study on the mechanism of action.** *Antiviral research*, 89(1), 83-88.
<https://www.sciencedirect.com/science/article/abs/pii/S0166354210008120?via%3Dihub>
15. Hamidpour, R., Hamidpour, S., Hamidpour, M., & Shahlari, M. (2014). **Chemistry, Pharmacology and Medicinal Property of Camphor (*Cinnamomum Camphora*) Traditional Remedy with the History of Treating Several Diseases.** *Global Journal of Medical Research*.
<https://scholar.google.com/citations?user=xrGgDigAAAAJ&hl=en>
16. Jean Michel Blanchard (2007). ***Cinnamomum camphora* CT cineole (ravintsara), a plant to help prevent nosocomial infections in the hospital environment.** *International Journal of Clinical Aromatherapy* Vol. 4 issue 1
17. Li, X., Duan, S., Chu, C., Xu, J., Zeng, G., Lam, A. K. Y., ... & Gu, H. (2013). ***Melaleuca alternifolia* concentrate inhibits in vitro entry of influenza virus into host cells.** *Molecules*, 18(8), 9550-9566. <https://www.mdpi.com/1420-3049/18/8/9550>
18. Li, Y., Xu, Y. L., ... & Xu, P. P. (2017). **Intranasal co-administration of 1, 8-cineole with influenza vaccine provide cross-protection against influenza virus infection.** *Phytomedicine*, 34, 127-135.
<https://www.sciencedirect.com/science/article/abs/pii/S0944711317301034?via%3Dihub>
19. Loizzo, M. R., Saab, A. M., Tundis, R., Statti, G. A., Menichini, F., Lampronti, I., ... & Doerr, H. W. (2008). **Phytochemical analysis and in vitro antiviral activities of the essential oils of seven Lebanon species.** *Chemistry & biodiversity*, 5(3), 461-470.
<https://onlinelibrary.wiley.com/doi/abs/10.1002/cbdv.200890045>
20. Mansard, M., Laurain-Mattar, D., & Couic-Marinier, F. (2019). **Huile essentielle de Ravintsara.** *Actualités Pharmaceutiques*, 58(585), 57-59.
<https://www.sciencedirect.com/science/article/pii/S0515370019300734?via%3Dihub>
21. Morales-Rico, C. L., ... & González-Camejo, I. (2012). **Composición química del aceite esencial de las partes aéreas de *Melaleuca quinquenervia*.** *Revista CENIC. Ciencias Químicas*, 43, 1-2.

- https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&ved=2ahUKEwig4qLa7uHoAhWhnuAKHSDZAasQFjABegQIAhAB&url=http%3A%2F%2Fwww.revistas.u-sach.cl%2Ffojs%2Findex.php%2Fblacpma%2Farticle%2Fdownload%2F2401%2F2210%2F&usg=AOvVaw3k2Urazeofgeg_ftc7wdK
22. Janine Müller, Johannes F.W. Greiner, Marie Zeuner, Viktoria Brotzmann, Johanna Schäfermann, Frederique Wieters, Darius Widera, Holger Sudhoff, Barbara Kaltschmidt, Christian Kaltschmidt; *Clin Sci (Lond)* 1 August 2016; 130 (15): 1339–1352. **1, 8-Cineole potentiates IRF3-mediated antiviral response in human stem cells and in an ex vivo model of rhinosinusitis.** *Clinical Science (Lond)* 1 August 2016; 130 (15): 1339–1352. <https://doi.org/10.1042/CS20160218> et <https://portlandpress.com/clinsci/article-abstract/130/15/1339/71448/1-8-Cineole-potentiates-IRF3-mediatedantiviral?redirectedFrom=fulltext>
 23. Riley, T. V. (2005). **Antiviral Activity of Tea Tree Oil–In Vitro and In Vivo.** TV Riley – 2005 – academia.edu <https://www.agrifutures.com.au/product/antiviral-activity-of-tea-tree-oil-in-vitro-and-in-vivo/>
 24. Siddique, S., et al. (2018). **Chemical characterization, antioxidant and antimicrobial activities of essential oil from Melaleuca quinquenervia leaves.** Indian Journal of Experimental Biology, 56, 686-693. https://www.researchgate.net/publication/327829462_Chemical_characterization_anti-oxidant_and_antimicrobial_activities_of_essential_oil_from_Melaleuca_quinquenervia_leaves
 25. Timpanaro, R., Garozzo, A., Bisignano, B., Stivala, A., Furneri, P. M., Tempera, G., & Castro, A. (2007). **Inhibitory effect of Melaleuca alternifolia (tea tree oil) on influenza A/PR/8 virus replication.** International Journal of Antimicrobial Agents, (29), S202-S203. <https://www.sciencedirect.com/science/article/abs/pii/S0166354210008120?via%3Dihub>
 26. Worth, H., ..& Dethlefsen, U. (2009). **Concomitant therapy with Cineole (Eucalyptole) reduces exacerbations in COPD: a placebo-controlled doubleblind trial.** Respiratory research, 10(1), 69. <https://respiratory-research.biomedcentral.com/articles/10.1186/1465-9921-10-69>
 27. Yang, Z., Wu, N., .. & Efferth, T. (2010). **Anti-infectious bronchitis virus (IBV) activity of 1, 8-cineole: Effect on nucleocapsid (N) protein.** Journal of Biomolecular Structure and Dynamics, 28(3), 323-330. <https://www.tandfonline.com/doi/abs/10.1080/07391102.2010.10507362>
 28. Zamora, A. C. P. (2015). **The Antiviral Properties of Melaleuca alternifolia concentrate (MAC) against West Nile virus** (Doctoral dissertation, Griffith University). <https://pdfs.semanticscholar.org/fc36/83837c5d872444e51c452bdd3f6a644fa079.pdf>

OTHER SCIENTIFIC PUBLICATIONS

Source : <https://www.aude-maillard.fr/4-huiles-essentielles-contre-le-coronavirus/>

29. Brun, P., Bernabè, G., Filippini, R. *et al.* **In Vitro Antimicrobial Activities of Commercially Available Tea Tree (*Melaleuca alternifolia*) Essential Oils.** *Curr Microbiol* **76**, 108–116 (2019). <https://doi.org/10.1007/s00284-018-1594-x>
30. Shih-Yu Lee, Po-Yu Chen, Jung-Chun Lin, Nicholas S. Kirkby, Ching-Huei Ou and Tsu-Chung Chang **Melaleuca alternifolia Induces Heme Oxygenase-1 Expression in Murine RAW264.7 Cells through Activation of the Nrf2-ARE Pathway.** *The American Journal of Chinese Medicine* Vol. 45, No. 08, pp. 1631-1648 (2017) <https://doi.org/10.1142/S0192415X17500872>
31. Akram Astani, Jürgen Reichling and Paul Schnitzler. **Screening for antiviral activities of isolated compounds from essential oils.** Hindawi. *Evidence-Based Complementary and Alternative Medicine* / 2011 <https://doi.org/10.1093/ecam/nep187>
32. Schnitzler P. **Essential Oils for the Treatment of Herpes Simplex Virus Infections.** *Chemotherapy* 2019;64:1-7. <https://doi.org/10.1159/000501062>

CONFIDENTIALITY NOTICE: The information contained in this transmission (including any files attached to it) is legally privileged and confidential and is intended solely for the use of the individual or entity to whom it is addressed. Any other use, dissemination, distribution, disclosure or copying of this message is strictly prohibited. If you have received this communication in error, please immediately notify the sender so that we may ensure the intended recipient receives a copy of the original transmission. We then ask that you kindly destroy your copy and delete the entire message from your computer system.

AVIS DE CONFIDENTIALITÉ : L'information contenue dans cette transmission (et tout document ci-joint) est confidentielle et privilégiée et est à l'usage exclusif de la personne ou de l'entité à qui elle est adressée. Tout autre usage, distribution, divulgation, ou copie de cette communication est strictement prohibé. Si vous avez reçu cette transmission par erreur, veuillez nous en aviser immédiatement pour que nous puissions envoyer le message au destinataire. Aussi, nous vous demandons de détruire toutes les copies et le supprimer de votre système informatique.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 19:46:44 +0000
To: Del Rio, Carlos
Subject: RE: released.

Thanks, Carlos.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Del Rio, Carlos (b) (6) >
Sent: Friday, April 17, 2020 11:16 AM
To: 'Birx, Deborah L. EOP/NSC' (b) (6); Fauci, Anthony (NIH/NIAID) [E]
(b) (6)
Cc: Rochelle Walensky MD, MPH (b) (6) >
Subject: released.

Here is link to the paper entitled "From Mitigation to Containment of the COVID-19 Pandemic – Putting the SARS-CoV-2 Genie Back in the Bottle" that Rochelle and I wrote for JAMA. Hope you find it useful. Feel free to distribute. Thanks again for all you are doing!

<https://jamanetwork.com/journals/jama/fullarticle/2764956>

Sincerely,

Carlos

This e-mail message (including any attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution

or copying of this message (including any attachments) is strictly prohibited.

If you have received this message in error, please contact the sender by reply e-mail message and destroy all copies of the original message (including attachments).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 19:40:55 +0000
To: Walensky, Rochelle,M.D.,M.P.H.
Subject: RE: released.

Thanks, Rochelle!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Walensky, Rochelle,M.D.,M.P.H. (b) (6) >
Sent: Friday, April 17, 2020 11:54 AM
To: Carlos del Rio (b) (6) >; 'Birx, Deborah L. EOP/NSC' (b) (6);
Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: RE: released.

Dear Drs. Birx and Fauci (Debbie and Tony, if I may),
So grateful for all you are doing. Please let us know if there is any way we can help.
My best from Boston,
Rochelle

Rochelle P. Walensky, MD, MPH
Chief, Division of Infectious Diseases
Steve and Deborah Gorlin MGH Research Scholar
Massachusetts General Hospital
Division of Infectious Disease
Professor, Harvard Medical School

55 Fruit Street, GRJ 504J floor
Boston, MA 02114-2696
Phone: (b) (6)
Fax: 617-726-7416
Email: (b) (6)
Pronouns: she/her/hers

From: Del Rio, Carlos (b) (6)]
Sent: Friday, April 17, 2020 11:16 AM
To: 'Birx, Deborah L. EOP/NSC' (b) (6)>; 'Fauci, Anthony (NIH/NIAID) [E]' (b) (6)>
Cc: Walensky, Rochelle,M.D.,M.P.H. (b) (6)>
Subject: released.

External Email - Use Caution

Here is link to the paper entitled "From Mitigation to Containment of the COVID-19 Pandemic – Putting the SARS-CoV-2 Genie Back in the Bottle" that Rochelle and I wrote for JAMA. Hope you find it useful. Feel free to distribute. Thanks again for all you are doing!

<https://jamanetwork.com/journals/jama/fullarticle/2764956>

Sincerely,

Carlos

This e-mail message (including any attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this message (including any attachments) is strictly prohibited.

If you have received this message in error, please contact the sender by reply e-mail message and destroy all copies of the original message (including attachments).

The information in this e-mail is intended only for the person to whom it is addressed. If you believe this e-mail was sent to you in error and the e-mail contains patient information, please contact the Partners Compliance HelpLine at <http://www.partners.org/complianceline> . If the e-mail was sent to you in error but does not contain patient information, please contact the sender and properly dispose of the e-mail.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 19:34:53 +0000
To: Jeffrey V. Ravetch
Cc: Lusso, Paolo (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; (b) (6); Cassetti, Cristina (NIH/NIAID) [E]; Erbeling, Emily (NIH/NIAID) [E]
Subject: FW: new manuscript
Attachments: Bournazos, et al.docx, Extended Figures.pdf

Jeff:

Very interesting paper. Could have wide applicability in viral disease. I will pass it on to our program people.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeffrey V. Ravetch (b) (6) >
Sent: Friday, April 17, 2020 1:26 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: new manuscript

Tony,

I've attached a pre-print of the story I briefly told you about related to Fc optimization of anti-viral antibodies to induce CD8 protective responses.

I'd be grateful for your comments.

And my sincere gratitude for keeping science at the front of this pandemic.

Best regards,

Jeff

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 19:30:56 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]; Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Concept Paper for NEJM on Novel Clinical Trial in COVID-19
Attachments: Composite EPO COVID-19.pdf

Andrea:

This is a former post-doc in my lab. Please read this, get back to her apologizing that I could not respond [REDACTED] (b) (5) I obviously can have no part in it.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Ehrenreich, Hannelore [REDACTED] (b) (6) >
Sent: Friday, April 17, 2020 1:46 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: Concept Paper for NEJM on Novel Clinical Trial in COVID-19

Dear Tony,

I am aware of the heavy load that is on your shoulders these days but I sincerely hope to get a brief answer to my E-mail.

In light of the present therapeutic situation in COVID-19, any measure to improve course and outcome of seriously affected individuals is of utmost importance. In the attached

[REDACTED] (b) (6), (b) (4)

We all would be extremely grateful for your feedback and for your collaboration!
In fact, I personally would be so proud to have you as senior coauthor as in former times! Please let me know what you think.

We could also discuss over the phone if you let me know which time would be convenient.

All my best, Hannelore

-----Ursprüngliche Nachricht-----

Von: Ehrenreich, Hannelore

Gesendet: Samstag, 21. März 2020 13:24

An: 'Fauci, Anthony (NIH/NIAID) [E]' <(b) (6)>

Betreff: THANK YOU from Germany

Dear Tony,

I know you are extremely busy these days... now even more than before due to this terrible corona crisis!

Just a brief note to let you know that I watched your excellent interviews and that I am extremely proud of you! For people here in our Max Planck Institute and the many biomedical institutions in Göttingen you are the greatest hero indeed in a tough time...

I wish you all strength and endurance needed to lead the world out of this crisis (despite questionable politicians)!
STAY HEALTHY!

All my best, Hannelore

Professor Hannelore Ehrenreich, MD, DVM
Clinical Neuroscience
Max Planck Institute of Experimental Medicine
Hermann-Rein-Str.3

37075 Göttingen

GERMANY

Tel: [REDACTED] (b) (6)

Fax: 49-551-3899 670

E-Mail: [REDACTED] (b) (6)

Prof. hon. University of Göttingen

Faculty of Biology & Psychology

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 19:21:39 +0000
To: Stover, Kathy (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: FOR ASF REVIEW: Draft MA re: NIAID COVID 19 Strategic Research Plan

Looks fine. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stover, Kathy (NIH/NIAID) [E] (b) (6) >
Sent: Friday, April 17, 2020 2:42 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6) >; Folkers, Greg (NIH/NIAID) [E] (b) (6) >; Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Subject: FOR ASF REVIEW: Draft MA re: NIAID COVID 19 Strategic Research Plan

Hi Dr. Fauci,

Please find attached for your review a draft media availability about NIAID's COVID-19 strategic research plan. We've named you as the spokesperson in the media avail.

Best,
Kathy

Kathy Stover
Branch Chief
News and Science Writing Branch
National Institute of Allergy and Infectious Diseases (NIAID)
Office of Communications and Government Relations
National Institutes of Health/HHS
31 Center Drive, Room 7A17E

Bethesda, MD 20892

Phone: (b) (6)

E-mail: (b) (6)

NIAID Media Line: (301) 402-1663

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 18:30:03 +0000
To: Hahn, Stephen; Birx, Deborah L. EOP/NSC; Redfield, Robert R. (CDC/OD); Kadlec, Robert (OS/ASPR/IO); (b) (6)
Subject: FW: Boston Globe: Nearly a third of 200 blood samples taken in Chelsea show exposure to coronavirus

Steve:

(b) (5)

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E]; (b) (6)
Sent: Saturday, April 18, 2020 1:54 PM
Subject: Boston Globe: Nearly a third of 200 blood samples taken in Chelsea show exposure to coronavirus

Nearly a third of 200 blood samples taken in Chelsea show exposure to coronavirus

Mass. General researcher says the results point to a 'raging epidemic,' but may also indicate the city is further along the disease curve than some other municipalities

By [Jonathan Saltzman](#) Globe Staff, Updated April 17, 2020, 6:26 p.m.



First responders loaded a patient into an

ambulance from a nursing home where multiple people have contracted COVID-19 in Chelsea, which has the highest concentration of COVID-19 infections in the state. Scott Eisen/Getty

Nearly one third of 200 Chelsea residents who gave a drop of blood to researchers on the street this week tested positive for antibodies linked to COVID-19, a startling indication of how widespread infections have been in the densely populated city.

Sixty-four residents who had a finger pricked in Bellingham Square on Tuesday and Wednesday had antibodies that the immune system makes to fight off the coronavirus, according to Massachusetts General Hospital physicians who ran the pilot study.

The 200 participants generally appeared healthy, but about half told the doctors they had had at least one symptom of COVID-19 in the past four weeks.

Public health experts already knew Chelsea had the state's highest rate of confirmed COVID-19 cases and that the actual rate was probably higher. At least 39 residents have died from the virus, and 712 had tested positive as of Tuesday, a rate of about 1,900 cases per 100,000 residents, or almost 2 percent.

Get Talking Points in your inbox An afternoon recap of the day's most important business news, delivered Monday through Friday.

But the Mass. General researchers — who excluded anyone who had tested positive for the virus in the standard nasal swab test — found that 32 percent of participants have had COVID-19, and many didn't know it.

"I think it's both good news and bad news," said Dr. John Iafrate, vice chairman of MGH's pathology department and the study's principal investigator. "The bad news is that there's a raging epidemic in Chelsea, and many people walking on the street don't know that they're carrying the virus and that they may be exposing uninfected individuals in their families."

"On the good-news side, it suggests that Chelsea has made its way through a good part of the epidemic," he said. "They're probably further along than other towns."

Scientists suspect that people who recover from COVID-19 may be at least temporarily immune from catching it again. Several biotechs and academic laboratories, in fact, are seeking blood donations from people who have recovered, in the hopes that their antibodies can help create a treatment or vaccine.

Chelsea's city manager, Thomas Ambrosino, said he learned the results of the pilot study Thursday in a conference call with the researchers. He was dismayed, but not shocked.

Related: Chelsea city manager sounds urgent alarm, calls for residents to stay home 24 hours a day

"We've long thought that the reported numbers are vastly under-counting what the actual infection is," said Ambrosino, who has called his city the epicenter of the crisis in Massachusetts. "Those reported numbers are based on positive COVID-19 tests, and we're all aware that a very, very small percentage of people in Chelsea and everywhere are getting COVID-19 tests."

“Still,” he added, “it’s kind of sobering that 30 percent of a random group of 200 people that are showing no symptoms are, in fact, infected. It’s all the more reason for everyone to be practicing physical distancing.”

Indeed, one of the doctors who tested volunteers in Bellingham Square said it’s possible that some of the people who had the antibodies are still contagious.

“Just because you have the antibodies doesn’t mean you’ve cleared the virus,” said Dr. Vivek Naranbhai, a clinical fellow in hematology and oncology.

Researchers said the test results, which had yet to be shared with state officials late Friday, couldn’t necessarily be extrapolated for the city’s roughly 40,000 residents. Still, the findings provided a valuable snapshot of a community that medical experts say is especially vulnerable to COVID-19.

Chelsea covers only about two square miles, across the Mystic River from Boston. For generations, it has attracted new immigrants, and about 65 percent of its residents are Latino. Many live in three-decker houses, Ambrosino said, where it’s hard for people to isolate themselves. Many work in the hospitality industry and health-related fields, where exposure to the virus is greater. And a lot of them must go to work during the pandemic.

To get Chelsea residents to participate in the study — which included a questionnaire that was available in English, Spanish, and Portuguese — investigators allowed them to remain anonymous. But that meant none of the participants received the results of the blood tests.

The doctors used a diagnostic device made by BioMedomix, of Morrisville, N.C., to analyze drops of blood. It resembled an over-the-counter pregnancy test and generated results on the street in about 10 minutes. Although the test hasn’t won the approval of the Food and Drug Administration, lafrate, the principal investigator, said Mass. General determined it’s reliable.

Within days, the physicians said, they hope to set up a medical tent outside the Mass. General Chelsea Healthcare Center to perform more antibodies tests with the device. The site will be located near a tent set up weeks ago to run standard PCR, or polymerase chain reaction, tests for people with active coronavirus symptoms. The latter uses nasal swabs to detect whether the virus is present at the time; the antibodies blood test reveals whether someone was infected in the past.

In addition to the new testing site, the researchers want to expand the study to other Massachusetts cities and towns. For all of those studies, Mass. General doctors plan to obtain the identities of participants so physicians can provide the results. But first the researchers need to come up with guidelines for what participants should do if they test positive for antibodies.

Dr. Dean Xerras, medical director of the Mass. General Chelsea Healthcare Center and a co-investigator in the study, said it illustrates why it’s essential for Chelsea and other communities to perform more tests, regardless of whether they detect antibodies or the virus itself.

“Knowing how many people are infected is critical,” said Xerras, a longtime member of the city’s board of health. “We need to get them isolated. We need to get masks delivered to the city. We need to launch more safe isolation sites. We need to be able to identify cases and then give people the things they need to prevent perpetuation of the spread.”

Chelsea and Revere officials, with help from the state Department of Public Health and the Massachusetts Emergency Management Agency, secured almost 150 rooms at a Quality Inn in Revere this week for residents who are recovering from COVID-19 and unable to isolate themselves at home, according to Ambrosino. So far, only a handful of those rooms are occupied.

Governor Charlie Baker on Thursday staunchly defended the state’s handling of the escalating outbreak in Chelsea, including asserting, without offering details, that city leaders have turned down help from his administration.

The governor's claim surprised officials in Chelsea who told the Globe this week that the state, and even health care providers, should have recognized the virus's rapid spread through the city sooner.

Jonathan Saltzman can be reached at jonathan.saltzman@globe.com

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: (b) (6)
Sent: Sat, 18 Apr 2020 12:28:50 -0400
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Fwd: working draft of NEJM
Attachments: COVID vaccine editorial_16April 7pm.docx, ATT00001.htm

Sent from my iPhone

Begin forwarded message:

From: "Corey MD, Larry" (b) (6) >
Date: April 18, 2020 at 12:34:13 AM EDT
To: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6) >, "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Cc: "Mascola, John (NIH/VRC) [E]" (b) (6)
Subject: working draft of NEJM

Here is the working draft . My manuscript typist too tired to work tonight so it reflects several changes I made tonight ; it should be readable ;

Larry

From: (b) (6)
Sent: Sat, 18 Apr 2020 12:27:56 -0400
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Fwd: JAMA - Heroes
Attachments: heroes.pdf, ATT00001.htm

Sent from my iPhone

Begin forwarded message:

From: Howard Bauchner <Howard.Bauchner@jamanetwork.org>
Date: April 18, 2020 at 5:10:15 AM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Cc: Phil Fontanarosa <Phil.Fontanarosa@jamanetwork.org>
Subject: JAMA - Heroes

There are many many heroes in this tragedy – but none more so than you, Maurizio, and Dr. Wenilang.

Howard Bauchner, MD
Editor in Chief of JAMA and the JAMA Network

Please respect the confidentiality of this email

Listen to my [chats with authors](#)

From: Howard Bauchner <Howard.Bauchner@jamanetwork.org>
Date: Saturday, April 18, 2020 at 4:07 AM
To: CECCONI HUNIMED <(b) (6)>
Subject: Re: Hello

I am well – (b) (6) – but you know all about that – remain in Chicago – at work everyday – no one is in; (b) (6)
– he will quarantine for the 2 weeks he is up there.

Yes – NY, London, Paris – all difficult times – great vector – the subway, underground, and metro – unmasked folks who were asymptomatic carriers – terrible.

Most of the US managing although still a heavy heavy lift in some places – NY, Boston, some in Chicago – but most of the US managing. The big issue like everywhere is how do we put society back together.

Will be published on Monday – our tribute to many people and 3 individuals.

HCB

Howard Bauchner, MD
Editor in Chief of JAMA and the JAMA Network

Please respect the confidentiality of this email

Listen to my [chats with authors](#)

From: CECCONI HUNIMED [REDACTED] (b) (6) >
Date: Friday, April 17, 2020 at 2:07 PM
To: Howard Bauchner <Howard.Bauchner@jamanetwork.org>
Subject: Hello

[Warning External Email]
Hello Howard,

I hope you are well. Just a line to say that the podcasts are incredible.
I hope you are ok. I am very sorry for the colleagues in New York. I know it's very tough there and also in other parts of US.
Things are getting better here.

Keep up the amazing work.

Kind regards,

Maurizio

Maurizio Cecconi MD FRCA FFICM MD(Res)
Head of Department Anaesthesia and Intensive Care Units
Humanitas Research Hospital
Professor of Anaesthesia and Intensive Care
Humanitas University


President Elect ESICM

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 13:46:56 +0000
To: Greg Folkers (b) (6); Morens, David (NIH/NIAID) [E]
Subject: FW: CDC: (b) (5)
(b) (5) <https://bit.ly/2Ki5Ry4>

We really need to talk about this. (b) (5)
(b) (5)

From: Morens, David (NIH/NIAID) [E] (b) (6)
Sent: Friday, April 17, 2020 6:49 PM
To: Folkers, Greg (NIH/NIAID) [E] <(b) (6)>
Cc: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: Re: CDC: (b) (5)
(b) (5) <https://bit.ly/2Ki5Ry4>

(b) (5)



Sent from my iPhone
David M Morens
OD, NIAID, NIH

On Apr 17, 2020, at 18:30, Folkers, Greg (NIH/NIAID) [E] (b) (6) wrote:

The estimates on this page have been updated from an earlier report published in December 2018 based on more recently available information. There is a trade-off between timeliness and accuracy of the burden estimates. To provide timely burden estimates to the public, clinicians, and public health decision-makers, we use preliminary data that may lead to over- or under-estimates of the true burden. However, each season's estimates will be finalized when data on testing practices and deaths for that season are available.

For the revised 2017-2018 estimates, we included additional information in our estimation regarding influenza testing practices. The surveillance system used to estimate influenza-related hospitalizations, FluSurv-NET, collects data on patients hospitalized with laboratory-confirmed influenza. Influenza testing is done at the request of the clinician, but not everyone is tested and influenza tests are not perfectly accurate. Thus, the reports of laboratory-confirmed influenza-related hospitalizations to FluSurv-NET are likely underestimates of the true number of hospitalizations. To adjust for this, CDC collects data annually from participating FluSurv-NET sites on the amount of influenza testing and the type of test that is used at the site, and this information is used to correct for the possible underestimate of influenza-related hospitalizations. These testing data are often not available for up to two years after the end of an influenza season, and thus the estimates are revised when additional testing data become available. For the original preliminary 2017-2018 burden estimates, data on testing practices during the 2014-2015 season were used to make preliminary estimates because this season had the highest levels of testing among the prior seasons for which data were available and resulted in the most conservative (lowest) estimates of burden. More recent data from the 2016-17 season show that influenza testing has been increasing among most age groups. The current estimates were made using the highest testing rate for each age-group during 2010-11 to 2016-17 and has resulted in some burden estimates being lower than previously estimated.

Additionally, the method we use to estimate influenza-associated deaths relies on additional data from FluSurv-NET and the National Center for Health Statistics (data on cause of deaths and numbers of deaths that occur in versus outside the hospital) that are also not available for up to two years after the end of the season being estimated.

The 2017-2018 estimates are still preliminary because not all of the required data are currently available. When those data become available, these estimates will be updated again and the results may change.

More answers to frequently asked questions about CDC's influenza burden estimates are available.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: (b) (6)
Sent: Fri, 17 Apr 2020 14:45:56 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Invitation to speak at virtual TIME 100 event

Let us make sure that we discuss this.

Begin forwarded message:

From: Alice Park <alice.park@time.com>
Date: April 17, 2020 at 2:07:17 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Cc: Cate Matthews <cate.matthews@time.com>
Subject: Re: Invitation to speak at virtual TIME 100 event

Hi Dr. Fauci -- I also should have added that we are happy to pre-tape the interview so it does not have to happen on April 23. In order for it to run on that date, we would love to record it some time Wed during the day or on Thurs morning. Hoping that helps with timing, and looking forward to hearing from you. Best, Alice

PLEASE NOTE NEW PHONE NUMBER

Alice Park

TIME

(b) (6)

alice.park@time.com

@aliceparkny

On Fri, Apr 17, 2020 at 9:35 AM Alice Park <alice.park@time.com>wrote:

Dear

Dr. Fauci,

Thank

you for making time to talk to me during the early weeks of the pandemic. I know your schedule is tight, but wanted to pass along an invitation to speak at a unique virtual summit we're holding next week, that I hope we can make work.

Building

on the impact of our annual TIME

100 and TIME 100 Health summits, as well as our ongoing coverage of COVID-19, on **Thursday, April 23,**

TIME will launch its first-ever virtual event series, "TIME Talks: Finding Hope." Our goal is to convene a group of the world's leading voices, including TIME 100 honorees, to spotlight the important work they're doing to combat this crisis, and to help our viewers navigate this new reality.

As part of our launch event, scheduled to take place between noon and 3 p.m. ET, we'd like to invite you

to participate in a short, 10- to 20-minute video interview with a TIME editor on public health policies that could be implemented at the national level to strengthen the responses to this and future pandemics—addressing in particular lessons learned from the initial response to the coronavirus.

We would also welcome your thoughts on how we plan to navigate out of the pandemic and what the new normal will look like. (Please note that we are open to discussing other topics as well.)

Each conversation will be streamed and promoted across TIME's platforms, which reach a combined audience of 100 million people around the world.

As

one of our invited speakers, you would also be part of an extraordinary community of leaders who are shaping our world. Past speakers at TIME events include House

Speaker

Nancy Pelosi,

Apple CEO

Tim Cook,

Primatologist

Jane Goodall,

White House Adviser

Jared Kushner,

Chef

José Andrés,

Me Too Movement Founder **Tarana Burke,**

Producer Director

Ryan Murphy,

and many others.

Thank

you in advance for considering this invitation. Cate, our program coordinator, and I are happy to help with any questions you may have.

Looking forward to hearing from you.

Best,

Alice

PLEASE NOTE NEW PHONE NUMBER

Alice Park

TIME

(b) (6)

alice.park@time.com

@aliceparkny

From: Fauci, Anthony (NIH/NIAD) [E]
Sent: Fri, 17 Apr 2020 16:00:09 +0000
To: Thomas R. Frieden
Subject: Re: Box It In
Attachments: image001.png, image002.png, image003.jpg

Thanks, Tom. I totally agree with this approach. I have been trying to catch you by phone but have gotten a voicemail with a message that the mailbox is full. Do I have the correct number?
Thanks, Tony

On Apr 17, 2020, at 11:00 AM, Thomas R. Frieden

(b) (6) wrote:

Tony,

Wishing you well. Wanted you to be aware that we're releasing a report at a media briefing this morning on how to "Box In COVID." This plan includes prioritized expansion of testing and building a corps of contact tracers in the US, using tried-and-true public health measures at scale. There are four essential actions to box in the virus: 1) Expand testing; 2) Isolate infected people to prevent spread; 3) Identify contacts who may have exposed; 4) Quarantine contacts. As you know, all four are crucial; if any one is lacking, the virus can escape and spread explosively again. Success requires a massive expansion of our public health capacity around the country and world.

The report is attached and can be downloaded [here](#). Please let me know how we can continue to be as supportive as possible.

All the best,

Tom

Tom Frieden, MD, MPH
President and CEO
www.DrTomFrieden.net
(b) (6)

<image001.png>

<image002.png>

<image003.jpg>

RESOLVE TO SAVE LIVES
An initiative of Vital Strategies

STAY CONNECTED
www.resolvetosavelives.org [facebook](#) [twitter](#)

<COV035_BoxItInBriefing_FINAL.pdf>





RESOLVE

TO SAVE LIVES

AN INITIATIVE OF VITAL STRATEGIES

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 17 Apr 2020 10:15:13 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: [REDACTED] (b) (4)

Please take a look at this and respond. Thanks.

From: Alfonso Arana <alfonso.arana@bizsecure.us>
Sent: Friday, April 17, 2020 5:53 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Cc: David Katz [REDACTED] (b) (6); Robert.Thompson@crlcorp.com
Subject: [REDACTED] (b) (4)

Dr. Fauci, good morning thank you for all you do for this great nation! We are very blessed to have you at the forefront of this pandemic. Not sure if you recall, [REDACTED] (b) (6) we have

(b) (4)

Alfonso Arana
President / CEO
Craft Artisan Design Inc. HUBZone
DBA. BizSecure
<https://bizsecure.us>

(b) (6)

CONFIDENTIALITY NOTICE: This e-mail message including attachments, if any, is intended only for the person or entity to which it is addressed and may contain confidential and /or privileged material. Any review, use, disclosure or distribution of such confidential information without the written authorization of Craft Artisan Design Inc. DBA A&A Solutions. is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message, by receiving this e-mail you acknowledge that any breach by you and/or your representatives of the above provisions may entitle A&A Solutions., to seek for damages.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 17 Apr 2020 02:48:07 +0000
To: Greg Folkers (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Hilary Marston's COVID-19 talk now archived for viewing

Greg:

Please see me tomorrow about some ideas that I have about COVID-19 slides.

Thanks,

Tony

-----Original Message-----

From: Roberts, Jacqueline (NIH/OD) [E] (b) (6)
Sent: Thursday, April 16, 2020 3:12 PM
To: NIH-STAFF@LIST.NIH.GOV
Subject: Hilary Marston's COVID-19 talk now archived for viewing

Dear Colleagues,

Thank you all for your support as we launch the new COVID-19 lecture series. The live videocast of yesterday's talk was in high demand and, unfortunately, many of you were unable to gain access. This was partly because of the large number of viewers. We are working to remedy the issues in preparation for next week's lecture.

Dr. Marston's talk, "The Biomedical Research Response to COVID-19: A View from NIAID," is now archived at <https://videocast.nih.gov/watch=36375>.

- The COVID-19 SIG Moderators

For more information about the COVID-19 Scientific Interest Group, refer to <https://oir.nih.gov/sigs/covid-19-scientific-interest-group>.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 17 Apr 2020 02:45:01 +0000
To: Collins, Francis (NIH/OD) [E]
Subject: RE: conspiracy gains momentum

Francis:

(b) (5)

Best,
Tony

From: Collins, Francis (NIH/OD) [E] (b) (6)
Sent: Thursday, April 16, 2020 5:02 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Tabak, Lawrence (NIH/OD) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E]
(b) (6); Burklow, John (NIH/OD) [E] (b) (6)
Subject: conspiracy gains momentum

(b) (5)

<https://www.mediaite.com/tv/foxs-bret-baier-sources-increasingly-confident-coronavirus-outbreak-started-in-wuhan-lab/>

(b) (5)

Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 17 Apr 2020 02:28:05 +0000
To: Pottinger, Matthew F. EOP/WHO; Birx, Deborah L. EOP/NSC
Cc: (b) (6)
Subject: RE: [WARNING: UNSCANNABLE EXTRACTION FAILED][EXTERNAL] Using grounded aircraft to treat COVID patients

Matt:

(b) (5)

(b) (5). Let us discuss further.

Best regards,
Tony

From: Pottinger, Matthew F. EOP/WHO (b) (6)
Sent: Thursday, April 16, 2020 7:54 PM
To: Birx, Deborah L. EOP/NSC <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E]
(b) (6)
Subject: FW: [WARNING: UNSCANNABLE EXTRACTION FAILED][EXTERNAL] Using grounded aircraft to treat COVID patients

Deb, Tony,

(b) (5)

Best,
Matt

From: Skinner, James B. EOP/NSC (b) (6)
Sent: Thursday, April 16, 2020 6:53 PM
To: Pottinger, Matthew F. EOP/WHO (b) (6)>
Cc: DL NSC NSA FO Staff <DL.NSAFOStaff@whmo.mil>
Subject: FW: [WARNING: UNSCANNABLE EXTRACTION FAILED][EXTERNAL] Using grounded aircraft to treat COVID patients

Matt,

I spoke to Leland earlier this afternoon and he asked I pass this along to you.

James

From: Leland Schwartz (b) (6)>
Sent: Thursday, April 16, 2020 6:08 PM

To: Skinner, James B. EOP/NSC (b) (6) >

Cc: Ralph Crafts (b) (6); BARBARA SCHEIDE <(b) (6)>; Ed Betts
(b) (6)

Subject: [WARNING: UNSCANNABLE EXTRACTION FAILED][EXTERNAL] Using grounded aircraft to treat COVID patients

Matt,

Oxygen therapy scientists can treat patients using the grounded airliners all over the country as mass treatment chambers.

Please watch this explanation from Extivita in Durham:

><https://www.youtube.com/watch?v=SWCHDuUQHSM&feature=youtu.be><

Please help us connect to the right people.

This could help save lives, get our economy restarted, and ensure continuity in the government.

Hope you're good. Catch up on the other side. Have figured out how to save local news.

Leland

(b) (6)

James,

Thanks very much for your help.

Leland



Leland Schwartz
Editor & Publisher
Fauquier Channel One
540 422 1376
editor@fauquierchannel.com
www.fauquierchannel.com

April 16, 2020

Matt Pottinger
Deputy National Security Advisor
The White House
1650 Pennsylvania Avenue, NW
Washington, DC 20502

Dear Sir,

Many of us in the hyperbaric medicine community believe that there exists a simple therapy to halt the inflammatory process and reverse the lung damage.

This process will also simultaneously provide many times over the amount of oxygenation offered by the coma-inducing intubation ventilator procedure.

We are reaching out to our network to make contact with the airlines to secure the use of an airplane with an onboard APU (Auxiliary Power Unit--used to pressurize the aircraft) for a month, to treat COVID-19 patients and show the effectiveness of the concept.

Initial testing indicates in one trial study 100% improvement while all others underway, although small scale, are showing great benefit at extremely low cost and patient risk.

So what is this new procedure? Hyperbaric Oxygen Therapy or HBOT; first used successfully in 1918 for Spanish Flu cases. HBOT is viable and appears to work well but we do not have the number of pressure vessels / HB chambers available to treat the possibly 100,000+ who need the therapy now.

Several of us in our small community have arrived at the same idea in several countries.

The idea is no longer new or unique.

Again, I am proposing use an aircraft as the pressure vessel. Every airplane with a pressurized cabin (i.e., all commercial airline aircraft) is routinely pressurized to around 9 psi (some go higher) while they are on the ground, as part of their normal airworthiness testing.

Myself and others have suggested that one or more of the hundreds of grounded aircraft be provided to complete the trial test.

737 Max are not flying but are a perfect pressure vessel for the procedure.

Could you help us contact Boeing, the airlines or the military?

No aircraft modification is required whatsoever so that is one of the issues off the table.

The aircraft remains parked on the ground with access for ambulatory patients via a stairway. No jetway is required unless we expand this in the future for non-ambulatory patients.

We would need to place standard DOT portable oxygen tanks in the cabin along with the associated manifold, pressure regulator, flow-meters and tubing.

Each patient will have his/her own anesthesia mask and breathing circuit.

There is no cross contamination between patients or the cabin environment atmosphere as each mask incorporates a Viral Filter Kit to help protect the technicians who are also breathing from a secure, clean source.

All safety issues are addressed in the plan.

The same process, once proven could be utilized by our military and of course our Navy who is experiencing possible outbreaks as we speak.

This is important to me personally

(b) (6)

The Patriot Clinic in Oklahoma City is my personal charity where we have provided over 15,000 free HBOT treatments for our beloved vets and 30,000+ at cost or below.

We are not asking for money. Nor, am I selling anything in this effort. With the help of a small group of supporters, (Ralph Crafts & family) my company is willing to provide the equipment, training and technical support to begin the process.

Thank you for your ongoing service to our country, and thank you for reading and considering my proposal.

I sure would appreciate your help.

Semper Fi!

Sincerely,
Edward A. Betts

Edward A. Betts
ANDI American Nitrox Divers International
74 Woodcleft Avenue
Freeport, NY USA 11520

(b) (6)

><http://www.andihq.com/><

(b) (6)

Matt Pottinger
Deputy National Security Advisor
The White House
1650 Pennsylvania Ave., NW
Washington, DC 20502

Sir:

As one old Marine to another Marine, this letter contains the “straight scoop,” and is intended to provide information that can help stop the spread of COVID-19, and ensure the continuity of critical segments of government.

Hyperbaric Oxygen Therapy (HBOT) has been in use for over 100 years, and was the only effective treatment for the 1918 flu pandemic. HBOT is being used worldwide to treat a variety of serious diseases, and has been proven to be immediately effective in treating severe COVID-19 cases, with a success rate close to 100%.

HBOT is simply breathing high-purity oxygen (92% or higher) for 60-90 minutes in a pressurized environment (typically between 8 and 15psi—the higher pressure is about the same pressure as doing a SCUBA dive to 33 feet). HBOT chambers can be 1-2 person sizes and portable, up to 12-seat chambers which are used for Navy operations. (b) (6) I have a one-person chamber in our home, and we can attest to its effectiveness in treating severe breathing problems, like pneumonia, infections, and wounds.

The currently publicized and widely accepted statement that there is no effective treatment for COVID-19 is wrong. HBOT treatments, usually just a single one-hour session, provide immediate improvements in lung function, blood-oxygen levels, and organ recovery. Unlike respirators, which do more damage than good and are basically a death sentence, HBOT provides an immediate path for recovery and healing.

A team of very experienced scientists and HBOT experts have developed a concept that will enable the effective treatment of large numbers of people by using some of the thousands of grounded commercial aircraft as large HBOT chambers.

I'm an old Marine Corps jet pilot, and we use our (b) (6) so I have the professional contacts to confirm and verify the efficacy of the concept.

Every airplane with a pressurized cabin (i.e., all airline aircraft) is routinely pressurized to around 9psi (some go higher) while they are on the ground, as part of their normal airworthiness testing.

We have equipment staged and ready to go now, to treat 25 COVID-19 patients at a time—we need an airplane, and we can be treating people and saving lives in about 36 hours.

The aircraft we need remain parked on the ground, no modifications are needed—we will simply place portable oxygen tanks in the cabin with the associated tubing, manifold, and pressure regulators, and each patient will have his/her own anesthesia mask.

There is no cross contamination between patients, because everyone is breathing oxygen from their own personal mask.

We are reaching out to our contacts in the airlines to ask for the use of an airplane and APU (Auxiliary Power Unit—used to pressurize the aircraft) for a month, to treat COVID-19 patients and show the effectiveness of the concept.

We could do the same thing with a single military transport aircraft (many of which have been configured for medical use).

As a Marine, and with my knowledge of HBOT, the recent death of the Theodore Roosevelt sailor is particularly upsetting, knowing that a couple of Senior Chiefs or Marine Master Sergeants could have configured an aircraft in Guam in a couple of hours and be treating all the sailors from the carrier.

We are not asking for money—my wife and I are paying for all the required equipment and support personnel.

HBOT chambers are easily implemented and supported—you could have one in your office (ours is 8' long and 34" in diameter when pressurized) and it would only take a couple of hours to train your corpsmen to operate it. I don't know of a better guarantee of continuity in the current pandemic.

Please note that (b) (6) I have no financial or political interests in the HBOT treatment concept, companies, or manufacturers—we receive no benefits/rewards, other than helping to save many lives.

You will receive a letter from Ed Betts—he's a good man, really knows his stuff, and I trust him with my life—please take what he says seriously.

Thank you for your ongoing service to our country, and thank you for reading and considering the information in this letter.

Semper Fi!

Respectfully,

Ralph E. Crafts
Marshall, Virginia

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 16 Apr 2020 12:37:38 +0000
To: Dr. Josh Backon
Subject: RE: Covid-19. thromboxane inhibitors, and heme binding (O2 desaturation)

You are not being ignored. The National Heart Lung and Blood Institute will take a look at this.

From: Dr. Josh Backon <backon@mail.huji.ac.il>
Sent: Thursday, April 16, 2020 8:09 AM
To: Coleman, Amanda (NIH/NIAID) [C] (b) (6); Fauci, Anthony (NIH/NIAID) [E]
(b) (6)
Subject: Fwd: Covid-19. thromboxane inhibitors, and heme binding (O2 desaturation)

Continue to ignore me.

http://www.htct.com.br/en-hemoglobin-value-may-be-decreased-avance-S2531137920300298?fbclid=IwAR3zdsJZE_1M5gxNpqzrlf862lNlbRMFPJ9qfRLnsC2FqZNkjCrsw4KDtGc

Dr. Josh Backon
backon@mail.huji.ac.il

----- Forwarded message -----

From: Coleman, Amanda (NIH/NIAID) [C] <(b) (6)>
Date: Thu, Apr 9, 2020 at 6:18 PM
Subject: RE: Covid-19. thromboxane inhibitors, and heme binding (O2 desaturation)
To: Dr. Josh Backon <backon@mail.huji.ac.il>

Dear Dr. Backon,

We very much appreciate the information you've provided, and I am sharing your updates with the relevant staff at NIH. We have directed you to the information we think is relevant for your request, and we hope that this has been helpful. We have no additional information to provide at this time. NIAID staff members will not be responding further.

Thank you,

Amanda Coleman, MPH [C]
Office of Scientific Coordination and Program Operations
Division of Microbiology and Infectious Diseases
NIAID, NIH, DHHS

From: Dr. Josh Backon <backon@mail.huji.ac.il>

Sent: Wednesday, April 8, 2020 7:37 AM

To: Coleman, Amanda (NIH/NIAID) [C] (b) (6); Fauci, Anthony (NIH/NIAID) [E]

(b) (6)

Subject: Covid-19, thromboxane inhibitors, and heme binding (O2 desaturation)

I have a suggestion for 3 potent antiviral agents, cheap and readily available, that may prevent viral shedding. No viral shedding? No infectivity. The concept is that EVERYONE should take these items. Two of the items also positively affect heme binding. Covid-19 binds to heme causing O2 desaturation, lung failure and death.

First a short bio:

Dr. Josh Backon was affiliated with the Hebrew University Faculty of Medicine for over 33 years. He has a good track record (84+ publications quoted by over 750 other researchers

www.google.com/scholar?start=0&q=%22backon++j.%22&hl=en&as_sdt=0,5
and in over 250-300 texts as per

<https://www.google.com/search?tbo=p&tbm=bks&q=%22backon+j.+%22&num=100>).

In the 1980's he was Consulting Editor of the Journal of Pediatric Endocrinology, Editor of Reviews in Pure and Applied Pharmacological Sciences, and Associate Editor of the International Journal of Adolescent Medicine and Health. From 1990-2004, he was a consultant on emergency planning and management at Israel's National Police Headquarters with Nitzav Mishneh Danny Fisher.

=====

Chloroquine, an antimalarial drug, is now being used to treat Covid-19. Its mechanism was found in the 1970's to inhibit thromboxane

https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=chloroquine+thromboxane&btnG=

The problem with chloroquine was that it also elevated levels of prostaglandin F2alpha. In 1980, Srivastava, an Indian biochemist working in Denmark found that GINGER is a potent inhibitor of thromboxane synthetase. I wrote a number of papers in the 1980's on use of ginger:

https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=backon+ginger&btnG=

- **CHLOROQUINE FOR TREATING COVID-19**

-

https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=chloroquine+covid-19&oq=ch&fbclid=IwAR1lLe376M22_IUr3UsD6_yz-sASmpGgIpI3h3PTOpCHA4Ycu321ZPevD-A

-

GINGER IS A POTENT ANTIVIRAL

https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=ginger+antiviral&oq=gin

THE SECOND ANTIVIRAL AGENT IS TURMERIC [add black pepper since piperine dramatically increases oral bioavailability of turmeric]

https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=turmeric+antiviral&oq=tur

Multisite inhibitors for enteric **coronavirus: antiviral cationic carbon dots based on curcumin**

D Ting, N Dong, L Fang, J Lu, J Bi... - ACS Applied Nano ..., 2018 - ACS Publications
... These results offer theoretical support for the development of CCM-CDs as a hopeful antiviral drug for the treatment of **coronavirus** infections, including PEDV ... Curcumin (CCM) is a polyphenol compound obtained from **turmeric** roots...

NAC AND PIPERINE TO INHIBIT INFLAMMATORY CYTOKINES (iNOS, NF KappaB, TNFalpha) INVOLVED IN ARDS

-

Mortality in COVID-19 patients is usually from ARDS (acute respiratory distress syndrome) via inflammatory cytokines. Apart from N-acetylcysteine which was found 3 years ago to elevate atrial natriuretic factor [found by Kierner in 2001 to zap inflammatory cytokines: iNOS, NF KappaB, and TNFalpha) now piperine in black pepper was found to inhibit inflammatory cytokines [piperine also dramatically increases oral bioavailability of turmeric [which has been used as a potent antiviral]:

N-ACETYLCYSTEINE

https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=n-acetylcysteine+%22inflammatory+cytokines%22&btnG=

PIPERINE

https://scholar.google.com/scholar?hl=en&as_sdt=0,5&q=piperine%20inflammatory%20cytokines&btnG=&fbclid=IwAR0kXZxI66JPLFPry2MDTDxOAelgGnmBZdKBw7c1v78Hfi7t0JJnx0Y2zuE

COVID-19 BINDS TO HEME

<http://web.archive.org/web/20200405061401/https://medium.com/@agaiziunas/covid-19-had-us-all-fooled-but-now-we-might-have-finally-found-its-secret-91182386efcb>

COVID-19: HYPOXIA, O₂ DESATURATION, COVID-19 BINDS TO HEME.
THUS NO MAX PEEP !! IT'S A PROBLEM OF FREE RADICAL
BIOCHEMISTRY.

THROMBOXANE AND HEME BINDING

https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=thromboxane+%27heme+binding%22&og=th&fbclid=IwAR3f5ECaUUnrSSyhCA6kpJ9z0nPaMM3ba7HtuFPpQ9B1PVrF9kdwayATcY0

INDIA: POPULATION 1,300,000,000: as of April 8th, only 5000 cases and 164 deaths:

[Indians eat GINGER, TURMERIC and BLACK PEPPER plus other spices which are thromboxane inhibitors]:

https://www.business-standard.com/article/current-affairs/coronavirus-live-updates-covid-19-cases-in-india-global-death-toll-state-wise-delhi-maharashtra-tablighi-nizamuddin-lockdown-extension-latest-news-120040800236_1.html

11 classic Indian spices: saffron, fenugreek, cardamom, cloves, cassia, cumin, coriander, and nutmeg
<https://www.thekitchn.com/11-essential-spices-for-indian-cooking-223152>

Access <http://scholar.google.com> for THROMBOXANE (and the name of each spice) and you'll see that each one is a thromboxane inhibitor

ANTIPARASITIC DRUG IVERMECTIN KILLS COVID-19

https://pharmafield.co.uk/pharma_news/study_shows_anti-parasitic_drug_ivermectin_kills_coronavirus/

IVERMECTIN AFFECTS THROMBOXANE

https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=%22ivermectin%22+thromboxane+&btnG

≡

CARBON DIOXIDE AS THROMBOXANE INHIBITORS

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1433448/>

<https://www.sciencedirect.com/science/article/abs/pii/0306987786900952>

Effect of carbon dioxide on **platelet** aggregation in cats

ÉS **Gabrielyan**, ÉA **Amroyan** - Bulletin of Experimental Biology and ..., 1984 - Springer
Products of the arachidonic acid cascade have been shown to play an important role in regulation of the blood supply to several organs, including the brain [i, 8]. Cyclic derivatives of arachidonic acid play a definite role in the mechanisms of action of many known ...

<https://link.springer.com/article/10.1007/BF00829637>

WHY CATS (FELINES) ARE MORE SUSCEPTIBLE TO COVID-19 THAN DOGS

https://www.the-scientist.com/news-opinion/cats-ferrets-susceptible-to-sars-cov-2-study-67374?utm_campaign=TS_DAILY+NEWSLETTER_2020&utm_source=hs_email&utm_medium=email&utm_content=85706789&hsenc=p2ANqtz--SZXoVVbO1SHcR025FPiWgMcM3_nz7fHSHOrKRp9f-LxTy9Bxj0Jsl7hJtDQ_oDM2xsozsH438n5c_1Mj-78bT3Rz2mQ&hsmi=85706789&fbclid=IwAR3bW76GVI4rConuw7YPcDL9IZE9JkQQSm9Lu_y-RE4y2LNmo0o6v_taFUk

https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1111/j.1476-5381.1983.tb09393.x?fbclid=IwAR1SzFky0R4mVyVvh9ayQP_U-zj4Cw1Vo4I9b2jRHebfjmSQCD6BykteHqQ

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 16 Apr 2020 11:48:56 +0000
To: (b) (6)
Subject: RE: Standing Up for Truth

David:

Many thanks for your kind note. It is much appreciated.

Best regards,

Tony (b) (6)

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6)
Sent: Monday, April 13, 2020 2:49 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E]
(b) (6)
Subject: Standing Up for Truth

4/13/20

Anthony S. Fauci, M.D.
Director, NIAID

Dear Dr. Fauci:

As a fellow graduate of Regis High School (b) (6) and very active alumnus, I am writing to you out of deep concern for our nation. I am reading reports in The NY Times that President Trump may be considering firing you for telling the truth about the negative consequences of delays in mobilizing the American response to the coronavirus threat. The Times had run articles in recent days detailing the pertinent facts that place the blame

for this delay squarely on President Trump. We can reasonably infer that significant loss of life and financial harm resulted from this delay.

The mission of Regis was to mold young men with leadership potential to be "men for others" in the Jesuit tradition. To achieve that goal Regis also sought to hone our intellectual talents and imbue us with Christian morality to succeed throughout our lives in a persistent pursuit of excellence, which embodies the truth. A mission to relentlessly pursue and proclaim the truth.

The fact that you have consistently and courageously pursued that mission during one of the darkest times in our history explains the extraordinary admiration in which you are held by millions of Americans. You have won their confidence, which has enabled so many to make exquisite sacrifices to win this crucial battle. People will follow heroes, which is precisely how the vast majority views you.

I am writing because I want you to know how important you are to America. We cannot lose you and we can not lose the value of truth. Truth must prevail or our precious democracy is in grave peril.

Consequently, and I know I speak for the vast majority of Americans whose decency is beyond question, if Donald Trump seeks your removal, please resist for the sake of our nation. An appeal to the populace will not go unanswered. Religious leaders will flock to your defense, as will the media and leading political leaders, including Biden and Cuomo. Republicans can not afford to alienate what you stand for. Jeopardizing the Catholic vote would be suicide.

In closing, know how proud all Regians are of you. You will always be an inspiration to those who understand the value of service to others.

Our prayers are with you.

David G. O'Brien (b) (6)
Attorney at Law

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 16 Apr 2020 11:35:55 +0000
To: Daniel Bednarik
Cc: Lerner, Andrea (NIH/NIAID) [E]
Subject: RE: BARDA Presentation

Thanks, Dan.
Best,
Tony

From: Daniel Bednarik <dbednarik@neximmune.com>
Sent: Tuesday, April 14, 2020 4:24 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: BARDA Presentation

Dear Tony:




Be well – we are all in your corner (and you have your own bobblehead likeness)!

Best,

Dan

Daniel Bednarik, Ph.D.
Senior Vice President
Molecular Engineering
NexImmune, Inc.
9119 Gaither Road
Gaithersburg MD 20877
(b) (6) (m)
www.neximmune.com

 **NexImmune**
Directing T cell function to restore natural immunity

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 16 Apr 2020 11:33:57 +0000
To: Schwetz, Tara (NIH/OD) [E]
Cc: Marston, Hilary (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]; Walsh, Elizabeth (NIH/OD) [E]
Subject: RE: Flagging NIH Media Products

Thanks, Tara. I appreciate the heads up. Stay well and safe.

Best,

Tony

From: Schwetz, Tara (NIH/OD) [E] (b) (6) >
Sent: Tuesday, April 14, 2020 4:46 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Marston, Hilary (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Barasch, Kimberly (NIH/NIAID) [C] (b) (6) >; Walsh, Elizabeth (NIH/OD) [E] (b) (6) >
Subject: Flagging NIH Media Products

Tony,

Hope all is well and that you are staying safe and healthy. (b) (5) PCP

[REDACTED]
[REDACTED]
[REDACTED]. Our plan is to batch and send these to Hilary, Patty, and Kim on Thursdays/Fridays each week, unless there is a time sensitivity to them. For the time-sensitive requests, I will flag them for you (after a couple levels of filtering).

So, that said, I am reaching out to flag the following time-sensitive items for your awareness and sharing with the remainder of the Task Force, as appropriate. You'll note that both of these are yours, so this email may be unnecessary. If so, apologies for adding to your (what much be crazy) inbox.

Item 1: National Institute of Allergy and Infectious Diseases Strategic Plan for COVID-19 Research (NEW)

Activity Type: Strategic Plan

Summary: A new strategic research plan from the National Institutes of Health aims to build on — and accelerate — new and existing research efforts to prevent, diagnose, and treat COVID-19, as well as understand the underlying causative agent of this disease, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The Plan prioritizes research to improve fundamental knowledge of SARS-CoV-2 virus and COVID-19 disease, develop diagnostics and assays, characterize and test therapeutics, as well as develop safe and effective vaccines targeted toward decreasing disease incidence, mitigating morbidity, and prevention mortality from this disease.

Impact on COVID-19 Pandemic Response: The strategic plan outlines a research plan targeted at prevention and mitigation of COVID-19 disease.

Office: NIAID, Office of the Director

NIH Point-of-Contact: Anthony Fauci, M.D.

NIH Point-of-Contact Email: (b) (6)

Action Date: Estimated 4/17/2020

Type of Action: Publication

Potential for Press Coverage: Mainstream Press

Press Release in Development?: Yes

Item 2: NIH study validates decontamination methods for re-use of N95 respirators

Activity Type: Significant scientific finding

Summary: NIAID/NIH-funded study shows that N95 respirators can be decontaminated effectively and maintain functional integrity for up to three uses. Researchers tested the decontamination of small sections of N95 filter fabric that had been exposed to SARS-CoV-2. Decontamination methods tested included vaporized hydrogen peroxide (VHP), 70-degree Celsius dry heat, ultraviolet light, and 70% ethanol spray. All four methods eliminated detectable viable virus from the N95 fabric test samples. The results will be posted on a preprint server (timing TBD). The findings are not yet peer-reviewed but are being shared to assist the public health response to COVID-19.

Impact on COVID-19 Pandemic Response: Study shows that respirators could be used multiple times (2-3 times depending on decontamination method)

ICO: NIAID

NIH Point-of-Contact: Vincent Munster, Ph.D., and Marshall Bloom, M.D., from NIAID's Laboratory of Virology are available to comment on this study.

POC Email: (b) (6)

Action Date: TBD week of April 13, 2020

Type of Action: Report/Publication

Potential for Press Coverage: Mainstream Press

Press Release in Development?: Yes

Hope you're getting some rest and taking care of yourself!

Best,

Tara A. Schwetz, PhD

Acting Director, NINR

Associate Deputy Director, NIH

A: Building 1, Room 138

P: (b) (6) | M: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 16 Apr 2020 11:32:27 +0000
To: (b) (6)
Subject: FW: New web portal --- UW IDEA: COVID-19 Treatment <https://bit.ly/3ckkv48>

Please take a look at this and then let us talk.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)
Sent: Tuesday, April 14, 2020 5:19 PM
Subject: New web portal --- UW IDEA: COVID-19 Treatment <https://bit.ly/3ckkv48>



Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 16 Apr 2020 11:24:00 +0000
To: Auchincloss, Hugh (NIH/NIAID) [C] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E]; Harper, Jill (NIH/NIAID) [E]
Subject: FW: Request: Proposal Summaries - POCs Due 4/15; Summaries Due 4/20
Attachments: 2020-04-14_Proposal POC Sign up.xlsx, IC Specific Proposals 4.14.pdf, ER Proposals 4.14.pdf

Please handle.

From: Schwetz, Tara (NIH/OD) [E] (b) (6)
Sent: Tuesday, April 14, 2020 8:52 PM
To: ICDDIR-L@list.nih.gov
Cc: List DEPDIR-L <DEPDIR-L@list.nih.gov>; NIH Director's Executive Committee <OD-SmallStaff@mail.nih.gov>
Subject: Request: Proposal Summaries - POCs Due 4/15; Summaries Due 4/20

Colleagues,

As discussed this afternoon, please find attached the POC sign-up sheet (tab 1; tabs 2-3 list the various proposals by category, theme, and IC), the IC-specific proposals, and the economic recovery proposals. We ask that you please complete the POC sign-up and send it to Jordan Gladman (b) (6) by **5 pm on Wednesday April 15**. We will then collate and distribute the completed spreadsheet to the Chairs for each of the themes and post it on the ICD SharePoint site. The individual proposals are imbedded in the pdf as folders sorted by theme. If you feel your proposal would fit better with a different working group, please feel free to engage with them.

We ask that, once the POCs have been identified, you quickly assemble to begin refining and synergizing your proposals. Each Chair should coordinate with their group to develop a 2 page max summary of the theme's research, along with a single combined budget. The summary should integrate the IC proposals as much as possible; however, it is fine (for valid/justifiable reasons) to describe a few unique projects that fall under the theme as well. That is, if they don't make sense to integrate, you don't have to, but please be sure to include them in the summary. These summaries should be sent to Larry and me (cc Jordan Gladman) by **noon on April 20**. We will build off these summaries to generate a document for Francis' review, which we ultimately hope will be informative as we prepare for a potential fourth supplement.

The ask in short:

- **April 15 at 5 pm** – send your POCs to Jordan, who will then distribute the completed spreadsheet to the chairs
- **April 20 at 12 pm** – chairs to send a 2 page summary of their theme (with combined budget)

Best,

Tara A. Schwetz, PhD
Acting Director, NINR

Associate Deputy Director, NIH

A: Building 1, Room 138

P: (b) (6) | M: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 16 Apr 2020 02:51:30 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Emergency clinical trial COVID PE
Attachments: 4_OVID_protocol_15042020.docx

Please take a look at this and take care of it. Thanks.

From: Kucher Nils <[REDACTED] (b) (6)>
Sent: Wednesday, April 15, 2020 5:29 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: Emergency clinical trial COVID PE

Dear Anthony

My background is clinical VTE research. I spent many years in Boston (Harvard Medical School).

We may have a solution for improving survival in COVID outpatients.

[REDACTED] (b) (4), (b) (3)

Would you be willing to discuss this urgent clinical trial proposal which was submitted today to Swiss authorities

My mobile is [REDACTED] (b) (6)

You can call me anytime.

Best regards

Nils

Prof. Dr. med. Nils Kucher
Director of Vascular Medicine

University Hospital Zurich
Switzerland
Rämistrasse 100, RAE C 13
CH-8091 Zürich
Tel: [REDACTED] (b) (6)
www.angiologie.usz.ch

USZ Universitäts
Spital Zürich

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 16 Apr 2020 02:50:34 +0000
To: DuBois, Raymond N.
Subject: RE: Mask wearing policy at our University Hospital

Ray:

Thank you for your note. I would keep the policy "voluntary" but I would "encourage" employees to wear them.

Best regards,

Tony

From: DuBois, Raymond N. (b) (6)
Sent: Wednesday, April 15, 2020 7:18 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Mask wearing policy at our University Hospital

Dear Dr. Fauci,

My name is Ray DuBois and in addition to being the Dean of Medicine here at the Medical University of South Carolina in Charleston, I chair the Board of Scientific Councilors for the NCI. The mask wearing policy for our Health System is developed by our infection control group and not by the College of Medicine.

Currently, we have a "**voluntary**" mask wearing policy for the health system and our main University Hospital. Based on your recent comments about asymptomatic and pre-symptomatic carriers of COVID-19, do you agree that keeping this voluntary is the correct approach?

Obviously, your opinion here is extremely well respected and I would like for us to provide the safest environment possible for our faculty, employees and patients.

Ray DuBois, M.D., Ph.D.
Dean of Medicine
The Medical University of South Carolina....Charleston, SC
Member of the National Academy of Medicine

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 16 Apr 2020 02:35:18 +0000
To: Bertuzzi, Stefano
Subject: RE: Announcement--ASM's COVID-19 Research Registry

Stefano:

Congratulations! Excellent idea and much needed. Our community will find it very valuable.

Best regards,

Tony

From: Bertuzzi, Stefano <sbertuzzi@asmusa.org>
Sent: Wednesday, April 15, 2020 10:21 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] (b) (6)>; Cassetti, Cristina (NIH/NIAID) [E] (b) (6); Beigel, John (NIH) [E] (b) (6)>
Subject: Announcement--ASM's COVID-19 Research Registry

Dear Tony and NIAID friends –

the mission of the American Society for Microbiology (ASM) to promote and advance the microbial sciences has perhaps never been more clearly in focus than during the current SARS-CoV-2 pandemic. Accelerating basic research is key to ASM's mission– it is where cure and prevention begin. It is impressive how rapidly research on SARS-CoV-2 /COVID-19 has advanced in just a few weeks, but easily accessing new and relevant research has been a challenge for basic researchers. When ASM's Council on Microbial Sciences held a COVID-19 summit to identify the most significant scientific work on the virus, the coronavirus researchers and clinical microbiologists raised the need for the scientific community to curate important COVID-19 research.

ASM is excited to announce the launch of the COVID-19 Research Registry, a platform curated and vetted by experts in the field of virology and related disciplines to provide immediate access to top COVID-19 research.

I am proud that **Lynn Enquist**, Ph.D., Henry L. Hillman Professor in Molecular Biology, Princeton University and former ASM President, will serve as Chief Curator for this Registry. **Dr. Harold Varmus**, Lewis Thomas University Professor of Medicine, Weill Cornell Medicine has agreed to join us as Chief Consultant on the project.

We are honored to have the following as Assistant Curators-in-Chief:

- Rozanne M. Sandri-Goldin, Ph.D., Chancellor's Professor, Microbiology & Molecular Genetics, University of California, Irvine and Editor-in-Chief of ASM's *Journal of Virology*
- Vaughn Cooper, Ph.D., Professor, Microbiology & Molecular Genetics, University of Pittsburgh, and current ASM Board member

The entire curatorial board is listed on the Registry site.

ASM is proud to add this initiative to our ongoing efforts. Through its capillary network of clinical microbiologists around the country and the world, ASM has accelerated communication and cleared roadblocks to ramp up SARS-CoV-2 testing. We continue to work closely with our dedicated colleagues, the indefatigable clinical microbiologists manning the front lines in hospitals and testing labs during this unprecedented global emergency. We send our thanks—and admiration—to these ASM members who are contributing directly to saving lives in this perilous time.

Our [COVID-19 resource page](#) provides important ASM updates and current information on the coronavirus. We are also working with the news media to provide authoritative ASM experts and reliable material on the microbiology of viral epidemics. ASM journals is also providing free access to more than [50 research articles published over the last year](#) in our [16 scholarly journals](#) and expediting review for submitted papers related to coronavirus, ensuring that new research is quickly made available to the scientific community.

We are hoping that researchers will find the COVID-19 Research Registry a useful resource. We look forward to your comments, questions or suggestions, since your input will be critical for improving this platform and making it useful for the scientific community. All feedback can be sent to covid19registry@asmusa.org. We are all in this together.

Sincerely,



Stefano Bertuzzi
Chief Executive Officer, ASM

Stefano Bertuzzi, Ph.D., M.P.H.
Chief Executive Officer
American Society for Microbiology (ASM)
1752 N St., NW
Washington, DC 20036-2904
Phone + (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 16 Apr 2020 02:08:26 +0000
To: Auchincloss, Hugh (NIH/NIAID) [C] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Request: Proposal Summaries - POCs Due 4/15; Summaries Due 4/20
Attachments: 2020-04-14_Proposal POC Sign up v1.0[1].xlsx, IC Specific Proposals 4.15[1].pdf, ER Proposals 4.15[1].pdf, COVID-19 Initiative Management-revised[1][6].docx

Please take a look at this and handle. Thanks.

From: Schwetz, Tara (NIH/OD) [E] (b) (6) >
Sent: Wednesday, April 15, 2020 8:59 PM
To: ICDDIR-L@list.nih.gov
Cc: List DEPDIR-L <DEPDIR-L@list.nih.gov>; NIH Director's Executive Committee <OD-SmallStaff@mail.nih.gov>; Gladman, Jordan (NIH/OD) [E] <(b) (6)>
Subject: Re: Request: Proposal Summaries - POCs Due 4/15; Summaries Due 4/20

All,

Please find attached the compiled sign-up sheet with IC POCs for the 12 themes, as well as updated packets to match the shifts that were brought to our attention (attachments #1-3).

As a reminder, please send the 2 page summaries for each theme (with combined budget), using the attached template (attachment #4), to Jordan Gladman by **April 20 at 12 pm**. Thanks to you and your staff for developing these!

Best,

Tara A. Schwetz, PhD
Acting Director, NINR
Associate Deputy Director, NIH
A: Building 1, Room 138
P: (b) (6) | M: (b) (6)

From: Tara Schwetz (b) (6) >
Date: Tuesday, April 14, 2020 at 9:01 PM
To: "ICDDIR-L@list.nih.gov" <ICDDIR-L@list.nih.gov>
Cc: List DEPDIR-L <DEPDIR-L@list.nih.gov>, NIH Director's Executive Committee <OD-SmallStaff@mail.nih.gov>
Subject: Request: Proposal Summaries - POCs Due 4/15; Summaries Due 4/20

Colleagues,

As discussed this afternoon, please find attached the POC sign-up sheet (tab 1; tabs 2-3 list the various proposals by category, theme, and IC), the IC-specific proposals, and the economic recovery proposals. We ask that you please complete the POC sign-up and send it to Jordan Gladman (jordan.gladman@nih.gov) by **5 pm on Wednesday April 15**. We will then collate and distribute the completed spreadsheet to the Chairs for each of the themes and post it on the ICD SharePoint site. The individual proposals are imbedded in the pdf as folders sorted by theme. If you feel your proposal would fit better with a different working group, please feel free to engage with them.

We ask that, once the POCs have been identified, you quickly assemble to begin refining and synergizing your proposals. Each Chair should coordinate with their group to develop a 2 page max summary of the theme's research, along with a single combined budget. The summary should integrate the IC proposals as much as possible; however, it is fine (for valid/justifiable reasons) to describe a few unique projects that fall under the theme as well. That is, if they don't make sense to integrate, you don't have to, but please be sure to include them in the summary. These summaries should be sent to Larry and me (cc Jordan Gladman) by **noon on April 20**. We will build off these summaries to generate a document for Francis' review, which we ultimately hope will be informative as we prepare for a potential fourth supplement.

The ask in short:

- **April 15 at 5 pm** – send your POCs to Jordan, who will then distribute the completed spreadsheet to the chairs
- **April 20 at 12 pm** – chairs to send a 2 page summary of their theme (with combined budget)

Best,

Tara A. Schwetz, PhD

Acting Director, NINR

Associate Deputy Director, NIH

A: Building 1, Room 138

P: (b) (6) | M: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 16 Apr 2020 01:58:31 +0000
To: Myles, Renate (NIH/OD) [E]
Cc: Collins, Francis (NIH/OD) [E]; Tabak, Lawrence (NIH/OD) [E]; Wolinetz, Carrie (NIH/OD) [E]; Burklow, John (NIH/OD) [E]; Fine, Amanda (NIH/OD) [E]; Lane, Cliff (NIH/NIAID) [E]; Billet, Courtney (NIH/NIAID) [E]; Stover, Kathy (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]
Subject: RE: FOR YOUR REVIEW: Draft ACTIV News Release
Attachments: OD_ACTIV_PPP_Release_4.15.2020 - with minor tracked edits.docx

Looks good. See my very minor tracked edits in attached document.

Thanks,

Tony

From: Myles, Renate (NIH/OD) [E] (b) (6)>
Sent: Wednesday, April 15, 2020 9:50 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Collins, Francis (NIH/OD) [E] (b) (6); Tabak, Lawrence (NIH/OD) [E] (b) (6); Wolinetz, Carrie (NIH/OD) [E] (b) (6)>; Burklow, John (NIH/OD) [E] (b) (6); Fine, Amanda (NIH/OD) [E] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b) (6); Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6)>
Subject: FOR YOUR REVIEW: Draft ACTIV News Release

Hi Dr. Fauci:

Dr. Collins asked that I send the draft ACTIV release for you review.

Best,
Renate

Renate Myles, MBA
Deputy Director for Public Affairs
Office of Communications and Public Liaison
National Institutes of Health
Tel: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 15 Apr 2020 22:26:51 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Greg Folkers (b) (6); Billet, Courtney (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: AIRI Presents Dr. Fauci with 2020 Public Service Award
Attachments: Fauci 2020 AIRI Public Service Award Letter.pdf

Patty:

Please put together (or have Kim do so) a letter of thanks, honor, and appreciation...yada yada. So that they know I have received the letter and look forward to receiving it at an appropriate time.

Thanks,

Tony

From: Collins, Francis (NIH/OD) [E] (b) (6) >
Sent: Wednesday, April 15, 2020 4:54 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Tabak, Lawrence (NIH/OD) [E] (b) (6) >
Subject: FW: AIRI Presents Dr. Fauci with 2020 Public Service Award

Congrats, Tony! Please try to take a minute to savor this. Or at least 15 seconds. 😊

Francis

From: Parker, Nicole <Nicole@lewis-burke.com>
Sent: Wednesday, April 15, 2020 4:10 PM
To: Collins, Francis (NIH/OD) [E] (b) (6) >; Wolinetz, Carrie (NIH/OD) [E] (b) (6); Hallett, Adrienne (NIH/OD) [E] (b) (6) >; Lauer, Michael (NIH/OD) [E] (b) (6) >
Cc: O'Hare, Libby <libby@lewis-burke.com>
Subject: AIRI Presents Dr. Fauci with 2020 Public Service Award

Good Afternoon,

On the behalf of the Association of Independent Research Institutes (AIRI), I wanted to notify you that AIRI has awarded Dr. Tony Fauci with its 2020 Public Service Award in recognition of his exemplary leadership during the novel coronavirus pandemic. The AIRI Public Service Award is the highest honor awarded by our organization and we're very pleased to present this award to Dr. Fauci. A list of past awardees can be found [here](#).

Please see the official award letter attached and let us know any questions.

Regards,

Nicole Parker, Ph.D.

AIRI Washington Office - Lewis-Burke Associates, LLC

440 1st Street NW Suite 700

Washington, DC 20001

202-289-7475

Nicole@lewis-burke.com

www.lewis-burke.com

Disclaimer: This message is intended only for the named recipient. If you are not the intended recipient you are notified that disclosing, copying, distributing or taking any action in reliance on the contents of this information is strictly prohibited.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 15 Apr 2020 15:57:38 +0000
To: Awwad, David (NIH/NIAID) [C]
Subject: Threat assessment 4/14
Attachments: Total Fauck Up, Re: Finis Covid Opus, Re: Total Fauck Up, Untitled

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 15 Apr 2020 10:45:28 +0000
To: Birx, Deborah L. EOP/NSC; Troye, Olivia EOP/NSC
Subject: RE: Does G6PD Deficiency Relate to COVID-19 Infection? | MedPage Today

The issue also comes up when people are on certain drugs.

From: Birx, Deborah L. EOP/NSC (b) (6) >
Sent: Wednesday, April 15, 2020 6:16 AM
To: Troye, Olivia EOP/NSC <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E]
(b) (6)
Subject: Re: Does G6PD Deficiency Relate to COVID-19 Infection? | MedPage Today

This one always comes up when we have differential responses to an infection (b) (5) PCP
– in HIV there are genetic links to better outcomes.

From: "Troye, Nsc" <(b) (6)>
Date: Tuesday, April 14, 2020 at 11:03 PM
To: "Birx, Deborah L. EOP/NSC" (b) (6) >, "Anthony Fauci [E]"
(b) (6) >
Subject: Does G6PD Deficiency Relate to COVID-19 Infection? | MedPage Today

Follow up article to some previous emails. Just wanted to send this your way.

<https://www.medpagetoday.com/infectiousdisease/covid19/85929>

Olivia Troye
Special Advisor for Homeland Security and Counterterrorism
Office of the Vice President
White House Coronavirus Task Force
Office: (b) (6)
Mobile: (b) (6) (Does not receive texts)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 15 Apr 2020 02:32:49 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: ASF - here that proposed op-ed for you and Dr. Birx penned by VP office
Attachments: Birx.Fauci Op-Ed clean - with Fauci tracked changes.docx

Greg:

Nice job. I have made a few edits that are tracked into the attached document. Please accept the changes and submit back to them.

Thanks,

Tony

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Sent: Monday, April 13, 2020 4:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: ASF - here that proposed op-ed for you and Dr. Birx penned by VP office

ASF – (b) (5). Please review if/when u have a chance.
Clean version and tracked version.

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Sent: Sunday, April 12, 2020 7:20 PM
To: Folkers, Greg (NIH/NIAID) [E] <(b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6) >; Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: RE: ASF / FW: proposed op-ed for you and Dr. Birx?

(b) (5)

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, April 8, 2020 5:13 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: ASF / FW: proposed op-ed for you and Dr. Birx?

From: Billet, Courtney (NIH/NIAID) [E] <(b) (6)>

(b) (5)

From: Miller, Darin B. EOP/OVP (b) (6)

Sent: Tuesday, April 7, 2020 3:07 PM

To: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>; Billet, Courtney (NIH/NIAID) [E]
(b) (6)>

Subject: Courtney, Patricia - op-ed by Fauci/Birx?

Hi Courtney and Patricia,

(b) (6), (b) (5)

Thanks!

Darin Miller

Deputy Press Secretary

Director of Strategic Communications

Office of the Vice President

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 15 Apr 2020 01:44:02 +0000
To: Johnson, Carolyn
Cc: Collins, Francis (NIH/OD) [E] (b) (6) Billet, Courtney (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Washington Post
Attachments: NIAID COVID-19 Strategic Plan Final 10April 2020.docx

Carolyn:

Thanks for the note. I understand that you will be hearing from Francis Collins on the Public Private Partnership (PPP) that we have put together to combine the resources and assets of industry and the academic community that is largely supported by NIH, particularly NIAID in the context of COVID-19. It is the functional equivalent of a National Strategy. We at NIAID and to some extent other institutes are leveraging our vast clinical trials networks that we built for other infectious diseases, particularly, but not exclusively HIV/AIDS, to provide the capacity to conduct clinical trials (NIH-sponsored as well as industry-sponsored) for both vaccines and therapeutics for COVID-19. For your interest, I am attaching a copy (not yet released) of the NIAID Strategic Plan for COVID-19 Research. It is an outline that will be supplemented with an implementation plan.

Best regards,
Tony

From: Johnson, Carolyn <Carolyn.Johnson@washpost.com>
Sent: Tuesday, April 14, 2020 10:23 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Washington Post

Dear Tony,

Is there a national strategy at the task force level to coordinate clinical research efforts nationally? We have heard lots of complaints that there isn't a national strategy. I talked to Cliff Lane about this, but we want to give you the chance to respond.

Carolyn

Carolyn Johnson
Washington Post
202-334-6248 (desk)
(b) (6) (cell)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 15 Apr 2020 01:35:53 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Call with VP and Senators on Thursday 4/15

I guess in person since I will have to be down there anyway

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, April 14, 2020 6:13 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: Call with VP and Senators on Thursday 4/15

(b) (5)

From: Edwards, Sara L. EOP/OVP <(b) (6)>
Sent: Tuesday, April 14, 2020 4:43 PM
To: McGuffee, Tyler Ann A. EOP/OVP <(b) (6)>; Good-Cohn, Meredith (CMS/OA) (b) (6); Shirley.Gathers (b) (6); (b) (6); Amerau, Colin C LT USN JS J4 (USA) <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Rom, Colin (FDA/OC) (b) (6)>
Cc: Lankford, Hannah A. EOP/OVP <(b) (6)>
Subject: Call with VP and Senators on Thursday 4/15

Good afternoon,

Vice President will be joining a call with Senate Democrats on Thursday April 16 at 1:00pm. The call will be routed through the (b) (5) similar to last week's call. Please have your principal dial into the (b) (5) at (b) (5) at 5 minutes prior to the start. They will be patched into the Vice President and then together into the Senate calls.

1PM-2PM Senate Democratic Caucus

(b) (5)

Please confirm your principal Thursday 4/16

Secretary Steven Mnuchin, Department of the Treasury – **by phone**
Administrator Seema Verma, Center for Medicare and Medicaid Services (CMS) – **by phone**
Dr. Anthony Fauci, Director, National Institute of Allergy and Infectious Diseases – **by phone**
Dr. Stephen Hahn, Commissioner of Food and Drugs, Food and Drug Administration – **by phone**
Rear Admiral John Polowczyk, Vice Director for Logistics, J4 – **by phone**
Ambassador Debbie Birx, M.D., White House Coronavirus Response Coordinator – **in-person**

Thank you,

Sara Edwards
Office of the Vice President

From: (b) (6)
Sent: Tue, 14 Apr 2020 13:55:46 -0400
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: Fwd: Dr. Fauci - FROM NBC4
Attachments: image001.png, ATT00001.htm, manuscript final draft revised.pdf, ATT00002.htm

Please check this out and respond as appropriate.

Begin forwarded message:

From: Melissa Mollet (b) (6)>
Date: April 14, 2020 at 10:22:13 AM EDT
To: (b) (6)>, "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>, "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>, "Fauci, Anthony (NIH/NIAID) [E]"
<(b) (6), Melissa Mollet (b) (6) "Mollet, Melissa (NBCUniversal, WRC)" <Melissa.Mollet@nbcuni.com>, Jeremy Schulman <jschulman@schulmanbh.com>
Subject: Dr. Fauci - FROM NBC4

Hello Dr. Fauci,

This is Melissa Mollet, reporter with NBC4 in Washington. I hope you are well - and safe - and are hanging in there during this unprecedented time. You have been doing an incredible job.

I know you're getting a million emails, so my apologies in advance. I really think this information (attached and below) could help and I feel a responsibility to pass it along.

There is an extremely promising COVID-19 therapy being used right now in Italy. The creator is a client of (b) (6) Bethesda law firm. The managing member of that firm, Jeremy Schulman, is CC'd on this e-mail. The creator is willing to work with the NIH to quickly bring his therapy to the U.S.

Please reach out with any questions at all.

Best -

Melissa Mollet
NBC Washington
4001 Nebraska Avenue NW
Washington, D.C. 20016
(b) (6) (Cellular)

Get Outlook for iOS

From: Jake Schaller <jschaller@schulmanbh.com>

Sent: Monday, April 13, 2020 5:36 PM

To: Mollet, Melissa (NBCUniversal, WRC)

Subject: [EXTERNAL] Therapy for COVID-19; Results of Trial in Italy

Melissa,

I wanted to expand a bit on the COVID-19 therapy I mentioned and provide some information about the man who is developing it. Hoping that you can get this into the right hands, as it seems like a very promising lead in this fight.

The therapy, invented by Professor Claudio De Simone, has shown extremely encouraging results in a preliminary trial at the Infectious Diseases Clinic of the University "La Sapienza" in Rome, Italy. Professor De Simone convinced the doctors there to start a trial on patients affected by COVID-19. Considering the excellent results obtained, the number of patients enrolled is increasing day after day. Our firm became aware of these results directly from Professor De Simone, who has been a client of our managing partner, Jeremy Schulman, since 2015.

The formulation employed in these patients at the La Sapienza Infectious Diseases Clinic is manufactured in France and known as "SIVOMIXX." The product is a specialized blend of eight different freeze-dried bacteria with considerable antiviral and anti-inflammatory activity. Patients admitted to the clinic at La Sapienza, presenting as positive for COVID-19 and with the typical symptoms of the disease, are being treated by oral bacteriotherapy utilizing SIVOMIXX. In each case, SIVOMIXX administration was followed by a dramatic improvement in their conditions. The key takeaways are that use of SIVOMIXX correlated with fewer deaths (zero in the treated group), fewer patients transferred to the ICU, and a dramatically reduced risk of patient intubations. The sponsors of the trial using SIVOMIXX are now beginning to enroll patients with severe cases who have been admitted to the ICU.

Attached to this email is a confidential dossier about the SIVOMIXX product and a summary of the ongoing study. Upon request, I am also able to send you an Excel file containing the raw data from the study, so NIH can review them, with the understanding that this should be treated as "highly confidential." Since the clinical trial is continuing in Italy, we expect to have results covering additional patients on a rolling basis. The researchers conducting the study intend to publish their results in the coming weeks. However, considering the pandemic and the lack of effective treatment options, we want to make NIH aware of Professor De Simone's therapy without any delay.

SIVOMIXX is a relatively new formulation developed by Professor De Simone, currently in limited commercial production at a manufacturing facility in France. Professor De Simone has sufficient supply available to utilize with 100-150 COVID-19 patients immediately. Professor De Simone could, on his own, arrange a small-scale supply to use with hundreds of additional patients in the United States. He is willing to provide his current inventory of the product to the United States government. He expects that the Trump administration could quickly confirm the efficacy of SIVOMIXX to significantly improve symptoms of COVID-19 and reduce the duration of patient hospital stays. After that, Professor De Simone is willing to collaborate with the administration to bring a large-scale production of SIVOMIXX for use throughout the United States, Italy (where he was born), and Switzerland (where he lives). Professor De Simone already has ongoing partnerships with a

number of manufacturing companies, including one in the United States, for the production of another one of his products (Visbiome, referenced below). With appropriate guidance and instruction from the Trump administration, we believe the U.S. manufacturing companies could re-tool to produce SIVOMIXX on a large scale within several weeks.

Professor De Simone (more information about him below) and Jeremy will do whatever it takes to bring this critical therapy to as many Americans as possible on an urgent basis. Jeremy can be reached at anytime on his cell phone—(b) (6)

Thanks so much for passing this on.

Best,

Jake

About Professor De Simone. Professor De Simone is a world-renowned expert in gastroenterology and the inventor of several highly successful probiotic medical foods. Until 2010, he was an Associate Professor for the Infectious Diseases Group at the Department of Medicine and Surgery of the University of L'Aquila, Italy. Subsequently, he was appointed Head of the Infectious Disease Department and Director of the AIDS Coordination Group of the Abruzzi region, Italy. He is currently a retired Professor of Internal Medicine, still collaborating with the University, and a Fellow of the American Gastroenterology Association. Professor De Simone's research specialties have been in the fields of immuno-pathogenesis of infectious diseases. He has published the results of his research activities in over 200 scientific articles, reviews, case reports, and book chapters. Professor De Simone is both a researcher and a medical practitioner. He tests his laboratory hypotheses in the university hospital clinic on patients with serious diseases. He was responsible for controlling the AIDS pandemic in Italy's Abruzzi region in the 1990's.

Products developed according to Professor De Simone's know-how have shown positive results in patients with serious diseases. One of his signature formulations, known as the "De Simone Formulation," is now sold in the United States as "Visbiome." The De Simone Formulation has been the subject of more than 70 published human clinical trials demonstrating its efficacy in managing severe gastrointestinal symptoms from such diseases as ulcerative colitis, pouchitis, and liver diseases. Concerning pouchitis, the De Simone Formulation is recognized by the world's professional gastroenterology societies as a "standard of care," an achievement that no other probiotic substance previously has attained. The De Simone Formulation became the "gold standard" in its therapeutic class. Its role in patient care has been endorsed in the guidelines published by the American Gastroenterology Association ("AGA"), the European Crohn's and Colitis Organization ("ECCO"), and the British Society of Gastroenterology, as well as in the New England Journal of Medicine.

SCHULMANBHATTACHARYA



James "Jake" Schaller
Attorney

jschaller@schulmanbh.com

www.SchulmanBH.com

Direct: (240) 356-9508

Cell: (b) (6)

Main Office:

The Clark Building
7500 Old Georgetown Road, Suite 901
Bethesda, Maryland 20814
Receptionist: (240) 356-8550
Fax: (240) 356-8558

Bio-Tech Corridor Office:

The GSK Building
14200 Shady Grove Road, Suite 600
Rockville, Maryland 20850

The information contained in this electronic message and any attached documents may be privileged, confidential, and protected from disclosure. If you are not the intended recipient, please note that any review, disclosure, copying, distribution, or use of the contents of this electronic message or any attached documents is prohibited. If you have received this communication in error, please destroy it and notify us immediately by telephone (240-356-8550) or by electronic mail to the sender of this email. Thank you.

Internal Revenue Service Circular 230 Disclosure: Schulman Bhattacharya, LLC does not provide tax advice. In compliance with IRS requirements, you are on notice that any advice contained in this communication (including any attachments) is not intended or written to be used, and cannot be used, for the purpose of (i) avoiding penalties under the Internal Revenue Code or (ii) promoting, marketing or recommending to another party, for tax purposes, any transaction or matter addressed herein.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 14 Apr 2020 16:15:32 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Mike Milken new Podcast Series: COVID-19 - will you join me as my guest?
All the best, Mike

What do you think? Let us discuss.

From: Michael Milken (mmilken@knowledgeu.com) <mmilken@knowledgeu.com>
Sent: Tuesday, April 14, 2020 5:16 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Billie Griffin (bgriffin@knowledgeu.com) <bgriffin@knowledgeu.com>; Katie Dinsmore (kdinsmore@knowledgeu.com) <kdinsmore@knowledgeu.com>
Subject: Mike Milken new Podcast Series: COVID-19 - will you join me as my guest? All the best, Mike

Dear Tony, I hope this email finds you well. I wanted to see if you had a few minutes to talk over the next few weeks. I recently began hosting a daily podcast that focuses on the COVID-19 pandemic and responses from thought leaders across industries – I would like for you to join me as my guest. I have also reached out to Hugh Auchincloss as well but still waiting to hear.

Our guests so far include Francis Collins, Alex Gorsky, David Baltimore (*Nobel Laureate*), Jim Allison (*Nobel Laureate*)/Pam Sharma, Jo Ann Jenkins, Eric Schmidt, Rod Hochman, Carmine Di Sibio, Arie Belldegrun, Peggy Hamburg, Rodney McMullen, Bruce Broussard, Vas Narasimhan, Joe Tsai, Steve Ballmer, Jeff Skoll, Sue Desmond-Hellmann, Rob Manfred, Judy Faulkner, Bob Bradway, Tal Zaks, Ray Dalio, David Solomon, Barbara Humpton, Dr. Steven Rosenberg, Dr. Richard Stone, Dr. Kurt Newman, Vivek Ramaswamy, Francis deSouza

I record the interviews on Mondays, Wednesdays-Fridays starting at 7:30 a.m. Pacific/10:30 a.m. Eastern. Each episode will last 10-20 minutes. Our team would get you set-up to join remotely by phone.

The interviews are available on the Milken Institute website as well as on Spotify and Apple Podcasts. I opened up the series with Francis Collins a few weeks ago, click [here](#) to have a listen.

If you're interested in joining me, my team (copied) will circle back to you with another email detailing the subject matter and technical information.

Please stay safe & healthy.

All the best,
Mike

From: (b) (6)
Sent: Tue, 14 Apr 2020 10:32:21 -0400
To: Tengiz Tsertsvadze
Subject: Re: US-Georgia biomedical collaboration

Tengiz:

Thank you for your kind note. I am pleased to see that Georgia has controlled the outbreak very well. Stay well.

Best regards,

Tony

On Apr 14, 2020, at 10:24 AM, Tengiz Tsertsvadze (b) (6) wrote:

Dear Dr. Fauci,

I am writing this letter on behalf of the community of infectious diseases specialists of Georgia to express our deepest respect to you. I recall with great pleasure all our previous meetings, especially the last one in 2017, when I, together with my team members, had an opportunity to visit you at NIH.

We are grateful to you and your team for the most important contribution to establishing US-Georgia biomedical collaboration that significantly increased our country's research and practical capacities. Your personal role in combating HIV and other emerging epidemics such as SARS, MERS, Zika, Ebola, cannot be overestimated. I am confident that your leading role in this fight against COVID-19 will be crucial for defeating the pandemic not only in the United States, but around the globe.

We closely follow your briefings and interviews on COVID-19 (including recent very interesting conversation with Dr. Howard Bauchner at JAMA) and as always your views are very apt and to the point. We fully agree that the approaches you suggest are the most effective way to defeat the pandemic. Most importantly your recommendations are applicable not only to the United States, but to other countries as well and we eagerly take them into consideration while planning our strategies here in my country of Georgia.

I would like to use this opportunity to update you on COVID-19 situation in my home country of Georgia: The country quickly responded to this threat first by stopping flights with China in January, followed by more strict measures after the first case was diagnosed on February 26. These measures included national lockdown, active contact tracing, isolation and quarantine. The Government of Georgia appointed me to lead the National Committee on the clinical management

of COVID-19. Our effort to contain the spread of the virus had been effective so far with 296 cases of COVID-19 and 3 lethal cases reported up to now.

We are impatiently awaiting results of vaccine and therapeutic trials supported by NIAID, which I am confident will help to defeat this pandemic disease. On our side, Georgia is committed to make its modest but important contribution to the global efforts.

Sincerely,

Tengiz Tsertsvadze, MD, PhD

Director General, Infectious Diseases, AIDS and Clinical Immunology Research Center

Professor of Medicine, Ivane Javakhishvili Tbilisi State University

<photo.jpg>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 14 Apr 2020 03:29:04 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Covid-19 logical treatment strategy based on patient's immunological response
Attachments: MEDRXIV-2020-058420v1-Gali Filho.pdf

From: Julio Gali (b) (6)
Sent: Monday, April 13, 2020 12:34 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Covid-19 logical treatment strategy based on patient's immunological response

Good afternoon Dr. Anthony Fauci.

After reading a lot of papers and studying basic science we have elaborated a treatment approach to the disease.

(b) (4)



Julio C. Gali Filho, MD

Research and Development, JJMED, Sorocaba, SP, Brazil

(b) (6)

(b) (6)

Julio C. Gali, MD, PhD

Department of Orthopaedics

Faculty of Medical Science and Health

Catholic University of Sao Paulo

Sorocaba/SP – Brazil

(b) (6)

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 14 Apr 2020 02:13:45 +0000
To: Hiatt, Fred
Subject: RE: fred checking in

Fred:

Thank you for your kind note. Am glad to hear that Joe is working on COVID-19. We need all the brightest minds we can get on this problem. Stay safe and well.

Best regards

Tony

From: Hiatt, Fred <fred.hiatt@washpost.com>
Sent: Monday, April 13, 2020 2:30 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: fred checking in

Tony,

I haven't wanted to bother you, but wanted to say thanks for all you are doing, and hope you are at least to a small extent finding a way to take care of yourself.

(b) (6) is hard at work at (b) (6) on a couple of coronavirus projects, so we're counting on him.

Of course any time you want to write something, our page is available.

Warmly,

Fred

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 14 Apr 2020 02:03:49 +0000
To: Glass, Roger (NIH/FIC) [E]
Cc: Kilmarx, Peter (NIH/FIC) [E]; Redfield, Robert R. (CDC/OD); Birx, Deborah L. EOP/NSC
Subject: RE: Support for a "U.S. COVID-19 Response Corps"

Great idea!!

From: Glass, Roger (NIH/FIC) [E] (b) (6) >
Sent: Monday, April 13, 2020 12:50 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Glass, Roger (NIH/FIC) [E] (b) (6) >; Kilmarx, Peter (NIH/FIC) [E] (b) (6) >
Subject: Support for a "U.S. COVID-19 Response Corps"

Hi Tony,

Greetings from (b) (6)

It's been good to see all the calls for ramping up a public health workforce to manage contact tracing and other aspects of the second phase of the response. I wanted to let you know that Peter Kilmarx has been calling for the formation of a "U.S. COVID-19 Response Corps" since March 21 (unrelated to NIH work). FEMA could hire thousands of temporary workers quickly with existing authorities and funding. CDC could provide training and technical assistance. The workforce would be deployed to and managed by state and local health departments at their request. There's a lot of enthusiasm for this from Jeff Duchin in Seattle, to Tom Frieden, CSIS, ASTHO, and 40 members of Congress (bicameral, bipartisan) who sent a letter to FEMA asking them to do this. The 7,000+ recently evacuated Peace Corps volunteers could be one recruiting source. Another approach is for CDC to fund state and local authorities for those who are able to hire at this speed and scale. There's more information in the string below.

This workforce issue is now such a critical part of the response, I wanted to share with you what we've learned and offer to help in any way.

Tony, all of NIH is so proud of your leadership and rooting for you to get this outbreak under control. Please keep up fight and let us know if and how we can help.

Warm wishes,
Roger

From: Kilmarx, Peter (NIH/FIC) [E]
Sent: Monday, April 13, 2020 8:45 AM
To: 'Conover, Craig' (b) (6); 'Angela Dunn' (b) (6); 'Cindy Burnett' (b) (6) >; 'Duchin, Jeff' (b) (6) >; 'Stephen Morrison' (b) (6)

(b) (6); 'John Monahan' (b) (6); 'Charles Holmes'
(b) (6); 'Jeremy Konyndyk' (b) (6);
(b) (6); 'Rebecca Katz' (b) (6); 'Tom Inglesby'
(b) (6); 'Glenn Blumhorst' (b) (6); Glass, Roger (NIH/FIC) [E]
(b) (6); 'Marcus Plescia' (b) (6); 'Vanessa Kerry'
(b) (6); 'Kenyon, Thomas' < (b) (6); 'Anna Carroll'
(b) (6); 'Scott Dowell' (b) (6); 'Jonathan Pearson'
(b) (6); 'suzannemarks@me.com' < (b) (6); 'O'Connor,
Eileen' (b) (6); 'Myers, Michael' (b) (6); 'Robynn Leidig'
(b) (6); 'Ariel Pablos' (b) (6); 'Gavin Yamey'
(b) (6); 'Jody Olsen' (b) (6); Bialy, Kevin (NIH/FIC) [E]
(b) (6); 'John Auerbach' < (b) (6); Brooks, John T.
(CDC/DDID/NCHSTP/DHPSE) (b) (6); 'Dara Lieberman' (b) (6); David
Gittelman (b) (6);

Subject: RE: COVID-19 Response Corps

Hi all,

Updates:

1. Johns Hopkins and ASTHO released "A National Plan to Enable Comprehensive COVID-19 Case Finding and Contact Tracing in the U.S." calling for 100,000 contact tracers. (Kudos!) "Potential workforce recruits may include . . . Peace Corps members."
http://www.centerforhealthsecurity.org/our-work/pubs_archive/pubs-pdfs/2020/a-national-plan-to-enable-comprehensive-COVID-19-case-finding-and-contact-tracing-in-the-US.pdf
2. WaPo article: "A plan to defeat coronavirus finally emerges, but it's not from the White House" covers the JHU/ASTHO plan and notes: "Experts [CSIS] have proposed transforming the Peace Corps into a national response corps that could perform many tasks, including contact tracing." [Not quite accurate. Peace Corps would be unchanged, but the evacuated volunteers would be hired into COVID-19 response.]
3. NY Times editorial from Tom Frieden calls for a "giant public health effort." "Recruits could include Peace Corps volunteers who were brought home when the pandemic spread."
<https://www.nytimes.com/2020/04/12/opinion/cdc-coronavirus.html>
4. Bill introduced by Sens. Susan Collins (R-ME), Chris Murphy (D-CT) and Dianne Feinstein (D-CA) would require federal agencies and departments facing special hiring needs during the pandemic to establish a process to expedite hiring of returned Peace Corps volunteers
<https://riponadvance.com/stories/collins-bipartisan-bill-would-ensure-benefits-for-evacuated-peace-corps-volunteers/>
5. From March 29: Policy report from former FDA Commissioners Scott Gottlieb and Mark McClellan calls for "massively" scaling contact tracing. "Surge the existing public-health workforce to conduct case finding and contact tracing." <https://www.aei.org/research-products/report/national-coronavirus-response-a-road-map-to-reopening/>
6. Mark McClellan responded to my email yesterday: "I'd suggest adding outreach to mayors and county execs if that hasn't happened yet. They are really on the front lines for this next phase."
7. I understand legislation is in the works, but don't have details.
8. No news from FEMA or indication to my knowledge that they are planning a substantial ramping up of staffing.
9. A key limitation on the impact of contact tracing will be the relative importance of asymptomatic spread.

10. A note on serology: The current U.S. cumulative incidence is 0.169%. The specificity of FDA EUA Cellex test is 95.6%. Not accounting for undiagnosed cases, Positive Predictive Value is only 3.5%. If underdiagnosis is 10:1, the PPV is still only 26.8%. Will be higher in higher-risk individuals, of course.

Any other updates please send to me.

Advocacy needed for scaling up public health workforce especially with governors and mayors.

PK

From: Kilmarx, Peter (NIH/FIC) [E]

Sent: Friday, April 10, 2020 1:53 PM

To: 'Conover, Craig' (b) (6); 'Angela Dunn' (b) (6); 'Cindy Burnett' (b) (6); 'Duchin, Jeff' (b) (6); 'Stephen Morrison' (b) (6); 'John Monahan' (b) (6); 'Charles Holmes' (b) (6); 'Jeremy Konyndyk' (b) (6); 'Rebecca Katz' (b) (6); 'Tom Inglesby' (b) (6); 'Glenn Blumhorst' (b) (6); 'Glass, Roger (NIH/FIC)' [E] (b) (6); 'Marcus Plescia' (b) (6); 'Vanessa Kerry' (b) (6); 'Kenyon, Thomas' (b) (6); 'Anna Carroll' (b) (6); 'Scott Dowell' (b) (6); 'Jonathan Pearson' (b) (6); 'suzannemarks@me.com' (b) (6); 'O'Connor, (b) (6); 'Myers, Michael' (b) (6); 'Robynn Leidig' (b) (6); 'Ariel Pablos' (b) (6); 'Gavin Yamey' (b) (6); 'Jody Olsen' (b) (6); 'Bialy, Kevin (NIH/FIC)' [E] (b) (6); 'John Auerbach' (b) (6); 'Brooks, John T. (CDC/DDID/NCHSTP/DHPSE)' (b) (6); 'Dara Lieberman' (b) (6)

Subject: RE: COVID-19 Response Corps

+ John Auerbach, president and CEO of Trust for America's Health

Thanks all for the robust discussion. Some updates:

1. ASTHO sent the attached memo to Congress today *RE: Contact Tracing Workforce* calling for "flexible long term and emergency supplemental funding to expand the . . . contact tracing workforce" at state, local, and related levels. It recommends against using FEMA for hiring. ASTHO notes that currently there are only 2,200 DIS nationwide while JHU estimates that 100,000 contact tracing employees are needed to address COVID-19 in the immediate future. The memo mainly calls for 1) \$3.6 B *emergency* funding through the CDC Crisis Cooperative Agreement to eligible jurisdictions, plus 2) a \$4.5 B *annual* Public Health Infrastructure Fund.
2. Resolve to Save Lives (Tom Frieden) is advocating for CDC to have the needed authority and political support to provide training, systems, and technical expertise, while the CDC Foundation and ASTHO provide staffing through direct assistance to health departments.
3. CDC could support curriculum development and training through the National Network of STD Clinical Prevention Training Centers <https://nnptc.org/> and/or TB Centers of Excellence https://www.cdc.gov/tb/education/tb_coe/default.htm

My take: We share the goal of rapidly and substantially ramping up the public health workforce and should emphasize that message. It would be very challenging for any of these potential approaches to reach 100,000 in the short term. I don't have any special allegiance to FEMA, but their traditional role in emergency response is quickly hiring many thousands of workers. They are hiring now, but not at this speed and scale. CDC and FEMA should have an MOU through which FEMA can hire staff and detail to CDC, but they don't seem to be pursuing. One model could be FEMA detailing staff to state and local authorities to manage the hiring process. FEMA is proud of their ability to get people from "door to desk" in one week. This would not be "federalizing" contact tracing or other public health activities. In all cases, the invitations and the oversight would come from the state and local authorities, who are best able to decide what mechanism(s) work for them. Lastly, this concept includes more than contact tracing. Congresswoman Susan Brooks (R-IN) in her podcast Wednesday noted that the state 211 call line has gone from 2,000 to 25,000-35,000 calls per day. So this concept would still have a role even if not direct public health functions.

Thanks,
PK

From: Kilmarx, Peter (NIH/FIC) [E]

Sent: Friday, April 10, 2020 8:05 AM

To: Conover, Craig <(b) (6)>; Angela Dunn <(b) (6)>; Cindy Burnett <(b) (6)>; Duchin, Jeff <(b) (6)>; Stephen Morrison <(b) (6)>; John Monahan <(b) (6)>; Charles Holmes <(b) (6)>; Jeremy Konyndyk <(b) (6)>; Rebecca Katz <(b) (6)>; Tom Inglesby <(b) (6)>; Glenn Blumhorst <(b) (6)>; Glass, Roger (NIH/FIC) [E] <(b) (6)>; Marcus Plescia <(b) (6)>; Vanessa Kerry <(b) (6)>; Kenyon, Thomas <(b) (6)>; Anna Carroll <(b) (6)>; Scott Dowell <(b) (6)>; Jonathan Pearson <(b) (6)>; O'Connor, Eileen <(b) (6)>; Myers, Michael <(b) (6)>; Robynn Leidig <(b) (6)>; Ariel Pablos <(b) (6)>; Gavin Yamey <(b) (6)>; Jody Olsen <(b) (6)>; Bialy, Kevin (NIH/FIC) [E] <(b) (6)>

Subject: COVID-19 Response Corps - CDC calling for public health army

Thanks Craig. This NEJM article is mainly about health care workers, but does mention other roles in social support.

Important development: CDC's Bob Redfield is calling for a public health army for contact tracing after this acute phase:

<https://www.npr.org/sections/health-shots/2020/04/10/831200054/cdc-director-very-aggressive-contact-tracing-needed-for-u-s-to-return-to-normal>

It turns out that the Centers for Disease Control and Prevention has been working on a plan to allow the U.S. to safely begin to scale back those policies. CDC Director Robert Redfield spoke with NPR on Thursday, saying that the plan relies on not only ramped-up testing but "very aggressive" contact tracing of those who do test positive for the coronavirus, and a major scale-up of personnel to do the necessary work.

I'm not sure CDC has the authority, capacity, or political support to hire an army at this time. This is a traditional FEMA role. CDC can provide training and technical assistance.

PK

From: Conover, Craig (b) (6)
Sent: Friday, April 10, 2020 7:27 AM
To: Kilmarx, Peter (NIH/FIC) [E] (b) (6)>; Angela Dunn (b) (6)>; Cindy Burnett (b) (6)>; Duchin, Jeff (b) (6)>; Stephen Morrison <(b) (6)>; John Monahan <(b) (6)>; Charles Holmes (b) (6)>; Jeremy Konyndyk (b) (6)>
<(b) (6)>; Rebecca Katz (b) (6)>; Tom Inglesby (b) (6)>; Glenn Blumhorst (b) (6)>; Glass, Roger (NIH/FIC) [E] (b) (6)>; Marcus Plescia (b) (6)>; Vanessa Kerry (b) (6)>; Kenyon, Thomas (b) (6)>; Anna Carroll (b) (6)>; Scott Dowell <(b) (6)>; Jonathan Pearson (b) (6)>; O'Connor, Eileen (b) (6)>; Myers, Michael (b) (6)>; Robynn Leidig (b) (6)>; Ariel Pablos (b) (6)>; Gavin Yamey (b) (6)>

Subject: NEJM- ensuring and sustaining a pandemic workforce

attached

From: Kilmarx, Peter (NIH/FIC) [E] (b) (6)>
Sent: Wednesday, April 8, 2020 5:53 PM
To: Conover, Craig (b) (6)>; Angela Dunn (b) (6)>; Cindy Burnett (b) (6)>; Duchin, Jeff (b) (6)>; Stephen Morrison (b) (6)>; John Monahan (b) (6)>; Charles Holmes (b) (6)>; Jeremy Konyndyk (b) (6)>
<(b) (6)>; Rebecca Katz (b) (6)>; Tom Inglesby (b) (6)>; Glenn Blumhorst (b) (6)>; Glass, Roger (NIH/FIC) [E] (b) (6)>; Marcus Plescia (b) (6)>; Vanessa Kerry (b) (6)>; Kenyon, Thomas (b) (6)>; Anna Carroll (b) (6)>; Scott Dowell <(b) (6)>; Jonathan Pearson (b) (6)>; O'Connor, Eileen (b) (6)>; Myers, Michael (b) (6)>; Robynn Leidig (b) (6)>; Ariel Pablos (b) (6)>; Gavin Yamey (b) (6)>

Subject: [External] RE: UPDATE: COVID-19 Response Corps

Welcome Marcus Plescia, chief medical officer of ASTHO!

Updates:

1. CSIS podcast "Coronavirus Crisis Update" with Congresswoman Susan Brooks (R-IN). She cosigned the CSIS OpEd with Ami Bera on the CRC and opens the episode with a discussion of engaging the returned Peace Corps volunteers <https://www.csis.org/podcasts/take-directed/coronavirus-crisis-update-hunker-down-hoosiers-congresswoman-susan-brooks> (This is a great series by the way.)
2. On Mar 27, 2020, Congressman Mike Quigley (D-IL-05) introduced the Mobilizing America to Help Act, "which would direct President Trump to invoke his existing authority to detail Peace Corps volunteers who have returned to the US from their posts, to the Federal Emergency Management Agency (FEMA) to support emergency relief in the wake of COVID-19." <https://quigley.house.gov/media-center/press-releases/quigley-urges-trump-assign-peace-corps-volunteers-covid-19-emergency>
3. Baltimore Sun column DAN RODRICKS, APR 03, 2020, "Put Peace Corps volunteers to work on U.S. soil to fight COVID-19": <https://www.baltimoresun.com/opinion/columnists/dan-rodricks/bs-md-rodricks-0405-20200403-viqbgjhwshne3fuqzy72nfcsoe-story.html>
4. Good conversations with Marcus @ASTHO and others today. Important to emphasize that state and local authorities have the lead. This would not be "federalizing" the response. It would be making federal employees available by request to integrate in state- and local-led activities. Some will welcome the extra hands. Some will prefer to have funding to do their own hiring. Paying salaries of state employees at risk for furlough to work on COVID-19 will make a lot of sense, but won't be enough. Need a menu of options.
5. Many concepts and plans for public health and social response are being circulated. All of them will need an expanded workforce.

Outreach:

6. I'm in touch with someone in Adam Boehler's office. Other outreach welcome.
7. I emailed Peggy Hamburg. No reply yet. Other outreach welcome.
8. Anyone who can contact Scott Gottlieb?
9. Here again is Monday's list: NGA and individual governors. Republicans who will be most interested and helpful are Baker (MA), DeWine (OH) and Hogan (MD). Democrats: Cuomo, Pritzker, Newsom, Whitmer, Inslee. AMA, ASTHO (done), APHA all good potential champions

Please amplify these links on social media.

Other updates and suggestions welcome as always. Send to me and I can send to others in a digest to reduce email traffic.

Thanks,
PK

From: Kilmarx, Peter (NIH/FIC) [E]

Sent: Tuesday, April 7, 2020 8:19 AM

To: 'Conover, Craig' <(b) (6)>; 'Angela Dunn' <(b) (6)>; 'Cindy Burnett' <(b) (6)>; 'Duchin, Jeff' <(b) (6)>; Stephen Morrison <(b) (6)>; 'John Monahan' <(b) (6)>; 'Charles Holmes' <(b) (6)>; 'Jeremy Konyndyk' <(b) (6)>; 'Rebecca Katz' <(b) (6)>; 'Tom Inglesby' <(b) (6)>; 'Glenn Blumhorst' <(b) (6)>; Glass, Roger (NIH/FIC) [E]

< (b) (6)>; 'Vanessa Kerry' (b) (6); 'Kenyon, Thomas'
(b) (6); 'Anna Carroll' < (b) (6)>; 'Scott Dowell'
(b) (6)>; 'Jonathan Pearson' (b) (6)>;
(b) (6) (b) (6); 'O'Connor, Eileen' (b) (6)
'Myers, Michael' (b) (6)>; 'Robynn Leidig' (b) (6)>; 'Ariel
Pablos' (b) (6)>; 'Gavin Yamey' < (b) (6)>

Subject: UPDATE: COVID-19 Response Corps - FEMA challenges

Here's a report about a challenge I didn't see until this morning. I don't know if grants to state and local authorities would be quicker than federal hiring by FEMA. Either way, the workforce is needed, but will take longer than one would like.

<https://www.nytimes.com/2020/04/03/climate/fema-staff-shortage-coronavirus.html>

FEMA, Racing to Provide Virus Relief, Is Running Short on Front-Line Staff

WASHINGTON — The Federal Emergency Management Agency, the office leading the federal government's coronavirus response nationwide, is running short of employees who are trained in some of its most important front-line jobs, according to interviews with current and former officials.

At the same time, the agency has been forced to halt a major hiring initiative, and has closed training facilities to avoid spreading the infection.

The number of available personnel who are qualified to lead field operations has fallen to 19 from 44 in less than six weeks, and staff members have been pulled from responding to other disasters, but training centers in Maryland and Alabama have been shuttered until mid-May. In addition, an effort to recruit new employees called "Harness" is on hold, according to a senior administration official with direct knowledge of FEMA's operations . . .

Craig Fugate, who ran the agency during the Obama administration, said FEMA's ability to deploy enough people was a significant challenge. "Can it be done? Yeah," Mr. Fugate said. "Will it be pretty? No."

From: Kilmarx, Peter (NIH/FIC) [E]

Sent: Monday, April 6, 2020 5:22 PM

To: Conover, Craig < (b) (6)>; Angela Dunn (b) (6)>; Cindy Burnett
(b) (6); Duchin, Jeff (b) (6); Stephen Morrison
(b) (6)>; John Monahan < (b) (6)>; Charles Holmes
< (b) (6)>; Jeremy Konyndyk (b) (6)
(b) (6)>; Rebecca Katz (b) (6) Tom Inglesby
(b) (6)>; Glenn Blumhorst (b) (6); Glass, Roger (NIH/FIC) [E]
(b) (6); Vanessa Kerry < (b) (6)>; Kenyon, Thomas
(b) (6)>; Anna Carroll (b) (6)>; Scott Dowell
< (b) (6)>; Jonathan Pearson < (b) (6)
(b) (6) O'Connor, Eileen (b) (6)>; Myers, Michael
(b) (6)>; Robynn Leidig (b) (6) Ariel Pablos
(b) (6)>; Gavin Yamey (b) (6)

Subject: NEWS: Bera-Brooks OpEd published in support of COVID-19 Response Corps

Welcome Vanessa Kerry!
Welcome Ariel Pablos-Méndez!
Welcome Gavin Yamey!

Hi all,

1. The OpEd is out on the CSIS website: <https://www.csis.org/analysis/covid-19-response-corps-can-help-stop-pandemic> It is co-authored by Congresswoman Susan Brooks (R-IN) and Congressman Ami Bera (D-CA), members of the CSIS Commission on Strengthening America's Health Security. Thanks very much to Steve Morrison for making this happen.
2. Here's the link to the press release on the 40-member letter to FEMA, Peace Corps, and CNCS from Senator Van Hollen:
 - a. <https://www.vanhollen.senate.gov/news/press-releases/sen-van-hollen-rep-phillips-lead-bipartisan-bicameral-letters-in-support-of-peace-corps-amicorps-volunteers>
 - b. Includes link to letter:
[vanhollen.senate.gov/imo/media/doc/Peace%20Corps%20covid19%20service%20opportunities%20letter%2004.02.20.pdf](https://www.vanhollen.senate.gov/imo/media/doc/Peace%20Corps%20covid19%20service%20opportunities%20letter%2004.02.20.pdf)

With this new, bipartisan OpEd, it's time to reach out to national, state and local authorities and opinion leaders to encourage implementation and create demand. Suggestions from one of us: NGA and individual governors. Republicans who will be most interested and helpful are Baker (MA), DeWine (OH) and Hogan (MD). Democrats: Cuomo, Pritzker, Newsom, Whitmer, Inslee. AMA, ASTHO, APHA all good potential champions.

Please also amplify on social media.

Updates and suggestions welcome as always.

PK

From: Kilmarx, Peter (NIH/FIC) [E]

Sent: Sunday, April 5, 2020 8:45 AM

To: Conover, Craig (b) (6); Angela Dunn (b) (6); Cindy Burnett (b) (6); Duchin, Jeff <(b) (6)>; Stephen Morrison (b) (6); John Monahan (b) (6); Charles Holmes (b) (6); Jeremy Konyndyk (b) (6); Rebecca Katz (b) (6); Tom Inglesby (b) (6); Glenn Blumhorst <(b) (6)>; Glass, Roger (NIH/FIC) [E] (b) (6); Kenyon, Thomas (b) (6); Anna Carroll (b) (6); Scott Dowell <(b) (6)>; Jonathan Pearson (b) (6); O'Connor, Eileen (b) (6); Myers, Michael (b) (6); Robynn Leidig (b) (6); (b) (6)

Subject: UPDATES: Next steps on COVID-19 Response Corps

Thanks all for our call Friday. (Glenn, Jonathan, Craig, Jeremy, Roger, Anna, Suzanne, Eileen, Michael.)

A few items from the call:

- Jonathan reported Sen Markey's office working on legislation for 10,000+ (?) response workforce
- Michael reported positive response from National Governors Association
- Eileen reaching out to Tom Bossert. Adam Boehler not yet. Shared OpEd in WSJ emphasizing testing - <https://www.wsj.com/articles/testing-is-our-way-out-11585869705>
- Jeremy has an OpEd in Daily Beast with Beth Cameron – <https://www.thedailybeast.com/coronavirus-shows-we-need-an-apollo-project-for-public-health>
- Craig in touch with Durbin's office. IL has ongoing need for large workforce. Much easier to get staff from feds. Slower to hire at state level. MA implementing 1,000-person contact tracing effort.
- John in touch with Pelosi's office, DeLauro, Conf of Mayors, League of Cities.
- Other potential champions – ASTHO, APHA, Josh Scharfstein @JHSPH
- General agreement that for bipartisan emergency approval should emphasize near-term (e.g., 2 year) imperatives of COVID-19 and economic emergencies, not a new permanent work force.
- General agreement that Peace Corps is the low-hanging fruit, but not all 7,000 RPCVs would do this and the need is much greater.
- CSIS OpEd with Ami Bera (D-CA) and Susan Brooks (R-IN) coming out in Politico or CSIS website by Monday

Other updates:

- Telcon Friday with Brooks staffer. They are putting together legislation, ideally bipartisan with Bera. Now fully briefed on CRC concept and potential implementation model. Clarified not duplicative of USPHS Ready Reserve Corps which is now authorized but not being implemented (to my knowledge) and would be different profile, i.e., USPHS has physicians, nurses, engineers, etc.
- Telcon Saturday with CDC COVID-19 Chief Medical Officer. Confirms many are thinking about the workforce issue. Notes that CDC unlikely to "own," but great suggestion to engage CDC-funded National Network of STD Clinical Prevention Training Centers for training. <https://nnptc.org/> with eight centers around the country. CRC concept may be brought to national response discussions with FEMA in Washington DC.
- FEMA contacts report they are hiring RPCVs, but do not report major speed up or scale up. FEMA recruiting email attached.
- Charles shared Vanessa Kerry OpEd emphasizing same themes: response workforce and jobs: <https://www.bostonherald.com/2020/04/01/massachusetts-general-hospital-infectious-disease-team-calls-on-state-to-harness-people-power/>

Next steps:

- Executive – support/impetus to FEMA to increase speed and scale
- Legislation – new appropriations for FEMA or CDC if needed
- National advocacy – media, opinion leaders
- Demand signal – state and local authorities requests
- Implementation and management details working out

Overall goal: Greatly increase COVID-19 response workforce to control disease and provide jobs. A COVID-19 Response Corps would be a (big) part of solution. RPCV ideal first cadre for CRC.

Please share any corrections, updates, suggestions.

Thanks,
PK

-----Original Appointment-----

From: Kilmarx, Peter (NIH/FIC) [E]

Sent: Thursday, April 2, 2020 5:34 PM

To: Conover, Craig; Angela Dunn; Cindy Burnett; Duchin, Jeff; Stephen Morrison; John Monahan; Charles Holmes; Jeremy Konyndyk (b) (6); Rebecca Katz; Tom Inglesby; Glenn Blumhorst; Glass, Roger (NIH/FIC) [E]; Kenyon, Thomas; Anna Carroll; Scott Dowell; Jonathan Pearson; (b) (6); O'Connor, Eileen; Myers, Michael; Robynn Leidig

Subject: *** Time correction - 8 am*** Next steps on COVID-19 Response Corps

When: Friday, April 3, 2020 8:00 AM-9:00 AM (UTC-05:00) Eastern Time (US & Canada).

Where: Zoom meeting

Peter Kilmarx (Fic Zoom2) is inviting you to a scheduled Zoom meeting. Zoom link below.

Agenda:

1. Welcome and introductions
2. Current status of advocacy
3. Implementation issues
4. Next steps:
 - a. Advocacy
 - b. Implementation
5. AOB

Topic: Next steps on COVID-19 Response Corps

Time: Apr 3, 2020 08:00 AM Eastern Time (US and Canada)

Join Zoom Meeting

(b) (4)

Meeting ID: (b) (4)

One tap mobile

+16465588656,, (b) (4) US (New York)

+13126266799,, (b) (4) US (Chicago)

Dial by your location

(b) (4)
(New York)
(Chicago)

(Houston)
(San Jose)

Meeting ID: (b) (4)

Find your local number: <https://zoom.us/j/ad1j8UhXN5>

From: Kilmarx, Peter (NIH/FIC) [E]

Sent: Thursday, April 2, 2020 1:29 PM

To: 'Conover, Craig' (b) (6); 'Angela Dunn' (b) (6); 'Cindy Burnett' (b) (6); 'Duchin, Jeff' <(b) (6)>; Stephen Morrison (b) (6); 'John Monahan' (b) (6); 'Charles Holmes' (b) (6); 'Jeremy Konyndyk' (b) (6); 'Rebecca Katz' <(b) (6)>; 'Tom Inglesby' (b) (6); 'Glenn Blumhorst' (b) (6); Glass, Roger (NIH/FIC) [E] (b) (6); 'Kenyon, Thomas' (b) (6); 'Anna Carroll' (b) (6); 'Scott Dowell' (b) (6); 'Jonathan Pearson' (b) (6); 'O'Connor, Eileen' (b) (6); 'Myers, Michael' (b) (6);

Subject: NEWS: Congressional letter to Peace Corps, CNCS, and FEMA on COVID-19 Response Corps

Hi all,

Big news. Herewith is a letter signed by 40 members of Congress asking FEMA, Peace Corps, and AmeriCorps to form a "COVID-19 Response Corps." This is now in the public domain. Press release forthcoming.

Please save the time for Zoom call 8 am tomorrow on next steps.

Also: Check out: <https://www.npr.org/sections/goatsandsoda/2020/04/01/825231838/coronavirus-sent-peace-corps-volunteers-home-it-could-also-give-them-a-new-missi>

The National Peace Corps Association is hoping to create and fund a group that draws on the evacuated volunteers and their skills to respond to the COVID-19 crisis in the United States. Workers would take on work like tracing the contacts of diagnosed individuals, monitoring the health of those in quarantine and staffing call centers. An agency such as the Federal Emergency Management Agency, the U.S. Centers for Disease Control and Prevention or AmeriCorps could potentially manage the group, says Blumhorst, who has been advocating for the project. Salaries could come from funding that's already been allotted to the COVID-19 response but hasn't yet been spent. The NPCA has discussed the idea with the offices of several members of Congress that are receptive and supportive, Blumhorst says, and they're planning to speak with more congresspeople and federal agencies and also hope to draw public attention to this potential project.

From: Kilmarx, Peter (NIH/FIC) [E]

Sent: Sunday, March 29, 2020 4:47 PM

To: Conover, Craig (b) (6); Angela Dunn (b) (6); Cindy Burnett (b) (6); Duchin, Jeff <(b) (6)>; Stephen Morrison (b) (6); John Monahan (b) (6); Charles Holmes (b) (6); Jeremy Konyndyk (b) (6); Rebecca Katz <(b) (6)>; Tom Inglesby (b) (6); Glenn Blumhorst: <(b) (6)>; Glass, Roger (NIH/FIC) [E] (b) (6); Kenyon, Thomas (b) (6); Anna Carroll (b) (6);

(b) (6); Scott Dowell

(b) (6)

Jonathan Pearson

(b) (6)

Subject: INFO: Update on COVID-19 Response Corps

Hi all and thanks for your support for a U.S. COVID-19 Response Corps engaging returned Peace Corps volunteers (RPCV). The latest (March 25) 2-page concept note attached.

Updates:

1. Steve is working on getting the OpEd out in press and/or on CSIS website by Tuesday. We'll let you know.
2. Glenn and Charles have found very good receptivity on the Hill.
3. I've had a couple very good calls with FEMA folks at senior levels (extensive RPCV network). They are already reaching out to RPCV and are well funded. They can get an RPCV on board in a week. They have a few different hiring mechanisms that would be appropriate. **The scale and speed need to be ramped up substantially.**
4. I've reached out to contacts at national mayors and governors associations with no reply. Also no reply from CDC (Jernigan and Schuchat).

Next steps – when OpEd comes out, amplify multiple levels to publicize and create demand.

The need for this is great. The feasibility looks very good.

Please share your suggestions.

Thanks to all,
PK

From: Kilmarx, Peter (NIH/FIC) [E]

Sent: Tuesday, March 24, 2020 6:02 PM

To: Charles Holmes (b) (6); Angela Dunn (b) (6); Cindy Burnett (b) (6); Conover, Craig (b) (6) Duchin, Jeff

(b) (6); Glass, Roger (NIH/FIC) [E] (b) (6); Glenn Blumhorst

(b) (6); Stephen Morrison (b) (6) John Monahan (b) (6)

Subject: RE: Call - follow-up: COVID-19 Response Corps

Hi again,
A draft Op Ed attached. It is largely drawn from the concept note.

Is there an appropriate champion among us who can take this forward?

Please share your suggestions and comments by noon tomorrow if possible.

Thanks,

PK

From: Kilmarx, Peter (NIH/FIC) [E]
Sent: Tuesday, March 24, 2020 2:17 PM
To: Charles Holmes (b) (6) >
Cc: Angela Dunn (b) (6) >; Cindy Burnett (b) (6); Conover, Craig (b) (6); Duchin, Jeff (b) (6) >; Glass, Roger (NIH/FIC) [E] (b) (6) >; Glenn Blumhorst (b) (6)
Stephen Morrison (b) (6); **John Monahan** <(b) (6)>
Subject: RE: Call - follow-up: COVID-19 Response Corps

Thanks Charles. This is very helpful.

I've updated the concept note – attached. Now a two-pager. Added training and prevention bullet. Decreased the numbers and budget based on feed back to date. Draft OpEd forthcoming.

Grateful if others can advocate as they are able (and others of us are not).

Glenn – please add anything on your meetings on the hill yesterday, the FEMA call, or advocacy plans.

My takeaway is that a FEMA disaster corps or FEMA-Americorps Corps is feasible.

- Call yesterday with Glenn and former FEMA staff: George Haddow and Micheal Coen
 - FEMA Corps is a partnership of FEMA and Americorps with about 1,200-1,800 members. Part of Americorps. FEMA pays 100%. Mainly younger, lower-skilled supervised work.
 - FEMA reservist disaster corps has 3,000-4,000 members. Mostly shorter-term deployments as temp employees. Many retired military. Can be activated with State of Emergency declarations.
 - FEMA currently has sent 3-4 liaisons to each state. Disaster corps not activated.
 - Onboarding 5,000 would be a big lift. Peace Corps has seconded staff to other agencies in past, so this could be an option.
 - Only private sector partner for FEMA is Red Cross. Not recommended for this.

More input:

- Jen Kates (KFF) and her colleague Josh Michaud – “think it is a great idea”
- Tom Frieden – “It’s a good idea.”
 - Robynn Leidig, Manager, Strategic Initiatives, Resolve To Save Lives – “Compelling idea and worth exploring”
 - Concern about risk to RPCVs, training and oversight needed
 - Lack of PPE, best to focus on tasks that don’t need PPE
 - Resentment of current staff worried about threat to their jobs
 - Fairness: should open to others - Americorps, VISTA, CDC PHAP, CSTE fellows, USAID Global Health Fellows
 - Management absorptive capacity limited at CDC. Consider ASTHO/ NACCHO or PHI.

From: Charles Holmes <(b) (6)>
Sent: Tuesday, March 24, 2020 7:36 AM
To: Kilmarx, Peter (NIH/FIC) [E] <(b) (6)>
Cc: Angela Dunn <(b) (6)>; Cindy Burnett <(b) (6)>; Conover, Craig <(b) (6)>; Duchin, Jeff <(b) (6)>; Glass, Roger (NIH/FIC) [E] <(b) (6)>; Glenn Blumhorst <(b) (6)>; Stephen Morrison <(b) (6)>
Subject: Re: Call - follow-up: COVID-19 Response Corps

Sen Van Hollen's office is interested and I'm slated to talk w them later today or tomorrow. Interested to know how the idea was received by others on the Hill. Best

On Mon, Mar 23, 2020 at 7:44 AM Kilmarx, Peter (NIH/FIC) [E] <(b) (6)> wrote:

Thanks Charles.

Draft OpEd forthcoming today. Everyone please think about authors.

Bill Frist and Tom Daschle? <https://www.rollcall.com/2018/07/09/opinion-an-open-health-diplomacy-hand-works-better-than-a-fist/> By Tom Daschle and Bill Frist, July 9, 2018.

From: Charles Holmes <(b) (6)>
Sent: Monday, March 23, 2020 7:37 AM
To: Kilmarx, Peter (NIH/FIC) [E] <(b) (6)>
Cc: Angela Dunn <(b) (6)>; Cindy Burnett <(b) (6)>; Conover, Craig <(b) (6)>; Duchin, Jeff <(b) (6)>; Glass, Roger (NIH/FIC) [E] <(b) (6)>; Glenn Blumhorst <(b) (6)>; Stephen Morrison <(b) (6)>
Subject: Re: Call - follow-up: COVID-19 Response Corps

Great feedback, Peter. More from Vanessa Kerry:

"Initial reaction is that this is fantastic and I would be happy to help in any capacity to support it. Please let me know how. Devil is in the details and the training of course. Truly a smart idea though"

Charles

On Mon, Mar 23, 2020 at 7:11 AM Kilmarx, Peter (NIH/FIC) [E] <(b) (6)> wrote:

Thanks Craig. This looks very comprehensive and something a trained RPCV (returned Peace Corps Volunteer) could help implement.

Glenn – good luck on the Hill today. Will be eager to hear about the reception.

Some feedback from others:

- John Monahan (Georgetown) – "Very creative, kudos!"

- Try to get authority on one of these COVID-19 response bills for returning Peace Corps folks to be redeployed notwithstanding other provisions of law.
 - Explore whether CRC could be incorporated into the programs FEMA already has to bring in short-term employees to help with emergency responses.
 - Some functions (home-delivered meals, staffing call centers, homeless populations and shelters) would more sense to supplement programs run by Americorps.
 - Cost seems high.
- Scott Dowell (Gates Foundation) – “A good and important idea”
 - Need a massive surge in the public health and community testing workforce over the coming months.
 - They are considering engaging the 30,000 medical students through AMSA (American Medical Student Association).
 - Tom Inglesby (Johns Hopkins) – “A fantastic idea and am very supportive”
 - Important issue to be worked through: How to address risk to individuals involved? (My response: training, equipping, and monitoring. Will add to next iteration of concept note. Note that Singapore has had no infections in HCW and in China after January/Wuhan, most HCW infections were from home, not from work.)
 - Tom’s working on concept to engage presumably immune COVID-19 survivors (as was done with Ebola).
 - Jeremy Konyndyk (CGD) – “Great idea.”
 - Need to think creatively about how to expand the public health workforce for the coming 18 months, especially for tasks like contact tracing. We’ll need to view CDC and local health dept folks not as boots on the ground but rather as force multipliers - sharing their skills with others and mentoring/managing larger teams to extend their reach.

From: Conover, Craig (b) (6) >
Sent: Sunday, March 22, 2020 5:01 PM
To: Kilmarx, Peter (NIH/FIC) [E] (b) (6); Stephen Morrison (b) (6)
 Glass, Roger (NIH/FIC) [E] (b) (6) >; Charles Holmes
 (b) (6); Glenn Blumhorst (b) (6)
 (b) (6); Duchin, Jeff <(b) (6)>; Angela Dunn
 (b) (6) >; Cindy Burnett (b) (6) >
Subject: Re: Call - follow-up: COVID-19 Response Corps

Thanks for all your work on this, Peter!

Re LTCs--attached is a draft document listing all the capabilities that need to be in place for LTCFs to respond to Covid-19.

Developing and disseminating guidance aimed at LTCFs is relatively easy--the failures are going to be around implementation.

This is one area where assistance would be valuable.

CC

From: Kilmarx, Peter (NIH/FIC) [E] (b) (6)>
Sent: Sunday, March 22, 2020 3:16 PM
To: Stephen Morrison <(b) (6)>; Glass, Roger (NIH/FIC) [E] (b) (6); Charles Holmes (b) (6)>; Glenn Blumhorst (b) (6) Duchin, Jeff (b) (6)>; Conover, Craig (b) (6); Angela Dunn (b) (6); Cindy Burnett (b) (6)
Subject: [External] RE: Call - follow-up: COVID-19 Response Corps

Thanks all for our call and support for this concept. Please let me know any critical additions or corrections to these notes.

- Jeff Duchin (Seattle) noted multiple possible roles in contact tracing, mitigation with homeless and incarcerated, adverse consequences of social distancing, infection control support, alternative care site coordination, lab specimen collection and transport. He shared concerns about infection prevention and their PPE shortage. CDC had 40 people deployed, but they departed. Longer deployments (e.g., >90 days) needed to validate onboarding and training effort. He will follow up with more detail on potential roles and numbers.
- Angela Dunn (Utah) agreed with roles in contact tracing, also staffing a call center, rural outreach and specimen collection. She said Utah was not a current priority for FEMA and CDC was conducting a transmission study. She shared Jeff's concern about the onboarding effort.
- Cindy Burnett (Utah) mentioned the need for social support in rural settings.
- Craig Conover (Illinois) added that for them the long-term care centers and homeless populations were priority concerns. It would be feasible and helpful to have staff able to collect specimen swabs.
- Charles Holmes (Georgetown) made an analogy to community health workers in Zambia and how much can be accomplished and enhanced with tablet-based approaches, workflow apps, and video instructions.
- Steve Morrison (CSIS) emphasized the importance of finding an organizational home, mentioning potential challenges for both CDC and FEMA. He noted timing of response packages being considered, the hunger for creative ideas, and urgency for this to be brought forward. He noted potential champions, listed with others below. He thinks the Peace Corps connection is a compelling factor.
- Glen Blumhorst (NPCA) expressed his support and insights on potential champions, e.g., three RPCV in the house. He is going to Capitol Hill tomorrow.
- Jody Olsen (Peace Corps) (prior to the call) expressed interest and noted that Peace Corps has no authority to operate in the United States. (The possibility of an Executive Order

detailing returned volunteers from Peace Corps to state and local authorities was mentioned by others on the call.) She also noted that Barbara Stewart, Director of CNCS (AmeriCorps and VISTA) has been inviting RPCVs to join.

Next steps:

1. Revise document (done, attached) to be shared with subject matter experts and potential champions. (There was not an exact delineation of who would share with whom. I will aim to CC; or ask for help with some contacts.)
2. Will draft Op-Ed in next 2 days.

Action: Share concept sheet with SMEs and champions avoiding any obvious minefields and duplication. Report back useful feedback.

SMEs/champions:

- Tom Ingelsby
- Beth Cameron
- Jeremy Konyndyk
- Rebecca Katz
- Scott Gottlieb
- Tom Frieden
- Scott Dowell
- John Monahan

Champions:

- Paul Allen Foundation
- Dick Durbin
- Biden campaign
- Chris Christie
- Carrie Hessler-Radelet
- Aaron Williams
- Patrick Leahy
- Chris Van Hollen
- Dick Durbin
- Debbi Bix
- Donna Shalala (RPCV – Iran 1962-64)
- Joseph P. Kennedy III (RPCV Dominican Republic 2004-06)
- John Garamendi (Ethiopia 1966-68)
- Aumua Amata (PC staff Northern Mariana Islands 1967-68)

Note – GS-7, Step 1 salary is \$37,301, Step 5 is \$42,273. I've re-set the budget at \$100,000 per person to account for benefits, training, travel, per diem, management, evaluation, PPE, phones, laptops, etc.

From: Kilmarx, Peter (NIH/FIC) [E]

Sent: Sunday, March 22, 2020 12:35 PM

To: Stephen Morrison (b) (6); Glass, Roger (NIH/FIC) [E] (b) (6); Charles Holmes <(b) (6)>; Blumhorst, Cathy (NIH/NINR) [E]

(b) (6); Glenn Blumhorst (b) (6);
(b) (6) Olsen, Jody (b) (6); Duchin, Jeff
(b) (6); Conover, Craig (b) (6) Angela Dunn
(b) (6)>

Subject: RE: Call: COVID-19 Response Corps

Hi all,

I'm looking forward to our WebEx meeting in 90 minutes. The concept note (unchanged) is attached. The WebEx info is below.

Here's an updated agenda:

1. Welcome and introductions
2. Background and proposal
3. Round robin perspectives
 - a. Public health – WA, IL, UT
 - b. Peace Corps – Jody
 - c. Strengthening the concept - all
 - d. Advocacy - all
 - e. Implementation - all
4. Next steps and way forward

-----Original Appointment-----

From: Kilmarx, Peter (NIH/FIC) [E]

Sent: Saturday, March 21, 2020 9:29 PM

To: Stephen Morrison; Glass, Roger (NIH/FIC) [E]; Charles Holmes; Blumhorst, Cathy (NIH/NINR) [E]; Glenn Blumhorst; (b) (6) Olsen, Jody; Duchin, Jeff; Conover, Craig; Angela Dunn

Subject: Call: COVID-19 Response Corps

When: Sunday, March 22, 2020 2:00 PM-3:00 PM (UTC-05:00) Eastern Time (US & Canada).

Where: WebEx

Please join tomorrow for WebEx discussion of developing a U.S. COVID-19 Response Corps. Concept sheet attached.

Agenda:

1. Welcome and introductions
2. Background and proposal
3. Round robin perspectives
4. Discussion
5. Next steps and way forward

-- Do not delete or change any of the following text. --

Join Webex meeting

Meeting number (access code): (b) (4) Meeting password: (b) (4)

Join from a video system or application

Dial (b) (4)

You can also dial (b) (4) and enter your meeting number.

Join by phone

Tap to call in from a mobile device (attendees only)

1-650-479-3208 Call-in toll number (US/Canada)

Global call-in numbers

Join using Microsoft Lync or Microsoft Skype for Business

Dial (b) (4)

Can't join the meeting?

If you are a host, [go here](#) to view host information. **IMPORTANT NOTICE:** Please note that this Webex service allows audio and other information sent during the session to be recorded, which may be discoverable in a legal matter. By joining this session, you automatically consent to such recordings. If you do not consent to being recorded, discuss your concerns with the host or do not join the session.

State of Illinois - CONFIDENTIALITY NOTICE: The information contained in this communication is confidential, may be attorney-client privileged or attorney work product, may constitute inside information or internal deliberative staff communication, and is intended only for the use of the addressee. Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify the sender immediately by return e-mail and destroy this communication and all copies thereof, including all attachments. Receipt by an unintended recipient does not waive attorney-client privilege, attorney work product privilege, or any other exemption from disclosure.

--

Charles B. Holmes, MD, MPH

Professor of Medicine

Faculty Co-Director, Center for Global Health Practice and Impact

Georgetown University Medical Center

Building D, Suite 120

4000 Reservoir Rd NW, Washington DC 20057

Phone (b) (6)

--

Charles B. Holmes, MD, MPH

Professor of Medicine

Faculty Co-Director, Center for Global Health Practice and Impact

Georgetown University Medical Center

Building D, Suite 120

4000 Reservoir Rd NW, Washington DC 20057

Phone (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 13 Apr 2020 15:25:44 +0000
To: Corey, Larry
Subject: FW: perhaps useful in the physical mitigation battle to buy 6 weeks
Attachments: [REDACTED] (b) (4)

Larry:

I will call you about this today. This is really important. [REDACTED] (b) (4)

[REDACTED]
Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Eisinger, Robert (NIH/NIAID) [E] [REDACTED] (b) (6) > **On Behalf Of** Fauci, Anthony (NIH/NIAID) [E]
Sent: Monday, April 13, 2020 7:10 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: FW: perhaps useful in the physical mitigation battle to buy 6 weeks

An email below from Larry Corey.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: [REDACTED] (b) (6)
Email: [REDACTED] (b) (6)

From: Corey MD, Larry (b) (6) >

Sent: Sunday, April 12, 2020 11:31 PM

To: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>; Marston, Hilary (NIH/NIAID) [E]
(b) (6) >

Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Subject: perhaps useful in the physical mitigation battle to buy 6 weeks

Here is data from Seattle up to this weekend

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 13 Apr 2020 14:37:16 +0000
To: Auchincloss, Hugh (NIH/NIAID) [E]
Subject: RE: Wayne and Catherine Reynolds and Bob Langer/MIT innovations

Thanks!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Auchincloss, Hugh (NIH/NIAID) [E] (b) (6)>
Sent: Monday, April 13, 2020 8:12 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: RE: Wayne and Catherine Reynolds and Bob Langer/MIT innovations

Possible response below:

Dear Wayne,

(b) (5)

Please give my best to Catherine and take care during these difficult times.
Best personal regards,
Tony

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Sent: Sunday, April 12, 2020 9:27 PM

To: Auchincloss, Hugh (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Subject: FW: Wayne and Catherine Reynolds and Bob Langer/MIT innovations

Hugh:

Please take a look at these 3 ideas. You may have heard of Bob Langer. He is somewhat of an inventive genius with whom we have worked before. I need to get back to Wayne and Catherine and I would like your help in my fashioning a response.

Thanks,

Tony

From: WAYNE REYNOLDS [REDACTED] (b) (6)
Sent: Monday, April 6, 2020 2:08 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Cc: Grady, Christine (NIH/CC/BEP) [E] [REDACTED] (b) (6)
Subject: Wayne and Catherine Reynolds and Bob Langer/MIT innovations

Tony,

Obviously, you have a few other issues on your daily agenda but, when you have a minute, we would appreciate your thoughts and guidance on three new Bob Langer biotech developments. We have attached three links to recent MIT News articles. These three innovations at the Langer Lab were originally funded by the Gates Foundation. We thought the last two breakthroughs, in particular, may be applicable to your current work. Thank you again for your continued guidance.

Best wishes,

Wayne Reynolds

Cell: [REDACTED] (b) (6)

Home: [REDACTED] (b) (6)

Heat stable micronutrients for better nutrition

<http://news.mit.edu/2019/micropartides-fight-malnutrition-1113>

On-patient invisible vaccination record

<http://news.mit.edu/2019/storing-vaccine-history-skin-1218>

Self-boosting vaccine platform for faster and stronger immune response

<http://news.mit.edu/2017/one-vaccine-injection-could-carry-many-doses-0914>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 13 Apr 2020 13:03:45 +0000
To: Jenny Fauci
Cc: [REDACTED] (b) (6)
Subject: RE: FW: Google Alert - Fauci AND Tony OR Anthony

[REDACTED] (b) (6)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [REDACTED] >
Sent: Monday, April 13, 2020 7:55 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Cc: [REDACTED] (b) (6)
Subject: Re: FW: Google Alert - Fauci AND Tony OR Anthony

Just finished it. Wow. [REDACTED] (b) (6)

On Sat, Apr 11, 2020 at 1:27 PM Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) > wrote:

If you have time, click to link on the bottom: "How Anthony Fauci Became America's Doctor". It is a long article in *New York* magazine written by Michael Spector a former Washington Post and NY Times writer who has known me for over 30 years. It is the most comprehensive report on me and my career – very insightful.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Google Alerts <googlealerts-noreply@google.com>
Sent: Saturday, April 11, 2020 11:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Google Alert - Fauci AND Tony OR Anthony

Google Alerts

Fauci AND Tony OR Anthony

As-it-happens update - April 11, 2020

WEB

Fauci: Virus antibody tests expected next week

North Platte Post

Dr. **Anthony Fauci** answers questions during Thursday's Coronavirus Task Force briefing.
WASHINGTON — The top U.S. infectious disease official ...



[Flag as irrelevant](#)

anthony fauci

The Bulwark Podcast

anthony fauci, anti-anti-trumpism, china, coronavirus, covid-19, donald trump, elections, hydroxychloroquine, masks, navy, peter navarro, white house, ...



[Flag as irrelevant](#)

CBS Evening News with Norah O'Donnell

Facebook

Dr. **Anthony Fauci** of the National Institute of Allergy and Infectious Diseases (NIAID): "This is not the time to feel that, since we have made such...



[Flag as irrelevant](#)

How **Anthony Fauci** Became America's Doctor by Michael Specter

Longform

A profile of the doctor who has run the National Institute of Allergy and Infectious Diseases for 36 years.



[Flag as irrelevant](#)

You have received this email because you have subscribed to **Google Alerts**.

[Unsubscribe](#)



[Receive this alert as RSS feed](#)

[Send Feedback](#)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 13 Apr 2020 10:16:00 +0000
To: Nicola Pizzoli
Subject: RE: COVID 19: Possible main cause of fatalities, it could be not respiratory

Thank you, Nicola

From: Nicola Pizzoli (b) (6)
Sent: Monday, April 13, 2020 6:07 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: COVID 19: Possible main cause of fatalities, it could be not respiratory

Good morning Dr Fauci,

I've been following you on COVID briefings from the White House every night. I trust your experience, professionalism and above all your wisdom in these weeks.

While I am a mechanical engineer and I run my food company for living, I have been interested and passionate to the global fight to the Coronavirus.

SUGGESTION: Could it be possible that people die of pulmonary micro thrombosis rather than respiratory issues? If this is the case, this is more a cardiovascular issue than a respiratory, and ventilation or intubation do not count as much as, instead, to give patients some drugs to prevent the thrombosis, such as ANTI-INFLAMMATORIES. If you ventilate a lung where blood doesn't get there, may be it's useless! In fact 9 out of 10 die. If the problem were cardiovascular and not respiratory, then it could be a venous microthrombosis and not pneumonia that determines fatality. And why are thrombi formed? Because there is an inflammation that induces thrombosis through a complex but well-known pathophysiological mechanisms.

I know this thesis is right the contrary of some recommendations that several doctors all over the world (in China first) had made so far: no ibuprofene, no antibiotics etc etc.

But I believe that some researches on the cardiovascular problem induced by inflammation would be worth doing it.

An apology for my English.
Thank you for your attention,

Stay healthy!
Kindest regards

Nicola

Nicola Pizzoli
President & CEO

T (b) (6) - C + (b) (6) - F +39 0516920293

Pizzoli S.p.A.
Via Zenualino Nord, 1 - 40054 Imbriù - Bologna



www.pizzoli.it

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 13 Apr 2020 02:17:18 +0000
To: (b) (6) (NIH/NHLBI) [E]
Cc: Redfield, Robert R. (CDC/OD)
Subject: RE: Comparison of COVID-19 statistics in US vs. China

(b) (6)

Thank you for your note. This pandemic has been extremely challenging for many countries around the globe including China and the USA. I can only say that I (and I am sure that Bob Redfield feels the same way) prefer to look forward and not to assign blame or fault. There are enough problems ahead that we must face together.

Best regards,

Tony

From: (b) (6) (NIH/NHLBI) [E] (b) (6) >
Sent: Sunday, April 12, 2020 9:51 PM
To: Redfield, Robert R. (CDC/OD) (b) (6) Fauci, Anthony (NIH/NIAID) [E]
(b) (6) >
Cc: (b) (6) (NIH/NHLBI) [E] (b) (6) >
Subject: RE: Comparison of COVID-19 statistics in US vs. China

Dear Dr. Redfield and Dr. Fauci,

After some hesitation, I decided to write you this message anyway and hope you don't mind.

I am concerned about the recent fight between the US and WHO because it may adversely impact the current global efforts in controlling the spread of COVID-19. As we all know, US has been leading WHO's efforts for decades and essentially WHO's role is mostly coordinating responses in low- and middle-income countries with support from the US and other high income countries. Frankly I was looking for leadership from the US CDC rather than WHO when I was doing (b) (6). Until COVID-19 is controlled in all countries, the infection could come back to hit us in this country again. Therefore it is now the worst time to undermine WHO's global coordinating capabilities.

What I learned from my former colleagues and friends in (b) (6) where I attended medical school and obtained my MSc in epidemiology might offer some explanation for the differences in COVID-19 statistics in US vs. China. Please find attached a couple of articles published by my former colleagues (b) (6), of which the 1st attachment is a more updated version.

- First, the maximum lockdown in Wuhan that started on January 23 and also in the rest of the entire Hubei province of 59 million people during the subsequent 2-3 days, coupled with maximum efforts in early identification, immediate isolation of identified infected individuals and close monitoring of contacts, did work and had to work according to epidemiological principles. China did it by invoking level 1 public health response that was historically reserved for smallpox, plague or cholera, which essentially enabled the entire country to be completely locked down for several weeks. Many villages and townships set up checkpoints to refuse

anyone to come in or go out; a driver from Hubei had to stay on an inter-provincial highway for 20 days surviving by begging instant noodles from people policing exits; all front doors of residents in a township in Hubei were sealed by local government officials and volunteers to prevent them from getting out of their houses.

- Second, there must be under-reporting of COVID-19 cases and deaths because the public health and hospital systems in Wuhan and a few other hardest hit municipalities were overwhelmed for one to two weeks; conceivably many infected individuals were not getting a chance for testing and some of them must have died without being identified as COVID-19. I'd say that this kind of under-reporting is unavoidable, especially in the epicenter of a new pandemic. Actually I suspect that such under-reporting could have happened in this country as well although perhaps to a lesser degree.
- Third, there could be a third category of casualties, that is, patients who were suffering from chronic diseases but couldn't get necessary treatments because hospitals were overwhelmed. I read a sad story in social media in which a patient who needed frequent dialysis committed suicide by jumping out of his window. It is highly likely that many such patients died during the lockdown even though I couldn't confirm the specific case or find any statistics. There could be many other collateral damages including socio-psychological effects.

Combined, the effect of the maximum lockdown, the under-reporting of COVID-19 cases and COVID-19 deaths as well as collateral deaths of other causes that were associated with the lockdown could be several times of the reported statistics from China. Here I'd not say that China purposely under-reported COVID-19 cases or deaths but rather, China pursued an extreme approach and achieved an extreme result, including severe collateral damages. Of note, Dr. Li Wenliang (the whistleblower) voiced concern on 12/30/2019 and was criticized for having not followed the legally proper reporting process but nevertheless the WHO China Office was informed on 12/31/2019 of a pneumonia of unknown cause, detected in the city of Wuhan in Hubei province, China (<https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen>).

We in the US and many other countries pursued different approaches, which are more humane but less effective in terms of blocking transmissions. This is the reality, which needs to be communicated with and recognized by the public; to make the humane approaches work as effectively as possible, we need everyone's support and cooperation, which cannot be achieved by blaming China or WHO. The public has to understand that we are in a pandemic, which means that tens of millions are supposed to be infected and millions are supposed to die from it, unless we take necessary actions to block the transmission and to take good care of the infected.

Finally, I'd like to say a few words for public health colleagues in China. In my personal view, to be fair, they have done their best to inform the global public health community of the COVID-19 outbreak in Wuhan, China by briefing WHO and many countries as soon as they identified COVID-19 (12/31/2019 – 1/3/2020); they shared the genetic sequence of the virus on 1/12/2020; and the number of scientific and medical publications in English shortly afterwards was unprecedented. I did a brief search and identified the following:

A Novel Coronavirus from Patients with Pneumonia in China, 2019 (1/24/2020)
<https://www.nejm.org/doi/full/10.1056/NEJMoa2001017>

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster (1/24/2020)
<https://www.sciencedirect.com/science/article/pii/S0140673620301549?via%3Dihub>

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China (1/24/2020)

[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)30183-5/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30183-5/fulltext)

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia (1/29/2020)

<https://www.nejm.org/doi/full/10.1056/NEJMoa2001316>

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding (1/30/2020)

[https://www.thelancet.com/article/S0140-6736\(20\)30251-8/fulltext](https://www.thelancet.com/article/S0140-6736(20)30251-8/fulltext)

A new coronavirus associated with human respiratory disease in China (2/3/2020)

<https://www.nature.com/articles/s41586-020-2008-3>

Early estimation of the case fatality rate of COVID-19 in mainland China: a data-driven analysis (2/12/2020)

<http://atm.amegroups.com/article/view/36613/html>

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China (2/24/2020)

<https://jamanetwork.com/journals/jama/fullarticle/2762130>

It is my hope that US and China could join forces to help low- and middle-income countries to control the pandemic so that it will not come back and hit us again after the current wave in this country is controlled.

I am not sending this message through the official channel because this is not part of my official duty and is purely my personal opinion.

Sincerely,

(b) (6)



Doing human subjects research? New policies will impact you! [Learn more](#).
Looking for NHLBI Clinical Trial Funding Opportunities? Learn more [here](#).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 13 Apr 2020 01:37:27 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: [COVID-19 Pneumonia] Official Letter from ImmuneMed Inc.
Attachments: Official Letter from ImmuneMed-NIAID.pdf

Please take a look at this and respond.

From: Sungpill Park <sppark@immunemed.co.kr>
Sent: Sunday, April 12, 2020 9:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: [COVID-19 Pneumonia] Official Letter from ImmuneMed Inc.

Dear **Dr. Anthony S. Fauci**,

My name is Sungpill Park, and I'm a representative of ImmuneMed, Inc. located in Korea.

We specialize in diagnosing and treating the infectious diseases.

Our company's **hzVSF(humanized Virus Suppressing Factor) v13** is under curable usage for COVID-19 pneumonia, utilizing Korea's compassionate use system for patients who do not have an alternative treatment.

I am writing with a strong conviction that the partnership between **the National Institute of Allergy and Infectious Diseases** and ImmuneMed, Inc. will bring the decrease of death rate for COVID-19 pneumonia.

I ask you humbly to please spend a minute of your busy time reading the attached letter from our CEO, Dr. Yoon-Won Kim, to find out more about the hzVSF treatment and how we can work together to cure COVID-19 pneumonia patients.

With Regards,

Sungpill Park, MBA

Vice President, Global Business Development
ImmuneMed, Inc.

C: (b) (6) / E: sppark@immunemed.co.kr

W: www.immunemed.co.kr/en/

***Notice :** The above message (and any attachment) is intended solely for the named address and may contain information that is privileged, confidential or otherwise protected under applicable law. Any unauthorized dissemination, distribution, copying or use of the information contained in this communication is strictly prohibited. If you have received this communication in error, please notify the sender by email and erase this communication immediately.*

- Tony Fauci will discuss the US pandemic and provide his perspective as a member of the White House Coronavirus Task Force addressing the 2019–20 coronavirus pandemic.
- George Gao will discuss China's response to the pandemic and lessons learned for the rest of the globe.
- Susan Weiss will discuss the viral characteristics of SARS COV2 , insights into its pathobiology, immunity and development of a pan-CoV antiviral.
- Richard Hatchett will discuss the development of new vaccines and treatments against COVID-19.
- Sanjay Gupta will comment on the health system response to the pandemic and challenges related to communication and public engagement in responding to COVID-19.

Following remarks from each panelist, we will have a moderated discussion amongst ourselves – I will ask you a set of questions (15 mins) and then we will take questions from the web (25 mins). To prepare me to be your moderator, please send me any questions you would like me to ask you. For those of you who would like to have a prep call, please let me know and I will set it up.

Best,
Victor

From: Mun, Jenny <JMun@nas.edu>

Sent: Wednesday, April 8, 2020 10:56 AM

To: [REDACTED] (b) (6)

[REDACTED]
[REDACTED]
[REDACTED]

Cc: Dzau, Victor J. <VDzau@nas.edu>; [REDACTED] (b) (6) Mun, Jenny <JMun@nas.edu>; Hannon, Emma <EHannon@nas.edu>; [REDACTED] (b) (6)

[REDACTED]
[REDACTED]

'ben.tinker@cnn.com' <ben.tinker@cnn.com>; 'Amanda.Sealy@cnn.com' <Amanda.Sealy@cnn.com>; 'Neel.Khairzada@turner.com' <Neel.Khairzada@turner.com>; 'Tia.Miller@turner.com' <Tia.Miller@turner.com>

Subject: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear Speakers:

I am the logistical contact for the COVID-19 session that will be held as part of the Annual Meeting (online) program on Saturday, April 25 at 2:00 pm EDT. Thank you for agreeing to participate in this session. To help you with your planning, I have provided additional details below.

Please note that the session will be live webcast and the general public will also be able to watch the session. Video from the session will also be uploaded on the NAS YouTube channel (<https://www.youtube.com/user/theNASciences>) after the meeting. We will need to obtain signed speaker release forms for your participation in this session. I have attached the speaker release form for your review and submission. **Please return the signed speaker release form by Monday, April 13.**

Session speakers are asked to connect 30 minutes prior to the session start time (**by Saturday, April 25 at 1:30 pm EDT**) to allow the technical staff to check connections and prepare for the session. Details on how to connect will be sent before the meeting.

We will list you in our promotional materials as noted below. If this is incorrect, please let me know.

Anthony S. Fauci, Director, National Institute of Allergy and Infectious Diseases

Jeremy Farrar, Director, Wellcome Trust

George F. Gao, Director-General, Chinese Center for Disease Control & Prevention

Sanjay Gupta, Chief Medical Correspondent, CNN

Richard J. Hatchett, CEO, Coalition for Epidemic Preparedness Innovations

Susan R. Weiss, Professor of Microbiology, Perelman School of Medicine, University of Pennsylvania

Since many of us have moved to remote work environments, you may already be proficient with Zoom and other online meeting/collaboration applications. I am attaching a 'speaker guidelines' file in case you have any questions on how best to prepare for and stage your remote talk. We have technical staff available to help you become familiar with Zoom and its settings – such as “sharing your screen” (if you have slide presentations that need to be shown during your talk). We can arrange for a training session this week or next week. If you would like to schedule a session, please let me know as soon as possible.

Dr. Dzau's office will be in touch regarding the agenda for this session. If you have any other questions, please let me know.

Regards, Jenny

Jenny Mun

Membership Director

National Academy of Sciences

jmun@nas.edu

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 23:00:07 +0000
To: Seth Berkley (Private)
Subject: RE: Checking in

Thanks, Seth!

From: Seth Berkley (Private) [REDACTED] (b) (6) >
Sent: Saturday, March 28, 2020 3:48 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6) >
Subject: Checking in


Hi Tony: You are doing an amazing job during these very difficult times!

Doing everything we can here to support WHO to work on global acceleration of SARS-CoV-2 vaccine development as well as support our 73 poorest countries for COVID-19 preparation and hopefully keeping routine vaccine coverage as high as possible. We are prepared to ultimately roll out a vaccine when one is ready. No need to respond, but wanted to give you a friendly shout-out. We are all thinking of you!

Best,

Seth

**The private email account of
Dr Seth Berkley**



Chief Executive Officer
Gavi, the Vaccine Alliance

Tel: [REDACTED] (b) (6)
Skype [REDACTED]
Twitter @GaviSeth

Email: [REDACTED] (b) (6)



The Global Health Campus, Chemin du Pommier 40,
1218 Le Grand-Saconnex, Switzerland

Tel: (b) (6)

Web: <http://www.gavi.org>

With the support of donors and partners, Gavi, the Vaccine Alliance is working to immunise an additional 300 million children between 2016 and 2020, preventing a further 5-6 million deaths. Join us and help to reach every child. Visit www.gavi.org, sign up for the Gavi newsletter and follow us on Facebook and Twitter.

NOTICE: This email, including any attachments to it, may be confidential and does not create any binding contract on behalf of Gavi or its partners. If this email was sent to you in error, please notify the sender immediately by reply e-mail, and please do not use, distribute, retain, print or copy the e-mail or any attachment.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 22:58:02 +0000
To: Herbert Mathewson
Subject: RE: PERSONAL: My April 1 blog on Tony Fauci, CUMC (b) (6)

Hub:

Many thanks for your kind note.
Warm regards,
Tony

From: Herbert Mathewson (b) (6)
Sent: Saturday, March 28, 2020 1:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: PERSONAL: My April 1 blog on Tony Fauci, CUMC (b) (6)

Tony, I have been writing an annual April 1 column for 30 years, first in my monthly newsletter at Cape Cod Hospital and now as my biweekly blog of medical fun facts at www.hubslit.org. This is a heads up before publication of this year's April 1blog about you and Biden.

I suspect that most of our classmates are, like me, boasting a bit about having you as a classmate. Your honesty and "truthiness" is most appreciated and greatly valued by us amidst the leadership chaos. Your success at "walking the line" is extraordinary.
Enjoy. Hub

HUB's LIST of medical fun facts

A data-based biweekly newsletter of medical fun facts

- [Home](#)
 - [Hub's List of Medical Fun Facts](#)
-

Vol. 230 April 1, 2020 Biden Picks His Running Mate



Press Conference

Former Vice President

Joe Biden

April 1, 2020

(Official Transcript)

BIDEN: Good morning everyone. I am glad to see all you reporters sitting 6 feet from each other. I know it is burdensome, but we must work together to defeat this awful Zika. . . Rebola. . . the flu . . . er, what?, . . . I mean, you know, the Coroner virus.

Speaking of the current virus crisis . . . boy that has a nice ring to it, doesn't it? . . . it almost rhymes . . . I would like to announce my pick of a running mate; Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Disease of NIH since 1984. . . almost twenty. . . er. . . many years ago.



Now before I start to answer your questions, let me give you some reasons for my choice.

Number 1: Dr. Fauci is smarter than I am, but I am taller and younger than he is.

Number 2: He is very experienced. He has worked with many Presidential administrations since he came to Washington . . . in the 1980's as I remember. He told Ronald Reagan about the AIDS epidemic, advised two Bushs . . . one of them gave him the Presidential Medal of Freedom . . . by the way, Ben Carson got his medal during that same ceremony, . . . where was I? Oh, yeh . . . two Clintons . . . yes two, remember Hilary's Health Care Plan?. . . and, of course, Obama or two.

Number 3: He gives very good TV interviews, even on Fox News with Sean Hannity trying to mislead the viewers.

Number 4: His medical training has given him that special skill that all physicians must have to succeed — “Always sound right, and if you don’t know an answer, make one up.” But he is like one of my famous namesakes on Dragnet . . . Sergeant Joe Friday . . . “Just the facts, Ma’am.”

Now I’ll take your questions.

[Sounds of shouting, general loud babbling, a baby crying, a chair falls over]

REPORTER: “ Mr. Biden have you moved away from your promise to pick a female running mate?”

BIDEN: Did I say that? When was that? . . . Oh, it was during one of those debates? . . . I wouldn’t call it a promise. It was a statement from which I am now socially distancing myself, and that makes it a very timely question. . . .This social distancing is for the pits. I haven’t smelled a good head of hair in weeks. . . for the record, my test was negative . . . and I will ensure that women’s voices will be heard in my administration by appointing several to my cabinet. Elizabeth Warren naturally will be Secretary of the Treasury. Kamala Harris as an experienced prosecutor would be an excellent head of the Department of Justice . . . I think she is Latino too, isn’t she?. . . I am not sure about Senator Amy Klobuchar from Minnesota and she has great hair, but Marianne Williamson, . . . remember, the psychic healer. . . could serve as Chief of the Alternate Universe . . .excuse me, Alternate Therapies within HHS. Adding Senator Gillibrand to the cabinet would weigh the group too heavily towards New York, since Dr. Fauci is from Brooklyn. I will, of course, appoint Tulsi Gabbard as Ambassador to America Samoa.

REPORTER: “Do you have any concerns about any regrettable incidents in Dr. Fauci’s past?”

BIDEN: Not really. My staff has vetted him very thoroughly. The only whiff of scandal we found was his medical school yearbook picture where he was being lifted by two of his taller classmates so as to appear as even taller than they. None of them were in black face.



Also some people may have difficulty knowing how to pronounce his name correctly. It is pronounced as “Fow-chi” with the soft “c” sound common to

many Italian names, . . . and as the Senator from Nevada I wish to say that I have many Italian-American friends who are hard-working, decent citizens, but I must excuse myself from this Corleone hearing for another important committee meeting . . . oh, sorry . . . was I channeling the Godfather again?. . . a great movie.

There is another small concern, since he is from New York City and his name ends in a vowel people may think he is associated with Rudy Giuliani. . . . but we know that he is taller than Mike.

We have completely debunked the New Yorker Magazine stories that Dr. Fauci has recommended internal alcohol to kill the coronavirus since external alcohol really doesn't work. In fact, he only recommended it as an antidote to the daily briefings of the White House Coronavirus Task Force. Dr. Fauci also noted that internal alcohol effects may be briefer than the briefings, so viewers may repeat a dose PRN (as necessary).

REPORTER: "Is it true that as noted in your background Press Release just handed out that Dr. Fauci was born on Christmas Eve, and are you concerned about any back lash from Trump supporters who regard Trump as the Second Coming."

BIDEN: Dr. Fauci is an American. Even though he was born in Brooklyn, there is no question about his citizenship eligibility for this office. I think that a resurgence of the Birther Movement which was so viscosly directed at my close friend and mentor, Barrack Obama, . . . there I finally got his name out there. . . would be very unfortunate. Next question.

REPORTER: "Has Dr. Fauci made any significant contributions in fields other than virology and infectious diseases."

BIDEN: Well let me tell you a down-to-earth, fascinating story of one of his most significant contributions. It will be a short one, I promise. Since the Coroner virus pandemic has taken over all the headlines, editorial pages, social media memes, political cartoons, TV shows, graphic artist shops, and a lot of other things swamping articles about the Opioid Deaths epidemic, Dr. Fauci has developed a new attention-getting graphic to replace the familiar 1-10 faces of pain levels; the 1-4 faces of Pandemic Panic levels.



REPORTER: "But face 4 is the same as face 2. Isn't that a confusing message."

BIDEN: Exactly

"Thank you Mr. Biden, and **Happy April Fools Day.**"

PS: (b) (6) yearbook picture that won't be in the blog.

(b) (6)



This entry was posted on Saturday, March 28th, 2020 at 10:01 AM and is filed under [coronavirus](#), [current events](#), [humor](#), [Infectious Disease](#), [politics](#). You can follow any responses to this entry through the [RSS 2.0](#) feed. You can [leave a response](#), or [trackback](#) from your own site. [Edit this entry.](#)

Post navigati

RECENT ISSUES

○ [Vol. 229 March 15, 2020](#)
[Beware the Ides of March](#)

- [Vol. 228 March 1, 2020 Physician Speeders, Roundup Off One Hook, and Don't Shoot the Cows](#)
- [Vol. 227 February 15, 2020 Milk is NOT Good For You?!](#)
- [Vol. 226 February 1, 2020 Current Controversies . . . other than impeachment.](#)

•

• YOU
ARE FOLLOWING
THIS BLOG

You are following
this blog, along
with 216 other
amazing people
([manage](#)).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 22:38:10 +0000
To: Holdren, John P.
Subject: RE: Antiviral SNA white paper

Thanks, John.

From: Holdren, John P. (b) (6)
Sent: Wednesday, March 25, 2020 4:27 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: Antiviral SNA white paper

Dear Tony –

I know you are overwhelmed, but the attached whitepaper on a vaccine-development idea might be worth a look. You may remember Chad Mirkin as a member of the Obama PCAST whose extraordinary contributions across a range of science and engineering issues have landed him in the NAS, NAE, and NAM, among other distinctions—a very smart guy.

Aside from that, thank you for your courageous truth-telling in the incredibly demanding situation in which we find ourselves.

My best,
John

John P. Holdren
Teresa and John Heinz Professor of Environmental Policy
John F. Kennedy School of Government
Professor of Environmental Science and Policy
Department of Earth and Planetary Sciences
Affiliated Professor
John A. Paulson School of Engineering and Applied Science
HARVARD UNIVERSITY

Assistant: (b) (6)

From: Chad A Mirkin (b) (6)
Sent: Wednesday, March 25, 2020 3:57 PM
To: Holdren, John P. (b) (6)>
Cc: Robert A Lamb (b) (6); Andrew Lee (b) (6)
Subject: Antiviral SNA white paper

Thanks and best regards, Chad

Dr. Fauci's March Madness Bracketology Pickles

The diagram is a hand-drawn bracketology for a tournament. The teams are listed on the left and right sides. The central area contains a large oval with the signature '-Tony F.' and the word 'CHAMPION' in a dashed box. The diagram is dated 3/11/20.

Left Side (East to South):

- Coronavirus
- Coronavirus
- Norwalk
- SARS
- MERS
- MERS
- Smallpox
- Smallpox
- Chicken pox
- Measles
- Measles
- Measles
- Measles

Right Side (West to Mid West to South):

- Influenza H1N1
- Influenza H1N1
- Monkey pox
- West Nile
- West Nile
- Rabies
- Ebola
- Ebola
- Polio
- Hepatitis B
- Zika
- Zika

Central Area:

- Coronavirus
- Ebola
- Coronavirus
- CHAMPION
- Tony F.

Bottom:

- © 3/11/20
- (b) (6)

John T. Brooks, MD

Email: [REDACTED] (b) (6)

Apologies for errors in my messages that may be due to my need to dictate.



KEEP
CALM
AND
WASH
YOUR
HANDS



U.S. Department of
Health and Human Services
Centers for Disease
Control and Prevention

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 22:18:05 +0000
To: John Dirks
Subject: RE: Great leadership

John:

Thanks for the note, Much appreciated.

Best,

Tony

From: John Dirks [REDACTED] (b) (6)
Sent: Wednesday, March 18, 2020 5:24 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: Great leadership

Tony, I admire the tremendous leadership and expertise you are providing during this COVID-19 crisis—I know it not easy—but your advice is so credible and listened to, Best John Dirks

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 22:17:08 +0000
To: Lewis M Drusin
Subject: RE: Coronavirus

Thanks, Lew

-----Original Message-----

From: Lewis M Drusin [REDACTED] (b) (6)>
Sent: Wednesday, March 18, 2020 11:24 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: Coronavirus

Tony

When people ask me about coronavirus, I just tell them to listen to you. Your calm, steadfast explanation of the science is a major factor in the public trusting government to resolve this incredible public health crisis. Hope you are doing well.

Best wishes as always

Lew

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 20:21:16 +0000
To: El-Gabalawy, Nadia (PHAC/ASPC)
Cc: [REDACTED] (b) (6)
Subject: RE: Hello from Canada!

Nadia:

Many thanks for your kind note.
Best regards,
Tony

From: El-Gabalawy, Nadia (PHAC/ASPC) [REDACTED] (b) (6)
Sent: Monday, March 30, 2020 2:48 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: Hello from Canada!

Hi Dr. Fauci,

I thought I would reach out to you amidst this crisis; I respect the work you're doing a great deal. [REDACTED] (b) (6)
[REDACTED] Hani El-Gabalawy, did a research sabbatical at NIH [REDACTED] (b) (6)
[REDACTED]
[REDACTED]

Amazing work that you're doing. I've been following your discussions and scientific innovation regarding COVID-19. I've been working for the federal government in Intelligence for about thirteen years and recently moved to the Canadian Public Health Laboratory Network Secretariat to support the Emergency Operations Centre at the National Microbiology Lab. I've been with the NML for almost my whole career.

Just a quick hello and deep respect for your work. My colleagues and Director have said that we're on the exact same page as you, in terms of your perspective and assessment of the pandemic. Although there is a border between us, know that we are in agreement with your work and I'm thrilled to see you advising the public. There is no better person to do the job.

Kindest regards,

Nadia El-Gabalawy
Team Lead, Support Services, Canadian Network for Public Health Intelligence
Public Health Agency of Canada/Government of Canada

[REDACTED] (b) (6)
[REDACTED] (b) (6)

Chef d'équipe, Services de soutien, Réseau canadien de renseignements sur la santé publique
Agence de la santé publique du Canada / Gouvernement du Canada

[REDACTED] (b) (6)
[REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 20:19:01 +0000
To: Anderson, Jennifer (NIH/NIAID) [E]
Cc: Lane, Cliff (NIH/NIAID) [E]; Clifton, Dawn (NIH/NIAID) [E]
Subject: RE: LIR Requests for DIR Supplemental Funding (non-COVID related) - PLEASE REVIEW

Looks fine.

From: Anderson, Jennifer (NIH/NIAID) [E] (b) (6)
Sent: Monday, March 30, 2020 9:38 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Lane, Cliff (NIH/NIAID) [E] (b) (6); Clifton, Dawn (NIH/NIAID) [E] (b) (6)>
Subject: LIR Requests for DIR Supplemental Funding (non-COVID related) - PLEASE REVIEW

Hi Dr. Fauci,

Please review the attached requests for DIR Supplemental Funding on behalf of LIR investigators. I have further summarized the requests in the table below. I took the liberty to provide a suggested ranking based on funding need. Dr. Lane has reviewed the requests and agrees with the rankings as well.

(b) (5)

Sincerely,
Jennifer

PI	Supplement Description	Cost	Priority Order for LAB
(b) (5)			

Jennifer M. Anderson, PhD

Deputy Branch Chief

IAMB/OAS/NIAID

9000 Rockville Pike, Bldg. 10 Rm. 6A19A

Bethesda, Maryland 20892

Office Phone : (b) (6)

NIH Cell: (b) (6)

Personal Cell: (b) (6)

FAX: 301-402-4122

From: Fauci, Anthony (NIH/NIAD) [E]
Sent: Sun, 12 Apr 2020 20:18:33 +0000
To: Brian Kelsall
Subject: RE: What can be done?

Thanks, Brian. That recommendation is in the works.

From: Brian Kelsall (b) (6)
Sent: Monday, March 30, 2020 10:17 PM
To: Fauci, Anthony (NIH/NIAD) [E] (b) (6)
Subject: Fwd: What can be done?

Dear Tony,
I'm lucky to have thoughtful neighbors. Please see the email that I received from Sue Edwards. Because of the likelihood that there are so many asymptomatic cases, isn't it time to recommend everyone where a mask of some kind? Not N95 masks or even surgical masks that should be reserved for first responders and hospital staff, but some face covering?
Best, Brian

Sent from my iPhone

Begin forwarded message:

From: Sue Edwards (b) (6) >
Date: March 30, 2020 at 1:15:06 PM EDT
To: Brian Kelsall (b) (6)
Subject: What can be done?

Why can't the CDC make a public service announcement that everyone should be wearing some kind of mask ☹️ in public? It doesn't have to be N95 or even surgical though that would be ideal (as is done in every Asian country) given that the virus is actually aerosolized (several studies confirm this) and that it can be spread by asymptomatic carriers (which account for possibly more than half of the positive cases - we will never know) it seems obvious that food markets are no different from hospitals and in many cases worse since at least in hospitals people are wearing some protective equipment... just say wear a cotton mask, a scarf, a bandanna, a DIY paper towel mask.. whatever- but no one should be going to a market without one and absolutely no one working in a store or stocking supplies or delivering food, packages, mail etc should be allowed to work without something covering the face- this includes pharmacists as well, obviously ☹️ wtf is wrong with this country?

What use are gloves? When the offending particles are escaping our faces and floating around for several hours, landing on everything around us... the only place it shouldn't be as critical is outdoors in the sunshine where UV light should deactivate viruses fairly quickly...

Sue

Hope you are all well - and can give me some hope that this message get through the thick skulls of the so called experts... even during the 1918 flu epidemic, everyone wore some facial covering when out in public places - what is going on?

EVERY ASIAN country is employing this approach with much greater success at slowing the rate of transmission — even India!

<https://www.nytimes.com/2020/03/27/health/us-coronavirus-face-masks.html>

<https://medium.com/better-humans/a-practical-guide-to-covid-containment-orifice-by-orifice-80c2f3f167be>

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 20:07:20 +0000
To: Harold Slavkin
Cc: Collins, Francis (NIH/OD) [E]
Subject: RE: reaching out thinking of you

Hal:

Thanks for your note. These divergent phenotypes are truly puzzling. I have copied Francis on this e-mail in case he has any additional thoughts.

Best regards,

Tony

From: Harold Slavkin (b) (6)>
Sent: Thursday, April 2, 2020 4:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Fwd: reaching out thinking of you

Begin forwarded message:

From: "Harold C. Slavkin" (b) (6)>
Subject: reaching out thinking of you
Date: April 2, 2020 at 11:39:40 AM PDT
To: (b) (6)
Cc: "Somerman, Martha (NIH/NIDCR) [E]" (b) (6)>

Hi Toni,

You continue to be "the role model" for leaders in biomedical research these many decades. I am so proud of your efforts during these remarkable times in history. Thank you!!! I cherish those 5 years (1995-2000) that I served as Director of NIDR (that became NIDCR) when we were able to co-sponsor efforts to utilize saliva as an informative fluid for HIV detection. For me that was an invaluable opportunity to be part of

Harold Varmus' leadership team and to continue my research within NIAMS.

I was inspired by your public comments a few nights ago on CNN regarding your observations of significant variance in the pathogenesis or phenotypes noted for subsets of critically ill patients with COVID-19 on ventilators in ICU. I was immediately reminded of David Feinberg (CEO of UCLA Health Sciences, more recently 5 years at Geisingers, and currently CEO of Google Health Companies) who used genotyping for populations around Lancaster PA and discovered about 3-4% with undiagnosed genetic diseases that translated into reduced costs of hospitalization, treatments, etc. Kaiser-Permanente Northern California, and many other systems, have also used this approach since sequencing has become cost effective. Perhaps a select sample of people who require ICU, and another that require ventilator, might inform the genotype of the most susceptible people and might also inform a target to use to discover what existing drug or therapy could be mobilized. Through your position, might there already be a large data set of whole genome sequences (e.g. military) that could be rapidly explored using bioinformatics?

As you may recall, my personal research activities have focused on craniofacial diseases and disorders. For example, Osteogenesis Imperfecta (O.I.) presents cardiopulmonary disorders in addition to bone and

tooth disorders. Since penetrance varies, cases of rare conditions can illuminate “hidden” SNP abnormalities in key gene clusters (e.g. MHC gene clusters, etc.). Considering lung disorders as you mentioned in your comments about pathogenesis, already known gene mutations that present several major phenotypes including pulmonary diseases could become very useful. Perhaps Francis and others at the NIH could create a trans-NIH approach that is enabled to visit this pandemic from the perspective of human phenotype variance discovered via genomics?

I asked Martha Somerman to explore the talents available at NIDCR (and beyond) related to connective tissue genetic diseases that associate with Types 1 and 11 collagens, elastins, and hyaluronic acid glycoproteins AND lung tissue fibrosis, etc. She may also reach out to you.

Meanwhile, thank you for your untiring efforts to use science to inform health policy. Of course, let me know if I can be of any use to you.

Always, Hal

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 19:42:21 +0000
To: Susan Corrigan
Subject: RE: Coronavirus

Susan:

Thank for the note. I hope that all is well with you.
Best regards,
Tony

From: Susan Corrigan [REDACTED] (b) (6) >
Sent: Wednesday, April 1, 2020 10:29 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: Coronavirus

Dear Dr. Fauci,

I have seen quite a bit of you on television. I live in Miami now. South Florida is the epicenter of the coronavirus. I wish Governor DeSantis would shut down the state of Florida. Thank you from [REDACTED] (b) (6)

Susan Corrigan

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 19:41:04 +0000
To: Nader, Ralph
Subject: RE: COVID-19 Question

Ralph:

I am so sorry that I took so long to get back to you. I receive over 1000 e-mails per day and even with staff screening, I do not see them for days. There is still an issue/problem with serologic tests in that they need to be validated as being sensitive and specific. Many tests that have been used thus far are not accurate and ARE MISLEADING. The UK bought millions of these from China and found that they were inadequate. The FDA is in the process of validating certain tests this week and if they pass, then we can expect to have tests within the next few weeks to do the things that you have suggested.

Best regards,
Tony

From: Nader, Ralph (b) (6)
Sent: Wednesday, April 1, 2020 9:35 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: COVID-19 Question

Dear Dr Fauci,

I hope this email finds you well.

Thank you for everything you are doing for our country in these difficult times.

I realize your time is extremely valuable – especially during these times.

I have one question - if you can help me answering it.

Why are serologic tests not made abundantly available during these times?

This will help in so many ways:

- Can it be used to triage healthcare workers? Naturally "vaccinated" healthcare workers may be better triaged to be on the front lines for example, taking care of COVID-19 patients. (In times of limited PPE, documentation of natural immunity is probably one of the best PPE's out there)

-Another major use for it:

People can be asked to remain home, until they have documentation of natural immunization.

Serologic tests are very cheap, can be mailed, and done at home.

Immunized individuals can carry the test as "proof" of immunity - and may be able to go back to work etc.

It is just a thought. It may be a very candid question that I am asking.

But while we are waiting for a vaccine (and this will take several months), some people may be able to benefit from a very cheap test (that can be done at home) to short-circuit that waiting time.

Thank you for everything you are doing to our country,

You are such an inspiration to us all.

I wish you all the best.

Thank you.

Ralph

Ralph Nader, MD

Renal Fellow - Boston Medical Center

Instructor of Medicine - Boston University School of Medicine

Email: (b) (6)

Phone: (b) (6)

Pager: (b) (6)

This electronic transmission may contain information that is privileged, confidential and exempt from disclosure under applicable law. If you are not the intended recipient, please notify me immediately as use of this information is strictly prohibited.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 19:29:52 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]; Stover, Kathy (NIH/NIAID) [E]
Subject: RE: documentary interview request: PBS + Topspin Productions

Let us discuss this tomorrow before we do anything. No one has any "exclusives" on anything about me.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)>
Sent: Sunday, April 12, 2020 3:27 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6)>
Subject: RE: documentary interview request: PBS + Topspin Productions

(b) (5)

From: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Sent: Sunday, April 12, 2020 3:01 PM
To: Billet, Courtney (NIH/NIAID) [E] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6)>
Subject: RE: documentary interview request: PBS + Topspin Productions

(b) (5)

(b) (5) Happy to discuss.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)>
Sent: Sunday, April 12, 2020 2:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>; Folkers, Greg (NIH/NIAID) [E]

(b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6)>

Subject: ASF: documentary interview request: PBS + Topspin Productions

We have received a request from the PBS program "American Masters" and Topspin Productions to do a documentary about you. Their near-term ask is one or two brief video-link phone interviews during the next few months. After the coronavirus pandemic has subsided, they would like to do "a proper sit-down in which you could tell us the stories that speak to the key moments in your remarkable career."

On the face of it, this might seem to overlap with the Tobias/Hoffman project, but in the end I think they'd be quite different products. Please let me know if you'd like us to seek clearance to proceed.

On Apr 7, 2020, at 9:26 AM, Lia Carney <lia@topspincontent.com> wrote:

Hi Laura,

Nice to speak yesterday. See below for formal request and information about the series. If you wouldn't mind confirming receipt of this email, I can make sure to let my partners in this project know it is in the correct hands. Stay safe and thank you.

Dear Dr. Fauci,

To re-introduce myself, I am Lia Dosik Carney, (b) (6) and an executive producer in Los Angeles. As you'll remember, we filmed with you last summer as a major participant in a documentary we were producing centered around infectious disease. Thank you again for participating and taking the time. It was great to hear about your extraordinary career as well as a few interesting stories about (b) (6)

Obviously events have taken over all of our lives. Like everyone else in this country, I am very grateful for your honest and steadfast leadership as we navigate our new reality. During this time, we've been rethinking how we want to proceed with our documentary and have come to realize focusing on you, your experiences over the decades, how you have met every challenge presented to you, would give all of us a roadmap for the future.

To that end we are now in partnership with AMERICAN MASTERS, PBS' flagship series that profiles and honors outstanding Americans. Together we would like to produce a comprehensive look at your life, your experiences and your insights into how to deal with the recurring diseases that continue to plague our lives.

I have included below an introductory email from American Masters Executive Producer, Michael Kantor, which will give you a broader sense of that exceptional PBS series and the extraordinary work they produce.

We all know how limited your time is now — and all of us are so appreciative of what you are doing. We respectfully hope you will allow us to chronicle your life in medicine. We know that as we emerge from this latest crisis — understanding how you were able to deal

with earlier plagues (HIV-Aids for instance) will — we hope — give all of us a better understanding of the challenges all of us will continue to face.

Appreciate your consideration. With respect, Lia

Dear Dr. Fauci,

My name is Michael Kantor and I am the Executive Producer of the PBS AMERICAN MASTERS series. I believe you know [REDACTED] (b) (6)

[REDACTED] I am writing today to see if you would allow us to make a film on your life and career. We would require very little of your precious time right now, perhaps one or two very brief video-link phone interviews over the next few months, just as you have appeared on Trevor Noah's *The Daily Show* and spoken with basketball star Steph Curry. Later this year, after the current crisis has subsided, we would find time in your busy schedule for a proper sit-down in which you could tell us the stories that speak to the key moments in your remarkable career.

I am excited to work with Lia Carney and Topspin Productions on this project, because it has been important to me to expand the roster of AMERICAN MASTERS films to include scientists. Over its 33 year history, our series has profiled artists such as Leonard Bernstein, Maya Angelou and Raul Julia, athletes including Billie Jean King and Ted Williams, and now we are presenting the stories of James Watson and Oliver Sacks in our pantheon of great films. Our series is dedicated to telling biographies with the utmost care, and for that reason we have been honored with awards like the Emmy, the Peabody, the Grammy and even an Oscar.

We would be honored to have you join us in our public television effort to educate Americans about the domestic and global health issues that have been the focus of your career. This letter is brief because we respect your time, but we sincerely hope that you will join us in creating a documentary of distinction for a broad and diverse national audience.

Sincerely yours,

Michael Kantor

Michael Kantor
Executive Producer
American Masters
Thirteen|WNET
825 Eighth Avenue
New York, NY 10019-7435

212-560-6975 (office)

<image001.png>

[American Masters website](#)

[Facebook](#) | [Twitter](#) | [Tumblr](#)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 18:25:39 +0000
To: Lane, Cliff (NIH/NIAID) [E]
Subject: RE: Clarification in the chapters on Human Immunodeficiency virus disease: AIDS and related disorders (Chapter 197) page 1445 and Toxoplasma infections (Chapter 223) page 1615, in Harrison's principles of internal medicine -20 th Ed

Thanks.

From: Lane, Cliff (NIH/NIAID) [E] (b) (6)
Sent: Sunday, April 12, 2020 2:24 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: Clarification in the chapters on Human Immunodeficiency virus disease: AIDS and related disorders (Chapter 197) page 1445 and Toxoplasma infections (Chapter 223) page 1615, in Harrison's principles of internal medicine -20 th Ed

I responded to him and copied Kami Kim. He misread the two sections. We are saying the same things. I did not copy you.

From: Anthony Fauci <(b) (6)>
Date: Sunday, April 12, 2020 at 2:13 PM
To: "Lane, Cliff (NIH/NIAID) [E]" (b) (6)
Subject: FW: Clarification in the chapters on Human Immunodeficiency virus disease: AIDS and related disorders (Chapter 197) page 1445 and Toxoplasma infections (Chapter 223) page 1615, in Harrison's principles of internal medicine -20 th Ed

Please take a look at this. We get these inquiries from Indians all the time. They read HPIM very carefully. Is there anything we need to change here?

From: Viswanathan Neelakantan (b) (6)>
Sent: Sunday, April 12, 2020 3:35 AM
To: (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Lane, Cliff (NIH/NIAID) [E] <(b) (6)>
Subject: Clarification in the chapters on Human Immunodeficiency virus disease: AIDS and related disorders (Chapter 197) page 1445 and Toxoplasma infections (Chapter 223) page 1615, in Harrison's principles of internal medicine -20 th Ed

Dear Professor Anthony Fauci and Professor Kami Kim,
Greetings from Pondicherry, India. This is Dr K Neelakantan Viswanathan, Senior Professor of Medicine in a medical school here.

Going through your excellent chapter, (Chapter 197) in page 1445, on AIDS and related disorders in HPIM-20, under secondary prophylaxis / maintenance therapy for Toxoplasmosis it is said that **"it may be discontinued in the setting of effective cART and increases in CD4+ T cell counts to > 200 / microliter for 6 months"**.

In page 1615, another wonderfully written chapter, (Chapter 223) on Toxoplasma infections, Professor Kami Kim has mentioned that “ **individuals who have completed initial therapy for TE should receive treatment indefinitely unless immune reconstitution with a CD4 + T cell count of >200 occurs as a consequence of cART**”.

Since both feature in the same textbook followed worldwide by medicos, could you please clarify the above?

I stand subject to any corrections.

Hoping that we fight Covid-19 effectively very soon. Stay safe.

Regards and best wishes,

Professor Dr K N Viswanathan

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 18:19:06 +0000
To: Daniel Lucey
Subject: RE: COVID-19: Rembrandt's Belshazzar's Feast in a time of chiaroscuro 2020 | Science Speaks:

Thanks, Dan.

-----Original Message-----

From: Daniel Lucey <(b) (6)>
Sent: Saturday, April 11, 2020 5:14 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Daniel Lucey <(b) (6)>
Subject: COVID-19: Rembrandt's Belshazzar's Feast in a time of chiaroscuro 2020 | Science Speaks:

Tony, Thank you for the immense 24/7 contribution you are making to our nation. Your wife is right; Pls get more sleep and meals! Before Easter tomorrow I am sharing this brief Old Testament story to which I gave a 2020 interpretation. Today's IDSA posting I am emphasizing that simultaneous antibody and virus RNA tests should be done on "relapsed" or "reinfected" Covid-19 patients e.g., South Korea (N=91), China, elsewhere. I am looking forward to giving NIAID Grand Rounds May 1st with Barney Graham and John Beigel. Dan (b) (6)
<https://sciencespeaksblog.org/2020/04/09/covid-19-rembrandts-belshazzars-feast-in-a-time-of-chiaroscuro-2020/>

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 18:12:01 +0000
To: Barton Haynes, M.D.
Subject: RE: coach K video for DHVI

Thanks, Bart. Glad to have you working on the COVID-19 issue.

From: Barton Haynes, M.D. [REDACTED] (b) (6) >
Sent: Sunday, April 12, 2020 8:47 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: RE: coach K video for DHVI

Coach K and I came to duke on the same day in 1980 and [REDACTED] (b) (6)
[REDACTED] ...when I was chair and he wasn't quite so famous, he used to see all my division chief recruits and help me recruit. He is a really good guy, as you know.

Am on the Francis Collins-appointed NIH working group for COVID19 vaccines, first meeting in the am...

Will continue to flog CoV2 simultaneously while making good progress on HIV. This past week had 4 HIV SABs, CHAVD, an IPCAVD, an HIVRAD we have with Scripps, and our GMP unit.....all on line. Not messing around.... All went really, really well.

Thanks for all you continue to do.

Best bart

From: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Sent: Saturday, April 11, 2020 10:32 PM
To: Barton Haynes, M.D. [REDACTED] (b) (6) >
Subject: RE: coach K video for DHVI

Very nice!!

From: Barton Haynes, M.D. <[REDACTED] (b) (6)>
Sent: Friday, April 3, 2020 8:21 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: coach K video for DHVI

Hi Tony; if you get a chance, here is a 3 min. video Coach K did last week for DHVI. I sent it to all 270 DHVI members and they were very inspired!

Thanks for sending your interview with K. It is terrific.

All the best B

From: Jon Jackson (b) (6) >

Sent: Thursday, March 26, 2020 12:59 PM

To: Barton Haynes, M.D. (b) (6) >

Subject: Re: saw your video

https://www.dropbox.com/s/2f6b142lv63e10f/IMG_0250.MOV?dl=0

Sent from my iPhone


From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 17:27:46 +0000
To: Folkers, Greg (NIH/NIAID) [E]; NIAID OD AM
Cc: Stover, Kathy (NIH/NIAID) [E]; Leifman, Laura (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]
Subject: RE: Serosurvey

OK. We can discuss.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)
Sent: Sunday, April 12, 2020 11:26 AM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Cc: Stover, Kathy (NIH/NIAID) [E] (b) (6); Leifman, Laura (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6)
Subject: RE: Serosurvey

Marilyn Marchione: I'm writing to request a chance to embed with a team doing a coronavirus serosurvey, to tell a public health story from the front lines as I believe I'm uniquely positioned to do.

(b) (5)



Let us discuss in a.m.

-----Original Message-----

From: Marchione, Marilyn <MMarchione@ap.org>
Sent: Sunday, April 12, 2020 10:56 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Leifman, Laura (NIH/NIAID) [E] <(b) (6)>
Subject: FW: Serosurvey

Hello Dr. Fauci,
I hope you are staying well in these trying times.

I'm writing to request a chance to embed with a team doing a coronavirus serosurvey, to tell a public health story from the front lines as I believe I'm uniquely positioned to do. I've made a similar request to the CDC, but the nationwide reach of the NIAID serosurvey might make my proposal easier to consider, so I'm coming hat in hand to you as well.

Twenty years ago, as a temporary CDC employee during a four-month Knight Journalism fellowship, I had the opportunity to take the EIS course in Atlanta and then work on several CDC outbreak and disease investigations. One was a serosurvey on Long Island after West Nile virus had recently emerged in the U.S.

I headed one of a dozen CDC teams that included a driver, a phlebotomist and a health aide from the New York state and Suffolk County health departments. We went door-to-door to consent participants, get blood samples and do interviews on exposure and symptoms.

I appreciate the tremendous scientific value that serosurveys offer and the kind of attention to detail and study rigor that's needed to get reliable information. I'm also a longtime medical journalist who understands and is sensitive to confidentiality, ethical and privacy concerns. I've been recognized by my peers as a science writing leader.

<https://casw.org/casw/article/marilynn-marchione-associated-press-wins-victor-cohn-prize>

I've attached some letters from CDC and other health officials regarding my work on the serosurvey, a photo of the EIS and CDC team (that's me toward the right in the front row) and the MMWR report resulting from our work. The field supervisor -- Dr. Anthony Marfin, now with the global vaccine group PATH ((b) (6)) is willing to speak to you on my behalf. Dr. Richard Besser, now president of the Robert Wood Johnson Foundation, was my fellowship supervisor and mentor at CDC. Others I worked with include Dr. Anne Schuchat, Dr. John Ward, Dr. Robert Tauxe and Dr. Lyle Petersen.

And of course, you know me from nearly three decades of medical writing, including the HIV/AIDS government trip to Africa when Tommy Thompson was healthy secretary.

The Associated Press reaches half of the world's population every day. I hope to offer a story that I and the AP are uniquely able to provide, to show and explain how public health is done and how science is accomplished during a pandemic. Thank you for considering my request.

Marilynn Marchione
Chief Medical Writer
The Associated Press

(b) (6)

mmarchione@ap.org

Twitter: @MMarchioneAP

The information contained in this communication is intended for the use of the designated recipients named above. If the reader of this communication is not the intended recipient, you are hereby notified that you have received this communication in error, and that any review, dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify The Associated Press immediately by telephone at +1-212-621-1500 and delete this email. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 17:12:57 +0000
To: Barton Haynes, M.D.
Subject: RE: Wall Street Journal story

Of course. No problem.

From: Barton Haynes, M.D. <(b) (6)>
Sent: Sunday, April 12, 2020 1:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: RE: Wall Street Journal story

If he wants also to talk to me should I also talk to him?

From: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Sent: Sunday, April 12, 2020 1:09 PM
To: Barton Haynes, M.D. <(b) (6)>
Subject: RE: Wall Street Journal story

Yes to your questions.

From: Barton Haynes, M.D. <(b) (6)>
Sent: Sunday, April 12, 2020 1:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: RE: Wall Street Journal story

I know you don't have time to answer these but if you do fine, if not, ok.

Just don't want to screw something up.

Is it fair to say that shelly was not only a mentor but a father figure. You and shelly were very close.

also fair to say shelly was your most important mentor in your career?

Tx bart

From: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Sent: Sunday, April 12, 2020 12:44 PM
To: Barton Haynes, M.D. <(b) (6)>
Subject: RE: Wall Street Journal story

Bart:

No problem. Go for it!

Best.

Tony

From: Barton Haynes, M.D. <(b) (6)>
Sent: Sunday, April 12, 2020 12:26 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: Wall Street Journal story

Hi tony; the fellow who wrote the article about you as point guard for St. Regis and the nation from the Wall street journal wants to talk to me about shelly wolff and you per below . is that ok? I will of course say only those things that are unbelievable but true....which are all wonderful..... best bart

From: Ben Cohen <ben.cohen@wsj.com>
Sent: Sunday, April 12, 2020 10:31 AM
To: Barton Haynes, M.D. (b) (6)
Subject: Wall Street Journal story

Dr. Haynes,

I'm a reporter from the Wall Street Journal and, more important, a friend of Ben's from Duke. I've written quite a bit about your mentor and friend Dr. Fauci in the last few weeks, and I'm working on another story now that I was hoping you might be able to help with.

This story is about *his* mentor, Dr. Wolff, and how Dr. Wolff helped turn Dr. Fauci into the person he is today. I would love to hear more about their relationship from your perspective. I know this is an insanely busy time, but would you have a few minutes to chat by phone?

Thanks very much for your help. I hope you're safe and well in Durham.

All best,
Ben

--

Ben Cohen
The Wall Street Journal
[212-416-3420](tel:212-416-3420) (o)
(b) (6)c
ben.cohen@wsj.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 17:10:22 +0000
To: Barton Haynes, M.D.
Subject: RE: Wall Street Journal story

Thanks.

From: Barton Haynes, M.D. (b) (6) >
Sent: Sunday, April 12, 2020 1:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6) >
Subject: RE: Wall Street Journal story

I am going to refer him to you per the last note. Best bart

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Sent: Sunday, April 12, 2020 1:09 PM
To: Barton Haynes, M.D. (b) (6) >
Subject: RE: Wall Street Journal story

Yes to your questions.

From: Barton Haynes, M.D. (b) (6) >
Sent: Sunday, April 12, 2020 1:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: RE: Wall Street Journal story

I know you don't have time to answer these but if you do fine, if not, ok.

Just don't want to screw something up.

Is it fair to say that shelly was not only a mentor but a father figure. You and shelly were very close.

also fair to say shelly was your most important mentor in your career?

Tx bart

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Sent: Sunday, April 12, 2020 12:44 PM
To: Barton Haynes, M.D. (b) (6) >
Subject: RE: Wall Street Journal story

Bart:

No problem. Go for it!

Best.

Tony

From: Barton Haynes, M.D. <(b) (6)>
Sent: Sunday, April 12, 2020 12:26 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: Wall Street Journal story

Hi tony; the fellow who wrote the article about you as point guard for St. Regis and the nation from the Wall street journal wants to talk to me about shelly wolff and you per below . is that ok? I will of course say only those things that are unbelievable but true....which are all wonderful..... best bart

From: Ben Cohen <ben.cohen@wsj.com>
Sent: Sunday, April 12, 2020 10:31 AM
To: Barton Haynes, M.D. (b) (6)
Subject: Wall Street Journal story

Dr. Haynes,

I'm a reporter from the Wall Street Journal and, more important, a friend of Ben's from Duke. I've written quite a bit about your mentor and friend Dr. Fauci in the last few weeks, and I'm working on another story now that I was hoping you might be able to help with.

This story is about *his* mentor, Dr. Wolff, and how Dr. Wolff helped turn Dr. Fauci into the person he is today. I would love to hear more about their relationship from your perspective. I know this is an insanely busy time, but would you have a few minutes to chat by phone?

Thanks very much for your help. I hope you're safe and well in Durham.

All best,
Ben

--

Ben Cohen
The Wall Street Journal
[212-416-3420](tel:212-416-3420) (o)
(b) (6) c)
ben.cohen@wsj.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 17:08:21 +0000
To: Neil Lacey - CDOT
Subject: RE: THANK YOU

Thanks, Neil. I appreciate your note.
Best,
Tony

From: Neil Lacey - CDOT <neil.lacey@state.co.us>
Sent: Sunday, April 12, 2020 1:05 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: THANK YOU

Thank you Dr. Birx and Dr. Fauci:

At a time when America needs it most both of you have courageously stood at the podium at the White House press briefings and explained what we all need to be doing during this paralyzing COVID-19 pandemic. When others have failed to lead, multiple task forces have struggled prioritizing safety first before economics, both of you have tag teamed presenting the data and the analytics of COVID-19 by decoding its complexities and giving us the "honest truth" in language that is easy to understand. The virus will end when it ends and not before. Thank you both for your service to the nation and for doing your jobs with conviction and commitment in doing the right thing - sticking to science and not yielding to politics. America is immensely grateful for both of you telling us all what we need to hear and what we need to do. You are both giants in the world of medicine.

Very appreciative,

Neil Lacey

(b) (6)

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 17:07:23 +0000
To: Barton Haynes, M.D.
Subject: RE: Wall Street Journal story

Bart:

I would be happy to talk to him about Shelly. People like to make stories as opposed to reporting on a story. Shelly was one of my best friends and mentor, but I was me way before I met Shelly, and so I am not really sure what he means by saying that Shelly "...helped turn Dr. Fauci into the person he is today".

Best,
Tony

From: Barton Haynes, M.D. (b) (6)
Sent: Sunday, April 12, 2020 12:45 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: RE: Wall Street Journal story

Of course the reason I am asking is that it is presumptuous for me to talk to him about shellys influence on you....perhaps I should just refer him to you?

Don't want to do anything either inappropriate, non helpful or what you don't want. Best bart

From: Barton Haynes, M.D.
Sent: Sunday, April 12, 2020 12:26 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: Wall Street Journal story

Hi tony; the fellow who wrote the article about you as point guard for St. Regis and the nation from the Wall street journal wants to talk to me about shelly wolff and you per below . is that ok? I will of course say only those things that are unbelievable but true....which are all wonderful..... best bart

From: Ben Cohen <ben.cohen@wsj.com>
Sent: Sunday, April 12, 2020 10:31 AM
To: Barton Haynes, M.D. (b) (6)
Subject: Wall Street Journal story

Dr. Haynes,


I'm a reporter from the Wall Street Journal and, more important, a friend of Ben's from Duke. I've written quite a bit about your mentor and friend Dr. Fauci in the last few weeks, and I'm working on another story now that I was hoping you might be able to help with.

This story is about *his* mentor, Dr. Wolff, and how Dr. Wolff helped turn Dr. Fauci into the person he is today. I would love to hear more about their relationship from your perspective. I know this is an insanely busy time, but would you have a few minutes to chat by phone?

Thanks very much for your help. I hope you're safe and well in Durham.

All best,
Ben

--

Ben Cohen
The Wall Street Journal
212-416-3420 (o)
 (b) (6) (v)
ben.cohen@wsj.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 12:30:56 +0000
To: Conley, Sean P. CDR USN WHMO/WHMU; Short, Marc T. EOP/OVP
Cc: Birx, Deborah L. EOP/NSC; Lane, Cliff (NIH/NIAID) [E]
Subject: RE: 15 minute Coronavirus machines

Thanks, Sean.

From: Conley, Sean P. CDR USN WHMO/WHMU (b) (6)
Sent: Saturday, April 11, 2020 11:18 PM
To: Short, Marc T. EOP/OVP (b) (6)>; Fauci, Anthony (NIH/NIAID) [E]
(b) (6)>
Cc: Birx, Deborah L. EOP/NSC <(b) (6)>; Lane, Cliff (NIH/NIAID) [E]
(b) (6)
Subject: Re: 15 minute Coronavirus machines

(b)(5) PCP

I'll look into the possibility of freeing up a machine for investigation.

Sean

Sent from my iPhone

On Apr 11, 2020, at 10:15 PM, Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
wrote:

Marc:

(b) (5)

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 12:30:19 +0000
To: Short, Marc T. EOP/OVP
Subject: RE: 15 minute Coronavrius machines

Marc:

Thanks for the note. Understood. I wish you a peaceful and enjoyable day with your family.
Best regards,
Tony

From: Short, Marc T. EOP/OVP (b) (6)
Sent: Saturday, April 11, 2020 11:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Conley, Sean P. CDR USN WHMO/WHMU (b) (6); Birx, Deborah L. EOP/NSC (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6)
Subject: Re: 15 minute Coronavrius machines

Dr Fauci,

You correctly noticed the symptoms but misdiagnosed the root cause. (b)(5) PCP

(b)(5) PCP

Apologies for a poor poker face. Best wishes to you and your family for a blessed Easter celebration of our Savior's resurrection .

Thanks for all you do,

Marc

Sent from my iPhone

On Apr 11, 2020, at 10:15 PM, Fauci, Anthony (NIH/NIAID) [E] (b) (6)
wrote:

Marc:



Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 12:28:27 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: Fearing appointment

Please respond as appropriate.

-----Original Message-----

From: Daniel Kölliker [REDACTED] (b) (6)>
Sent: Sunday, April 12, 2020 4:53 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: Fearing appointment

Dear Mr Fauci,

We are really wondering over here in Europe why you don't take a dedicated opinion on COVID-19 and share your opinion at the daily briefings to the extent of your personal believes.

We really expect you to oppose the president wherever you have a different opinion, which we believe is based on facts.

Please consider our request and don't let the president keep spreading his lies to the people of the United States.

We would really appreciate watching you on the briefings telling the nation the truth that is based on your experience straight to the point.

Thank you so much,
Daniel Kölliker and acquaintances

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 12:27:36 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: [REDACTED] (b) (4)
[REDACTED]
Attachments: [REDACTED] (b) (4)

Please take a look at this and respond as you see fit. Thanks.

From: [REDACTED] (b) (6)
Sent: Sunday, April 12, 2020 5:54 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: [REDACTED] (b) (4)
[REDACTED]

Dear Dr. Fauci

I know that you are very occupied.

[REDACTED] (b) (4)

Please handle the draft confidentially.

Thank you very much!
Sincerely, D. Novosel, Switzerland

www.novosel.ch

From: (b) (6)
Sent: Sat, 11 Apr 2020 22:57:51 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]; Mascola, John (NIH/VRC) [E]
Subject: Teleconference next week

I have asked John Mascola to connect with you to set up a conference call with John, me, Carl, Emily some time next week. Subject is out of the box thinking about COVID-19

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 11 Apr 2020 22:08:16 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: Letter sent on behalf of Chancellor Jeffrey P. Gold, M.D.

This is another email from Jeff Gold at UNMC in response to an email that you sent him.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email: (b) (6)

From: Gold, Jeffrey P (b) (6) >
Sent: Saturday, April 11, 2020 3:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Re: Letter sent on behalf of Chancellor Jeffrey P. Gold, M.D.

Tony,
Many thanks for taking the time to respond. Please let me know if I can help in any way.
Our mobile device app (developed with Apple) has been quite helpful and is growing in use (over 10K) as a screening, referral and surveillance tool for several user sets.
Just one of the many areas we continue to develop.
Best wishes
jeff

From: "M. Anthony S. Fauci" (b) (6) >
Date: Saturday, April 11, 2020 at 1:52 PM
To: "Gold, Jeffrey P" (b) (6)
Subject: RE: Letter sent on behalf of Chancellor Jeffrey P. Gold, M.D.

Non-UNMC email

Jeff:

Many thanks for your kind note. Hope that all is well with you.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6) On Behalf Of Gold, Jeffrey P
Sent: Friday, April 10, 2020 12:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Gold, Jeffrey P (b) (6)
Subject: Letter sent on behalf of Chancellor Jeffrey P. Gold, M.D.
Importance: High

April 10, 2020

Anthony S. Fauci, M.D.
Director
National Institute of Allergy and Infectious Diseases
5601 Fishers Lane, MSC 9806
Bethesda, MD 20892-9806
(b) (6)

Dear Dr. Fauci:

I write simply to thank you and congratulate you for your incredible efforts during the management of this pandemic as it reaches across our nation. The unique challenges that this pandemic has created have also created opportunities, and we here at the University of Nebraska Medical Center have proudly participated with our federal, state and local partners during this COVID-19 pandemic as well as over the last 16 years, having matured an extensive program in the research, education, and clinical components of highly infectious diseases and biocontainment.

The UNMC Center for Global Health Security has been the umbrella organization that has organized all of these components and continues to have strong leadership from retired military public health as well as gifted research scientists from across the nation. As a co-founding partner of NETEC, as a recipient of the Regional Disaster Health Service Awards, and as a close collaborator with the Department of Health and Human Services, the Department of Defense, the Department of Homeland Security and the Department of State, we have enjoyed the opportunity to always "lean in" as the need arises.

I am sure your days are full not only of the complex logistics and tension that fill leadership roles at this time but also maintaining a "steady hand on the rudder" as we navigate these challenging waters. I think back to my days at New York Presbyterian and Cornell Med, knowing that we are both Cornell Med grads, both did our residency and fellowship training in New York, and have had the opportunity to interact back so many years ago. I do remember quite well the first time that we met and have always reflected warmly at having even a brief opportunity to interact.

I do not write to ask for anything but to just simply thank you for all that you continue to do and know that you always have a friend here in Nebraska. I wish you and your family the very best as we continue this journey.

Most sincerely,

(b) (6)

Jeffrey P. Gold, M.D.
Chancellor

JPG (b) (6)

(b) (6)
Administrative Associate I
Chancellor Jeffrey P. Gold's Office

University of Nebraska Medical Center
986605 Nebraska Medical Center | Omaha, NE 68198-6605
(b) (6) fax 402.559.4396

(b) (6)

[UNMC](#) | [Facebook \[facebook.com\]](#) | [Twitter \[twitter.com\]](#) | [Instagram \[instagram.com\]](#) | [YouTube \[youtube.com\]](#) | [Flickr \[flickr.com\]](#)

The information in this e-mail may be privileged and confidential, intended only for the use of the addressee(s) above. Any unauthorized use or disclosure of this information is prohibited. If you have received this e-mail by mistake, please delete it and immediately contact the sender.

The information in this e-mail may be privileged and confidential, intended only for the use of the addressee(s) above. Any unauthorized use or disclosure of this information is prohibited. If you have received this e-mail by mistake, please delete it and immediately contact the sender.

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 11 Apr 2020 22:02:38 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: Please send me your cell phone #.
Attachments: COVID-19 Craig Schirmer Memo 04.10.20.pdf

This email is from Jeffrey Sachs.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email: (b) (6)

-----Original Message-----

From: Jeffrey Sachs (b) (6)
Sent: Saturday, April 11, 2020 4:50 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Re: Please send me your cell phone #.

(b) (4)

Looking forward to speaking,

Jeff

On 4/11/20, 4:28 PM, "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) > wrote:

Mine is (b) (6)

From: (b) (6)
Sent: Sat, 11 Apr 2020 16:25:18 -0400
To: Evans, Michele (NIH/NIA/IRP) [E]
Subject: Re: Covid-19 Health Disparities

Michele:
Many thanks for your note.
Best regards,
Tony

On Apr 7, 2020, at 8:28 PM, Evans, Michele (NIH/NIA/IRP) [E]
(b) (6) wrote:

Dear Dr. Fauci,

Thank you from the bottom of my heart for highlighting the health disparities and disproportionate burden of disease influencing outcome of Covid-19 infections in African Americans. Participants in my observational, longitudinal, epidemiologic Baltimore-based study, HANDLS <https://handls.nih.gov/> are terrified by the level of disease they are seeing in their communities across Baltimore. We have been on the phone with and texting participants to educate them, support them in their efforts to get tested, remind them of the importance of social distancing and self-isolation when appropriate to protect their health. We are acutely aware of their fragility. Testing in Baltimore is limited. The National Guard has set up community testing at the Pimlico Race Track; however, although we have deployed our mobile medical research vehicles to Pimlico in the past to conduct our study, the current crime rate is such that our participants and community residents in general do not go to the Pimlico area especially if they are on foot. The other issue with testing for African Americans and our participants is the need to have a health care provider that one can contract to discuss symptoms to get a referral for testing. The unravelling of the Affordable Care Act has severely impacted access for African Americans across the nation and especially in Baltimore. Our participants are calling my staff clinician and nurse practitioner for referrals if they have symptoms. We have reached out to colleagues at

Health Care for the Homeless, JHU and other medical entities to facilitate access.

Thank you all you are doing. Since I work in Baltimore, I haven't seen you in person since [REDACTED] (b) (6). The current pandemic however, reminds me of the days of the AIDS epidemic when I worked as Sam Broder's special assistant for underserved populations while Peggy Hamburg worked for you. I was in awe of you and Sam then and I remain in awe of you today. I have known many Regis men...but you are clearly head and shoulders above them all.

Michele K. Evans, M.D.
Deputy Scientific Director & Chief,
Health Disparities Research Section
National Institute on Aging
National Institutes of Health
NIH Biomedical Research Program
251 Bayview Boulevard
Suite 100 Room 4C-222
Baltimore, Maryland 21224
Email: [REDACTED] (b) (6)
Tel. [REDACTED] (b) (6)
<https://irp.nih.gov/pi/michele-evans>
<https://handls.nih.gov/>

From: (b) (6)
Sent: Sat, 11 Apr 2020 16:22:40 -0400
To: Janet Tobias
Cc: Conrad, Patricia (NIH/NIAID) [E]; (b) (6)
Subject: Re: Updates: Film

Janet

All this sounds fine and workable.

Thanks,

Tony

On Apr 7, 2020, at 8:31 PM, Janet Tobias <janet@ikanamedia.com> wrote:

Dear Tony and Patty:

Responses to Burklow's questions to me from your group call yesterday:

1) I think we have landed in the right place for the film about your life. Nat Geo, Disney, and Bob Iger himself, all understand the need for discretion now but are wildly supportive about releasing a film that will celebrate the importance of your life, science and public health. I wanted the best home, broadest distribution, and strongest team for your film. You have entrusted me with your story, so I just want to do right by it. We are really happy with the filming that we have done so far personal (b) (6) home, school) to work (office etc).

3) The other film we have been working on (ENDING AIDS), which follows globally the HVTN trials/latest Aids research to complete "the toolbox" is definitely still happening. It is now in pause with COVID-19....but will move forward again when we get through this. Filming at research sites in South Africa, US, and Latin America has been great...and when you have time — in the future — I will outline. You obviously are a key subject in ENDING AIDS also, but ENDING AIDS will spend a lot of time with doctors at the field research sites and with volunteers in the trials. The Aids conference and meetings footage we have shot with you will be shared between films, smartly and distinctly. ENDING AIDS will be released a year plus later than the release of your biographical film—I am focused on your film now. Howard Hughes Medical Institute remains the educational partner on ENDING AIDS. In the fall we will finalize the broadcast/streaming partner for ENDING AIDS. So, bottom line it will be released a year after your film, and will be a film focused on showing in detail where we are now with aids research and the key people in the chain from you to a young female volunteer in South Africa/a young male volunteer in Birmingham.

FILMING REQUESTS for your film now.

4) NO more asking to film with the Task Force.

5) I do have two personal filming requests for you — would it be possible to drive to NIH with you once or twice a week and capture your working/appropriate conversations in the car. That will be so helpful narratively to tracking your scientific and communication leadership. The footage we did that first day is truly

great. We will just turn around and come back after the ride there--- in our follow car (we have NIH access badges). Secondly, would it be possible to sit down with you on camera for 15 minutes once a week (on the weekend?) at the office or on the back deck/some safe location to talk with me in real time about what you are managing with treatments, vaccines, etc. so we can pull the scientific/communication narrative on COVID-19 through your film.

6) We love the live truck and the walks, so whenever that works we will be there.

7) I NEVER ever want to interfere with the work on the Task Force, lives are at stake. IF something doesn't work for filming no questions asked we don't do it, we stop, cancel/pivot. No need to explain, the team here understands and only wants to do what works for you, your team.... (b) (6).

With appreciation,

Janet

From: (b) (6)
Sent: Sat, 11 Apr 2020 16:14:53 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Invitation to speak to ABEA in virtual meeting

No

Begin forwarded message:

From: "Allen, Clint (NIH/NIDCD) [E]" (b) (6) >
Date: April 8, 2020 at 9:16:55 AM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Subject: Invitation to speak to ABEA in virtual meeting

Dr. Fauci –

Almost embarrassed to ask, but would you be willing/able to speak virtually to the **American Broncho-Esophagological Association** (abea.net) on Friday April 24th? This year marks the 100th anniversary of this venerable organization that brings together clinicians (mainly Otolaryngologists) who care for patients with complex upper aerodigestive tract disorders. Our annual National Meeting has been cancelled and we are hosting a virtual meeting in its stead.

As Otolaryngologists, we are currently and expect to continue to be dramatically impacted by the current pandemic, given that our care for patients routinely includes upper airway endoscopy (30-40 scope procedures a day is routine) which as you know is a high-risk aerosolizing procedure. As I'm sure you are aware, Otolaryngologists have been amongst the hardest hit clinicians in terms of patient-to-provider transmission of COVID-19.

Your input for 10-15 minutes would be an honor. Discussion topics could include general comments about the pandemic, a sense of what to expect in the coming months and years, and *what we can do as medical leaders to prepare for these changes in the US and abroad*.

If this is something you are interested in, with whom on your communications team could I communicate?

Thanks so much for the consideration – your brief presence and input would mean a great deal to our society.

Clint Allen

From: (b) (6)
Sent: Sat, 11 Apr 2020 16:08:26 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Council of Scientific Society Presidents Support of Science Award
Attachments: Fauci_CSSP_Award.pdf, ATT00001.htm, CSSP Brochure_2019 v3.pdf, ATT00002.htm

Let us discuss. They want to give me an award virtually. Probably should accept if it requires no time or work

Begin forwarded message:

From: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Date: April 9, 2020 at 10:52:49 AM EDT
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: FW: Council of Scientific Society Presidents Support of Science Award

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mosher, Sharon <smosher@jsg.utexas.edu>
Sent: Thursday, April 9, 2020 10:31 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Barasch, Kimberly (NIH/NIAID) [C] (b) (6)>; Conrad, Patricia

(NIH/NIAID) [E] < (b) (6) >

Subject: Council of Scientific Society Presidents Support of Science Award

Dear Dr. Fauci;

Council of Scientific Society Presidents (CSSP) would like to honor you with our Support of Science Award at our May Leadership Workshop (virtual). The purpose of this award is to honor those who have proven their outstanding support of U.S. science, free scientific communication, and a support of basic science research. The expertise with which you guide the United States through these unprecedented COVID-19 times simply reinforces the dedication you exhibit to ensure the greatest safety to the greatest number of US citizens.

Dr. Martin Apple talked to Kim Barasch earlier this week. Please find the attached formal invitation letter she indicated that was needed. I have also attached a PDF of a brochure, though most information is on our [website](#).

If you or Kim have any questions, please let me know by email or phone.

Sincerely,

Sharon Mosher

Sharon Mosher
Farish Chair and Professor
The University of Texas at Austin
Jackson School of Geosciences
2305 Speedway, Stop C1160
Austin, TX 78712-1692

(b) (6) (cell)
smosher@jsg.utexas.edu

From: (b) (6)
Sent: Sat, 11 Apr 2020 16:04:03 -0400
To: Alison Galvani
Cc: Conrad, Patricia (NIH/NIAID) [E]; Seyed Moghadas; Singer, Burton H
Subject: Re: Your Submission THELANCETID-D-20-01518R1

Thanks, Alison

On Apr 9, 2020, at 7:46 PM, Alison Galvani (b) (6) >wrote:

Hi Tony,
I thought you might be interested in our projections regarding ventilator needs in the US. The brief report (attached) was accepted at Lancet ID yesterday. Funded by NIAID :)
Take care,
Alison

----- Forwarded message -----

From: Phoebe Hall <em@editorialmanager.com>
Date: Wed, Apr 8, 2020 at 9:36 AM
Subject: Your Submission THELANCETID-D-20-01518R1
To: Galvani, Alison (b) (6)

Dear Professor Galvani,

Reference: THELANCETID-D-20-01518R1, Projecting the demand for ventilators at the peak of COVID-19 outbreaks in the United States

I am pleased to tell you that your submission, Projecting the demand for ventilators at the peak of COVID-19 outbreaks in the United States, has been accepted for publication in The Lancet Infectious Diseases.

In due course you will receive, electronically, a set of pdf proofs of your article. Please note that because of our varied and international readership, The Lancet Infectious Diseases edits heavily to a strict house style. Thus, changes will inevitably be made to your manuscript at this time. There will also probably be a few final editorial queries at this stage. Please correct and return these pages by the deadline stated in the covering email.

Finally, please note that The Lancet Infectious Diseases is committed to support authors in making their work publicly and freely available. The editors encourage authors to post a word-processed document (NOT the published journal article as

PDF) of their peer-reviewed, accepted article on personal or institutional websites any time after publication in print or online. Your document should include the article citation and a link to The Lancet Infectious Diseases's homepage. Please note that posting and distribution of PDF or HTML documents, however, is not acceptable and breaches your copyright agreement.

Please complete the following Journal Publishing Agreement:

<https://nam05.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.thelancet.com%2Ffor-authors%2Fforms%3Fsection%3Djpa&data=02%7C01%7Calison.galvani%40yale.edu%7C1c0ddd00e9ca413f771008d7dbc1e529%7Cdd8cbebb21394df8b4114e3e87abeb5c%7C0%7C0%7C637219498130294598&sdata=WoXBAmJNsM9SBkFaeGKAzvANg%2BSzbZAw94aQ5%2BAtp%2FY%3D&reserved=0>

Please retain a copy for your files and email a completed copy to HALLP@science.regn.net. Please ensure all the pages are returned.

WHO AUTHORS

If you or any of your co-authors are employed directly by the World Health Organization, you have the option of either signing Elsevier's standard agreement or our WHO/Elsevier non-exclusive licence agreement. Please contact our Deputy Operations Manager, Marco Conforti (m.conforti@elsevier.com) for a copy of the WHO agreement.

Yours sincerely,

Phoebe Hall
Senior Editor
The Lancet Infectious Diseases

E-mail: phoebe.hall@lancet.com

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL:
<https://nam05.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.editorialmanager.com%2Fthelancetid%2Flogin.asp%3Fa%3Dr&data=02%7C01%7Calison.galvani%40yale.edu%7C1c0ddd00e9ca413f771008d7dbc1e529%7Cd8cbeb21394df8b4114e3e87abeb5c%7C0%7C0%7C637219498130294598&sdata=jK1kjtzbMH6UMOPZ%2BvavnATDZkeB9y2up55tmxUA5A%3D&reserved=0>). Please contact the publication office if you have any questions.

—

Alison Galvani, PhD

Director, Yale Center for Infectious Disease Modeling and Analysis (CIDMA)

Burnett and Stender Families Professor of Epidemiology
Yale School of Public Health
Yale School of Medicine
New Haven, CT 06520

(b) (6)

<http://cidma.yale.edu/>

Follow me at @Alison_Galvani

Follow CIDMA @YCIDMA

<Brief report on ventilator needs.docx>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 11 Apr 2020 19:56:00 +0000
To: Jack Killen
Cc: Auchincloss, Hugh (NIH/NIAID) [E]
Subject: RE: From Jack Killen & Fred Boykin

Jack:

Many thanks for your kind note. (b) (6)

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jack Killen (b) (6)
Sent: Tuesday, April 7, 2020 1:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Auchincloss, Hugh (NIH/NIAID) [E] (b) (6)
Subject: From Jack Killen & Fred Boykin

Dear Tony:

This is a quick note to say Fred and I have been watching you every day, in awe, for weeks now. We could not be more grateful for your leadership, wisdom, courage, and integrity. Our country could not be more fortunate that you are still there in guiding us through this terrible time. Needless to say, many memories of our years working together have been in the forefront of our minds.

On a personal note, (b) (6)
(b) (6)

My epidemic battling skills are rusty, but if there is anything I can do to help in any way, please know I are here for you. Fred is as well.

Godspeed, and please take care of yourself. Best to you, (b) (6) and your family.

Jack Killen MD

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 11 Apr 2020 19:50:06 +0000
To: George GAO
Subject: RE: Vaccine—confidential PPT

George:

Thank you for your kind note. All is well despite some crazy people in this world.

Warm regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: George GAO (b) (6)
Sent: Wednesday, April 8, 2020 4:36 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: Vaccine—confidential PPT

Tony

I saw some news (hope it is fake) that are being attacked by some people. Hope you are well under such a irrational situation.

(b) (4) Thank you for your introduction.

All the best and stay safe.

Bw

George

发自我的iPhone

在 2020年3月29日, 09:07, Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
写道 :

George:

Thanks for the note. I understand completely. No problem. We will get through this together.

Bed regards,

Tony

On Mar 28, 2020, at 8:50 PM, George GAO (b) (6) wrote:

Dear Tony

I know you are working extremely hard with a lot of pressure. Hope the US situation is getting better eventually. I saw the Science interview, how could I say such a word "big mistake" about others ? That was journalist's wording. Hope you understand. It was NOT a real interview but a QaA through social media for several days when ge asked me what China has done and is working on. Lets work together to get the virus out of the earth.

Best wishes

George

发自我的iPhone

在 2020年3月3日, 21:10, Fauci, Anthony (NIH/NIAID) [E]
(b) (6) 写道 :

George:

Thanks for the note. I will send this to Dr. John Mascola Director of the NIAID Vaccine Research Center and Dr. Barney Graham to follow-up with you.

Best regards,


Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: George GAO (b) (6)
Sent: Tuesday, March 3, 2020 7:12 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Vaccine—confidential PPT

Dear Tony
Hope this email finds you well and the US will soon get the COVID-19 down.



All the best
George

发自我的iPhone
<20200303 For Gao laoshi.pptx>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 11 Apr 2020 19:27:03 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Subject: RE: ASF - note from Mary Jane Walker !! FW: Catching up

Thanks, Mary Jane!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Sent: Thursday, April 9, 2020 10:23 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Mary Jane Walker (b) (6)
Subject: ASF - note from Mary Jane Walker !! FW: Catching up

From: Mary Jane Walker <(b) (6)>
Subject: Catching up
Date: April 6, 2020 at 9:23:13 PM EDT
To: (b) (6)

Hi Tony,

I hope that you are doing well despite all that you are dealing with around COVID-19. It has been many years since I had the opportunity to work with you but my job at NIAID was one of my favorite positions and gave me a great start to my career. So, when I saw the below graphic, it made me smile and I wanted to send you a note.

I truly appreciate how you are handling the COVID-19 situation. Your comments are a breath of fresh air amidst politics and uncertainty. With daily White House press briefings, increased security and scrutiny, 24/7 media interviews and great popularity, you seem to be holding up well - as you always do. Your recent interview with JAMA's Editor-in-Chief Howard Bauchner was particularly well done and very enlightening.

Thank you for everything that you are doing and please stay healthy!

Kind regards,

Mary Jane



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 11 Apr 2020 18:35:53 +0000
To: Crawford, Chase (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]; Billet, Courtney (NIH/NIAID) [E]; Haskins, Melinda (NIH/NIAID) [E]; Selgrade, Sara (NIH/NIAID) [E]
Subject: RE: Attn Dr. Fauci: Key Points for Congressional Black Caucus Briefing Call - Monday 11:30a.m.

Thanks. Please make sure that it is printed out and given to me before the briefing.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Crawford, Chase (NIH/NIAID) [E] (b) (6)
Sent: Friday, April 10, 2020 7:19 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Haskins, Melinda (NIH/NIAID) [E] (b) (6)>; Selgrade, Sara (NIH/NIAID) [E] (b) (6)
Subject: RE: Attn Dr. Fauci: Key Points for Congressional Black Caucus Briefing Call - Monday 11:30a.m.

Dr. Fauci,

Attached is an updated "one-pager" for your call on Monday with members of the Congressional Black Caucus. At Greg's recommendation, we have added information on the NIH-supported serosurvey that was announced this afternoon.

Please let me know if I can be of further assistance (Chase cell: (b) (6))

Thanks,
Chase

From: Crawford, Chase (NIH/NIAID) [E]
Sent: Friday, April 10, 2020 5:16 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>; Billet, Courtney (NIH/NIAID) [E] <(b) (6)>; Haskins, Melinda (NIH/NIAID) [E] <(b) (6)>; Selgrade, Sara (NIH/NIAID) [E] <(b) (6)>
Subject: Attn Dr. Fauci: Key Points for Congressional Black Caucus Briefing Call - Monday 11:30a.m.

Dr. Fauci,

On Monday, April 13th, at 11:30 a.m., you are scheduled to participate in an informal discussion/telebriefing regarding health disparities and COVID-19 with members of the Congressional Black Caucus (CBC). Rep. Barbara Lee (D-CA, including Oakland and Berkeley) – former CBC chair – made the request. A list of expected call participants is below the signature line of this email.

I have attached a “one-pager” to provide some background on health disparities and COVID-19 that includes information on NIH COVID-19 research that may be relevant to the discussion. As you are aware, we do not have any COVID-19 studies directly focused on the African American community. Hilary and Greg have provided input.

Please let me know if I can be of further assistance (Chase cell: (b) (6))

Thanks,
Chase

List of CBC call participants

Rep. Barbara Lee
Rep. Karen Bass (CBC Chair)
Rep. Robin Kelly (CBC Health Braintrust Chair)
Rep. G.K. Butterfield
Rep. Yvette Clarke
Rep. Cedric Richmond
Rep. Brenda Lawrence

Rep. Steve Horsford
Rep. Ayanna Pressley

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 11 Apr 2020 18:10:39 +0000
To: (b) (6)
Subject: FW: Wpost: Gilead's experimental drug remdesivir shows 'hopeful' signs in small group of coronavirus patients <https://wapo.st/2wzjsy2>

Geeez....

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Sent: Friday, April 10, 2020 5:30 PM
Subject: Wpost: Gilead's experimental drug remdesivir shows 'hopeful' signs in small group of coronavirus patients <https://wapo.st/2wzjsy2>

Business

Gilead's experimental drug remdesivir shows 'hopeful' signs in small group of coronavirus patients

Two-thirds of severely ill patients showed improvement in their oxygen therapy level when treated with the antiviral drug



Two ampuls of remdesivir are pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, April 8, 2020, as the spread of coronavirus disease (covid-19) continues. Ulrich Perrey/Pool via REUTERS (Pool/Reuters)

By

Christopher Rowland

April 10, 2020 at 5:25 p.m. EDT

A majority of a small group of patients showed improvements after being treated with an experimental coronavirus treatment made by Gilead Sciences, bolstering hopes for finding a treatment for the disease, according to a study published in the New England Journal of Medicine Friday.

The group of patients received the anti-viral drug remdesivir as part of a “compassionate use” trial, not a double-blind placebo-controlled trial which would offer more definitive evidence. Also, the cohort of patients was small, only 53 patients in the United States and around the world. Those limiting factors prevent scientists from declaring that the drug works.

Still, the improvements offered positive news about a drug seen by global health authorities as offering the best shot at becoming a treatment for the disease.

Thirty six patients out of 53 — or two-thirds — showed improvement in oxygen support, trial authors said. Seventeen of 30 patients who were on ventilators were able to be taken off the life-support machines.

“We cannot draw definitive conclusions from these data, but the observations from this group of hospitalized patients who received remdesivir are hopeful,” said Jonathan D. Grein, MD, Director of Hospital Epidemiology, Cedars-Sinai Medical Center, Los Angeles, and lead author of the journal article. “We look forward to the results of controlled clinical trials to potentially validate these findings.”

While 68 percent of the patients showed improvement in the level of oxygen support they needed, 13 percent died, the NEJM study said. That 13 percent compares favorably to mortality rates of 17 to 78 percent in China among severely ill patients, the authors wrote.

Gilead's stock has been bolstered for weeks by expectations over remdesivir.

Remdesivir was discovered by Gilead in the hunt for antiviral drugs about a decade ago, and the National Institutes of Health has partnered with the company to explore its benefits. It was shown to work against an array of viruses in laboratory tests.

It showed effectiveness in primates infected with Ebola but failed in a trial in the Democratic Republic of Congo in humans with the deadly disease. It has shown effectiveness as a preventive therapy in primates for MERS, which is a coronavirus cousin of the Covid-19 virus.

There are no treatments approved by the Food and Drug Administration to treat coronavirus, but the FDA has granted an emergency use authorization for the use of hydroxychloroquine and chloroquine, two decades-old anti-malarial drugs. There is scant evidence that the therapy works, but President Trump has repeatedly boosted the promise of the drugs.

Even while multiple full clinical trials of remdesivir continue, Gilead has been swamped with requests for "compassionate use" of the drug. Under compassionate use rules, physicians can obtain experimental drugs for their seriously ill patients when there is nothing else to try.

Gilead said last week that it had enough of the experimental drug on hand to treat up to 140,000 people under compassionate use programs.

0 Comments



Christopher Rowland

Chris Rowland joined The Washington Post business team in 2018 after serving as the Washington bureau chief for the Boston Globe, leading coverage of two presidential elections and overseeing political enterprise reporting. He previously covered health care for the Globe in Boston. [Follow](#)

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 11 Apr 2020 18:09:19 +0000
To: [REDACTED] (b) (6)
Subject: FW: New Yorker: How Anthony Fauci Became America's Doctor
<https://bit.ly/2y3h3fi>

This is the actual article for which I previously sent you a link.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] [REDACTED] (b) (6) >
Sent: Friday, April 10, 2020 4:30 PM
Subject: New Yorker: How Anthony Fauci Became America's Doctor <https://bit.ly/2y3h3fi>

Annals of Medicine
April 20, 2020 Issue

How Anthony Fauci Became America's Doctor

*An infectious-disease expert's long crusade against some of
humanity's most virulent threats.*

By Michael Specter
April 10, 2020



"You stay completely apolitical and non-ideological," Fauci says. "I'm a scientist and I'm a physician. And that's it." Illustration by Tyler Comrie. Photograph by Win McNamee / Getty

Just before midnight on March 22nd, the President of the United States prepared to tweet. Millions of Americans, in the hope of safeguarding their health and fighting the rapidly escalating spread of COVID-19, had already begun to follow the sober recommendation of Anthony S. Fauci, the country's leading expert on infectious disease. Fauci had warned Americans to "hunker down significantly more than we as a country are doing." Donald Trump disagreed. "WE CANNOT LET THE CURE BE WORSE THAN THE PROBLEM ITSELF," he tweeted.

Trump had seen enough of "social distancing." In an election year, he was watching the stock market collapse, unemployment spike, and the national mood devolve into collective anxiety. "I would love to have the country opened up, and just rarin' to go by Easter," he said, on Fox News. "You'll have packed churches all over our country. I think it'll be a beautiful time."

Trump's Easter forecast came more than two months after the first U.S. case of COVID-19 was identified, in Washington State, and more than a hundred days after the novel coronavirus emerged, first from bats and then from a live-animal market in the Chinese city of Wuhan. Every day, more people were falling sick and dying. Despite a catastrophic lack of

testing capacity, it was clear that the virus had reached every corner of the nation. With the Easter holiday just a few weeks away, there was not a single public-health official in the United States who appeared to share the President's rosy surmises.

Anthony Fauci certainly did not. At seventy-nine, Fauci has run the National Institute of Allergy and Infectious Diseases for thirty-six years, through six Administrations and a long procession of viral epidemics: H.I.V., SARS, avian influenza, swine flu, Zika, and Ebola among them. As a member of the Administration's coronavirus task force, Fauci seemed to believe that the government's actions could be directed, even if the President's pronouncements could not. At White House briefings, it has regularly fallen to Fauci to gently amend Trump's absurdities, half-truths, and outright lies. No, there is no evidence that the malaria drug hydroxychloroquine will provide a "miracle" treatment to stave off the infection. No, there won't be a vaccine for at least a year. When the President insisted for many weeks on denying the government's inability to deliver test kits for the virus, Fauci, testifying before Congress, put the matter bluntly. "That's a failing," he said. "Let's admit it."

When Trump was not dismissing the severity of the crisis, he was blaming others for it: the Chinese, the Europeans, and, as always, Barack Obama. He blamed governors who were desperate for federal help and had been reduced to fighting one another for lifesaving ventilators. In one briefing, Governor Andrew Cuomo, of New York, said, "It's like being on eBay with fifty other states, bidding on a ventilator." Trump even accused hospital workers in New York City of pilfering surgical masks and other vital protective equipment that they needed to stay alive. "Are they going out the back door?" Trump wondered aloud.

As a reporter who writes mainly on science and public-health issues, I've known Fauci since the H.I.V./AIDS epidemic exploded, in the mid-eighties. He once explained to me that he has developed a method for dealing with political leaders in times of crisis: "I go to my favorite book of philosophy, 'The Godfather,' and say, 'It's nothing personal, it's strictly business.' " He continued, "You just have a job to do. Even when somebody's acting ridiculous, you can't chide them for it. You've

got to deal with them. Because if you don't deal with them, then you're out of the picture."

Since his days of advising Ronald Reagan and George H. W. Bush, Fauci has maintained a simple credo: "You stay completely apolitical and non-ideological, and you stick to what it is that you do. I'm a scientist and I'm a physician. And that's it." He learned the value of candor early. "Some wise person who used to be in the White House, in the Nixon Administration, told me a very interesting dictum to live by," he told me in 2016, during a public conversation we had at the fifty-year reunion of his medical-school class. "He said, 'When you go into the White House, you should be prepared that that is the last time you will ever go in. Because if you go in saying, I'm going to tell somebody something they want to hear, then you've shot yourself in the foot.' Now everybody knows I'm going to tell them exactly what's the truth."

Americans have come to rely on Fauci's authoritative presence. Perhaps not since the Vietnam era, when Walter Cronkite, the avuncular anchor of the "CBS Evening News," was routinely described as the most trusted man in America, has the country depended so completely on one person to deliver a daily dose of plain talk. In one national poll, released last Thursday, seventy-eight per cent of participants approved of Fauci's performance. Only seven per cent disapproved.

On March 23rd, Fauci failed to appear at the daily briefing in the White House pressroom. Twitter promptly lost its mind. #NoFauci became a top trending topic, followed closely by #whereisFauci and #letTonyspeak. There was speculation that Trump, who is inclined to fire anyone who disagrees with him or, worse, garners some praise in the media, had lost patience with Fauci. As one of Fauci's old friends told me, "This is a President who doesn't give a shit about Fauci's accomplishments, his history, or his learning. If anything, they're negatives."

The truth was less alarming. "I was tied up in a task-force meeting, and we were trying to work out some difficult policies," Fauci said. "I have no trouble with the President. When I talk to him, he listens." My experience with Fauci suggested that this last statement was perhaps a triumph of pragmatism over accuracy. His priority, as he's made clear, is

to do what is necessary to save lives. So I was not surprised to receive an e-mail from Fauci the following day, saying that he had been asked to refrain from participating in personal profiles. It seemed that it was one thing for him to talk about the news with reporters or even to chat on Instagram with Stephen Curry, the Golden State Warriors star. But focussing on himself, rather than on the President, was another thing entirely.

Fauci and Trump are about as odd a duo as American political life has ever produced. Both men are in their seventies. Both come from the outer boroughs of New York City. Both are direct, even blunt. But that's where the resemblance ends. Fauci has always been a person of unusual discipline. Nearing eighty, he works about eighteen hours a day. Long ago, when his three children were young, he and his wife, Christine Grady, who runs the bioethics department at the National Institutes of Health, decided to maintain the sanctity of family dinners by starting them when he got home from the office, at around nine o'clock. For decades, Fauci has taken long lunchtime runs, but, during the crisis, he's cut back his routine to power walking—and only on weekends. Fauci parses his words with care and believes, above all, in the power of facts and the efficacy of data.

ADVERTISEMENT

David Baltimore, a Nobel laureate and a pioneer of molecular biology, told me, “Tony is unique, in that he has such credibility with politicians that he's been able to insert hard facts into the conversation. That has been wonderful for our country and the world.” According to David Relman, a microbiologist at Stanford University who for years has advised the government on biological threats, “Tony has essentially become the embodiment of the biomedical and public-health research enterprise in the United States. Nobody is a more tireless champion of the truth and the facts. I am not entirely sure what we would do without him.”

Fauci can be impatient with the compromises of politics. In my conversations with him, he has responded furiously when a dicey amendment, a bogus rider, or a “poison pill” is attached to a public-

health bill. He recalled one congressional provision, in 2016, that tried to make it “legally permissible to fly the Confederate flag at national cemeteries. I am not kidding.” When dealing with politicians, he told me, he relies on the pseudo-Latin expression *Illegitimi non carborundum*: Don’t let the bastards grind you down. But he has inspired respect throughout the political world and beyond. Fauci’s office walls are covered with scores of photographs of him with Presidents, senators, visiting Prime Ministers, business leaders, actors. In October, 1988, George H. W. Bush, during a Presidential debate with Michael Dukakis, was asked who his heroes were. “I think of Dr. Fauci,” Bush replied. “You’ve probably never heard of him. . . . He’s a very fine researcher, a top doctor at the National Institutes of Health, working hard, doing something about research on this disease of AIDS.” These days, nearly everyone has heard of Fauci. Pandemic-memorabilia entrepreneurs have put his face on bottle openers, coffee mugs, and bumper stickers: “In Dr. Fauci we trust.” The National Bobblehead Hall of Fame and Museum has produced a seven-inch likeness of him, partly to raise money to produce protective gear for medical workers. There’s a Facebook group called Dr. Fauci Speaks, We Listen, and another called Dr. Fauci Memes for Social Distance Teens. A petition has circulated to nominate him as *People’s* “sexiest man alive.”

On right-wing social media and talk radio, Fauci has a different image: he is routinely disparaged as a closet lefty who is exaggerating the threat of the coronavirus. “Has anyone else noticed that every suggestion by Dr. Doom Fauci just happens to also be the worst possible thing for the economy?” the conservative Internet TV host Bill Mitchell tweeted. “That’s not an accident folks.” An analysis in the *Times* found more than seventy Twitter accounts that have pushed the hashtag #FauciFraud, with some tweeting out anti-Fauci bile hundreds of times a day. “There seems to be a concerted effort on the part of Trump supporters to spread misinformation about the virus,” Carl Bergstrom, a professor of biology at the University of Washington who has studied misinformation, told the paper. “There is this sense that experts are untrustworthy, and have agendas that aren’t aligned with the people.” Fauci has received so many personal threats that the Justice Department recently approved a security

detail for him. Fauci shrugged it off, telling reporters, “I’ve chosen this life.”

The crisis that the world now faces comes as no surprise to Fauci. On January 10, 2017, ten days before Trump took the oath of office, Fauci delivered the keynote address at a conference at Georgetown University, titled “Pandemic Preparedness for the Next Administration.” After describing his years of managing epidemics, he posed a series of questions to the audience: “Will there be a resurgence of Zika? We’re getting into the summer in South America. Are we going to see a resurgence or not? What about influenza? Are we going to get a new pandemic?”

Fauci’s last point, he emphasized, was almost certainly the most important: the possibility that some unknown, powerfully infectious pathogen could emerge to threaten the world. “What about things that we’re not even thinking about?” he said. He let the question drift out over the hall. “What is for sure,” he concluded, “is that, no matter what, history has told us definitively that it will happen.”

On the day that Anthony Stephen Fauci was born, the front-page headline in the *Times* was “PRESIDENT TO GIVE EMERGENCY FACTS TO NATION ON RADIO.” It was Christmas Eve, 1940. The Second World War had begun, and the United States was less than a year away from joining the fight.

Fauci grew up in southwest Brooklyn, first in Bensonhurst and later in Dyker Heights, where his family ran a pharmacy and lived in an apartment upstairs. The pharmacy was across the street from the Shrine Church of St. Bernadette. When Mass was finished on Sundays, Fauci recalled, people would walk over to get prescriptions filled and to buy whatever else they needed for the coming week. Tony’s father, Stephen, dispensed medications, and was known to customers as Doc. His mother, Eugenia, worked the register, along with his older sister, Denise. From an early age, Tony spent evenings and weekends riding around the neighborhood on his Schwinn, making deliveries.

Fauci's parents were born in New York; one set of grandparents had emigrated from Naples, the other from Sicily. Anthony first took Communion at the age of seven and was confirmed at twelve. He went to elementary school at Our Lady of Guadalupe, in Bensonhurst. "I had no idea at the time when I was there, being taught by the Dominican nuns, that I would be interested in science," he said. "I was interested in a lot of things, mostly sports, but certainly not science."

In those days, baseball was the social glue of Brooklyn. The borough was Dodger territory and Ebbets Field was consecrated ground—but Fauci was devoted to the Yankees, who played in the faraway Bronx. In the midst of the coronavirus crisis, I e-mailed to ask about this anomaly, not necessarily expecting an answer. He replied almost instantly. "You probably are unaware, but half the kids in Brooklyn were Yankee fans," he wrote. "We spent our days arguing who was better: Duke Snider versus Mickey Mantle; Roy Campanella versus Yogi Berra; Pee Wee Reese versus Phil Rizzuto and on and on. Those were the days, my friend."

Fauci has often referred to his father as "laid-back," which, if true, must be a characteristic that skips a generation. "Tony has always been driven," Michael Osterholm, the director of the University of Minnesota's Center for Infectious Disease Research and Policy, and a longtime friend of Fauci's, told me. "Whatever he was doing, he had to do it better than anybody else. I don't know if it was certainty or something else. But he was meant to lead. Always. Everyone who knew him knew that. And Tony knew it, too."

In 1954, he began attending Regis, a private Jesuit high school on the Upper East Side. Rigorous, small, competitive, and tuition-free, Regis is considered one of the finest all-male schools in the country. Fauci thrived there, though the commute between Dyker Heights and Eighty-fourth and Madison was long. He once estimated that he had spent the equivalent of seventy days of his teen-age life on the various subways and buses he took to get to and from school.

Fauci revelled in the demanding coursework. "We took four years of Greek, four years of Latin, three years of French, ancient history, theology," he recalled. He developed an ability to set out an argument

and to bolster it with evidence—good preparation, it turned out, for testifying before Congress. Last year, at a dinner that Regis held in his honor, he said that the school had taught him “to communicate scientific principles, or principles of basic and clinical research, without getting very profuse and off on tangents.”

At the time, though, Fauci had no interest in becoming a doctor. “I was captain of the Regis High School basketball team,” he once told me. “I thought this was what I wanted to do with myself. But, being a realist, I very quickly found out that a five-seven, really fast, good-shooting point guard will never be as good as a really fast, good-shooting seven-footer. I decided to change the direction of my career.”

At school, Fauci’s accomplished peers were headed to careers in medicine, engineering, and the law. At home, he was steeped in the humanities: “Virtually all my relatives on my mother’s side—her father, her brother, and her sister’s children—are artists.” His mother helped tip the balance. “She never really pressured me in any way, but I think I subtly picked up the vibrations that she wanted very much for me to be a physician,” Fauci said. “There was this tension—would it be humanities and classics, or would it be science? As I analyzed that, it seemed to me that being a physician was the perfect melding of both of those aspirations.”

From Regis, Fauci went on to another Jesuit institution, Holy Cross, in Worcester, Massachusetts. His high-school faculty had left him little choice in the matter. “They just wouldn’t write a recommendation for you if you wanted to apply to Harvard or to Cornell, or Columbia,” he said. Fauci enrolled in 1958 and was pleased to find that the university took a broad view of premedical studies. He signed up for a program called Bachelor of Arts–Greek Classics–Premed. “It was really kind of bizarre,” he recalled. “We did a lot of classics, Greek, Latin, Romance languages. . . . We took many credits of philosophy, everything from epistemology to philosophical psychology, logic, etc. But we took enough biology and physics and science to get you into medical school.”

During the summers, Fauci worked construction jobs. One year, he found himself assigned to a crew that was building a new library at

Cornell Medical College, on the Upper East Side. “On lunch break, when the crew were eating their hero sandwiches and making catcalls to nurses, I snuck into the auditorium to take a peek,” Fauci recalled in 1998, at the medical school’s centennial celebration. “I got goosebumps as I entered, looked around the empty room, and imagined what it would be like to attend this extraordinary institution. After a few minutes at the doorway, a guard came and politely told me to leave, since my dirty boots were soiling the floor. I looked at him and said proudly that I would be attending this institution a year from now. He laughed and said, ‘Right, kid, and next year I am going to be Police Commissioner.’ ”

Fauci graduated first in his class from Cornell in 1966, just as America’s involvement in Vietnam was accelerating. Every new physician was required to perform some kind of military service. “We were gathered in the auditorium at Cornell, early in our fourth year of medical school,” Fauci recalled. “Unlike today, we had only two women in the class and seventy-nine men. The recruiter from the armed forces came there and said, ‘Believe it or not, when you graduate from medical school at the end of the year, except for the two women, everyone in this room is going to be either in the Army, the Air Force, the Navy, or the Public Health Service. So you’re going to have to make your choice. Sign up and give your preferences.’ ”


Fauci wanted to work in the U.S. Public Health Service; his fallback was the Navy. He got his first choice, and ended up at the National Institutes of Health, which was then establishing itself as the country’s primary center for biomedical research. Nearly everyone in academic medicine spent some time at one of its branches; except for three years back at Cornell to complete his internship and residency, Fauci has spent five decades there.

In 1972, Fauci started as a senior researcher at the National Institute of Allergy and Infectious Diseases. He was drawn to investigating ailments that were difficult but not impossible to treat. “I wanted something that could make you very sick and kill you unless I intervened. And if I

intervene, you're essentially cured," he told Ushma Neill, the editor of *The Journal of Clinical Investigation*, in 2014. "Now, that seems a little bit too simplistic, but that's really the nature of most infectious diseases."

Working in the lab of Sheldon Wolff, Fauci studied the molecular nature of fever. The field of immunology was still young, but scientists were rapidly learning how to manipulate the smallest components of individual cells, which opened the way to a decade of discovery.

Chronic fevers can have a number of underlying causes, among them an uncommon condition known as vasculitis—an inflammation of the blood cells that often occurs when the body's immune system mistakenly attacks its own blood vessels. Many of Fauci's vasculitis patients suffered from rare inflammatory diseases, such as granulomatosis with polyangiitis, which damages blood vessels in the lungs, kidneys, and other organs. The disease was almost always fatal. Fauci and his infectious-disease colleagues at the N.I.H. were frequently asked to visit the National Cancer Institute, which was in the same building as his lab, to consult on patients who were receiving chemotherapy. The drugs suppressed tumors, but they were highly toxic. And they had another side effect, Fauci told me: "Those people are susceptible to a lot of things like infections and bleeding, because the treatment has destroyed their immune systems."



In 1990, Fauci was the government's leading researcher focussed on the AIDS epidemic. Photograph by George Tames / The New York Times / Redux

Fauci, together with Wolff, his mentor, wondered if this side effect could be harnessed to help vasculitis patients, whose immune systems were overactive. "I thought if we could somehow give a cancer drug at a low enough dose perhaps we could turn the disease off without any of the secondary complications," he recalled recently. "First we did it in a few patients, and, much to our delight, they had a total remission. Before you know it, we ended up curing a very, very lethal, albeit uncommon, disease."

For the first time, this technique enabled researchers to do effective work on lupus, rheumatoid arthritis, and transplant rejection. "If you look at immunology, it has from the very beginning been inextricably linked to infectious diseases," Fauci said. "What is the immune system for? The immune system protects you against invaders from without—microorganisms—as well as, in some cases, the emergence of certain tumors from within."

In 1981, a strange new syndrome emerged that transformed Fauci's research and, eventually, the lives of millions of people around the

world. “All of a sudden, this new disease comes along,” Fauci recalled, referring to what would soon come to be known as AIDS. “Even before the cause of it was proven to be H.I.V., everybody in the field knew that it had to be a virus. I said to myself, ‘Here it is, a virus, still to be determined, that’s affecting profoundly and destroying the human immune system.’ ” Fauci believed that he had been training all his life for a threat like this one. He was an expert in viruses and in the immune system—and he had always been attracted to combatting serious, even fatal diseases. “I wanted to be where the action was,” he said.

At first, few public-health officials seemed to care. In June of 1981, the *Morbidity and Mortality Weekly Report*, a publication of the Centers for Disease Control, issued a paper that included an account of five young men, all gay, who had contracted pneumocystis, a form of pneumonia that had previously been reported only in people with dramatically impaired immune systems. The young men described in the study had all been healthy. “I thought it was a fluke,” Fauci recalled. “I put it aside on my desk, thinking that maybe this was some drug that they had taken that suppressed their immune system.”

A month later, an even more alarming report arrived from the C.D.C. Fauci read it with an uneasy sense that a disaster was looming: “I made the decision that I was going to stop what I was doing, much to the chagrin of my mentors, who were saying, ‘Why do you want to give up a great trajectory of a career to study a handful of gay men with this strange disease?’ But, deep down, I really knew that this was going to explode.”

Fauci wrote a paper to sound the alarm. “I called it my *apologia pro vita sua*—an explanation for what I’m doing,” he said. In the paper, Fauci pointed out that, although the disease “seems to selectively affect a particular segment of our society,” it demanded a medical solution. Moreover, he warned, “any assumption that the syndrome will remain restricted to a particular segment of our society is truly an assumption without a scientific basis.” Fauci sent the manuscript to *The New England Journal of Medicine*, in late 1981. It was rejected. “One of the reviewers said I was being alarmist,” Fauci said. He tried a different

journal, *The Annals of Internal Medicine*, and the following June the paper was published.

In the laboratory, Fauci began making progress. He had been investigating B cells, which are involved in the production of antibodies. In 1983—before H.I.V. was even known by that name—his lab became the first to report that B cells became hyperactive in patients with AIDS. When a healthy person is invaded by a virus, antibodies mount a defense, but, when H.I.V. hijacked B cells, the antibody system went awry. Fauci and his team had identified one of the crucial features of AIDS. “We made that observation without having any idea of what we were dealing with,” he said in an interview for an N.I.H. oral history. “I think that speaks for sound scientific and clinical observation.” The politics of seeking a cure, though, would be far harder to manage.

On October 11, 1988, more than a thousand AIDS activists gathered outside the headquarters of the Food and Drug Administration, in Rockville, Maryland, to protest the agency’s glacial reaction to the epidemic. The activists knew that their community needed new treatments if they were to avoid catastrophe—but they were stymied by the F.D.A.’s drug-approval process, a remarkably inflexible system that typically took years.

That same day, another group of protesters marched onto the campus of the National Institutes of Health, in Bethesda, Maryland. They were headed for Building 31, the home of the National Institute of Allergy and Infectious Diseases. Fauci, who had become the institute’s director in 1984, was now the government’s leading scientist focussed on the AIDS epidemic. Even though he was not running the F.D.A., he appeared almost daily in the media to discuss the crisis. “My face was the face of the federal government,” Fauci told me. He was asked the same question nearly every day: why wasn’t the government moving faster? It didn’t help that the Reagan Administration seemed so indifferent to the plague.

Fauci watched from his office window as activists surrounded the building and tried to scale its walls. Some were dressed in black robes

and carried scythes. Many waved pink-and-black banners, bearing the words “NIH Wake Up!” or “Stop Killing Us!” All over campus, a chant could be heard: “Fuck you, Fauci!”

“God, I hated him,” Larry Kramer, the writer and activist who helped establish the two most important AIDS advocacy groups in the country, the Gay Men’s Health Crisis and ACT UP, said. “As far as I was concerned, he was the central focus of evil in the world.” Kramer attacked Fauci relentlessly in the media. He called him an “incompetent idiot” and a “pill-pushing” tool of the medical establishment, insulted his wife, and even compared him to Adolf Eichmann. In 1988, Kramer published a scathing open letter. “Anthony Fauci, you are a murderer,” he wrote. “Your refusal to hear the screams of AIDS activists early in the crisis resulted in the deaths of thousands of Queers.”

As the epidemic spread and the death toll rose, it was common for gay activists to view Fauci and NIAID with rage. Fauci did not control the drug-approval process, but he was seen as a barrier to opening access to clinical trials, in which volunteers could receive potentially lifesaving medications.

For most people infected with H.I.V., taking experimental drugs was the only alternative to simply waiting for death. Yet the F.D.A.’s arcane rules prevented the vast majority of patients from qualifying for trials. For instance, a significant number of H.I.V. patients suffered from pneumocystis pneumonia. The condition—the same one observed in the initial C.D.C. report—could be fatal, so many who had it used an experimental antimicrobial medication called pentamidine, which had proved highly effective. But people who took experimental medications were barred from participating in other clinical trials.

At first, Fauci held to the standard N.I.H. line that research need not focus on the immediate welfare of patients. “When we had clinical trials, we, the scientific community and the regulatory community, did not listen” to the activists, he recalled. “It was, at the time, an attitude that many of us had, and I probably had it myself.” He was right about that. I covered the AIDS epidemic for the *Washington Post*, and it was clear to me that Fauci was inclined to enforce the paternalistic medical tradition in which he had trained: doctors and scientists were unquestioned

authorities, and drug development had to follow a rigid process that included animal testing and rigorous clinical trials. Otherwise, the benefits and the risks of these drugs could not be adequately assessed. In 1987, the F.D.A. approved the first drug to treat H.I.V.—azidothymidine, or AZT—and the announcement was met with a burst of hope. But the drug's liabilities were evident almost instantly. It had harsh side effects, and the benefits wore off; the virus itself soon became resistant to the drug. When new clinical studies began, involving cocktails of AZT and similar compounds, tens of thousands of people asked to participate. Again, though, volunteers were not accepted if they used other experimental drugs. The anger among activists grew more intense. "They started becoming amazingly iconoclastic and confrontational, and that scared the hell out of the scientists, who were fundamentally quite conservative," Fauci told me at his medical-school reunion. "When they were demonstrating on the N.I.H. campus, disrupting Wall Street, disrupting St. Patrick's Cathedral, instead of listening to them, scientists withdrew."

Without entirely understanding his own motives, Fauci decided to look beyond the activists' furious rhetoric and style. He recalls telling himself, "Let me put aside the goth dress—the earrings and the Mohawk haircuts and the black jackets—and just listen to what they have to say. And what they were saying made absolutely perfect sense." It helped that Fauci had something in common with the activists: "They were all New York guys. I had a little affinity to them because I'm a New Yorker. And I said, What would I do if I were in their shoes? And it was very clear: I would have done exactly the same thing."

The activists knew that they were facing a mercilessly lethal disease. In the summer of 1985, I travelled to New York to write my first long story on the toll that the epidemic was taking on the city's gay community. I interviewed dozens of men. To the best of my knowledge, only two of them are still alive: Larry Kramer, who is now eighty-four, and a political activist who prefers to remain anonymous.

Fauci, too, came to understand the severity of the crisis. "Everyone died," he said. "I was used to treating people who had little hope and then saving their lives—that was so wonderful. But, with AIDS in those

days, I saved no one. It was the darkest time of my life.” Faced with mounting evidence that his cautious approach made no sense, he did something that few public officials do: he reversed himself. Fauci transformed from a conventional bench scientist into a public-health activist who happened to work for the federal government. “I had to change,” he told me.

When the demonstrators marched on the N.I.H. campus in 1988, Fauci no longer saw a threat. “I looked at them, and I saw people who were in pain,” he recalled in an article in *Holy Cross Magazine*. He asked the police and the F.B.I. not to arrest any of them. Then he invited a handful of protest leaders to his office. “That began a relationship over many years,” Fauci said. “They let me into their camp. I went to the gay bathhouses and spoke to them. I went to San Francisco, to the Castro District, and I discussed the problems they were having, the degree of suffering that was going on in the community, the need for them to get involved in clinical trials, since there were no other possibilities for them to get access to drugs. And I earned their confidence.”

Fauci, in his mid-forties, was the youngest director of an N.I.H. institute in a century, and he lacked the political influence to act independently. Even in his own field, he struggled to recruit allies. “I couldn’t convince my own people in infectious-disease leadership to take on H.I.V./AIDS,” he told me. So he created a division within his institute devoted to the disease.

One day, in the late eighties, Fauci asked me to stop by his office in Building 31 on the N.I.H. campus. He told me that he had a wild idea: he wanted to hire Mark Harrington, ACT UP’s point man on drug-treatment trials. Harrington, a prominent AIDS researcher and activist, had no formal scientific training. But Fauci, like most of those who had seen him testify before Congress or speak to a crowd, was dazzled by his brilliance.

Harrington discussed the idea with Fauci, but decided that the job would be a disaster for him. “There’s no way I could have functioned within that bureaucracy,” he told me recently. “The people I respect would have

seen me as a sellout.” Yet Harrington continued to make a profound impression on Fauci’s thinking.

Harrington was passionately committed to loosening up the F.D.A.’s restrictive regime. “It was murder,” he told me. “I don’t know any other way to describe it.” Harrington, who went on to win a MacArthur “genius” grant for his work on the disease, established himself as the most knowledgeable student of the agency’s byzantine regulations. In meetings with Fauci and other officials, he urged them to move faster and with greater compassion for those who were suffering.

There are three stages in most F.D.A. clinical trials. The first tests whether a drug is safe. The second assesses its efficacy. The last stage, conducted in larger groups, confirms that the drug works and that there are no serious adverse reactions. Harrington argued that people with no alternative should be granted access to those drugs as soon as they had been proved safe, even if their effectiveness remained unknown.

At first, Fauci was concerned that, if people taking multiple experimental medications joined clinical trials, the results would be hopelessly muddled. He was also afraid that granting sick people unrestricted access to unapproved drugs would deter them from participating in the trials at all. Harrington and other activists reassured him that they were committed to strictly monitored drug trials that would provide enough data to know what worked and what did not.

Fauci is a realist, and the facts were obvious to anyone who cared to look. Traditional methods of testing drugs weren’t working.

Underground networks were growing everywhere. With so many AIDS patients taking untested medications, federal health officials had to concede that their system was broken. Even the most fundamental protocol of a clinical trial—giving some participants a placebo—came into question. In a study conducted in San Francisco in 1989, nearly all the volunteers had their medicine analyzed, to see whether they were receiving an active dose. Those who learned that they had been given placebos almost invariably dropped out.

“There was a feeling in science that doctors know best, scientists know best,” Fauci said. “We love our patients, but they don’t really know what’s best for them. Then, when we dealt with this disease that was

brand new—that was frightening, that was killing people in a way that was historic—the people who were impacted by the disease wanted to have something to say about how we conducted research.”

There were still moments of confrontation. In May, 1990, hundreds of ACT UP activists returned to the N.I.H., demanding more AIDS treatments and greater representation of women and people of color in clinical trials. At a planning session for the protest, a young activist named Tony Malliaris performed a rap song called “Storm the NIH,” which included the lyrics “I don’t know what Fauci thinks, but this ain’t Denmark, and something stinks.” (Malliaris died five years later, still in his early thirties.)

Fauci was undeterred. He threw his influence behind a program called Parallel Track, which made unapproved AIDS drugs available as soon as they were demonstrated to be safe, even as clinical trials were continuing. The initiative would not have succeeded without Fauci. But he always acknowledged that his approach had been shaped largely by the constructive pressure he received from AIDS advocacy groups and from leaders like Harrington.

This more inclusive approach ushered in a revolution in American medicine. Patients today demand as much information as possible about treatments they might receive, and no longer act as if their doctors’ advice came straight from Mt. Olympus. They scour the Internet, assemble statistics, and often arrive at the hospital with a folder full of medical information. The F.D.A., for its part, will no longer consider approving a new drug until it has consulted representatives of groups who would use it. “There are strict scientific principles that have to be adhered to in medicine,” Fauci told me. “At the same time, a humanistic touch is needed in dealing with people. You have to combine social aspects, ethical aspects, personal aspects with cold, clean science.”

In 2002, I wrote a Profile of Larry Kramer for this magazine. By then, he and Fauci had become friends, with each expressing gratitude for the other’s work in those years. Fauci told me, “In American medicine, there are two eras: before Larry and after Larry. There is no question in my mind that Larry helped change medicine in this country. When all the

screaming and the histrionics are forgotten, that will remain.” Kramer, who spent years in a constant rage at Fauci, now calls him “the only true and great hero” among government officials in the AIDS crisis.

As Trump defends his Administration’s response to the pandemic, he has suggested repeatedly that COVID-19 was impossible to predict. “There’s never been anything like this in history,” he said, at a press conference on March 19th. “Nobody knew there would be a pandemic or epidemic of this proportion.”

As everyone with even a casual interest in the history of science knows, pandemics have altered the destiny of humanity at least since 430 B.C., when Athens was struck by a plague that killed as many as two-thirds of its residents, just as the Spartans were laying siege. Beginning in 165 A.D., smallpox helped ruin the Roman Empire, sowing more destruction than foreign armies ever could. And, in the fourteenth century, the Black Death swept through Europe, killing more than half the population, according to recent estimates.

Yet, by the middle of the twentieth century, many scientists had begun to conceive of a world that was largely free of infectious epidemics. In 1951, Sir Frank Macfarlane Burnet, a future Nobel laureate in medicine, wrote, “The fever hospitals are vanishing or being turned to other uses. With full use of the knowledge we already possess, the effective control of every important infectious disease”—with the exception of polio—“is possible.” His optimism was understandable. Antibiotics had made many lethal diseases easy to treat; improvements in sanitary conditions had transformed the lives of hundreds of millions of people. In developed countries, typhoid, cholera, and measles—major killers throughout history—had largely passed into memory; even tuberculosis, one of the great scourges of humanity, had been in decline for nearly half a century. By 1972, Macfarlane, writing with the microbiologist David White, was predicting that the “most likely forecast about the future of infectious diseases is that it will be very dull.”

When Fauci was a young trainee, these kinds of predictions sometimes made him wonder if he had picked the wrong career. “I became

concerned that I was entering . . . an area of biomedical research that was disappearing,” he recalled in one speech. But, since 1984, when Fauci became the director of NIAID, there has not been a single day in which some epidemic has not threatened the globe. According to the World Health Organization, AIDS has killed more than thirty million people, and nearly forty million are now living with H.I.V. Tuberculosis, far from sliding into obscurity, infects roughly a quarter of the human population; the W.H.O. says that one and a half million people died from the disease in 2018.

But the greatest threat that humanity faces, by far, is a global outbreak of a lethal virus for which no treatment has been found. In just a few months, COVID-19 has forced billions of people, in nearly every country on earth, into a panicked withdrawal from society. Another pandemic like this might appear in two years, or in ten, or in a century. But I have never met a virologist or an epidemiologist who believes we won’t encounter one.

For a deadly virus to flourish, it must meet three critical conditions. First, a new virus—one to which no one has yet developed immunity—must emerge from the animal reservoirs that produce and harbor such pathogens. Second, the virus has to make humans sick. (The vast majority do not.) Finally, it must be able to spread efficiently, through coughing, sneezing, or shaking hands. That combination is rare, but, when it appears, the consequences are almost always disastrous.

The Nobel Prize-winning molecular biologist Joshua Lederberg, who died in 2008, was for years the world’s most visionary voice about emerging infectious diseases. “Some people think I am being hysterical, but there are catastrophes ahead,” he once wrote. “We live in evolutionary competition with microbes—bacteria and viruses. There is no guarantee that we will be the survivors.”

In 2003, Lederberg joined the future F.D.A. commissioner Margaret Hamburg and the pandemic specialist Mark Smolinski to edit a seminal report, in which prominent scientists argued for a much more aggressive defense of the planet. Titled “Microbial Threats to Health,” the report recommended that the U.S. greatly expand its early-warning systems, particularly in the developing world. It also urged leaders to strengthen

their ability to respond to microbial threats, with new efforts on the federal, state, and local levels. The recommendations were almost completely ignored.

The next year, a highly pathogenic form of avian influenza, H5N1, leaped from waterfowl to chickens and then to humans. Public-health officials were petrified. In Bangkok, I met with Scott Dowell, who led the Thailand office of the C.D.C.'s International Emerging Infections Program. "The world just has no idea what it's going to see if this thing comes," he told me. He paused and then reframed his thought. "When, really. It's when. I don't think we can afford the luxury of the word 'if' anymore."

In a sense, the world was lucky with H5N1. Although the U.S. and other countries mounted a diffident response, the virus turned out to be deadly but not very contagious. Five years later, the situation was reversed. A new influenza virus, designated H1N1, infected nearly a quarter of the global population before vaccines became widely available. This time, the virus was highly contagious but not nearly as deadly as most strains of influenza. The fact that the outbreak was less virulent than public-health officials had feared created its own danger; by encouraging complacency, it did more to expose the world to the risk of a devastating new pandemic than anything else that had happened in decades.

Although Congress had appropriated money to stockpile antiviral medications and protective gear, many scientists felt that the effort was grossly insufficient. "We spend many billions of dollars every year on missile-defense systems," Seth Berkley, a medical epidemiologist who leads the Global Vaccine Alliance, told me. "And yet we will not spend pennies on the dollar to prepare for a catastrophe that is far more likely to affect us all."

After the Ebola outbreak of 2014, Barack Obama implemented one of Lederberg's central recommendations: he established the White House's National Security Council Directorate for Global Health Security and Biodefense, an early-warning system for disease in the developing world. Trump disbanded it in 2018, as part of an effort to streamline the N.S.C. In an appearance before Congress, Fauci was asked if the decision was a mistake. He responded diplomatically: "I wouldn't

necessarily characterize it as a mistake. I would say we worked very well with that office. It would be nice if the office was still there.”

The combination of money and political will can have extraordinary effects on public health. Under the George W. Bush Administration, Fauci was the principal architect of a landmark program called PEPFAR, the President’s Emergency Plan for AIDS Relief.

By the time Bush took office, therapies for H.I.V. had become widely available in Western countries. But, for millions of people in the developing world, these drugs were too expensive or too difficult to obtain. Bush felt that it was unacceptable for the poorest people on earth to die because they could not afford medication that was dispensed routinely in the rich world. He asked Fauci to implement an initiative to prevent and treat H.I.V. on a global scale. It has been uniformly held up as a model of the ways in which global public-health programs can save lives. “PEPFAR has turned around declining life expectancies in many countries and likely saved some countries—even an entire continent—from economic ruin,” Harold Varmus, a former director of the N.I.H. and of the National Cancer Institute, wrote in the quarterly journal *Science & Diplomacy*.

But Fauci has at times struggled to compel politicians and businesses to attack the problems that he considers most worrisome. Over the years, he has become concerned about the possible impact of new viruses, particularly a lethal strain of influenza. Other viruses are more consistently deadly; some, like measles, are more contagious. But no virus that we know of is capable of killing as rapidly and as efficiently. “We need a major paradigm shift with influenza vaccines,” Fauci told me, four years ago. “The situation is a mess.”

Because the flu virus evolves so rapidly, experts deciding how to formulate vaccines can make only a highly educated guess about which strains are most likely to make people sick. Each February, epidemiologists study outbreaks around the world—especially in the Southern Hemisphere, where flu season is under way—to assess which strains might make their way north. The result is always better than

nothing. In many years, though, it is woefully inadequate. In the flu season of 2014-15, the vaccine protected less than a fifth of the people who received it. In 2017-18, it worked for a little more than a third. Fauci has long supported the development of an alternative: a universal influenza vaccine, which would provide lasting defense against all strains. “Similar to tetanus, a universal flu vaccine probably would be given every ten years,” he said. “And, if you get one that is really universal, you can vaccinate just about everyone in the world.” But such a vaccine would cost hundreds of millions of dollars to develop and test—and would replace a product that most consumers already think of as good enough. No one has come close to raising the money that such a project will require.

By the beginning of the new millennium, it had become clear that the next microbial threat might not come from a bat or a duck. It could just as well be created by a human being. After the terrorist attacks of September 11, 2001, anonymous letters laced with deadly anthrax spores began arriving at media companies and congressional offices. In the following months, twenty-two people were infected by inhaling anthrax and five died. Suddenly, biological terror posed an entirely new threat—one that has become only more significant and complex in the ensuing years. In 2016, James Clapper, who was the director of National Intelligence during the Obama Administration, listed gene editing as a potential weapon of mass destruction. Many scientists were furious, but he had a point. Researchers have deployed these tools to rewrite the genes of mosquitoes so that they are unable to transmit malaria. If their success in the lab translates to the field, it will be a historic triumph. But the research also raises an alarming possibility: if a scientist can modify the genes of an insect to protect people from malaria, he could almost certainly use the same technology to add a deadly toxin. Fauci often cites a similar but more immediate paradox. Thanks to genetic engineering, we are more equipped than ever to respond to the threat of a viral pandemic. After the COVID-19 outbreak began, it took scientists less than a month to sequence the genome of the virus. By the

end of February, the instructions were on the Internet, and the virus had been re-created in laboratories around the world, by scientists seeking to develop drugs and vaccines.

And yet, despite our mastery of molecular biology, we live in an era in which someone can wake up with an infection in China—or France, Australia, or any other place with an airport—and fly to San Francisco in time for dinner, spreading the virus long before he suspects that there’s anything wrong. For most of human history, a virus like COVID-19 might have killed many people in the community where it originated, but then stopped spreading. According to a comprehensive analysis carried out by the *Times*, at least four hundred and thirty thousand people have arrived in the U.S. on direct flights from China since the outbreak began. Forty thousand have arrived in the two months since Trump imposed restrictions on travellers from China trying to enter the country.

Fauci insists that an adequate defense against future pandemics will have to be flexible. “I have been saying for eight, ten years that we should make a list of microbes and try to develop a basic platform vaccine,” he told me in 2016. A platform vaccine addresses an entire class of virus, not just a particular strain. “We keep trying to develop a vaccine for one thing—usually the last one—and it’s a waste of time,” he said. “Every time we get hit, it is always something we didn’t expect. So, instead of predetermining what it is you’re going to prepare for, make universal platforms.”

Such an approach is eminently possible. Using gene-sequence information and synthetic DNA, biologists are now capable of making parts of a vaccine in advance. It takes almost no time to sequence a viral strain, and with that information it should be possible to complete a bespoke vaccine in a matter of weeks. “You could build a chassis for the vaccine, and you would have it on the shelf,” Fauci said. “Then all you would need to do is insert the gene of the protein you want to express and make a gazillion doses and send it out.”

There are even more futuristic aspirations: the genomics pioneer J. Craig Venter has proposed using a sort of 3-D printer to manufacture vaccines on demand. It is already possible to print the nucleotides that make up DNA and assemble them. Venter argues that, in the time it takes for an

infected person to fly from one side of the world to the other, we should be able to print, assemble, and administer a vaccine.

To even contemplate creating these kinds of treatments, Fauci says, would require building an entirely new system for making vaccines before a pandemic arises. But, in addition to the scientific obstacles, this would cost billions of dollars, and no company or politician has been willing to spend the money. Perhaps, just as AIDS transformed our approach to clinical trials, our experience with COVID-19 will change our attitudes about preventing infectious diseases. A proper investment in both research and emergency preparedness would have prevented at least some of the unspeakable human loss we are now experiencing and the economic crash that has just begun.

The COVID-19 epidemic will eventually fade, but the public will demand a reckoning. Inevitably, there will be an investigation, along the lines of the 9/11 Commission, to look into the ramifications of the President's denialism, the shortages in testing and medical equipment, and the dismissal of so many warning signs. Fauci will not necessarily escape criticism. He is an excellent spokesman for the value of scientific research, but he runs a single institute, and he lacks the authority to broadly reshape our response to pandemics. "The kinds of things we really desperately need as foundational tools for dealing with this stuff aren't necessarily research enterprises," Harold Varmus told me. "Tony isn't running C.D.C. He's not running FEMA. To tell him to stockpile defense mechanisms or to move forward surveillance tools into massive operations around the world—that's just not his remit."

Even Fauci's current value as a scientific adviser has been limited by the President's contempt for expertise. Trump's coronavirus kitchen cabinet consists of people like his son-in-law, Jared Kushner, who has no medical knowledge or experience managing crises—yet has been appointed to direct the response to the biggest medical emergency since the influenza pandemic of 1918. Trump has also turned for advice to Dr. Mehmet Oz, who for years has endorsed worthless treatments and used his television show to promote notorious quacks. Trump even seems to think that his trade adviser, Peter Navarro, should debate Fauci about the value of specific drugs. When Navarro, who has a doctoral degree in

economics, was asked about his medical qualifications, he said, “I have a Ph.D. And I understand how to read statistical studies, whether it’s in medicine, the law, economics, or whatever.”

Among Navarro’s enthusiasms is the malaria drug hydroxychloroquine, which he believes could cure COVID-19. There is currently no evidence to support this conclusion, as Fauci has pointed out on several occasions. On April 5th, as Trump continued to tout the drug as a miracle cure, a reporter at the daily briefing asked Fauci to comment. Trump refused to allow him to speak. In an appearance two days later, Trump kept up the hype. “I say try it,” he said. “You’re not gonna die from this pill.” Not long afterward, he even suggested that zinc might help.

To plan a coherent biological future, rather than simply scramble to contain each new pandemic, will require an entirely new kind of political commitment. It would certainly include the creation of a permanent position, a special assistant to the President for biological defense. Similar jobs have existed in the past, but not for long, and not with enough influence to matter. David Relman, the Stanford professor, told me, “This kind of job needs somebody with the authority to preside over domestic and international threats, both natural and deliberate. And that person has to sit in the White House with immediate access to the President. Without that, we will really have nothing that can work.”

Until then, we have Fauci, a seventy-nine-year-old infectious-disease expert pinned between Donald Trump and the American people. It can’t be easy. As Fauci recently put it, with characteristic candor, “I give the appearance of being optimistic. But, deep down, I just do everything I possibly can, assuming that the worst will happen, and I’ve got to stop the worst from happening.” ♦

Published in the print edition of the April 20, 2020, issue, with the headline “The Good Doctor.”

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 11 Apr 2020 16:30:40 +0000
To: Del Rio, Carlos; (b) (6)
Cc: (b) (6)
Subject: RE: Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 Infection

Thanks, Carlos. As you know since Cliff has been in touch with the IDSA, the HHS guidelines will be coming out this week.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Del Rio, Carlos (b) (6)>
Sent: Saturday, April 11, 2020 12:08 PM
To: (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 Infection

IDSA guidelines are out
<https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/>

Carlos del Rio, MD.
Sent from my iPhone

This e-mail message (including any attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this message (including any attachments) is strictly prohibited.

If you have received this message in error, please contact the sender by reply e-mail message and destroy all copies of the original message (including attachments).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 11 Apr 2020 16:25:29 +0000
To: (b) (6)
Subject: FW: Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 Infection

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Del Rio, Carlos (b) (6)>
Sent: Saturday, April 11, 2020 12:08 PM
To: (b) (6); Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 Infection

IDSA guidelines are out
<https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/>

Carlos del Rio, MD.
Sent from my iPhone

This e-mail message (including any attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this message (including any attachments) is strictly prohibited.

If you have received this message in error, please contact the sender by reply e-mail message and destroy all copies of the original message (including attachments).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 10 Apr 2020 15:12:24 +0000
To: [REDACTED] (b) (6)
Subject: FW: Atlantic's coverage - Fauci as "heartthrob"

David Bradley is the Chairman of *The Atlantic*. Geeez....

From: David Bradley <dbradley@theatlantic.com>
Sent: Friday, April 10, 2020 10:20 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: Atlantic's coverage - Fauci as "heartthrob"

Hi Tony,

[REDACTED] (b) (6) I send you greetings and the deepest appreciation.

I am only one of your millions of followers who feel in your debt. But, I am the only one with a magazine that has dedicated a whole article to "the thirst for Tony Fauci."

This will be the least important item on today's to-do list. But, someday, your grandchildren and their children, in turn, will want to read this: <https://www.theatlantic.com/technology/archive/2020/04/anthony-fauci-coronavirus-crush/609544/>

My best wishes to you.

David

David G. Bradley
Chairman
Atlantic Media

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 10 Apr 2020 15:10:47 +0000
To: David Bradley
Subject: RE: Atlantic's coverage - Fauci as "heartthrob"

David:

Many thanks for sending this. I could not have even begun to make this up.... Please stay safe and well.

Warm regards,

Tony

From: David Bradley <dbradley@theatlantic.com>
Sent: Friday, April 10, 2020 10:20 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Atlantic's coverage - Fauci as "heartthrob"

Hi Tony,

(b) (6) I send you greetings and the deepest appreciation.

I am only one of your millions of followers who feel in your debt. But, I am the only one with a magazine that has dedicated a whole article to "the thirst for Tony Fauci."

This will be the least important item on today's to-do list. But, someday, your grandchildren and their children, in turn, will want to read

this: <https://www.theatlantic.com/technology/archive/2020/04/anthony-fauci-coronavirus-crush/609544/>

My best wishes to you.

David

David G. Bradley
Chairman
Atlantic Media

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 10 Apr 2020 01:37:52 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Haskins, Melinda (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Letter from Rep. C. Smith to Sec Azar and Dir Fauci
Attachments: 2020-04-09 Smith to Azar and Fauci re Lyme and COVID19.pdf

FYI

From: Griswold, Kelsey <[REDACTED]> (b) (6)
Sent: Thursday, April 9, 2020 8:41 PM
To: Griswold, Kelsey [REDACTED] (b) (6)>
Subject: Letter from Rep. C. Smith to Sec Azar and Dir Fauci

Good Evening All,

Attached is a letter from Congressman Smith to Secretary Azar and Director Fauci. Please let me know if there are questions or concerns associated with this.

Best,

Kelsey A. Griswold | Legislative Director
Congressman Christopher H. Smith (NJ-04)
2373 Rayburn HOB
Washington, DC 20515
p: [REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 10 Apr 2020 01:35:00 +0000
To: (b) (6)
Subject: RE: We Believe in You

(b) (6):

Many thanks for your e-mail. Stay well and safe.
Best regards,
Tony

From: (b) (6)
Sent: Thursday, April 9, 2020 8:07 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: We Believe in You

Tony,
I would only hope that one of your staff see my email and are prudent to know that this is being sent to him by one of his kin and passes it along to you.

Sincerely,

(b) (6)

On Thursday, April 9, 2020, 05:54:17 PM EDT, Fauci, Anthony (NIH/NIAID) [E] (b) (6) wrote:

My work with the Coronavirus Task Force and the large volume of incoming emails precludes me or my staff from answering each individual message. I would encourage you to visit www.coronavirus.gov for the latest information and guidance related to COVID-19.

Thank you, and best regards.

Anthony S. Fauci, M.D.

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 9 Apr 2020 21:24:50 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: COVID 19 Briefing Document and COVID Vaccine Overview
Attachments: Overview of COVID-19 Vaccine Development_April9.pdf, Briefing Document NIAID Involvement with Pharma in COVID19_April 9_with table.pdf

The email below is from Larry Corey.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email: (b) (6)

From: Corey MD, Larry (b) (6) >
Sent: Thursday, April 9, 2020 3:50 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>; Marston, Hilary (NIH/NIAID) [E] (b) (6) >
Cc: Mascola, John (NIH/VRC) [E] (b) (6); Erbelding, Emily (NIH/NIAID) [E] (b) (6) >; Dieffenbach, Carl (NIH/NIAID) [E] (b) (6) >; Lane, Cliff (NIH/NIAID) [E] (b) (6)
Subject: COVID 19 Briefing Document and COVID Vaccine Overview

Tony,

We are sending you two documents relating to our strategy for COVID vaccine development . The

(b) (4)



(b)(7)

Larry

From: (b) (6)
Sent: Thu, 9 Apr 2020 17:18:14 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: INTERVIEW REQUEST with Dr Anthony Fauci - Radio-Canada News Program 24h/60min

Let us discuss

Begin forwarded message:

From: NATHALIE LEMIEUX <nathalie.lemieux@radio-canada.ca>
Date: April 9, 2020 at 5:02:20 PM EDT
To: "NIAID NEWS (NIH/NIAID)" <NIAIDNEWS@niaid.nih.gov>, "Fauci, Anthony (NIH/NIAID) [E]" (b) (6), "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Subject: INTERVIEW REQUEST with Dr Anthony Fauci - Radio-Canada News Program 24h/60min

Hello

My name is Nathalie Lemieux and I am a research journalist for 24h in 60min, an information and public affairs program hosted by Anne-Marie Dussault and broadcast on the CBC/Radio-Canada's French national news network. <https://ici.radio-canada.ca/tele/24-60/site> We are based in Montréal and the broadcast is aired across Canada weekdays on prime time (between 7pm and 8PM ET)

As we are also living through this Covid-19 pandemia, we would be delighted to do an interview with Dr Anthony Fauci

*Of course, host Anne-Marie Dussault can do the interview in English

When: subject to Dr Fauci's availability ...

How: Skype or Facetime (in respect of containment obligations)

How long: 7-8 min

Could this proposal be of interest to Dr Fauci?

Thank you for letting me know the possibilities... we are aware of Dr Fauci's tight

schedule

You can reach me at any time via this email nathalie.lemieux@radio-canada.ca or on my cell phone: (b) (6)

--

Nathalie Lemieux

Journaliste à la recherche

Émission 24 heures en 60 minutes

RDI/Radio-Canada

Cell: (b) (6)



RADIO-CANADA

From: (b) (6)
Sent: Thu, 9 Apr 2020 16:51:32 -0400
To: Stover, Kathy (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: Re: FOR ASF REVIEW: Draft PR re: SARS-CoV-2 serosurvey study launch

Looks fine! Thanks

On Apr 9, 2020, at 1:48 PM, Stover, Kathy (NIH/NIAID) [E]
(b) (6) >wrote:

Hi Dr. Fauci,

Please find attached for your review a draft press release announcing the launch of Dr. Memoli's serostudy to detect previously undiagnosed coronavirus infections. Your draft quote is as follows:

"This study will give us a clearer picture of the true magnitude of the COVID-19 pandemic in the United States by telling us how many people in different communities have been infected without knowing it, because they had a very mild, undocumented illness or did not access testing while they were sick," said Anthony S. Fauci, M.D., NIAID director. "These crucial data will help us measure the impact of our public health efforts now and guide our COVID-19 response moving forward."

Thanks much,
Kathy

Kathy Stover
Branch Chief
News and Science Writing Branch
National Institute of Allergy and Infectious Diseases (NIAID)
Office of Communications and Government Relations
National Institutes of Health/HHS
31 Center Drive, Room 7A17E
Bethesda, MD 20892
Phone: (b) (6)
E-mail: (b) (6)

NIAID Media Line: (301) 402-1663

<SARSCoV2 serosurvey Release FOG cleared.docx>

<SARSCoV2 serosurvey NSWB Clearance Form.doc>

<SARS_COV2_SERUM_SAMPLING_Clean Changes_Copy_4.2.2020.docx>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 9 Apr 2020 16:40:28 +0000
To: [REDACTED] (b) (6) [E]
Subject: FW: New Yorker: Fauci Urges Trump to Attack the Coronavirus as if It Were an Inspector General

This Borowitz guy is something else....

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] [REDACTED] (b) (6)
Sent: Thursday, April 9, 2020 12:33 PM
To: NIAID COGCORE <COGCORE@mail.nih.gov>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: New Yorker: Fauci Urges Trump to Attack the Coronavirus as if It Were an Inspector General

Satire from The Borowitz Report

Fauci Urges Trump to Attack the Coronavirus as if It Were an Inspector General



By Andy Borowitz
April 8, 2020



Photograph by Lo Scalzo / Bloomberg / Getty

WASHINGTON ([The Borowitz Report](#))—In what he described as a “potentially major breakthrough,” Dr. Anthony Fauci has convinced [Donald Trump](#) to attack [COVID-19](#) as if it were an inspector general. Fauci, who has been frustrated in his efforts to get through to Trump, compared the global pandemic to an inspector general while in a closed-door meeting with the President on Wednesday.

“What do you hate more than anything, Mr. President?” Fauci asked.

“Jim Acosta,” Trump immediately replied.

“O.K., fine. But, besides Jim Acosta,” Fauci said, “it would be an inspector general, right?”

“You’re right, Tony,” Trump agreed. “I hate those losers.”

“Well, think of *COVID-19* as the worst inspector general in the world,” Fauci continued. “It’s overseeing everything you do and making you follow the law. It’s keeping you from spending taxpayer money on anything you want. You wouldn’t stand for that, would you?”

Reportedly, Trump appeared shaken by Fauci’s analogy. “Damn it, Tony, when you put it that way, we’ve got to do something about *COVID-19*,” he said.

Speaking to reporters, Fauci said that he was “cautiously optimistic” that his inspector-general analogy would finally spur Trump to action, but added, “Jared could still screw this up.”

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 9 Apr 2020 10:17:45 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Mediaset, Italian television broadcast, interview request

FYI

From: Alessandro Matarante <alessandro.matarante@outlook.it>
Sent: Thursday, April 9, 2020 5:49 AM
To: Fauci, Anthony (NIH/NIAID) [E] <afauci@niaid.nih.gov>
Cc: Barasch, Kimberly (NIH/NIAID) [C] <kimberly.barasch@nih.gov>; Conrad, Patricia (NIH/NIAID) [E] <conradpa@niaid.nih.gov>
Subject: Mediaset, Italian television broadcast, interview request

Hello Dr. Anthony Fauci,

I'm Alessandro Matarante, an Italian reporter, currently working for Mediaset, Italy's most important television broadcast. Specifically, I work for Quarta Repubblica, a program aired every Monday in prime-time, led by reporter Nicola Porro.

I'm writing this e-mail because it would be a pleasure and an honor for us to interview you about the coronavirus emergency and the way the United States are facing it.

Clearly, we are available to consider any kind of day and hour to make the interview, and so we are to consider together the contents of the interview.

Hoping for a positive answer,
I wish you a pleasant day.

Alessandro - (b) (6)

https://www.mediasetplay.mediaset.it/programmi-tv/quartarepubblica_b100002038

From: (b) (6)
Sent: Wed, 8 Apr 2020 17:17:42 -0400
To: Lusso, Paolo (NIH/NIAID) [E]
Subject: Re: Research Day organized by the Italian Embassy

Paolo:

I am very, very sorry, but I just cannot do this right now. I am swamped and my time is not my own. I hope that they understand.

Best,
Tony

On Apr 8, 2020, at 4:00 PM, Lusso, Paolo (NIH/NIAID) [E]

(b) (6) wrote:

Dear Tony:

I am sorry to bother you with another request during this period. The Italian Embassy is organizing its yearly Research Day (Giornata della Ricerca) that this year will be held strictly online (via Zoom or other e-meeting tool) and centered entirely on the Coronavirus pandemic.

The Italian Ambassador, Mr. Varricchio, would be delighted if you accept to be his guest of honor at the event and asked me to informally enquire with you, before sending an official invitation, if there is any chance you could participate. He understands how crazy your schedule is during this crisis. They would like you to deliver a 30 min lecture on a theme of your choice, preferably related to the state of the art of the pandemic management. The tentative date for the event is between April 20 and April 30, but they are waiting to finalize the date based on your preference, if you are able to accept (even in early May).

Please, let me know if you can accommodate this additional engagement. You will make them very very happy!

All the best,

Paolo

Paolo Lusso, M.D., Ph.D.
Chief, Section of Viral Pathogenesis
Laboratory of Immunoregulation
Bldg. 10, Rm. 6A11
NIAID, NIH
Bethesda, MD 20892

Phone: [REDACTED] (b) (6) (personal)

[REDACTED] (b) (6) (lab)

Fax: (301) 480-5291

E-mail [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6)
Sent: Wed, 8 Apr 2020 16:58:55 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: request of interview by Giuseppe Sarcina, corriere della Sera

Let us discuss

Begin forwarded message:

From: Sarcina Giuseppe <gsarcina@rcs.it>
Date: April 8, 2020 at 4:16:32 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Subject: R: request of interview by Giuseppe Sarcina, corriere della Sera

Dear Doc. Fauci,
this is Giuseppe Sarcina, the us correspondent of Corriere della Sera, the main italian newspaper.
I understood that you are looking at the italian case with great attention.
I wonder if you can grant me a short interview.
I have sent an email march 21. But then I saw that you spoke with an other italian newspaper. So I would like to have a chance to have your voice for our Readers as well. Corriere della Sera is a newspaper based in Milano, Lombardy, The region most affected by the coronavirus.
Thank you
Warm Regards
Giuseppe Sarcina
Washington dc

(b) (6)>
Oggetto: request of interview by Giuseppe Sarcina, corriere della Sera

Dear Doc. Fauci,
this is Giuseppe Sarcina, the us correspondent of Corriere della Sera, the main italian newspaper.
I understood that you are looking at the italian case with great attention.
I wonder if you can grant me a short interview.
That would be really helpful for our readers

Thank you
Warm Regards
Giuseppe Sarcina
Washington dc

(b) (6) "GRAAFF, Peter Jan"
(b) (6) >, "POOLE, Marcia" (b) (6), Tarik Mohammed
(b) (6), Carlos
Navarro Colorado (b) (6)
, Ryan Morhard < (b) (6),
"BRIAND, Sylvie" (b) (6), "MORGAN, Oliver" (b) (6) >,
"Harries, Jenny" < (b) (6), "Awwad, David (NIH/NIAD)
[C]" (b) (6) >, "SIMONSON, Stewart" (b) (6),
"SINGER, Peter Alexander" (b) (6) >, "Jayatunga, Wikum"
(b) (6)
"Julie.HALL" < (b) (6) >, Amelie
RIOUX (b) (6)
"SHIN, Young-Soo" (b) (6) >,
(b) (6) >, Feng Ding
(b) (6)
<
"SMITH, Ian Michael"
(b) (6) >, "AYLWARD, Raymond Bruce J." (b) (6) >,
(b) (6)
Cc: SHOC <shoc@who.int>, Office of the Director-General <DGOoffice@who.int>,
"SCHWARTLANDER, Bernhard F." (b) (6) >, "MAHJOUR,
Jaouad" (b) (6), "FALL, Ibrahima Soce" (b) (6) >, "GREIN,
Thomas" (b) (6) >, "MINHAS, Raman" (b) (6) >, "COX, Paul
Michael" (b) (6) >, "AL-SHORBAJI, Farah" (b) (6) >,
"POOLE, Marcia" < (b) (6) >, "DRURY, Patrick Anthony"
(b) (6) >, "GRAAFF, Peter Jan" (b) (6) >, "Dr VAN
KERKHOVE, Maria" (b) (6) >, "FARES, Christine Youssef"
(b) (6)

Subject: Global Health Leaders Call, Thursday, 8 April at 14:30 CET

Dear colleagues,

On behalf of Mike Ryan, allow me to share with you the draft COVID-19 Strategy Update, which will be subject of discussion at tomorrow's Global Health Leaders Call at 14.30 CET.

The epidemiological update and analysis, as well as the **Zoom connection** will be shared tomorrow morning.

Please find below, the key questions for your consideration and input.

1. What is your view on the latest epidemiology, virus transmission and severity in affected countries ?
2. What are the emerging issues/challenges that you see as important ?
3. What should be the priorities for the 1-2 weeks?
4. Any other issues you see as important?

If you experience any technical difficulties joining this conference call, please contact the WHO HQ EOC operator at: **+41 22 79 15 533**

Kind regards,

Sophia

Sophia Kabir

Executive Officer

Office of the Executive Director

WHO Health Emergencies Programme (WHE)

Tel. (b) (6)

Mobile (b) (6)

Website: [WHO in emergencies](#) | [WHO Facebook](#) | [WHO Twitter](#)



HEALTH
EMERGENCIES
programme

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Apr 2020 17:28:01 +0000
To: Awwad, David (NIH/NIAID) [C]
Subject: FW: NIAID Information RE: Update Your PIV Card (HHS ID Badge) Certificates Before They Expire

Do I need to do anything?

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-2263
FAX: (301) 496-4409
E-mail: afauci@niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: NIAID News and Information (NIH/NIAID) <niaidnewsinfo@niaid.nih.gov>
Sent: Wednesday, April 8, 2020 10:18 AM
To: NIAID Announcements <NIAID-announce@niaid.nih.gov>
Subject: NIAID Information RE: Update Your PIV Card (HHS ID Badge) Certificates Before They Expire

(b) (2)

-----Original Message-----

From: ORS Information Line <orsinfo@ors.od.nih.gov>
Sent: Tuesday, April 7, 2020 6:23 PM

To: NIH-STAFF@LIST.NIH.GOV

Subject: Update Your PIV Card (HHS ID Badge) Certificates Before They Expire

(b) (2)



If you need help, please contact the NIH IT Service Desk: <http://itservicedesk.nih.gov/>
301-496-4357 (HELP), 301-496-8294 (TTY), or 1-866-319-4357 (HELP)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Apr 2020 17:25:25 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Stover, Kathy (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]; Doepel, Laurie (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]
Subject: RE: PR HHS Treatment Guidelines for COVID-19

We should include in the statement something about [REDACTED] (b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] [REDACTED] (b) (6) >
Sent: Wednesday, April 8, 2020 12:58 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Cc: Folkers, Greg (NIH/NIAID) [E] [REDACTED] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6) >; Stover, Kathy (NIH/NIAID) [E] [REDACTED] (b) (6) >; Routh, Jennifer (NIH/NIAID) [E] [REDACTED] (b) (6); Doepel, Laurie (NIH/NIAID) [E] [REDACTED] (b) (6); Lane, Cliff (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: ASF: PR HHS Treatment Guidelines for COVID-19

This is a press release that we (Laurie) drafted for HHS to announce the HHS treatment guidelines. Cliff has reviewed. I know how slammed you are. In the interest of time, I would like to move this to Bill Hall now, with the understanding that we can catch up with any changes you might have before the release is actually issued.

FYI, the release includes a quote for you as follows:

[REDACTED] (b) (5)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Apr 2020 16:59:29 +0000
To: Barillas, Carolina (NIH/NIAID) [E]
Cc: Holland, Steven (NIH/NIAID) [E]; Auchincloss, Hugh (NIH/NIAID) [E]
Subject: RE: Article - BCG protection from COVID-19 mortality

Thanks, Carolina.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Barillas, Carolina (NIH/NIAID) [E] <(b) (6)>
Sent: Wednesday, April 8, 2020 12:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Holland, Steven (NIH/NIAID) [E] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] (b) (6)>
Subject: Article - BCG protection from COVID-19 mortality

Hello everyone,

I found this article that comes to a similar conclusion regarding the protective role of universal BCG vaccination on COVID-19 mortality. I will be working with an epidemiologist from Virginia Tech to see if we can provide stronger quantitative analysis and modelling.
All the best,

Carolina

Carolina Barillas Mury, M.D., Ph.D.
Chief, Mosquito Immunity and Vector Competence Section
Laboratory of Malaria and Vector Research
National Institutes of Health
12735 Twinbrook Parkway, Room 2E-20C

Rockville, MD 20852

Phone: (b) (6) Fax: (301) 480 0930

E-mail: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Apr 2020 15:09:38 +0000
To: [REDACTED] (b) (6)
Subject: FW: Google Alert - Fauci AND Tony OR Anthony

Click on the "Cuomo Crush" and "Fauci Fever" link below. It will blow your mind.
Our society is really totally nuts.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Google Alerts <googlealerts-noreply@google.com>
Sent: Tuesday, April 7, 2020 11:30 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: Google Alert - Fauci AND Tony OR Anthony

Google Alerts

Fauci AND Tony OR Anthony

As-it-happens update - April 8, 2020

NEWS

Dr. Anthony Fauci, Trump address Iowa's lack of shelter-in-place

Little Village

Speaking at President Trump's press conference late Monday afternoon, Dr. **Anthony Fauci** mentioned Iowa, and a clip of his comments was quickly ...



[Flag as irrelevant](#)

Dr. Fauci: 'We need to put our foot on the accelerator' to see an end to COVID-19 pandemic

fox4kc.com

WASHINGTON — Even though he says the worst is yet to come, Dr. **Anthony Fauci**, the nation's top infectious-disease expert, has seen signs of ...



[Flag as irrelevant](#)

Fauci: African-American Community at Higher Risk for Coronavirus Complications

NBC4 Washington

Dr. **Anthony Fauci**, director of the NIAID, spoke on Tuesday about the impact the coronavirus pandemic is having on the ... Read More ...



[Flag as irrelevant](#)

John Calipari Confirms Bill Clinton, Mark Cuban, and Dr. Fauci as Guests on "Coffee With Cal"

kentuckysportsradio.com

Anthony Fauci. Every Monday for the next 25 weeks, Calipari's show will "feature positive messaging and conversation with high-profile guests from the ...



[Flag as irrelevant](#)

'Cuomo Crush' and 'Fauci Fever' — Sexualization Of These Men Is a Real Thing on The Internet

Talent Recap

The coronavirus pandemic has led brothers Andrew and Chris Cuomo and Dr.

Anthony Fauci to the forefront COVID news and updates, but it also ...



[Flag as irrelevant](#)



Before the White House, Trump called NIH 'terrible,' questioned vaccines

KPQ

President Donald Trump speaks to the press while Director of the National Institute of Allergy and Infectious Diseases **Anthony Fauci** speaks during a ...



[Flag as irrelevant](#)

You have received this email because you have subscribed to **Google Alerts**.

[Unsubscribe](#)



[Receive this alert as RSS feed](#)

[Send Feedback](#)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Apr 2020 13:23:07 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: On the record

Yes. Please point him to what I said yesterday.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, April 8, 2020 9:20 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: On the record

Pls see below....Bob Franken...

-----Original Message-----

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)>
Sent: Wednesday, April 8, 2020 9:03 AM
To: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Cc: Stover, Kathy (NIH/NIAID) [E] (b) (6) Routh, Jennifer (NIH/NIAID) [E] (b) (6)
Subject: RE: On the record

I think he probably knows Bob Franken personally so I'm wondering if you might want to flag this for him, as he might decide it warrants a personal response.

Otherwise, he did speak about health disparities at yesterday's WH press conference, and we could certainly point Franken to those comments and then also direct him to NIMHD. (b) (5)
(b) (5)

-----Original Message-----

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Sent: Wednesday, April 8, 2020 8:56 AM
To: Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6) Routh, Jennifer (NIH/NIAID) [E] (b) (6)
Cc: NIAID OCGR NSWB <NIAIDOCGRNSWB@mail.nih.gov>
Subject: FW: On the record

Defer to you to decide on this

-----Original Message-----

From: Bob Franken (b) (6) >

Sent: Wednesday, April 8, 2020 5:17 AM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >

Subject: On the record

Tony:

For my syndicated column, I want to do a piece on the racial aspect of coronavirus. I'm not seeing any breakdown of deaths in the poorer areas as opposed to the more prosperous ones.

Isn't that the telling statistic here that the economically less well off live in areas where medical services are inadequate and as a result they have more underlying conditions that make them more vulnerable? Isn't it relevant that people of color are predominantly among the poorer in our country for a variety of reasons?

I will appreciate your comments, particularly since you have so little to do these days.

Warmest regards,

Bob

Bob Franken

www.bobfranken.tv

From: (b) (6)
Sent: Wed, 8 Apr 2020 07:18:27 -0400
To: (b) (6)
Subject: Re: last questions, i promise

In first response, I meant to say "I always qualified the statement....." .not "I almost qualified the statement..."

On Apr 8, 2020, at 7:04 AM, Michael Specter (b) (6) >wrote:

Thank you. Will do all this and take out (b) (6)

On Wed, Apr 8, 2020 at 03:59 Fauci, Anthony (NIH/NIAID) [E]
<(b) (6)>wrote:

Michael:

See comments below in red.

Thanks,

Tony

From: Michael Specter <(b) (6)>
Sent: Wednesday, April 8, 2020 1:25 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: last questions, i promise

Hi. Mostly these are two second yes or no answers - though I need to understand the b cell issue better.

Thank you for all this. Hang in there:

1.)

Fauci has at times struggled to compel politicians and businesses to attack the problems that he considers most worrisome. Over the years, he has become especially concerned about the possible impact of a lethal strain of influenza." True, but I almost qualified the

statement and said it most likely would be influenza, but I was concerned with any type of novel respiratory virus that efficiently spread from human to human and that had a high degree of morbidity and mortality

2.) Dyker Heights versus Bensonhurst:

-
- What do we say about where he grew up.? He always says Bensonhurst. The apartment was technically in Dyker Heights, though the neighborhood lines shift. And I never see him mention moving neighborhoods. Did he move? Yes. I moved. I was born at [REDACTED] (b) (6) in the middle of the Bensonhurst section of Brooklyn. When I was 9 years old my father opened a Pharmacy on 8302-13th Avenue at the outer edge of the Dyker Heights Section of Brooklyn (only We moved into an apartment over the pharmacy.
-

3.) [the question below is the meaning of hyperactive. Does it mean producing too many B cells or that they were too active, as in working too hard, producing too many antibodies??] Not necessarily too many B cells. It means that the B cells that are there, are aberrantly turned on

He had been investigating B-cells, which are involved in the production of antibodies. In 1983—before H.I.V. was even known by that name—his lab became the first to report that B-cells became hyperactive in patients with AIDS. The virus was somehow leading its hosts to overproduce a defense that normally would keep them healthy. Fauci had identified one of the crucial features of AIDS. “We made that observation without having any idea of what we were dealing with,” he said. “I think that speaks for sound scientific and clinical observation.” The politics of seeking a cure, though, would be far harder to manage.

- 4.). This I asked before you could not speak to me but we can take me out of it. Or do whatever you like: I asked Fauci if he thought that novel coronavirus would force a change in attitude among political leaders and funding agencies. [REDACTED] (b) (6)
[REDACTED] (b) (6)
-

5.). This you have said in more than one place. People kind of became alarmed when you were absent so just want to be sure you don't mind it in here: **No problem.**

Fauci said that there was nothing meaningful about his absence from the Mar.23 White House briefing, “I was tied up in a task force meeting, and we were trying to work out some difficult policies and the topic of the briefing that day was more related to other members of the Task Force. He also said, “I have no trouble with the President. When I talk to him, he listens.”

Michael Specter
Staff Writer
The New Yorker

Adjunct Professor of Bioengineering

Stanford University

(b) (6)

Phone: (Work, Cell, SMS) + (b) (6)

--

Michael Specter
Staff Writer
The New Yorker
Adjunct Professor of Bioengineering
Stanford University

(b) (6)

Phone: (Work, Cell, SMS) (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Apr 2020 10:42:24 +0000
To: Perez-Stable, Eliseo (NIH/NIMHD) [E]
Subject: RE: WH Briefing

Thanks, Eliseo. Stay safe and well.
Best,
Tony

From: Perez-Stable, Eliseo (NIH/NIMHD) [E] (b) (6) >
Sent: Tuesday, April 7, 2020 11:53 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: WH Briefing

Hey Tony, you are the man! Best, Eliseo

From: Natasha Williams (b) (6)
Date: Tuesday, April 7, 2020 at 8:42 PM
To: Eliseo Perez Stable (b) (6) >, Courtney Aklin
(b) (6) >
Subject: WH Briefing

Hello Eliseo and Courtney,

During the White House briefing on COVID-19 this evening, there was a discussion on the disproportionate impact of COVID-19 on African Americans, health disparities and data collection. Please see CSPAN Clips below I cued up.

<https://www.c-span.org/video/?c4866877/user-clip-covid-19-african-american-community>

<https://www.c-span.org/video/?c4866892/user-clip-dr-fauci-health-disparities-african-american-community>

<https://www.c-span.org/video/?c4866897/user-clip-data-collection-question-african-american-community>

I know we are not commenting but I would like to recommend that we have some talking points prepared and on hold in case we receive congressional inquiries. These topics are also receiving coverage on the networks.

Thank you,
Natasha

Natasha H. Williams, PhD, JD, LLM, MPH
Legislative Liaison

National Institute on Minority Health and Health Disparities
National Institutes of Health
Bethesda, MD 20892

Email: (b) (6)

Phone: (b) (6) | www.nimhd.nih.gov

Connect with us: [Twitter](#) | [Facebook](#) | [YouTube](#) | [Email Updates](#)

NIMHD
National Institute on Minority Health and Health Disparities



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Apr 2020 03:06:30 +0000
To: Grogan, Joseph J. EOP/WHO
Cc: Bonner, Maria K. EOP/WHO;Campana, Alexandra D.
EOP/WHO; (b) (6);Barasch, Kimberly (NIH/NIAID) [C];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: [EXTERNAL] RE: Good news

Joe:

I would be happy to speak with him. However, it would have to wait until Thursday since tomorrow is impossible. I believe that we can work this out. Perhaps we can arrange for a call between me ,the CEO and some knowledgeable people in my program.

Best regards,

Tony

From: Grogan, Joseph J. EOP/WHO (b) (6)>
Sent: Tuesday, April 7, 2020 10:19 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Bonner, Maria K. EOP/WHO (b) (6)>; Campana, Alexandra D. EOP/WHO (b) (6)>
Subject: Fwd: [EXTERNAL] RE: Good news

Dr., I would never abuse your personal email, but since the ceo of Lilly wants to speak with you, I thought I would share this request. Just let me know how to respond (b) (5)

Sent from my iPhone

Begin forwarded message:

From: Shawn O'Neail (b) (6)
Date: April 7, 2020 at 10:07:37 PM EDT
To: "Grogan, Joseph J. EOP/WHO" (b) (6)>, "Bonner, Maria K. EOP/WHO" (b) (6)
Subject: [EXTERNAL] RE: Good news

You bet.

Joe – Have an enormous request – for help or counsel.

(b) (4)

My CEO, Dave Ricks, would like to speak with Dr. Fauci in this regard (given his role at the Institute). I know that is a tall order – but underscores the importance.

I did reach out to Dr. Fauci's Chief but received an automated reply indicated he was behind in email – any thoughts in the regard greatly appreciated....

Best, Shawn

=====

Shawn O'Neail
Vice President, Government Affairs
Eli Lilly and Company
(b) (6) (office) | (b) (6) (mobile)
(b) (6) | >www.lilly.com<



CONFIDENTIALITY NOTICE: This e-mail message (including all attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Grogan, Joseph J. EOP/WHO <(b) (6)>
Sent: Tuesday, April 7, 2020 9:31 AM
To: Shawn O'Neail (b) (6); Bonner, Maria K. EOP/WHO (b) (6)
Subject: [EXTERNAL] RE: Good news

EXTERNAL EMAIL: Use caution before replying, clicking links, and opening attachments.

This is great. Thank you for sharing and everything you are doing. Joe

From: Shawn O'Neail (b) (6)>
Sent: Tuesday, April 7, 2020 9:26 AM
To: Grogan, Joseph J. EOP/WHO <(b) (6)>; Bonner, Maria K. EOP/WHO (b) (6)>
Subject: [EXTERNAL] Good news

Hi Joe and Maria

I want to share an important update about Lilly's efforts to address insulin affordability. In response to the crisis caused by COVID-19, Lilly is introducing the Lilly Insulin Value Program, allowing anyone with commercial insurance - and those without insurance - to fill their monthly prescription of Lilly insulin for \$35. The program is effective today and

covers most Lilly insulins. Details and more information can be found in the press release here attached.

Lilly has introduced several solutions in recent years to help meet the individual financial circumstances of people living with diabetes that are still in effect during the COVID-19 crisis, including:

- The Lilly Diabetes Solution Center, through which representatives can direct people to the \$35 savings card, as well as affordability options that may reduce their out-of-pocket costs further – such as free insulin for people with minimal income, or no income at all, that has been donated by Lilly to non-profit organizations.
- Three non-branded versions of our insulin options with list prices 50 percent lower than the branded versions.
- In January, the company announced plans to donate at least 200,000 KwikPens® to relief agencies over the next three years.

Hope all is well with you....

Shawn

=====

Shawn O'Neail
Vice President, Government Affairs
Eli Lilly and Company
(b) (6) office | (b) (6) (mobile)
(b) (6) | >>www.lilly.com<<

The Lilly logo, featuring the word "Lilly" in a stylized, cursive script.

CONFIDENTIALITY NOTICE: This e-mail message (including all attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Apr 2020 02:41:56 +0000
To: (b) (6)
Subject: FW: [EXTERNAL] RE: Good news

Cliff:

Let us discuss this. How do you think that I should respond?

Thanks,

Tony

From: Grogan, Joseph J. EOP/WHO (b) (6)
Sent: Tuesday, April 7, 2020 10:19 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Bonner, Maria K. EOP/WHO (b) (6); Campana, Alexandra D. EOP/WHO (b) (6)
Subject: Fwd: [EXTERNAL] RE: Good news

Dr., I would never abuse your personal email, but since the ceo of Lilly wants to speak with you, I thought I would share this request. Just let me know how to respond, (b) (5)

Sent from my iPhone

Begin forwarded message:

From: Shawn O'Neil (b) (6)
Date: April 7, 2020 at 10:07:37 PM EDT
To: "Grogan, Joseph J. EOP/WHO" <(b) (6)>, "Bonner, Maria K. EOP/WHO" (b) (6)
Subject: [EXTERNAL] RE: Good news

You bet.

Joe – Have an enormous request – for help or counsel.

(b) (4)

My CEO, Dave Ricks, would like to speak with Dr. Fauci in this regard (given his role at the Institute). I know that is a tall order – but underscores the importance.

I did reach out to Dr. Fauci's Chief but received an automated reply indicated he was behind in email – any thoughts in the regard greatly appreciated....

Best, Shawn

=====

Shawn O'Neil
Vice President, Government Affairs
Eli Lilly and Company
(b) (6) (office) | (b) (6) (mobile)
(b) (6) | >www.lilly.com<



CONFIDENTIALITY NOTICE: This e-mail message (including all attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Grogan, Joseph J. EOP/WHO (b) (6)>
Sent: Tuesday, April 7, 2020 9:31 AM
To: Shawn O'Neil (b) (6) Bonner, Maria K. EOP/WHO
(b) (6)>
Subject: [EXTERNAL] RE: Good news

EXTERNAL EMAIL: Use caution before replying, clicking links, and opening attachments.

This is great. Thank you for sharing and everything you are doing. Joe

From: Shawn O'Neil (b) (6)
Sent: Tuesday, April 7, 2020 9:26 AM
To: Grogan, Joseph J. EOP/WHO (b) (6) Bonner, Maria K.
EOP/WHO (b) (6)>
Subject: [EXTERNAL] Good news

Hi Joe and Maria

I want to share an important update about Lilly's efforts to address insulin affordability. In response to the crisis caused by COVID-19, Lilly is introducing the Lilly Insulin Value Program, allowing anyone with commercial insurance - and those without insurance - to fill their monthly prescription of Lilly insulin for \$35. The program is effective today and covers most Lilly insulins. Details and more information can be found in the press release here attached.

Lilly has introduced several solutions in recent years to help meet the individual financial circumstances of people living with diabetes that are still in effect during the COVID-19 crisis, including:

- The Lilly Diabetes Solution Center, through which representatives can direct people to the \$35 savings card, as well as affordability options that may reduce their out-of-pocket costs further – such as free insulin for people with minimal income, or no income at all, that has been donated by Lilly to non-profit organizations.
- Three non-branded versions of our insulin options with list prices 50 percent lower than the branded versions.
- In January, the company announced plans to donate at least 200,000 KwikPens® to relief agencies over the next three years.

Hope all is well with you....

Shawn

=====

Shawn O'Neill
Vice President, Government Affairs
Eli Lilly and Company
(b) (6) (office) | (b) (6) (mobile)
(b) (6) | >>www.lilly.com<<

The Lilly logo, featuring the word "Lilly" in a stylized, cursive script.

CONFIDENTIALITY NOTICE: This e-mail message (including all attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Conrad, Patricia (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 7 Apr 2020 22:58:33 +0000
To: Chris Joffe; Fauci, Anthony (NIH/NIAID) [E]
Subject: RE: Supporting Schools In Covid-19

Due to the high demand on Dr. Fauci's time during the current outbreak – we must decline your request at this time. Thank you for your understanding.

Best,

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health

(b) (6) (office)

(b) (6) (cell)

From: Chris Joffe <Chris@joffeemergencyservices.com>
Sent: Tuesday, April 7, 2020 6:46 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Supporting Schools In Covid-19

Dr. Fauci -

I'm a safety/security consultant to independent and charter schools. I run a firm supporting ~1,000 of them. What, if anything, would you want them to know? **I'm wondering if there's any chance in the world you'd be willing to join us and a few hundred schools for a 15 - 30-minute webinar one day next week?**

Specifically, schools are looking for information/perspective as it relates to what to expect as we return to a new normal and the like. Beyond that, they've begun to ask questions such as what we can be thinking about for this short period of time between the return to school and the development of a vaccine. What would best practice look like for us to educate, but maintain social distance? I believe we can manage a lot of the operationalizing but would be immensely grateful for some high-level guidance to follow.

I recognize how incredibly busy this time is for you and would be so incredibly grateful for any time you might be willing to spare for this audience.

With immense gratitude,

Chris Joffe

--

Chris Joffe
CEO | Joffe Emergency Services
HQ | Santa Monica, CA
Twitter: [@joffechris](https://twitter.com/joffechris)

(b) (6)

Executive Assistant

E: (b) (6)

P: (b) (6)

■

From: [REDACTED] (b) (6)
Sent: Tue, 7 Apr 2020 13:12:39 -0400
To: Lane, Cliff (NIH/NIAID) [E]
Subject: Fwd: [REDACTED] (b) (4)
[REDACTED]
Attachments: [REDACTED] (b) (4)
[REDACTED]

Here it is

Begin forwarded message:

From: "Gelfand, Jeffrey A.,M.D." [REDACTED] (b) (6)
Date: April 7, 2020 at 9:39:51 AM EDT
To: "Callahan, Michael V.,M.D." [REDACTED] (b) (6), "Fauci,
Anthony (NIH/NIAID) [E]" [REDACTED] (b) (6)
Subject: [REDACTED] (b) (4)
[REDACTED]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 7 Apr 2020 15:45:18 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]
Subject: RE: NFLPA-NFL Task Force

(b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, April 7, 2020 11:09 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: NFLPA-NFL Task Force

Pls see below — (b) (5)

From: Billet, Courtney (NIH/NIAID) [E] (b) (6) >
Sent: Saturday, April 4, 2020 12:06 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6) >; Auchincloss, Hugh (NIH/NIAID) [E]
(b) (6) >
Subject: RE: NFLPA-NFL Task Force

(b) (5)

From: (b) (6)
Sent: Saturday, April 4, 2020 11:01 AM

To: Billet, Courtney (NIH/NIAID) [E] (b) (6) >

Cc: Thom Mayer (b) (6) >

Subject: NFLPA-NFL Task Force

Hi Courtney,

1st, I hope you, your family and your loved ones are harboring safely through this storm. 2nd, thanks for your efforts and those of Dr. Fauci-he is truly a national treasure during this crisis and it is deeply appreciated.

I appreciate your help and introductions on how our players can be helpful. As you know Drew and Brittany Brees made a \$5M contribution to the Louisiana coronavirus efforts and they have done a lot of press. Drew's message has been "Hang in there-hang tough! We are in this together."

I've done several webinars with our players and their families, both educating them and pointing out their role both with friends and family as well as on social media to let NFL fans know that whether or not we have an NFL season depends to a large extent upon those fans following the guidelines zealously-as zealously as they follow NFL games!

That message seems to be getting through.

I write now with a request for a little bit of Dr. Fauci's time in about 2 weeks. I requested that we stand up a joint NFLPA-NFL Task Force to scenario plan a pathway to getting NFL Club facilities open, with a view towards if and when we might look towards an NFL season, even if games are played with no fans. My request is to have Dr. Fauci give a telephone briefing to our group on this difficult topic, which would of course be confidential. The floor would be his and I can brief him prior to the call on what we have been working on. If he were willing, we can do the call anytime, probably during the week of April 13, although of course the modeling shows that would be during the peak of the outbreak. We could also do it the week before or after.

Thanks so much for considering this. We are mindful of the psychological toll the virus is taking and the lift NFL games would give to a sports-starved population, but only if it can be done safely for the players and the fans who (ultimately) allow them to play this great game.

Again, thanks!

Best,

Doc

Thom Mayer, MD, FACEP, FAAP, FACHE

Medical Director



NFL Players Association

11150 Sunset Hills Road, Ste 305

Reston, VA 20190

Mobile: [REDACTED] (b) (6)

NFLPA.COM

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 7 Apr 2020 15:24:35 +0000
To: Barillas, Carolina (NIH/NIAID) [E]
Cc: Holland, Steven (NIH/NIAID) [E]; Auchincloss, Hugh (NIH/NIAID) [E]; [REDACTED] (b) (6)
Subject: RE: BCG protection from COVID-19 mortality

Carolina:

[REDACTED] (b) (5)

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Barillas, Carolina (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Sent: Tuesday, April 7, 2020 11:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Cc: Holland, Steven (NIH/NIAID) [E] [REDACTED] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: BCG protection from COVID-19 mortality

Good morning Tony,

All the best,

Carolina

Carolina Barillas Mury, M.D., Ph.D.
Chief, Mosquito Immunity and Vector Competence Section
Laboratory of Malaria and Vector Research
National Institutes of Health
12735 Twinbrook Parkway, Room 2E-20C
Rockville, MD 20852
Phone: (b) (6) Fax: (301) 480 0930
E-mail: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 7 Apr 2020 14:51:59 +0000
To: Alison Galvani
Subject: RE: Your PNAS article "Projecting hospital utilization during the COVID-19 outbreaks in the United States" has published

Alison:

Thanks for sending this. I hope that all is well with you. Keep up your great work.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Alison Galvani (b) (6)
Sent: Friday, April 3, 2020 3:34 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Singer, Burton H (b) (6); Seyed Moghadas (b) (6)

Subject: Fwd: Your PNAS article "Projecting hospital utilization during the COVID-19 outbreaks in the United States" has published

Hi Tony,

Please find attached our second COVID publication. This one focuses on projections of the number of ICU beds that will be needed at the peak of the outbreak.

Please don't hesitate to let me know if we can be of any assistance.

Take care,
Alison

----- Forwarded message -----

From: <journalstaff@pnascentral.org>

Date: Fri, Apr 3, 2020 at 2:06 PM

Subject: Your PNAS article "Projecting hospital utilization during the COVID-19 outbreaks in the United States" has published

To: (b) (6)

PNAS is pleased to announce that your paper "Projecting hospital utilization during the COVID-19 outbreaks in the United States" has published online at: www.pnas.org. Did you know article-level metrics data and article downloads are now available for all PNAS articles? Article-level metrics provide a new way of measuring the reach and impact of an article by tracking the mentions it receives online. Clicking on the "Authors & Info" tab near the top of each article and scrolling down will reveal a summary of mentions of the article across news sites, blogs, social media, and other online sources- which are visualized in a colorful icon, or "badge." The number in the middle of the badge is the Altmetric score, which is based on the volume, type, and author of the mentions. You can click on the badge or "view more" to explore the individual mentions from each source. Article downloads by month and by article format appear below the badge.

Stay connected to PNAS:

[Follow Us on Twitter](#)

[Find Us on Facebook](#)

--

Alison Galvani, PhD

Director, Yale Center for Infectious Disease Modeling and Analysis (CIDMA)
Burnett and Stender Families Professor of Epidemiology
Yale School of Public Health
Yale School of Medicine
New Haven, CT 06520

(b) (6)
<http://cidma.yale.edu/>

Follow me at @Alison_Galvani
Follow CIDMA @YCIDMA

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 7 Apr 2020 14:47:59 +0000
To: Glass, Roger (NIH/FIC) [E]
Subject: RE: To cheer you up!

Thanks, Roger!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Glass, Roger (NIH/FIC) [E] (b) (6) >
Sent: Friday, April 3, 2020 12:36 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: To cheer you up!

Tony

Read the last lines and see the photo! Your words from the past are remembered and have changed the careers of our fellows.

No need to respond.

Roger

Sent from my iPad

Begin forwarded message:

From: (b) (6)
Date: April 3, 2020 at 11:30:23 AM CDT
To: "Glass, Roger (NIH/FIC) [E]" (b) (6) >
Subject: Hello

Dr. Glass,

I hope you are well and I wanted to check in to see how you are doing in this scary and traumatic time for our world.

During these times, I'm especially thankful for the training I received from the Fogarty Institute. I remember your wise words at our Fogarty orientation in 2011- on why investing in Global health is so critical. No truer words have been spoken especially at times like these!


I'm currently communicating with my former colleagues in Zambia (Mpanji and Innocent pictured here with

me <https://www.thermofisher.com/blog/behindthebench/using-sanger-sequencing-to-detect-drug-resistance-mutations-in-hiv-in-zambia/>) from CIDRZ to see how testing can be brought up via the public health infrastructure in place currently. Thankfully, the number of cases is very low, although the unreported cases are much higher than likely captured

(<https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6>). My friend who is a Lieutenant Physician actually likely contracted COVID-19 in January and wrote that she and others had treated a patient returning from Wuhan who was pregnant of respiratory illness upon coming back to Lusaka to deliver, only to die of pleural effusion later. They subsequently developed flu-like symptoms and resolved, but these are the types of cases that likely go undetected and can potentially contribute to community spread of the disease.

Thank you again for being such a wonderful role model, and I look to leaders like you and Dr. Fauci to help our nation think with prudent but difficult decisions.

Kind regards,
Lillian



Why invest in global health?

- Good for science- the new frontier
- Good for diplomacy - "smart power"
- Good for humanity - correct health disparities
- Good for business & competition
- Good for our war on terrorism
- Good for our own future

...just the right thing to do !

KIRIN E. JOGAKKY
INTERNATIONAL
CENTRE

Research to Develop and Optimize Interventions Against Infectious Disease Threats



**Implementation: Delivery of
Proven Interventions to
Patients and Populations**



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 7 Apr 2020 14:44:25 +0000
To: [REDACTED] (b) (6)
Subject: FW: [REDACTED] (b) (4)

Attachments: [REDACTED] (b) (4)

What do you think of this study?

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-2263
FAX: (301) 496-4409
E-mail: afauci@niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Gelfand, Jeffrey A., M.D. [REDACTED] (b) (6) >
Sent: Tuesday, April 7, 2020 9:39 AM
To: Callahan, Michael V., M.D. <[REDACTED] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E]
[REDACTED] (b) (6) >
Subject: FW: [REDACTED] (b) (4)
[REDACTED]
Importance: High

Dear Tony and Michael: [REDACTED] (b) (4)
[REDACTED] (b) (4)

Hang in there –
Jeff Gelfand
Mark Poznansky

Vaccine and Immunotherapy Center
Division of Infectious Diseases
Massachusetts General Hospital

(b) (6) (C)-Jeff
(b) (6) -Mark

From: Chen, Huabiao, M.D. <(b) (6)>
Sent: Monday, April 6, 2020 9:07 PM
To: Gelfand, Jeffrey A., M.D. (b) (6)>; Poznansky, Mark, M.B., Ch.B., Ph.D.
(b) (6)
Subject: Re: (b) (4)

Dear Jeff and Mark,

(b) (4)

Thanks,
Huabiao

From: Chen, Huabiao, M.D. (b) (6)>
Sent: Monday, April 6, 2020 12:41 PM
To: Gelfand, Jeffrey A., M.D. (b) (6)>
Subject: Re: (b) (4)

attached please find the supporting information in PDF

From: Chen, Huabiao, M.D. (b) (6)>
Sent: Monday, April 6, 2020 12:23 PM
To: Gelfand, Jeffrey A., M.D. (b) (6)
Subject: Re: (b) (4)

If needed please download the supporting information (b) (4)

From: Gelfand, Jeffrey A., M.D. <(b) (6)>
Sent: Monday, April 6, 2020 12:16 PM
To: Chen, Huabiao, M.D. (b) (6)>

Subject: RE: [REDACTED] (b) (4)

Wow! Reading it now...Jeff

From: Chen, Huabiao, M.D. [REDACTED] (b) (6)

Sent: Monday, April 6, 2020 11:46 AM

To: Gelfand, Jeffrey A., M.D. [REDACTED] (b) (6) >

Subject: [REDACTED] (b) (4)

Importance: High

Dear Jeff,

I had a Chance getting this information from [REDACTED] (b) (6) Dr. Danlei Mou who works very diligently and seriously on this clinical study. You may be interested in this primary information. Please keep it confidential.

Best, Huabiao

The information in this e-mail is intended only for the person to whom it is addressed. If you believe this e-mail was sent to you in error and the e-mail contains patient information, please contact the Partners Compliance HelpLine at <http://www.partners.org/complianceline> . If the e-mail was sent to you in error but does not contain patient information, please contact the sender and properly dispose of the e-mail.

From: Fauci, Anthony (NIH/NIAD) [E]
Sent: Sat, 11 Apr 2020 23:21:25 +0000
To: Upton, Fred
Subject: RE: GOP lawmakers: Fauci may be doing more harm than good | TheHill

Thanks, Fred. I appreciate your note.
Best regards,
Tony

-----Original Message-----

From: Upton, Fred (b) (6) >
Sent: Saturday, April 11, 2020 6:31 PM
To: Fauci, Anthony (NIH/NIAD) [E] (b) (6)
Subject: Re: GOP lawmakers: Fauci may be doing more harm than good | TheHill

Update. Biggs and Buck are the only 2 members of Congress that voted agn the first two bills dealing with COVID-19. The first vote had only the 2 of them vote no. NRN

Sent from my iPhone

> On Apr 11, 2020, at 5:45 PM, Upton, Fred (b) (6) > wrote:

>

> It's upton again and no need to respond. U may get asked about this story and u should know that both Buck and Biggs were among the 40 that voted no on the 2nd package which provided assistance and testing (think it was \$13B). It was not a surprise that they voted no as they r joined with Tom Massie in almost everything. Keep being a science truth teller ☐ ☐

> <https://thehill.com/homenews/coronavirus-report/492359-gop-lawmakers-fauci-may-be-doing-more-harm-than-good>

>

>

> Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 11 Apr 2020 19:26:02 +0000
To: Upton, Fred
Subject: RE: It's Fred upton

Fred:

Thanks for the note. The answer is almost certainly yes, but there would not be enough of them whereby we can compare the results in those who were receiving Hydroxychloroquine or not for their lupus. Large natural history studies, which we will be initiating could possibly answer that question.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Upton, Fred (b) (6)
Sent: Friday, April 10, 2020 6:01 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: It's Fred upton

U gave me your email at the Capitol briefing. Question, with all the discussion on hydrox.—have there been any Covid-19 cases that have struck lupus victims? TY

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 15 Apr 2020 22:29:20 +0000
To: Bergmann, Kenneth
Cc: Lerner, Andrea (NIH/NIAID) [E]
Subject: RE: a thought on selective vulnerability to SARS-CoV-2

Thanks, Ken. Interesting concept. I will run it by our program people.

From: Bergmann, Kenneth [REDACTED] (b) (6) >
Sent: Wednesday, April 15, 2020 4:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: RE: a thought on selective vulnerability to SARS-CoV-2

Hi, Tony

This is not my field but I had some ideas, so thank you for indulging me in thinking about "why not kids." I attached citations I found useful. Hope you are not sorry you asked... 😊

(b) (5)



Best regards,

Ken

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, April 07, 2020 9:50 AM
To: Bergmann, Kenneth (b) (6)
Subject: RE: a thought on selective vulnerability to SARS-CoV-2

Ken:

Thanks for the note. I have thought about the same or similar issues. (b) (5)

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Bergmann, Kenneth (b) (6) >
Sent: Saturday, April 4, 2020 9:39 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: a thought on selective vulnerability to SARS-CoV-2

Dear Dr. Fauci

I read with interest your JAMA Viewpoint of February 25.

(b) (6), (b) (5)

Thank you for all you do.

Sincerely

Ken

Kenneth J. Bergmann, MD, FAAN
Senior Medical Officer
Division of Neurology I, Office of Neuroscience
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Building 22, Room 4143
10903 New Hampshire Avenue,
Silver Spring, MD 20993-0002
Office: (b) (6)
Mobile: (b) (6)
Email (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 15 Apr 2020 22:28:57 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: a thought on selective vulnerability to SARS-CoV-2
Attachments: 1_Mab induced Cytokine Storm NEJM 2006.pdf, 2_Covid_pregnancy.pdf, 3_Neonate_innate_immunity_2018.pdf, 4_nihms832701.pdf, 5_12948_2017_Article_77.pdf

Please check this out with program people. Thanks.

From: Bergmann, Kenneth <(b) (6)>
Sent: Wednesday, April 15, 2020 4:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: RE: a thought on selective vulnerability to SARS-CoV-2

Hi, Tony

This is not my field but I had some ideas, so thank you for indulging me in thinking about "why not kids." I attached citations I found useful. Hope you are not sorry you asked... 😊

(b) (5)



(b) (5)

Best regards,

Ken

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, April 07, 2020 9:50 AM
To: Bergmann, Kenneth <(b) (6)>
Subject: RE: a thought on selective vulnerability to SARS-CoV-2

Ken:

Thanks for the note. I have thought about the same or similar issues. (b) (5)

(b) (5)

(b) (5)

(b) (5)

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not

accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Bergmann, Kenneth [REDACTED] (b) (6)

Sent: Saturday, April 4, 2020 9:39 AM

To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >

Subject: a thought on selective vulnerability to SARS-CoV-2

Dear Dr. Fauci

I read with interest your JAMA Viewpoint of February 25.

[REDACTED] (b) (6), (b) (5)

Thank you for all you do.

Sincerely

Ken

Kenneth J. Bergmann, MD, FAAN
Senior Medical Officer
Division of Neurology I, Office of Neuroscience
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Building 22, Room 4143
10903 New Hampshire Avenue,
Silver Spring, MD 20993-0002

Office: [REDACTED] (b) (6)

Mobile: [REDACTED] (b) (6)

Email: [REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Apr 2020 22:44:30 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Subject: FW: Collection of COVID-19 patient data from medical records

Please take a look at this and figure out whether we should do something.

From: Hahn, Stephen <(b) (6)>
Sent: Thursday, March 26, 2020 5:40 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Redfield, Robert R. (CDC/OD) (b) (6); Debi Birx <(b) (6)>
Cc: Abernethy, Amy (FDA/OC) <(b) (6)>; Lenihan, Keagan (FDA/OC) (b) (6)
Subject: Collection of COVID-19 patient: data from medical records

Tony, Bob and Debi,

Amy is working on a pathway to collect data from electronic medical records in selected areas of the country (addressing all of the appropriate privacy concerns). We're looking for data elements to collect and wonder if your teams could give us some insight from a public health perspective. I am copying Amy to see if she has anything else to add. Perhaps you could assign someone to work with Amy.

Thanks

Steve

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Apr 2020 18:55:23 +0000
To: Kamoie, Brian
Subject: RE: Thank You

Thanks, Brian. I appreciate your note.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Kamoie, Brian (b) (6) >
Sent: Saturday, April 18, 2020 12:33 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Thank You

Tony,


Thank you for all that you are doing in the fight against COVID-19. Your steady leadership and grounding in the science, and your ability to communicate complex information clearly to policymakers and the public, are what the world needs during this crisis. I know we will see the other side of this pandemic, and you will have once again saved many lives with your work.

I am one step removed from this response, as I am on a detail assignment from FEMA to the Naval Academy, but have been sharing information with the Superintendent and his senior leadership team so that they can make good decisions to protect the community while meeting the Academy's mission. I have thought back to the H1N1 response in 2009-2010 many times since this began.

Again, thank you for what you're doing. My best wishes to you and your family.

Best,
Brian





the hippocampus, the hippocampal region is the most vulnerable to ischemia (Morgan and McGaugh, 1963; Amaral and Watanabe, 1995; Amaral and Amaral, 2001). The hippocampus is composed of several subregions, including the dentate gyrus, CA1, CA2, CA3, and CA4. The dentate gyrus is the most vulnerable subregion, followed by CA1, CA3, and CA4, while CA2 is the least vulnerable (Morgan and McGaugh, 1963; Amaral and Watanabe, 1995; Amaral and Amaral, 2001).

The hippocampus is a critical region for learning and memory. The hippocampus is involved in the formation of new memories and the consolidation of existing memories. The hippocampus is also involved in the regulation of learning and memory. The hippocampus is a critical region for learning and memory.

The hippocampus is a critical region for learning and memory. The hippocampus is involved in the formation of new memories and the consolidation of existing memories. The hippocampus is also involved in the regulation of learning and memory. The hippocampus is a critical region for learning and memory.

The hippocampus is a critical region for learning and memory. The hippocampus is involved in the formation of new memories and the consolidation of existing memories. The hippocampus is also involved in the regulation of learning and memory. The hippocampus is a critical region for learning and memory.


The hippocampus is a critical region for learning and memory. The hippocampus is involved in the formation of new memories and the consolidation of existing memories. The hippocampus is also involved in the regulation of learning and memory. The hippocampus is a critical region for learning and memory.

The hippocampus is a critical region for learning and memory. The hippocampus is involved in the formation of new memories and the consolidation of existing memories. The hippocampus is also involved in the regulation of learning and memory. The hippocampus is a critical region for learning and memory.

The hippocampus is a critical region for learning and memory. The hippocampus is involved in the formation of new memories and the consolidation of existing memories. The hippocampus is also involved in the regulation of learning and memory. The hippocampus is a critical region for learning and memory.

The hippocampus is a critical region for learning and memory. The hippocampus is involved in the formation of new memories and the consolidation of existing memories. The hippocampus is also involved in the regulation of learning and memory. The hippocampus is a critical region for learning and memory.

The hippocampus is a critical region for learning and memory. The hippocampus is involved in the formation of new memories and the consolidation of existing memories. The hippocampus is also involved in the regulation of learning and memory. The hippocampus is a critical region for learning and memory.



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 16 Apr 2020 03:00:26 +0000
To: Collins, Francis (NIH/OD) [E]; Myles, Renate (NIH/OD) [E]; Tabak, Lawrence (NIH/OD) [E]; Wolinetz, Carrie (NIH/OD) [E]; Lane, Cliff (NIH/NIAID) [E]
Cc: Burklow, John (NIH/OD) [E]; Fine, Amanda (NIH/OD) [E]; Wojtowicz, Emma (NIH/OD) [E]; Fritz, Craig (NIH/OD) [E]; Billet, Courtney (NIH/NIAID) [E]; Stover, Kathy (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]
Subject: RE: For review tonight: draft Sec. Azar statement on ACTIV

Ditto.

From: Collins, Francis (NIH/OD) [E] (b) (6)
Sent: Wednesday, April 15, 2020 10:57 PM
To: Myles, Renate (NIH/OD) [E] (b) (6)>; Tabak, Lawrence (NIH/OD) [E] (b) (6)>; Wolinetz, Carrie (NIH/OD) [E] <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b) (6)
Cc: Burklow, John (NIH/OD) [E] (b) (6); Fine, Amanda (NIH/OD) [E] (b) (6); Wojtowicz, Emma (NIH/OD) [E] (b) (6); Fritz, Craig (NIH/OD) [E] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6)>
Subject: RE: For review tonight: draft Sec. Azar statement on ACTIV

Looks generally OK
FC

From: Myles, Renate (NIH/OD) [E] (b) (6)>
Sent: Wednesday, April 15, 2020 10:44 PM
To: Collins, Francis (NIH/OD) [E] (b) (6)>; Tabak, Lawrence (NIH/OD) [E] (b) (6)>; Wolinetz, Carrie (NIH/OD) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b) (6)
Cc: Burklow, John (NIH/OD) [E] (b) (6); Fine, Amanda (NIH/OD) [E] (b) (6)>; Wojtowicz, Emma (NIH/OD) [E] (b) (6)>; Fritz, Craig (NIH/OD) [E] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6)
Subject: FW: For review tonight: draft Sec. Azar statement on ACTIV
Importance: High

Good evening:

I'm sending this directly to principals given the quick turnaround. I've let ASPA know that the goal is to issue the release sometime tomorrow.

Thanks,
Renate

From: Brennan, Patrick (OS/ASPA) (b) (6)
Sent: Wednesday, April 15, 2020 10:20 PM
To: Burklow, John (NIH/OD) [E] (b) (6)>; Fritz, Craig (NIH/OD) [E] (b) (6);
Myles, Renate (NIH/OD) [E] (b) (6)>; Fine, Amanda (NIH/OD) [E]
(b) (6)>; Wojtowicz, Emma (NIH/OD) [E] (b) (6)>; Akinso, Woleola
(NIH/OD) [E] (b) (6)>; Stimson, Brian (HHS/OGC) (b) (6)>; Charrow,
Robert (HHS/OGC) (b) (6)>
Cc: Murphy, Ryan (OS/ASPA) (b) (6)>; Pratt, Michael (OS/ASPA)
(b) (6)>; Oakley, Caitlin B. (OS/ASPA) <(b) (6)>
Subject: For review tonight: draft Sec. Azar statement on ACTIV

NIH and OGC,

Can you let me know if the below and attached statement from the Secretary looks OK? **Assuming it is going tonight from NIH, approval as soon as possible would be great.** Thank you!

- Patrick

Patrick Brennan
Director of Speechwriting
Department of Health and Human Services
Office: (b) (6) | Cell: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 13 Apr 2020 01:14:17 +0000
To: Mascola, John (NIH/VRC) [E]
Cc: Erbeling, Emily (NIH/NIAID) [E]; Dieffenbach, Carl (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Pursuant to My Email on Friday
Attachments: Vaccine strategy-200411-v 13.pptx, Secretary Determination Memorandum-Project Warp Speed-041120 1825 draft.doc

John:

Let us briefly discuss this tomorrow AM. (b) (5)

Best,
Tony

From: Kadlec, Robert (OS/ASPR/IO) (b) (6)>
Sent: Sunday, April 12, 2020 8:59 PM
To: Hassell, David (Chris) (OS/ASPR/IO) (b) (6); Collins, Francis (NIH/OD) [E]
(b) (6) Mascola, John (NIH/VRC) [E]
(b) (6); Bright, Rick (OS/ASPR/BARDA) (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Disbrow, Gary (OS/ASPR/BARDA) (b) (6); Patrick, Vanessa (OS/ASPR/BARDA) (CTR) (b) (6)>; Moughalian, Jen (HHS/ASFR) (b) (6)
Redfield, Robert R. (CDC/OD) (b) (6)>; Messonnier, Nancy (CDC/DDID/NCIRD/OD) (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6)>; Marks, Peter (FDA/CBER) (b) (6)>; Yeskey, Kevin (OS/ASPR/IO) (b) (6)
Cc: Harrison, Brian (HHS/IOS) (b) (6); Dareshori, Zack (HHS/IOS) (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6); Stecker, Judy (OS/IOS) (b) (6) Shuy, Bryan (OS/ASPR/IO) (b) (6)>; Wolinetz, Carrie (NIH/OD) [E] (b) (6)>
Subject: Pursuant to My Email on Friday

I want to share with you the product of the BCG team who drafted the attached briefing and Decision Memo drafted for the Secretary's review tomorrow. I want to thank all those who contributed over this holiday weekend to offer their ideas and concepts that is represented in these products. This represents just a first step of many steps that first outlines a concept that will then be operationalized into a historic effort for not only the Department and agencies who will contribute to it, but to our Nation. Again, thank you for your contributions and commitment. Best Bob

✕ ✕

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 13 Apr 2020 00:32:55 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]
Subject: RE: daily data call from Sec Ofc

This looks really good. Thanks.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)
Sent: Sunday, April 12, 2020 7:27 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] (b) (6)
Subject: ASF: daily data call from Sec Ofc

Per request from the Secretary's office that I sent you this morning, below is what I propose to submit tomorrow morning for the new daily 9am data call. I will plan to submit pretty much the same thing every day. I will not clog your in-box with it unless there is a significant update.

RFI from Staff Sec:

1. For tomorrow's press conference, what information or topics do you recommend be included in the President's remarks? Please provide talking point-level details and support.

Nothing specific from NIAID at this time.

2. For tomorrow's press conference, on what information (if any) do you intend to speak?

Specific topics will depend on questions from reporters. Dr. Fauci has been asked about the effect of social distancing; considerations that would factor into returning the country to normal life; off-label use of treatments such as hydrochloroquine; the status of clinical trials; and the disproportionate impact of COVID-19 on communities of color.

NIAID-specific talking points:

- NIAID has mobilized a rapid research response to quickly develop effective countermeasures for COVID-19, including diagnostics, vaccines to prevent disease and treatments.

- NIAID is supporting a clinical trial of the antiviral remdesivir and is investigating other treatments, including antibody therapies and other antivirals, for their activity against SARS-CoV-2. Well-designed clinical trials are the best way to evaluate potential treatments for safety and efficacy.
- NIAID is supporting an early-stage clinical trial of an investigational vaccine called mRNA-1273, developed by NIAID scientists and the biotechnology company Moderna. The study launched first in Seattle, with a second site recently added in Atlanta. NIAID is researching additional vaccine candidates.
- NIAID has launched a serosurvey study that aims to determine how many adults in the United States without a confirmed history of COVID-19 have antibodies to the virus. Researchers will collect and analyze blood samples from as many as 10,000 adult volunteers without a confirmed history of COVID-19. The results will help illuminate the extent to which the novel coronavirus has spread undetected in the United States and provide insights into which communities and populations are most affected. [NOTE: This serosurvey is for research purposes. It is not meant to be a way for people to access antibody testing for personal knowledge of prior infection history. If it is portrayed as a way for people to “get tested” to understand their own infection history, we can expect that people will inaccurately blame the government for not receiving results in a timely manner. People can request to learn about their results, which will be available only after weeks or months of analysis.]
- NIAID is expanding its portfolio of basic research on coronaviruses and emerging pathogens to characterize SARS-CoV-2 (the virus that causes COVID-19) and understand how it causes disease. NIAID also is using animal models to better understand the infection and to investigate optimal ways to treat and prevent COVID-19.

3. Are there topics or announcements for future press conferences (other than tomorrow's) that you would like to flag for the President's speechwriting team?

For HHS to consider mentioning: [REDACTED] (b) (5)

From: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (5)
Sent: Sunday, April 12, 2020 1:55 PM
To: Billet, Courtney (NIH/NIAID) [E] <[REDACTED]> (b) (5)
Subject: RE: Staff Sec POC - NIAID

OK. Sounds fine. Do what you can do.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6) >
Sent: Sunday, April 12, 2020 10:59 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Stover, Kathy (NIH/NIAID) [E] (b) (6) >; Routh, Jennifer (NIH/NIAID) [E] (b) (6) >; Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Subject: FW: Staff Sec POC - NIAID

FYI – per request below, HHS is setting up a daily data call. We need to tell them at 9am what you are going to discuss at the daily press conference at the end of the day. My observation is that this may be hard to predict. However, we can certainly come up with some boilerplate talking points that we re-submit every day, emphasizing the importance of properly designed clinical trials as the best way to identify treatments.

From: Boyse, Natalie (OS/ASPA) (b) (6)
Sent: Saturday, April 11, 2020 7:04 PM
To: Billet, Courtney (NIH/NIAID) [E] (b) (6) >
Cc: Bird, Catherine (OS/OGC) (b) (6) >; Puesan, Cesar (HHS/OS/IOS) (b) (6) >; Agnew, Ann (HHS/IOS) (b) (6) >; Brennan, Patrick (OS/ASPA) <(b) (6)>
Subject: Staff Sec POC - NIAID

Hi Courtney -

I hope you're having a good weekend. Just wanted to touch base because starting tomorrow, we will be receiving requests for information from Staff Sec **each evening** ahead of the next day's press conference - for a turnaround **by 9am the following morning**. Staff Sec is requesting feedback (see the questions below) from task force experts, including Dr. Fauci, on information they recommend be included in the next day's press conference.

Could you please help me identify a primary POC at NIAID that I can work with to get information to Staff Sec?

(b) (5)

Thank you,
Natalie

Natalie Boyse
Special Assistant, Immediate Office of the Secretary
U.S. Department of Health & Human Services
M: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 11 Apr 2020 03:05:04 +0000
To: Collins, Francis (NIH/OD) [E]
Cc: Tabak, Lawrence (NIH/OD) [E]; Lane, Cliff (NIH/NIAID) [E]; Mascola, John (NIH/VRC) [E]
Subject: RE: COVID-19 Advisory Panel Recommendations Following UP on Secretary Meeting this Am.

I am sorry, but I am way behind on e-mails and I just saw this. What is going on here?

From: Collins, Francis (NIH/OD) [E] (b) (6) >
Sent: Friday, April 10, 2020 11:02 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Tabak, Lawrence (NIH/OD) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Mascola, John (NIH/VRC) [E] (b) (6)
Subject: FW: COVID-19 Advisory Panel Recommendations Following UP on Secretary Meeting this Am.
Importance: High

Just saw this. Huh? (b) (5)
.?

From: Kadlec, Robert (OS/ASPR/IO) (b) (6) >
Sent: Friday, April 10, 2020 7:27 PM
To: Hassell, David (Chris) (OS/ASPR/IO) (b) (6) >; Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Collins, Francis (NIH/OD) [E] (b) (6); 'sh1@fda.hhs.gov' (b) (6) >; Mascola, John (NIH/VRC) [E] (b) (6); Dareshori, Zack (HHS/IOS) < (b) (6) >; Bright, Rick (OS/ASPR/BARDA) (b) (6) >; Disbrow, Gary (OS/ASPR/BARDA) (b) (6) >; Blatner, Gretta (OS/ASPR/BARDA) (b) (6) >; Patrick, Vanessa (OS/ASPR/BARDA) (CTR) (b) (6); Moughalian, Jen (HHS/ASFR) (b) (6) >; Shuy, Bryan (OS/ASPR/IO) (b) (6); Redd, John (OS/ASPR/SPPR) (b) (6); Redfield, Robert R. (CDC/OD) (b) (6); Strength-McGaughey, Tracie (CDC/DDNID/NCIPC/OD) (b) (6) >; Yeskey, Kevin (OS/ASPR/IO) (b) (6) >; Marks, Peter (FDA/CBER) (b) (6) >; Cochran, Norris (HHS/ASFR) (b) (6) >; Messonnier, Nancy (CDC/DDID/NCIRD/OD) (b) (6) >; Lane, Cliff (NIH/NIAID) [E] (b) (6) >; Johnson, Robert (OS/ASPR/BARDA) (b) (6) >; Gershman, Lynn E. (CDC/DDPHSIS/OD) (b) (6) >; Lenihan, Keagan (FDA/OC) < (b) (6) >; Mark Hartell (b) (6); Mascola, John (NIH/VRC) [E]

(b) (6); Suhana, Tina (NIH/VRC) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Mango, Paul (HHS/IOS) (b) (6); Shuy, Bryan (OS/ASPR/IO) (b) (6)
Cc: Harrison, Brian (HHS/IOS) (b) (6); Stecker, Judy (OS/IOS) (b) (6); Ford-Barnes, Arwenthia (OS/ASPR/IO) (b) (6); Tignor, Beth (HHS/IOS) (b) (6); Moreno, Rafael (OS/ASPR) (b) (6); Callahan, Victoria (OS/ASPR/IO) (CTR) (b) (6); Kemp, Micha (OS/ASPR/MFHC) (b) (6); Holland, Tara (OS/ASPR/EMMO) (b) (6)>

Subject: RE: COVID-19 Advisory Panel Recommendations Following UP on Secretary Meeting this Am.

Importance: High

First thank you all for participating on Wednesday's evening call and producing the briefing memo for the Secretary's review. As a consequence of that meeting and discussion, he fully endorsed the recommendations of the vaccine portfolio you recommended. He, however, expressed, concern about (b) (5)

(b) (5)

(b) (5)

This is an ambitious and challenging undertaking but one driven by the necessity to mitigate the public health, economic and national security threat this virus represents to our citizens, nation and our way of life. The Secretary is confident that together with our private sector partners this is achievable.

Have a restful holiday weekend.

Bob

From: Hassell, David (Chris) (OS/ASPR/IO) (b) (6)

Sent: Thursday, April 9, 2020 3:13 PM

To: Kadlec, Robert (OS/ASPR/IO) (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Collins, Francis (NIH/OD) [E] (b) (6);

(b) (6)>; Dareshori, Zack (HHS/IOS)
(b) (6)>; Bright, Rick (OS/ASPR/BARDA) (b) (6); Disbrow,
Gary (OS/ASPR/BARDA) (b) (6)>; Ford-Barnes, Arwenchia (OS/ASPR/IO)
< (b) (6); Blatner, Gretta (OS/ASPR/BARDA)
(b) (6)>; Patrick, Vanessa (OS/ASPR/BARDA) (CTR)
(b) (6)>; Moughalian, Jen (HHS/ASFR) (b) (6)>; Shuy,
Bryan (OS/ASPR/IO) (b) (6) Redd, John (OS/ASPR/SPPR)
(b) (6); Tignor, Beth (HHS/IOS) (b) (6)>; Redfield, Robert R.
(CDC/OD) (b) (6)>; Strength-McGaughey, Tracie (CDC/DDNID/NCIPC/OD)
(b) (6)>; Yeskey, Kevin (OS/ASPR/IO) (b) (6)>; Callahan, Victoria
(OS/ASPR/IO) (CTR) (b) (6)>; Moreno, Rafael (OS/ASPR)
(b) (6)>; Marks, Peter (FDA/CBER) (b) (6)>; Cochran,
Norris (HHS/ASFR) (b) (6)>; Messonnier, Nancy (CDC/DDID/NCIRD/OD)
(b) (6)>; Windom, Robert (OS/ASPR/IO) (b) (6)>; Lane, Cliff
(NIH/NIAID) [E] (b) (6) Holland, Tara (OS/ASPR/EMMO)
(b) (6)>; Johnson, Robert (OS/ASPR/BARDA) (b) (6)>;
Gershman, Lynn E. (CDC/DDPHSIS/OD) (b) (6)>; Kemp, Micha (OS/ASPR/MFHC)
(b) (6)>; Lenihan, Keagan (FDA/OC) (b) (6)>; Mark
Hartell (b) (6)>; Mascola, John (NIH/VRC)
[E] (b) (6)>; Suhana, Tina (NIH/VRC) [E] (b) (6)>; Marston,
Hilary (NIH/NIAID) [E] < (b) (6)>; Fauci, Anthony (NIH/NIAID) [E]
(b) (6)

Subject: COVID-19 Advisory Panel Recommendations

Dear Panel members—

Secretary Azar requested a summary paper with a recommendation from the Panel re the BARDA vaccine portfolio. His deadline was 3:30pm today.

Based on the discussion last night and other discussions with the BARDA team, (b) (5)
(b) (6) Please let me know as soon as possible if this is
not the case.

Apologies for the fast turn. Thank you again for your participation in the Panel.

Chris

<< File: COVID Vaccines Briefing Memo V.3.docx >>

-----Original Appointment-----

From: Kadlec, Robert (OS/ASPR/IO) (b) (6)>

Sent: Monday, April 6, 2020 1:36 PM

To: Kadlec, Robert (OS/ASPR/IO); Conrad, Patricia (NIH/NIAID) [E]; Collins, Francis (NIH/OD) [E]; (b) (6); Dareshori, Zack (HHS/IOS); Bright, Rick (OS/ASPR/BARDA); Disbrow, Gary (OS/ASPR/BARDA); Ford-Barnes, Arwenithia (OS/ASPR/IO); Blatner, Gretta (OS/ASPR/BARDA); Patrick, Vanessa (OS/ASPR/BARDA) (CTR); Moughalian, Jen (HHS/ASFR); Shuy, Bryan (OS/ASPR/IO); Redd, John (OS/ASPR/SPPR); Tignor, Beth (HHS/IOS); Redfield, Robert R. (CDC/OD); Strength-McGaughey, Tracie (CDC/DDNID/NCIPC/OD); Hassell, David (Chris) (OS/ASPR/IO); Yeskey, Kevin (OS/ASPR/IO); Callahan, Victoria (OS/ASPR/IO) (CTR); Moreno, Rafael (OS/ASPR); Marks, Peter (FDA/CBER); Cochran, Norris (HHS/ASFR); Messonnier, Nancy (CDC/DDID/NCIRD/OD); Windom, Robert (OS/ASPR/IO); Lane, Cliff (NIH/NIAID) [E]; Holland, Tara (OS/ASPR/EMMO); Johnson, Robert (OS/ASPR/BARDA); Gershman, Lynn E. (CDC/DDPHSIS/OD); Kemp, Micha (OS/ASPR/MFHC); Lenihan, Keagan (FDA/OC); Mark Hartell (b) (6); Mascola, John (NIH/VRC) [E]; Suhana, Tina (NIH/VRC) [E]; Marston, Hilary (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]

Subject: #2 – COVID-19 Advisory Panel

When: Wednesday, April 8, 2020 5:15 PM-6:30 PM (UTC-05:00) Eastern Time (US & Canada).

Where: WEBEx - (b) (5)

Presentation for Wednesday. **THIS IS THE UPDATED VERSION** 4:26pm

<< File: BARDA COVID Vaccines White Paper 20200405b.docx >>

Meeting Objective:

- (1) Complete review of BARDA vaccine portfolio (to include related NIH and DoD programs), with emphasis on discussion among Panel members;
- (2) Formulate a recommendation to Secretary Azar to either endorse or modify current vaccine strategy, plans, proposed funding and contracts.

Agenda

Brief review of vaccine programs

- BARDA (deeper dive after Sunday overview)
- NIAID
- DoD

Discussion

Recommendation to Secretary Azar

For convenience, below are the presentation and White Paper from last Sunday evening.

<< File: BARDA COVID Portfolio Review 20200405b.pptx >> << File: Vaccine Discussion with S1 and HHS Leadership V2 FINAL - Gary.pdf >>

Hi Arwenithia Ford-Barnes,

You updated this WebEx meeting:

#2 COVID-19 Advisory Panel on behalf of Dr. Robert Kadlec

Host: Arwenthia Ford-Barnes

When it's time, start your meeting from here:

Start the meeting

When: Wednesday, April 8, 2020, 5:15 pm (1 hr 15 mins), Eastern Daylight Time (New York, GMT-04:00).

Access Information

Meeting Number:

(b) (5)

Password:

(This meeting does not require a password.)

Host Key:

(b) (5) (Use this key during the meeting if you ever need to reclaim the host role.)

Audio Connection

(b) (5) (Meeting Server Main Number)

Access Code:

(b) (5)

Delivering the power of collaboration
The meetingserver.hhs.gov team

© 2020 Cisco and/or its affiliates. All rights reserved

<< File: BARDA COVID Vaccines White Paper 20200405b.docx >> << File: BARDA COVID Portfolio Review 20200405b.pptx >> << File: Vaccine Discussion with S1 and HHS Leadership V2 FINAL - Gary.pdf >>

From: (b) (6)
Sent: Thu, 9 Apr 2020 16:48:20 -0400
To: Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Hello

How do we nicely say no to this person?

Begin forwarded message:

From: "Sachdev, Amit (HHS/IOS)" (b) (6)
Date: April 9, 2020 at 2:04:56 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) >
Subject: Hello

Hi Dr. Fauci, my name is Amit Sachdev. I am a White House fellow and physician most recently at the Brigham.

I know you are super busy and I would love to partner with you and write a op ed on coronavirus and unite the nation.

If you have a few minutes, I would love to speak. I think (b) (5)
(b) (5)

Thank you for your time and consideration.

Sincerely,
Amit

(b) (6)

Sent from my iPhone

From: (b) (6)
Sent: Wed, 8 Apr 2020 20:14:10 -0400
To: Adams, Jerome (HHS/OASH)
Subject: Re: Blacks/ minorities

Please text to me your cell phone number

On Apr 8, 2020, at 7:29 PM, Adams, Jerome (HHS/OASH)

(b) (6)

Also, Deb has the data and knows it better than anyone,

(b) (5)

(b) (5)

VADM Jerome Adams
20th US Surgeon General

On Apr 8, 2020, at 7:13 PM, Adams, Jerome (HHS/OASH)

(b) (6) wrote:

With greatest of respect to the two of you,

(b) (5)

(b) (5)

(b) (5).

Jerome

VADM Jerome Adams
20th US Surgeon General

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Apr 2020 14:38:40 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: HHS Sponsored Coronavirus Clinical Guidelines - Heads up

FYI

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stecker, Judy (OS/IOS) (b) (6)
Sent: Wednesday, April 8, 2020 9:59 AM
To: Harrison, Brian (HHS/IOS) (b) (6)
Cc: (b) (6) (OS/IOS) (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b) (6)>
Subject: Re: HHS Sponsored Coronavirus Clinical Guidelines - Heads up

Thank you. Will have Beth connect with Patricia ASAP.

Sent from my iPhone

On Apr 8, 2020, at 9:48 AM, Harrison, Brian (HHS/IOS) (b) (6)> wrote:

Sounds good, Dr. Fauci - we greatly appreciate the effort that you/Cliff and your team have put into this.

Look forward to receiving and discussing the guidelines (no need for a separate meeting with me first - we can go straight to the Secretary) and agree that they will not be subjected to additional layers of formal clearance given the circumstances.

Adding Judy to quickly help coordinate a time to meet with the Secretary.

Thanks again,

BH

Brian Harrison
Chief of Staff
U.S. Department of Health and Human Services

(b) (6)

(b) (6)

On Apr 8, 2020, at 7:46 AM, (b) (6) (OS/IOS) (b) (6) > wrote:

Thank you Tony. Obviously we will prioritize time to meet/discuss. I'm at your disposal.

AMA

On Apr 7, 2020, at 11:01 PM, Fauci, Anthony (NIH/NIAID) [E]

(b) (6) > wrote:

Brian:

(b)(5) - PCP

(b) (5)

(b) (5) Happy to

discuss further before I brief the Secretary.

Best regards,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Apr 2020 13:49:56 +0000
To: Harrison, Brian (HHS/IOS)
Subject: RE: HHS Sponsored Coronavirus Clinical Guidelines - Heads up

Thanks, Brian.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Harrison, Brian (HHS/IOS) (b) (6) >
Sent: Wednesday, April 8, 2020 9:49 AM
To: (b) (6) (OS/IOS) (b) (6) >
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Stecker, Judy (OS/IOS) (b) (6)
Subject: Re: HHS Sponsored Coronavirus Clinical Guidelines - Heads up

Sounds good, Dr, Fauci - we greatly appreciate the effort that you/Cliff and your team have put into this.

Look forward to receiving and discussing the guidelines (no need for a separate meeting with me first - we can go straight to the Secretary) and agree that they will not be subjected to additional layers of formal clearance given the circumstances.

Adding Judy to quickly help coordinate a time to meet with the Secretary.

Thanks again,

BH

Brian Harrison
Chief of Staff
U.S. Department of Health and Human Services
(b) (6)

(b) (6)

On Apr 8, 2020, at 7:46 AM, (b) (6) (OS/IOS) (b) (6) > wrote:

Thank you Tony. Obviously we will prioritize time to meet/discuss. I'm at your disposal.
AMA

On Apr 7, 2020, at 11:01 PM, Fauci, Anthony (NIH/NIAID) [E]
(b) (6) > wrote:

Brian:

(b) (5)

(b) (5). Happy to discuss further before I brief the
Secretary.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 7 Apr 2020 14:48:49 +0000
To: Becks, Karen (HHS/IOS)
Subject: RE: Crazy COVID-19 face cover idea

Karen:

Thanks for your note.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Becks, Karen (HHS/IOS) (b) (6)
Sent: Friday, April 3, 2020 12:54 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Crazy COVID-19 face cover idea

Hi, Dr. Fauci.

Thank you so much for keeping things honest and know that I am such a champion of you.

I hope that reaching out is okay. I work at HHS/IOS team. As I sit here at home and have been thinking about the shortage of medical supplies, doggie cones actually can be used as protection for our health care workers. Just a thought that looks and sounds crazy but can help.

Stay safe.

Kindest Regards,

Karen Becks

U.S. Department of Health and Human Services

Immediate Office of the Secretary

200 Independence Avenue, SW

Washington, DC 20201

Desk: (b) (6)

Mobile: (b) (6)

Brian Kamoie

DHS/FEMA

(b) (6) (mobile)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 2 Apr 2020 22:05:53 +0000
To: (b) (6)
Subject: RE: Greetings from your former employee (UNCLASSIFIED)

(b) (6)

Many thanks for your kind note. I hope that all is well with you.
Best regards..
Tony

-----Original Message-----

From: (b) (6) (b) (6)
Sent: Thursday, April 2, 2020 4:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Greetings from your former employee (UNCLASSIFIED)

CLASSIFICATION: UNCLASSIFIED

Dear Dr. Fauci,

I was in touch with (b) (6) back in January and he said you all were underwater there with coronavirus. I can only imagine how much busier you are now, with COVID-19 taking hold across America.

We (myself, husband, and family) have followed the news since the start. In watching, I was reminded of the old sign we had posted on the printer between (b) (6) and my desk for quite some time that read, "Keep Calm and Trust Fauci". I can't recall whether we put that up during the Ebola outbreak or Zika, but never has it been more true. We never cease to be amazed at how well you carry yourself, respond to politically loaded questions, and get the truth out in such a way that any viewer can understand.

You also never seem to frustrate from answering the same questions which I am sure must get old. There has been one question I have yet to hear asked however. Who is cutting your hair? I know you used to have a regular gal but with social distancing, we are speculating that perhaps there is a White House barber you use. Of course we know how busy you are so don't expect a reply, just wanted to throw you a question you may not have had yet. I am also wondering how your office tree is doing. How many bungee cords are supporting it these days?

We have found plenty of reasons to smile with the whole family getting in on what we're dubbing the ASF #1 Fan Club. From memes, to cartoons, to t-shirts, we are all here supporting you and wishing for your continued health and success. I am attaching some of our shenanigans in hopes you get a kick out of it and to provide some comic relief.

You've been thanked over and over but I must say it too. Thank you, Dr. Fauci, for all that you do. And thank you to the staff behind the scenes that makes it happen. (b) (6) is no doubt just as busy as you as always (b) (6), are you reading this email? Hi!). When we see you at all hours from the NIH studio and your office, I think of the media staff support you receive, and especially assistance from (b) (6) for helping the ship run smoothly while you are constantly engaged, (b) (6) and your family, the list goes on. Thank you and thanks to your team.

Best wishes,

(b) (6)

(b) (6)

Directorate of Human Resources
USAG Fort Detrick

CLASSIFICATION: UNCLASSIFIED

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 27 Mar 2020 11:23:56 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: Reaching out about partnerships and COVID-19. // confidential

The email below is from Maria Freire.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email: (b) (6)

From: Freire, Maria (FNIH) [T] (b) (6)
Sent: Friday, March 27, 2020 6:03 AM
To: Collins, Francis (NIH/OD) [E] (b) (6); Wholley, David (FNIH) [T] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6)>
Subject: Re: Reaching out about partnerships and COVID-19. // confidential

Yes, quite a note. It is good to see such willingness to pitch in and the things J&J is doing. Let us know what he says. We stand ready to help. Best, M.

From: "Collins, Francis (NIH/OD) [E]" (b) (6)>
Date: Friday, March 27, 2020 at 4:37:15 AM
To: "Wholley, David (FNIH) [T]" <(b) (6)>
Cc: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>, "Lane, Cliff (NIH/NIAID) [E]" (b) (6)>, "Freire, Maria (FNIH) [T]" (b) (6)
Subject: FW: Reaching out about partnerships and COVID-19. // confidential

Hi David,

Quite a message from Paul below. He seems open to the idea of a virtual meeting, to see what collaborative efforts might be most important. I'll try to speak with him today or tomorrow.

Francis

From: Stoffels, Paul [JJCUS] (b) (6)>
Sent: Friday, March 27, 2020 3:54 AM

To: Collins, Francis (NIH/OD) [E] (b) (6)

Cc: Castilejos, Carlos [JJCUS] (b) (6)

Subject: Re: Reaching out about partnerships and COVID-19. // confidential

Francis,

(b) (4)

Lots to talk about. Happy to find a productive way to contribute in the discussion you are planning to have.

we can talk this afternoon US time or over the weekend.
I'm working (b) (6) at the moment.

Carlos can provide more information on the (b) (6) if you want.

Best regards,

Paul

Sent from my iPad

On Mar 27, 2020, at 1:37 AM, Collins, Francis (NIH/OD) [E] (b) (6) wrote:

WARNING: This email originated from outside the company. Do not click on links unless you recognize the sender and have confidence the content is safe. If you have concerns about this email, send it as an attachment to 'SuspiciousEmail@ITS.JNJ.COM'.

Hi again Paul,

One more question – is the pharma collaboration mentioned in the BioCentury story below the same thing as the Gates COVID Therapeutic Accelerator Program? Or is this something different? I'm just trying to understand the landscape.

Best, Francis

Pharmas on one page with action plan to solve COVID-19 together
BIOCENTURY IS PROVIDING THIS STORY FOR FREE GIVEN THE URGENT NEED FOR INFORMATION ABOUT THE COVID-19 CRISIS.
BY C. SIMONE FISHBURN, EDITOR IN CHIEF | MAR 25, 2020 | 9:17 PM EDT
A grand-scale behind-the-scenes effort by the pharmaceutical companies is under way to expedite the creation of therapies and vaccines to treat COVID-19.

According to the participants who spoke with BioCentury under conditions of anonymity, R&D heads from at least 10 companies have been gathering several times a week, setting in motion an action plan to use their top talent in different disciplines to produce an industry-wide response, the likes of which haven't been seen since the private sector's coordinated contribution during World War II.

Regulatory heads and manufacturing heads have been holding meetings as well, coordinating to minimize duplication of effort, streamline work and advance efficient testing of compounds and vaccines.

The R&D group is creating working principles to accelerate new COVID-19 therapies and vaccines agnostic to their market potential, eliminating bureaucratic and technical or scientific barriers, and focusing on filling gaps not adequately filled by other initiatives and which the consortium is uniquely suited to address.

The pharma group's leaders also intend to offer resources to biotechs and academic groups pursuing countermeasures who may not want to join the effort but could benefit from expert guidance.

Flying the plane as they build it, the collaborators intend to create a clearing house of ideas for testing of molecules and vaccines, with working groups to vet the ideas and expedite testing on the most promising via clinical or preclinical testing.

According to the participants who spoke to BioCentury, the structure will probably evolve over time. Currently, the model involves five working groups, for clinical phase repurposing, novel small molecule antivirals, novel antibodies, preventive vaccines and preclinical repurposing. Each will be headed by a pharma R&D executive and will be responsible for prioritizing potential compounds and specifying actions.

Two platform groups will integrate across modalities: a clinical trial acceleration group and a data sharing group.

"This is not a time to think about proprietary information or IP or margins. We need to break down the barriers and solve the problem," said one participant involved in the consortium.

From: Collins, Francis (NIH/OD) [E]
Sent: Thursday, March 26, 2020 4:25 PM
To: Stoffels, Paul [JJCUS] (b) (6) >
Subject: RE: Reaching out about partnerships and COVID-19

Hi Paul,

I have done some work on the idea of an "AMP like" COVID project. As I mentioned, Mikael Dolsten has been quite enthusiastic. For FDA, Peter Marks, Janet Woodcock, and Steve Hahn were all extremely positive about this opportunity for a shared consideration about priorities. Tony Fauci and his team are totally in favor, and the FNIH (David Wholley and Maria Freire) stands ready to serve as convener. I thought the first step would be a 90 to 120-minute virtual meeting – hopefully next week. Attached is a draft precis of what this might look like; I have left out the roster because that is very much a work in progress.

Meanwhile I saw reports that there are related partnership discussions going on amongst pharmas: <https://www.globenewswire.com/news-release/2020/03/26/2006713/0/en/Novartis-and-life-sciences-companies-commit-expertise-and-assets-to-the-fight-against-COVID-19-pandemic-alongside-Bill-Melinda-Gates-Foundation.html>

I am wondering how this might all fit together.

Do you have a few minutes to speak with me about this? I'm at (b) (6), and I'd greatly value your advice. Just let me know when you might be able to call, so that I'm not in the midst of a Zoom meeting.

Best, Francis

From: Stoffels, Paul [JJCUS] (b) (6) >
Sent: Tuesday, March 24, 2020 12:58 PM
To: Collins, Francis (NIH/OD) [E] (b) (6)
Subject: Re: Reaching out about partnerships and COVID-19

Absolutely worthwhile. I will write an email in the next hours.
(b) (4).

Paul

Verstuurd vanaf mijn iPhone

Op 24 mrt. 2020 om 17:55 heeft Collins, Francis (NIH/OD) [E]
(b) (6) > het volgende geschreven:

Hey again Paul,

Really hoping to hear your thoughts on this proposal. FDA is highly enthusiastic. Dolsten is in. Other pharma R&D Chiefs that would be most helpful? Jay Bradner? John Reed? Roger Perlmutter?

Thanks, Francis

From: Collins, Francis (NIH/OD) [E]
Sent: Monday, March 23, 2020 5:17 PM
To: Stoffels, Paul (b) (6) >
Subject: Reaching out about partnerships and COVID-19

Dear Paul,

I've been thinking that this is a time where we ought to have the best and brightest minds from industry, NIH, academia, and FDA around the same table to identify ways that we can move the coronavirus agenda forward to life-saving products as quickly as possible. Several pharmas and biotechs have been reaching out to NIH to identify viral assays and animal models that can

be run in a BSL-3 facility. Other similar contacts I've had with pharma and biotech tell me that there is a high degree of interest and willingness to combine forces at this time of crisis.

This isn't exactly a precise recipe for AMP-COVID, but it has some of the same flavor. Would it be useful for FNIH to convene a virtual meeting with a few heads of R&D (hopefully you; Mikael Dolsten has already expressed enthusiasm; and I'd be interested in your suggestions of others), FDA (Marks and Woodcock), leaders from NIAID and a few other NIH Institutes with equity in this space. We might be able to make a short list of catalytic actions that neither sector can do optimally right now, but together we can do rapidly.

The focus would be on therapeutics and vaccines. But I can imagine a separate session on diagnostics.

Does this sound worthwhile to you?

Thanks, I always value your advice and partnership.

Francis

From: Fauci, Anthony (NIH/NIAD) [E]
Sent: Thu, 2 Apr 2020 10:58:08 +0000
To: Mascola, John (NIH/VRC) [E]
Subject: FW: Secretary's Medical Countermeasure Advisory Panel

As per our discussion.

From: Kadlec, Robert (OS/ASPR/IO) (b) (6)>
Sent: Thursday, April 2, 2020 6:46 AM
To: Bright, Rick (OS/ASPR/BARDA) (b) (6); Disbrow, Gary (OS/ASPR/BARDA) (b) (6); Lambert, Linda (OS/ASPR/BARDA) (b) (6)
Cc: Shuy, Bryan (OS/ASPR/IO) (b) (6)>; Harrison, Brian (HHS/IOS) (b) (6); Hassell, David (Chris) (OS/ASPR/IO) (b) (6)>
Subject: Secretary's Medical Countermeasure Advisory Panel
Importance: High

Rick, Gary and Linda:

The Secretary has directed me to establish a HHS Senior Advisory Panel of key HHS Operating Divisions(NIH, CDC & FDA) to include head of agencies or their designees to oversee and provide recommendations to the Secretary concerning the development and procurement medical countermeasures (MCM), (vaccines, therapeutics, diagnostics and devices). In meeting this directive, I have asked Dr. Chris Hassell to organize and serve as the intermediary to schedule and coordinate. It is the intent to hold the first virtual meeting of this panel Sunday, 4 April time TBD. The frequency of further meetings will be determined at the inaugural meeting.

The Agenda should include :

- Overall COVID-19 Strategy & Plan (5 min)
- Activities to Date (e.g. industry outreach, RFP BAA etc.) (5 min)
- High level overview of current MCM portfolio (5 min)
- Detailed briefing of current vaccine technical development efforts, timeline and costs (30 min)
- Discussion by participants (30 min)

I ask that the materials for this meeting be submitted by noon April 3 to the APSR IO to be reviewed and be distributed to the Panel membership by noon Saturday April 4. Thank you

Bob

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 31 Mar 2020 01:57:13 +0000
To: Kavesh, William
Subject: RE: Medical staff need COVID-19 NIH survival data on N-95 respirators to help alleviate shortage

Dr. Kavesh:

Thanks for your note. This issue is now being actively discussed at the Task Force meetings. No guarantee, but I believe that there will be movement in that direction.

Best regards,

Tony

From: Kavesh, William <(b) (6)>
Sent: Monday, March 30, 2020 5:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Medical staff need COVID-19 NIH survival data on N-95 respirators to help alleviate shortage

Dear Dr. Fauci,

The biggest concern of my hospital colleagues is the shortage of protective masks. If any research is being done that might drive safe reuse of N-95 respirators, no one I know has seen it. These should be simple studies to do.

If the virus is shown to die within a few days and moisture dries up, then the number of masks needing disposal could drop drastically.

In that situation, each provider at risk could be given five N-95 masks, one for each day of the week. The provider would wear the N-95 mask for one working day, say Monday, and then place it into a paper bag in a secure location. The provider would not use that mask again until the following Monday; ie seven days later.

The only question, then, would be: how many times can this be repeated? Will the mask lose any protective qualities over time?

Please assign someone to do these studies soon.

I'm also very pleased that our national leaders now seem to be listening to you more closely.

Thank you for your efforts.

William Kavesh MD, MPH
CMC Philadelphia VA Medical Center

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 24 Mar 2020 15:26:47 +0000
To: Gottlieb, Lawrence A.
Subject: RE: Support

Many thanks!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Gottlieb, Lawrence A. (b) (6)
Sent: Tuesday, March 24, 2020 11:19 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Support

Dr. Fauci,

Just want to express my support for your indefatigable efforts to thwart the spread of the Coronavirus. Many, many years ago, I was a lab assistant for Dr. Edward L. Kuff and Dr. Karen Lueders, at NCI in building 37!!! Bravo for all you are doing.

Lawrence Gottlieb, PMP, MBA, COR, FAC/PPM III
Senior IT Project Manager
Enterprise Portfolio Management Division
Office of Information & Technology
US Department of Veterans Affairs
810 Vermont Avenue, NW
Washington, DC 20420
(b) (6)
Office: (b) (6)
Cell: (b) (6)

“Alea iacta est” - Caesar



VA Core Values: Integrity Commitment Advocacy Respect Excellence

VA



U.S. Department of Veterans Affairs

Office of Information and Technology
Enterprise Program Management Office

